assay_subcellular_fraction,chembl_id,assay_tax_id,relationship_type,bao_format,assay_organism,assay_category,src_assay_id,assay_tissue,assay_id,tissue_id,doc_id,assay_strain,src_id,cell_id,description,assay_type,assay_test_type,assay_cell_type,curated_by,confidence_score,variant_id,tid
,CHEMBL615117,,H,BAO_0000019,,,,,1,,11087,,1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,Autocuration,8,,12052
,CHEMBL615118,,U,BAO_0000219,,,,,2,,684,,1,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,Autocuration,0,,22226
,CHEMBL615119,,U,BAO_0000019,,,,,3,,15453,,1,,,B,,,Autocuration,0,,22226
,CHEMBL615120,9913.0,H,BAO_0000249,Bos taurus,,,,4,,17841,,1,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Autocuration,4,,104729
,CHEMBL615121,9606.0,N,BAO_0000219,Homo sapiens,,,,5,,17430,,1,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,143B,Intermediate,1,,80001
,CHEMBL615122,9606.0,N,BAO_0000219,Homo sapiens,,,,6,,17430,,1,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,143B,Intermediate,1,,80001
,CHEMBL615123,10090.0,N,BAO_0000219,Mus musculus,,,,7,,13799,,1,163.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,143B,Intermediate,1,,80001
,CHEMBL615124,9606.0,N,BAO_0000219,Homo sapiens,,,,8,,17774,,1,163.0,In vitro cell cytotoxicity was determined against 143B cell line,F,,143B,Expert,1,,80001
,CHEMBL615125,9606.0,N,BAO_0000219,Homo sapiens,,,,9,,3801,,1,163.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,143B,Intermediate,1,,80001
,CHEMBL615126,9606.0,N,BAO_0000219,Homo sapiens,,,,10,,17430,,1,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,143B,Intermediate,1,,80001
,CHEMBL615127,9606.0,N,BAO_0000219,Homo sapiens,,,,11,,17430,,1,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,143B,Intermediate,1,,80001
,CHEMBL615128,9606.0,N,BAO_0000219,Homo sapiens,,,,12,,17774,,1,163.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,143B,Expert,1,,80001
,CHEMBL857900,1280.0,N,BAO_0000218,Staphylococcus aureus,,,,13,,11324,,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Intermediate,1,,50185
,CHEMBL615129,1280.0,N,BAO_0000218,Staphylococcus aureus,,,,14,,11324,,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Intermediate,1,,50185
,CHEMBL615130,1280.0,N,BAO_0000218,Staphylococcus aureus,,,,15,,11324,,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Intermediate,1,,50185
,CHEMBL615131,1280.0,N,BAO_0000218,Staphylococcus aureus,,,,16,,11324,,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Intermediate,1,,50185
,CHEMBL884521,10116.0,D,BAO_0000357,Rattus norvegicus,,,,17,,11347,,1,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Expert,9,,100122
,CHEMBL615132,,H,BAO_0000357,,,,,18,,16474,,1,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,Autocuration,8,,12054
,CHEMBL615133,,H,BAO_0000019,,,,,19,,10091,,1,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,Autocuration,8,,12054
,CHEMBL615134,,H,BAO_0000357,,,,,20,,16474,,1,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,Autocuration,8,,12054
,CHEMBL615135,,H,BAO_0000357,,,,,21,,16474,,1,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,Autocuration,8,,12054
,CHEMBL615136,,H,BAO_0000357,,,,,22,,16474,,1,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,Autocuration,8,,12054
,CHEMBL615137,,H,BAO_0000357,,,,,23,,16474,,1,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,Autocuration,8,,12054
,CHEMBL615138,,H,BAO_0000357,,,,,24,,16474,,1,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,Autocuration,8,,12054
,CHEMBL836324,,U,BAO_0000219,,,,,25,,14352,,1,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,Autocuration,0,,22226
,CHEMBL615139,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,26,,5646,,1,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Autocuration,8,,12054
,CHEMBL615140,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,27,,5646,,1,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Autocuration,8,,12054
,CHEMBL615141,,H,BAO_0000219,,,,,28,,10997,,1,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,Autocuration,8,,12426
,CHEMBL615142,3847.0,H,BAO_0000357,soya bean,,,,29,,6309,,1,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,Autocuration,8,,12054
,CHEMBL615143,3847.0,H,BAO_0000357,Glycine max,,,,30,,167,,1,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Autocuration,8,,12054
,CHEMBL615144,3847.0,H,BAO_0000357,Glycine max,,,,31,,167,,1,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Autocuration,8,,12054
,CHEMBL872867,3847.0,H,BAO_0000357,Glycine max,,,,32,,11087,,1,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Autocuration,8,,12054
,CHEMBL615145,3847.0,H,BAO_0000357,Glycine max,,,,33,,11087,,1,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Autocuration,8,,12054
,CHEMBL615146,3847.0,H,BAO_0000357,Glycine max,,,,34,,13622,,1,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Autocuration,8,,12054
,CHEMBL615147,3847.0,H,BAO_0000357,Glycine max,,,,35,,13622,,1,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Autocuration,8,,12054
,CHEMBL615148,10116.0,U,BAO_0000019,Rattus norvegicus,,,,36,,11347,,1,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Autocuration,0,,22226
,CHEMBL615149,562.0,U,BAO_0000019,Escherichia coli,,,,37,,5926,,1,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Autocuration,0,,22226
,CHEMBL615150,,U,BAO_0000019,,,,,38,,4567,,1,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,Autocuration,0,,22226
,CHEMBL615151,,M,BAO_0000225,,,,,39,,3782,,1,,Dissociation constant towards 16S rRNA construct A,B,,,Intermediate,3,,22222
,CHEMBL615152,,M,BAO_0000225,,,,,40,,3782,,1,,Dissociation constant towards 16S rRNA construct B,B,,,Intermediate,3,,22222
,CHEMBL615153,562.0,M,BAO_0000225,Escherichia coli,,,,41,,4466,,1,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Expert,3,,100263
,CHEMBL615154,562.0,M,BAO_0000225,Escherichia coli,,,,42,,6592,,1,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Expert,3,,100263
,CHEMBL615155,,H,BAO_0000019,,,,,43,,898,,1,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,Autocuration,8,,13053
,CHEMBL615156,,H,BAO_0000019,,,,,44,,898,,1,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,Autocuration,8,,13053
,CHEMBL615157,9606.0,H,BAO_0000019,Homo sapiens,,,,45,,13163,,1,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Autocuration,8,,20001
,CHEMBL615158,9606.0,H,BAO_0000019,Homo sapiens,,,,46,,13163,,1,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Autocuration,8,,20001
,CHEMBL615159,10116.0,D,BAO_0000019,Rattus norvegicus,,,,47,,10691,,1,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Expert,9,,12971
,CHEMBL615172,10116.0,D,BAO_0000019,Rattus norvegicus,,,,48,,10691,,1,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Expert,9,,12971
,CHEMBL615173,10116.0,D,BAO_0000019,Rattus norvegicus,,,,49,,10691,,1,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Expert,9,,12971
,CHEMBL615174,10116.0,D,BAO_0000019,Rattus norvegicus,,,,50,,10691,,1,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Expert,9,,12971
,CHEMBL884518,,H,BAO_0000019,,,,,51,,898,,1,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,Autocuration,8,,13053
,CHEMBL615175,,H,BAO_0000357,,,,,52,,912,,1,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,Autocuration,8,,11512
,CHEMBL615176,,H,BAO_0000357,,,,,53,,912,,1,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,Autocuration,8,,11512
,CHEMBL615177,,H,BAO_0000357,,,,,54,,912,,1,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,Autocuration,8,,11512
Membranes,CHEMBL615178,10116.0,D,BAO_0000249,Rattus norvegicus,,,,55,,15103,,1,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Autocuration,5,,104740
,CHEMBL615179,9606.0,N,BAO_0000219,Homo sapiens,,,,56,,5116,,1,506.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,1A9,Intermediate,1,,80002
,CHEMBL615180,10116.0,D,BAO_0000219,Rattus norvegicus,,,,57,,14578,,1,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,Oocytes,Autocuration,7,,104835
,CHEMBL615181,10116.0,D,BAO_0000219,Rattus norvegicus,,,,58,,14578,,1,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,Oocytes,Autocuration,7,,104821
,CHEMBL615182,10116.0,D,BAO_0000219,Rattus norvegicus,,,,59,,14578,,1,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,Oocytes,Autocuration,7,,104848
,CHEMBL615183,9606.0,N,BAO_0000219,Homo sapiens,,,,60,,4787,,1,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,1A9,Expert,1,,80002
,CHEMBL615184,9606.0,N,BAO_0000219,Homo sapiens,,,,61,,4787,,1,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,1A9,Intermediate,1,,80002
,CHEMBL615185,9606.0,N,BAO_0000219,Homo sapiens,,,,62,,3547,,1,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,1A9,Intermediate,1,,80002
,CHEMBL615186,9606.0,N,BAO_0000219,Homo sapiens,,,,63,,3547,,1,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,1A9,Intermediate,1,,80002
,CHEMBL615187,9606.0,N,BAO_0000219,Homo sapiens,,,,64,,6726,,1,506.0,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,1A9,Intermediate,1,,80002
,CHEMBL885343,9606.0,N,BAO_0000219,Homo sapiens,,,,65,,3455,,1,506.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,1A9,Expert,1,,80002
,CHEMBL615188,9606.0,N,BAO_0000219,Homo sapiens,,,,66,,5726,,1,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,1A9,Intermediate,1,,80002
,CHEMBL615189,9606.0,N,BAO_0000219,Homo sapiens,,,,67,,5726,,1,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,1A9,Intermediate,1,,80002
,CHEMBL615190,9606.0,N,BAO_0000219,Homo sapiens,,,,68,,5726,,1,506.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,1A9,Intermediate,1,,80002
,CHEMBL615191,9606.0,N,BAO_0000219,Homo sapiens,,,,69,,3395,,1,506.0,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,1A9,Intermediate,1,,80002
,CHEMBL615192,9606.0,N,BAO_0000219,Homo sapiens,,,,70,,3415,,1,506.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,1A9,Expert,1,,80002
,CHEMBL827083,9606.0,N,BAO_0000219,Homo sapiens,,,,71,,3415,,1,506.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,1A9,Expert,1,,80002
,CHEMBL615193,9606.0,N,BAO_0000219,Homo sapiens,,,,72,,17099,,1,506.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,1A9,Expert,1,,80002
,CHEMBL615194,9606.0,N,BAO_0000219,Homo sapiens,,,,73,,17099,,1,506.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,1A9,Intermediate,1,,80002
,CHEMBL615195,9606.0,N,BAO_0000219,Homo sapiens,,,,74,,17099,,1,506.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,1A9,Intermediate,1,,80002
,CHEMBL615196,9606.0,N,BAO_0000219,Homo sapiens,,,,75,,17099,,1,506.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,1A9,Intermediate,1,,80002
,CHEMBL615197,9606.0,N,BAO_0000219,Homo sapiens,,,,76,,17721,,1,503.0,Inhibitory concentration against Jurkat cells,F,,Jurkat,Intermediate,1,,81072
,CHEMBL615198,,U,BAO_0000019,,,,,77,,1229,,1,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL615199,10116.0,D,BAO_0000357,Rattus norvegicus,,,,78,,11347,,1,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Expert,9,,100121
,CHEMBL615200,,H,BAO_0000357,,,,,79,,17117,,1,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,Expert,8,,11231
,CHEMBL615201,,H,BAO_0000357,,,,,80,,17117,,1,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,Expert,8,,11231
,CHEMBL615202,,H,BAO_0000357,,,,,81,,17117,,1,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,Expert,8,,11231
Microsomes,CHEMBL615203,5476.0,H,BAO_0000251,Candida albicans,,,,82,,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Autocuration,8,,11231
Microsomes,CHEMBL615204,5476.0,H,BAO_0000251,Candida albicans,,,,83,,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Autocuration,8,,11231
Microsomes,CHEMBL615205,4932.0,H,BAO_0000251,Saccharomyces cerevisiae,,,,84,,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Autocuration,8,,11231
Microsomes,CHEMBL615206,4932.0,H,BAO_0000251,Saccharomyces cerevisiae,,,,85,,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Autocuration,8,,11231
Microsomes,CHEMBL615207,9823.0,H,BAO_0000251,Sus scrofa,,,Liver,86,2107.0,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Autocuration,8,,12083
,CHEMBL827084,10116.0,H,BAO_0000019,Rattus norvegicus,,,,87,,791,,1,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Autocuration,8,,11231
,CHEMBL615208,10116.0,H,BAO_0000019,Rattus norvegicus,,,,88,,791,,1,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Autocuration,8,,11231
,CHEMBL615209,10116.0,H,BAO_0000019,Rattus norvegicus,,,,89,,791,,1,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Autocuration,8,,11231
Microsomes,CHEMBL615210,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,90,2107.0,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Autocuration,9,,12083
Microsomes,CHEMBL615211,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,91,2107.0,11375,,1,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Autocuration,9,,12083
Microsomes,CHEMBL615212,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,92,2107.0,153,,1,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Autocuration,9,,12083
,CHEMBL615213,,H,BAO_0000357,,,,,93,,8269,,1,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,Expert,8,,11377
,CHEMBL615273,,H,BAO_0000357,,,,,94,,8269,,1,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,Expert,8,,11377
,CHEMBL615274,9606.0,N,BAO_0000219,Homo sapiens,,,,95,,17653,,1,726.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,HepG2,Expert,1,,81020
,CHEMBL615275,9606.0,N,BAO_0000219,Homo sapiens,,,,96,,14277,,1,726.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,HepG2,Intermediate,1,,81020
,CHEMBL615276,9606.0,N,BAO_0000219,Homo sapiens,,,,97,,1717,,1,726.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,HepG2,Intermediate,1,,81020
,CHEMBL615277,9606.0,N,BAO_0000219,Homo sapiens,,,,98,,14091,,1,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,HepG2,Intermediate,1,,81020
,CHEMBL615326,9606.0,N,BAO_0000219,Homo sapiens,,,,99,,14091,,1,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,HepG2,Intermediate,1,,81020
,CHEMBL883130,10407.0,N,BAO_0000218,Hepatitis B virus,,,,100,,17653,,1,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Expert,1,,50606
,CHEMBL884519,9606.0,N,BAO_0000219,Homo sapiens,,,,101,,13105,,1,726.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,HepG2,Intermediate,1,,81020
,CHEMBL615327,9606.0,N,BAO_0000219,Homo sapiens,,,,102,,1717,,1,726.0,Concentration required to inhibit 50% of 2.2.15 cell line,F,,HepG2,Intermediate,1,,81020
,CHEMBL615328,9606.0,N,BAO_0000219,Homo sapiens,,,,103,,13105,,1,726.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,HepG2,Intermediate,1,,81020
,CHEMBL615329,9606.0,N,BAO_0000218,Homo sapiens,,,,104,,13600,,1,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615330,9606.0,N,BAO_0000218,Homo sapiens,,,,105,,13467,,1,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615331,10407.0,N,BAO_0000218,Hepatitis B virus,,,,106,,17477,,1,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,2.2.15,Expert,1,,50606
,CHEMBL615332,9606.0,N,BAO_0000218,Homo sapiens,,,,107,,1593,,1,,In vitro anti-HBV activity in 2.2.15 cells,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615333,9606.0,N,BAO_0000218,Homo sapiens,,,,108,,1593,,1,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615334,9606.0,N,BAO_0000218,Homo sapiens,,,,109,,15089,,1,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615335,9606.0,N,BAO_0000218,Homo sapiens,,,,110,,15089,,1,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615336,9606.0,N,BAO_0000218,Homo sapiens,,,,111,,1593,,1,,Cytotoxicity in 2.2.15 cells,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615337,9606.0,N,BAO_0000218,Homo sapiens,,,,112,,1593,,1,,Cytotoxicity in 2.2.15 cells; Not determined,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615338,9606.0,N,BAO_0000218,Homo sapiens,,,,113,,13600,,1,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615339,9606.0,N,BAO_0000218,Homo sapiens,,,,114,,13467,,1,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615340,9606.0,N,BAO_0000218,Homo sapiens,,,,115,,13467,,1,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,2.2.15,Intermediate,1,,50587
,CHEMBL615341,9606.0,N,BAO_0000219,Homo sapiens,,,,116,,14764,,1,726.0,Antiviral activity against HBV was determined in 2.215 cell line,F,,HepG2,Intermediate,1,,81020
Microsomes,CHEMBL615342,9606.0,U,BAO_0000251,Homo sapiens,,,,117,,6531,,1,,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Autocuration,0,,22226
,CHEMBL615343,,U,BAO_0000019,,,,,118,,17322,,1,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,Autocuration,0,,22226
,CHEMBL615344,9606.0,N,BAO_0000219,Homo sapiens,,,,119,,17072,,1,388.0,Inhibitory concentration against 2008 (ovarian) cells,F,,2008,Intermediate,1,,80612
,CHEMBL615345,9606.0,N,BAO_0000219,Homo sapiens,,,,120,,16936,,1,388.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,2008,Intermediate,1,,80612
,CHEMBL615346,9606.0,N,BAO_0000219,Homo sapiens,,,,121,,16936,,1,388.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,2008,Intermediate,1,,80612
,CHEMBL615347,9606.0,N,BAO_0000219,Homo sapiens,,,,122,,17146,,1,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,2008,Intermediate,1,,80612
,CHEMBL615348,9606.0,N,BAO_0000219,Homo sapiens,,,,123,,17146,,1,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,2008,Intermediate,1,,80612
,CHEMBL827085,9606.0,N,BAO_0000219,Homo sapiens,,,,124,,10797,,1,561.0,In vitro inhibition of 2008/R ovarian cancer cell line,F,,2008/R,Intermediate,1,,80613
,CHEMBL615349,9606.0,N,BAO_0000219,Homo sapiens,,,,125,,10797,,1,561.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,2008/R,Intermediate,1,,80613
,CHEMBL615350,9606.0,N,BAO_0000219,Homo sapiens,,,,126,,10797,,1,389.0,In vitro inhibition of 2008/S ovarian cancer cell line,F,,2008/S,Intermediate,1,,80614
,CHEMBL615351,9606.0,N,BAO_0000219,Homo sapiens,,,,127,,10797,,1,389.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,2008/S,Intermediate,1,,80614
,CHEMBL615352,9606.0,S,BAO_0000220,Homo sapiens,,,,128,,4823,,1,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Expert,2,,100256
,CHEMBL615353,9606.0,S,BAO_0000220,Homo sapiens,,,,129,,12912,,1,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Intermediate,2,,100256
,CHEMBL615354,,S,BAO_0000220,,,,,130,,2957,,1,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,Expert,2,,100256
,CHEMBL615355,,S,BAO_0000220,,,,,131,,2957,,1,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,Expert,2,,100256
,CHEMBL615356,,S,BAO_0000220,,,,,132,,3260,,1,,Inhibitory activity against 20S proteosome,B,,,Intermediate,2,,100256
,CHEMBL615357,9606.0,U,BAO_0000019,Homo sapiens,,,,133,,3451,,1,,Compound was tested for inhibitory activity against tryptase,B,,,Autocuration,0,,22226
,CHEMBL615358,9606.0,N,BAO_0000219,Homo sapiens,,,,134,,13885,,1,726.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,HepG2,Intermediate,1,,81020
,CHEMBL827086,9606.0,N,BAO_0000219,Homo sapiens,,,,135,,13885,,1,726.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,HepG2,Intermediate,1,,81020
,CHEMBL615359,,U,BAO_0000019,,,,,136,,3676,,1,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,Autocuration,0,,22226
,CHEMBL615360,,H,BAO_0000357,,,,,137,,6043,,1,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,Autocuration,8,,235
,CHEMBL615361,10116.0,U,BAO_0000218,Rattus norvegicus,,,Heart,138,948.0,11140,,1,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Autocuration,0,,22226
,CHEMBL615362,,H,BAO_0000019,,,,,139,,10543,,1,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,Autocuration,8,,19640
,CHEMBL615363,,H,BAO_0000019,,,,,140,,10543,,1,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,Expert,8,,19640
,CHEMBL615364,,H,BAO_0000357,,,,,141,,10543,,1,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,Autocuration,8,,19640
,CHEMBL615365,,H,BAO_0000019,,,,,142,,10543,,1,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,Expert,8,,19640
,CHEMBL615366,10090.0,N,BAO_0000219,Mus musculus,,,,143,,11365,,1,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,P338,Intermediate,1,,80360
,CHEMBL615367,10090.0,N,BAO_0000219,Mus musculus,,,,144,,11365,,1,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,P338,Intermediate,1,,80360
,CHEMBL615368,9606.0,N,BAO_0000219,Homo sapiens,,,,145,,11803,,1,554.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,PBL,Intermediate,1,,80384
,CHEMBL615369,9940.0,U,BAO_0000019,Ovis aries,,,,146,,11803,,1,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Autocuration,0,,22226
,CHEMBL615370,9940.0,U,BAO_0000019,Ovis aries,,,,147,,11803,,1,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Autocuration,0,,22226
,CHEMBL615673,,H,BAO_0000357,,,,,148,,12278,,1,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,Autocuration,8,,191
,CHEMBL615674,9606.0,U,BAO_0000019,Homo sapiens,,,,149,,8249,,1,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Autocuration,0,,22226
,CHEMBL615675,9606.0,U,BAO_0000019,Homo sapiens,,,,150,,8249,,1,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Autocuration,0,,22226
,CHEMBL615676,9606.0,U,BAO_0000219,Homo sapiens,,,,151,,8249,,1,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,CCRF-CEM,Autocuration,0,,22226
,CHEMBL615677,9606.0,U,BAO_0000219,Homo sapiens,,,,152,,8249,,1,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,CCRF-CEM,Autocuration,0,,22226
,CHEMBL615678,9606.0,U,BAO_0000219,Homo sapiens,,,,153,,8249,,1,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,CCRF-CEM,Autocuration,0,,22226
,CHEMBL615679,9606.0,U,BAO_0000219,Homo sapiens,,,,154,,8249,,1,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,CCRF-CEM,Autocuration,0,,22226
,CHEMBL615680,9606.0,U,BAO_0000019,Homo sapiens,,,,155,,8249,,1,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Autocuration,0,,22226
,CHEMBL615681,9606.0,U,BAO_0000019,Homo sapiens,,,,156,,8249,,1,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Autocuration,0,,22226
,CHEMBL857972,,H,BAO_0000249,,,,,157,,16992,,1,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,Autocuration,6,,104290
,CHEMBL857899,1314.0,N,BAO_0000218,Streptococcus pyogenes,,,,158,,10543,,1,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Intermediate,1,,50264
,CHEMBL615371,10335.0,N,BAO_0000218,Human herpesvirus 3,,,,159,,17833,,1,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Intermediate,1,,50527
,CHEMBL615372,10335.0,N,BAO_0000218,vericilla zoster virus,,,,160,,17290,,1,468.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,HEL,Expert,1,,50527
,CHEMBL615373,10335.0,N,BAO_0000218,vericilla zoster virus,,,,161,,17290,,1,,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,Intermediate,1,,50527
,CHEMBL615374,10335.0,N,BAO_0000218,vericilla zoster virus,,,,162,,17290,,1,,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,Intermediate,1,,50527
,CHEMBL615375,561.0,N,BAO_0000218,escherichia cloac,,,,163,,10932,,1,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,Intermediate,1,,50145
,CHEMBL615376,,U,BAO_0000019,,,,,164,,9707,,1,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,Autocuration,0,,22226
,CHEMBL615377,5476.0,H,BAO_0000249,Candida albicans,,,,165,,2346,,1,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Expert,8,,11143
,CHEMBL615378,284593.0,H,BAO_0000357,Candida glabrata CBS 138,,,,166,,2205,,1,,"Inhibition of 1,3-beta-glucan synthase",B,,,Expert,8,,18077
,CHEMBL615379,9606.0,N,BAO_0000219,Homo sapiens,,,,167,,11900,,1,832.0,Inhibition of growth of 1-87 human tumor cell line,F,,1-87 tumor cell line,Intermediate,1,,80609
,CHEMBL615380,10116.0,D,BAO_0000219,Rattus norvegicus,,,,168,,14864,,1,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Expert,9,,12166
,CHEMBL615381,3847.0,D,BAO_0000357,Glycine max,,,,169,,16474,,1,,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Autocuration,9,,100171
,CHEMBL615382,3847.0,D,BAO_0000357,Glycine max,,,,170,,16474,,1,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Autocuration,9,,100171
,CHEMBL615383,3847.0,D,BAO_0000357,Glycine max,,,,171,,16474,,1,,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Autocuration,9,,100171
,CHEMBL615384,3847.0,D,BAO_0000357,Glycine max,,,,172,,16474,,1,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Autocuration,9,,100171
,CHEMBL615385,3847.0,D,BAO_0000357,Glycine max,,,,173,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Autocuration,9,,100171
,CHEMBL615386,3847.0,D,BAO_0000357,Glycine max,,,,174,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Autocuration,9,,100171
,CHEMBL615387,3847.0,D,BAO_0000357,Glycine max,,,,175,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Autocuration,9,,100171
,CHEMBL615388,3847.0,D,BAO_0000357,Glycine max,,,,176,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Autocuration,9,,100171
,CHEMBL615214,3847.0,D,BAO_0000357,Glycine max,,,,177,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Autocuration,9,,100171
,CHEMBL827087,3847.0,D,BAO_0000357,Glycine max,,,,178,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Autocuration,9,,100171
,CHEMBL615215,3847.0,D,BAO_0000357,Glycine max,,,,179,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Autocuration,9,,100171
,CHEMBL615216,3847.0,D,BAO_0000357,Glycine max,,,,180,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Autocuration,9,,100171
,CHEMBL615217,3847.0,D,BAO_0000357,Glycine max,,,,181,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Autocuration,9,,100171
,CHEMBL615218,3847.0,D,BAO_0000357,Glycine max,,,,182,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Autocuration,9,,100171
,CHEMBL615219,3847.0,D,BAO_0000357,Glycine max,,,,183,,3094,,1,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Autocuration,9,,100171
,CHEMBL615220,10090.0,U,BAO_0000019,Mus musculus,,,,184,,10413,,1,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Autocuration,0,,22226
,CHEMBL615221,10090.0,N,BAO_0000219,Mus musculus,,,,185,,16929,,1,294.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,C3H 10T1/2,Intermediate,1,,80049
,CHEMBL615222,,U,BAO_0000019,,,,,186,,1229,,1,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL615223,,H,BAO_0000357,,,,,187,,16587,,1,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,Autocuration,8,,11489
,CHEMBL615224,,H,BAO_0000357,,,,,188,,16587,,1,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,Autocuration,8,,11862
,CHEMBL615225,,H,BAO_0000357,,,,,189,,16587,,1,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,Autocuration,8,,11862
,CHEMBL615226,,H,BAO_0000357,,,,,190,,16587,,1,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,Autocuration,8,,11489
,CHEMBL615227,,H,BAO_0000357,,,,,191,,16587,,1,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,Autocuration,8,,11862
,CHEMBL615228,9913.0,D,BAO_0000019,Bos taurus,,,,192,,8058,,1,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Expert,9,,12347
,CHEMBL615229,10116.0,D,BAO_0000357,Rattus norvegicus,,,,193,,9065,,1,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Expert,9,,100120
,CHEMBL615230,10116.0,D,BAO_0000357,Rattus norvegicus,,,Adrenal gland,194,2369.0,8865,,1,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Expert,9,,100120
,CHEMBL615231,10116.0,D,BAO_0000357,Rattus norvegicus,,,,195,,9066,,1,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Expert,9,,100120
,CHEMBL884520,10116.0,D,BAO_0000357,Rattus norvegicus,,,,196,,8394,,1,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Expert,9,,100120
,CHEMBL615232,10116.0,D,BAO_0000357,Rattus norvegicus,,,,197,,8394,,1,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Expert,9,,100120
,CHEMBL615233,,H,BAO_0000019,,,,,198,,6431,,1,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,Autocuration,8,,10328
,CHEMBL827088,,H,BAO_0000357,,,,,199,,6431,,1,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,Autocuration,8,,11490
,CHEMBL615234,,H,BAO_0000357,,,,,200,,6431,,1,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,Autocuration,8,,11490
,CHEMBL615235,,H,BAO_0000019,,,,,201,,9295,,1,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,Autocuration,8,,11134
,CHEMBL615236,,H,BAO_0000019,,,,,202,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,Autocuration,8,,12052
,CHEMBL615237,,H,BAO_0000019,,,,,203,,13622,,1,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,Autocuration,8,,11134
,CHEMBL615238,,H,BAO_0000019,,,,,204,,12079,,1,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Autocuration,8,,11134
,CHEMBL615239,,H,BAO_0000019,,,,,205,,13622,,1,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,Autocuration,8,,11134
,CHEMBL615240,9606.0,D,BAO_0000019,Homo sapiens,,,,206,,12079,,1,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Autocuration,9,,11134
,CHEMBL615241,,H,BAO_0000019,,,,,207,,13500,,1,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,Expert,8,,11835
,CHEMBL615242,,H,BAO_0000357,,,,,208,,13723,,1,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,Expert,8,,11601
,CHEMBL615243,,H,BAO_0000019,,,,,209,,16474,,1,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,Autocuration,8,,11134
,CHEMBL615244,,H,BAO_0000019,,,,,210,,1630,,1,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,Autocuration,8,,11134
,CHEMBL615245,,H,BAO_0000019,,,,,211,,167,,1,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,Autocuration,8,,11134
,CHEMBL615246,,H,BAO_0000019,,,,,212,,16474,,1,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,Autocuration,8,,11134
,CHEMBL615247,,H,BAO_0000019,,,,,213,,167,,1,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,Autocuration,8,,11134
,CHEMBL615248,,H,BAO_0000019,,,,,214,,16474,,1,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,Autocuration,8,,11134
,CHEMBL615249,,H,BAO_0000357,,,,,215,,10091,,1,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,Autocuration,8,,11601
,CHEMBL615250,,H,BAO_0000357,,,,,216,,11966,,1,,Tested for inhibition against porcine 12-LO,B,,,Autocuration,8,,11601
,CHEMBL615251,,H,BAO_0000019,,,,,217,,951,,1,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,Autocuration,8,,12052
,CHEMBL615252,,H,BAO_0000019,,,,,218,,10997,,1,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,Autocuration,8,,12052
,CHEMBL828340,,H,BAO_0000019,,,,,219,,10193,,1,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,Expert,8,,12052
,CHEMBL615253,,H,BAO_0000019,,,,,220,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,Autocuration,8,,12052
,CHEMBL615254,,H,BAO_0000019,,,,,221,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,Autocuration,8,,12052
,CHEMBL615255,,H,BAO_0000019,,,,,222,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,Autocuration,8,,12052
,CHEMBL615256,,H,BAO_0000019,,,,,223,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,Autocuration,8,,12052
,CHEMBL615257,,H,BAO_0000019,,,,,224,,10193,,1,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,Autocuration,8,,12052
,CHEMBL615258,,H,BAO_0000019,,,,,225,,11087,,1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,Autocuration,8,,12052
,CHEMBL615259,9606.0,N,BAO_0000219,Homo sapiens,,,,226,,15569,,1,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,41M,Intermediate,1,,80007
,CHEMBL615260,9606.0,N,BAO_0000219,Homo sapiens,,,,227,,12989,,1,621.0,In vitro antitumor activity against 41M cell line.,F,,41M,Expert,1,,80007
,CHEMBL615261,9606.0,N,BAO_0000219,Homo sapiens,,,,228,,16745,,1,621.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,41M,Intermediate,1,,80007
,CHEMBL615262,9606.0,N,BAO_0000219,Homo sapiens,,,,229,,15569,,1,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,41M,Intermediate,1,,80007
,CHEMBL615263,9606.0,N,BAO_0000219,Homo sapiens,,,,230,,12989,,1,621.0,In vitro antitumor activity against 41McisR cell line.,F,,41M,Expert,1,,80007
,CHEMBL838393,9606.0,N,BAO_0000219,Homo sapiens,,,,231,,12989,,1,621.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,41M,Expert,1,,80007
,CHEMBL615264,9606.0,N,BAO_0000219,Homo sapiens,,,,232,,16745,,1,621.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,41M,Intermediate,1,,80007
,CHEMBL615265,9606.0,D,BAO_0000357,Homo sapiens,,,,233,,6210,,1,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Expert,9,,84
,CHEMBL615266,9606.0,D,BAO_0000357,Homo sapiens,,,,234,,6210,,1,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Expert,9,,68
,CHEMBL615267,,H,BAO_0000357,,,,,235,,6226,,1,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Expert,8,,68
,CHEMBL615268,,H,BAO_0000357,,,,,236,,17855,,1,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,Expert,8,,10201
,CHEMBL615269,,H,BAO_0000357,,,,,237,,17855,,1,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,Expert,8,,10201
,CHEMBL615270,,H,BAO_0000357,,,,,238,,17855,,1,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,Expert,8,,10201
,CHEMBL615271,,H,BAO_0000357,,,,,239,,10413,,1,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,Autocuration,8,,12220
,CHEMBL615272,562.0,H,BAO_0000357,Escherichia coli,,,,240,,10413,,1,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Autocuration,8,,11303
,CHEMBL615103,562.0,H,BAO_0000357,Escherichia coli,,,,241,,10413,,1,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Autocuration,8,,11303
,CHEMBL615104,562.0,H,BAO_0000357,Escherichia coli,,,,242,,10413,,1,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Autocuration,8,,11303
,CHEMBL615105,,H,BAO_0000357,,,,,243,,10413,,1,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,Autocuration,8,,12220
,CHEMBL872866,,H,BAO_0000357,,,,,244,,10413,,1,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,Autocuration,8,,12220
,CHEMBL615106,9823.0,H,BAO_0000357,Sus scrofa,,,,245,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615107,9823.0,H,BAO_0000019,Sus scrofa,,,,246,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Autocuration,8,,11303
,CHEMBL615108,9823.0,H,BAO_0000357,Sus scrofa,,,,247,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615109,9823.0,H,BAO_0000357,Sus scrofa,,,,248,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615110,9823.0,H,BAO_0000357,Sus scrofa,,,,249,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL840105,9823.0,H,BAO_0000019,Sus scrofa,,,,250,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615111,9823.0,H,BAO_0000019,Sus scrofa,,,,251,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615112,9823.0,H,BAO_0000019,Sus scrofa,,,,252,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615113,9823.0,H,BAO_0000019,Sus scrofa,,,,253,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615114,9823.0,H,BAO_0000019,Sus scrofa,,,,254,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Autocuration,8,,11303
,CHEMBL615115,9823.0,H,BAO_0000357,Sus scrofa,,,,255,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615116,9823.0,H,BAO_0000019,Sus scrofa,,,,256,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Autocuration,8,,11303
,CHEMBL615698,,H,BAO_0000357,,,,,257,,7323,,1,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,Autocuration,8,,11303
,CHEMBL615699,9823.0,U,BAO_0000019,Sus scrofa,,,,258,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Autocuration,0,,22226
,CHEMBL615700,9823.0,U,BAO_0000019,Sus scrofa,,,,259,,7587,,1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Autocuration,0,,22226
,CHEMBL615701,4932.0,H,BAO_0000357,Saccharomyces cerevisiae,,,,260,,13750,,1,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Expert,8,,100249
,CHEMBL615702,10116.0,U,BAO_0000019,Rattus norvegicus,,,,261,,7662,,1,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Autocuration,0,,22226
,CHEMBL615703,10116.0,U,BAO_0000019,Rattus norvegicus,,,,262,,7662,,1,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Autocuration,0,,22226
,CHEMBL615704,10116.0,U,BAO_0000019,Rattus norvegicus,,,,263,,7662,,1,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Autocuration,0,,22226
,CHEMBL615705,,H,BAO_0000019,,,,,264,,12211,,1,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,Autocuration,6,,104698
,CHEMBL615706,,H,BAO_0000019,,,,,265,,12211,,1,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,Autocuration,6,,104698
,CHEMBL615707,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,266,2116.0,12211,,1,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Intermediate,9,,20033
,CHEMBL615708,,H,BAO_0000019,,,,,267,,12211,,1,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,Expert,8,,10623
,CHEMBL615709,,H,BAO_0000357,,,,,268,,15453,,1,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,Autocuration,8,,121
,CHEMBL615710,10116.0,U,BAO_0000218,Rattus norvegicus,,,,269,,11884,,1,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Autocuration,0,,22226
,CHEMBL615711,,H,BAO_0000019,,,,,270,,7185,,1,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,Autocuration,8,,12688
,CHEMBL615712,9606.0,D,BAO_0000357,Homo sapiens,,,,271,,6876,,1,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Expert,9,,121
,CHEMBL836325,9606.0,D,BAO_0000357,Homo sapiens,,,,272,,6876,,1,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Expert,9,,121
,CHEMBL615713,,H,BAO_0000019,,,,,273,,11863,,1,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,Autocuration,8,,12198
,CHEMBL615714,,H,BAO_0000357,,,,,274,,11863,,1,,Inhibition constant of high-affinity 5-HT uptake,B,,,Autocuration,8,,12198
,CHEMBL615715,,H,BAO_0000019,,,,,275,,11863,,1,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,Autocuration,8,,12198
,CHEMBL615716,,H,BAO_0000019,,,,,276,,11863,,1,,Maximum rate was determined for high affinity transport of 5-HT,F,,,Autocuration,8,,12198
,CHEMBL615717,,H,BAO_0000019,,,,,277,,4639,,1,,Compound was tested for agonistic activity against 5-HT uptake,F,,,Autocuration,4,,104714
,CHEMBL881818,,H,BAO_0000019,,,,,278,,15796,,1,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,Expert,8,,10577
,CHEMBL884540,9913.0,H,BAO_0000357,Bos taurus,,,,279,,15796,,1,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Expert,8,,105
,CHEMBL615718,10116.0,D,BAO_0000224,Rattus norvegicus,,,,280,,12801,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Autocuration,5,,104744
,CHEMBL615719,,H,BAO_0000224,,,,,281,,12801,,1,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,Autocuration,4,,104744
Membranes,CHEMBL615720,,H,BAO_0000249,,,,,282,,12120,,1,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,Autocuration,4,,104744
Membranes,CHEMBL615721,,H,BAO_0000249,,,,,283,,12120,,1,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,Autocuration,4,,104744
,CHEMBL615722,,H,BAO_0000019,,,,,284,,11963,,1,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,Autocuration,4,,104744
,CHEMBL615723,,H,BAO_0000019,,,,,285,,11701,,1,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,Autocuration,8,,51
,CHEMBL615724,,H,BAO_0000221,,,,Hippocampus,286,10000000.0,9995,,1,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615725,,H,BAO_0000221,,,,Hippocampus,287,10000000.0,9995,,1,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615726,,H,BAO_0000221,,,,Hippocampus,288,10000000.0,9995,,1,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615727,,H,BAO_0000218,,,,,289,,16394,,1,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,Autocuration,8,,10576
,CHEMBL615728,10141.0,D,BAO_0000019,Cavia porcellus,,,,290,,11574,,1,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Intermediate,9,,105570
,CHEMBL857971,,H,BAO_0000219,,,,,291,,15779,,1,449.0,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,279
,CHEMBL615729,,H,BAO_0000357,,,,,292,,15363,,1,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL615730,10116.0,D,BAO_0000019,Rattus norvegicus,,,,293,,15363,,1,,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Expert,9,,12687
,CHEMBL615731,,H,BAO_0000019,,,,,294,,15329,,1,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,Expert,8,,12687
,CHEMBL615732,,H,BAO_0000019,,,,,295,,15329,,1,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,Expert,8,,12687
,CHEMBL615733,,H,BAO_0000019,,,,,296,,15329,,1,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,Expert,8,,12687
,CHEMBL615734,,H,BAO_0000019,,,,,297,,15329,,1,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,Expert,8,,12687
,CHEMBL615735,,H,BAO_0000019,,,,,298,,15329,,1,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,Autocuration,8,,12687
,CHEMBL615736,,H,BAO_0000019,,,,,299,,15329,,1,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,Expert,8,,12687
,CHEMBL615737,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,300,2116.0,273,,1,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL615738,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,301,2116.0,273,,1,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Intermediate,9,,20033
,CHEMBL615739,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,302,2116.0,273,,1,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL615278,,H,BAO_0000357,,,,,303,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,Autocuration,8,,10623
,CHEMBL615279,10116.0,D,BAO_0000019,Rattus norvegicus,,,,304,,1317,,1,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Expert,9,,10623
,CHEMBL615280,,H,BAO_0000357,,,,,305,,12409,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,Expert,8,,168
,CHEMBL615281,9031.0,U,BAO_0000019,Gallus gallus,,,,306,,11126,,1,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Autocuration,0,,22226
,CHEMBL615282,9606.0,U,BAO_0000019,Homo sapiens,,,,307,,11126,,1,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Autocuration,0,,22226
,CHEMBL615283,9606.0,U,BAO_0000019,Homo sapiens,,,,308,,11126,,1,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Autocuration,0,,22226
,CHEMBL615284,9606.0,N,BAO_0000219,Homo sapiens,,,,309,,11126,,1,649.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,HL-60,Autocuration,1,,80156
,CHEMBL615285,9606.0,U,BAO_0000019,Homo sapiens,,,,310,,11126,,1,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Autocuration,0,,22226
,CHEMBL615286,9606.0,U,BAO_0000019,Homo sapiens,,,,311,,11126,,1,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Autocuration,0,,22226
,CHEMBL615287,9606.0,D,BAO_0000219,Homo sapiens,,,,312,,17807,,1,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,Oocytes,Autocuration,7,,104703
,CHEMBL615288,,S,BAO_0000220,,,,,313,,16575,,1,,Chymotryptic inhibitory activity against 26S proteasome,F,,,Intermediate,2,,100256
,CHEMBL615289,,S,BAO_0000220,,,,,314,,15407,,1,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,Intermediate,2,,100256
,CHEMBL615290,9606.0,N,BAO_0000219,Homo sapiens,,,,315,,10797,,1,478.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL884522,9606.0,N,BAO_0000219,Homo sapiens,,,,316,,10797,,1,478.0,In vitro inhibition of 2780/S ovarian cancer cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL615291,9606.0,U,BAO_0000019,Homo sapiens,,,,317,,3469,,1,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Autocuration,0,,22226
,CHEMBL615292,,M,BAO_0000225,,,,,318,,16037,,1,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,Intermediate,3,,22222
,CHEMBL615293,,M,BAO_0000225,,,,,319,,16037,,1,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,Intermediate,3,,22222
,CHEMBL615294,,M,BAO_0000225,,,,,320,,16037,,1,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,Intermediate,3,,22222
,CHEMBL615295,,M,BAO_0000225,,,,,321,,16037,,1,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,Intermediate,3,,22222
,CHEMBL825021,9606.0,U,BAO_0000019,Homo sapiens,,,,322,,16524,,1,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Autocuration,0,,22226
,CHEMBL615296,9606.0,U,BAO_0000019,Homo sapiens,,,,323,,16524,,1,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Autocuration,0,,22226
,CHEMBL615297,9606.0,U,BAO_0000019,Homo sapiens,,,,324,,16524,,1,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Autocuration,0,,22226
,CHEMBL615298,10029.0,U,BAO_0000019,Cricetulus griseus,,,,325,,16758,,1,,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Autocuration,0,,22226
,CHEMBL615299,10029.0,U,BAO_0000019,Cricetulus griseus,,,,326,,16758,,1,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Autocuration,0,,22226
,CHEMBL615300,10029.0,U,BAO_0000019,Cricetulus griseus,,,,327,,16758,,1,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Autocuration,0,,22226
,CHEMBL615301,,H,BAO_0000357,,,,,328,,14360,,1,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,Autocuration,8,,241
,CHEMBL615302,9606.0,D,BAO_0000357,Homo sapiens,,,,329,,14360,,1,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Expert,9,,241
,CHEMBL615303,10116.0,U,BAO_0000019,Rattus norvegicus,,,,330,,9964,,1,,Selectivity ratio of ID50 in liver and heart,B,,,Autocuration,0,,22226
,CHEMBL615304,,H,BAO_0000019,,,,,331,,9964,,1,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,Autocuration,8,,12132
,CHEMBL615305,,H,BAO_0000019,,,,,332,,9964,,1,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,Autocuration,8,,12132
,CHEMBL615306,,H,BAO_0000218,,,,,333,,9964,,1,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,Autocuration,8,,12132
,CHEMBL615307,,H,BAO_0000218,,,,,334,,9964,,1,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,Autocuration,8,,12132
,CHEMBL615308,,H,BAO_0000218,,,,,335,,9964,,1,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,Autocuration,8,,12132
,CHEMBL615309,,H,BAO_0000218,,,,,336,,9964,,1,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,Autocuration,8,,12132
,CHEMBL615310,,U,BAO_0000019,,,,,337,,9964,,1,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,Autocuration,0,,22226
,CHEMBL615311,,H,BAO_0000019,,,,,338,,9964,,1,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,Autocuration,8,,12132
,CHEMBL615312,9606.0,U,BAO_0000019,Homo sapiens,,,,339,,9964,,1,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Autocuration,0,,22226
,CHEMBL615313,,H,BAO_0000019,,,,,340,,9964,,1,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,Autocuration,8,,12132
,CHEMBL615314,,H,BAO_0000019,,,,,341,,9964,,1,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,Autocuration,8,,12132
,CHEMBL615315,,H,BAO_0000019,,,,,342,,9964,,1,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,Autocuration,8,,12132
,CHEMBL615316,10116.0,U,BAO_0000218,Rattus norvegicus,,,,343,,9964,,1,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Autocuration,0,,22226
,CHEMBL615317,,H,BAO_0000218,,,,,344,,9964,,1,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,Autocuration,8,,12132
,CHEMBL615318,,H,BAO_0000218,,,,,345,,9964,,1,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,Autocuration,8,,12132
,CHEMBL615319,10116.0,U,BAO_0000218,Rattus norvegicus,,,,346,,9964,,1,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Autocuration,0,,22226
,CHEMBL615320,,H,BAO_0000019,,,,,347,,9964,,1,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,Autocuration,8,,12132
,CHEMBL615321,,H,BAO_0000019,,,,,348,,9964,,1,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,Autocuration,8,,12132
,CHEMBL615322,10116.0,U,BAO_0000019,Rattus norvegicus,,,,349,,3796,,1,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Autocuration,0,,22226
,CHEMBL615323,562.0,H,BAO_0000357,Escherichia coli,,,,350,,4251,,1,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Autocuration,8,,19690
,CHEMBL615407,562.0,H,BAO_0000357,Escherichia coli,,,,351,,4251,,1,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Autocuration,8,,19690
,CHEMBL857267,562.0,H,BAO_0000357,Escherichia coli,,,,352,,4251,,1,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Autocuration,8,,19690
,CHEMBL615408,562.0,H,BAO_0000357,Escherichia coli,,,,353,,4251,,1,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Autocuration,8,,19690
,CHEMBL615409,,H,BAO_0000357,,,,,354,,166,,1,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,Autocuration,8,,19690
,CHEMBL615410,,H,BAO_0000357,,,,,355,,17861,,1,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,Autocuration,8,,19690
,CHEMBL615411,,H,BAO_0000357,,,,,356,,166,,1,,Inhibition constant against 3-dehydroquinate synthase,B,,,Autocuration,8,,19690
,CHEMBL615412,,H,BAO_0000357,,,,,357,,166,,1,,Association rate constant against 3-dehydroquinate synthase,B,,,Autocuration,8,,19690
,CHEMBL615413,,H,BAO_0000357,,,,,358,,166,,1,,Rate constant against 3-dehydroquinate synthase,B,,,Autocuration,8,,19690
,CHEMBL615414,,U,BAO_0000019,,,,,359,,3548,,1,,Inhibitory activity against fuc-TVII,B,,,Autocuration,0,,22226
Microsomes,CHEMBL615415,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,360,2107.0,9877,,1,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615416,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,361,2107.0,9877,,1,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615417,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,362,2107.0,9877,,1,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615418,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,363,2107.0,9877,,1,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615419,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,364,2107.0,9877,,1,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615420,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,365,2107.0,9877,,1,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615421,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,366,2107.0,9877,,1,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615422,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,367,2107.0,9877,,1,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615423,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,368,2107.0,9877,,1,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Autocuration,9,,12236
Microsomes,CHEMBL872868,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,369,2107.0,9877,,1,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Autocuration,9,,12236
Microsomes,CHEMBL615424,10116.0,D,BAO_0000251,Rattus norvegicus,,,Liver,370,2107.0,9877,,1,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Autocuration,9,,12236
,CHEMBL825022,,H,BAO_0000224,,,,,371,,3003,,1,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,Autocuration,4,,104832
,CHEMBL615425,,H,BAO_0000224,,,,,372,,3003,,1,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,Autocuration,4,,104832
,CHEMBL615426,,H,BAO_0000224,,,,,373,,3003,,1,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,Autocuration,4,,104832
,CHEMBL615427,9606.0,D,BAO_0000357,Homo sapiens,,,,374,,17185,,1,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Expert,9,,10612
,CHEMBL615428,9606.0,N,BAO_0000219,Homo sapiens,,,,375,,6072,,1,844.0,Cytotoxicity on 3677 melanoma cells,F,,3677 melanoma cell line,Intermediate,1,,80616
,CHEMBL615429,9606.0,N,BAO_0000219,Homo sapiens,,,,376,,6072,,1,844.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,3677 melanoma cell line,Intermediate,1,,80616
,CHEMBL615430,10090.0,N,BAO_0000219,Mus musculus,,,,377,,5018,,1,700.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,MC-38,Intermediate,1,,80617
,CHEMBL615431,9606.0,U,BAO_0000019,Homo sapiens,,,,378,,2852,,1,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Intermediate,0,,22226
,CHEMBL615432,,U,BAO_0000218,,,,,379,,8663,,1,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,B16,Autocuration,0,,22226
,CHEMBL615433,,U,BAO_0000218,,,,,380,,8663,,1,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,B16,Autocuration,0,,22226
,CHEMBL615434,12131.0,D,BAO_0000019,Human rhinovirus 14,,,,381,,3245,,1,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Expert,9,,12464
,CHEMBL615435,169066.0,N,BAO_0000218,Human rhinovirus sp.,,,,382,,3245,,1,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Intermediate,1,,50085
,CHEMBL615436,169066.0,N,BAO_0000218,human rhinovirus type 14,,,,383,,3877,,1,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,Intermediate,1,,50679
,CHEMBL615437,169066.0,N,BAO_0000218,human rhinovirus type 14,,,,384,,3877,,1,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,Intermediate,1,,50679
,CHEMBL615438,12131.0,D,BAO_0000019,Human rhinovirus 14,,,,385,,5861,,1,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Expert,9,,12464
,CHEMBL615439,12131.0,D,BAO_0000019,Human rhinovirus 14,,,,386,,5861,,1,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Expert,9,,12464
,CHEMBL615440,12131.0,D,BAO_0000019,Human rhinovirus 14,,,,387,,5861,,1,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Expert,9,,12464
,CHEMBL615441,12131.0,D,BAO_0000019,Human rhinovirus 14,,,,388,,5861,,1,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Expert,9,,12464
,CHEMBL615641,12059.0,N,BAO_0000218,Enterovirus,,,,389,,13748,,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Intermediate,1,,50665
,CHEMBL872065,12059.0,N,BAO_0000218,Enterovirus,,,,390,,13748,,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Intermediate,1,,50665
,CHEMBL825023,12059.0,N,BAO_0000218,Enterovirus,,,,391,,13748,,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Intermediate,1,,50665
,CHEMBL615642,12059.0,N,BAO_0000218,Enterovirus,,,,392,,13748,,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Intermediate,1,,50665
,CHEMBL615643,147712.0,H,BAO_0000357,Human rhinovirus B,,,,393,,13748,,1,,Inhibition of human rhinovirus 3C protease,B,,,Expert,8,,12464
,CHEMBL615644,9606.0,U,BAO_0000019,Homo sapiens,,,,394,,17699,,1,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Autocuration,0,,22226
,CHEMBL615645,10090.0,N,BAO_0000218,Mus musculus,,,,395,,7145,,1,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,3EM 37,Intermediate,1,,80619
,CHEMBL615646,10090.0,N,BAO_0000218,Mus musculus,,,,396,,7145,,1,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,3EM 37,Intermediate,1,,80619
,CHEMBL615647,10090.0,N,BAO_0000218,Mus musculus,,,,397,,7145,,1,833.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,3EM 37,Intermediate,1,,80619
,CHEMBL615648,10090.0,N,BAO_0000218,Mus musculus,,,,398,,7145,,1,833.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,3EM 37,Intermediate,1,,80619
,CHEMBL615649,10090.0,N,BAO_0000218,Mus musculus,,,,399,,7145,,1,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,3EM 37,Intermediate,1,,80619
,CHEMBL615650,10090.0,N,BAO_0000218,Mus musculus,,,,400,,7145,,1,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,3EM 37,Intermediate,1,,80619
,CHEMBL615651,10090.0,N,BAO_0000218,Mus musculus,,,,401,,5325,,1,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615652,10090.0,N,BAO_0000218,Mus musculus,,,,402,,5325,,1,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615653,10090.0,N,BAO_0000218,Mus musculus,,,,403,,5325,,1,847.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,3LL cell line,Expert,1,,80620
,CHEMBL615654,10090.0,N,BAO_0000219,Mus musculus,,,,404,,16169,,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615655,10090.0,N,BAO_0000219,Mus musculus,,,,405,,16169,,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL825024,10090.0,N,BAO_0000219,Mus musculus,,,,406,,16169,,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615656,10090.0,N,BAO_0000219,Mus musculus,,,,407,,16169,,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615657,10090.0,N,BAO_0000219,Mus musculus,,,,408,,16169,,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615658,10090.0,N,BAO_0000219,Mus musculus,,,,409,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615659,10090.0,N,BAO_0000219,Mus musculus,,,,410,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615660,10090.0,N,BAO_0000219,Mus musculus,,,,411,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615661,10090.0,N,BAO_0000219,Mus musculus,,,,412,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615662,10090.0,N,BAO_0000219,Mus musculus,,,,413,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615663,10090.0,N,BAO_0000219,Mus musculus,,,,414,,16169,,1,847.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615664,10090.0,N,BAO_0000219,Mus musculus,,,,415,,16169,,1,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615665,10090.0,N,BAO_0000219,Mus musculus,,,,416,,16169,,1,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615666,10090.0,N,BAO_0000219,Mus musculus,,,,417,,16169,,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615667,10090.0,N,BAO_0000219,Mus musculus,,,,418,,16169,,1,847.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615668,10090.0,N,BAO_0000219,Mus musculus,,,,419,,16169,,1,847.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615669,10090.0,N,BAO_0000219,Mus musculus,,,,420,,16169,,1,847.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615670,10090.0,N,BAO_0000219,Mus musculus,,,,421,,16169,,1,847.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL836739,10090.0,N,BAO_0000219,Mus musculus,,,,422,,16169,,1,847.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615671,10090.0,N,BAO_0000219,Mus musculus,,,,423,,16169,,1,847.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615672,10090.0,N,BAO_0000219,Mus musculus,,,,424,,16169,,1,847.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615791,10090.0,N,BAO_0000219,Mus musculus,,,,425,,16169,,1,847.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615792,10090.0,N,BAO_0000219,Mus musculus,,,,426,,16169,,1,847.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615793,10090.0,N,BAO_0000219,Mus musculus,,,,427,,16169,,1,847.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615794,10090.0,N,BAO_0000219,Mus musculus,,,,428,,16169,,1,847.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615795,10090.0,N,BAO_0000219,Mus musculus,,,,429,,16169,,1,847.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,Intermediate,1,,80620
,CHEMBL615590,9606.0,N,BAO_0000219,Homo sapiens,,,,430,,15547,,1,971.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,3LLD122,Intermediate,1,,80621
,CHEMBL615591,,U,BAO_0000218,,,,,431,,8663,,1,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,Autocuration,0,,22226
,CHEMBL615592,,U,BAO_0000218,,,,,432,,8663,,1,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,Autocuration,0,,22226
,CHEMBL615593,,U,BAO_0000218,,,,,433,,8663,,1,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,Autocuration,0,,22226
,CHEMBL615594,,U,BAO_0000218,,,,,434,,8663,,1,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,Autocuration,0,,22226
,CHEMBL615595,10090.0,N,BAO_0000219,Mus musculus,,,,435,,4504,,1,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615596,10090.0,N,BAO_0000219,Mus musculus,,,,436,,4504,,1,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615597,,H,BAO_0000219,,,,,437,,12695,,1,723.0,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,NIH3T3,Expert,8,,11169
,CHEMBL615598,10090.0,N,BAO_0000219,Mus musculus,,,,438,,12695,,1,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615599,10090.0,N,BAO_0000219,Mus musculus,,,,439,,12695,,1,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615600,10090.0,N,BAO_0000219,Mus musculus,,,,440,,17642,,1,723.0,Effective dose against murine 3T3 fibroblasts cells,F,,NIH3T3,Expert,1,,80951
,CHEMBL615601,10090.0,N,BAO_0000219,Mus musculus,,,,441,,17642,,1,723.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,NIH3T3,Expert,1,,80951
,CHEMBL615602,10090.0,N,BAO_0000219,Mus musculus,,,,442,,12340,,1,723.0,Cytotoxic effect on 3T3 cells,F,,NIH3T3,Expert,1,,80951
,CHEMBL615603,10090.0,N,BAO_0000219,Mus musculus,,,,443,,12340,,1,723.0,Cytotoxic effect on 3T3 cells,F,,NIH3T3,Expert,1,,80951
,CHEMBL615604,10090.0,N,BAO_0000219,Mus musculus,,,,444,,12716,,1,723.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615605,10090.0,N,BAO_0000219,Mus musculus,,,,445,,6277,,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615606,10090.0,N,BAO_0000219,Mus musculus,,,,446,,6277,,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL884526,10090.0,N,BAO_0000219,Mus musculus,,,,447,,6277,,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,NIH3T3,Expert,1,,80951
,CHEMBL615607,10090.0,N,BAO_0000219,Mus musculus,,,,448,,6277,,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,NIH3T3,Expert,1,,80951
,CHEMBL615608,10090.0,N,BAO_0000219,Mus musculus,,,,449,,6277,,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615609,10090.0,N,BAO_0000219,Mus musculus,,,,450,,6277,,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,NIH3T3,Expert,1,,80951
,CHEMBL615682,10090.0,N,BAO_0000219,Mus musculus,,,,451,,6277,,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,NIH3T3,Expert,1,,80951
,CHEMBL615683,10090.0,N,BAO_0000219,Mus musculus,,,,452,,6277,,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615684,10090.0,N,BAO_0000218,Mus musculus,,,,453,,17780,,1,723.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,NIH3T3,Expert,1,,80951
,CHEMBL615685,10090.0,D,BAO_0000219,Mus musculus,,,,454,,12751,,1,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Autocuration,7,,104860
,CHEMBL615686,10090.0,N,BAO_0000219,Mus musculus,,,,455,,12380,,1,723.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,NIH3T3,Expert,1,,80951
,CHEMBL615687,10090.0,N,BAO_0000219,Mus musculus,,,,456,,14892,,1,723.0,Inhibitory activity against 3T3 cell line,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL884523,10090.0,N,BAO_0000219,Mus musculus,,,,457,,12695,,1,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615688,,H,BAO_0000019,,,,,458,,12695,,1,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,Expert,8,,11169
,CHEMBL615689,10090.0,N,BAO_0000219,Mus musculus,,,,459,,12695,,1,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615690,10090.0,N,BAO_0000219,Mus musculus,,,,460,,12695,,1,723.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615691,,H,BAO_0000019,,,,,461,,12695,,1,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,Expert,8,,11169
,CHEMBL615692,,H,BAO_0000019,,,,,462,,12695,,1,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,Expert,8,,11169
,CHEMBL615693,10090.0,N,BAO_0000219,Mus musculus,,,,463,,6277,,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615324,10090.0,N,BAO_0000219,Mus musculus,,,,464,,6277,,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,NIH3T3,Expert,1,,80951
,CHEMBL615325,9606.0,D,BAO_0000219,Homo sapiens,,,,465,,4959,,1,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,NIH3T3,Expert,9,,9
,CHEMBL615490,9606.0,D,BAO_0000219,Homo sapiens,,,,466,,4959,,1,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,NIH3T3,Expert,9,,9
,CHEMBL615491,9606.0,D,BAO_0000219,Homo sapiens,,,,467,,4959,,1,723.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,NIH3T3,Expert,9,,188
,CHEMBL615492,9606.0,D,BAO_0000219,Homo sapiens,,,,468,,4959,,1,723.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,NIH3T3,Expert,9,,188
,CHEMBL615493,10090.0,N,BAO_0000219,Mus musculus,,,,469,,12082,,1,723.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615494,10090.0,N,BAO_0000219,Mus musculus,,,,470,,12082,,1,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615495,10090.0,N,BAO_0000219,Mus musculus,,,,471,,12082,,1,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615496,10090.0,N,BAO_0000219,Mus musculus,,,,472,,12082,,1,723.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615497,10090.0,N,BAO_0000219,Mus musculus,,,,473,,2643,,1,723.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615498,10090.0,N,BAO_0000219,Mus musculus,,,,474,,11926,,1,723.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,NIH3T3,Expert,1,,80951
,CHEMBL615499,10090.0,N,BAO_0000219,Mus musculus,,,,475,,15204,,1,723.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,NIH3T3,Intermediate,1,,80951
,CHEMBL835522,10090.0,N,BAO_0000219,Mus musculus,,,,476,,15992,,1,723.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,NIH3T3,Expert,1,,80951
,CHEMBL615500,10090.0,N,BAO_0000219,Mus musculus,,,,477,,16279,,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615501,10090.0,N,BAO_0000219,Mus musculus,,,,478,,16279,,1,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615502,10090.0,N,BAO_0000219,Mus musculus,,,,479,,16279,,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615503,10090.0,N,BAO_0000219,Mus musculus,,,,480,,16279,,1,723.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615504,10090.0,N,BAO_0000219,Mus musculus,,,,481,,16279,,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615505,10090.0,N,BAO_0000219,Mus musculus,,,,482,,16279,,1,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615506,10090.0,N,BAO_0000219,Mus musculus,,,,483,,12831,,1,723.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,NIH3T3,Expert,1,,80951
,CHEMBL615507,10090.0,N,BAO_0000219,Mus musculus,,,,484,,13497,,1,723.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,NIH3T3,Intermediate,1,,80951
,CHEMBL615508,,N,BAO_0000218,,,,,485,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615509,10090.0,N,BAO_0000219,Mus musculus,,,,486,,13618,,1,620.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615510,10090.0,N,BAO_0000219,Mus musculus,,,,487,,11902,,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615511,10090.0,N,BAO_0000219,Mus musculus,,,,488,,11902,,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615512,10090.0,N,BAO_0000219,Mus musculus,,,,489,,11902,,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615513,10090.0,N,BAO_0000218,Mus musculus,,,,490,,14840,,1,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615514,10090.0,N,BAO_0000218,Mus musculus,,,,491,,14840,,1,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615515,,N,BAO_0000219,,,,,492,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615516,,N,BAO_0000219,,,,,493,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615517,,N,BAO_0000219,,,,,494,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615518,,N,BAO_0000219,,,,,495,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615519,,N,BAO_0000219,,,,,496,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615520,,N,BAO_0000218,,,,,497,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615521,,N,BAO_0000218,,,,,498,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615522,,N,BAO_0000218,,,,,499,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615523,,N,BAO_0000218,,,,,500,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615524,,N,BAO_0000218,,,,,501,,13715,,1,620.0,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615525,,N,BAO_0000218,,,,,502,,13715,,1,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615526,,N,BAO_0000218,,,,,503,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615527,,N,BAO_0000218,,,,,504,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615528,,N,BAO_0000218,,,,,505,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615529,,N,BAO_0000218,,,,,506,,13715,,1,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615530,,N,BAO_0000218,,,,,507,,13715,,1,620.0,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615531,,N,BAO_0000218,,,,,508,,13715,,1,620.0,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615532,,N,BAO_0000219,,,,,509,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615533,,N,BAO_0000219,,,,,510,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615534,,N,BAO_0000219,,,,,511,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615535,,N,BAO_0000218,,,,,512,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615536,,N,BAO_0000218,,,,,513,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615537,,N,BAO_0000218,,,,,514,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615538,,N,BAO_0000218,,,,,515,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL836166,,N,BAO_0000218,,,,,516,,13715,,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615539,,H,BAO_0000219,,,,,517,,6411,,1,620.0,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,3T3-L1,Expert,8,,11214
,CHEMBL615540,10090.0,N,BAO_0000219,Mus musculus,,,,518,,6411,,1,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615541,,H,BAO_0000219,,,,,519,,6411,,1,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,3T3-L1,Expert,8,,11214
,CHEMBL615542,10090.0,N,BAO_0000219,Mus musculus,,,,520,,3966,,1,620.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,3T3-L1,Expert,1,,80006
,CHEMBL615543,10090.0,N,BAO_0000219,Mus musculus,,,,521,,3966,,1,620.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,3T3-L1,Intermediate,1,,80006
,CHEMBL615544,10090.0,N,BAO_0000219,Mus musculus,,,,522,,15556,,1,620.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,3T3-L1,Expert,1,,80006
,CHEMBL615545,10090.0,N,BAO_0000219,Mus musculus,,,,523,,5845,,1,620.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,3T3-L1,Expert,1,,80006
,CHEMBL615546,10090.0,N,BAO_0000219,Mus musculus,,,,524,,14422,,1,620.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,3T3-L1,Expert,1,,80006
,CHEMBL615547,10090.0,N,BAO_0000219,Mus musculus,,,,525,,5845,,1,620.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,3T3-L1,Expert,1,,80006
,CHEMBL615548,10090.0,N,BAO_0000219,Mus musculus,,,,526,,14508,,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615549,10090.0,N,BAO_0000219,Mus musculus,,,,527,,14508,,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615550,10090.0,N,BAO_0000219,Mus musculus,,,,528,,14508,,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,3T3-L1,Expert,1,,80006
,CHEMBL615551,10116.0,N,BAO_0000219,Rattus norvegicus,,,,529,,6349,,1,1118.0,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,3Y1 cell line,Intermediate,1,,80622
,CHEMBL615552,10116.0,N,BAO_0000219,Rattus norvegicus,,,,530,,15899,,1,1118.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,3Y1 cell line,Expert,1,,80622
,CHEMBL615553,10116.0,N,BAO_0000219,Rattus norvegicus,,,,531,,15899,,1,1118.0,Cytotoxicity in 3Y1 cells.,F,,3Y1 cell line,Expert,1,,80622
,CHEMBL615554,10116.0,N,BAO_0000219,Rattus norvegicus,,,,532,,15899,,1,1118.0,Cytostatic effect in 3Y1 cells.,F,,3Y1 cell line,Expert,1,,80622
,CHEMBL615555,10116.0,N,BAO_0000219,Rattus norvegicus,,,,533,,15899,,1,1118.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,3Y1 cell line,Intermediate,1,,80622
,CHEMBL615556,10116.0,N,BAO_0000219,Rattus norvegicus,,,,534,,17038,,1,1118.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,3Y1 cell line,Expert,1,,80622
,CHEMBL615557,,U,BAO_0000019,,,,,535,,12421,,1,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,Autocuration,0,,22226
,CHEMBL615558,,U,BAO_0000019,,,,,536,,12947,,1,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,Autocuration,0,,22226
,CHEMBL872066,,U,BAO_0000019,,,,,537,,12947,,1,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,Autocuration,0,,22226
,CHEMBL615559,9823.0,D,BAO_0000019,Sus scrofa,,,,538,,4896,,1,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Expert,9,,11607
,CHEMBL615560,,H,BAO_0000019,,,,,539,,6148,,1,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,Autocuration,8,,11607
,CHEMBL615561,,H,BAO_0000019,,,,,540,,16432,,1,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,Autocuration,8,,11607
,CHEMBL857062,,H,BAO_0000019,,,,,541,,4978,,1,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,Expert,8,,11607
,CHEMBL615562,,H,BAO_0000019,,,,,542,,4978,,1,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,Expert,8,,11607
,CHEMBL615563,,H,BAO_0000019,,,,,543,,3723,,1,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,Autocuration,8,,11607
,CHEMBL615564,,H,BAO_0000357,,,,,544,,3518,,1,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,Autocuration,8,,11607
,CHEMBL615565,,H,BAO_0000019,,,,,545,,4164,,1,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,Autocuration,8,,11607
,CHEMBL615566,,H,BAO_0000019,,,,,546,,3518,,1,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,Autocuration,8,,11607
,CHEMBL615567,9823.0,D,BAO_0000019,Sus scrofa,,,,547,,4164,,1,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Expert,9,,11607
,CHEMBL615568,,H,BAO_0000019,,,,,548,,3518,,1,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,Autocuration,8,,11607
,CHEMBL615569,,H,BAO_0000357,,,,,549,,3518,,1,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,Autocuration,8,,11607
,CHEMBL615570,,H,BAO_0000019,,,,,550,,4978,,1,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,Autocuration,8,,11607
,CHEMBL615571,,H,BAO_0000019,,,,,551,,4978,,1,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,Autocuration,8,,11607
,CHEMBL615572,,H,BAO_0000224,,,,,552,,6455,,1,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,Autocuration,4,,104733
,CHEMBL615573,,U,BAO_0000019,,,,,553,,2222,,1,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,0,,22226
,CHEMBL615574,,U,BAO_0000019,,,,,554,,13020,,1,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,Autocuration,0,,22226
,CHEMBL615575,,U,BAO_0000019,,,,,555,,13021,,1,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,Autocuration,0,,22226
,CHEMBL615576,,H,BAO_0000357,,,,,556,,14532,,1,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,Autocuration,8,,10619
,CHEMBL615577,,H,BAO_0000357,,,,,557,,14118,,1,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,10619
,CHEMBL615578,,H,BAO_0000221,,,,Hippocampus,558,10000000.0,11884,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL615579,,H,BAO_0000357,,,,,559,,13969,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,51
,CHEMBL615580,,H,BAO_0000357,,,,,560,,13392,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL615581,,H,BAO_0000019,,,,,561,,14430,,1,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,Expert,8,,51
,CHEMBL615582,,H,BAO_0000221,,,,Hippocampus,562,10000000.0,12248,,1,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615583,,H,BAO_0000221,,,,Hippocampus,563,10000000.0,12249,,1,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615584,,H,BAO_0000221,,,,Hippocampus,564,10000000.0,9995,,1,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL833691,,H,BAO_0000221,,,,Hippocampus,565,10000000.0,9995,,1,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615585,,H,BAO_0000221,,,,Hippocampus,566,10000000.0,9995,,1,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615586,,H,BAO_0000221,,,,Hippocampus,567,10000000.0,9995,,1,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL884524,,H,BAO_0000221,,,,Hippocampus,568,10000000.0,9995,,1,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615587,,H,BAO_0000221,,,,Hippocampus,569,10000000.0,12249,,1,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615588,,H,BAO_0000221,,,,Hippocampus,570,10000000.0,11799,,1,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,Autocuration,8,,51
Membranes,CHEMBL615589,10116.0,D,BAO_0000249,Rattus norvegicus,,,,571,,14331,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Expert,9,,10576
,CHEMBL615442,9913.0,H,BAO_0000221,Bos taurus,,,Hippocampus,572,10000000.0,11884,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Expert,8,,51
,CHEMBL615443,,H,BAO_0000221,,,,Hippocampus,573,10000000.0,14331,,1,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,Autocuration,8,,51
,CHEMBL615444,,H,BAO_0000221,,,,Hippocampus,574,10000000.0,11701,,1,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615445,,H,BAO_0000221,,,,Hippocampus,575,10000000.0,11701,,1,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,Expert,8,,51
,CHEMBL615446,,H,BAO_0000221,,,,Hippocampus,576,10000000.0,12248,,1,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615447,,H,BAO_0000219,,,,,577,,12248,,1,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL615448,,H,BAO_0000221,,,,Hippocampus,578,10000000.0,12248,,1,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,Expert,8,,51
,CHEMBL615449,,H,BAO_0000221,,,,Hippocampus,579,10000000.0,12249,,1,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,Expert,8,,51
,CHEMBL615450,,H,BAO_0000219,,,,,580,,12248,,1,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL615451,,H,BAO_0000221,,,,Hippocampus,581,10000000.0,11799,,1,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,Expert,8,,51
,CHEMBL615452,,H,BAO_0000357,,,,,582,,634,,1,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,Autocuration,8,,51
,CHEMBL615453,,H,BAO_0000221,,,,Hippocampus,583,10000000.0,9995,,1,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615454,,H,BAO_0000221,,,,Hippocampus,584,10000000.0,9995,,1,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615455,,H,BAO_0000221,,,,Hippocampus,585,10000000.0,9995,,1,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615456,,H,BAO_0000221,,,,Hippocampus,586,10000000.0,9995,,1,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615457,,H,BAO_0000221,,,,Hippocampus,587,10000000.0,9995,,1,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL615458,,H,BAO_0000218,,,,Hippocampus,588,10000000.0,12210,,1,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,Expert,8,,51
,CHEMBL615459,,H,BAO_0000221,,,,Hippocampus,589,10000000.0,13311,,1,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Expert,8,,51
,CHEMBL615460,9606.0,D,BAO_0000219,Homo sapiens,,,,590,,2331,,1,449.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,CHO,Expert,9,,51
,CHEMBL615461,10141.0,H,BAO_0000019,Cavia porcellus,,,,591,,1375,,1,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Autocuration,8,,51
,CHEMBL615462,10141.0,H,BAO_0000019,Cavia porcellus,,,,592,,1375,,1,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Autocuration,8,,51
,CHEMBL615463,10141.0,H,BAO_0000221,Cavia porcellus,,,Hippocampus,593,10000000.0,11574,,1,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Autocuration,8,,51
,CHEMBL615464,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,594,2116.0,12867,,1,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Autocuration,8,,51
,CHEMBL615465,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,595,2116.0,12867,,1,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Autocuration,8,,51
,CHEMBL615466,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,596,2116.0,12867,,1,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Autocuration,8,,51
,CHEMBL615467,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,597,2116.0,12867,,1,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Autocuration,8,,51
,CHEMBL615468,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,598,2116.0,12867,,1,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Autocuration,8,,51
,CHEMBL615469,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,599,2116.0,12867,,1,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Autocuration,8,,51
,CHEMBL615470,10141.0,H,BAO_0000357,Cavia porcellus,,,,600,,11574,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615471,10141.0,H,BAO_0000357,Cavia porcellus,,,,601,,13114,,1,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615472,10141.0,H,BAO_0000357,Cavia porcellus,,,,602,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL883242,10141.0,H,BAO_0000221,Cavia porcellus,,,Hippocampus,603,10000000.0,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Autocuration,8,,106
,CHEMBL615473,10141.0,H,BAO_0000221,Cavia porcellus,,,Hippocampus,604,10000000.0,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Autocuration,8,,106
,CHEMBL615474,10029.0,H,BAO_0000218,Cricetulus griseus,,,,605,,11883,,1,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,CHO,Autocuration,8,,11863
,CHEMBL615475,,H,BAO_0000357,,,,,606,,17785,,1,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615476,,H,BAO_0000219,,,,,607,,1558,,1,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,HeLa,Autocuration,8,,51
,CHEMBL615477,,H,BAO_0000219,,,,,608,,1558,,1,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,HeLa,Autocuration,8,,51
,CHEMBL615478,,H,BAO_0000019,,,,,609,,15740,,1,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL615160,,H,BAO_0000219,,,,,610,,17624,,1,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL615161,,H,BAO_0000219,,,,,611,,17624,,1,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,CHO,Expert,8,,51
,CHEMBL615162,,H,BAO_0000219,,,,,612,,17624,,1,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615163,,H,BAO_0000219,,,,,613,,17624,,1,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615164,,H,BAO_0000219,,,,,614,,17624,,1,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Expert,8,,51
,CHEMBL615165,,H,BAO_0000219,,,,,615,,17624,,1,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Expert,8,,51
,CHEMBL615166,,H,BAO_0000219,,,,,616,,17624,,1,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,CHO,Autocuration,8,,51
,CHEMBL615167,,H,BAO_0000219,,,,,617,,14256,,1,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,Autocuration,8,,51
,CHEMBL615168,9606.0,D,BAO_0000219,Homo sapiens,,,,618,,3445,,1,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,HeLa,Expert,9,,51
,CHEMBL615169,9606.0,D,BAO_0000219,Homo sapiens,,,,619,,3445,,1,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,HeLa,Expert,9,,51
,CHEMBL615170,9606.0,D,BAO_0000219,Homo sapiens,,,,620,,17200,,1,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,CHO,Expert,9,,51
,CHEMBL615171,9606.0,D,BAO_0000219,Homo sapiens,,,,621,,17200,,1,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,CHO,Expert,9,,51
,CHEMBL615694,,H,BAO_0000019,,,,,622,,15180,,1,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL615695,,H,BAO_0000019,,,,,623,,15180,,1,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL615696,,H,BAO_0000019,,,,,624,,16026,,1,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,51
,CHEMBL615697,,H,BAO_0000219,,,,,625,,2759,,1,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL859410,9606.0,D,BAO_0000219,Homo sapiens,,,,626,,2759,,1,449.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,CHO,Expert,9,,51
,CHEMBL615841,,H,BAO_0000219,,,,,627,,2759,,1,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,CHO,Autocuration,8,,51
,CHEMBL615842,9606.0,D,BAO_0000219,Homo sapiens,,,,628,,2759,,1,449.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,CHO,Expert,9,,51
,CHEMBL835003,,H,BAO_0000219,,,,,629,,2759,,1,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL615843,,H,BAO_0000219,,,,,630,,2759,,1,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,CHO,Autocuration,8,,51
,CHEMBL615979,9606.0,D,BAO_0000219,Homo sapiens,,,,631,,2759,,1,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,CHO,Expert,9,,51
,CHEMBL615980,,H,BAO_0000219,,,,,632,,2759,,1,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,CHO,Autocuration,8,,51
,CHEMBL615981,9606.0,D,BAO_0000219,Homo sapiens,,,,633,,2759,,1,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,CHO,Expert,9,,51
,CHEMBL615982,9606.0,D,BAO_0000019,Homo sapiens,,,,634,,3445,,1,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Expert,9,,51
,CHEMBL615983,9606.0,D,BAO_0000019,Homo sapiens,,,,635,,5272,,1,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Expert,9,,51
,CHEMBL615984,9606.0,D,BAO_0000019,Homo sapiens,,,,636,,5272,,1,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Expert,9,,51
,CHEMBL615985,9606.0,D,BAO_0000019,Homo sapiens,,,,637,,5272,,1,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Expert,9,,51
,CHEMBL615986,,H,BAO_0000219,,,,,638,,17624,,1,449.0,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,Autocuration,8,,51
,CHEMBL615987,,H,BAO_0000219,,,,,639,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,Autocuration,8,,51
,CHEMBL615988,,H,BAO_0000219,,,,,640,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615989,,H,BAO_0000219,,,,,641,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,Expert,8,,51
,CHEMBL615990,,H,BAO_0000219,,,,,642,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615991,,H,BAO_0000219,,,,,643,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615992,,H,BAO_0000219,,,,,644,,17624,,1,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,Autocuration,8,,51
,CHEMBL615993,,H,BAO_0000219,,,,,645,,17624,,1,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615994,,H,BAO_0000219,,,,,646,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,Expert,8,,51
,CHEMBL615995,,H,BAO_0000219,,,,,647,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615996,,H,BAO_0000219,,,,,648,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,Autocuration,8,,51
,CHEMBL615997,,H,BAO_0000219,,,,,649,,17624,,1,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,CHO,Autocuration,8,,51
,CHEMBL615998,,H,BAO_0000019,,,,,650,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,Autocuration,8,,51
,CHEMBL615999,,H,BAO_0000019,,,,,651,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,Autocuration,8,,51
,CHEMBL616000,,H,BAO_0000019,,,,,652,,6563,,1,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,Autocuration,8,,51
,CHEMBL616001,,H,BAO_0000219,,,,,653,,17296,,1,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,Autocuration,8,,51
,CHEMBL616002,9606.0,D,BAO_0000019,Homo sapiens,,,,654,,6876,,1,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Expert,9,,51
,CHEMBL616003,,H,BAO_0000019,,,,,655,,6876,,1,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,Expert,8,,51
,CHEMBL616004,9606.0,D,BAO_0000019,Homo sapiens,,,,656,,5272,,1,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Expert,9,,51
,CHEMBL616005,9606.0,D,BAO_0000019,Homo sapiens,,,,657,,5272,,1,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Expert,9,,51
,CHEMBL616006,,H,BAO_0000019,,,,,658,,5548,,1,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,Autocuration,8,,51
,CHEMBL616007,,H,BAO_0000019,,,,,659,,5548,,1,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,Expert,8,,51
,CHEMBL616008,,H,BAO_0000019,,,,,660,,5548,,1,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,Autocuration,8,,51
,CHEMBL616009,,H,BAO_0000019,,,,,661,,5548,,1,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,Autocuration,8,,51
,CHEMBL616010,,H,BAO_0000019,,,,,662,,5929,,1,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,Expert,8,,51
,CHEMBL616011,9606.0,D,BAO_0000019,Homo sapiens,,,,663,,5929,,1,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Expert,9,,51
,CHEMBL615740,9606.0,D,BAO_0000019,Homo sapiens,,,,664,,5929,,1,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Expert,9,,51
,CHEMBL615741,,H,BAO_0000019,,,,,665,,16245,,1,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,51
,CHEMBL615742,,H,BAO_0000019,,,,,666,,5640,,1,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,Expert,8,,51
,CHEMBL615743,,H,BAO_0000019,,,,,667,,5640,,1,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,Autocuration,8,,51
,CHEMBL615744,,H,BAO_0000219,,,,,668,,14509,,1,449.0,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,CHO,Autocuration,8,,51
,CHEMBL615745,,H,BAO_0000219,,,,,669,,14509,,1,449.0,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,CHO,Expert,8,,51
,CHEMBL615746,,H,BAO_0000357,,,,,670,,15331,,1,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,51
,CHEMBL615747,,H,BAO_0000357,,,,,671,,15331,,1,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,51
,CHEMBL615748,,H,BAO_0000019,,,,,672,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,Autocuration,8,,51
,CHEMBL615749,,H,BAO_0000019,,,,,673,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,Autocuration,8,,51
,CHEMBL615750,,H,BAO_0000019,,,,,674,,6563,,1,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,Autocuration,8,,51
,CHEMBL616259,9606.0,D,BAO_0000019,Homo sapiens,,,,675,,6563,,1,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Expert,9,,51
,CHEMBL616260,,H,BAO_0000019,,,,,676,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,Autocuration,8,,51
,CHEMBL616261,9606.0,D,BAO_0000019,Homo sapiens,,,,677,,5272,,1,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Expert,9,,51
,CHEMBL616262,9606.0,D,BAO_0000019,Homo sapiens,,,,678,,5272,,1,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Expert,9,,51
,CHEMBL616263,9606.0,D,BAO_0000019,Homo sapiens,,,,679,,5272,,1,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Expert,9,,51
,CHEMBL616264,9606.0,D,BAO_0000019,Homo sapiens,,,,680,,5272,,1,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Expert,9,,51
,CHEMBL616265,9606.0,D,BAO_0000019,Homo sapiens,,,,681,,5272,,1,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Expert,9,,51
,CHEMBL616266,9606.0,D,BAO_0000019,Homo sapiens,,,,682,,5272,,1,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Expert,9,,51
,CHEMBL616267,9606.0,D,BAO_0000019,Homo sapiens,,,,683,,5272,,1,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Expert,9,,51
,CHEMBL616268,9606.0,D,BAO_0000019,Homo sapiens,,,,684,,5272,,1,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Expert,9,,51
,CHEMBL616269,9606.0,D,BAO_0000357,Homo sapiens,,,,685,,16146,,1,,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL884528,,H,BAO_0000219,,,,,686,,17624,,1,449.0,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL616270,,D,BAO_0000219,,,,,687,,13706,,1,722.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,HEK293,Expert,9,,105
,CHEMBL616271,,H,BAO_0000219,,,,,688,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL616272,,H,BAO_0000219,,,,,689,,17624,,1,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL616273,,H,BAO_0000357,,,,,690,,6861,,1,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,Expert,8,,51
,CHEMBL616274,9606.0,D,BAO_0000357,Homo sapiens,,,,691,,17200,,1,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL616275,,H,BAO_0000219,,,,,692,,17624,,1,449.0,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL616276,,H,BAO_0000219,,,,,693,,17624,,1,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL616277,10116.0,U,BAO_0000218,Rattus norvegicus,,,,694,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL616278,10116.0,U,BAO_0000218,Rattus norvegicus,,,,695,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL616279,10116.0,U,BAO_0000218,Rattus norvegicus,,,,696,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL616280,10116.0,U,BAO_0000218,Rattus norvegicus,,,,697,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL616281,10116.0,U,BAO_0000218,Rattus norvegicus,,,,698,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Autocuration,0,,22226
,CHEMBL616282,10116.0,U,BAO_0000218,Rattus norvegicus,,,,699,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL616283,10116.0,U,BAO_0000218,Rattus norvegicus,,,,700,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL616284,10116.0,U,BAO_0000218,Rattus norvegicus,,,,701,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL616285,10116.0,U,BAO_0000218,Rattus norvegicus,,,,702,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL616286,10116.0,U,BAO_0000218,Rattus norvegicus,,,,703,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL616287,10116.0,U,BAO_0000218,Rattus norvegicus,,,,704,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Autocuration,0,,22226
,CHEMBL616288,10116.0,U,BAO_0000218,Rattus norvegicus,,,,705,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL616289,10116.0,U,BAO_0000218,Rattus norvegicus,,,,706,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL615610,10116.0,U,BAO_0000218,Rattus norvegicus,,,,707,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Autocuration,0,,22226
,CHEMBL615611,10116.0,U,BAO_0000218,Rattus norvegicus,,,,708,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL615612,10116.0,U,BAO_0000218,Rattus norvegicus,,,,709,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Autocuration,0,,22226
,CHEMBL615613,10116.0,U,BAO_0000218,Rattus norvegicus,,,,710,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Autocuration,0,,22226
,CHEMBL615614,10116.0,U,BAO_0000218,Rattus norvegicus,,,,711,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Autocuration,0,,22226
,CHEMBL615615,10116.0,U,BAO_0000218,Rattus norvegicus,,,,712,,12058,,1,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Autocuration,0,,22226
,CHEMBL615616,,H,BAO_0000019,,,,,713,,11440,,1,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,Autocuration,4,,105093
,CHEMBL615617,,H,BAO_0000249,,,,Hypothalamus,714,1898.0,6238,,1,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,Autocuration,8,,11923
,CHEMBL615618,,H,BAO_0000019,,,,,715,,10046,,1,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,Autocuration,8,,10577
,CHEMBL615619,,H,BAO_0000019,,,,,716,,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,Autocuration,8,,10577
,CHEMBL615620,,H,BAO_0000019,,,,,717,,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,Expert,8,,10577
,CHEMBL615621,,H,BAO_0000357,,,,,718,,167,,1,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,Autocuration,8,,55
,CHEMBL615622,,H,BAO_0000357,,,,,719,,167,,1,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,Autocuration,8,,55
,CHEMBL615623,,H,BAO_0000019,,,,,720,,11520,,1,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,Autocuration,8,,12166
,CHEMBL615624,,H,BAO_0000019,,,,,721,,11520,,1,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,Autocuration,8,,12166
,CHEMBL615625,,H,BAO_0000019,,,,,722,,11520,,1,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,Autocuration,8,,12166
,CHEMBL767045,,H,BAO_0000019,,,,,723,,11520,,1,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,Autocuration,8,,12166
,CHEMBL615626,10141.0,H,BAO_0000019,Cavia porcellus,,,,724,,135,,1,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Autocuration,8,,55
,CHEMBL615627,10141.0,H,BAO_0000019,Cavia porcellus,,,,725,,135,,1,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Autocuration,8,,55
,CHEMBL615628,10141.0,H,BAO_0000019,Cavia porcellus,,,,726,,11311,,1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Autocuration,8,,55
,CHEMBL615629,10141.0,H,BAO_0000357,Cavia porcellus,,,,727,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Autocuration,8,,55
,CHEMBL615630,9606.0,D,BAO_0000357,Homo sapiens,,,,728,,12281,,1,,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Expert,9,,55
,CHEMBL615631,,H,BAO_0000219,,,,,729,,11311,,1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,55
,CHEMBL615632,,H,BAO_0000218,,,,,730,,12576,,1,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,Autocuration,8,,17087
,CHEMBL615633,,H,BAO_0000357,,,,,731,,12281,,1,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,Autocuration,8,,17087
,CHEMBL615634,,H,BAO_0000218,,,,,732,,12576,,1,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,Autocuration,8,,17087
,CHEMBL615635,9823.0,H,BAO_0000019,Sus scrofa,,,,733,,11089,,1,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Expert,8,,55
,CHEMBL615636,,H,BAO_0000357,,,,,734,,11006,,1,,In vitro inhibition of rat 5-Lipoxygenase,B,,,Expert,8,,12166
,CHEMBL615637,10116.0,D,BAO_0000357,Rattus norvegicus,,,,735,,11481,,1,,Inhibitory activity against 5-Lipoxygenase,B,,,Expert,9,,12166
,CHEMBL615638,,H,BAO_0000219,,,,,736,,10864,,1,702.0,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,RBL-1,Expert,8,,12166
,CHEMBL615639,,H,BAO_0000219,,,,,737,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,Autocuration,8,,12166
,CHEMBL615640,,H,BAO_0000219,,,,,738,,11311,,1,702.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,RBL-1,Autocuration,8,,12166
,CHEMBL615796,,H,BAO_0000019,,,,,739,,11311,,1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,Autocuration,8,,12166
,CHEMBL615845,,H,BAO_0000219,,,,,740,,11311,,1,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,12166
,CHEMBL615846,,H,BAO_0000357,,,,,741,,11006,,1,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,Autocuration,8,,12166
,CHEMBL615847,,H,BAO_0000219,,,,,742,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL615848,,H,BAO_0000357,,,,,743,,11311,,1,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL615849,10116.0,U,BAO_0000019,Rattus norvegicus,,,,744,,11481,,1,,Ratio of IC50 against 5-LO and COX,B,,,Autocuration,0,,22226
,CHEMBL615850,,H,BAO_0000357,,,,,745,,11006,,1,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,Autocuration,8,,12166
,CHEMBL615851,,H,BAO_0000357,,,,,746,,11006,,1,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,Autocuration,8,,12166
,CHEMBL615852,,H,BAO_0000219,,,,,747,,11311,,1,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,Autocuration,8,,12166
,CHEMBL615853,,H,BAO_0000019,,,,,748,,11006,,1,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,Autocuration,8,,12166
,CHEMBL884527,,H,BAO_0000357,,,,Prostate gland,749,2367.0,4288,,1,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,Autocuration,8,,120
,CHEMBL872871,8932.0,U,BAO_0000019,Columba livia,,,,750,,7587,,1,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Autocuration,0,,22226
,CHEMBL615854,8932.0,U,BAO_0000019,Columba livia,,,,751,,7587,,1,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Autocuration,0,,22226
,CHEMBL767046,8932.0,U,BAO_0000019,Columba livia,,,,752,,7587,,1,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Autocuration,0,,22226
,CHEMBL615855,,H,BAO_0000357,,,,,753,,11249,,1,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,Autocuration,8,,10732
,CHEMBL615856,10116.0,D,BAO_0000019,Rattus norvegicus,,,,754,,8003,,1,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Expert,9,,12198
,CHEMBL615857,10116.0,D,BAO_0000019,Rattus norvegicus,,,,755,,8003,,1,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Expert,9,,12198
,CHEMBL615858,10116.0,D,BAO_0000019,Rattus norvegicus,,,,756,,8003,,1,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Expert,9,,12198
,CHEMBL615859,,H,BAO_0000221,,,,Hippocampus,757,10000000.0,12416,,1,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,Expert,8,,10576
,CHEMBL615860,,H,BAO_0000357,,,,,758,,16293,,1,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,Autocuration,8,,51
,CHEMBL615861,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,759,,13047,,1,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Autocuration,0,,22226
,CHEMBL615862,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,760,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Autocuration,0,,22226
,CHEMBL615863,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,761,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Autocuration,0,,22226
,CHEMBL615864,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,762,,13047,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Autocuration,0,,22226
,CHEMBL615865,,H,BAO_0000221,,,,Hippocampus,763,10000000.0,10085,,1,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,Autocuration,4,,104744
,CHEMBL615866,,H,BAO_0000221,,,,Hippocampus,764,10000000.0,10085,,1,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,Autocuration,4,,104744
,CHEMBL615867,,H,BAO_0000221,,,,Hippocampus,765,10000000.0,10085,,1,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,Autocuration,4,,104744
Membranes,CHEMBL615868,,H,BAO_0000249,,,,,766,,9841,,1,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,Autocuration,4,,104744
,CHEMBL615869,10116.0,D,BAO_0000249,Rattus norvegicus,,,,767,,8822,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Autocuration,5,,104744
,CHEMBL615870,10116.0,D,BAO_0000019,Rattus norvegicus,,,,768,,9806,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Autocuration,5,,104744
,CHEMBL615871,10116.0,D,BAO_0000019,Rattus norvegicus,,,,769,,9806,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Autocuration,5,,104744
,CHEMBL615872,,H,BAO_0000224,,,,,770,,8868,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,Autocuration,4,,104744
,CHEMBL833492,,H,BAO_0000221,,,,Hippocampus,771,10000000.0,9036,,1,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,Autocuration,4,,104744
,CHEMBL615873,,H,BAO_0000221,,,,Hippocampus,772,10000000.0,11374,,1,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,Autocuration,4,,104744
,CHEMBL615479,,H,BAO_0000224,,,,,773,,10881,,1,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,Autocuration,4,,104744
,CHEMBL615480,,H,BAO_0000019,,,,,774,,8822,,1,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,Autocuration,4,,104744
,CHEMBL615481,10116.0,D,BAO_0000249,Rattus norvegicus,,,,775,,9806,,1,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Autocuration,5,,104744
,CHEMBL872869,,H,BAO_0000019,,,,,776,,15463,,1,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,Autocuration,4,,104744
,CHEMBL615482,,H,BAO_0000019,,,,,777,,15463,,1,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,Autocuration,4,,104744
,CHEMBL615483,,H,BAO_0000221,,,,Brain,778,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,Autocuration,4,,104744
,CHEMBL615484,,H,BAO_0000221,,,,Brain,779,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,Autocuration,4,,104744
,CHEMBL615485,,H,BAO_0000019,,,,,780,,8569,,1,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,Autocuration,4,,104744
,CHEMBL615486,10116.0,D,BAO_0000224,Rattus norvegicus,,,,781,,10062,,1,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,5,,104744
,CHEMBL615487,,H,BAO_0000224,,,,,782,,4771,,1,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,Autocuration,4,,104744
,CHEMBL615488,,H,BAO_0000224,,,,,783,,10062,,1,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,4,,104744
,CHEMBL615489,,H,BAO_0000224,,,,,784,,10062,,1,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,4,,104744
,CHEMBL615389,,H,BAO_0000224,,,,,785,,10062,,1,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,4,,104744
,CHEMBL615390,,H,BAO_0000019,,,,,786,,15463,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,Autocuration,4,,104744
,CHEMBL615391,,H,BAO_0000019,,,,,787,,15463,,1,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,Autocuration,4,,104744
,CHEMBL615392,,H,BAO_0000224,,,,,788,,9098,,1,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,Autocuration,4,,104744
,CHEMBL615393,10116.0,U,BAO_0000019,Rattus norvegicus,,,,789,,3070,,1,,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Autocuration,0,,22226
,CHEMBL615394,,H,BAO_0000221,,,,Brain,790,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,Autocuration,4,,104744
,CHEMBL615395,,H,BAO_0000221,,,,Brain,791,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,Autocuration,4,,104744
,CHEMBL615396,,H,BAO_0000224,,,,,792,,6398,,1,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,Autocuration,4,,104744
,CHEMBL615397,,H,BAO_0000221,,,,Brain,793,955.0,1344,,1,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,Autocuration,4,,104744
,CHEMBL615398,,H,BAO_0000019,,,,,794,,11963,,1,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,Autocuration,4,,104744
,CHEMBL615399,10116.0,U,BAO_0000019,Rattus norvegicus,,,,795,,8908,,1,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Autocuration,0,,22226
,CHEMBL615400,,H,BAO_0000019,,,,,796,,9098,,1,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,Autocuration,4,,104744
,CHEMBL615401,10116.0,D,BAO_0000019,Rattus norvegicus,,,,797,,8841,,1,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Autocuration,5,,104744
,CHEMBL615402,10116.0,U,BAO_0000019,Rattus norvegicus,,,,798,,8814,,1,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Autocuration,0,,22226
,CHEMBL615403,,H,BAO_0000019,,,,,799,,11752,,1,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,Autocuration,4,,104744
,CHEMBL615404,,H,BAO_0000221,,,,Brain,800,955.0,11642,,1,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,Autocuration,4,,104744
,CHEMBL615781,,H,BAO_0000019,,,,,801,,11642,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,Autocuration,4,,104744
,CHEMBL615782,,H,BAO_0000220,,,,Brain,802,955.0,9231,,1,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,Autocuration,4,,104744
,CHEMBL615783,,H,BAO_0000221,,,,Brain,803,955.0,11351,,1,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,Autocuration,4,,104744
,CHEMBL873481,,U,BAO_0000019,,,,,804,,4639,,1,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,Autocuration,0,,22226
,CHEMBL615784,,U,BAO_0000019,,,,,805,,1205,,1,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,Autocuration,0,,22226
,CHEMBL615785,,H,BAO_0000357,,,,,806,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,Expert,8,,10576
,CHEMBL615786,,H,BAO_0000249,,,,,807,,13241,,1,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,10576
,CHEMBL615787,,H,BAO_0000218,,,,,808,,16245,,1,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,Autocuration,8,,10576
,CHEMBL615788,,H,BAO_0000218,,,,,809,,16245,,1,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,Autocuration,8,,10576
,CHEMBL767044,,H,BAO_0000019,,,,,810,,12438,,1,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,10576
,CHEMBL615789,,H,BAO_0000218,,,,,811,,16245,,1,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,Autocuration,8,,10576
,CHEMBL615790,,H,BAO_0000218,,,,,812,,16245,,1,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,Autocuration,8,,10576
,CHEMBL615813,,H,BAO_0000019,,,,,813,,15740,,1,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,Autocuration,8,,10576
,CHEMBL615814,,H,BAO_0000219,,,,,814,,15535,,1,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,Autocuration,8,,10576
,CHEMBL615815,,H,BAO_0000219,,,,,815,,15535,,1,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,Expert,8,,51
,CHEMBL615816,,H,BAO_0000219,,,,,816,,15535,,1,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,Autocuration,8,,10576
,CHEMBL615817,,H,BAO_0000249,,,,,817,,9888,,1,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,Expert,8,,10576
,CHEMBL615818,,H,BAO_0000221,,,,Hippocampus,818,10000000.0,10085,,1,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL615819,,H,BAO_0000221,,,,Hippocampus,819,10000000.0,10085,,1,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
Membranes,CHEMBL615820,,H,BAO_0000249,,,,,820,,17331,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,Expert,8,,10576
,CHEMBL615821,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,821,10000000.0,10845,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL615822,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,822,10000000.0,10845,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Expert,9,,10576
,CHEMBL615823,,H,BAO_0000221,,,,Hippocampus,823,10000000.0,10845,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615824,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,824,10000000.0,10845,,1,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Expert,9,,10576
,CHEMBL615825,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,825,10000000.0,10845,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Expert,9,,10576
,CHEMBL615826,,H,BAO_0000357,,,,,826,,13730,,1,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615827,,H,BAO_0000249,,,,,827,,13508,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615828,,H,BAO_0000249,,,,Hippocampus,828,10000000.0,13508,,1,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615829,,H,BAO_0000221,,,,Hippocampus,829,10000000.0,12073,,1,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Expert,8,,10576
,CHEMBL615830,,H,BAO_0000221,,,,Hippocampus,830,10000000.0,4671,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL615831,,H,BAO_0000221,,,,Hippocampus,831,10000000.0,13631,,1,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,Expert,8,,10576
,CHEMBL615832,,H,BAO_0000357,,,,,832,,12438,,1,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL615833,,H,BAO_0000019,,,,,833,,10483,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL615834,,H,BAO_0000221,,,,Hippocampus,834,10000000.0,10483,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL615835,,H,BAO_0000249,,,,,835,,12352,,1,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,Intermediate,8,,10576
,CHEMBL615836,,H,BAO_0000249,,,,Hippocampus,836,10000000.0,14732,,1,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,Autocuration,8,,10576
,CHEMBL615837,10116.0,D,BAO_0000019,Rattus norvegicus,,,,837,,11049,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Expert,9,,10576
,CHEMBL615838,10116.0,D,BAO_0000019,Rattus norvegicus,,,,838,,11049,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Expert,9,,10576
,CHEMBL615839,,H,BAO_0000249,,,,,839,,13657,,1,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,Expert,8,,10576
,CHEMBL884525,,H,BAO_0000019,,,,,840,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL615840,,H,BAO_0000249,,,,,841,,2014,,1,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,Autocuration,8,,10576
,CHEMBL615405,,H,BAO_0000221,,,,Hippocampus,842,10000000.0,3086,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Expert,8,,10576
,CHEMBL615406,,H,BAO_0000019,,,,,843,,15854,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,Expert,8,,10576
,CHEMBL615900,,H,BAO_0000221,,,,Hippocampus,844,10000000.0,10922,,1,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,Expert,8,,10576
,CHEMBL615901,,H,BAO_0000221,,,,Hippocampus,845,10000000.0,13346,,1,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,Expert,8,,10576
,CHEMBL615902,,H,BAO_0000357,,,,,846,,15311,,1,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,Expert,8,,10576
,CHEMBL615903,,H,BAO_0000221,,,,Hippocampus,847,10000000.0,10922,,1,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,Autocuration,8,,10576
,CHEMBL615904,,H,BAO_0000357,,,,,848,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,Autocuration,8,,10576
,CHEMBL615905,,H,BAO_0000357,,,,,849,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,Expert,8,,10576
,CHEMBL615906,,H,BAO_0000019,,,,,850,,9742,,1,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,Autocuration,8,,10576
,CHEMBL615907,,H,BAO_0000019,,,,,851,,9742,,1,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,Autocuration,8,,10576
,CHEMBL615908,,H,BAO_0000019,,,,,852,,12304,,1,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,Expert,8,,10576
,CHEMBL615909,,H,BAO_0000221,,,,Hippocampus,853,10000000.0,15789,,1,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL615910,,H,BAO_0000019,,,,,854,,9912,,1,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,Autocuration,8,,10576
,CHEMBL615911,,H,BAO_0000019,,,,,855,,9912,,1,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,Autocuration,8,,10576
,CHEMBL615912,,H,BAO_0000019,,,,,856,,9912,,1,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,Autocuration,8,,10576
,CHEMBL615913,,H,BAO_0000019,,,,,857,,16693,,1,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615914,,H,BAO_0000357,,,,,858,,13276,,1,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL615915,,H,BAO_0000221,,,,Hippocampus,859,10000000.0,12678,,1,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,Autocuration,8,,10576
,CHEMBL615916,,H,BAO_0000357,,,,,860,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,Autocuration,8,,10576
,CHEMBL615917,,H,BAO_0000357,,,,,861,,12443,,1,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,Expert,8,,10576
,CHEMBL615918,,H,BAO_0000357,,,,,862,,13830,,1,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL615919,,H,BAO_0000249,,,,Hippocampus,863,10000000.0,14286,,1,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,Expert,8,,10576
,CHEMBL615920,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,864,10000000.0,14356,,1,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Expert,9,,10576
,CHEMBL615921,,H,BAO_0000357,,,,,865,,15306,,1,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL615922,,H,BAO_0000357,,,,,866,,15306,,1,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,Expert,8,,10576
,CHEMBL881290,10116.0,D,BAO_0000249,Rattus norvegicus,,,,867,,16616,,1,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Expert,9,,10576
,CHEMBL615923,,H,BAO_0000221,,,,Hippocampus,868,10000000.0,3651,,1,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,Autocuration,8,,10576
,CHEMBL615924,,H,BAO_0000221,,,,Hippocampus,869,10000000.0,14331,,1,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,Autocuration,8,,10576
,CHEMBL615925,,H,BAO_0000221,,,,Hippocampus,870,10000000.0,14331,,1,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,Autocuration,8,,10576
,CHEMBL615926,10116.0,D,BAO_0000357,Rattus norvegicus,,,,871,,14178,,1,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL615927,10116.0,D,BAO_0000019,Rattus norvegicus,,,,872,,10639,,1,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL615928,,H,BAO_0000221,,,,Hippocampus,873,10000000.0,12306,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL615929,10116.0,D,BAO_0000357,Rattus norvegicus,,,,874,,1348,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Expert,9,,10576
,CHEMBL615930,,H,BAO_0000221,,,,Hippocampus,875,10000000.0,13605,,1,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL615931,,H,BAO_0000219,,,,,876,,17624,,1,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL615932,,H,BAO_0000219,,,,,877,,17624,,1,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL615933,,H,BAO_0000219,,,,,878,,17624,,1,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL615934,,H,BAO_0000357,,,,,879,,15267,,1,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615935,,H,BAO_0000357,,,,,880,,16532,,1,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,Autocuration,8,,51
,CHEMBL615936,,H,BAO_0000019,,,,,881,,6563,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,Autocuration,8,,51
,CHEMBL615937,,H,BAO_0000219,,,,,882,,4751,,1,449.0,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,CHO,Autocuration,8,,51
,CHEMBL615938,,H,BAO_0000357,,,,,883,,15463,,1,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615797,,H,BAO_0000357,,,,,884,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,Autocuration,8,,51
,CHEMBL615798,,H,BAO_0000357,,,,,885,,5640,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL872870,,H,BAO_0000357,,,,,886,,6563,,1,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,Autocuration,8,,51
,CHEMBL615799,,H,BAO_0000357,,,,,887,,5548,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,Autocuration,8,,51
,CHEMBL615800,,H,BAO_0000357,,,,,888,,6347,,1,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615801,,H,BAO_0000219,,,,,889,,17296,,1,722.0,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,Autocuration,8,,51
,CHEMBL615802,,H,BAO_0000019,,,,,890,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,Autocuration,8,,51
,CHEMBL615803,,H,BAO_0000357,,,,,891,,15740,,1,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,Autocuration,8,,51
,CHEMBL835002,,H,BAO_0000019,,,,,892,,5640,,1,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,Expert,8,,51
,CHEMBL615804,,H,BAO_0000019,,,,,893,,5640,,1,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,Autocuration,8,,51
,CHEMBL615805,,H,BAO_0000219,,,,,894,,17211,,1,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,HeLa,Expert,8,,51
,CHEMBL615806,,H,BAO_0000219,,,,,895,,4751,,1,449.0,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,CHO,Autocuration,8,,51
,CHEMBL615807,9606.0,D,BAO_0000357,Homo sapiens,,,,896,,6491,,1,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Expert,9,,51
,CHEMBL615808,,H,BAO_0000357,,,,,897,,4707,,1,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,Autocuration,8,,51
,CHEMBL615809,9606.0,D,BAO_0000357,Homo sapiens,,,,898,,13910,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL615810,,H,BAO_0000219,,,,,899,,16190,,1,308.0,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,HeLa,Autocuration,8,,51
,CHEMBL615811,,H,BAO_0000357,,,,,900,,16633,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615812,,H,BAO_0000219,,,,,901,,11898,,1,449.0,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL615751,,H,BAO_0000219,,,,,902,,11898,,1,449.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL615752,,H,BAO_0000357,,,,,903,,14331,,1,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615753,,H,BAO_0000219,,,,,904,,17624,,1,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,CHO,Expert,8,,51
,CHEMBL615754,,H,BAO_0000219,,,,,905,,17624,,1,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,CHO,Autocuration,8,,51
,CHEMBL615755,,H,BAO_0000357,,,,,906,,3307,,1,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615756,9606.0,D,BAO_0000219,Homo sapiens,,,,907,,6563,,1,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,CHO,Expert,9,,51
,CHEMBL615757,,H,BAO_0000019,,,,,908,,14165,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615758,,H,BAO_0000357,,,,,909,,5732,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL615759,,H,BAO_0000357,,,,,910,,13366,,1,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,Expert,8,,51
,CHEMBL615760,,H,BAO_0000357,,,,,911,,17626,,1,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615761,,H,BAO_0000219,,,,,912,,6588,,1,308.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,HeLa,Expert,8,,51
,CHEMBL872104,,H,BAO_0000357,,,,,913,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615762,,H,BAO_0000357,,,,,914,,15463,,1,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615763,,H,BAO_0000357,,,,,915,,15463,,1,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615764,,H,BAO_0000357,,,,,916,,14770,,1,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,51
,CHEMBL615765,,H,BAO_0000219,,,,,917,,16245,,1,1167.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,Cell line,Autocuration,8,,51
,CHEMBL615766,,H,BAO_0000019,,,,,918,,16245,,1,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,Autocuration,8,,51
,CHEMBL615767,,H,BAO_0000357,,,,,919,,5548,,1,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615768,,H,BAO_0000357,,,,,920,,5548,,1,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,51
,CHEMBL615769,,H,BAO_0000357,,,,,921,,5548,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615770,,H,BAO_0000357,,,,,922,,6876,,1,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,Expert,8,,51
,CHEMBL615771,,H,BAO_0000357,,,,,923,,2598,,1,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615772,,H,BAO_0000357,,,,,924,,17785,,1,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,Expert,8,,51
,CHEMBL615773,,H,BAO_0000357,,,,,925,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL615774,,H,BAO_0000357,,,,,926,,5929,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,51
,CHEMBL615775,,H,BAO_0000357,,,,,927,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL615776,,H,BAO_0000357,,,,,928,,1558,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL615777,,H,BAO_0000357,,,,,929,,16026,,1,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,51
,CHEMBL615778,,H,BAO_0000219,,,,,930,,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL615779,9606.0,D,BAO_0000357,Homo sapiens,,,,931,,15874,,1,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Expert,9,,51
,CHEMBL615780,,H,BAO_0000357,,,,,932,,15874,,1,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL616298,,H,BAO_0000357,,,,,933,,3935,,1,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616299,,H,BAO_0000357,,,,,934,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616300,,H,BAO_0000219,,,,,935,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,51
,CHEMBL616301,,H,BAO_0000219,,,,,936,,13729,,1,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,CHO-K1,Expert,8,,51
,CHEMBL616302,,H,BAO_0000019,,,,,937,,15413,,1,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616117,,H,BAO_0000019,,,,,938,,15413,,1,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,Autocuration,8,,51
,CHEMBL616118,,H,BAO_0000019,,,,,939,,15413,,1,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,Autocuration,8,,51
,CHEMBL616119,,H,BAO_0000019,,,,,940,,15413,,1,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,Autocuration,8,,51
,CHEMBL616120,9606.0,D,BAO_0000219,Homo sapiens,,,,941,,3445,,1,308.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,HeLa,Expert,9,,51
,CHEMBL616121,,H,BAO_0000357,,,,,942,,15740,,1,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616122,,H,BAO_0000357,,,,,943,,15740,,1,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,Autocuration,8,,51
,CHEMBL616123,,H,BAO_0000357,,,,,944,,17626,,1,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616124,9606.0,D,BAO_0000357,Homo sapiens,,,,945,,4234,,1,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL616125,,H,BAO_0000357,,,,,946,,5640,,1,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,Expert,8,,51
,CHEMBL616126,10116.0,H,BAO_0000357,Rattus norvegicus,,,,947,,5272,,1,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Expert,8,,51
,CHEMBL616127,,H,BAO_0000219,,,,,948,,4622,,1,449.0,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,CHO,Autocuration,8,,51
,CHEMBL616128,,H,BAO_0000019,,,,,949,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL616129,,H,BAO_0000357,,,,,950,,3025,,1,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,Autocuration,8,,51
,CHEMBL616130,,H,BAO_0000357,,,,,951,,15315,,1,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL616131,,H,BAO_0000357,,,,,952,,15267,,1,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,Autocuration,8,,51
,CHEMBL616132,,H,BAO_0000219,,,,,953,,17158,,1,308.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,HeLa,Autocuration,8,,51
,CHEMBL616133,9606.0,D,BAO_0000219,Homo sapiens,,,,954,,14214,,1,308.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,HeLa,Expert,9,,51
,CHEMBL616134,,H,BAO_0000357,,,,,955,,17133,,1,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL616135,,H,BAO_0000357,,,,,956,,16532,,1,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,Autocuration,8,,51
,CHEMBL616136,9606.0,D,BAO_0000357,Homo sapiens,,,,957,,2391,,1,,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Expert,9,,51
,CHEMBL616137,,H,BAO_0000019,,,,,958,,14447,,1,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,Autocuration,8,,51
,CHEMBL872105,,H,BAO_0000019,,,,,959,,14447,,1,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,Autocuration,8,,51
,CHEMBL616138,,H,BAO_0000357,,,,,960,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,Autocuration,8,,51
,CHEMBL616139,9606.0,D,BAO_0000357,Homo sapiens,,,,961,,13051,,1,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL616140,,H,BAO_0000019,,,,,962,,16026,,1,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,Autocuration,8,,51
,CHEMBL616141,,H,BAO_0000019,,,,,963,,17085,,1,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,Expert,8,,51
,CHEMBL616142,,H,BAO_0000357,,,,,964,,17133,,1,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL616143,,H,BAO_0000357,,,,,965,,17133,,1,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,Autocuration,8,,51
,CHEMBL616144,,H,BAO_0000219,,,,,966,,17211,,1,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,Autocuration,8,,51
,CHEMBL616145,,H,BAO_0000219,,,,,967,,17211,,1,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,HeLa,Autocuration,8,,51
,CHEMBL616012,,H,BAO_0000219,,,,,968,,17211,,1,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,Autocuration,8,,51
,CHEMBL616013,,H,BAO_0000219,,,,,969,,17211,,1,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,Autocuration,8,,51
,CHEMBL616014,,H,BAO_0000019,,,,,970,,16394,,1,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,Autocuration,8,,51
,CHEMBL616015,,H,BAO_0000019,,,,,971,,16394,,1,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,Autocuration,8,,51
,CHEMBL616016,,H,BAO_0000019,,,,,972,,16394,,1,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,Autocuration,8,,51
,CHEMBL616017,,H,BAO_0000218,,,,,973,,16394,,1,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,Autocuration,8,,51
,CHEMBL616018,,H,BAO_0000019,,,,,974,,16394,,1,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,Autocuration,8,,51
,CHEMBL616019,,H,BAO_0000019,,,,,975,,15740,,1,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,Autocuration,8,,51
,CHEMBL616020,,H,BAO_0000019,,,,,976,,15740,,1,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,Autocuration,8,,51
,CHEMBL858018,,H,BAO_0000357,,,,,977,,15740,,1,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616021,,H,BAO_0000219,,,,,978,,17296,,1,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,Autocuration,8,,51
,CHEMBL616022,,H,BAO_0000019,,,,,979,,5640,,1,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,Expert,8,,51
,CHEMBL616023,,H,BAO_0000019,,,,,980,,5640,,1,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,Autocuration,8,,51
,CHEMBL616024,,H,BAO_0000019,,,,,981,,5640,,1,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,Autocuration,8,,51
,CHEMBL616025,,H,BAO_0000019,,,,,982,,5640,,1,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,Autocuration,8,,51
,CHEMBL616026,,H,BAO_0000219,,,,,983,,2759,,1,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,Autocuration,8,,51
,CHEMBL616027,,H,BAO_0000019,,,,,984,,16394,,1,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,Autocuration,8,,51
,CHEMBL616028,9606.0,D,BAO_0000019,Homo sapiens,,,,985,,16394,,1,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Expert,9,,51
,CHEMBL616029,9606.0,D,BAO_0000019,Homo sapiens,,,,986,,3445,,1,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Expert,9,,51
,CHEMBL616030,,H,BAO_0000219,,,,,987,,4316,,1,449.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,CHO,Expert,8,,51
,CHEMBL616031,,H,BAO_0000019,,,,,988,,4316,,1,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,Expert,8,,51
,CHEMBL616032,9606.0,D,BAO_0000019,Homo sapiens,,,,989,,15180,,1,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Expert,9,,51
,CHEMBL616033,9606.0,D,BAO_0000019,Homo sapiens,,,,990,,15180,,1,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Expert,9,,51
,CHEMBL616034,,H,BAO_0000019,,,,,991,,15042,,1,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,Autocuration,8,,51
,CHEMBL616035,,H,BAO_0000019,,,,,992,,15042,,1,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,Autocuration,8,,51
,CHEMBL616036,,H,BAO_0000019,,,,,993,,15042,,1,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL616037,,H,BAO_0000019,,,,,994,,15042,,1,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,Autocuration,8,,51
,CHEMBL616038,,H,BAO_0000019,,,,,995,,15042,,1,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,Autocuration,8,,51
,CHEMBL616039,,H,BAO_0000019,,,,,996,,15042,,1,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,Autocuration,8,,51
,CHEMBL616040,,H,BAO_0000019,,,,,997,,15042,,1,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL616041,9606.0,D,BAO_0000219,Homo sapiens,,,,998,,15180,,1,308.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,Expert,9,,51
,CHEMBL616042,9606.0,D,BAO_0000219,Homo sapiens,,,,999,,15180,,1,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,Expert,9,,51
,CHEMBL616043,9606.0,D,BAO_0000219,Homo sapiens,,,,1000,,15180,,1,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,Expert,9,,51
,CHEMBL616044,,H,BAO_0000019,,,,,1001,,16245,,1,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,51
,CHEMBL616045,,H,BAO_0000019,,,,,1002,,16026,,1,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,51
,CHEMBL616046,,H,BAO_0000219,,,,,1003,,17296,,1,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,Autocuration,8,,51
,CHEMBL616047,,H,BAO_0000219,,,,,1004,,2759,,1,449.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,CHO,Autocuration,8,,51
,CHEMBL616048,,H,BAO_0000219,,,,,1005,,2759,,1,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,CHO,Autocuration,8,,51
,CHEMBL616049,9606.0,D,BAO_0000219,Homo sapiens,,,,1006,,2759,,1,449.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,CHO,Expert,9,,51
,CHEMBL616050,,H,BAO_0000219,,,,,1007,,2759,,1,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,CHO,Autocuration,8,,51
,CHEMBL616051,,H,BAO_0000219,,,,,1008,,15419,,1,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,Expert,8,,51
,CHEMBL616212,,H,BAO_0000219,,,,,1009,,15419,,1,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,Autocuration,8,,51
,CHEMBL616213,,H,BAO_0000019,,,,,1010,,16026,,1,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,51
,CHEMBL616214,,H,BAO_0000219,,,,,1011,,1414,,1,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,Expert,8,,51
,CHEMBL616215,,H,BAO_0000219,,,,,1012,,1414,,1,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,Expert,8,,51
,CHEMBL616216,,H,BAO_0000357,,,,,1013,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,51
,CHEMBL616217,,H,BAO_0000019,,,,,1014,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,Autocuration,8,,51
,CHEMBL616218,,H,BAO_0000357,,,,,1015,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616219,,H,BAO_0000357,,,,,1016,,5105,,1,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616220,,H,BAO_0000357,,,,,1017,,16312,,1,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL833493,9606.0,D,BAO_0000357,Homo sapiens,,,,1018,,15180,,1,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL616221,,H,BAO_0000357,,,,,1019,,5033,,1,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616222,9606.0,D,BAO_0000219,Homo sapiens,,,,1020,,16909,,1,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,CHO,Expert,9,,51
,CHEMBL616223,,H,BAO_0000019,,,,,1021,,2590,,1,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,51
,CHEMBL616224,,H,BAO_0000019,,,,,1022,,2590,,1,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,Autocuration,8,,51
,CHEMBL616225,,H,BAO_0000019,,,,,1023,,16394,,1,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,Expert,8,,51
,CHEMBL616226,9606.0,D,BAO_0000219,Homo sapiens,,,,1024,,4540,,1,722.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,HEK293,Expert,9,,51
,CHEMBL616227,,H,BAO_0000219,,,,,1025,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,HEK293,Autocuration,8,,51
,CHEMBL616228,,H,BAO_0000219,,,,,1026,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,HEK293,Autocuration,8,,51
,CHEMBL616229,,H,BAO_0000219,,,,,1027,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,HEK293,Autocuration,8,,51
,CHEMBL616230,,H,BAO_0000219,,,,,1028,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,HEK293,Autocuration,8,,51
,CHEMBL616231,,H,BAO_0000219,,,,,1029,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,HEK293,Autocuration,8,,51
,CHEMBL616232,,H,BAO_0000357,,,,,1030,,6166,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,51
,CHEMBL616233,,H,BAO_0000219,,,,,1031,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,HEK293,Autocuration,8,,51
,CHEMBL857973,,H,BAO_0000219,,,,,1032,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,HEK293,Autocuration,8,,51
,CHEMBL616234,,H,BAO_0000219,,,,,1033,,15316,,1,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,Autocuration,8,,51
,CHEMBL616235,,H,BAO_0000357,,,,,1034,,14875,,1,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616236,,H,BAO_0000219,,,,,1035,,14727,,1,308.0,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,HeLa,Expert,8,,51
,CHEMBL616237,,H,BAO_0000019,,,,,1036,,14727,,1,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,Expert,8,,51
,CHEMBL616238,,H,BAO_0000219,,,,,1037,,15146,,1,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,HEK293,Autocuration,8,,51
,CHEMBL616239,,H,BAO_0000219,,,,,1038,,5213,,1,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,HEK293,Autocuration,8,,51
,CHEMBL616240,,H,BAO_0000219,,,,,1039,,16429,,1,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,Autocuration,8,,51
,CHEMBL616241,9606.0,D,BAO_0000219,Homo sapiens,,,,1040,,15042,,1,308.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,HeLa,Expert,9,,51
,CHEMBL616242,,H,BAO_0000219,,,,,1041,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,HEK293,Autocuration,8,,51
,CHEMBL616243,,H,BAO_0000219,,,,,1042,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,HEK293,Autocuration,8,,51
,CHEMBL616244,,D,BAO_0000357,,,,,1043,,17200,,1,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,51
,CHEMBL616245,9606.0,D,BAO_0000357,Homo sapiens,,,,1044,,13051,,1,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Autocuration,9,,51
,CHEMBL616246,,H,BAO_0000357,,,,,1045,,5486,,1,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,Autocuration,8,,106
,CHEMBL616247,,H,BAO_0000357,,,,,1046,,5254,,1,,Binding affinity against 5-HT1D receptor,B,,,Autocuration,8,,105
,CHEMBL616248,,H,BAO_0000357,,,,,1047,,5254,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,105
,CHEMBL616249,,H,BAO_0000357,,,,,1048,,15331,,1,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,107
,CHEMBL616250,9606.0,H,BAO_0000357,Homo sapiens,,,,1049,,13506,,1,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Autocuration,8,,10576
,CHEMBL616251,,H,BAO_0000357,,,,,1050,,15267,,1,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616252,,H,BAO_0000218,,,,,1051,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,Autocuration,8,,11863
,CHEMBL616253,,H,BAO_0000218,,,,,1052,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,Autocuration,8,,11863
,CHEMBL616254,,H,BAO_0000218,,,,,1053,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,Autocuration,8,,11863
,CHEMBL616255,10090.0,D,BAO_0000218,Mus musculus,,,,1054,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Expert,9,,11863
,CHEMBL832872,10090.0,D,BAO_0000218,Mus musculus,,,,1055,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Expert,9,,11863
,CHEMBL616256,10090.0,D,BAO_0000218,Mus musculus,,,,1056,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Expert,9,,11863
,CHEMBL616257,10090.0,D,BAO_0000218,Mus musculus,,,,1057,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Expert,9,,11863
,CHEMBL616258,10090.0,D,BAO_0000218,Mus musculus,,,,1058,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Expert,9,,11863
,CHEMBL616384,10090.0,D,BAO_0000218,Mus musculus,,,,1059,,16616,,1,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Expert,9,,11863
,CHEMBL616385,,H,BAO_0000221,,,,Hippocampus,1060,10000000.0,10297,,1,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Autocuration,8,,11863
,CHEMBL616386,,H,BAO_0000357,,,,,1061,,13704,,1,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,Expert,8,,11863
,CHEMBL616387,10090.0,D,BAO_0000221,Mus musculus,,,Hippocampus,1062,10000000.0,10297,,1,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Expert,9,,11863
,CHEMBL616388,,H,BAO_0000221,,,,Hippocampus,1063,10000000.0,10297,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,Autocuration,8,,11863
,CHEMBL616389,10090.0,D,BAO_0000221,Mus musculus,,,Hippocampus,1064,10000000.0,10297,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Expert,9,,11863
,CHEMBL616390,,H,BAO_0000221,,,,Hippocampus,1065,10000000.0,10297,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,Autocuration,8,,11863
,CHEMBL616391,,H,BAO_0000357,,,,,1066,,217,,1,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,Autocuration,8,,11863
,CHEMBL616392,10090.0,D,BAO_0000221,Mus musculus,,,Hippocampus,1067,10000000.0,10297,,1,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Expert,9,,11863
,CHEMBL616393,9823.0,H,BAO_0000357,Sus scrofa,,,,1068,,4921,,1,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616394,9823.0,H,BAO_0000357,Sus scrofa,,,,1069,,4921,,1,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Autocuration,8,,51
,CHEMBL616395,9823.0,H,BAO_0000019,Sus scrofa,,,,1070,,4996,,1,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Autocuration,8,,51
,CHEMBL616396,9823.0,H,BAO_0000357,Sus scrofa,,,,1071,,12918,,1,,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Autocuration,8,,51
,CHEMBL872907,9823.0,H,BAO_0000019,Sus scrofa,,,,1072,,5333,,1,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Autocuration,8,,51
,CHEMBL616397,9823.0,H,BAO_0000019,Sus scrofa,,,,1073,,4437,,1,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Autocuration,8,,51
,CHEMBL616398,9823.0,H,BAO_0000019,Sus scrofa,,,,1074,,1742,,1,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Autocuration,8,,51
,CHEMBL616399,9823.0,H,BAO_0000357,Sus scrofa,,,,1075,,16688,,1,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL857065,9823.0,H,BAO_0000357,Sus scrofa,,,,1076,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,51
,CHEMBL616400,9823.0,H,BAO_0000019,Sus scrofa,,,,1077,,12861,,1,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Expert,8,,51
,CHEMBL616401,9823.0,H,BAO_0000019,Sus scrofa,,,,1078,,12861,,1,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Autocuration,8,,51
,CHEMBL616402,,H,BAO_0000019,,,,,1079,,12490,,1,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,Expert,8,,10624
,CHEMBL616403,9823.0,H,BAO_0000019,Sus scrofa,,,,1080,,11828,,1,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL616404,9823.0,H,BAO_0000221,Sus scrofa,,,Hippocampus,1081,10000000.0,11866,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL616405,9823.0,H,BAO_0000249,Sus scrofa,,,,1082,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL616406,9823.0,H,BAO_0000019,Sus scrofa,,,,1083,,12918,,1,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Autocuration,8,,51
,CHEMBL616407,9823.0,H,BAO_0000019,Sus scrofa,,,,1084,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Expert,8,,51
,CHEMBL616408,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1085,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Autocuration,8,,51
,CHEMBL616409,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1086,,15796,,1,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Expert,9,,10576
,CHEMBL616410,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1087,10000000.0,3651,,1,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Expert,9,,10576
,CHEMBL616411,,H,BAO_0000357,,,,,1088,,188,,1,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,Autocuration,8,,10576
Membranes,CHEMBL616412,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1089,,16616,,1,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Expert,9,,10576
Membranes,CHEMBL616413,10116.0,D,BAO_0000249,Rattus norvegicus,,,Hippocampus,1090,10000000.0,16616,,1,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Expert,9,,10576
,CHEMBL616414,,H,BAO_0000221,,,,Hippocampus,1091,10000000.0,12306,,1,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL616415,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1092,10000000.0,17167,,1,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Expert,9,,10576
,CHEMBL616416,,H,BAO_0000019,,,,,1093,,14776,,1,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,Autocuration,8,,10576
,CHEMBL616417,,H,BAO_0000357,,,,,1094,,12158,,1,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL616418,,H,BAO_0000357,,,,,1095,,13481,,1,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,Autocuration,8,,10576
,CHEMBL616419,,H,BAO_0000219,,,,,1096,,13427,,1,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,Autocuration,8,,10576
,CHEMBL616420,,H,BAO_0000357,,,,,1097,,10210,,1,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
Membranes,CHEMBL616421,,H,BAO_0000249,,,,,1098,,10205,,1,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Autocuration,8,,10576
Membranes,CHEMBL616422,,H,BAO_0000249,,,,,1099,,10205,,1,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Autocuration,8,,10576
Membranes,CHEMBL616423,,H,BAO_0000249,,,,,1100,,10205,,1,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,Expert,8,,10576
,CHEMBL616424,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1101,,12280,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Expert,9,,10576
,CHEMBL616425,,H,BAO_0000357,,,,,1102,,17386,,1,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL616426,,H,BAO_0000357,,,,,1103,,13654,,1,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,Expert,8,,10576
,CHEMBL616427,,H,BAO_0000221,,,,Hippocampus,1104,10000000.0,14423,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,Autocuration,8,,10576
,CHEMBL616428,,H,BAO_0000221,,,,Hippocampus,1105,10000000.0,15412,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,Autocuration,8,,10576
,CHEMBL616290,,H,BAO_0000221,,,,Hippocampus,1106,10000000.0,12073,,1,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616052,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1107,,4101,,1,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616053,,H,BAO_0000357,,,,,1108,,10062,,1,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616054,,H,BAO_0000249,,,,,1109,,6238,,1,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616055,,H,BAO_0000357,,,,,1110,,16273,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616056,,H,BAO_0000357,,,,,1111,,11139,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,Autocuration,8,,10576
,CHEMBL616057,,H,BAO_0000019,,,,,1112,,16796,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,Expert,8,,10576
,CHEMBL616058,10116.0,D,BAO_0000221,Rattus norvegicus,,,Brain,1113,955.0,9548,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Expert,9,,10576
,CHEMBL616059,,H,BAO_0000221,,,,Brain,1114,955.0,10381,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Autocuration,8,,10576
,CHEMBL616060,,H,BAO_0000249,,,,,1115,,13408,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616061,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1116,10000000.0,13825,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL616062,,H,BAO_0000221,,,,Hippocampus,1117,10000000.0,11147,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,Expert,8,,10576
,CHEMBL616063,,H,BAO_0000249,,,,,1118,,10552,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616064,,H,BAO_0000249,,,,Striatum,1119,2435.0,10552,,1,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,Autocuration,8,,10576
Membranes,CHEMBL616065,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1120,,17136,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Expert,9,,10576
Membranes,CHEMBL616066,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1121,,5778,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Expert,9,,10576
,CHEMBL616067,,H,BAO_0000221,,,,Hippocampus,1122,10000000.0,13481,,1,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616068,,H,BAO_0000221,,,,Hippocampus,1123,10000000.0,13481,,1,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,Autocuration,8,,10576
,CHEMBL616069,,H,BAO_0000221,,,,Hippocampus,1124,10000000.0,13630,,1,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,Intermediate,8,,10576
,CHEMBL616070,,H,BAO_0000249,,,,,1125,,16245,,1,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Expert,8,,10576
,CHEMBL616071,,H,BAO_0000221,,,,Hippocampus,1126,10000000.0,14509,,1,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616072,,H,BAO_0000221,,,,Hippocampus,1127,10000000.0,14509,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL616073,,H,BAO_0000221,,,,Hippocampus,1128,10000000.0,14509,,1,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,Autocuration,8,,10576
,CHEMBL616074,,H,BAO_0000221,,,,Hippocampus,1129,10000000.0,14509,,1,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,Autocuration,8,,10576
,CHEMBL616075,,H,BAO_0000019,,,,,1130,,14256,,1,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,Expert,8,,10576
,CHEMBL616076,,H,BAO_0000357,,,,,1131,,11139,,1,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616077,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1132,,11047,,1,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Expert,9,,10576
,CHEMBL616078,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1133,,11047,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Expert,9,,10576
,CHEMBL616079,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1134,,11047,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Expert,9,,10576
,CHEMBL616080,10116.0,D,BAO_0000219,Rattus norvegicus,,,,1135,,2395,,1,485.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,CHO-K1,Expert,9,,10576
,CHEMBL616081,,H,BAO_0000357,,,,,1136,,9699,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616082,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1137,10000000.0,12028,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Expert,9,,10576
,CHEMBL616083,,H,BAO_0000221,,,,Hippocampus,1138,10000000.0,12028,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Autocuration,8,,10576
,CHEMBL616084,,H,BAO_0000019,,,,,1139,,5815,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,Autocuration,8,,10576
,CHEMBL616085,,H,BAO_0000019,,,,,1140,,16616,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,Expert,8,,10576
,CHEMBL616086,,H,BAO_0000019,,,,,1141,,5815,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL616087,,H,BAO_0000221,,,,Hippocampus,1142,10000000.0,2761,,1,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,Autocuration,8,,10576
,CHEMBL616088,,H,BAO_0000357,,,,,1143,,13133,,1,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,Expert,8,,10576
,CHEMBL616089,,H,BAO_0000019,,,,,1144,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,Autocuration,8,,10576
,CHEMBL616090,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1145,,13278,,1,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Expert,9,,10576
,CHEMBL616091,,H,BAO_0000357,,,,,1146,,15874,,1,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
Membranes,CHEMBL616092,,H,BAO_0000249,,,,Striatum,1147,2435.0,10552,,1,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,Autocuration,8,,10576
,CHEMBL616093,,H,BAO_0000357,,,,,1148,,11130,,1,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,Autocuration,8,,10576
,CHEMBL616094,,H,BAO_0000218,,,,,1149,,11130,,1,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,Autocuration,8,,10576
,CHEMBL616095,,H,BAO_0000221,,,,Brain,1150,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,Autocuration,8,,10576
,CHEMBL616096,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1151,,13670,,1,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616097,,H,BAO_0000249,,,,,1152,,9888,,1,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,Expert,8,,10576
Membranes,CHEMBL616098,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1153,,3678,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Expert,9,,10576
,CHEMBL616099,,H,BAO_0000221,,,,Hippocampus,1154,10000000.0,11332,,1,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616100,,H,BAO_0000221,,,,Hippocampus,1155,10000000.0,11332,,1,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616101,,H,BAO_0000357,,,,,1156,,1185,,1,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL616102,,H,BAO_0000249,,,,,1157,,2014,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,Expert,8,,10576
,CHEMBL616103,,H,BAO_0000357,,,,,1158,,1185,,1,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616104,,H,BAO_0000019,,,,,1159,,14429,,1,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,Expert,8,,10576
,CHEMBL616105,,H,BAO_0000019,,,,,1160,,16288,,1,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,Expert,8,,10576
,CHEMBL616106,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1161,,5432,,1,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616107,,H,BAO_0000019,,,,,1162,,14429,,1,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,Autocuration,8,,10576
,CHEMBL616108,,H,BAO_0000357,,,,,1163,,13672,,1,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,Expert,8,,10576
,CHEMBL616109,,H,BAO_0000221,,,,Hippocampus,1164,10000000.0,11296,,1,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,Expert,8,,10576
,CHEMBL616110,,H,BAO_0000357,,,,,1165,,11296,,1,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,Autocuration,8,,10576
,CHEMBL616111,,H,BAO_0000219,,,,,1166,,14749,,1,449.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,CHO,Expert,8,,10576
,CHEMBL616112,,H,BAO_0000019,,,,,1167,,15086,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL616113,,H,BAO_0000221,,,,Hippocampus,1168,10000000.0,13462,,1,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,Autocuration,8,,10576
,CHEMBL616114,,H,BAO_0000019,,,,,1169,,15363,,1,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616115,,H,BAO_0000019,,,,,1170,,15363,,1,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616116,,H,BAO_0000357,,,,,1171,,10796,,1,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL615844,,H,BAO_0000221,,,,Brain,1172,955.0,12816,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL615939,,H,BAO_0000221,,,,Hippocampus,1173,10000000.0,13542,,1,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL615940,,H,BAO_0000019,,,,,1174,,13308,,1,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,Expert,8,,10576
,CHEMBL615941,,H,BAO_0000221,,,,Hippocampus,1175,10000000.0,13541,,1,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,Expert,8,,10576
,CHEMBL615942,,H,BAO_0000221,,,,Hippocampus,1176,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,Autocuration,8,,10576
,CHEMBL615943,,H,BAO_0000221,,,,Hippocampus,1177,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL615944,,H,BAO_0000221,,,,Hippocampus,1178,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,Autocuration,8,,10576
,CHEMBL615945,,H,BAO_0000221,,,,Hippocampus,1179,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,Autocuration,8,,10576
,CHEMBL615946,,H,BAO_0000221,,,,Hippocampus,1180,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,Autocuration,8,,10576
,CHEMBL615947,,H,BAO_0000221,,,,Hippocampus,1181,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,Autocuration,8,,10576
,CHEMBL615948,,H,BAO_0000221,,,,Hippocampus,1182,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,Autocuration,8,,10576
,CHEMBL615949,,H,BAO_0000221,,,,Hippocampus,1183,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,Autocuration,8,,10576
,CHEMBL615950,,H,BAO_0000221,,,,Hippocampus,1184,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,Autocuration,8,,10576
,CHEMBL615951,,H,BAO_0000221,,,,Hippocampus,1185,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,Autocuration,8,,10576
,CHEMBL615952,,H,BAO_0000221,,,,Hippocampus,1186,10000000.0,10058,,1,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,Autocuration,8,,10576
,CHEMBL615953,,H,BAO_0000221,,,,Hippocampus,1187,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,Autocuration,8,,10576
,CHEMBL615954,,H,BAO_0000221,,,,Hippocampus,1188,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,Autocuration,8,,10576
,CHEMBL615955,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1189,10000000.0,10058,,1,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Expert,9,,10576
,CHEMBL615956,,H,BAO_0000221,,,,Hippocampus,1190,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,Autocuration,8,,10576
,CHEMBL615957,,H,BAO_0000221,,,,Hippocampus,1191,10000000.0,10058,,1,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,Autocuration,8,,10576
,CHEMBL615958,,H,BAO_0000019,,,,,1192,,12879,,1,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,Expert,8,,10576
,CHEMBL615959,,H,BAO_0000019,,,,,1193,,11964,,1,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,Expert,8,,10576
,CHEMBL615960,,H,BAO_0000019,,,,,1194,,11964,,1,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,Autocuration,8,,10576
,CHEMBL615961,,H,BAO_0000019,,,,,1195,,11964,,1,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,Autocuration,8,,10576
,CHEMBL615962,,H,BAO_0000221,,,,Brain,1196,955.0,9548,,1,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Expert,8,,10576
,CHEMBL615963,,H,BAO_0000019,,,,,1197,,9098,,1,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,Expert,8,,10576
,CHEMBL615964,,H,BAO_0000019,,,,,1198,,9098,,1,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,Autocuration,8,,10576
,CHEMBL615965,,H,BAO_0000019,,,,,1199,,9098,,1,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,Autocuration,8,,10576
,CHEMBL615966,,H,BAO_0000219,,,,,1200,,13248,,1,449.0,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,CHO,Expert,8,,10576
,CHEMBL615967,,H,BAO_0000249,,,,,1201,,3147,,1,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,Expert,8,,10576
,CHEMBL615968,,H,BAO_0000019,,,,,1202,,13949,,1,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL615969,,H,BAO_0000218,,,,,1203,,11883,,1,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,CHO,Autocuration,8,,10576
,CHEMBL615970,,H,BAO_0000218,,,,,1204,,11883,,1,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,Autocuration,8,,10576
,CHEMBL615971,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1205,,11883,,1,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Expert,9,,10576
Membranes,CHEMBL615972,,H,BAO_0000249,,,,,1206,,15535,,1,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Expert,8,,10576
,CHEMBL615973,,H,BAO_0000249,,,,,1207,,15535,,1,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,Autocuration,8,,10576
,CHEMBL615974,,H,BAO_0000249,,,,,1208,,15535,,1,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,Autocuration,8,,10576
,CHEMBL615975,9606.0,D,BAO_0000219,Homo sapiens,,,,1209,,16372,,1,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,CHO,Expert,9,,51
,CHEMBL615976,,H,BAO_0000249,,,,,1210,,14608,,1,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,Expert,8,,10576
,CHEMBL872106,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1211,10000000.0,4795,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Expert,9,,10576
,CHEMBL615977,,H,BAO_0000357,,,,,1212,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL615978,,H,BAO_0000357,,,,,1213,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,Autocuration,8,,10576
,CHEMBL616166,,H,BAO_0000357,,,,,1214,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,Autocuration,8,,10576
,CHEMBL616167,,H,BAO_0000357,,,,,1215,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,Autocuration,8,,10576
,CHEMBL616168,,H,BAO_0000357,,,,,1216,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,Autocuration,8,,10576
,CHEMBL616169,,H,BAO_0000357,,,,,1217,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,Autocuration,8,,10576
,CHEMBL616170,,H,BAO_0000357,,,,,1218,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,Autocuration,8,,10576
,CHEMBL616171,,H,BAO_0000357,,,,,1219,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,Autocuration,8,,10576
,CHEMBL616172,,H,BAO_0000357,,,,,1220,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,Autocuration,8,,10576
,CHEMBL616173,,H,BAO_0000357,,,,,1221,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,Autocuration,8,,10576
,CHEMBL616174,,H,BAO_0000357,,,,,1222,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,Autocuration,8,,10576
,CHEMBL616175,,H,BAO_0000357,,,,,1223,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,Autocuration,8,,10576
,CHEMBL616176,,H,BAO_0000357,,,,,1224,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,Autocuration,8,,10576
,CHEMBL616177,,H,BAO_0000357,,,,,1225,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,Autocuration,8,,10576
,CHEMBL616178,,H,BAO_0000357,,,,,1226,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,Autocuration,8,,10576
,CHEMBL616179,,H,BAO_0000019,,,,,1227,,9742,,1,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,Autocuration,8,,10576
,CHEMBL616180,,H,BAO_0000357,,,,,1228,,12073,,1,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616181,,H,BAO_0000357,,,,,1229,,4101,,1,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL616182,,H,BAO_0000019,,,,,1230,,15360,,1,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,Autocuration,8,,10576
,CHEMBL616183,,H,BAO_0000221,,,,Hippocampus,1231,10000000.0,11576,,1,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL615874,,H,BAO_0000019,,,,,1232,,5834,,1,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,Expert,8,,10576
,CHEMBL615875,10116.0,D,BAO_0000219,Rattus norvegicus,,,,1233,,2395,,1,485.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,CHO-K1,Expert,9,,10576
,CHEMBL615876,,H,BAO_0000019,,,,,1234,,1375,,1,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,Autocuration,8,,10576
,CHEMBL615877,,H,BAO_0000019,,,,,1235,,1375,,1,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,Autocuration,8,,10576
,CHEMBL615878,,H,BAO_0000357,,,,,1236,,3967,,1,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,Autocuration,8,,10576
,CHEMBL615879,,H,BAO_0000357,,,,,1237,,12884,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,Expert,8,,10576
,CHEMBL615880,,H,BAO_0000357,,,,,1238,,2343,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,Expert,8,,10576
,CHEMBL615881,,H,BAO_0000019,,,,,1239,,11511,,1,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Autocuration,8,,10576
,CHEMBL615882,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1240,,11511,,1,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Expert,9,,10576
,CHEMBL615883,,H,BAO_0000218,,,,,1241,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,Autocuration,8,,10576
,CHEMBL615884,,H,BAO_0000218,,,,,1242,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,Autocuration,8,,10576
,CHEMBL615885,,H,BAO_0000218,,,,,1243,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,Autocuration,8,,10576
,CHEMBL615886,,H,BAO_0000218,,,,,1244,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,Autocuration,8,,10576
,CHEMBL615887,,H,BAO_0000218,,,,,1245,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,Autocuration,8,,10576
,CHEMBL615888,,H,BAO_0000218,,,,,1246,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,Autocuration,8,,10576
,CHEMBL615889,,H,BAO_0000218,,,,,1247,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,Autocuration,8,,10576
,CHEMBL615890,,H,BAO_0000218,,,,,1248,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,Autocuration,8,,10576
,CHEMBL615891,,H,BAO_0000218,,,,,1249,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,Autocuration,8,,10576
,CHEMBL615892,,H,BAO_0000218,,,,,1250,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,Autocuration,8,,10576
,CHEMBL615893,,H,BAO_0000218,,,,,1251,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,Autocuration,8,,10576
,CHEMBL615894,,H,BAO_0000218,,,,,1252,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,Autocuration,8,,10576
,CHEMBL615895,,H,BAO_0000218,,,,,1253,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,Autocuration,8,,10576
,CHEMBL615896,,H,BAO_0000218,,,,,1254,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,Autocuration,8,,10576
,CHEMBL615897,,H,BAO_0000218,,,,,1255,,16394,,1,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,Autocuration,8,,10576
Membranes,CHEMBL615898,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1256,,16616,,1,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Expert,9,,10576
,CHEMBL615899,,H,BAO_0000019,,,,,1257,,16796,,1,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,Autocuration,8,,10576
,CHEMBL616291,,H,BAO_0000019,,,,,1258,,16796,,1,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,Autocuration,8,,10576
,CHEMBL616292,,H,BAO_0000357,,,,,1259,,15629,,1,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,Autocuration,8,,10576
,CHEMBL616293,,H,BAO_0000249,,,,,1260,,13241,,1,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,Autocuration,8,,10576
,CHEMBL616294,,H,BAO_0000221,,,,Hippocampus,1261,10000000.0,12073,,1,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Expert,8,,10576
,CHEMBL616295,,H,BAO_0000249,,,,Hippocampus,1262,10000000.0,14286,,1,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,Autocuration,8,,10576
,CHEMBL616296,,H,BAO_0000221,,,,Brain,1263,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,Autocuration,8,,10576
,CHEMBL616297,,H,BAO_0000019,,,,,1264,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616605,,H,BAO_0000019,,,,,1265,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616606,,H,BAO_0000019,,,,,1266,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616607,,H,BAO_0000019,,,,,1267,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,Autocuration,8,,10576
,CHEMBL616608,,H,BAO_0000019,,,,,1268,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,Expert,8,,10576
,CHEMBL616609,,H,BAO_0000019,,,,,1269,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616610,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1270,,13630,,1,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Expert,9,,10576
,CHEMBL616611,,H,BAO_0000019,,,,,1271,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616612,,H,BAO_0000019,,,,,1272,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,Expert,8,,10576
,CHEMBL616613,,H,BAO_0000019,,,,,1273,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616614,,H,BAO_0000019,,,,,1274,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,Expert,8,,10576
,CHEMBL616615,,H,BAO_0000019,,,,,1275,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616616,,H,BAO_0000019,,,,,1276,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,Expert,8,,10576
,CHEMBL616617,,H,BAO_0000019,,,,,1277,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616618,,H,BAO_0000019,,,,,1278,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616619,,H,BAO_0000019,,,,,1279,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616620,,H,BAO_0000019,,,,,1280,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,Expert,8,,10576
,CHEMBL616621,,H,BAO_0000019,,,,,1281,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,Expert,8,,10576
,CHEMBL616622,,H,BAO_0000019,,,,,1282,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,Autocuration,8,,10576
,CHEMBL616146,,H,BAO_0000019,,,,,1283,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,Expert,8,,10576
,CHEMBL832873,,H,BAO_0000019,,,,,1284,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616147,,H,BAO_0000019,,,,,1285,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,Autocuration,8,,10576
,CHEMBL872872,,H,BAO_0000019,,,,,1286,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616148,,H,BAO_0000019,,,,,1287,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,Autocuration,8,,10576
,CHEMBL616149,,H,BAO_0000221,,,,Hippocampus,1288,10000000.0,9783,,1,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,Autocuration,8,,10576
,CHEMBL616150,,H,BAO_0000221,,,,Hippocampus,1289,10000000.0,9783,,1,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,Expert,8,,10576
Membranes,CHEMBL616151,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1290,,14331,,1,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Expert,9,,10576
,CHEMBL872873,,H,BAO_0000221,,,,Hippocampus,1291,10000000.0,15260,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,Expert,8,,10576
,CHEMBL616670,,H,BAO_0000221,,,,Hippocampus,1292,10000000.0,15260,,1,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,Autocuration,8,,10576
,CHEMBL616671,,H,BAO_0000221,,,,Hippocampus,1293,10000000.0,15260,,1,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,Autocuration,8,,10576
,CHEMBL884861,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1294,,16616,,1,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Expert,9,,10576
,CHEMBL616672,,H,BAO_0000357,,,,,1295,,15629,,1,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616673,,H,BAO_0000019,,,,,1296,,15086,,1,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,Autocuration,8,,10576
,CHEMBL616674,,H,BAO_0000019,,,,,1297,,5717,,1,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,Expert,8,,10576
,CHEMBL616675,,H,BAO_0000357,,,,,1298,,12652,,1,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL616676,,H,BAO_0000221,,,,Hippocampus,1299,10000000.0,14608,,1,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,Autocuration,8,,10576
,CHEMBL616677,,H,BAO_0000221,,,,Hippocampus,1300,10000000.0,12306,,1,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL616678,,H,BAO_0000221,,,,Hippocampus,1301,10000000.0,12306,,1,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL616679,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1302,,15247,,1,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616680,,H,BAO_0000221,,,,Hippocampus,1303,10000000.0,17529,,1,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,Expert,8,,10576
,CHEMBL616681,,H,BAO_0000221,,,,Hippocampus,1304,10000000.0,14826,,1,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616682,,H,BAO_0000221,,,,Hippocampus,1305,10000000.0,14826,,1,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616683,,H,BAO_0000221,,,,Hippocampus,1306,10000000.0,13241,,1,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616684,,H,BAO_0000221,,,,Hippocampus,1307,10000000.0,14093,,1,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616685,,H,BAO_0000221,,,,Hippocampus,1308,10000000.0,14093,,1,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,Autocuration,8,,10576
,CHEMBL616686,,H,BAO_0000221,,,,Brain,1309,955.0,14442,,1,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,Autocuration,8,,10576
,CHEMBL616687,,H,BAO_0000357,,,,,1310,,9919,,1,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,Autocuration,8,,10576
,CHEMBL616688,,H,BAO_0000357,,,,,1311,,9919,,1,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,Autocuration,8,,10576
,CHEMBL616689,,H,BAO_0000221,,,,Hippocampus,1312,10000000.0,11440,,1,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,Autocuration,8,,10576
,CHEMBL616690,,H,BAO_0000357,,,,,1313,,11257,,1,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL616691,,H,BAO_0000357,,,,,1314,,10330,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL616692,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1315,10000000.0,17331,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Expert,9,,10576
,CHEMBL616693,,H,BAO_0000249,,,,,1316,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,Expert,8,,10576
,CHEMBL616694,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1317,,12058,,1,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Expert,9,,10576
,CHEMBL616695,,H,BAO_0000221,,,,Hippocampus,1318,10000000.0,9699,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,Autocuration,8,,10576
,CHEMBL616696,,H,BAO_0000357,,,,,1319,,9547,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,Autocuration,8,,10576
,CHEMBL616697,,H,BAO_0000357,,,,,1320,,10330,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616698,,H,BAO_0000357,,,,,1321,,14331,,1,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL616949,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1322,,14060,,1,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616950,,H,BAO_0000221,,,,Hippocampus,1323,10000000.0,14744,,1,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL832875,,H,BAO_0000357,,,,,1324,,13506,,1,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Autocuration,8,,10576
,CHEMBL616951,,H,BAO_0000221,,,,Brain,1325,955.0,10862,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,Expert,8,,10576
,CHEMBL616952,,H,BAO_0000221,,,,Brain,1326,955.0,10862,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,Expert,8,,10576
,CHEMBL616953,,H,BAO_0000357,,,,,1327,,10062,,1,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,Expert,8,,10576
,CHEMBL616954,,H,BAO_0000357,,,,,1328,,12073,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,Autocuration,8,,10576
,CHEMBL616955,,H,BAO_0000357,,,,,1329,,14875,,1,,GTPgammaS radioligand binding assay,B,,,Autocuration,8,,106
,CHEMBL616956,,H,BAO_0000357,,,,,1330,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,Autocuration,8,,106
,CHEMBL616957,,H,BAO_0000019,,,,,1331,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,Autocuration,8,,106
,CHEMBL616958,,H,BAO_0000019,,,,,1332,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,Autocuration,8,,106
,CHEMBL616959,,H,BAO_0000357,,,,,1333,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616960,,H,BAO_0000357,,,,,1334,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,Autocuration,8,,106
,CHEMBL616961,,H,BAO_0000019,,,,,1335,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,Autocuration,8,,106
,CHEMBL616962,,H,BAO_0000219,,,,,1336,,17211,,1,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,HeLa,Expert,8,,106
,CHEMBL616963,,H,BAO_0000219,,,,,1337,,17211,,1,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,HeLa,Autocuration,8,,106
,CHEMBL616524,9606.0,D,BAO_0000357,Homo sapiens,,,,1338,,6491,,1,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Expert,9,,106
,CHEMBL616525,,H,BAO_0000219,,,,,1339,,16190,,1,449.0,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL872908,,H,BAO_0000019,,,,,1340,,14165,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,Autocuration,8,,106
,CHEMBL616526,,H,BAO_0000019,,,,,1341,,14165,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,Autocuration,8,,106
,CHEMBL616527,9606.0,D,BAO_0000357,Homo sapiens,,,,1342,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616528,,H,BAO_0000219,,,,,1343,,6328,,1,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,Expert,8,,106
,CHEMBL616529,,H,BAO_0000357,,,,,1344,,14770,,1,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,106
,CHEMBL616530,,H,BAO_0000357,,,,,1345,,2598,,1,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,Autocuration,8,,106
,CHEMBL616531,,H,BAO_0000357,,,,,1346,,6897,,1,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,Expert,8,,106
,CHEMBL616532,,H,BAO_0000357,,,,,1347,,6897,,1,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616533,,H,BAO_0000357,,,,,1348,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616534,,H,BAO_0000357,,,,,1349,,5843,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Expert,8,,106
,CHEMBL616535,,H,BAO_0000357,,,,,1350,,14454,,1,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,Expert,8,,106
,CHEMBL616536,,H,BAO_0000357,,,,,1351,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,Autocuration,8,,106
,CHEMBL616537,,H,BAO_0000357,,,,,1352,,3935,,1,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616538,,H,BAO_0000219,,,,,1353,,13729,,1,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,CHO-K1,Expert,8,,106
,CHEMBL616539,,H,BAO_0000019,,,,,1354,,14251,,1,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,Expert,8,,106
,CHEMBL616540,,H,BAO_0000019,,,,,1355,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,Expert,8,,106
,CHEMBL616429,,H,BAO_0000357,,,,,1356,,3025,,1,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,Autocuration,8,,106
,CHEMBL616430,,H,BAO_0000357,,,,,1357,,15315,,1,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,Expert,8,,106
,CHEMBL616431,9606.0,D,BAO_0000219,Homo sapiens,,,,1358,,14214,,1,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Expert,9,,106
,CHEMBL616432,9606.0,D,BAO_0000357,Homo sapiens,,,,1359,,3804,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616433,9606.0,D,BAO_0000357,Homo sapiens,,,,1360,,2391,,1,,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Expert,9,,106
,CHEMBL616434,9606.0,D,BAO_0000357,Homo sapiens,,,,1361,,4175,,1,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616435,,H,BAO_0000219,,,,,1362,,17296,,1,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,CHO,Autocuration,8,,106
,CHEMBL616436,,H,BAO_0000019,,,,,1363,,17085,,1,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,Expert,8,,106
,CHEMBL616437,,H,BAO_0000219,,,,,1364,,17211,,1,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,HeLa,Autocuration,8,,106
,CHEMBL616438,,H,BAO_0000219,,,,,1365,,17211,,1,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,HeLa,Autocuration,8,,106
,CHEMBL616439,,H,BAO_0000219,,,,,1366,,17211,,1,308.0,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,HeLa,Autocuration,8,,106
,CHEMBL616440,9606.0,D,BAO_0000357,Homo sapiens,,,,1367,,15926,,1,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Expert,9,,106
,CHEMBL616441,,H,BAO_0000219,,,,,1368,,16312,,1,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,CHO-K1,Autocuration,8,,106
,CHEMBL616442,,H,BAO_0000357,,,,,1369,,5843,,1,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,Expert,8,,106
,CHEMBL616443,,H,BAO_0000357,,,,,1370,,5843,,1,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,106
,CHEMBL616444,,H,BAO_0000219,,,,,1371,,16312,,1,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,CHO-K1,Expert,8,,106
,CHEMBL616445,9606.0,D,BAO_0000357,Homo sapiens,,,,1372,,15926,,1,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616446,9606.0,D,BAO_0000357,Homo sapiens,,,,1373,,15926,,1,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616447,9606.0,D,BAO_0000219,Homo sapiens,,,,1374,,4540,,1,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,Expert,9,,106
,CHEMBL616448,,H,BAO_0000357,,,,,1375,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,Autocuration,8,,106
,CHEMBL616449,,H,BAO_0000219,,,,,1376,,17296,,1,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL616450,,H,BAO_0000219,,,,,1377,,17296,,1,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,CHO,Autocuration,8,,106
,CHEMBL857974,,H,BAO_0000219,,,,,1378,,17296,,1,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL616451,,H,BAO_0000219,,,,,1379,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL616452,,H,BAO_0000219,,,,,1380,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL616453,,H,BAO_0000219,,,,,1381,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,CHO,Autocuration,8,,106
,CHEMBL616454,,H,BAO_0000219,,,,,1382,,4199,,1,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,Autocuration,8,,106
,CHEMBL616455,9606.0,D,BAO_0000357,Homo sapiens,,,,1383,,14875,,1,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616456,,H,BAO_0000219,,,,,1384,,15146,,1,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,CHO,Autocuration,8,,106
,CHEMBL616457,,H,BAO_0000357,,,,,1385,,5213,,1,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,Autocuration,8,,106
,CHEMBL616458,,H,BAO_0000219,,,,,1386,,14818,,1,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,CHO,Autocuration,8,,106
,CHEMBL616459,,H,BAO_0000219,,,,,1387,,4829,,1,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,106
,CHEMBL616460,,H,BAO_0000019,,,,,1388,,14454,,1,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,Expert,8,,106
,CHEMBL616461,,H,BAO_0000019,,,,,1389,,14454,,1,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,Expert,8,,106
,CHEMBL616462,,H,BAO_0000219,,,,,1390,,14875,,1,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,CHO,Autocuration,8,,106
,CHEMBL616463,,H,BAO_0000219,,,,,1391,,14875,,1,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,CHO,Autocuration,8,,106
,CHEMBL616464,,H,BAO_0000019,,,,,1392,,15250,,1,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,Autocuration,8,,105
,CHEMBL616465,,H,BAO_0000219,,,,,1393,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,CHO,Autocuration,8,,105
,CHEMBL832874,,H,BAO_0000357,,,,,1394,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,17105
,CHEMBL616184,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1395,,3025,,1,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Autocuration,8,,106
,CHEMBL616185,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1396,,14998,,1,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Autocuration,8,,106
,CHEMBL616186,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1397,,14998,,1,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Intermediate,8,,106
,CHEMBL616187,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1398,,14998,,1,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Autocuration,8,,106
,CHEMBL616188,,H,BAO_0000357,,,,,1399,,13969,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,Expert,8,,10577
,CHEMBL873475,,D,BAO_0000357,,,,,1400,,13392,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,Intermediate,9,,10577
,CHEMBL616189,10116.0,D,BAO_0000019,Rattus norvegicus,,,Striatum,1401,2435.0,3651,,1,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Expert,9,,10577
,CHEMBL616190,,H,BAO_0000357,,,,,1402,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,Expert,8,,10577
,CHEMBL616191,,H,BAO_0000357,,,,,1403,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,Autocuration,8,,10576
,CHEMBL616192,,H,BAO_0000357,,,,,1404,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,Autocuration,8,,10576
,CHEMBL616193,,H,BAO_0000357,,,,,1405,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,Autocuration,8,,10576
,CHEMBL616194,,H,BAO_0000357,,,,,1406,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,Autocuration,8,,10576
,CHEMBL616195,,H,BAO_0000357,,,,,1407,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,Autocuration,8,,10576
,CHEMBL616196,,H,BAO_0000357,,,,,1408,,13863,,1,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,Autocuration,8,,10576
,CHEMBL616197,,H,BAO_0000249,,,,Hippocampus,1409,10000000.0,4622,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,Autocuration,8,,10576
,CHEMBL616198,,H,BAO_0000019,,,,,1410,,14911,,1,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,Intermediate,8,,10576
,CHEMBL616199,,H,BAO_0000221,,,,Hippocampus,1411,10000000.0,12678,,1,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,Autocuration,8,,10576
,CHEMBL616200,,H,BAO_0000221,,,,Hippocampus,1412,10000000.0,12678,,1,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,Expert,8,,10576
,CHEMBL616201,,H,BAO_0000221,,,,Hippocampus,1413,10000000.0,14235,,1,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL616202,,H,BAO_0000221,,,,Hippocampus,1414,10000000.0,14949,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,Expert,8,,10576
,CHEMBL616203,,H,BAO_0000221,,,,Hippocampus,1415,10000000.0,14949,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,Expert,8,,10576
,CHEMBL616204,,H,BAO_0000221,,,,Hippocampus,1416,10000000.0,14949,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,Expert,8,,10576
,CHEMBL616205,,H,BAO_0000221,,,,Hippocampus,1417,10000000.0,14949,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,Expert,8,,10576
,CHEMBL616206,,H,BAO_0000221,,,,Hippocampus,1418,10000000.0,14949,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,Expert,8,,10576
,CHEMBL616207,,H,BAO_0000249,,,,,1419,,16118,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,Expert,8,,10576
,CHEMBL616208,,H,BAO_0000249,,,,,1420,,3268,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,Autocuration,8,,10576
,CHEMBL616209,,H,BAO_0000249,,,,,1421,,3268,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,Autocuration,8,,10576
,CHEMBL616210,,H,BAO_0000357,,,,,1422,,16117,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,Expert,8,,10576
,CHEMBL616211,,H,BAO_0000221,,,,Hippocampus,1423,10000000.0,9783,,1,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,Expert,8,,10576
,CHEMBL616504,,H,BAO_0000221,,,,Hippocampus,1424,10000000.0,9783,,1,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,Autocuration,8,,10576
,CHEMBL616505,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1425,10000000.0,14356,,1,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616506,,H,BAO_0000019,,,,,1426,,15740,,1,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,Autocuration,8,,10576
,CHEMBL872107,,H,BAO_0000221,,,,Hippocampus,1427,10000000.0,12306,,1,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,Autocuration,8,,10576
,CHEMBL616507,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1428,10000000.0,13348,,1,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Expert,9,,10576
,CHEMBL616303,,H,BAO_0000249,,,,,1429,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,Autocuration,8,,10576
,CHEMBL616304,,H,BAO_0000221,,,,Hippocampus,1430,10000000.0,15260,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,Autocuration,8,,10576
,CHEMBL616305,,H,BAO_0000221,,,,Hippocampus,1431,10000000.0,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL616306,,H,BAO_0000221,,,,Hippocampus,1432,10000000.0,15260,,1,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,Intermediate,8,,10576
,CHEMBL616307,,H,BAO_0000357,,,,,1433,,12851,,1,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL881829,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1434,10000000.0,2148,,1,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Expert,9,,10576
,CHEMBL616308,,H,BAO_0000357,,,,,1435,,13134,,1,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,Expert,8,,10576
,CHEMBL616309,,H,BAO_0000019,,,,,1436,,12462,,1,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,Autocuration,8,,10576
,CHEMBL616310,,H,BAO_0000019,,,,,1437,,12462,,1,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,Expert,8,,10576
,CHEMBL616311,,H,BAO_0000219,,,,,1438,,12462,,1,449.0,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,CHO,Autocuration,8,,10576
,CHEMBL616312,,H,BAO_0000357,,,,,1439,,11933,,1,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL616313,,H,BAO_0000357,,,,,1440,,11933,,1,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,Autocuration,8,,10576
,CHEMBL616314,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1441,10000000.0,403,,1,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616315,,H,BAO_0000221,,,,Hippocampus,1442,10000000.0,15538,,1,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616567,,H,BAO_0000221,,,,Hippocampus,1443,10000000.0,15538,,1,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,Autocuration,8,,10576
,CHEMBL616568,,H,BAO_0000221,,,,Hippocampus,1444,10000000.0,15538,,1,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,Autocuration,8,,10576
,CHEMBL616569,,H,BAO_0000019,,,,,1445,,12464,,1,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,Intermediate,8,,10576
,CHEMBL616570,,H,BAO_0000357,,,,,1446,,1455,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,Expert,8,,10576
,CHEMBL616571,,H,BAO_0000357,,,,,1447,,12652,,1,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,Autocuration,8,,10576
,CHEMBL616572,,H,BAO_0000221,,,,Hippocampus,1448,10000000.0,12639,,1,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,Autocuration,8,,10576
,CHEMBL616573,,H,BAO_0000249,,,,,1449,,13949,,1,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,Expert,8,,10576
,CHEMBL616574,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1450,,12463,,1,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL616575,,H,BAO_0000221,,,,Hippocampus,1451,10000000.0,14829,,1,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,Expert,8,,10576
,CHEMBL872108,,H,BAO_0000221,,,,Hippocampus,1452,10000000.0,14829,,1,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,Autocuration,8,,10576
,CHEMBL616576,,H,BAO_0000357,,,,,1453,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,Autocuration,8,,10576
,CHEMBL616577,,H,BAO_0000249,,,,,1454,,403,,1,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,Autocuration,8,,10576
,CHEMBL616578,,H,BAO_0000249,,,,,1455,,403,,1,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,Autocuration,8,,10576
,CHEMBL616579,,H,BAO_0000357,,,,,1456,,3967,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,Expert,8,,10576
,CHEMBL616580,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1457,,12771,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Expert,9,,10576
,CHEMBL616581,,H,BAO_0000019,,,,,1458,,15086,,1,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,Autocuration,8,,10576
,CHEMBL616582,,H,BAO_0000221,,,,Hippocampus,1459,10000000.0,14909,,1,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616583,,H,BAO_0000221,,,,Hippocampus,1460,10000000.0,14949,,1,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,Expert,8,,10576
,CHEMBL616584,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1461,10000000.0,2309,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL616585,,H,BAO_0000357,,,,,1462,,4170,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL616586,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1463,10000000.0,11642,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Expert,9,,10576
,CHEMBL616587,,H,BAO_0000221,,,,Hippocampus,1464,10000000.0,11642,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616588,,H,BAO_0000221,,,,Hippocampus,1465,10000000.0,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616589,,H,BAO_0000221,,,,Hippocampus,1466,10000000.0,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,Autocuration,8,,10576
,CHEMBL616590,,H,BAO_0000221,,,,Hippocampus,1467,10000000.0,12953,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,10576
,CHEMBL616591,,H,BAO_0000219,,,,,1468,,12903,,1,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,CHO,Expert,8,,10576
,CHEMBL616592,,H,BAO_0000357,,,,,1469,,12536,,1,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
,CHEMBL616593,,H,BAO_0000357,,,,,1470,,10058,,1,,The inhibition activity of 5-HT1A at 1 uM,B,,,Autocuration,8,,10576
,CHEMBL616594,,H,BAO_0000219,,,,,1471,,12902,,1,485.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,CHO-K1,Expert,8,,10576
,CHEMBL616595,,H,BAO_0000249,,,,,1472,,14057,,1,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,Expert,8,,10576
,CHEMBL616596,,H,BAO_0000357,,,,,1473,,11296,,1,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,Autocuration,8,,10576
,CHEMBL616597,,H,BAO_0000221,,,,Hippocampus,1474,10000000.0,11296,,1,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616598,,H,BAO_0000221,,,,Hippocampus,1475,10000000.0,11296,,1,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,Expert,8,,10576
Membranes,CHEMBL616599,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1476,,16616,,1,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Expert,9,,10576
Membranes,CHEMBL616600,10116.0,D,BAO_0000249,Rattus norvegicus,,,Hippocampus,1477,10000000.0,16616,,1,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Expert,9,,10576
,CHEMBL616601,,H,BAO_0000019,,,,,1478,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,Autocuration,8,,10576
,CHEMBL616602,,H,BAO_0000019,,,,,1479,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,Autocuration,8,,10576
,CHEMBL616603,,H,BAO_0000019,,,,,1480,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,Autocuration,8,,10576
,CHEMBL616604,,H,BAO_0000019,,,,,1481,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,Autocuration,8,,10576
,CHEMBL616316,,H,BAO_0000249,,,,,1482,,17136,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,Autocuration,8,,10576
,CHEMBL616317,,H,BAO_0000249,,,,,1483,,17136,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,Autocuration,8,,10576
,CHEMBL616318,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1484,,16616,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Expert,9,,10576
,CHEMBL616319,,H,BAO_0000221,,,,Hippocampus,1485,10000000.0,17331,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,Autocuration,8,,10576
,CHEMBL616320,,H,BAO_0000221,,,,Hippocampus,1486,10000000.0,17331,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,Autocuration,8,,10576
,CHEMBL616321,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1487,10000000.0,17167,,1,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Expert,9,,10576
,CHEMBL616322,,H,BAO_0000019,,,,,1488,,15740,,1,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,Autocuration,8,,10576
,CHEMBL616323,,H,BAO_0000019,,,,,1489,,15740,,1,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,Autocuration,8,,10576
,CHEMBL616324,,H,BAO_0000357,,,,,1490,,4671,,1,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,Autocuration,8,,10576
,CHEMBL616325,,H,BAO_0000221,,,,Hippocampus,1491,10000000.0,10058,,1,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,Autocuration,8,,10576
,CHEMBL616326,,H,BAO_0000221,,,,Hippocampus,1492,10000000.0,10058,,1,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,Autocuration,8,,10576
,CHEMBL616327,,H,BAO_0000221,,,,Hippocampus,1493,10000000.0,10058,,1,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,Autocuration,8,,10576
,CHEMBL616328,,H,BAO_0000357,,,,,1494,,12073,,1,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,10576
,CHEMBL858110,,H,BAO_0000249,,,,,1495,,2759,,1,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,Autocuration,8,,10576
,CHEMBL616329,,H,BAO_0000249,,,,,1496,,2759,,1,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,Autocuration,8,,10576
,CHEMBL616330,,H,BAO_0000249,,,,,1497,,2759,,1,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,Autocuration,8,,10576
,CHEMBL616331,,H,BAO_0000249,,,,,1498,,2759,,1,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,Autocuration,8,,10576
,CHEMBL616332,,H,BAO_0000249,,,,,1499,,2759,,1,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,Autocuration,8,,10576
,CHEMBL857063,,H,BAO_0000249,,,,Brain,1500,955.0,9737,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,Autocuration,8,,10576
,CHEMBL616333,,H,BAO_0000019,,,,,1501,,9737,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,Autocuration,8,,10576
,CHEMBL616334,,H,BAO_0000019,,,,,1502,,5717,,1,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,Expert,8,,10576
,CHEMBL616335,,H,BAO_0000221,,,,Hippocampus,1503,10000000.0,12253,,1,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616336,,H,BAO_0000019,,,,,1504,,14025,,1,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,Autocuration,8,,10576
,CHEMBL616337,,H,BAO_0000249,,,,,1505,,10425,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL616338,,H,BAO_0000019,,,,,1506,,14998,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,Autocuration,8,,10576
,CHEMBL616339,,H,BAO_0000221,,,,Hippocampus,1507,10000000.0,13694,,1,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,Autocuration,8,,10576
,CHEMBL616340,,H,BAO_0000221,,,,Hippocampus,1508,10000000.0,13694,,1,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,Autocuration,8,,10576
,CHEMBL616341,,H,BAO_0000357,,,,,1509,,4342,,1,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,10576
,CHEMBL616342,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1510,,12936,,1,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,10576
,CHEMBL616343,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1511,,13144,,1,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Expert,9,,10576
,CHEMBL616344,,H,BAO_0000019,,,,,1512,,13343,,1,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,Expert,8,,10576
,CHEMBL616345,,H,BAO_0000357,,,,,1513,,12132,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,Expert,8,,10576
,CHEMBL616346,,H,BAO_0000019,,,,,1514,,15419,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,Expert,8,,10576
,CHEMBL616347,,H,BAO_0000221,,,,Hippocampus,1515,10000000.0,1479,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Autocuration,8,,10576
,CHEMBL616348,,H,BAO_0000019,,,,,1516,,14287,,1,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,Expert,8,,10576
,CHEMBL616349,,H,BAO_0000357,,,,,1517,,13116,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,10576
Membranes,CHEMBL616152,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1518,,2759,,1,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Expert,9,,10576
,CHEMBL616153,,H,BAO_0000249,,,,,1519,,2759,,1,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,Autocuration,8,,10576
,CHEMBL616154,,H,BAO_0000019,,,,,1520,,14748,,1,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,Expert,8,,10576
,CHEMBL616155,,H,BAO_0000019,,,,,1521,,12304,,1,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,Autocuration,8,,10576
,CHEMBL616156,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1522,10000000.0,12409,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL616157,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,1523,10000000.0,12409,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Expert,9,,10576
,CHEMBL616158,,H,BAO_0000221,,,,Hippocampus,1524,10000000.0,13267,,1,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,Autocuration,8,,10576
,CHEMBL616159,,H,BAO_0000357,,,,,1525,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,Autocuration,8,,10576
,CHEMBL616160,,H,BAO_0000357,,,,,1526,,14256,,1,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,Expert,8,,10576
,CHEMBL616161,,H,BAO_0000019,,,,,1527,,16567,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,Autocuration,8,,10576
,CHEMBL616162,,H,BAO_0000019,,,,,1528,,15740,,1,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,Autocuration,8,,10576
,CHEMBL616163,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1529,,13278,,1,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Expert,9,,12687
Membranes,CHEMBL616164,,H,BAO_0000249,,,,,1530,,1970,,1,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Expert,8,,10626
,CHEMBL616165,,H,BAO_0000221,,,,Brain,1531,955.0,10034,,1,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,Autocuration,8,,10576
,CHEMBL616355,10116.0,H,BAO_0000019,Rattus norvegicus,,,,1532,,13348,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Autocuration,8,,51
,CHEMBL616356,,H,BAO_0000019,,,,,1533,,13630,,1,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,Autocuration,8,,10576
,CHEMBL616357,,H,BAO_0000221,,,,Brain,1534,955.0,10862,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,Autocuration,8,,10576
,CHEMBL616358,,H,BAO_0000019,,,,,1535,,12058,,1,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Autocuration,8,,10576
,CHEMBL616359,,H,BAO_0000357,,,,,1536,,4639,,1,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616360,,H,BAO_0000357,,,,,1537,,15453,,1,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,Expert,8,,51
,CHEMBL616361,,H,BAO_0000357,,,,,1538,,4820,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL616362,,H,BAO_0000357,,,,,1539,,1089,,1,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
Brain membranes,CHEMBL616363,,H,BAO_0000249,,,,,1540,,386,,1,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,Autocuration,8,,51
,CHEMBL616364,,H,BAO_0000357,,,,,1541,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,Autocuration,8,,51
,CHEMBL616365,,H,BAO_0000357,,,,,1542,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616366,,H,BAO_0000357,,,,,1543,,4402,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,Expert,8,,51
,CHEMBL872906,,H,BAO_0000357,,,,,1544,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,Expert,8,,51
,CHEMBL616367,,H,BAO_0000357,,,,,1545,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,Autocuration,8,,51
,CHEMBL616368,,H,BAO_0000357,,,,,1546,,2474,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616369,,H,BAO_0000357,,,,,1547,,4775,,1,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL616370,9606.0,D,BAO_0000357,Homo sapiens,,,,1548,,14294,,1,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Expert,9,,51
,CHEMBL616371,9606.0,D,BAO_0000357,Homo sapiens,,,,1549,,14294,,1,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Expert,9,,51
,CHEMBL616372,,H,BAO_0000219,,,,,1550,,12249,,1,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,Autocuration,8,,51
,CHEMBL616373,,H,BAO_0000219,,,,,1551,,11376,,1,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,Expert,8,,51
,CHEMBL616374,,H,BAO_0000218,,,,,1552,,2474,,1,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,Autocuration,8,,51
,CHEMBL616375,,H,BAO_0000221,,,,Hippocampus,1553,10000000.0,13311,,1,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,Autocuration,8,,51
,CHEMBL616376,,H,BAO_0000357,,,,,1554,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL857064,,H,BAO_0000357,,,,,1555,,1633,,1,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,Expert,8,,51
,CHEMBL616377,,H,BAO_0000357,,,,,1556,,11866,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL616378,,H,BAO_0000357,,,,,1557,,4373,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,Autocuration,8,,51
,CHEMBL616379,,H,BAO_0000357,,,,,1558,,4687,,1,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,51
,CHEMBL616380,,H,BAO_0000357,,,,,1559,,16946,,1,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616381,,H,BAO_0000357,,,,,1560,,13291,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,Autocuration,8,,11863
,CHEMBL616382,,H,BAO_0000357,,,,,1561,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616383,,H,BAO_0000357,,,,,1562,,10812,,1,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,Autocuration,8,,11863
,CHEMBL616350,10090.0,D,BAO_0000219,Mus musculus,,,,1563,,3032,,1,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,CHO,Expert,9,,11863
,CHEMBL616351,,H,BAO_0000357,,,,,1564,,16655,,1,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616352,,H,BAO_0000357,,,,,1565,,14532,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,Autocuration,8,,11863
,CHEMBL616353,,H,BAO_0000357,,,,,1566,,13944,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616354,,H,BAO_0000357,,,,,1567,,13033,,1,,Binding affinity against serotonergic 5-HT1a receptor,B,,,Autocuration,8,,11863
,CHEMBL616508,,H,BAO_0000357,,,,,1568,,10321,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,11863
,CHEMBL616559,10090.0,D,BAO_0000357,Mus musculus,,,,1569,,2968,,1,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,11863
,CHEMBL616560,,H,BAO_0000357,,,,,1570,,13964,,1,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616561,,H,BAO_0000357,,,,,1571,,15527,,1,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,Autocuration,8,,11863
,CHEMBL616562,,H,BAO_0000219,,,,,1572,,12248,,1,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,Autocuration,8,,11863
,CHEMBL616563,,H,BAO_0000219,,,,,1573,,12249,,1,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,Autocuration,8,,11863
,CHEMBL616564,,H,BAO_0000357,,,,,1574,,15120,,1,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616565,,H,BAO_0000357,,,,,1575,,13313,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,Autocuration,8,,11863
,CHEMBL616566,,H,BAO_0000218,,,,,1576,,2613,,1,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616989,,H,BAO_0000357,,,,,1577,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,Autocuration,8,,11863
,CHEMBL857975,,H,BAO_0000357,,,,,1578,,2201,,1,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616990,10090.0,D,BAO_0000357,Mus musculus,,,,1579,,1274,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Expert,9,,11863
,CHEMBL616991,,H,BAO_0000357,,,,,1580,,1317,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,Autocuration,8,,11863
,CHEMBL616992,,H,BAO_0000357,,,,,1581,,12146,,1,,Tested against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616993,,H,BAO_0000357,,,,,1582,,14059,,1,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,11863
,CHEMBL616994,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1583,,14025,,1,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Expert,8,,106
,CHEMBL616995,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1584,,14025,,1,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Autocuration,8,,106
,CHEMBL616996,9593.0,D,BAO_0000219,Gorilla gorilla,,,,1585,,14447,,1,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,HEK293,Intermediate,9,,105571
,CHEMBL616997,10141.0,H,BAO_0000218,Cavia porcellus,,,,1586,,3025,,1,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Autocuration,8,,106
,CHEMBL616998,10141.0,H,BAO_0000218,Cavia porcellus,,,,1587,,3025,,1,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Autocuration,8,,106
,CHEMBL616999,10141.0,H,BAO_0000019,Cavia porcellus,,,,1588,,15329,,1,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Autocuration,8,,106
,CHEMBL617000,10141.0,H,BAO_0000019,Cavia porcellus,,,,1589,,15329,,1,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Autocuration,8,,106
,CHEMBL617001,10141.0,H,BAO_0000019,Cavia porcellus,,,,1590,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Autocuration,8,,106
,CHEMBL858111,10141.0,H,BAO_0000019,Cavia porcellus,,,,1591,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Autocuration,8,,106
,CHEMBL617002,,H,BAO_0000019,,,,,1592,,14165,,1,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,Autocuration,8,,106
,CHEMBL617003,,H,BAO_0000019,,,,,1593,,14214,,1,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,Autocuration,8,,106
,CHEMBL617004,,H,BAO_0000019,,,,,1594,,14214,,1,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,Autocuration,8,,106
,CHEMBL617005,9606.0,D,BAO_0000019,Homo sapiens,,,,1595,,14214,,1,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Expert,9,,106
,CHEMBL616623,9606.0,D,BAO_0000219,Homo sapiens,,,,1596,,13729,,1,485.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,CHO-K1,Expert,9,,106
,CHEMBL616624,,H,BAO_0000219,,,,,1597,,3025,,1,449.0,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,CHO,Autocuration,8,,106
,CHEMBL883243,,H,BAO_0000357,,,,,1598,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616625,,H,BAO_0000019,,,,,1599,,2391,,1,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,Autocuration,8,,106
,CHEMBL616626,,H,BAO_0000219,,,,,1600,,14956,,1,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,CHO,Expert,8,,106
,CHEMBL616627,,H,BAO_0000219,,,,,1601,,2598,,1,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,CHO,Autocuration,8,,106
,CHEMBL616628,,H,BAO_0000219,,,,,1602,,2598,,1,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,CHO,Autocuration,8,,106
,CHEMBL616629,,H,BAO_0000219,,,,,1603,,2598,,1,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,CHO,Autocuration,8,,106
,CHEMBL616630,,H,BAO_0000219,,,,,1604,,2598,,1,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,CHO,Autocuration,8,,106
,CHEMBL616631,,H,BAO_0000019,,,,,1605,,14956,,1,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,Expert,8,,106
,CHEMBL616632,,H,BAO_0000019,,,,,1606,,14956,,1,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,Autocuration,8,,106
,CHEMBL616633,9606.0,D,BAO_0000357,Homo sapiens,,,,1607,,14214,,1,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616634,,H,BAO_0000219,,,,,1608,,3463,,1,449.0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,CHO,Expert,8,,106
,CHEMBL616635,,H,BAO_0000357,,,,,1609,,15331,,1,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,106
,CHEMBL885358,9606.0,D,BAO_0000357,Homo sapiens,,,,1610,,16146,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,106
,CHEMBL616636,9606.0,D,BAO_0000219,Homo sapiens,,,,1611,,14159,,1,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,CHO,Expert,9,,106
,CHEMBL616637,,H,BAO_0000219,,,,,1612,,14158,,1,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,CHO,Expert,8,,106
,CHEMBL616638,,H,BAO_0000357,,,,,1613,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616639,,H,BAO_0000219,,,,,1614,,15250,,1,449.0,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,CHO,Expert,8,,106
,CHEMBL616640,,H,BAO_0000219,,,,,1615,,15250,,1,449.0,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,CHO,Expert,8,,106
,CHEMBL616641,,H,BAO_0000219,,,,,1616,,15331,,1,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,CHO,Expert,8,,106
,CHEMBL616642,,H,BAO_0000219,,,,,1617,,15332,,1,449.0,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,CHO,Expert,8,,106
,CHEMBL616643,,H,BAO_0000219,,,,,1618,,14956,,1,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,CHO,Expert,8,,106
,CHEMBL616644,,H,BAO_0000357,,,,,1619,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,Autocuration,8,,106
,CHEMBL616645,,H,BAO_0000357,,,,,1620,,14875,,1,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,Autocuration,8,,106
,CHEMBL616646,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1621,,14454,,1,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Autocuration,8,,105
,CHEMBL616647,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1622,,14454,,1,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Expert,8,,105
,CHEMBL616509,,H,BAO_0000357,,,,,1623,,16288,,1,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,Autocuration,8,,105
,CHEMBL616510,,H,BAO_0000357,,,,,1624,,16288,,1,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,Autocuration,8,,105
,CHEMBL616511,,H,BAO_0000357,,,,,1625,,16312,,1,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616512,9913.0,H,BAO_0000357,Bos taurus,,,,1626,,1348,,1,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Expert,8,,105
,CHEMBL616513,9913.0,H,BAO_0000357,Bos taurus,,,,1627,,5834,,1,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Autocuration,8,,105
,CHEMBL616514,9913.0,H,BAO_0000019,Bos taurus,,,Striatum,1628,2435.0,13366,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Autocuration,8,,105
,CHEMBL616515,9913.0,H,BAO_0000357,Bos taurus,,,,1629,,1414,,1,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Expert,8,,105
,CHEMBL616516,9913.0,H,BAO_0000019,Bos taurus,,,,1630,,14998,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Autocuration,8,,105
,CHEMBL616517,9913.0,H,BAO_0000357,Bos taurus,,,,1631,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Autocuration,8,,105
,CHEMBL616518,9913.0,H,BAO_0000357,Bos taurus,,,,1632,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Autocuration,8,,105
,CHEMBL616519,9913.0,H,BAO_0000357,Bos taurus,,,,1633,,10639,,1,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Autocuration,8,,105
,CHEMBL616520,9913.0,H,BAO_0000357,Bos taurus,,,,1634,,10639,,1,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Autocuration,8,,105
,CHEMBL616521,9913.0,H,BAO_0000357,Bos taurus,,,,1635,,1375,,1,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Autocuration,8,,105
,CHEMBL616522,9913.0,H,BAO_0000357,Bos taurus,,,,1636,,1375,,1,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Autocuration,8,,105
,CHEMBL884531,9913.0,H,BAO_0000357,Bos taurus,,,,1637,,16532,,1,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Autocuration,8,,105
,CHEMBL616523,9913.0,H,BAO_0000357,Bos taurus,,,,1638,,11147,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL616731,9913.0,H,BAO_0000019,Bos taurus,,,Striatum,1639,2435.0,13366,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Autocuration,8,,105
,CHEMBL616732,9913.0,H,BAO_0000019,Bos taurus,,,,1640,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Autocuration,8,,105
,CHEMBL616733,9913.0,H,BAO_0000357,Bos taurus,,,,1641,,16532,,1,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Autocuration,8,,105
,CHEMBL616734,9913.0,H,BAO_0000357,Bos taurus,,,,1642,,16532,,1,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Autocuration,8,,105
,CHEMBL616735,9913.0,H,BAO_0000249,Bos taurus,,,,1643,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Autocuration,8,,105
,CHEMBL616736,9913.0,H,BAO_0000249,Bos taurus,,,,1644,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Autocuration,8,,105
,CHEMBL616737,9913.0,H,BAO_0000019,Bos taurus,,,,1645,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Expert,8,,105
,CHEMBL616738,9913.0,H,BAO_0000019,Bos taurus,,,,1646,,14025,,1,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Autocuration,8,,105
,CHEMBL616739,9913.0,H,BAO_0000019,Bos taurus,,,,1647,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Expert,8,,105
,CHEMBL616740,9913.0,H,BAO_0000019,Bos taurus,,,,1648,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Expert,8,,105
,CHEMBL616741,9913.0,H,BAO_0000019,Bos taurus,,,,1649,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Expert,8,,105
,CHEMBL616742,9593.0,H,BAO_0000219,Gorilla gorilla,,,,1650,,14447,,1,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,HEK293,Autocuration,8,,105
,CHEMBL616743,10141.0,D,BAO_0000019,Cavia porcellus,,,,1651,,1375,,1,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Intermediate,9,,105570
,CHEMBL616744,10141.0,D,BAO_0000019,Cavia porcellus,,,,1652,,1375,,1,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Intermediate,9,,105570
,CHEMBL616745,10141.0,D,BAO_0000019,Cavia porcellus,,,,1653,,12409,,1,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Intermediate,9,,105570
,CHEMBL616746,10141.0,D,BAO_0000019,Cavia porcellus,,,,1654,,12409,,1,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Intermediate,9,,105570
,CHEMBL616747,10141.0,D,BAO_0000019,Cavia porcellus,,,,1655,,12409,,1,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Intermediate,9,,105570
,CHEMBL616748,10141.0,D,BAO_0000019,Cavia porcellus,,,,1656,,12409,,1,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Intermediate,9,,105570
,CHEMBL616648,10141.0,D,BAO_0000019,Cavia porcellus,,,,1657,,12409,,1,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Intermediate,9,,105570
,CHEMBL616649,10141.0,D,BAO_0000357,Cavia porcellus,,,,1658,,11574,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Intermediate,9,,105570
,CHEMBL616650,10141.0,D,BAO_0000357,Cavia porcellus,,,,1659,,1558,,1,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Intermediate,9,,105570
,CHEMBL616651,10141.0,D,BAO_0000218,Cavia porcellus,,,,1660,,12409,,1,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Intermediate,9,,105570
,CHEMBL616652,10141.0,D,BAO_0000218,Cavia porcellus,,,,1661,,12409,,1,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Intermediate,9,,105570
,CHEMBL616653,10141.0,D,BAO_0000218,Cavia porcellus,,,,1662,,12409,,1,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Intermediate,9,,105570
,CHEMBL616654,10141.0,D,BAO_0000218,Cavia porcellus,,,,1663,,12409,,1,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Intermediate,9,,105570
,CHEMBL616655,10141.0,D,BAO_0000019,Cavia porcellus,,,,1664,,12253,,1,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Intermediate,9,,105570
,CHEMBL616656,10141.0,D,BAO_0000357,Cavia porcellus,,,,1665,,12936,,1,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Intermediate,9,,105570
,CHEMBL616657,10141.0,H,BAO_0000019,Cavia porcellus,,,,1666,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Autocuration,8,,105
,CHEMBL616658,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,1667,2435.0,12409,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Intermediate,9,,105570
,CHEMBL616659,10141.0,D,BAO_0000357,Cavia porcellus,,,,1668,,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Intermediate,9,,105570
,CHEMBL616660,,H,BAO_0000357,,,,,1669,,5254,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,51
,CHEMBL616661,,H,BAO_0000357,,,,,1670,,13051,,1,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,Autocuration,8,,106
,CHEMBL616662,,H,BAO_0000019,,,,,1671,,3463,,1,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,Expert,8,,105
,CHEMBL616663,,H,BAO_0000019,,,,,1672,,15315,,1,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,105
,CHEMBL616664,,H,BAO_0000019,,,,,1673,,6011,,1,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,105
,CHEMBL881820,9606.0,D,BAO_0000219,Homo sapiens,,,,1674,,14159,,1,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,CHO,Expert,9,,105
,CHEMBL616665,,H,BAO_0000219,,,,,1675,,14159,,1,449.0,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,CHO,Autocuration,8,,105
,CHEMBL616666,,H,BAO_0000219,,,,,1676,,15250,,1,449.0,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,CHO,Expert,8,,105
,CHEMBL616667,,H,BAO_0000219,,,,,1677,,15250,,1,449.0,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,CHO,Autocuration,8,,105
,CHEMBL616668,,H,BAO_0000219,,,,,1678,,15331,,1,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,CHO,Expert,8,,105
,CHEMBL616669,9606.0,D,BAO_0000219,Homo sapiens,,,,1679,,15332,,1,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,CHO,Expert,9,,105
,CHEMBL617040,,H,BAO_0000219,,,,,1680,,15332,,1,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,CHO,Expert,8,,105
,CHEMBL617041,,H,BAO_0000219,,,,,1681,,3294,,1,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,CHO,Autocuration,8,,105
,CHEMBL617042,,H,BAO_0000219,,,,,1682,,14158,,1,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,CHO,Expert,8,,105
,CHEMBL617043,,H,BAO_0000219,,,,,1683,,14956,,1,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,CHO,Expert,8,,105
,CHEMBL617044,,H,BAO_0000019,,,,,1684,,12469,,1,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,105
,CHEMBL617045,,H,BAO_0000219,,,,,1685,,3463,,1,449.0,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,CHO,Expert,8,,105
,CHEMBL617046,9606.0,D,BAO_0000219,Homo sapiens,,,,1686,,15250,,1,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,CHO,Expert,9,,105
,CHEMBL617047,9606.0,D,BAO_0000219,Homo sapiens,,,,1687,,15250,,1,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,CHO,Expert,9,,105
,CHEMBL617048,,H,BAO_0000019,,,,,1688,,14956,,1,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,Expert,8,,105
,CHEMBL616897,,H,BAO_0000019,,,,,1689,,14159,,1,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,Autocuration,8,,105
,CHEMBL616898,9606.0,D,BAO_0000019,Homo sapiens,,,,1690,,14159,,1,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Expert,9,,105
,CHEMBL858201,9606.0,D,BAO_0000219,Homo sapiens,,,,1691,,14499,,1,449.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,CHO,Expert,9,,105
,CHEMBL616899,,H,BAO_0000019,,,,,1692,,15315,,1,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,105
,CHEMBL616900,,H,BAO_0000219,,,,,1693,,3294,,1,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,Autocuration,8,,105
,CHEMBL616901,,H,BAO_0000219,,,,,1694,,3463,,1,449.0,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,CHO,Expert,8,,105
,CHEMBL616902,,H,BAO_0000357,,,,,1695,,15331,,1,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,105
,CHEMBL616903,9606.0,D,BAO_0000219,Homo sapiens,,,,1696,,14159,,1,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,Expert,9,,105
,CHEMBL616904,,H,BAO_0000219,,,,,1697,,14158,,1,449.0,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,CHO,Expert,8,,105
,CHEMBL616905,,H,BAO_0000357,,,,,1698,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616906,,H,BAO_0000219,,,,,1699,,15250,,1,449.0,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,CHO,Expert,8,,105
,CHEMBL616907,,H,BAO_0000219,,,,,1700,,15250,,1,449.0,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,Expert,8,,105
,CHEMBL616908,,H,BAO_0000219,,,,,1701,,15331,,1,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,Expert,8,,105
,CHEMBL616909,9606.0,D,BAO_0000219,Homo sapiens,,,,1702,,15332,,1,449.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,Expert,9,,105
,CHEMBL616910,9606.0,D,BAO_0000219,Homo sapiens,,,,1703,,14499,,1,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,Expert,9,,105
,CHEMBL616911,,H,BAO_0000219,,,,,1704,,15332,,1,449.0,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,Expert,8,,105
,CHEMBL616912,,H,BAO_0000219,,,,,1705,,14956,,1,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,Expert,8,,105
,CHEMBL616913,,H,BAO_0000357,,,,,1706,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,Autocuration,8,,105
,CHEMBL616914,9606.0,D,BAO_0000219,Homo sapiens,,,,1707,,6011,,1,449.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,CHO,Expert,9,,105
,CHEMBL616915,,H,BAO_0000219,,,,,1708,,16190,,1,449.0,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,8,,105
,CHEMBL616916,,H,BAO_0000019,,,,,1709,,14165,,1,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,Autocuration,8,,105
,CHEMBL616917,9606.0,D,BAO_0000357,Homo sapiens,,,,1710,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616918,,H,BAO_0000357,,,,,1711,,15527,,1,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,Autocuration,8,,105
,CHEMBL616919,,H,BAO_0000219,,,,,1712,,6328,,1,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,Expert,8,,105
,CHEMBL616920,,H,BAO_0000357,,,,,1713,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL872914,,H,BAO_0000357,,,,,1714,,14770,,1,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,105
,CHEMBL616921,,H,BAO_0000357,,,,,1715,,2598,,1,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,Autocuration,8,,105
,CHEMBL616922,,H,BAO_0000357,,,,,1716,,6897,,1,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,Expert,8,,105
,CHEMBL616923,,H,BAO_0000357,,,,,1717,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616924,,H,BAO_0000357,,,,,1718,,5843,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,Expert,8,,105
,CHEMBL875909,,H,BAO_0000357,,,,,1719,,14454,,1,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,Expert,8,,105
,CHEMBL616925,,H,BAO_0000357,,,,,1720,,14454,,1,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,Autocuration,8,,105
,CHEMBL616926,,H,BAO_0000357,,,,,1721,,14454,,1,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,Autocuration,8,,105
,CHEMBL616927,,H,BAO_0000357,,,,,1722,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616928,,H,BAO_0000219,,,,,1723,,13729,,1,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,CHO-K1,Expert,8,,105
,CHEMBL616929,9606.0,D,BAO_0000219,Homo sapiens,,,,1724,,6011,,1,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Expert,9,,105
,CHEMBL616930,9606.0,D,BAO_0000357,Homo sapiens,,,,1725,,4234,,1,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616931,,H,BAO_0000019,,,,,1726,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,Expert,8,,105
,CHEMBL616932,,H,BAO_0000357,,,,,1727,,3025,,1,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,Autocuration,8,,105
,CHEMBL616933,,H,BAO_0000357,,,,,1728,,15315,,1,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,Expert,8,,105
,CHEMBL616934,9606.0,D,BAO_0000219,Homo sapiens,,,,1729,,14214,,1,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Expert,9,,105
,CHEMBL616935,9606.0,D,BAO_0000357,Homo sapiens,,,,1730,,3804,,1,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616936,,H,BAO_0000357,,,,,1731,,16700,,1,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,Autocuration,8,,105
,CHEMBL616937,9606.0,D,BAO_0000357,Homo sapiens,,,,1732,,2391,,1,,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Expert,9,,105
,CHEMBL616938,9606.0,D,BAO_0000357,Homo sapiens,,,,1733,,4175,,1,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616939,,H,BAO_0000019,,,,,1734,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616940,,H,BAO_0000019,,,,,1735,,17085,,1,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,Expert,8,,105
,CHEMBL616941,9606.0,D,BAO_0000357,Homo sapiens,,,,1736,,15926,,1,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Expert,9,,105
,CHEMBL616942,,H,BAO_0000219,,,,,1737,,16312,,1,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,CHO-K1,Autocuration,8,,105
,CHEMBL616943,,H,BAO_0000219,,,,,1738,,16312,,1,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,CHO-K1,Autocuration,8,,105
,CHEMBL616944,,H,BAO_0000219,,,,,1739,,14956,,1,449.0,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,CHO,Autocuration,4,,104802
,CHEMBL616945,,H,BAO_0000019,,,,,1740,,3294,,1,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,Autocuration,8,,105
,CHEMBL616946,,H,BAO_0000357,,,,,1741,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,105
,CHEMBL616947,,H,BAO_0000019,,,,,1742,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,Autocuration,8,,105
,CHEMBL616948,,H,BAO_0000219,,,,,1743,,16312,,1,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,CHO-K1,Expert,8,,105
,CHEMBL616851,,H,BAO_0000357,,,,,1744,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616852,,H,BAO_0000357,,,,,1745,,5105,,1,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616853,,H,BAO_0000357,,,,,1746,,14499,,1,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616854,9606.0,D,BAO_0000357,Homo sapiens,,,,1747,,15926,,1,,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616855,9606.0,D,BAO_0000219,Homo sapiens,,,,1748,,4540,,1,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,Expert,9,,105
,CHEMBL616856,,H,BAO_0000219,,,,,1749,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,CHO,Autocuration,8,,105
,CHEMBL616857,,H,BAO_0000219,,,,,1750,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,105
,CHEMBL616858,,H,BAO_0000357,,,,,1751,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL616859,,H,BAO_0000219,,,,,1752,,15779,,1,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,105
,CHEMBL616860,,H,BAO_0000219,,,,,1753,,15779,,1,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,CHO,Autocuration,8,,105
,CHEMBL616861,,H,BAO_0000219,,,,,1754,,17451,,1,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,HEK293,Autocuration,8,,105
,CHEMBL616541,,H,BAO_0000219,,,,,1755,,17451,,1,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,HEK293,Autocuration,8,,105
,CHEMBL616542,,H,BAO_0000219,,,,,1756,,17451,,1,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,HEK293,Autocuration,8,,105
,CHEMBL616543,,H,BAO_0000219,,,,,1757,,4199,,1,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,Autocuration,8,,105
,CHEMBL616544,9606.0,D,BAO_0000357,Homo sapiens,,,,1758,,14875,,1,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL616545,,H,BAO_0000219,,,,,1759,,15146,,1,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,CHO,Autocuration,8,,105
,CHEMBL616546,,H,BAO_0000357,,,,,1760,,5213,,1,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,Autocuration,8,,105
,CHEMBL616547,,H,BAO_0000219,,,,,1761,,14818,,1,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,CHO,Autocuration,8,,105
,CHEMBL616548,,H,BAO_0000219,,,,,1762,,4829,,1,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,105
,CHEMBL616549,,H,BAO_0000019,,,,,1763,,14454,,1,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,Expert,8,,105
,CHEMBL616550,,H,BAO_0000019,,,,,1764,,14454,,1,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,Expert,8,,105
,CHEMBL857066,,H,BAO_0000357,,,,,1765,,5254,,1,,Binding affinity against 5-HT2C receptor,B,,,Autocuration,8,,108
,CHEMBL616551,,H,BAO_0000357,,,,,1766,,5254,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,108
,CHEMBL616552,,H,BAO_0000357,,,,,1767,,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,Autocuration,8,,10577
,CHEMBL832876,,H,BAO_0000019,,,,,1768,,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,Autocuration,8,,10577
,CHEMBL616553,,H,BAO_0000019,,,,,1769,,12352,,1,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,Expert,8,,10577
,CHEMBL616554,,H,BAO_0000357,,,,,1770,,9098,,1,,Binding affinity towards 5-HT1B was determined,B,,,Autocuration,8,,10577
,CHEMBL616555,,H,BAO_0000019,,,,,1771,,14430,,1,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,Expert,8,,10577
,CHEMBL616556,,H,BAO_0000019,,,,,1772,,13657,,1,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,Expert,8,,10577
,CHEMBL616557,,H,BAO_0000019,,,,,1773,,13657,,1,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,Autocuration,8,,10577
,CHEMBL616558,,H,BAO_0000019,,,,,1774,,15854,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,Expert,8,,10577
,CHEMBL616749,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1775,,10639,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Expert,9,,10577
,CHEMBL616750,,H,BAO_0000357,,,,,1776,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,Autocuration,8,,10577
,CHEMBL616751,,H,BAO_0000357,,,,,1777,,10025,,1,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,Autocuration,8,,10577
,CHEMBL616752,,H,BAO_0000249,,,,,1778,,14286,,1,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,Autocuration,8,,10577
,CHEMBL616753,,H,BAO_0000019,,,,Striatum,1779,2435.0,3651,,1,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,Autocuration,8,,10577
,CHEMBL616754,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1780,,14178,,1,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,10577
,CHEMBL616755,,H,BAO_0000019,,,,,1781,,10639,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,Autocuration,8,,10577
,CHEMBL616756,,H,BAO_0000019,,,,Striatum,1782,2435.0,13605,,1,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,Autocuration,8,,10577
,CHEMBL616757,,H,BAO_0000019,,,,Striatum,1783,2435.0,5834,,1,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,Autocuration,8,,10577
,CHEMBL616758,,H,BAO_0000357,,,,Striatum,1784,2435.0,10922,,1,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,Autocuration,8,,10577
,CHEMBL616759,,H,BAO_0000249,,,,,1785,,14286,,1,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,Autocuration,8,,10577
,CHEMBL616760,,H,BAO_0000357,,,,,1786,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,Autocuration,8,,10577
,CHEMBL616761,,H,BAO_0000019,,,,Striatum,1787,2435.0,14826,,1,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,Autocuration,8,,10577
,CHEMBL616762,,H,BAO_0000019,,,,Striatum,1788,2435.0,9699,,1,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,Autocuration,8,,10577
,CHEMBL616763,,H,BAO_0000019,,,,,1789,,14423,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,Autocuration,8,,10577
,CHEMBL872909,,H,BAO_0000357,,,,,1790,,10062,,1,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,Expert,8,,10577
,CHEMBL616764,,H,BAO_0000357,,,,,1791,,10062,,1,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,10577
,CHEMBL616765,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1792,,12280,,1,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,10577
,CHEMBL616766,,H,BAO_0000357,,,,Striatum,1793,2435.0,15412,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,Autocuration,8,,10577
,CHEMBL616767,,H,BAO_0000357,,,,Striatum,1794,2435.0,15412,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,Autocuration,8,,10577
,CHEMBL616768,,H,BAO_0000357,,,,,1795,,10062,,1,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,10577
,CHEMBL616769,,H,BAO_0000357,,,,,1796,,11147,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,10577
,CHEMBL616770,,H,BAO_0000019,,,,,1797,,9547,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,Autocuration,8,,10577
,CHEMBL616771,,H,BAO_0000019,,,,,1798,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,Autocuration,8,,10577
,CHEMBL616772,,H,BAO_0000019,,,,Striatum,1799,2435.0,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,Autocuration,8,,10577
,CHEMBL616773,,H,BAO_0000019,,,,,1800,,9098,,1,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,Expert,8,,10577
,CHEMBL616774,,H,BAO_0000019,,,,,1801,,9098,,1,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,Autocuration,8,,10577
,CHEMBL616775,,H,BAO_0000357,,,,,1802,,9699,,1,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,10577
,CHEMBL616776,,H,BAO_0000249,,,,,1803,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,Autocuration,8,,10577
,CHEMBL616777,,H,BAO_0000357,,,,,1804,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,Autocuration,8,,10577
,CHEMBL616778,,H,BAO_0000357,,,,,1805,,16700,,1,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,Autocuration,8,,10577
,CHEMBL616779,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1806,,403,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Expert,9,,10577
,CHEMBL616780,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1807,,12771,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Expert,9,,10577
,CHEMBL616781,,H,BAO_0000019,,,,,1808,,11642,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,Autocuration,8,,10577
,CHEMBL616782,,H,BAO_0000357,,,,,1809,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,Autocuration,8,,10577
,CHEMBL616783,,H,BAO_0000357,,,,,1810,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,Autocuration,8,,10577
,CHEMBL616784,,H,BAO_0000019,,,,Striatum,1811,2435.0,12953,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,Expert,8,,10577
,CHEMBL616785,,H,BAO_0000357,,,,,1812,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,Autocuration,8,,10577
,CHEMBL857067,,H,BAO_0000249,,,,Brain,1813,955.0,9737,,1,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,Autocuration,8,,10577
,CHEMBL616786,,H,BAO_0000019,,,,,1814,,9737,,1,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,Autocuration,8,,10577
,CHEMBL616787,,H,BAO_0000249,,,,Brain,1815,955.0,9737,,1,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,Autocuration,8,,10577
,CHEMBL616788,,H,BAO_0000357,,,,,1816,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,Autocuration,8,,10577
,CHEMBL616789,,H,BAO_0000357,,,,,1817,,5033,,1,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,10577
,CHEMBL616790,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1818,,9786,,1,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Expert,9,,10577
,CHEMBL616791,,H,BAO_0000357,,,,,1819,,13116,,1,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,Expert,8,,10577
,CHEMBL616792,,H,BAO_0000019,,,,,1820,,16429,,1,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,Autocuration,8,,10577
,CHEMBL616793,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1821,,12409,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Expert,9,,10577
,CHEMBL616794,,H,BAO_0000357,,,,,1822,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,10577
,CHEMBL616795,,H,BAO_0000357,,,,,1823,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,10577
,CHEMBL616796,,H,BAO_0000019,,,,,1824,,5486,,1,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,Autocuration,4,,104686
,CHEMBL616797,,H,BAO_0000357,,,,,1825,,4639,,1,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
Brain membranes,CHEMBL616798,,H,BAO_0000249,,,,,1826,,386,,1,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,Autocuration,8,,106
,CHEMBL616799,,H,BAO_0000357,,,,,1827,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,Autocuration,8,,106
,CHEMBL616800,,H,BAO_0000357,,,,,1828,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,Autocuration,8,,106
,CHEMBL616801,,H,BAO_0000357,,,,,1829,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616802,,H,BAO_0000357,,,,,1830,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,Autocuration,8,,106
,CHEMBL616803,,H,BAO_0000357,,,,,1831,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,Autocuration,8,,106
,CHEMBL857068,,H,BAO_0000357,,,,,1832,,1633,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,Expert,8,,106
,CHEMBL616804,,H,BAO_0000357,,,,,1833,,1633,,1,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,Autocuration,8,,106
,CHEMBL616805,,H,BAO_0000357,,,,,1834,,4373,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,Autocuration,8,,106
,CHEMBL616806,,H,BAO_0000357,,,,,1835,,4687,,1,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616807,,H,BAO_0000357,,,,,1836,,11574,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Autocuration,8,,106
,CHEMBL616808,,H,BAO_0000357,,,,,1837,,10321,,1,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,Autocuration,8,,106
,CHEMBL616809,,H,BAO_0000357,,,,,1838,,15527,,1,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,106
,CHEMBL616810,,H,BAO_0000357,,,,,1839,,17200,,1,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,Autocuration,8,,106
,CHEMBL616811,,H,BAO_0000224,,,,,1840,,14423,,1,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,Autocuration,4,,104802
,CHEMBL616812,9913.0,H,BAO_0000357,Bos taurus,,,,1841,,5834,,1,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Autocuration,8,,108
,CHEMBL616813,9823.0,H,BAO_0000357,Sus scrofa,,,,1842,,11473,,1,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL616814,9823.0,H,BAO_0000357,Sus scrofa,,,,1843,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL616815,9823.0,H,BAO_0000357,Sus scrofa,,,,1844,,10639,,1,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Autocuration,8,,108
,CHEMBL616816,9823.0,H,BAO_0000357,Sus scrofa,,,,1845,,10639,,1,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Autocuration,8,,108
,CHEMBL616817,9823.0,H,BAO_0000357,Sus scrofa,,,,1846,,14331,,1,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Autocuration,8,,108
,CHEMBL616818,9823.0,H,BAO_0000357,Sus scrofa,,,,1847,,10796,,1,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Autocuration,8,,108
,CHEMBL616819,9823.0,H,BAO_0000357,Sus scrofa,,,,1848,,9098,,1,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Expert,8,,108
,CHEMBL616820,9823.0,H,BAO_0000357,Sus scrofa,,,,1849,,14331,,1,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Expert,8,,108
,CHEMBL616821,9823.0,H,BAO_0000019,Sus scrofa,,,,1850,,11828,,1,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Expert,8,,108
,CHEMBL616822,9823.0,H,BAO_0000357,Sus scrofa,,,,1851,,11866,,1,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Autocuration,8,,108
,CHEMBL616823,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1852,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Autocuration,8,,108
,CHEMBL616824,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1853,,188,,1,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Autocuration,9,,12689
,CHEMBL616825,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1854,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Autocuration,9,,12689
,CHEMBL616826,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1855,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Autocuration,9,,12689
,CHEMBL616827,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1856,,11624,,1,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Expert,9,,12689
,CHEMBL616828,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1857,,11139,,1,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Autocuration,9,,12689
,CHEMBL616829,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1858,,11147,,1,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Autocuration,9,,12689
,CHEMBL616830,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1859,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Autocuration,9,,12689
,CHEMBL616831,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1860,,11624,,1,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Expert,9,,12689
,CHEMBL616832,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1861,,11662,,1,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Autocuration,9,,12689
,CHEMBL616833,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1862,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Autocuration,9,,12689
,CHEMBL616834,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1863,,11662,,1,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Expert,9,,12689
,CHEMBL829595,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1864,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Autocuration,9,,12689
,CHEMBL616835,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1865,,9098,,1,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Autocuration,9,,12689
,CHEMBL872910,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1866,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Autocuration,9,,12689
,CHEMBL616836,,H,BAO_0000357,,,,,1867,,11933,,1,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,Expert,8,,12689
,CHEMBL616837,10116.0,D,BAO_0000357,Rattus norvegicus,,,,1868,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Autocuration,9,,12689
,CHEMBL616466,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1869,,12253,,1,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Autocuration,9,,12689
,CHEMBL616467,10116.0,D,BAO_0000219,Rattus norvegicus,,,,1870,,12253,,1,722.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,HEK293,Autocuration,9,,12689
,CHEMBL616468,,H,BAO_0000357,,,,,1871,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,Autocuration,8,,108
,CHEMBL616469,,H,BAO_0000357,,,,,1872,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL616470,,H,BAO_0000357,,,,,1873,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL616471,,H,BAO_0000357,,,,,1874,,11574,,1,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Autocuration,8,,12689
,CHEMBL616472,,H,BAO_0000357,,,,,1875,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,Autocuration,8,,12689
,CHEMBL616473,,H,BAO_0000357,,,,,1876,,13944,,1,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Autocuration,8,,12689
,CHEMBL616474,,H,BAO_0000357,,,,,1877,,13033,,1,,Binding affinity against serotonergic 5-HT1c receptor,B,,,Autocuration,8,,12689
,CHEMBL616475,,H,BAO_0000357,,,,,1878,,10321,,1,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,Autocuration,8,,12689
,CHEMBL616476,,H,BAO_0000357,,,,,1879,,11866,,1,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,Autocuration,8,,12689
,CHEMBL616477,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1880,,14454,,1,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Autocuration,8,,105
,CHEMBL616478,,H,BAO_0000224,,,,,1881,,11574,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616479,,H,BAO_0000224,,,,,1882,,11574,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616480,,H,BAO_0000019,,,,,1883,,13631,,1,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,Autocuration,4,,104686
,CHEMBL616481,10116.0,D,BAO_0000019,Rattus norvegicus,,,,1884,,9630,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Autocuration,5,,104686
,CHEMBL616482,10116.0,D,BAO_0000249,Rattus norvegicus,,,,1885,,8822,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Autocuration,5,,104686
,CHEMBL884713,10116.0,D,BAO_0000221,Rattus norvegicus,,,Brain,1886,955.0,9064,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Autocuration,5,,104686
,CHEMBL616483,,H,BAO_0000224,,,,,1887,,8868,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,Autocuration,4,,104686
,CHEMBL616484,,H,BAO_0000224,,,,,1888,,9064,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,Autocuration,4,,104686
,CHEMBL616485,,H,BAO_0000019,,,,,1889,,9806,,1,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,Autocuration,4,,104686
,CHEMBL616486,,H,BAO_0000224,,,,,1890,,9098,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,Autocuration,4,,104686
,CHEMBL616487,,H,BAO_0000224,,,,,1891,,8868,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,Autocuration,4,,104686
,CHEMBL616488,,H,BAO_0000224,,,,,1892,,12765,,1,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,Autocuration,4,,104686
,CHEMBL616489,,H,BAO_0000019,,,,,1893,,11049,,1,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616490,,H,BAO_0000019,,,,,1894,,11049,,1,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616491,,H,BAO_0000019,,,,,1895,,11049,,1,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,Autocuration,4,,104686
,CHEMBL616492,,H,BAO_0000019,,,,,1896,,11049,,1,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,Autocuration,4,,104686
,CHEMBL616493,,H,BAO_0000019,,,,,1897,,11049,,1,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616494,,H,BAO_0000019,,,,,1898,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,Autocuration,4,,104686
,CHEMBL616495,,H,BAO_0000019,,,,,1899,,11473,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL616496,,H,BAO_0000019,,,,,1900,,3086,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,Autocuration,4,,104686
,CHEMBL616497,,H,BAO_0000019,,,,,1901,,11049,,1,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616498,,H,BAO_0000019,,,,,1902,,11049,,1,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616499,,H,BAO_0000019,,,,,1903,,10639,,1,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,Autocuration,4,,104686
,CHEMBL616500,,H,BAO_0000019,,,,,1904,,10922,,1,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,Autocuration,4,,104686
,CHEMBL616501,10116.0,D,BAO_0000221,Rattus norvegicus,,,Brain,1905,955.0,9064,,1,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Autocuration,5,,104686
,CHEMBL616502,,H,BAO_0000221,,,,Brain,1906,955.0,10748,,1,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,Autocuration,4,,104686
Membranes,CHEMBL884529,,H,BAO_0000249,,,,,1907,,11614,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Autocuration,4,,104686
Membranes,CHEMBL616503,,H,BAO_0000249,,,,,1908,,11615,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Autocuration,4,,104686
,CHEMBL616964,,H,BAO_0000224,,,,,1909,,11615,,1,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
Membranes,CHEMBL616965,,H,BAO_0000249,,,,,1910,,11614,,1,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Autocuration,4,,104686
,CHEMBL616966,,H,BAO_0000224,,,,,1911,,11702,,1,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,Autocuration,4,,104686
,CHEMBL616967,,H,BAO_0000224,,,,,1912,,11702,,1,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,Autocuration,4,,104686
,CHEMBL616968,10116.0,D,BAO_0000224,Rattus norvegicus,,,,1913,,11702,,1,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL616969,,H,BAO_0000224,,,,,1914,,11702,,1,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,Autocuration,4,,104686
,CHEMBL884530,,H,BAO_0000019,,,,,1915,,13346,,1,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,Autocuration,4,,104686
,CHEMBL616970,,H,BAO_0000224,,,,,1916,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL616971,,H,BAO_0000224,,,,,1917,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,Autocuration,4,,104686
,CHEMBL616972,,H,BAO_0000224,,,,,1918,,10025,,1,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,Autocuration,4,,104686
,CHEMBL616973,,H,BAO_0000224,,,,,1919,,9036,,1,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,Autocuration,4,,104686
,CHEMBL616974,,H,BAO_0000224,,,,,1920,,9036,,1,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,Autocuration,4,,104686
,CHEMBL616975,,H,BAO_0000019,,,,,1921,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,Autocuration,4,,104686
,CHEMBL616976,,H,BAO_0000019,,,,,1922,,12304,,1,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,Autocuration,4,,104686
,CHEMBL616977,,H,BAO_0000224,,,,,1923,,13276,,1,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL616978,,H,BAO_0000224,,,,,1924,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,Autocuration,4,,104686
,CHEMBL616979,,H,BAO_0000224,,,,,1925,,12443,,1,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,Autocuration,4,,104686
,CHEMBL616980,,H,BAO_0000224,,,,,1926,,13830,,1,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
Membranes,CHEMBL616981,,H,BAO_0000249,,,,,1927,,9592,,1,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,Autocuration,4,,104686
Membranes,CHEMBL616982,,H,BAO_0000249,,,,,1928,,9592,,1,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,Autocuration,4,,104686
,CHEMBL616983,,H,BAO_0000224,,,,,1929,,10881,,1,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,Autocuration,4,,104686
,CHEMBL616984,,H,BAO_0000019,,,,,1930,,13605,,1,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,Autocuration,4,,104686
,CHEMBL616985,10116.0,D,BAO_0000224,Rattus norvegicus,,,,1931,,11624,,1,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL616986,,H,BAO_0000224,,,,,1932,,4101,,1,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,Autocuration,4,,104686
,CHEMBL616987,,H,BAO_0000224,,,,,1933,,4101,,1,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,Autocuration,4,,104686
,CHEMBL616988,,H,BAO_0000019,,,,,1934,,15360,,1,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,Autocuration,4,,104686
,CHEMBL617243,,H,BAO_0000019,,,,,1935,,11576,,1,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,Autocuration,4,,104686
,CHEMBL617244,,H,BAO_0000019,,,,,1936,,5834,,1,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,Autocuration,4,,104686
,CHEMBL617245,10116.0,D,BAO_0000219,Rattus norvegicus,,,,1937,,2395,,1,485.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,Autocuration,5,,104686
Membranes,CHEMBL617246,,H,BAO_0000249,,,,,1938,,11965,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Autocuration,4,,104686
,CHEMBL617546,,H,BAO_0000224,,,,,1939,,3967,,1,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,Autocuration,4,,104686
Brain membranes,CHEMBL617547,,H,BAO_0000249,,,,,1940,,11130,,1,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,Autocuration,4,,104686
,CHEMBL617548,,H,BAO_0000219,,,,,1941,,13427,,1,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,Autocuration,4,,104686
,CHEMBL617549,,H,BAO_0000224,,,,,1942,,9443,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617550,,H,BAO_0000224,,,,,1943,,9443,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,Autocuration,4,,104686
,CHEMBL617551,,H,BAO_0000224,,,,,1944,,11825,,1,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,Autocuration,4,,104686
Membranes,CHEMBL617552,,H,BAO_0000249,,,,,1945,,12120,,1,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,Autocuration,4,,104686
Membranes,CHEMBL617553,,H,BAO_0000249,,,,,1946,,12120,,1,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,Autocuration,4,,104686
,CHEMBL617554,,H,BAO_0000019,,,,Thoracic aorta,1947,1515.0,11963,,1,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,Autocuration,4,,104686
,CHEMBL617555,,H,BAO_0000019,,,,,1948,,9069,,1,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617556,,H,BAO_0000224,,,,,1949,,8868,,1,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,Autocuration,4,,104686
,CHEMBL617557,,H,BAO_0000357,,,,,1950,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,Autocuration,8,,10624
,CHEMBL617558,,H,BAO_0000357,,,,,1951,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,Autocuration,8,,10624
,CHEMBL617559,,H,BAO_0000357,,,,,1952,,13969,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,Expert,8,,17106
,CHEMBL617560,,D,BAO_0000357,,,,,1953,,13392,,1,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,Expert,9,,17106
,CHEMBL617561,,H,BAO_0000249,,,,,1954,,1742,,1,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,Autocuration,8,,17106
,CHEMBL617562,,H,BAO_0000249,,,,,1955,,1742,,1,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,Autocuration,8,,17106
,CHEMBL617563,,H,BAO_0000357,,,,Striatum,1956,2435.0,14331,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,Autocuration,8,,17106
,CHEMBL617564,,H,BAO_0000019,,,,,1957,,12861,,1,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,17106
,CHEMBL617565,,H,BAO_0000019,,,,,1958,,12861,,1,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,Expert,8,,17106
,CHEMBL856076,,H,BAO_0000357,,,,,1959,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,17106
,CHEMBL617566,,H,BAO_0000019,,,,,1960,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,Autocuration,8,,17106
,CHEMBL875911,,H,BAO_0000019,,,,,1961,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,Expert,8,,17106
,CHEMBL617567,,H,BAO_0000019,,,,,1962,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,Autocuration,8,,17106
,CHEMBL617568,,H,BAO_0000249,,,,,1963,,675,,1,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,Autocuration,8,,17106
,CHEMBL617569,,H,BAO_0000019,,,,,1964,,12490,,1,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,Expert,8,,17106
,CHEMBL617570,,H,BAO_0000249,,,,,1965,,11828,,1,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,Expert,8,,17106
,CHEMBL617571,,H,BAO_0000357,,,,,1966,,11866,,1,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,Autocuration,8,,17106
,CHEMBL617572,9823.0,H,BAO_0000357,Sus scrofa,,,,1967,,773,,1,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Autocuration,8,,105
,CHEMBL617573,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,1968,,13047,,1,,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Expert,8,,105
,CHEMBL617574,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,1969,,13047,,1,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Autocuration,8,,105
,CHEMBL617575,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,1970,,13047,,1,,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Expert,8,,105
,CHEMBL617576,,H,BAO_0000357,,,,,1971,,188,,1,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,Autocuration,8,,10578
,CHEMBL617577,,H,BAO_0000019,,,,,1972,,10639,,1,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,Autocuration,8,,10578
,CHEMBL617578,,H,BAO_0000019,,,,,1973,,12438,,1,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,Autocuration,8,,10578
,CHEMBL617579,,H,BAO_0000357,,,,,1974,,12438,,1,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,10578
,CHEMBL617580,,H,BAO_0000019,,,,,1975,,15854,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,Expert,8,,10578
,CHEMBL617581,,H,BAO_0000249,,,,,1976,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,Autocuration,8,,10578
,CHEMBL617582,,H,BAO_0000357,,,,,1977,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,Autocuration,8,,10578
,CHEMBL617583,,H,BAO_0000019,,,,,1978,,3389,,1,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,Expert,8,,10578
,CHEMBL617584,,H,BAO_0000357,,,,,1979,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,Autocuration,8,,105
,CHEMBL617585,,H,BAO_0000357,,,,,1980,,4639,,1,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL875912,,H,BAO_0000357,,,,,1981,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL617586,,H,BAO_0000357,,,,,1982,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL617587,,H,BAO_0000357,,,,,1983,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,Autocuration,8,,105
,CHEMBL617588,,H,BAO_0000357,,,,,1984,,11866,,1,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,Autocuration,8,,105
,CHEMBL857980,,H,BAO_0000357,,,,,1985,,4687,,1,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL617589,,H,BAO_0000357,,,,,1986,,12146,,1,,Tested against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,105
,CHEMBL617590,,H,BAO_0000357,,,,,1987,,10321,,1,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL617591,,H,BAO_0000219,,,,,1988,,13267,,1,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,105
,CHEMBL617592,9606.0,D,BAO_0000357,Homo sapiens,,,,1989,,1274,,1,,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Expert,9,,105
,CHEMBL617593,,H,BAO_0000357,,,,,1990,,15250,,1,,,B,,,Autocuration,8,,105
,CHEMBL617594,,H,BAO_0000219,,,,,1991,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,106
,CHEMBL617595,,H,BAO_0000219,,,,,1992,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,105
,CHEMBL617596,,H,BAO_0000219,,,,,1993,,13706,,1,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,HEK293,Autocuration,8,,105
,CHEMBL617597,,H,BAO_0000219,,,,,1994,,13706,,1,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,HEK293,Autocuration,8,,105
,CHEMBL617598,,H,BAO_0000019,,,,,1995,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,Autocuration,8,,105
,CHEMBL872916,,H,BAO_0000357,,,,,1996,,13366,,1,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,Autocuration,8,,105
,CHEMBL617599,,H,BAO_0000357,,,,,1997,,13366,,1,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,Expert,8,,105
,CHEMBL617091,,H,BAO_0000357,,,,,1998,,1558,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,Autocuration,8,,105
,CHEMBL617092,,H,BAO_0000219,,,,,1999,,12902,,1,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,CHO-K1,Expert,8,,105
,CHEMBL617093,,H,BAO_0000219,,,,,2000,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,105
,CHEMBL617094,,H,BAO_0000019,,,,,2001,,13706,,1,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,Autocuration,8,,105
,CHEMBL617095,,H,BAO_0000019,,,,,2002,,13706,,1,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,Autocuration,8,,105
,CHEMBL617096,,H,BAO_0000019,,,,,2003,,14251,,1,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,Autocuration,8,,105
,CHEMBL617097,,H,BAO_0000019,,,,,2004,,14251,,1,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,Autocuration,8,,105
,CHEMBL617098,,H,BAO_0000019,,,,,2005,,14251,,1,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,Autocuration,8,,105
,CHEMBL617301,,H,BAO_0000357,,,,,2006,,13313,,1,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL617302,,H,BAO_0000357,,,,,2007,,13313,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL617303,,H,BAO_0000357,,,,,2008,,13366,,1,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,Autocuration,8,,105
,CHEMBL617304,,H,BAO_0000357,,,,,2009,,13051,,1,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,Expert,8,,105
,CHEMBL617305,,H,BAO_0000219,,,,,2010,,12903,,1,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,Expert,8,,105
,CHEMBL617306,9606.0,D,BAO_0000219,Homo sapiens,,,,2011,,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Autocuration,9,,105
,CHEMBL617307,,H,BAO_0000357,,,,,2012,,5619,,1,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,Autocuration,8,,17106
,CHEMBL617308,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,2013,,13047,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Autocuration,8,,105
,CHEMBL617309,,H,BAO_0000357,,,,,2014,,16633,,1,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,Autocuration,8,,105
,CHEMBL617310,,H,BAO_0000357,,,,,2015,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,Autocuration,8,,105
,CHEMBL617311,,H,BAO_0000357,,,,,2016,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,Autocuration,8,,105
,CHEMBL617312,,H,BAO_0000357,,,,,2017,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,105
,CHEMBL617313,,H,BAO_0000357,,,,,2018,,3269,,1,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,Autocuration,8,,105
,CHEMBL617314,,H,BAO_0000357,,,,,2019,,12409,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,Expert,8,,105
,CHEMBL617315,,H,BAO_0000019,,,,,2020,,13706,,1,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,Autocuration,8,,106
,CHEMBL617316,,H,BAO_0000219,,,,,2021,,13706,,1,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,HEK293,Autocuration,8,,106
,CHEMBL617317,,H,BAO_0000219,,,,,2022,,13706,,1,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,HEK293,Autocuration,8,,106
,CHEMBL617318,,H,BAO_0000219,,,,,2023,,12903,,1,449.0,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,106
,CHEMBL617319,,H,BAO_0000019,,,,,2024,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,Autocuration,8,,106
,CHEMBL617320,,D,BAO_0000357,,,,,2025,,13366,,1,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,Expert,9,,106
,CHEMBL617321,,D,BAO_0000357,,,,,2026,,13366,,1,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,Expert,9,,106
,CHEMBL617322,,D,BAO_0000357,,,,,2027,,13366,,1,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,Expert,9,,106
,CHEMBL616862,,H,BAO_0000357,,,,,2028,,13366,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,106
,CHEMBL616863,,H,BAO_0000357,,,,,2029,,13366,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,8,,106
,CHEMBL616864,,H,BAO_0000219,,,,,2030,,12469,,1,449.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,CHO,Autocuration,8,,106
,CHEMBL616865,,H,BAO_0000219,,,,,2031,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,106
,CHEMBL616866,,H,BAO_0000219,,,,,2032,,13706,,1,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,106
,CHEMBL616867,,H,BAO_0000019,,,,,2033,,13706,,1,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,Autocuration,8,,106
,CHEMBL616868,,H,BAO_0000219,,,,,2034,,12902,,1,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,CHO-K1,Expert,8,,106
,CHEMBL616869,,H,BAO_0000357,,,,,2035,,13051,,1,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,Expert,8,,105
,CHEMBL616870,,H,BAO_0000219,,,,,2036,,12903,,1,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,Expert,8,,106
,CHEMBL616871,,H,BAO_0000219,,,,,2037,,1558,,1,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,CHO-K1,Autocuration,8,,105
,CHEMBL616872,,H,BAO_0000219,,,,,2038,,1558,,1,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,CHO-K1,Autocuration,8,,105
,CHEMBL616873,,H,BAO_0000219,,,,,2039,,1558,,1,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,CHO-K1,Autocuration,8,,105
,CHEMBL616838,,H,BAO_0000219,,,,,2040,,1558,,1,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,CHO-K1,Autocuration,8,,105
,CHEMBL616839,,H,BAO_0000357,,,,,2041,,1558,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,Autocuration,8,,105
,CHEMBL616840,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,2042,,13047,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Autocuration,8,,106
,CHEMBL616841,,H,BAO_0000357,,,,,2043,,13313,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL616842,,H,BAO_0000357,,,,,2044,,13313,,1,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,Autocuration,8,,105
,CHEMBL857976,,H,BAO_0000357,,,,,2045,,12409,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,Expert,8,,105
,CHEMBL616843,,H,BAO_0000219,,,,,2046,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,10618
,CHEMBL616844,9606.0,D,BAO_0000357,Homo sapiens,,,,2047,,1348,,1,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Expert,9,,10618
,CHEMBL616845,,H,BAO_0000357,,,,,2048,,1348,,1,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,Autocuration,8,,10618
,CHEMBL616846,9606.0,D,BAO_0000357,Homo sapiens,,,,2049,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Expert,9,,10618
,CHEMBL616847,,H,BAO_0000357,,,,,2050,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,Autocuration,8,,10618
,CHEMBL616848,,H,BAO_0000019,,,,,2051,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,Autocuration,8,,10618
,CHEMBL616849,,H,BAO_0000357,,,,,2052,,3935,,1,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL872911,,H,BAO_0000357,,,,,2053,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL616850,,H,BAO_0000019,,,,,2054,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL616699,9606.0,D,BAO_0000219,Homo sapiens,,,,2055,,12936,,1,449.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,CHO,Expert,9,,10618
,CHEMBL616700,,H,BAO_0000357,,,,,2056,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,Autocuration,8,,10618
,CHEMBL616701,,H,BAO_0000219,,,,,2057,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,10618
,CHEMBL616702,,H,BAO_0000219,,,,,2058,,15779,,1,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,10618
,CHEMBL616703,,H,BAO_0000219,,,,,2059,,15779,,1,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,CHO,Autocuration,8,,10618
,CHEMBL616704,,H,BAO_0000357,,,,,2060,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,Autocuration,8,,10618
,CHEMBL616705,,H,BAO_0000219,,,,,2061,,4199,,1,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,Autocuration,8,,10618
,CHEMBL616706,,H,BAO_0000357,,,,,2062,,14875,,1,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL616707,,H,BAO_0000219,,,,,2063,,15146,,1,449.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,CHO,Autocuration,8,,10618
,CHEMBL616708,,H,BAO_0000357,,,,,2064,,5213,,1,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,Autocuration,8,,10618
,CHEMBL616709,,H,BAO_0000357,,,,,2065,,12146,,1,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,10618
,CHEMBL616710,,H,BAO_0000219,,,,,2066,,13267,,1,449.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,CHO,Autocuration,8,,10618
,CHEMBL616711,,H,BAO_0000219,,,,,2067,,14818,,1,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,CHO,Autocuration,8,,10618
,CHEMBL616712,,H,BAO_0000219,,,,,2068,,4829,,1,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,10618
,CHEMBL616713,,H,BAO_0000357,,,,,2069,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,Autocuration,8,,10618
,CHEMBL616714,,H,BAO_0000357,,,,,2070,,4373,,1,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,Autocuration,8,,10618
,CHEMBL616715,,H,BAO_0000357,,,,,2071,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL616716,,H,BAO_0000357,,,,,2072,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,Autocuration,8,,10618
,CHEMBL616717,,H,BAO_0000019,,,,,2073,,17085,,1,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,Autocuration,8,,279
,CHEMBL616718,,H,BAO_0000019,,,,,2074,,17085,,1,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,Expert,8,,279
,CHEMBL875905,,H,BAO_0000019,,,,,2075,,16209,,1,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,Autocuration,8,,279
,CHEMBL616719,,H,BAO_0000019,,,,,2076,,16209,,1,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,Autocuration,8,,279
,CHEMBL616720,,H,BAO_0000019,,,,,2077,,17085,,1,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,Expert,8,,279
,CHEMBL616721,,H,BAO_0000357,,,,,2078,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL616722,,H,BAO_0000219,,,,,2079,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,279
,CHEMBL616723,,H,BAO_0000357,,,,,2080,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,Autocuration,8,,279
,CHEMBL616724,,H,BAO_0000219,,,,,2081,,16190,,1,449.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,CHO,Autocuration,8,,279
,CHEMBL616725,,H,BAO_0000357,,,,,2082,,16190,,1,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,Autocuration,8,,279
,CHEMBL616726,,H,BAO_0000357,,,,,2083,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL616727,,H,BAO_0000357,,,,,2084,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,Autocuration,8,,279
,CHEMBL616728,,H,BAO_0000357,,,,,2085,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,Autocuration,8,,279
,CHEMBL616729,,H,BAO_0000357,,,,,2086,,6866,,1,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL616730,,H,BAO_0000019,,,,,2087,,17085,,1,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,Expert,8,,279
,CHEMBL617125,,H,BAO_0000357,,,,,2088,,16312,,1,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL857977,,H,BAO_0000357,,,,,2089,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,Autocuration,8,,279
,CHEMBL617126,,H,BAO_0000219,,,,,2090,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,Autocuration,8,,279
,CHEMBL617127,,H,BAO_0000219,,,,,2091,,4199,,1,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,CHO,Autocuration,8,,279
,CHEMBL617128,,H,BAO_0000357,,,,,2092,,14875,,1,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL617129,,H,BAO_0000219,,,,,2093,,15146,,1,449.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,CHO,Autocuration,8,,279
,CHEMBL617130,,H,BAO_0000357,,,,,2094,,5213,,1,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,Autocuration,8,,279
,CHEMBL617131,,H,BAO_0000219,,,,,2095,,14818,,1,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,CHO,Autocuration,8,,279
,CHEMBL617132,,H,BAO_0000219,,,,,2096,,4829,,1,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,279
,CHEMBL617133,,H,BAO_0000219,,,,,2097,,4829,,1,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,Autocuration,8,,279
,CHEMBL617134,,H,BAO_0000357,,,,,2098,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,Autocuration,8,,279
,CHEMBL617135,,H,BAO_0000357,,,,,2099,,4373,,1,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,Autocuration,8,,279
,CHEMBL617136,,H,BAO_0000357,,,,,2100,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,Autocuration,8,,279
,CHEMBL617137,,H,BAO_0000019,,,,,2101,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,Autocuration,4,,104686
,CHEMBL617138,,H,BAO_0000019,,,,,2102,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,Autocuration,4,,104686
,CHEMBL617139,,H,BAO_0000019,,,,,2103,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,Autocuration,4,,104686
,CHEMBL617140,,H,BAO_0000019,,,,,2104,,14093,,1,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617141,,H,BAO_0000218,,,,,2105,,11200,,1,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,Autocuration,4,,104686
,CHEMBL858112,,H,BAO_0000019,,,,,2106,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617142,,H,BAO_0000019,,,,,2107,,12352,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,Intermediate,8,,17005
,CHEMBL617143,9913.0,U,BAO_0000019,Bos taurus,,,,2108,,13657,,1,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Autocuration,0,,22226
,CHEMBL617144,9913.0,U,BAO_0000019,Bos taurus,,,,2109,,14331,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Autocuration,0,,22226
,CHEMBL617145,9913.0,U,BAO_0000019,Bos taurus,,,,2110,,14331,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Autocuration,0,,22226
,CHEMBL617146,,U,BAO_0000019,,,,,2111,,14331,,1,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,Autocuration,0,,22226
,CHEMBL617147,10141.0,H,BAO_0000019,Cavia porcellus,,,,2112,,12685,,1,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Autocuration,4,,104784
,CHEMBL617148,10141.0,H,BAO_0000019,Cavia porcellus,,,,2113,,14389,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Autocuration,4,,104784
,CHEMBL617149,10141.0,H,BAO_0000019,Cavia porcellus,,,,2114,,14386,,1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Autocuration,4,,104784
,CHEMBL617150,,H,BAO_0000224,,,,,2115,,5732,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,Autocuration,4,,104784
,CHEMBL617151,,H,BAO_0000224,,,,,2116,,16293,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,Autocuration,4,,104784
,CHEMBL617201,,H,BAO_0000224,,,,,2117,,2078,,1,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617202,,H,BAO_0000357,,,,,2118,,5486,,1,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,Autocuration,8,,10209
,CHEMBL617203,,H,BAO_0000218,,,,,2119,,11820,,1,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,Autocuration,4,,104826
,CHEMBL617204,,H,BAO_0000019,,,,,2120,,10297,,1,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Autocuration,4,,104826
,CHEMBL617205,,H,BAO_0000224,,,,,2121,,13704,,1,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,Autocuration,4,,104826
,CHEMBL617206,10090.0,D,BAO_0000019,Mus musculus,,,,2122,,10297,,1,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Autocuration,5,,104826
,CHEMBL617207,,H,BAO_0000218,,,,,2123,,11820,,1,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,Autocuration,4,,104826
,CHEMBL617208,10090.0,D,BAO_0000019,Mus musculus,,,,2124,,10297,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Autocuration,5,,104826
,CHEMBL617209,,H,BAO_0000224,,,,,2125,,11555,,1,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104826
,CHEMBL617210,,H,BAO_0000224,,,,,2126,,11555,,1,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,Autocuration,4,,104826
,CHEMBL617211,,H,BAO_0000224,,,,,2127,,11555,,1,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,Autocuration,4,,104826
,CHEMBL617212,10090.0,D,BAO_0000019,Mus musculus,,,,2128,,10297,,1,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Autocuration,5,,104826
,CHEMBL617213,9823.0,H,BAO_0000224,Sus scrofa,,,,2129,,16688,,1,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Autocuration,4,,104784
,CHEMBL617214,9823.0,H,BAO_0000224,Sus scrofa,,,,2130,,16688,,1,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Autocuration,4,,104784
,CHEMBL617215,,U,BAO_0000221,,,,,2131,,5333,,1,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,Autocuration,0,,22226
,CHEMBL617216,,U,BAO_0000221,,,,,2132,,4437,,1,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,Autocuration,0,,22226
,CHEMBL617217,9823.0,H,BAO_0000357,Sus scrofa,,,,2133,,5033,,1,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617218,,H,BAO_0000019,,,,,2134,,15267,,1,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL872913,,H,BAO_0000019,,,,,2135,,15267,,1,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617219,,H,BAO_0000019,,,,,2136,,11820,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,Autocuration,4,,104826
,CHEMBL873482,,H,BAO_0000224,,,,,2137,,9069,,1,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617220,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2138,,9162,,1,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Autocuration,5,,104686
,CHEMBL617221,,H,BAO_0000019,,,,,2139,,9162,,1,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,Autocuration,4,,104686
,CHEMBL617222,,H,BAO_0000019,,,,,2140,,9162,,1,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,Autocuration,4,,104686
,CHEMBL875906,,H,BAO_0000019,,,,,2141,,10428,,1,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,Autocuration,4,,104686
,CHEMBL617223,,H,BAO_0000019,,,,,2142,,9628,,1,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,Autocuration,4,,104686
,CHEMBL617224,,H,BAO_0000224,,,,,2143,,12704,,1,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617225,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2144,,15453,,1,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Autocuration,5,,104686
,CHEMBL617226,,H,BAO_0000224,,,,,2145,,188,,1,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,Autocuration,4,,104686
,CHEMBL617227,,H,BAO_0000224,,,,,2146,,10349,,1,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617228,,H,BAO_0000224,,,,,2147,,10349,,1,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617229,,H,BAO_0000224,,,,,2148,,8868,,1,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,Autocuration,4,,104686
,CHEMBL617230,,H,BAO_0000224,,,,,2149,,10025,,1,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,Autocuration,4,,104686
,CHEMBL617231,,H,BAO_0000224,,,,,2150,,10025,,1,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,Autocuration,4,,104686
,CHEMBL617232,,H,BAO_0000224,,,,,2151,,11702,,1,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617233,,H,BAO_0000224,,,,,2152,,11702,,1,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617234,,H,BAO_0000224,,,,,2153,,11702,,1,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,Autocuration,4,,104686
,CHEMBL617235,,H,BAO_0000019,,,,,2154,,11702,,1,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,Autocuration,4,,104686
,CHEMBL617236,,H,BAO_0000019,,,,,2155,,11702,,1,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,Autocuration,4,,104686
,CHEMBL617237,,H,BAO_0000221,,,,Hippocampus,2156,10000000.0,10085,,1,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,Autocuration,4,,104686
,CHEMBL617238,,H,BAO_0000221,,,,Hippocampus,2157,10000000.0,10085,,1,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,Autocuration,4,,104686
,CHEMBL617239,10116.0,D,BAO_0000221,Rattus norvegicus,,,Brain,2158,955.0,9630,,1,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Autocuration,5,,104686
,CHEMBL617240,,H,BAO_0000019,,,,,2159,,11070,,1,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,Autocuration,4,,104686
Membranes,CHEMBL617241,,H,BAO_0000249,,,,,2160,,9841,,1,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Autocuration,4,,104686
Membranes,CHEMBL875907,,H,BAO_0000249,,,,,2161,,9841,,1,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Autocuration,4,,104686
,CHEMBL617242,,H,BAO_0000019,,,,,2162,,13291,,1,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,Autocuration,4,,104686
,CHEMBL617152,,H,BAO_0000019,,,,,2163,,10590,,1,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,Autocuration,4,,104686
,CHEMBL617153,10116.0,D,BAO_0000221,Rattus norvegicus,,,Brain,2164,955.0,9064,,1,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Autocuration,5,,104686
Membranes,CHEMBL617154,10116.0,D,BAO_0000249,Rattus norvegicus,,,,2165,,12268,,1,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Autocuration,5,,104686
,CHEMBL617155,,H,BAO_0000221,,,,Brain,2166,955.0,13508,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617156,,H,BAO_0000019,,,,,2167,,11279,,1,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,Autocuration,4,,104686
,CHEMBL617157,,H,BAO_0000019,,,,,2168,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617158,,H,BAO_0000019,,,,,2169,,11200,,1,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617159,,H,BAO_0000019,,,,,2170,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,Autocuration,4,,104686
,CHEMBL617160,,H,BAO_0000019,,,,,2171,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,Autocuration,4,,104686
,CHEMBL858113,,H,BAO_0000019,,,,,2172,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617247,,H,BAO_0000220,,,,Brain,2173,955.0,9231,,1,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,Autocuration,4,,104686
,CHEMBL617248,,H,BAO_0000019,,,,,2174,,9737,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617249,,H,BAO_0000249,,,,Brain,2175,955.0,9737,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,Autocuration,4,,104686
,CHEMBL617250,,H,BAO_0000019,,,,,2176,,9737,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,Autocuration,4,,104686
,CHEMBL617251,,H,BAO_0000019,,,,,2177,,9737,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617252,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2178,,11828,,1,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617006,,H,BAO_0000019,,,,,2179,,12253,,1,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,Autocuration,4,,104686
,CHEMBL617007,,H,BAO_0000019,,,,,2180,,12253,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,Autocuration,4,,104686
,CHEMBL617008,,H,BAO_0000019,,,,,2181,,11279,,1,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,Autocuration,4,,104686
,CHEMBL617009,,H,BAO_0000019,,,,,2182,,11866,,1,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,Autocuration,4,,104686
,CHEMBL617010,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2183,,14424,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Autocuration,5,,104686
,CHEMBL857978,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2184,,15180,,1,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617011,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2185,,15180,,1,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617012,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2186,,9786,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Autocuration,5,,104686
,CHEMBL617013,,H,BAO_0000224,,,,,2187,,12132,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617014,,H,BAO_0000249,,,,,2188,,5486,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,Autocuration,4,,104686
,CHEMBL617015,,H,BAO_0000019,,,,,2189,,15316,,1,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617016,,H,BAO_0000019,,,,,2190,,16429,,1,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,Autocuration,4,,104686
,CHEMBL617017,,H,BAO_0000224,,,,,2191,,14617,,1,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,Autocuration,4,,104686
,CHEMBL617018,,H,BAO_0000221,,,,Brain,2192,955.0,11351,,1,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,Autocuration,4,,104686
,CHEMBL617019,,H,BAO_0000019,,,,,2193,,11279,,1,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,Autocuration,4,,104686
,CHEMBL617020,,H,BAO_0000019,,,,,2194,,9523,,1,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617021,,H,BAO_0000019,,,,,2195,,9523,,1,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617022,,H,BAO_0000019,,,,,2196,,9523,,1,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617023,,H,BAO_0000019,,,,,2197,,9523,,1,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617024,,H,BAO_0000019,,,,,2198,,9523,,1,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617025,,H,BAO_0000019,,,,,2199,,9523,,1,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,Autocuration,4,,105075
,CHEMBL617026,,H,BAO_0000224,,,,,2200,,9523,,1,,Hill coefficient of compound was determined,B,,,Autocuration,4,,105075
,CHEMBL617027,,U,BAO_0000019,,,,,2201,,4771,,1,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,Autocuration,0,,22226
,CHEMBL617028,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2202,,5033,,1,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Autocuration,5,,104686
,CHEMBL617029,,H,BAO_0000019,,,,,2203,,10845,,1,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,Expert,8,,12687
,CHEMBL875908,,H,BAO_0000019,,,,,2204,,10845,,1,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,Expert,8,,12687
,CHEMBL617030,,H,BAO_0000357,,,,,2205,,16288,,1,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,Autocuration,8,,12687
,CHEMBL617031,,H,BAO_0000019,,,,,2206,,16288,,1,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,Autocuration,8,,12687
,CHEMBL617032,,H,BAO_0000019,,,,,2207,,16190,,1,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,Autocuration,8,,12687
,CHEMBL617033,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2208,,12463,,1,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Autocuration,5,,104686
,CHEMBL617034,,H,BAO_0000224,,,,,2209,,9699,,1,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,Autocuration,4,,104686
,CHEMBL617035,,H,BAO_0000224,,,,,2210,,9699,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617036,,H,BAO_0000019,,,,,2211,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,Autocuration,4,,104686
,CHEMBL617037,,H,BAO_0000224,,,,,2212,,1205,,1,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617038,,U,BAO_0000219,,,,,2213,,11376,,1,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,Autocuration,0,,22226
,CHEMBL617039,,H,BAO_0000219,,,,,2214,,11376,,1,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,Autocuration,4,,104784
,CHEMBL617161,,H,BAO_0000224,,,,,2215,,4639,,1,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617162,,H,BAO_0000224,,,,,2216,,2222,,1,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617163,,H,BAO_0000224,,,,,2217,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617164,,H,BAO_0000224,,,,,2218,,1089,,1,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
Brain membranes,CHEMBL617165,,H,BAO_0000249,,,,,2219,,386,,1,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,Autocuration,4,,104784
,CHEMBL617166,,H,BAO_0000224,,,,,2220,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104784
,CHEMBL617167,,H,BAO_0000224,,,,,2221,,17066,,1,,Binding affinity towards 5-HT2 receptor,B,,,Autocuration,4,,104784
,CHEMBL872912,,H,BAO_0000224,,,,,2222,,959,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617168,,H,BAO_0000224,,,,,2223,,6398,,1,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,Autocuration,4,,104784
,CHEMBL617169,,H,BAO_0000224,,,,,2224,,11889,,1,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,Autocuration,4,,104686
,CHEMBL617170,,H,BAO_0000224,,,,,2225,,4221,,1,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617171,,H,BAO_0000224,,,,,2226,,11026,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,Autocuration,4,,104784
,CHEMBL617172,,H,BAO_0000224,,,,,2227,,11866,,1,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,Autocuration,4,,104784
,CHEMBL617173,,H,BAO_0000224,,,,,2228,,4221,,1,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL617174,,U,BAO_0000019,,,,,2229,,13950,,1,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,0,,22226
,CHEMBL617175,,H,BAO_0000224,,,,,2230,,1263,,1,,5-hydroxytryptamine 2 receptor binding affinity,B,,,Autocuration,4,,104784
,CHEMBL617176,,H,BAO_0000357,,,,,2231,,13291,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,Autocuration,8,,17005
,CHEMBL617177,,H,BAO_0000357,,,,,2232,,10812,,1,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,Autocuration,8,,17005
,CHEMBL617178,,H,BAO_0000224,,,,,2233,,13020,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,Autocuration,4,,104784
,CHEMBL617179,,H,BAO_0000224,,,,,2234,,13021,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,Autocuration,4,,104784
,CHEMBL617180,,H,BAO_0000224,,,,,2235,,13020,,1,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,Autocuration,4,,104784
,CHEMBL617181,,H,BAO_0000357,,,,,2236,,14532,,1,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,Autocuration,8,,17005
,CHEMBL617182,,H,BAO_0000357,,,,,2237,,13944,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617183,,H,BAO_0000357,,,,,2238,,14331,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617184,,H,BAO_0000357,,,,,2239,,14118,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,Autocuration,8,,17005
,CHEMBL617185,,H,BAO_0000357,,,,,2240,,13033,,1,,Binding affinity against serotonergic 5-HT2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617186,,H,BAO_0000357,,,,,2241,,10321,,1,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,Autocuration,8,,17005
,CHEMBL617187,,H,BAO_0000357,,,,,2242,,12918,,1,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617188,,H,BAO_0000357,,,,,2243,,15120,,1,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617189,,H,BAO_0000218,,,,,2244,,2613,,1,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617190,9606.0,D,BAO_0000224,Homo sapiens,,,,2245,,13378,,1,,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Autocuration,5,,104784
,CHEMBL617191,9606.0,D,BAO_0000219,Homo sapiens,,,,2246,,2331,,1,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,CHO,Autocuration,5,,104784
,CHEMBL617192,9606.0,D,BAO_0000219,Homo sapiens,,,,2247,,2331,,1,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,CHO,Autocuration,5,,104784
,CHEMBL617193,9606.0,D,BAO_0000219,Homo sapiens,,,,2248,,2331,,1,449.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,CHO,Autocuration,5,,104784
,CHEMBL617194,9606.0,D,BAO_0000219,Homo sapiens,,,,2249,,2331,,1,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,CHO,Autocuration,5,,104784
,CHEMBL617195,,H,BAO_0000224,,,,,2250,,4170,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104784
,CHEMBL881830,,H,BAO_0000224,,,,,2251,,15453,,1,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Autocuration,4,,104784
,CHEMBL617196,,H,BAO_0000357,,,,,2252,,1479,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,8,,17005
,CHEMBL617197,,H,BAO_0000224,,,,,2253,,11139,,1,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,Autocuration,4,,104686
,CHEMBL617198,,H,BAO_0000357,,,,,2254,,13969,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,Expert,8,,17005
,CHEMBL873476,,H,BAO_0000357,,,,,2255,,13392,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,17005
,CHEMBL617199,,H,BAO_0000019,,,,,2256,,14430,,1,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,Expert,8,,17005
,CHEMBL617200,10141.0,H,BAO_0000357,Cavia porcellus,,,,2257,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617484,,H,BAO_0000357,,,,,2258,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Autocuration,8,,51
,CHEMBL617485,,H,BAO_0000357,,,,,2259,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Autocuration,8,,107
,CHEMBL617486,,H,BAO_0000357,,,,,2260,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Autocuration,8,,51
,CHEMBL858022,,H,BAO_0000357,,,,,2261,,13463,,1,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,Autocuration,8,,107
,CHEMBL617049,,H,BAO_0000219,,,,,2262,,6347,,1,449.0,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,CHO,Autocuration,8,,107
,CHEMBL617050,9606.0,D,BAO_0000219,Homo sapiens,,,,2263,,6857,,1,449.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,Expert,9,,107
,CHEMBL617051,,H,BAO_0000219,,,,,2264,,4176,,1,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,Autocuration,8,,107
,CHEMBL617052,,H,BAO_0000219,,,,,2265,,4176,,1,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,Autocuration,8,,107
,CHEMBL617053,,H,BAO_0000219,,,,,2266,,4176,,1,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,Autocuration,8,,107
,CHEMBL617054,,H,BAO_0000219,,,,,2267,,6347,,1,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,CHO,Autocuration,8,,107
,CHEMBL617055,,H,BAO_0000219,,,,,2268,,6347,,1,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,CHO,Autocuration,8,,107
,CHEMBL882924,,H,BAO_0000357,,,,,2269,,15331,,1,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,Autocuration,8,,107
,CHEMBL617056,9606.0,D,BAO_0000357,Homo sapiens,,,,2270,,16146,,1,,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617057,,H,BAO_0000219,,,,,2271,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,107
,CHEMBL617058,,H,BAO_0000219,,,,,2272,,13631,,1,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,Expert,8,,107
,CHEMBL617059,,H,BAO_0000357,,,,,2273,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,Autocuration,8,,107
,CHEMBL617060,,H,BAO_0000219,,,,,2274,,4011,,1,449.0,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,CHO,Autocuration,8,,107
,CHEMBL617061,,H,BAO_0000219,,,,,2275,,4012,,1,449.0,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,CHO,Expert,8,,107
,CHEMBL617062,,H,BAO_0000219,,,,,2276,,6366,,1,307.0,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,L929,Expert,8,,107
,CHEMBL617063,,H,BAO_0000219,,,,,2277,,15949,,1,449.0,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,Expert,8,,107
,CHEMBL617064,,H,BAO_0000019,,,,,2278,,14093,,1,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,Autocuration,8,,107
,CHEMBL617065,,H,BAO_0000019,,,,,2279,,13481,,1,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,Autocuration,8,,107
,CHEMBL617066,,H,BAO_0000219,,,,,2280,,6347,,1,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,CHO,Autocuration,8,,107
,CHEMBL617067,,H,BAO_0000219,,,,,2281,,6347,,1,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,CHO,Autocuration,8,,107
,CHEMBL617068,,H,BAO_0000019,,,,,2282,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,Autocuration,8,,107
,CHEMBL617069,,H,BAO_0000019,,,,,2283,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,Autocuration,8,,107
,CHEMBL617070,,H,BAO_0000019,,,,,2284,,13481,,1,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,Autocuration,8,,107
,CHEMBL617071,,H,BAO_0000357,,,,,2285,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,Autocuration,8,,107
,CHEMBL872915,,H,BAO_0000357,,,,,2286,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,Autocuration,8,,107
,CHEMBL617072,,H,BAO_0000357,,,,,2287,,14755,,1,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,Autocuration,8,,107
,CHEMBL617073,,H,BAO_0000357,,,,,2288,,16441,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,Autocuration,8,,107
,CHEMBL617074,,H,BAO_0000357,,,,,2289,,14744,,1,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,Autocuration,8,,107
,CHEMBL617075,,H,BAO_0000219,,,,,2290,,16659,,1,449.0,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,Expert,8,,107
,CHEMBL617076,,H,BAO_0000357,,,,,2291,,3307,,1,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617077,9606.0,D,BAO_0000019,Homo sapiens,,,,2292,,6857,,1,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Expert,9,,107
,CHEMBL617078,,H,BAO_0000357,,,,,2293,,5635,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,Expert,8,,107
,CHEMBL617079,9606.0,D,BAO_0000357,Homo sapiens,,,,2294,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617080,,H,BAO_0000357,,,,,2295,,15527,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,107
,CHEMBL617081,,H,BAO_0000219,,,,,2296,,6588,,1,449.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,CHO,Expert,8,,107
,CHEMBL617082,,H,BAO_0000219,,,,,2297,,13631,,1,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,Expert,8,,107
,CHEMBL617083,,H,BAO_0000357,,,,,2298,,17723,,1,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617084,,H,BAO_0000357,,,,,2299,,14770,,1,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,Autocuration,8,,107
,CHEMBL617085,9606.0,D,BAO_0000357,Homo sapiens,,,,2300,,16293,,1,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617086,,H,BAO_0000357,,,,,2301,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,107
,CHEMBL617087,,H,BAO_0000219,,,,,2302,,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,Autocuration,8,,107
,CHEMBL617088,,H,BAO_0000357,,,,,2303,,15363,,1,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617089,,H,BAO_0000357,,,,,2304,,15363,,1,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617090,,H,BAO_0000019,,,,,2305,,16441,,1,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,Expert,8,,107
,CHEMBL617513,,H,BAO_0000357,,,,,2306,,8,,1,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,Autocuration,8,,107
,CHEMBL617514,,H,BAO_0000219,,,,,2307,,4176,,1,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL617515,,H,BAO_0000019,,,,,2308,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617516,,H,BAO_0000357,,,,,2309,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Autocuration,8,,107
,CHEMBL617517,9606.0,D,BAO_0000357,Homo sapiens,,,,2310,,17200,,1,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Expert,9,,107
,CHEMBL617518,9606.0,D,BAO_0000219,Homo sapiens,,,,2311,,4013,,1,449.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,CHO,Expert,9,,107
,CHEMBL617519,,H,BAO_0000357,,,,,2312,,5088,,1,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617520,9606.0,D,BAO_0000357,Homo sapiens,,,,2313,,5088,,1,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617521,,H,BAO_0000357,,,,,2314,,5088,,1,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,Autocuration,8,,107
,CHEMBL617522,9606.0,D,BAO_0000357,Homo sapiens,,,,2315,,5088,,1,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617523,,H,BAO_0000357,,,,,2316,,5088,,1,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,107
,CHEMBL617524,,H,BAO_0000357,,,,,2317,,5088,,1,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,Autocuration,8,,107
,CHEMBL617525,,H,BAO_0000019,,,,,2318,,9786,,1,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,Autocuration,4,,104686
,CHEMBL617526,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2319,,9205,,1,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Autocuration,5,,104686
,CHEMBL617527,,H,BAO_0000224,,,,,2320,,11257,,1,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,Autocuration,4,,104686
,CHEMBL617528,,H,BAO_0000019,,,,,2321,,9362,,1,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,Autocuration,4,,104686
,CHEMBL617529,,H,BAO_0000019,,,,,2322,,9362,,1,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,Autocuration,4,,104686
,CHEMBL617530,,H,BAO_0000224,,,,,2323,,10590,,1,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,Autocuration,4,,104686
,CHEMBL617531,,H,BAO_0000019,,,,,2324,,10468,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,Autocuration,4,,104686
,CHEMBL617532,,H,BAO_0000019,,,,,2325,,13050,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617533,,H,BAO_0000019,,,,,2326,,11624,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617534,,H,BAO_0000019,,,,,2327,,10468,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,Autocuration,4,,104686
,CHEMBL617535,,H,BAO_0000224,,,,,2328,,10330,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617536,,H,BAO_0000224,,,,,2329,,10062,,1,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,Autocuration,4,,104686
,CHEMBL617537,,H,BAO_0000224,,,,,2330,,11642,,1,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617538,,H,BAO_0000224,,,,,2331,,10062,,1,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617539,,H,BAO_0000219,,,,,2332,,13427,,1,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,Autocuration,4,,104686
,CHEMBL617540,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2333,,12280,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617541,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2334,,4101,,1,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Autocuration,5,,104686
,CHEMBL617542,,H,BAO_0000224,,,,,2335,,10062,,1,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617543,,H,BAO_0000224,,,,,2336,,11147,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,Autocuration,4,,104686
,CHEMBL617544,10116.0,D,BAO_0000219,Rattus norvegicus,,,,2337,,2395,,1,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,Autocuration,5,,104686
,CHEMBL617545,10116.0,D,BAO_0000219,Rattus norvegicus,,,,2338,,2395,,1,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,Autocuration,5,,104686
,CHEMBL617413,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2339,,9098,,1,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Autocuration,5,,104686
,CHEMBL617414,,H,BAO_0000019,,,,,2340,,9098,,1,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617415,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2341,,9098,,1,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Autocuration,5,,104686
,CHEMBL617416,,H,BAO_0000224,,,,,2342,,9443,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617417,,H,BAO_0000224,,,,,2343,,9443,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,Autocuration,4,,104686
,CHEMBL617418,,H,BAO_0000019,,,,,2344,,9699,,1,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,Autocuration,4,,104686
,CHEMBL617419,,H,BAO_0000019,,,,,2345,,9699,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,Autocuration,4,,104686
,CHEMBL617420,,H,BAO_0000224,,,,,2346,,9098,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,Autocuration,4,,104686
,CHEMBL617421,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2347,,3070,,1,,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617422,,H,BAO_0000224,,,,,2348,,9547,,1,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,Autocuration,4,,104686
,CHEMBL617423,,H,BAO_0000019,,,,,2349,,10444,,1,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,Autocuration,4,,104686
,CHEMBL617424,,H,BAO_0000019,,,,,2350,,14617,,1,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,Autocuration,4,,104686
,CHEMBL617425,,H,BAO_0000019,,,,,2351,,14617,,1,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,Autocuration,4,,104686
,CHEMBL617426,,H,BAO_0000224,,,,,2352,,11130,,1,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,Autocuration,4,,104686
,CHEMBL617427,,H,BAO_0000218,,,,,2353,,11130,,1,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,Autocuration,4,,104686
,CHEMBL617428,,H,BAO_0000221,,,,Brain,2354,955.0,14542,,1,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,Autocuration,4,,104686
,CHEMBL617429,,H,BAO_0000224,,,,,2355,,2797,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,Autocuration,4,,104686
,CHEMBL617430,,H,BAO_0000019,,,,,2356,,11332,,1,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617431,,H,BAO_0000019,,,,,2357,,11332,,1,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617432,,H,BAO_0000019,,,,Frontal cortex,2358,1870.0,10752,,1,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,Autocuration,4,,104686
,CHEMBL617433,,H,BAO_0000224,,,,,2359,,1185,,1,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617434,,H,BAO_0000224,,,,,2360,,1185,,1,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617435,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2361,,11624,,1,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Autocuration,5,,104686
,CHEMBL617436,,H,BAO_0000019,,,,,2362,,1344,,1,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,Autocuration,4,,104686
,CHEMBL617437,10116.0,D,BAO_0000019,Rattus norvegicus,,,Striatum,2363,2435.0,15453,,1,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Autocuration,5,,104686
,CHEMBL617438,,H,BAO_0000019,,,,,2364,,11662,,1,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,Autocuration,4,,104686
,CHEMBL617439,,H,BAO_0000019,,,,,2365,,11662,,1,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,Autocuration,4,,104686
,CHEMBL617440,,H,BAO_0000224,,,,,2366,,10796,,1,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617441,,H,BAO_0000224,,,,,2367,,9069,,1,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL872918,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2368,,8814,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Autocuration,5,,104686
,CHEMBL617442,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2369,,8908,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Autocuration,5,,104686
,CHEMBL617443,,H,BAO_0000019,,,,,2370,,9098,,1,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,Autocuration,4,,104686
,CHEMBL617444,,H,BAO_0000019,,,,,2371,,9098,,1,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,Autocuration,4,,104686
,CHEMBL617445,,H,BAO_0000019,,,,,2372,,9098,,1,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,Autocuration,4,,104686
,CHEMBL617446,,H,BAO_0000019,,,,,2373,,9098,,1,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617447,,H,BAO_0000249,,,,,2374,,9098,,1,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,Autocuration,4,,104686
,CHEMBL617448,,H,BAO_0000019,,,,,2375,,9098,,1,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,Autocuration,4,,104686
,CHEMBL617449,,H,BAO_0000019,,,,,2376,,9098,,1,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,Autocuration,4,,104686
,CHEMBL617450,,H,BAO_0000019,,,,,2377,,9161,,1,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,Autocuration,4,,104686
,CHEMBL617451,,H,BAO_0000019,,,,,2378,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,Autocuration,4,,104686
,CHEMBL617452,,H,BAO_0000019,,,,,2379,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,Autocuration,4,,104686
,CHEMBL617453,,H,BAO_0000019,,,,,2380,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,Autocuration,4,,104686
,CHEMBL617660,,H,BAO_0000019,,,,,2381,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,Autocuration,4,,104686
,CHEMBL617661,,H,BAO_0000019,,,,,2382,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,Autocuration,4,,104686
,CHEMBL617662,,H,BAO_0000019,,,,,2383,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,Autocuration,4,,104686
,CHEMBL872919,,H,BAO_0000019,,,,,2384,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,Autocuration,4,,104686
,CHEMBL617663,,H,BAO_0000019,,,,,2385,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,Autocuration,4,,104686
,CHEMBL617664,,H,BAO_0000019,,,,,2386,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,Autocuration,4,,104686
,CHEMBL617665,,H,BAO_0000019,,,,,2387,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,Autocuration,4,,104686
,CHEMBL617666,,H,BAO_0000019,,,,,2388,,9161,,1,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,Autocuration,4,,104686
,CHEMBL617667,,H,BAO_0000019,,,,,2389,,12094,,1,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,Autocuration,4,,104686
,CHEMBL617668,,H,BAO_0000249,,,,,2390,,12018,,1,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,Autocuration,4,,104686
,CHEMBL617669,,H,BAO_0000249,,,,,2391,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,Autocuration,4,,104686
,CHEMBL617670,,H,BAO_0000224,,,,,2392,,15260,,1,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617671,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2393,,11624,,1,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617672,,H,BAO_0000224,,,,,2394,,13654,,1,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617673,,H,BAO_0000019,,,,,2395,,9541,,1,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,Autocuration,4,,104686
,CHEMBL617674,,H,BAO_0000224,,,,,2396,,11933,,1,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,Autocuration,4,,104686
,CHEMBL617675,,H,BAO_0000019,,,,,2397,,15538,,1,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,Autocuration,4,,104686
,CHEMBL617676,,H,BAO_0000019,,,,,2398,,15538,,1,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,Autocuration,4,,104686
,CHEMBL617677,,H,BAO_0000019,,,,,2399,,15538,,1,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,Autocuration,4,,104686
,CHEMBL617678,,D,BAO_0000019,,,,,2400,,8841,,1,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617679,,H,BAO_0000224,,,,,2401,,1455,,1,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,Autocuration,4,,104686
,CHEMBL617680,,H,BAO_0000224,,,,,2402,,1455,,1,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,Autocuration,4,,104686
,CHEMBL617681,,H,BAO_0000019,,,,,2403,,11752,,1,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,Autocuration,4,,104686
,CHEMBL617682,,H,BAO_0000221,,,,Brain,2404,955.0,11642,,1,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,Autocuration,4,,104686
,CHEMBL617683,,H,BAO_0000224,,,,,2405,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,Autocuration,4,,104686
,CHEMBL617684,,H,BAO_0000224,,,,,2406,,3967,,1,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,Autocuration,4,,104686
,CHEMBL617685,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2407,,12771,,1,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Autocuration,5,,104686
,CHEMBL617686,,H,BAO_0000019,,,,,2408,,11642,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,Autocuration,4,,104686
,CHEMBL617687,,H,BAO_0000224,,,,,2409,,11628,,1,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,Autocuration,4,,104686
,CHEMBL617688,,H,BAO_0000224,,,,,2410,,13654,,1,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Autocuration,4,,104686
,CHEMBL617689,,H,BAO_0000019,,,,,2411,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617690,,H,BAO_0000019,,,,,2412,,11200,,1,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,Autocuration,4,,104686
,CHEMBL617691,,H,BAO_0000218,,,,,2413,,11200,,1,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,Autocuration,4,,104686
,CHEMBL617692,,H,BAO_0000218,,,,,2414,,11200,,1,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,Autocuration,4,,104686
,CHEMBL617693,,H,BAO_0000218,,,,,2415,,11200,,1,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,Autocuration,4,,104686
,CHEMBL617694,,H,BAO_0000218,,,,,2416,,11200,,1,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,Autocuration,4,,104686
,CHEMBL857985,,H,BAO_0000221,,,,Brain,2417,955.0,15436,,1,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,Expert,8,,12687
,CHEMBL617695,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2418,,15436,,1,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Expert,9,,12687
,CHEMBL617696,,H,BAO_0000019,,,,,2419,,14025,,1,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,Autocuration,8,,12687
,CHEMBL617697,,H,BAO_0000357,,,,,2420,,4342,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,Autocuration,8,,12687
,CHEMBL617257,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2421,,13735,,1,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Expert,9,,12687
,CHEMBL617258,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2422,,5816,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Expert,9,,12687
,CHEMBL617259,,H,BAO_0000019,,,,,2423,,14287,,1,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,Expert,8,,12687
,CHEMBL617260,,H,BAO_0000357,,,,,2424,,15738,,1,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,Autocuration,8,,12687
,CHEMBL617261,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2425,,15738,,1,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL617262,,H,BAO_0000019,,,,,2426,,15026,,1,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617263,,H,BAO_0000019,,,,,2427,,16647,,1,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,Expert,8,,12687
,CHEMBL617264,,H,BAO_0000019,,,,,2428,,16647,,1,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,Autocuration,8,,12687
,CHEMBL617265,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2429,,13345,,1,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
Membranes,CHEMBL617266,,H,BAO_0000249,,,,,2430,,1543,,1,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617267,,H,BAO_0000019,,,,,2431,,12444,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,Autocuration,8,,12687
,CHEMBL617268,,H,BAO_0000019,,,,,2432,,16404,,1,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,Expert,8,,12687
,CHEMBL617269,,H,BAO_0000219,,,,,2433,,16404,,1,449.0,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,CHO,Autocuration,8,,12687
,CHEMBL617323,,H,BAO_0000357,,,,,2434,,15577,,1,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,Expert,8,,12687
,CHEMBL617324,,H,BAO_0000357,,,,,2435,,15577,,1,,Serotonergic activity of the compound.,B,,,Autocuration,8,,12687
,CHEMBL617325,,H,BAO_0000249,,,,,2436,,2495,,1,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,Autocuration,8,,12687
,CHEMBL617326,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2437,,15042,,1,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Expert,9,,12687
,CHEMBL617327,,H,BAO_0000249,,,,,2438,,15026,,1,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,Expert,8,,12687
,CHEMBL617328,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2439,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Expert,9,,12687
,CHEMBL617329,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2440,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Expert,9,,12687
,CHEMBL617330,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2441,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Expert,9,,12687
,CHEMBL617331,,H,BAO_0000357,,,,,2442,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617332,,H,BAO_0000357,,,,,2443,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,Autocuration,8,,12687
,CHEMBL617333,,H,BAO_0000357,,,,,2444,,4820,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617334,,H,BAO_0000357,,,,,2445,,6736,,1,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,Autocuration,8,,107
,CHEMBL617335,,H,BAO_0000357,,,,,2446,,5163,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,Autocuration,8,,107
,CHEMBL617336,,H,BAO_0000357,,,,,2447,,5163,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,Autocuration,8,,107
,CHEMBL617337,,H,BAO_0000357,,,,,2448,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,Autocuration,8,,107
,CHEMBL617338,9606.0,D,BAO_0000357,Homo sapiens,,,,2449,,14294,,1,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Expert,9,,107
,CHEMBL617339,,H,BAO_0000357,,,,,2450,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617340,,H,BAO_0000357,,,,,2451,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617341,,H,BAO_0000357,,,,,2452,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,Autocuration,8,,107
,CHEMBL617342,,H,BAO_0000357,,,,,2453,,6736,,1,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617343,,H,BAO_0000357,,,,,2454,,5163,,1,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617344,,H,BAO_0000219,,,,,2455,,16911,,1,723.0,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,NIH3T3,Expert,8,,107
,CHEMBL617345,,H,BAO_0000357,,,,,2456,,6841,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Expert,8,,107
,CHEMBL617346,,H,BAO_0000357,,,,,2457,,6119,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,Expert,8,,107
,CHEMBL617347,,H,BAO_0000357,,,,,2458,,3962,,1,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617348,,H,BAO_0000357,,,,,2459,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,Autocuration,8,,107
,CHEMBL617349,,H,BAO_0000357,,,,,2460,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,Autocuration,8,,107
,CHEMBL617350,,H,BAO_0000019,,,,,2461,,3962,,1,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,Autocuration,8,,107
,CHEMBL872339,,H,BAO_0000357,,,,,2462,,1633,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,Expert,8,,107
,CHEMBL617351,,H,BAO_0000357,,,,,2463,,4373,,1,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,Autocuration,8,,107
,CHEMBL617352,,H,BAO_0000357,,,,,2464,,6576,,1,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617353,,H,BAO_0000357,,,,,2465,,4687,,1,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617354,,H,BAO_0000357,,,,,2466,,16946,,1,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617355,,H,BAO_0000357,,,,,2467,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617356,10090.0,H,BAO_0000219,Mus musculus,,,,2468,,3032,,1,449.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,CHO,Expert,8,,107
,CHEMBL617357,,H,BAO_0000357,,,,,2469,,16655,,1,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617358,,H,BAO_0000357,,,,,2470,,13964,,1,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617359,,H,BAO_0000357,,,,,2471,,16989,,1,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,107
,CHEMBL617360,,H,BAO_0000357,,,,,2472,,16117,,1,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,Autocuration,8,,107
,CHEMBL875913,,H,BAO_0000357,,,,,2473,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,Autocuration,8,,107
,CHEMBL617361,,H,BAO_0000357,,,,,2474,,3269,,1,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617362,9606.0,D,BAO_0000357,Homo sapiens,,,,2475,,1274,,1,,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL617363,,H,BAO_0000357,,,,,2476,,1317,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,Autocuration,8,,107
,CHEMBL617364,,H,BAO_0000357,,,,,2477,,12146,,1,,Tested against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617365,,H,BAO_0000224,,,,,2478,,12652,,1,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,Autocuration,4,,105075
,CHEMBL617366,,H,BAO_0000224,,,,,2479,,12652,,1,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,Autocuration,4,,105075
,CHEMBL617367,,H,BAO_0000224,,,,,2480,,12652,,1,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,Autocuration,4,,105075
,CHEMBL617368,,H,BAO_0000224,,,,,2481,,12652,,1,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,Autocuration,4,,105075
,CHEMBL617369,,H,BAO_0000357,,,,,2482,,16647,,1,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,Autocuration,8,,107
,CHEMBL617370,9606.0,D,BAO_0000219,Homo sapiens,,,,2483,,15851,,1,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,HEK293,Expert,9,,227
,CHEMBL617371,9606.0,D,BAO_0000219,Homo sapiens,,,,2484,,6857,,1,449.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,Expert,9,,227
,CHEMBL617372,,H,BAO_0000357,,,,,2485,,3805,,1,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,Autocuration,8,,227
,CHEMBL617373,9606.0,D,BAO_0000357,Homo sapiens,,,,2486,,6491,,1,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Expert,9,,227
,CHEMBL617374,,H,BAO_0000019,,,,,2487,,14093,,1,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,Autocuration,8,,227
,CHEMBL617375,,H,BAO_0000019,,,,,2488,,13481,,1,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,Autocuration,8,,227
,CHEMBL617376,,H,BAO_0000019,,,,,2489,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,Autocuration,8,,227
,CHEMBL617377,,H,BAO_0000019,,,,,2490,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,Autocuration,8,,227
,CHEMBL617378,,H,BAO_0000019,,,,,2491,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,Autocuration,8,,227
,CHEMBL617379,,H,BAO_0000019,,,,,2492,,13481,,1,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,Autocuration,8,,227
,CHEMBL617380,,H,BAO_0000357,,,,,2493,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,Autocuration,8,,227
,CHEMBL617381,,H,BAO_0000357,,,,,2494,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,Autocuration,8,,227
,CHEMBL617382,,H,BAO_0000357,,,,,2495,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,Autocuration,8,,227
,CHEMBL617383,,H,BAO_0000357,,,,,2496,,12369,,1,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617384,,H,BAO_0000357,,,,,2497,,12369,,1,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,Expert,8,,107
,CHEMBL617385,,H,BAO_0000357,,,,,2498,,12369,,1,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,Expert,8,,107
,CHEMBL617386,,H,BAO_0000019,,,,,2499,,14447,,1,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,Autocuration,8,,107
,CHEMBL617387,,H,BAO_0000019,,,,,2500,,14447,,1,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,Autocuration,8,,107
,CHEMBL617388,,H,BAO_0000219,,,,,2501,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,Autocuration,8,,107
,CHEMBL617389,,H,BAO_0000219,,,,,2502,,6857,,1,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,Autocuration,8,,107
,CHEMBL617390,9606.0,D,BAO_0000219,Homo sapiens,,,,2503,,6857,,1,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,Expert,9,,107
,CHEMBL617391,,H,BAO_0000224,,,,,2504,,5635,,1,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,Autocuration,4,,104817
,CHEMBL617392,,H,BAO_0000357,,,,,2505,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,107
,CHEMBL617393,,H,BAO_0000019,,,,,2506,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,Autocuration,8,,107
,CHEMBL617394,,H,BAO_0000219,,,,,2507,,5105,,1,307.0,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,L929,Autocuration,8,,107
,CHEMBL617395,,H,BAO_0000219,,,,,2508,,5104,,1,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,L929,Expert,8,,107
,CHEMBL617396,,H,BAO_0000219,,,,,2509,,5105,,1,307.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,L929,Expert,8,,107
,CHEMBL617397,,H,BAO_0000219,,,,,2510,,5105,,1,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,L929,Autocuration,8,,107
,CHEMBL617398,,H,BAO_0000357,,,,,2511,,5254,,1,,Binding affinity against 5-HT2A receptor,B,,,Autocuration,8,,107
,CHEMBL617399,,H,BAO_0000357,,,,,2512,,5254,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,107
,CHEMBL617400,,H,BAO_0000219,,,,,2513,,13267,,1,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL617401,,H,BAO_0000219,,,,,2514,,13267,,1,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL617402,9606.0,D,BAO_0000219,Homo sapiens,,,,2515,,14157,,1,722.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,HEK293,Expert,9,,107
,CHEMBL617403,9606.0,D,BAO_0000219,Homo sapiens,,,,2516,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,Expert,9,,107
,CHEMBL617404,,H,BAO_0000357,,,,,2517,,14068,,1,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,Expert,8,,107
,CHEMBL857981,9606.0,D,BAO_0000219,Homo sapiens,,,,2518,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,Expert,9,,107
,CHEMBL617405,9606.0,D,BAO_0000219,Homo sapiens,,,,2519,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,Expert,9,,107
,CHEMBL617253,9606.0,D,BAO_0000219,Homo sapiens,,,,2520,,4540,,1,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,HEK293,Expert,9,,107
,CHEMBL617254,,H,BAO_0000357,,,,,2521,,6166,,1,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,Expert,8,,107
,CHEMBL617255,,H,BAO_0000219,,,,,2522,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL617256,,H,BAO_0000219,,,,,2523,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL616874,,H,BAO_0000219,,,,,2524,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL616875,9606.0,D,BAO_0000219,Homo sapiens,,,,2525,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,HEK293,Expert,9,,107
,CHEMBL616876,,H,BAO_0000219,,,,,2526,,14391,,1,722.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,Expert,8,,107
,CHEMBL616877,,H,BAO_0000219,,,,,2527,,15851,,1,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,HEK293,Expert,8,,107
,CHEMBL616878,9606.0,D,BAO_0000219,Homo sapiens,,,,2528,,15851,,1,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,HEK293,Expert,9,,107
,CHEMBL616879,,H,BAO_0000219,,,,,2529,,3832,,1,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,HEK293,Expert,8,,107
,CHEMBL616880,,H,BAO_0000219,,,,,2530,,3833,,1,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,HEK293,Expert,8,,107
,CHEMBL616881,9606.0,D,BAO_0000219,Homo sapiens,,,,2531,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,Expert,9,,107
,CHEMBL616882,,H,BAO_0000219,,,,,2532,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,NIH3T3,Autocuration,8,,107
,CHEMBL616883,,H,BAO_0000219,,,,,2533,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,Autocuration,8,,107
,CHEMBL616884,,H,BAO_0000219,,,,,2534,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,Autocuration,8,,107
,CHEMBL616885,,H,BAO_0000219,,,,,2535,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL616886,,H,BAO_0000219,,,,,2536,,1883,,1,485.0,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,CHO-K1,Autocuration,8,,107
,CHEMBL616887,,H,BAO_0000219,,,,,2537,,1883,,1,485.0,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,CHO-K1,Expert,8,,107
,CHEMBL616888,9606.0,D,BAO_0000357,Homo sapiens,,,,2538,,14875,,1,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,107
,CHEMBL616889,,H,BAO_0000219,,,,,2539,,15146,,1,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,HEK293,Autocuration,8,,107
,CHEMBL616890,,H,BAO_0000219,,,,,2540,,5213,,1,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,HEK293,Autocuration,8,,107
,CHEMBL616891,9606.0,D,BAO_0000219,Homo sapiens,,,,2541,,16404,,1,449.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,CHO,Expert,9,,107
,CHEMBL616892,,H,BAO_0000219,,,,,2542,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,HEK293,Autocuration,8,,107
,CHEMBL616893,,H,BAO_0000219,,,,,2543,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,HEK293,Autocuration,8,,107
,CHEMBL616894,,H,BAO_0000219,,,,,2544,,12652,,1,723.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,NIH3T3,Autocuration,8,,10620
,CHEMBL616895,,H,BAO_0000219,,,,,2545,,4682,,1,723.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,NIH3T3,Expert,8,,107
,CHEMBL616896,,H,BAO_0000019,,,,,2546,,12652,,1,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,Autocuration,8,,10620
,CHEMBL617099,,H,BAO_0000357,,,,,2547,,4921,,1,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,10621
,CHEMBL617100,,H,BAO_0000357,,,,,2548,,4921,,1,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,Autocuration,8,,10621
,CHEMBL884532,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,2549,,16312,,1,,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Autocuration,8,,107
,CHEMBL617101,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,2550,,14998,,1,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Expert,8,,107
,CHEMBL617102,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,2551,,14025,,1,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Expert,8,,107
,CHEMBL617103,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,2552,,13047,,1,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Autocuration,8,,107
,CHEMBL617104,9986.0,H,BAO_0000357,Oryctolagus cuniculus,,,,2553,,13047,,1,,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Expert,8,,107
,CHEMBL857979,,H,BAO_0000219,,,,,2554,,1883,,1,485.0,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,10576
,CHEMBL857502,,H,BAO_0000019,,,,,2555,,13463,,1,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,Autocuration,8,,12687
,CHEMBL617105,,H,BAO_0000019,,,,,2556,,13463,,1,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,Autocuration,8,,12687
,CHEMBL858021,,H,BAO_0000019,,,,Stomach,2557,945.0,13463,,1,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,Autocuration,8,,12687
,CHEMBL875910,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,2558,945.0,13463,,1,,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Expert,9,,12687
,CHEMBL617106,,H,BAO_0000019,,,,,2559,,13463,,1,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,Autocuration,8,,12687
,CHEMBL617107,,H,BAO_0000219,,,,,2560,,16326,,1,723.0,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,NIH3T3,Expert,8,,12687
,CHEMBL617108,,H,BAO_0000019,,,,,2561,,14093,,1,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,Autocuration,8,,12687
,CHEMBL617109,,H,BAO_0000019,,,,,2562,,14093,,1,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,Autocuration,8,,12687
,CHEMBL617110,,H,BAO_0000357,,,,,2563,,15740,,1,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617111,,H,BAO_0000357,,,,,2564,,16633,,1,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,Autocuration,8,,12687
,CHEMBL617112,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2565,,17200,,1,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Expert,9,,12687
,CHEMBL617113,,H,BAO_0000357,,,,,2566,,17133,,1,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617114,,H,BAO_0000357,,,,,2567,,17133,,1,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617115,,H,BAO_0000357,,,,,2568,,17133,,1,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617116,,H,BAO_0000219,,,,,2569,,17200,,1,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Autocuration,8,,12687
,CHEMBL617117,,H,BAO_0000019,,,,,2570,,15363,,1,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,Autocuration,8,,12687
,CHEMBL617118,,H,BAO_0000357,,,,,2571,,17200,,1,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Autocuration,8,,12687
,CHEMBL617119,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2572,,17200,,1,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Expert,9,,12687
,CHEMBL617120,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2573,,17200,,1,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Expert,9,,12687
,CHEMBL617121,10116.0,D,BAO_0000219,Rattus norvegicus,,,,2574,,17200,,1,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Expert,9,,12687
,CHEMBL617122,,H,BAO_0000219,,,,,2575,,17200,,1,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Autocuration,8,,12687
,CHEMBL617123,,H,BAO_0000019,,,,,2576,,17211,,1,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617124,,H,BAO_0000019,,,,,2577,,17331,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,Expert,8,,12687
,CHEMBL617600,,H,BAO_0000249,,,,,2578,,13565,,1,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,Expert,8,,12687
,CHEMBL617601,,H,BAO_0000357,,,,,2579,,13730,,1,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL882923,,H,BAO_0000019,,,,,2580,,12416,,1,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,Expert,8,,12687
,CHEMBL617602,,H,BAO_0000357,,,,,2581,,15295,,1,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617603,,H,BAO_0000019,,,,,2582,,1742,,1,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,Autocuration,8,,12687
,CHEMBL617604,,H,BAO_0000357,,,,,2583,,15295,,1,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617605,,H,BAO_0000019,,,,,2584,,14970,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL617606,,H,BAO_0000019,,,,,2585,,16693,,1,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL617607,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2586,,14776,,1,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL617455,,H,BAO_0000249,,,,,2587,,14286,,1,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Autocuration,8,,12687
,CHEMBL617456,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2588,,17200,,1,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Expert,9,,12687
,CHEMBL617457,,H,BAO_0000357,,,,,2589,,15306,,1,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,Expert,8,,12687
,CHEMBL617458,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2590,,14178,,1,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL617459,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2591,,14229,,1,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Expert,9,,12687
,CHEMBL617460,,H,BAO_0000357,,,,,2592,,12884,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,Expert,8,,12687
,CHEMBL617461,,H,BAO_0000357,,,,,2593,,13149,,1,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,Expert,8,,12687
,CHEMBL617462,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2594,,15295,,1,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Expert,9,,12687
,CHEMBL617463,,H,BAO_0000357,,,,,2595,,15740,,1,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,Autocuration,8,,12687
,CHEMBL617464,,H,BAO_0000019,,,,,2596,,15185,,1,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,Autocuration,8,,12687
,CHEMBL617465,,H,BAO_0000019,,,,,2597,,15185,,1,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,Autocuration,8,,12687
,CHEMBL617466,,H,BAO_0000019,,,,,2598,,17529,,1,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,Expert,8,,12687
,CHEMBL617467,,H,BAO_0000019,,,,,2599,,14826,,1,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,Autocuration,8,,12687
,CHEMBL617468,,H,BAO_0000019,,,,,2600,,17211,,1,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,Expert,8,,12687
,CHEMBL617469,,H,BAO_0000019,,,,,2601,,14826,,1,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,Autocuration,8,,12687
,CHEMBL617470,,H,BAO_0000019,,,,,2602,,14093,,1,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617471,,H,BAO_0000019,,,,,2603,,14093,,1,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,Autocuration,8,,12687
,CHEMBL617472,,H,BAO_0000219,,,,,2604,,13246,,1,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,NIH3T3,Expert,8,,12687
,CHEMBL617473,,H,BAO_0000357,,,,,2605,,13246,,1,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,Expert,8,,12687
,CHEMBL617474,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2606,,15436,,1,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Expert,9,,12687
,CHEMBL617475,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2607,,15436,,1,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Expert,9,,12687
,CHEMBL617476,,H,BAO_0000221,,,,Brain,2608,955.0,14442,,1,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,Autocuration,8,,12687
,CHEMBL617477,,H,BAO_0000357,,,,,2609,,12457,,1,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,12687
,CHEMBL617478,,H,BAO_0000219,,,,,2610,,12457,,1,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,NIH3T3,Expert,8,,12687
,CHEMBL617479,,H,BAO_0000221,,,,,2611,,14755,,1,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,Autocuration,8,,12687
,CHEMBL617480,,H,BAO_0000357,,,,,2612,,4707,,1,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617481,,H,BAO_0000357,,,,,2613,,13297,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,Expert,8,,12687
,CHEMBL617482,,H,BAO_0000019,,,,,2614,,17331,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,Expert,8,,12687
,CHEMBL617483,,H,BAO_0000019,,,,,2615,,4664,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL621528,,H,BAO_0000357,,,,,2616,,16633,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,12687
,CHEMBL621529,10116.0,D,BAO_0000219,Rattus norvegicus,,,,2617,,4664,,1,723.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,NIH3T3,Expert,9,,12687
,CHEMBL621530,,H,BAO_0000357,,,,,2618,,16133,,1,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,Expert,8,,12687
,CHEMBL621531,,H,BAO_0000357,,,,,2619,,16133,,1,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL621532,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2620,,14060,,1,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL621533,,H,BAO_0000357,,,,,2621,,16326,,1,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,Expert,8,,12687
,CHEMBL621534,,H,BAO_0000219,,,,,2622,,16659,,1,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,Expert,8,,12687
,CHEMBL621535,,H,BAO_0000019,,,,,2623,,14776,,1,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,Autocuration,8,,12687
,CHEMBL621536,,H,BAO_0000357,,,,,2624,,13481,,1,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,Autocuration,8,,12687
,CHEMBL621537,,H,BAO_0000357,,,,,2625,,17386,,1,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL621538,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2626,,6611,,1,,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL621539,,H,BAO_0000019,,,,,2627,,14423,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,Autocuration,8,,12687
,CHEMBL621540,,H,BAO_0000019,,,,,2628,,15412,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,Autocuration,8,,12687
,CHEMBL621541,,H,BAO_0000019,,,,,2629,,15412,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,Autocuration,8,,12687
,CHEMBL621542,,H,BAO_0000019,,,,,2630,,6238,,1,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL621543,,H,BAO_0000357,,,,,2631,,6648,,1,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,Expert,8,,12687
,CHEMBL621544,,H,BAO_0000357,,,,,2632,,5667,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL621545,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2633,,6611,,1,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Expert,9,,12687
,CHEMBL621546,,H,BAO_0000357,,,,,2634,,13481,,1,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL621547,,H,BAO_0000357,,,,,2635,,13481,,1,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,Autocuration,8,,12687
,CHEMBL618692,,H,BAO_0000219,,,,,2636,,15558,,1,723.0,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,NIH3T3,Expert,8,,12687
,CHEMBL618693,,H,BAO_0000357,,,,,2637,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL872922,,H,BAO_0000357,,,,,2638,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,12687
,CHEMBL618694,,H,BAO_0000357,,,,,2639,,6013,,1,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,Autocuration,8,,12687
,CHEMBL618695,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2640,,6013,,1,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Expert,9,,12687
,CHEMBL618696,,H,BAO_0000357,,,,,2641,,6013,,1,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,Autocuration,8,,12687
,CHEMBL618697,,H,BAO_0000357,,,,,2642,,6013,,1,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,Expert,8,,12687
,CHEMBL618892,,H,BAO_0000357,,,,,2643,,6013,,1,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,Autocuration,8,,12687
,CHEMBL618893,,H,BAO_0000357,,,,,2644,,6013,,1,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL618894,,H,BAO_0000357,,,,,2645,,16293,,1,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL618895,,H,BAO_0000219,,,,,2646,,17175,,1,723.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,NIH3T3,Expert,8,,12687
,CHEMBL618896,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2647,,13278,,1,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Expert,9,,12687
,CHEMBL618897,,H,BAO_0000019,,,,Caudate-putamen,2648,5383.0,3682,,1,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,Autocuration,8,,12687
,CHEMBL618898,,H,BAO_0000357,,,,,2649,,2014,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,Autocuration,8,,12687
,CHEMBL618899,,H,BAO_0000357,,,,,2650,,2014,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,Autocuration,8,,12687
,CHEMBL618900,,H,BAO_0000357,,,,,2651,,4932,,1,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,Autocuration,8,,12687
,CHEMBL618901,,H,BAO_0000019,,,,,2652,,4932,,1,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,Autocuration,8,,12687
,CHEMBL618902,,H,BAO_0000357,,,,,2653,,3935,,1,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL618903,10116.0,D,BAO_0000221,Rattus norvegicus,,,Hippocampus,2654,10000000.0,5432,,1,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL618904,,H,BAO_0000357,,,,,2655,,15818,,1,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL618905,,H,BAO_0000357,,,,,2656,,13672,,1,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,Autocuration,8,,12687
,CHEMBL618906,,H,BAO_0000357,,,,,2657,,13672,,1,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,Autocuration,8,,12687
,CHEMBL618907,,H,BAO_0000219,,,,,2658,,14749,,1,723.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,NIH3T3,Expert,8,,12687
,CHEMBL618908,,H,BAO_0000019,,,,,2659,,13462,,1,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,Autocuration,8,,12687
,CHEMBL617909,,H,BAO_0000357,,,,,2660,,15740,,1,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617910,,H,BAO_0000019,,,,,2661,,16647,,1,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,Expert,8,,12687
,CHEMBL617911,,H,BAO_0000221,,,,Brain,2662,955.0,13345,,1,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,Autocuration,8,,12687
,CHEMBL872923,,H,BAO_0000249,,,,,2663,,16740,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Autocuration,8,,12687
,CHEMBL617912,,H,BAO_0000249,,,,,2664,,16740,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Autocuration,8,,12687
,CHEMBL617913,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2665,,15535,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Expert,9,,12687
,CHEMBL617914,,H,BAO_0000249,,,,,2666,,16740,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Expert,8,,12687
,CHEMBL617915,,H,BAO_0000249,,,,,2667,,16740,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Autocuration,8,,12687
,CHEMBL617916,,H,BAO_0000249,,,,,2668,,16740,,1,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,Autocuration,8,,12687
,CHEMBL617917,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2669,,4795,,1,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Expert,9,,12687
,CHEMBL617918,,H,BAO_0000019,,,,,2670,,8,,1,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,Expert,8,,12687
,CHEMBL617919,,H,BAO_0000019,,,,,2671,,8,,1,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,Autocuration,8,,12687
,CHEMBL617920,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2672,,17200,,1,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Expert,9,,12687
,CHEMBL617921,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2673,,2148,,1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Expert,9,,12687
,CHEMBL617922,10116.0,D,BAO_0000224,Rattus norvegicus,,,,2674,,13345,,1,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Expert,5,,105102
,CHEMBL617923,,H,BAO_0000357,,,,,2675,,5088,,1,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617924,,H,BAO_0000357,,,,,2676,,5088,,1,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617925,,H,BAO_0000357,,,,,2677,,17133,,1,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,Autocuration,8,,12687
,CHEMBL617926,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2678,,17133,,1,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Expert,9,,12687
,CHEMBL617927,,H,BAO_0000357,,,,,2679,,16532,,1,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,Autocuration,8,,12687
,CHEMBL617928,,H,BAO_0000357,,,,,2680,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,8,,12687
,CHEMBL617929,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2681,,2309,,1,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Expert,9,,12687
,CHEMBL617930,,H,BAO_0000019,,,,,2682,,12953,,1,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,Expert,8,,12687
,CHEMBL617931,,H,BAO_0000019,,,,,2683,,12953,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,Autocuration,8,,12687
,CHEMBL617932,,H,BAO_0000019,,,,,2684,,12953,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,Autocuration,8,,12687
,CHEMBL617933,,H,BAO_0000219,,,,,2685,,16659,,1,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,CHO,Autocuration,8,,12687
,CHEMBL617934,,H,BAO_0000019,,,,,2686,,16740,,1,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,Autocuration,8,,12687
,CHEMBL617935,,H,BAO_0000019,,,,,2687,,16740,,1,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,Autocuration,8,,12687
,CHEMBL617936,,H,BAO_0000357,,,,,2688,,17133,,1,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,Autocuration,8,,12687
,CHEMBL617937,,H,BAO_0000019,,,,,2689,,17211,,1,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,Autocuration,8,,12687
,CHEMBL617938,,H,BAO_0000019,,,,,2690,,17331,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,Autocuration,8,,12687
,CHEMBL617939,,H,BAO_0000218,,,,,2691,,16633,,1,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,Autocuration,8,,12687
,CHEMBL617940,,H,BAO_0000218,,,,,2692,,16633,,1,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,Autocuration,8,,12687
,CHEMBL617941,,H,BAO_0000218,,,,,2693,,16633,,1,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,Autocuration,8,,12687
,CHEMBL617942,,H,BAO_0000357,,,,,2694,,15026,,1,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,Expert,8,,12687
,CHEMBL617943,,H,BAO_0000357,,,,,2695,,15026,,1,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,Expert,8,,12687
,CHEMBL617944,,H,BAO_0000224,,,,,2696,,16404,,1,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,Expert,4,,105093
,CHEMBL617945,,H,BAO_0000224,,,,,2697,,16404,,1,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,Expert,4,,105093
,CHEMBL617946,,H,BAO_0000224,,,,,2698,,16404,,1,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,Expert,4,,105075
,CHEMBL617947,,H,BAO_0000357,,,,,2699,,16404,,1,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,Autocuration,8,,12687
,CHEMBL617948,,H,BAO_0000357,,,,,2700,,16326,,1,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,Expert,8,,12687
,CHEMBL858116,,H,BAO_0000019,,,,,2701,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,Autocuration,8,,12687
,CHEMBL617949,,H,BAO_0000019,,,,,2702,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,Autocuration,8,,12687
,CHEMBL617950,,H,BAO_0000019,,,,,2703,,15329,,1,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,Autocuration,8,,12687
,CHEMBL617951,,H,BAO_0000019,,,,Thoracic aorta,2704,1515.0,16404,,1,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,Expert,8,,12687
,CHEMBL617952,,H,BAO_0000019,,,,Thoracic aorta,2705,1515.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,Expert,8,,12687
,CHEMBL617953,,H,BAO_0000019,,,,Thoracic aorta,2706,1515.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,Autocuration,8,,12687
,CHEMBL617954,,H,BAO_0000357,,,,,2707,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,12687
,CHEMBL617955,,H,BAO_0000019,,,,,2708,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,Expert,8,,12687
,CHEMBL857071,,H,BAO_0000019,,,,,2709,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,Autocuration,8,,12687
,CHEMBL617270,,H,BAO_0000019,,,,,2710,,12490,,1,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,Expert,8,,12687
,CHEMBL617271,,H,BAO_0000219,,,,,2711,,12827,,1,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,N1E-115,Autocuration,8,,12687
,CHEMBL617272,,H,BAO_0000219,,,,,2712,,12827,,1,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,N1E-115,Autocuration,8,,12687
,CHEMBL617273,,H,BAO_0000019,,,,,2713,,12918,,1,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,Autocuration,8,,12687
,CHEMBL617274,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2714,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Expert,9,,12687
,CHEMBL617275,,H,BAO_0000357,,,,,2715,,17723,,1,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617276,,H,BAO_0000357,,,,,2716,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617277,,H,BAO_0000357,,,,,2717,,16293,,1,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617278,,H,BAO_0000019,,,,,2718,,3857,,1,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL617279,,H,BAO_0000019,,,,,2719,,3857,,1,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,Expert,8,,108
,CHEMBL617280,,H,BAO_0000019,,,,,2720,,3857,,1,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL617281,,H,BAO_0000357,,,,,2721,,15363,,1,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617282,,H,BAO_0000357,,,,,2722,,15363,,1,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617283,,H,BAO_0000019,,,,,2723,,16441,,1,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,Expert,8,,108
,CHEMBL617284,,H,BAO_0000019,,,,,2724,,16441,,1,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,Expert,8,,108
,CHEMBL617285,,H,BAO_0000219,,,,,2725,,4176,,1,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617286,,H,BAO_0000019,,,,,2726,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617287,9606.0,D,BAO_0000357,Homo sapiens,,,,2727,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Expert,9,,108
,CHEMBL617288,,H,BAO_0000357,,,,,2728,,5088,,1,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,Expert,8,,108
,CHEMBL617289,,H,BAO_0000357,,,,,2729,,5088,,1,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,Autocuration,8,,108
,CHEMBL872917,,H,BAO_0000357,,,,,2730,,5088,,1,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL617290,,H,BAO_0000357,,,,,2731,,5088,,1,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,108
,CHEMBL617291,,H,BAO_0000219,,,,,2732,,16659,,1,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,108
,CHEMBL617292,,H,BAO_0000219,,,,,2733,,16659,,1,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,CHO,Autocuration,8,,108
,CHEMBL617293,,H,BAO_0000219,,,,,2734,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,Autocuration,8,,108
,CHEMBL617294,9606.0,D,BAO_0000219,Homo sapiens,,,,2735,,6857,,1,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,Expert,9,,108
,CHEMBL617295,,H,BAO_0000019,,,,,2736,,3857,,1,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,Expert,8,,108
,CHEMBL617296,,H,BAO_0000357,,,,,2737,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,108
,CHEMBL617297,,H,BAO_0000019,,,,,2738,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,Autocuration,8,,108
,CHEMBL617298,,H,BAO_0000219,,,,,2739,,5104,,1,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,CHO,Expert,8,,108
,CHEMBL617299,,H,BAO_0000219,,,,,2740,,5105,,1,449.0,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,CHO,Expert,8,,108
,CHEMBL617300,,H,BAO_0000219,,,,,2741,,5105,,1,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,CHO,Autocuration,8,,108
,CHEMBL617454,,H,BAO_0000357,,,,,2742,,5254,,1,,Binding affinity against 5-HT2C receptor,B,,,Autocuration,8,,108
,CHEMBL617505,,H,BAO_0000219,,,,,2743,,13267,,1,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617506,9606.0,D,BAO_0000219,Homo sapiens,,,,2744,,14157,,1,722.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,HEK293,Expert,9,,108
,CHEMBL617507,9606.0,D,BAO_0000219,Homo sapiens,,,,2745,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,HEK293,Expert,9,,108
,CHEMBL617508,,H,BAO_0000357,,,,,2746,,14068,,1,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,Expert,8,,108
,CHEMBL857982,9606.0,D,BAO_0000219,Homo sapiens,,,,2747,,12936,,1,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,HEK293,Expert,9,,108
,CHEMBL617509,9606.0,D,BAO_0000219,Homo sapiens,,,,2748,,4540,,1,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,HEK293,Expert,9,,108
,CHEMBL617510,9606.0,D,BAO_0000219,Homo sapiens,,,,2749,,4540,,1,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,HEK293,Expert,9,,108
,CHEMBL617511,,H,BAO_0000357,,,,,2750,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,Autocuration,8,,108
,CHEMBL617512,,H,BAO_0000219,,,,,2751,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617749,,H,BAO_0000219,,,,,2752,,17296,,1,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617750,,H,BAO_0000219,,,,,2753,,15779,,1,722.0,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,Autocuration,8,,108
,CHEMBL617751,,H,BAO_0000219,,,,,2754,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,Autocuration,8,,108
,CHEMBL617752,,H,BAO_0000219,,,,,2755,,14391,,1,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,Expert,8,,108
,CHEMBL617753,,H,BAO_0000219,,,,,2756,,15779,,1,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,HEK293,Autocuration,8,,108
,CHEMBL617754,,H,BAO_0000219,,,,,2757,,15851,,1,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,HEK293,Expert,8,,108
,CHEMBL617755,9606.0,D,BAO_0000219,Homo sapiens,,,,2758,,15851,,1,722.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,HEK293,Expert,9,,108
,CHEMBL617756,,H,BAO_0000219,,,,,2759,,15779,,1,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,HEK293,Autocuration,8,,108
,CHEMBL617757,,H,BAO_0000219,,,,,2760,,3832,,1,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,HEK293,Expert,8,,108
,CHEMBL617758,,H,BAO_0000219,,,,,2761,,3833,,1,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,HEK293,Expert,8,,108
,CHEMBL617759,,H,BAO_0000219,,,,,2762,,17451,,1,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,NIH3T3,Autocuration,8,,108
,CHEMBL617760,,H,BAO_0000219,,,,,2763,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617761,,H,BAO_0000219,,,,,2764,,1883,,1,485.0,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,CHO-K1,Expert,8,,108
,CHEMBL617762,9606.0,D,BAO_0000357,Homo sapiens,,,,2765,,4321,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,108
,CHEMBL617763,,H,BAO_0000357,,,,,2766,,14875,,1,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL857983,,H,BAO_0000219,,,,,2767,,15146,,1,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,HEK293,Autocuration,8,,108
,CHEMBL617764,,H,BAO_0000219,,,,,2768,,5213,,1,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,HEK293,Autocuration,8,,108
,CHEMBL617765,,H,BAO_0000219,,,,,2769,,16404,,1,308.0,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,HeLa,Autocuration,8,,108
,CHEMBL617766,,H,BAO_0000019,,,,,2770,,13267,,1,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,Autocuration,8,,108
,CHEMBL617767,,H,BAO_0000221,,,,Hippocampus,2771,10000000.0,13267,,1,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,Autocuration,8,,108
,CHEMBL617768,,H,BAO_0000219,,,,,2772,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,HEK293,Autocuration,8,,108
,CHEMBL617769,,H,BAO_0000219,,,,,2773,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,HEK293,Autocuration,8,,108
,CHEMBL858023,,H,BAO_0000357,,,,,2774,,13463,,1,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,Autocuration,8,,11864
,CHEMBL617770,,H,BAO_0000019,,,,Stomach,2775,945.0,13463,,1,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,Autocuration,8,,11864
,CHEMBL617771,,H,BAO_0000019,,,,Stomach,2776,945.0,13463,,1,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,Autocuration,8,,11864
,CHEMBL617772,,H,BAO_0000219,,,,,2777,,12652,,1,625.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,A9,Autocuration,8,,11864
,CHEMBL617773,,H,BAO_0000219,,,,,2778,,4682,,1,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,NIH3T3,Autocuration,8,,11864
,CHEMBL617850,,H,BAO_0000219,,,,,2779,,4682,,1,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,NIH3T3,Autocuration,8,,11864
,CHEMBL617851,,H,BAO_0000219,,,,,2780,,4682,,1,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,NIH3T3,Autocuration,8,,11864
,CHEMBL617852,,H,BAO_0000019,,,,,2781,,12652,,1,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,Autocuration,8,,11864
,CHEMBL858024,10090.0,H,BAO_0000019,Mus musculus,,,Stomach,2782,945.0,13463,,1,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Autocuration,8,,12689
,CHEMBL617853,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,2783,945.0,13463,,1,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Expert,9,,12689
,CHEMBL617854,,H,BAO_0000357,,,,,2784,,13969,,1,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,Expert,8,,108
,CHEMBL873477,9823.0,H,BAO_0000357,Sus scrofa,,,,2785,,13392,,1,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL617855,,H,BAO_0000357,,,,,2786,,13392,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL617856,,H,BAO_0000019,,,,,2787,,14430,,1,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,Expert,8,,108
,CHEMBL617857,,H,BAO_0000019,,,,,2788,,1742,,1,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,Autocuration,8,,108
,CHEMBL617858,,H,BAO_0000249,,,,,2789,,14286,,1,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,Autocuration,8,,108
,CHEMBL617859,,H,BAO_0000357,,,,,2790,,5619,,1,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617860,,H,BAO_0000357,,,,,2791,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617861,,H,BAO_0000357,,,,,2792,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,108
,CHEMBL617862,,H,BAO_0000019,,,,,2793,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,Expert,8,,108
,CHEMBL617863,,H,BAO_0000019,,,,,2794,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,Autocuration,8,,108
,CHEMBL617864,,H,BAO_0000249,,,,,2795,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,Autocuration,8,,108
,CHEMBL617649,,H,BAO_0000249,,,,,2796,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,Autocuration,8,,108
,CHEMBL617650,9823.0,H,BAO_0000019,Sus scrofa,,,,2797,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Expert,8,,108
,CHEMBL617651,9823.0,H,BAO_0000019,Sus scrofa,,,,2798,,12919,,1,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Expert,8,,108
,CHEMBL617652,9823.0,H,BAO_0000357,Sus scrofa,,,,2799,,16429,,1,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Autocuration,8,,108
,CHEMBL857072,9823.0,H,BAO_0000019,Sus scrofa,,,,2800,,773,,1,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Autocuration,8,,108
,CHEMBL617653,9823.0,H,BAO_0000357,Sus scrofa,,,,2801,,5033,,1,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617654,,H,BAO_0000019,,,,,2802,,12861,,1,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,Autocuration,8,,12687
,CHEMBL617655,,H,BAO_0000019,,,,,2803,,14093,,1,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,Autocuration,8,,12689
,CHEMBL617656,,H,BAO_0000357,,,,,2804,,14970,,1,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,Expert,8,,12689
,CHEMBL617657,,H,BAO_0000357,,,,,2805,,14970,,1,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,Autocuration,8,,12689
,CHEMBL617658,,H,BAO_0000357,,,,,2806,,14970,,1,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,Autocuration,8,,12689
,CHEMBL617659,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2807,,14178,,1,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,12689
,CHEMBL617838,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2808,,14178,,1,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,12689
Brain membranes,CHEMBL617839,10116.0,D,BAO_0000249,Rattus norvegicus,,,,2809,,14229,,1,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Expert,9,,12689
,CHEMBL617840,,H,BAO_0000357,,,,,2810,,16532,,1,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,Autocuration,8,,12689
,CHEMBL617841,,H,BAO_0000019,,,,,2811,,14826,,1,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,Autocuration,8,,12689
,CHEMBL875915,,H,BAO_0000019,,,,,2812,,17211,,1,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,Autocuration,8,,12689
,CHEMBL617842,,H,BAO_0000219,,,,,2813,,17211,,1,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,Expert,8,,12689
,CHEMBL617843,,H,BAO_0000219,,,,,2814,,13246,,1,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,NIH3T3,Expert,8,,12689
,CHEMBL617844,,H,BAO_0000357,,,,,2815,,13246,,1,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,Expert,8,,12689
,CHEMBL617845,,H,BAO_0000357,,,,,2816,,12457,,1,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,12689
,CHEMBL617846,,H,BAO_0000219,,,,,2817,,12457,,1,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,NIH3T3,Expert,8,,12689
,CHEMBL617847,,H,BAO_0000357,,,,,2818,,4707,,1,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,Autocuration,8,,12689
,CHEMBL617848,,H,BAO_0000357,,,,,2819,,13297,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,12689
,CHEMBL617849,,H,BAO_0000357,,,,,2820,,16633,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,12689
,CHEMBL621507,,H,BAO_0000357,,,,,2821,,16133,,1,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,Expert,8,,12689
,CHEMBL621508,,H,BAO_0000357,,,,,2822,,16326,,1,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,Expert,8,,12689
,CHEMBL621509,,H,BAO_0000019,,,,,2823,,14423,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,Autocuration,8,,12689
,CHEMBL621510,,H,BAO_0000019,,,,,2824,,15412,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,Autocuration,8,,12689
,CHEMBL621511,,H,BAO_0000019,,,,,2825,,15412,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,Autocuration,8,,12689
,CHEMBL621512,,H,BAO_0000219,,,,,2826,,15558,,1,625.0,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,A9,Expert,8,,12689
,CHEMBL621513,,H,BAO_0000357,,,,,2827,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,12689
,CHEMBL621514,,H,BAO_0000357,,,,,2828,,6013,,1,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,Expert,8,,12689
,CHEMBL621515,,H,BAO_0000219,,,,,2829,,17175,,1,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,Expert,8,,12689
,CHEMBL621516,,H,BAO_0000219,,,,,2830,,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,Autocuration,8,,12689
,CHEMBL621517,,H,BAO_0000019,,,,Caudate-putamen,2831,5383.0,3682,,1,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,Autocuration,8,,12689
,CHEMBL621518,,H,BAO_0000357,,,,,2832,,4932,,1,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,Autocuration,8,,12689
,CHEMBL621519,,H,BAO_0000019,,,,,2833,,4932,,1,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,Autocuration,8,,12689
,CHEMBL621520,,H,BAO_0000357,,,,,2834,,3935,,1,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL621521,,H,BAO_0000357,,,,,2835,,15818,,1,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL621522,,H,BAO_0000357,,,,,2836,,15818,,1,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL621523,,H,BAO_0000219,,,,,2837,,14749,,1,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,Expert,8,,12689
,CHEMBL621524,,H,BAO_0000357,,,,,2838,,15740,,1,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL621525,10116.0,D,BAO_0000357,Rattus norvegicus,,,,2839,,17133,,1,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Expert,9,,12689
,CHEMBL872921,,H,BAO_0000357,,,,,2840,,16532,,1,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,Autocuration,8,,12689
,CHEMBL621526,,H,BAO_0000357,,,,,2841,,12369,,1,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL621527,,H,BAO_0000219,,,,,2842,,12369,,1,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,Expert,8,,12689
,CHEMBL617865,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2843,,2309,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Expert,9,,12689
,CHEMBL617866,,H,BAO_0000357,,,,,2844,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,12689
,CHEMBL617867,,H,BAO_0000019,,,,,2845,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,Autocuration,8,,12689
,CHEMBL617487,,H,BAO_0000357,,,,,2846,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,Autocuration,8,,12689
,CHEMBL617488,,H,BAO_0000357,,,,,2847,,12953,,1,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,12689
,CHEMBL617489,,H,BAO_0000357,,,,,2848,,17133,,1,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,Autocuration,8,,12689
,CHEMBL617490,,H,BAO_0000019,,,,,2849,,17211,,1,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,Autocuration,8,,12689
,CHEMBL617491,,H,BAO_0000019,,,,,2850,,17211,,1,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,Autocuration,8,,12689
,CHEMBL617492,,H,BAO_0000019,,,,,2851,,14025,,1,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,Autocuration,8,,12689
,CHEMBL617493,,H,BAO_0000019,,,,,2852,,14998,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,Autocuration,8,,12689
,CHEMBL617494,,H,BAO_0000357,,,,,2853,,4342,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,Autocuration,8,,12689
,CHEMBL617495,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2854,,13735,,1,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Expert,9,,12689
,CHEMBL617496,,H,BAO_0000357,,,,,2855,,13181,,1,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,12689
,CHEMBL617497,,H,BAO_0000219,,,,,2856,,1883,,1,485.0,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,CHO-K1,Autocuration,8,,12689
,CHEMBL617498,,H,BAO_0000357,,,,,2857,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,Autocuration,8,,12689
,CHEMBL617499,,H,BAO_0000357,,,,,2858,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,Autocuration,8,,12689
,CHEMBL617500,,H,BAO_0000019,,,,,2859,,14579,,1,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,Autocuration,8,,12689
,CHEMBL617501,,H,BAO_0000357,,,,,2860,,4639,,1,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617502,,H,BAO_0000357,,,,,2861,,4820,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL617503,,H,BAO_0000357,,,,,2862,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,Autocuration,8,,227
,CHEMBL617504,,H,BAO_0000357,,,,,2863,,14755,,1,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,Autocuration,8,,227
,CHEMBL617406,,H,BAO_0000357,,,,,2864,,14744,,1,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,Autocuration,8,,227
,CHEMBL617407,9606.0,D,BAO_0000019,Homo sapiens,,,,2865,,6857,,1,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Expert,9,,227
,CHEMBL617408,,H,BAO_0000357,,,,,2866,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,227
,CHEMBL617409,,H,BAO_0000357,,,,,2867,,15363,,1,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617410,,H,BAO_0000357,,,,,2868,,15363,,1,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617411,,H,BAO_0000357,,,,,2869,,15363,,1,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617412,,H,BAO_0000019,,,,,2870,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617774,9606.0,D,BAO_0000357,Homo sapiens,,,,2871,,17200,,1,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Expert,9,,227
,CHEMBL617775,9606.0,D,BAO_0000219,Homo sapiens,,,,2872,,15851,,1,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,HEK293,Expert,9,,227
,CHEMBL617776,9606.0,D,BAO_0000219,Homo sapiens,,,,2873,,15851,,1,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,HEK293,Expert,9,,227
,CHEMBL617777,9606.0,D,BAO_0000219,Homo sapiens,,,,2874,,6857,,1,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,Expert,9,,227
,CHEMBL617778,9606.0,D,BAO_0000219,Homo sapiens,,,,2875,,6857,,1,449.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,Expert,9,,227
,CHEMBL617779,,H,BAO_0000219,,,,,2876,,15779,,1,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,Autocuration,8,,227
,CHEMBL617780,,H,BAO_0000219,,,,,2877,,15851,,1,722.0,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,HEK293,Expert,8,,227
,CHEMBL617781,,H,BAO_0000219,,,,,2878,,15779,,1,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,HEK293,Autocuration,8,,227
,CHEMBL617782,9606.0,D,BAO_0000219,Homo sapiens,,,,2879,,14157,,1,722.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,HEK293,Expert,9,,227
,CHEMBL617783,9606.0,D,BAO_0000219,Homo sapiens,,,,2880,,4540,,1,722.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,HEK293,Expert,9,,227
,CHEMBL617784,,H,BAO_0000357,,,,,2881,,6166,,1,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,Autocuration,8,,227
,CHEMBL617785,,H,BAO_0000219,,,,,2882,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,HEK293,Autocuration,8,,227
,CHEMBL857984,,H,BAO_0000219,,,,,2883,,14391,,1,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,HEK293,Expert,8,,227
,CHEMBL617786,,H,BAO_0000219,,,,,2884,,3832,,1,722.0,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,HEK293,Expert,8,,227
,CHEMBL617787,,H,BAO_0000219,,,,,2885,,3833,,1,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,HEK293,Expert,8,,227
,CHEMBL617788,9606.0,D,BAO_0000219,Homo sapiens,,,,2886,,15851,,1,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,HEK293,Expert,9,,227
,CHEMBL617789,9606.0,D,BAO_0000219,Homo sapiens,,,,2887,,15851,,1,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,HEK293,Expert,9,,227
,CHEMBL617790,,H,BAO_0000219,,,,,2888,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,HEK293,Autocuration,8,,227
,CHEMBL617791,,H,BAO_0000219,,,,,2889,,1883,,1,485.0,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,CHO-K1,Expert,8,,227
,CHEMBL617608,,H,BAO_0000357,,,,,2890,,4321,,1,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,Expert,8,,227
,CHEMBL617609,,H,BAO_0000219,,,,,2891,,15146,,1,722.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,HEK293,Autocuration,8,,227
,CHEMBL617610,,H,BAO_0000219,,,,,2892,,5213,,1,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,HEK293,Autocuration,8,,227
,CHEMBL617611,,H,BAO_0000219,,,,,2893,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,HEK293,Autocuration,8,,227
,CHEMBL617612,,H,BAO_0000219,,,,,2894,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,Autocuration,8,,227
,CHEMBL617613,,H,BAO_0000219,,,,,2895,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,Autocuration,8,,227
,CHEMBL617614,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,2896,,14025,,1,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Autocuration,8,,227
,CHEMBL617615,,H,BAO_0000019,,,,Stomach,2897,945.0,13463,,1,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,Expert,8,,12688
,CHEMBL858114,,H,BAO_0000357,,,,Stomach,2898,945.0,7259,,1,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,Expert,8,,12688
,CHEMBL617616,,H,BAO_0000357,,,,Stomach,2899,945.0,7259,,1,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,Autocuration,8,,12688
,CHEMBL617617,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,2900,945.0,7185,,1,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Expert,9,,12688
,CHEMBL875914,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2901,,7185,,1,,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Expert,9,,12688
,CHEMBL617618,,H,BAO_0000019,,,,Stomach,2902,945.0,13267,,1,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,Autocuration,8,,12688
,CHEMBL617619,10116.0,D,BAO_0000357,Rattus norvegicus,,,Stomach,2903,945.0,13735,,1,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Expert,9,,12688
,CHEMBL617620,,H,BAO_0000019,,,,,2904,,15738,,1,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,Autocuration,8,,12688
,CHEMBL617621,,H,BAO_0000019,,,,,2905,,15738,,1,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,Autocuration,8,,12688
,CHEMBL617622,,H,BAO_0000019,,,,,2906,,15738,,1,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,Autocuration,8,,12688
,CHEMBL617623,10116.0,D,BAO_0000357,Rattus norvegicus,,,Stomach,2907,945.0,12936,,1,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Expert,9,,12688
,CHEMBL617624,10116.0,D,BAO_0000357,Rattus norvegicus,,,Stomach,2908,945.0,12936,,1,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Expert,9,,12688
,CHEMBL617625,10116.0,D,BAO_0000357,Rattus norvegicus,,,Stomach,2909,945.0,12936,,1,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Expert,9,,12688
,CHEMBL617626,10116.0,D,BAO_0000357,Rattus norvegicus,,,Stomach,2910,945.0,12936,,1,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Expert,9,,12688
,CHEMBL617627,,H,BAO_0000019,,,,Stomach,2911,945.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Autocuration,8,,12688
,CHEMBL617628,,H,BAO_0000019,,,,Stomach,2912,945.0,16404,,1,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Expert,8,,12688
,CHEMBL617629,,H,BAO_0000019,,,,Stomach,2913,945.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,Autocuration,8,,12688
,CHEMBL858115,,H,BAO_0000019,,,,Stomach,2914,945.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,Autocuration,8,,12688
,CHEMBL617630,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,2915,945.0,16404,,1,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Expert,9,,12688
,CHEMBL617631,,H,BAO_0000019,,,,Thoracic aorta,2916,1515.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,Autocuration,8,,12688
,CHEMBL617632,,H,BAO_0000357,,,,,2917,,7483,,1,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,Autocuration,8,,12688
,CHEMBL617633,,H,BAO_0000357,,,,,2918,,7483,,1,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,Expert,8,,12688
,CHEMBL617634,,H,BAO_0000357,,,,,2919,,7483,,1,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,Autocuration,8,,12688
,CHEMBL617635,,H,BAO_0000357,,,,,2920,,7483,,1,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,Autocuration,8,,12688
,CHEMBL617637,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,2922,945.0,16404,,1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Autocuration,9,,12688
,CHEMBL617638,,H,BAO_0000357,,,,,2923,,6347,,1,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Autocuration,8,,227
,CHEMBL617639,,H,BAO_0000357,,,,,2924,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,Autocuration,8,,227
,CHEMBL617640,,H,BAO_0000357,,,,,2925,,4373,,1,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,Autocuration,8,,227
,CHEMBL617641,,H,BAO_0000357,,,,,2926,,4687,,1,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617642,,H,BAO_0000357,,,,,2927,,16946,,1,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617643,,H,BAO_0000357,,,,,2928,,16633,,1,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617644,,H,BAO_0000357,,,,,2929,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,Autocuration,8,,227
,CHEMBL617645,,H,BAO_0000357,,,,,2930,,16633,,1,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,Autocuration,8,,227
,CHEMBL617646,,H,BAO_0000357,,,,,2931,,15026,,1,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Expert,8,,108
,CHEMBL617647,9913.0,H,BAO_0000357,Bos taurus,,,,2932,,15738,,1,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Autocuration,8,,108
,CHEMBL617648,9913.0,H,BAO_0000357,Bos taurus,,,,2933,,15738,,1,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Autocuration,8,,108
,CHEMBL617875,9913.0,H,BAO_0000357,Bos taurus,,,,2934,,15738,,1,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Autocuration,8,,108
,CHEMBL617876,9913.0,H,BAO_0000357,Bos taurus,,,,2935,,15738,,1,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Autocuration,8,,108
,CHEMBL617877,9913.0,H,BAO_0000357,Bos taurus,,,,2936,,16404,,1,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Expert,8,,108
,CHEMBL617878,9913.0,H,BAO_0000357,Bos taurus,,,,2937,,15026,,1,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Expert,8,,108
,CHEMBL617879,9913.0,H,BAO_0000357,Bos taurus,,,,2938,,15738,,1,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Autocuration,8,,108
,CHEMBL617880,10141.0,H,BAO_0000019,Cavia porcellus,,,,2939,,16312,,1,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Autocuration,8,,108
,CHEMBL617881,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,2940,2435.0,5486,,1,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Intermediate,9,,20033
,CHEMBL857073,,H,BAO_0000357,,,,,2941,,5254,,1,,Binding affinity against 5-HT1A receptor,B,,,Autocuration,8,,51
,CHEMBL617882,,H,BAO_0000219,,,,,2942,,3857,,1,449.0,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,CHO,Expert,8,,108
,CHEMBL617883,9606.0,D,BAO_0000219,Homo sapiens,,,,2943,,6857,,1,449.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,Expert,9,,108
,CHEMBL617884,,H,BAO_0000219,,,,,2944,,4176,,1,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,Autocuration,8,,108
,CHEMBL617885,,H,BAO_0000219,,,,,2945,,6347,,1,449.0,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,CHO,Autocuration,8,,108
,CHEMBL617886,,H,BAO_0000219,,,,,2946,,6347,,1,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,CHO,Autocuration,8,,108
,CHEMBL617887,9606.0,D,BAO_0000357,Homo sapiens,,,,2947,,16146,,1,,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,108
,CHEMBL617888,,H,BAO_0000357,,,,,2948,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,Autocuration,8,,108
,CHEMBL617889,,H,BAO_0000019,,,,,2949,,3857,,1,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,Autocuration,8,,108
,CHEMBL617890,,H,BAO_0000357,,,,,2950,,5635,,1,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL617891,,H,BAO_0000357,,,,,2951,,5635,,1,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,Autocuration,8,,108
,CHEMBL617892,,H,BAO_0000357,,,,,2952,,5635,,1,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,Autocuration,8,,108
,CHEMBL617893,,H,BAO_0000219,,,,,2953,,4012,,1,449.0,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,CHO,Expert,8,,108
,CHEMBL617894,,H,BAO_0000219,,,,,2954,,6366,,1,449.0,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,CHO,Expert,8,,108
,CHEMBL617895,,H,BAO_0000219,,,,,2955,,15949,,1,449.0,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,Expert,8,,108
,CHEMBL617896,,H,BAO_0000219,,,,,2956,,17211,,1,449.0,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,CHO,Autocuration,8,,108
,CHEMBL617897,9606.0,D,BAO_0000357,Homo sapiens,,,,2957,,6491,,1,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Expert,9,,108
,CHEMBL617898,,H,BAO_0000019,,,,,2958,,14093,,1,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,Autocuration,8,,108
,CHEMBL617899,,H,BAO_0000019,,,,,2959,,13481,,1,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,Autocuration,8,,108
,CHEMBL617900,10116.0,H,BAO_0000219,Rattus norvegicus,,,,2960,,6347,,1,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,CHO,Expert,8,,108
,CHEMBL617901,,H,BAO_0000019,,,,,2961,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,Autocuration,8,,108
,CHEMBL617902,,H,BAO_0000019,,,,,2962,,14093,,1,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,Autocuration,8,,108
,CHEMBL617903,,H,BAO_0000019,,,,,2963,,13481,,1,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,Autocuration,8,,108
,CHEMBL617904,,H,BAO_0000357,,,,,2964,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,Autocuration,8,,108
,CHEMBL617905,,H,BAO_0000357,,,,,2965,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL617906,,H,BAO_0000357,,,,,2966,,14442,,1,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,Autocuration,8,,108
,CHEMBL617907,,H,BAO_0000357,,,,,2967,,14755,,1,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,Autocuration,8,,108
,CHEMBL617908,,H,BAO_0000357,,,,,2968,,14744,,1,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,Autocuration,8,,108
,CHEMBL620617,,H,BAO_0000219,,,,,2969,,16659,,1,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,Expert,8,,108
,CHEMBL620618,9606.0,D,BAO_0000019,Homo sapiens,,,,2970,,6857,,1,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Expert,9,,108
,CHEMBL620619,,H,BAO_0000357,,,,,2971,,5635,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,Expert,8,,108
,CHEMBL620620,9606.0,D,BAO_0000357,Homo sapiens,,,,2972,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,108
,CHEMBL620621,,H,BAO_0000357,,,,,2973,,16209,,1,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,Autocuration,8,,108
Membranes,CHEMBL872920,10116.0,D,BAO_0000249,Rattus norvegicus,,,,2974,,5778,,1,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Autocuration,7,,104698
,CHEMBL620622,,H,BAO_0000223,,,,,2975,,5094,,1,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,Autocuration,6,,104698
,CHEMBL620623,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2976,,809,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Autocuration,7,,104698
,CHEMBL620624,,H,BAO_0000019,,,,,2977,,1578,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,Autocuration,6,,104698
,CHEMBL620625,,H,BAO_0000019,,,,,2978,,809,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,Autocuration,6,,104698
,CHEMBL620626,,H,BAO_0000219,,,,,2979,,12469,,1,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,Autocuration,6,,104698
,CHEMBL621307,,H,BAO_0000019,,,,,2980,,14290,,1,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,Autocuration,6,,104698
,CHEMBL621308,,H,BAO_0000019,,,,,2981,,14290,,1,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,Autocuration,6,,104698
,CHEMBL621309,,H,BAO_0000223,,,,,2982,,10609,,1,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,Autocuration,6,,104698
,CHEMBL621310,,H,BAO_0000223,,,,,2983,,10609,,1,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,Autocuration,6,,104698
,CHEMBL621311,,H,BAO_0000223,,,,,2984,,10609,,1,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,Autocuration,6,,104698
,CHEMBL621502,,H,BAO_0000249,,,,,2985,,15253,,1,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,Autocuration,6,,104698
,CHEMBL621503,,H,BAO_0000249,,,,,2986,,15253,,1,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,Autocuration,6,,104698
Membranes,CHEMBL621504,,H,BAO_0000249,,,,,2987,,11683,,1,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,Autocuration,6,,104698
,CHEMBL621505,,H,BAO_0000223,,,,,2988,,12092,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL621506,,H,BAO_0000019,,,,,2989,,1946,,1,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,Autocuration,6,,104698
,CHEMBL619781,,H,BAO_0000223,,,,,2990,,11623,,1,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,Autocuration,6,,104698
,CHEMBL619782,,H,BAO_0000223,,,,,2991,,11623,,1,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,Autocuration,6,,104698
,CHEMBL619783,,H,BAO_0000019,,,,,2992,,14788,,1,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,Autocuration,6,,104698
,CHEMBL619784,10116.0,D,BAO_0000019,Rattus norvegicus,,,,2993,,5432,,1,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619785,,H,BAO_0000249,,,,,2994,,14826,,1,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,Autocuration,6,,104698
,CHEMBL619786,,H,BAO_0000223,,,,,2995,,2222,,1,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL619787,,H,BAO_0000019,,,,,2996,,11963,,1,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,Autocuration,6,,104698
,CHEMBL872925,,H,BAO_0000019,,,,,2997,,14145,,1,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,Autocuration,6,,104698
,CHEMBL619788,,H,BAO_0000019,,,,,2998,,17819,,1,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,Autocuration,6,,104698
,CHEMBL619789,,H,BAO_0000249,,,,,2999,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,Autocuration,6,,104698
,CHEMBL619790,,H,BAO_0000249,,,,,3000,,10394,,1,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,Autocuration,6,,104698
,CHEMBL619791,,H,BAO_0000019,,,,,3001,,15034,,1,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,Autocuration,6,,104698
,CHEMBL619792,,H,BAO_0000019,,,,,3002,,691,,1,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,Autocuration,6,,104698
Membranes,CHEMBL619793,,H,BAO_0000249,,,,,3003,,12092,,1,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,Autocuration,6,,104698
,CHEMBL619794,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3004,,11752,,1,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619795,,H,BAO_0000221,,,,Brain,3005,955.0,11752,,1,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,Autocuration,6,,104698
,CHEMBL619796,,H,BAO_0000019,,,,,3006,,301,,1,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,Autocuration,6,,104698
,CHEMBL620448,,H,BAO_0000223,,,,,3007,,16532,,1,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,Autocuration,6,,104698
,CHEMBL620449,,H,BAO_0000223,,,,,3008,,16532,,1,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,Autocuration,6,,104698
,CHEMBL620450,,H,BAO_0000223,,,,,3009,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,Autocuration,6,,104698
,CHEMBL620451,,H,BAO_0000223,,,,,3010,,11684,,1,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,Autocuration,6,,104698
,CHEMBL620631,,H,BAO_0000223,,,,,3011,,11684,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,Autocuration,6,,104698
,CHEMBL620632,,H,BAO_0000019,,,,,3012,,12953,,1,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,Autocuration,6,,104698
,CHEMBL620633,,H,BAO_0000019,,,,,3013,,12953,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,Autocuration,6,,104698
,CHEMBL620634,,H,BAO_0000223,,,,,3014,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,Autocuration,6,,104698
,CHEMBL620635,,H,BAO_0000019,,,,,3015,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,Autocuration,6,,104698
,CHEMBL620636,,H,BAO_0000218,,,,,3016,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620637,,H,BAO_0000218,,,,,3017,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620638,,H,BAO_0000218,,,,,3018,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620639,,H,BAO_0000218,,,,,3019,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620640,,H,BAO_0000218,,,,,3020,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620641,,H,BAO_0000218,,,,,3021,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620642,,H,BAO_0000218,,,,,3022,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620643,,H,BAO_0000218,,,,,3023,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620644,,H,BAO_0000218,,,,,3024,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620645,,H,BAO_0000218,,,,,3025,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620646,,H,BAO_0000218,,,,,3026,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620647,,H,BAO_0000218,,,,,3027,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620648,,H,BAO_0000218,,,,,3028,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620649,,H,BAO_0000218,,,,,3029,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620650,,H,BAO_0000218,,,,,3030,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620651,,H,BAO_0000218,,,,,3031,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL872875,,H,BAO_0000218,,,,,3032,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620652,,H,BAO_0000218,,,,,3033,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL620653,,H,BAO_0000019,,,,,3034,,10609,,1,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,Autocuration,6,,104698
,CHEMBL857076,,H,BAO_0000019,,,,,3035,,12861,,1,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,Autocuration,6,,104698
,CHEMBL620654,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3036,,12861,,1,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL620655,,H,BAO_0000223,,,,,3037,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,6,,104698
Brain membranes,CHEMBL620656,,H,BAO_0000249,,,,,3038,,10728,,1,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,Autocuration,6,,104698
Brain membranes,CHEMBL620657,,H,BAO_0000249,,,,,3039,,10728,,1,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,Autocuration,6,,104698
,CHEMBL620658,,H,BAO_0000357,,,,,3040,,5163,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,Autocuration,8,,108
,CHEMBL620659,,H,BAO_0000357,,,,,3041,,5163,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,Autocuration,8,,108
,CHEMBL620660,,H,BAO_0000357,,,,,3042,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,Autocuration,8,,108
,CHEMBL620661,,H,BAO_0000357,,,,,3043,,5014,,1,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL620662,,H,BAO_0000357,,,,,3044,,5635,,1,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL620663,,H,BAO_0000357,,,,,3045,,5163,,1,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL620664,,H,BAO_0000357,,,,,3046,,6841,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,Autocuration,8,,108
,CHEMBL620665,,H,BAO_0000357,,,,,3047,,6119,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,Expert,8,,108
,CHEMBL620666,,H,BAO_0000357,,,,,3048,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,Autocuration,8,,108
,CHEMBL620667,,H,BAO_0000357,,,,,3049,,1633,,1,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,Autocuration,8,,108
,CHEMBL620668,,H,BAO_0000357,,,,,3050,,1633,,1,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,Expert,8,,108
,CHEMBL620669,,H,BAO_0000357,,,,,3051,,4373,,1,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,Autocuration,8,,108
,CHEMBL620670,,H,BAO_0000357,,,,,3052,,6576,,1,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL620671,,H,BAO_0000357,,,,,3053,,4687,,1,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL620672,,H,BAO_0000357,,,,,3054,,12146,,1,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,Autocuration,8,,108
,CHEMBL620673,,H,BAO_0000357,,,,,3055,,12146,,1,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,Autocuration,8,,108
,CHEMBL620674,,H,BAO_0000357,,,,,3056,,16946,,1,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL620675,,H,BAO_0000357,,,,,3057,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL620676,,H,BAO_0000357,,,,,3058,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,Autocuration,8,,108
,CHEMBL621382,,H,BAO_0000357,,,,,3059,,3269,,1,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,Autocuration,8,,108
,CHEMBL621383,9606.0,D,BAO_0000357,Homo sapiens,,,,3060,,1274,,1,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Expert,9,,108
,CHEMBL621384,,H,BAO_0000357,,,,,3061,,1317,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,Autocuration,8,,108
,CHEMBL621385,9913.0,H,BAO_0000357,Bos taurus,,,,3062,,5834,,1,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Autocuration,8,,144
,CHEMBL617989,9913.0,H,BAO_0000357,Bos taurus,,,,3063,,11147,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Autocuration,8,,144
,CHEMBL617990,10141.0,H,BAO_0000019,Cavia porcellus,,,,3064,,14145,,1,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Expert,4,,104714
,CHEMBL875085,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3065,2116.0,10561,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617991,10141.0,H,BAO_0000019,Cavia porcellus,,,,3066,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Autocuration,4,,104714
,CHEMBL617992,10141.0,H,BAO_0000019,Cavia porcellus,,,,3067,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Autocuration,4,,104714
,CHEMBL617993,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3068,2116.0,10561,,1,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617994,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3069,2116.0,11454,,1,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Autocuration,4,,104714
,CHEMBL617995,10141.0,H,BAO_0000019,Cavia porcellus,,,,3070,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Autocuration,4,,104714
,CHEMBL617996,10141.0,H,BAO_0000019,Cavia porcellus,,,,3071,,4639,,1,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Autocuration,4,,104714
,CHEMBL617997,10141.0,H,BAO_0000019,Cavia porcellus,,,,3072,,4639,,1,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Autocuration,4,,104714
,CHEMBL617998,10141.0,H,BAO_0000019,Cavia porcellus,,,,3073,,4639,,1,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Autocuration,4,,104714
,CHEMBL617999,10141.0,H,BAO_0000019,Cavia porcellus,,,,3074,,4639,,1,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Autocuration,4,,104714
,CHEMBL618000,10141.0,H,BAO_0000019,Cavia porcellus,,,,3075,,4639,,1,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Autocuration,4,,104714
,CHEMBL617815,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3076,2116.0,15253,,1,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Autocuration,4,,104714
,CHEMBL617816,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3077,2116.0,15253,,1,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Autocuration,4,,104714
,CHEMBL617817,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3078,2116.0,11963,,1,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Autocuration,4,,104714
,CHEMBL617818,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3079,2116.0,1946,,1,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617819,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3080,2116.0,1946,,1,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Autocuration,4,,104714
,CHEMBL617820,10141.0,H,BAO_0000223,Cavia porcellus,,,,3081,,12045,,1,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Autocuration,4,,104714
,CHEMBL617821,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3082,2116.0,1559,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617822,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3083,2116.0,273,,1,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Autocuration,4,,104714
,CHEMBL617823,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3084,2116.0,273,,1,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Autocuration,4,,104714
,CHEMBL617824,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3085,2116.0,188,,1,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Autocuration,4,,104714
,CHEMBL617825,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3086,2116.0,12919,,1,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Autocuration,4,,104714
,CHEMBL617826,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3087,2116.0,12918,,1,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Autocuration,4,,104714
,CHEMBL617827,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3088,2116.0,1559,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617828,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3089,2116.0,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Autocuration,4,,104714
,CHEMBL617829,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3090,2116.0,1559,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Autocuration,4,,104714
,CHEMBL617830,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3091,2116.0,1559,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Autocuration,4,,104714
,CHEMBL617831,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3092,2116.0,1559,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Autocuration,4,,104714
,CHEMBL617832,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3093,2116.0,14424,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Autocuration,4,,104714
,CHEMBL617833,10141.0,U,BAO_0000019,Cavia porcellus,,,,3094,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Autocuration,0,,22226
,CHEMBL617834,,H,BAO_0000357,,,,,3095,,5486,,1,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,Autocuration,8,,51
,CHEMBL617835,9606.0,D,BAO_0000223,Homo sapiens,,,,3096,,6491,,1,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Expert,5,,104714
,CHEMBL617836,,H,BAO_0000223,,,,,3097,,6013,,1,,Binding affinity towards 5-HT3 receptor,B,,,Autocuration,4,,104714
,CHEMBL617837,,H,BAO_0000223,,,,,3098,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,4,,104714
,CHEMBL620392,,H,BAO_0000019,,,,,3099,,12861,,1,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,Autocuration,4,,104714
,CHEMBL620393,,H,BAO_0000223,,,,,3100,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL620394,,H,BAO_0000223,,,,,3101,,5105,,1,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL620395,,H,BAO_0000223,,,,,3102,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,Autocuration,4,,104714
,CHEMBL620396,,U,BAO_0000019,,,,,3103,,3935,,1,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,Autocuration,0,,22226
,CHEMBL620582,,H,BAO_0000219,,,,,3104,,13657,,1,433.0,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,NG108-15,Expert,4,,105030
,CHEMBL620583,,H,BAO_0000218,,,,,3105,,10369,,1,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,Autocuration,4,,105030
,CHEMBL620584,,H,BAO_0000019,,,,,3106,,10369,,1,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,Autocuration,4,,105030
,CHEMBL620585,,H,BAO_0000224,,,,,3107,,12918,,1,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,Autocuration,4,,105030
,CHEMBL620586,,H,BAO_0000224,,,,,3108,,12918,,1,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,Autocuration,4,,105030
,CHEMBL620587,,H,BAO_0000019,,,,,3109,,10369,,1,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,Autocuration,4,,105030
,CHEMBL620588,,H,BAO_0000019,,,,,3110,,773,,1,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,Autocuration,4,,105030
,CHEMBL620589,,H,BAO_0000218,,,,,3111,,12918,,1,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,Autocuration,4,,105030
,CHEMBL620590,,H,BAO_0000219,,,,,3112,,10561,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,Autocuration,4,,105030
,CHEMBL617956,,H,BAO_0000019,,,,,3113,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,Autocuration,4,,105030
,CHEMBL617957,,H,BAO_0000019,,,,,3114,,12827,,1,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,Autocuration,4,,105030
,CHEMBL617958,,H,BAO_0000224,,,,,3115,,12918,,1,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,Autocuration,4,,105030
,CHEMBL617959,,H,BAO_0000219,,,,,3116,,273,,1,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,Autocuration,4,,105030
,CHEMBL617960,,H,BAO_0000219,,,,,3117,,273,,1,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,Autocuration,4,,105030
,CHEMBL617961,,H,BAO_0000224,,,,,3118,,10561,,1,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Autocuration,4,,105030
,CHEMBL617962,,H,BAO_0000219,,,,,3119,,5033,,1,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,Autocuration,4,,105030
,CHEMBL617963,,H,BAO_0000219,,,,,3120,,16429,,1,339.0,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,N1E-115,Autocuration,4,,105030
,CHEMBL617964,,H,BAO_0000019,,,,,3121,,10322,,1,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,Autocuration,8,,11765
,CHEMBL617965,,H,BAO_0000219,,,,,3122,,14331,,1,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,Autocuration,8,,11765
,CHEMBL617966,10090.0,D,BAO_0000357,Mus musculus,,,,3123,,13462,,1,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Autocuration,9,,10630
,CHEMBL857074,,H,BAO_0000019,,,,,3124,,12861,,1,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,Autocuration,8,,17106
,CHEMBL617967,9823.0,H,BAO_0000357,Sus scrofa,,,,3125,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL617968,9823.0,H,BAO_0000357,Sus scrofa,,,,3126,,12861,,1,,Binding activity radioligand.,B,,,Autocuration,8,,144
,CHEMBL617969,9986.0,H,BAO_0000223,Oryctolagus cuniculus,,,,3127,,10561,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Autocuration,4,,104714
,CHEMBL617970,9986.0,H,BAO_0000223,Oryctolagus cuniculus,,,,3128,,10561,,1,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Autocuration,4,,104714
,CHEMBL617971,9986.0,H,BAO_0000223,Oryctolagus cuniculus,,,,3129,,10561,,1,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Autocuration,4,,104714
,CHEMBL617972,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3130,,10561,,1,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Autocuration,4,,104714
,CHEMBL617973,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3131,,273,,1,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Autocuration,4,,104714
,CHEMBL617974,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3132,,273,,1,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Autocuration,4,,104714
,CHEMBL617975,9986.0,H,BAO_0000221,Oryctolagus cuniculus,,,Ileum,3133,2116.0,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Autocuration,4,,104714
,CHEMBL617976,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3134,,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Autocuration,4,,104714
,CHEMBL617977,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3135,,273,,1,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Autocuration,4,,104714
,CHEMBL617978,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3136,,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Autocuration,4,,104714
,CHEMBL617979,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3137,,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Autocuration,4,,104714
,CHEMBL617980,9986.0,H,BAO_0000219,Oryctolagus cuniculus,,,,3138,,13047,,1,449.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,4,,104714
,CHEMBL617981,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3139,,1650,,1,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL617982,,H,BAO_0000019,,,,,3140,,16288,,1,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,Autocuration,8,,12020
,CHEMBL617983,,H,BAO_0000357,,,,,3141,,16288,,1,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,Autocuration,8,,12020
,CHEMBL617984,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3142,,10254,,1,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Autocuration,7,,104698
,CHEMBL617985,,H,BAO_0000019,,,,,3143,,14532,,1,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,Autocuration,6,,104698
,CHEMBL617986,,H,BAO_0000218,,,,Heart,3144,948.0,13392,,1,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,Autocuration,6,,104698
,CHEMBL617987,,H,BAO_0000019,,,,Heart,3145,948.0,13392,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,Autocuration,6,,104698
,CHEMBL617988,,H,BAO_0000019,,,,Heart,3146,948.0,13392,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,Autocuration,6,,104698
,CHEMBL617792,,H,BAO_0000019,,,,Heart,3147,948.0,13392,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,Autocuration,6,,104698
,CHEMBL617793,,H,BAO_0000019,,,,Heart,3148,948.0,13392,,1,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,Autocuration,6,,104698
,CHEMBL617794,,H,BAO_0000019,,,,,3149,,13392,,1,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,Autocuration,6,,104698
,CHEMBL617795,,H,BAO_0000019,,,,,3150,,13392,,1,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,Autocuration,6,,104698
,CHEMBL617796,,H,BAO_0000019,,,,,3151,,13392,,1,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,Autocuration,6,,104698
,CHEMBL617797,,H,BAO_0000019,,,,,3152,,13392,,1,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,Autocuration,6,,104698
,CHEMBL617798,10116.0,D,BAO_0000218,Rattus norvegicus,,,,3153,,1089,,1,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Autocuration,7,,104698
,CHEMBL617799,,H,BAO_0000218,,,,,3154,,1089,,1,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,Autocuration,6,,104698
,CHEMBL617800,10116.0,D,BAO_0000218,Rattus norvegicus,,,,3155,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,7,,104698
,CHEMBL617801,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3156,,11454,,1,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Autocuration,7,,104698
,CHEMBL617802,10116.0,D,BAO_0000218,Rattus norvegicus,,,,3157,,12205,,1,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Autocuration,7,,104698
,CHEMBL617803,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3158,,1089,,1,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Autocuration,7,,104698
,CHEMBL617804,,H,BAO_0000019,,,,,3159,,5094,,1,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,Autocuration,6,,104698
,CHEMBL617805,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3160,,2622,,1,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL617806,,H,BAO_0000223,,,,,3161,,245,,1,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL617807,,H,BAO_0000019,,,,,3162,,14788,,1,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,Autocuration,6,,104698
,CHEMBL617808,,H,BAO_0000019,,,,,3163,,14788,,1,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,Autocuration,6,,104698
,CHEMBL617809,,H,BAO_0000249,,,,,3164,,3020,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,Autocuration,6,,104698
,CHEMBL617810,,H,BAO_0000019,,,,,3165,,1742,,1,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,Autocuration,6,,104698
,CHEMBL617811,,H,BAO_0000249,,,,Brain,3166,955.0,17394,,1,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,Autocuration,6,,104698
,CHEMBL617812,,H,BAO_0000221,,,,Brain,3167,955.0,17394,,1,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,Autocuration,6,,104698
,CHEMBL617813,,H,BAO_0000249,,,,,3168,,17394,,1,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,Autocuration,6,,104698
,CHEMBL617814,,H,BAO_0000249,,,,,3169,,14286,,1,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,Autocuration,6,,104698
,CHEMBL617698,,H,BAO_0000019,,,,,3170,,14178,,1,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,Autocuration,6,,104698
,CHEMBL617699,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3171,,14178,,1,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Autocuration,7,,104698
,CHEMBL617700,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3172,,14178,,1,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Autocuration,7,,104698
,CHEMBL617701,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3173,,14178,,1,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL617702,,H,BAO_0000019,,,,,3174,,15034,,1,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,Autocuration,6,,104698
Membranes,CHEMBL617703,,H,BAO_0000249,,,,,3175,,1089,,1,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,Autocuration,6,,104698
,CHEMBL617704,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3176,,1089,,1,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL617705,,H,BAO_0000223,,,,,3177,,16532,,1,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,Autocuration,6,,104698
,CHEMBL617706,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3178,,12801,,1,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL617707,,H,BAO_0000219,,,,,3179,,15194,,1,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,NG108-15,Autocuration,6,,104698
,CHEMBL617708,,H,BAO_0000219,,,,,3180,,15194,,1,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,NG108-15,Autocuration,6,,104698
,CHEMBL617709,,H,BAO_0000019,,,,,3181,,15194,,1,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,Autocuration,6,,104698
,CHEMBL617710,,H,BAO_0000019,,,,,3182,,15194,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,Autocuration,6,,104698
,CHEMBL882925,,H,BAO_0000019,,,,,3183,,15194,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,Autocuration,6,,104698
,CHEMBL617711,,H,BAO_0000019,,,,,3184,,15194,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,Autocuration,6,,104698
,CHEMBL617712,,H,BAO_0000019,,,,,3185,,10610,,1,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,Autocuration,6,,104698
,CHEMBL617713,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3186,,10355,,1,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Autocuration,7,,104698
,CHEMBL617714,,H,BAO_0000019,,,,,3187,,691,,1,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,Autocuration,6,,104698
,CHEMBL617715,,H,BAO_0000218,,,,,3188,,10611,,1,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,Autocuration,6,,104698
,CHEMBL617716,,H,BAO_0000218,,,,,3189,,12801,,1,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617717,,H,BAO_0000218,,,,,3190,,10609,,1,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,Autocuration,6,,104698
,CHEMBL617718,,H,BAO_0000218,,,,,3191,,11454,,1,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617719,,H,BAO_0000218,,,,,3192,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617720,,H,BAO_0000218,,,,,3193,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,Autocuration,6,,104698
,CHEMBL617721,10116.0,D,BAO_0000218,Rattus norvegicus,,,,3194,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,7,,104698
,CHEMBL617722,,H,BAO_0000218,,,,,3195,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617723,,H,BAO_0000218,,,,,3196,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617724,,H,BAO_0000218,,,,,3197,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617725,,H,BAO_0000218,,,,,3198,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617726,,H,BAO_0000218,,,,,3199,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617727,,H,BAO_0000218,,,,,3200,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617728,,H,BAO_0000218,,,,,3201,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617729,,H,BAO_0000218,,,,,3202,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617730,,H,BAO_0000218,,,,,3203,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617731,,H,BAO_0000218,,,,,3204,,11454,,1,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617732,,H,BAO_0000218,,,,,3205,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617733,,H,BAO_0000218,,,,,3206,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617734,,H,BAO_0000218,,,,,3207,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL872874,,H,BAO_0000218,,,,,3208,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,Autocuration,6,,104698
,CHEMBL617735,,H,BAO_0000218,,,,,3209,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,Autocuration,6,,104698
,CHEMBL617736,,H,BAO_0000218,,,,,3210,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,Autocuration,6,,104698
,CHEMBL617737,,H,BAO_0000218,,,,,3211,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,Autocuration,6,,104698
,CHEMBL617738,,H,BAO_0000218,,,,,3212,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,Autocuration,6,,104698
,CHEMBL617739,,H,BAO_0000218,,,,,3213,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617740,,H,BAO_0000218,,,,,3214,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617741,,H,BAO_0000218,,,,,3215,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617742,,H,BAO_0000218,,,,,3216,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617743,,H,BAO_0000218,,,,,3217,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617744,,H,BAO_0000218,,,,,3218,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617745,,H,BAO_0000218,,,,,3219,,11454,,1,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Autocuration,6,,104698
,CHEMBL617746,,H,BAO_0000218,,,,,3220,,670,,1,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,Autocuration,6,,104698
,CHEMBL617747,,H,BAO_0000218,,,,,3221,,670,,1,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,Autocuration,6,,104698
,CHEMBL617748,,H,BAO_0000218,,,,,3222,,10321,,1,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,Autocuration,6,,104698
,CHEMBL618909,,H,BAO_0000218,,,,,3223,,10321,,1,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,Autocuration,6,,104698
,CHEMBL618910,,H,BAO_0000218,,,,,3224,,10321,,1,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,Autocuration,6,,104698
,CHEMBL618911,,H,BAO_0000218,,,,,3225,,10321,,1,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,Autocuration,6,,104698
,CHEMBL618912,,H,BAO_0000218,,,,,3226,,10321,,1,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,Autocuration,6,,104698
,CHEMBL618913,,H,BAO_0000218,,,,,3227,,10322,,1,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,Autocuration,6,,104698
,CHEMBL618914,,H,BAO_0000019,,,,,3228,,15412,,1,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,Autocuration,6,,104698
,CHEMBL618915,,H,BAO_0000019,,,,,3229,,15412,,1,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,Autocuration,6,,104698
,CHEMBL618916,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3230,,15412,,1,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL618917,,H,BAO_0000019,,,,,3231,,15412,,1,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,Autocuration,6,,104698
,CHEMBL618918,,D,BAO_0000221,,,,Hippocampus,3232,10000000.0,15412,,1,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,Intermediate,7,,104698
,CHEMBL618919,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3233,,15412,,1,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Autocuration,7,,104698
,CHEMBL618920,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3234,,17394,,1,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL618921,,H,BAO_0000223,,,,,3235,,12457,,1,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL618922,,H,BAO_0000019,,,,,3236,,12457,,1,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL618923,,H,BAO_0000019,,,,,3237,,12205,,1,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,Autocuration,6,,104698
,CHEMBL618924,,H,BAO_0000019,,,,,3238,,14532,,1,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,Autocuration,6,,104698
,CHEMBL618925,,H,BAO_0000019,,,,,3239,,1122,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,Autocuration,6,,104698
,CHEMBL618926,,H,BAO_0000019,,,,,3240,,5094,,1,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,Autocuration,6,,104698
,CHEMBL618927,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3241,2116.0,809,,1,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Intermediate,9,,20033
,CHEMBL618928,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3242,2116.0,809,,1,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Intermediate,9,,20033
,CHEMBL618929,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3243,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Intermediate,9,,20033
,CHEMBL618930,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3244,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Intermediate,9,,20033
,CHEMBL618931,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3245,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Intermediate,9,,20033
,CHEMBL619594,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3246,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Intermediate,9,,20033
,CHEMBL619595,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3247,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Intermediate,9,,20033
,CHEMBL619596,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3248,2116.0,13961,,1,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL619755,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3249,2116.0,13961,,1,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Intermediate,9,,20033
,CHEMBL619756,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3250,2116.0,809,,1,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Intermediate,9,,20033
,CHEMBL619757,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3251,2116.0,809,,1,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Intermediate,9,,20033
,CHEMBL619758,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3252,2116.0,809,,1,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Intermediate,9,,20033
,CHEMBL619759,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3253,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Intermediate,9,,20033
,CHEMBL619760,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3254,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Intermediate,9,,20033
,CHEMBL619761,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3255,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Intermediate,9,,20033
,CHEMBL619762,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3256,2116.0,14290,,1,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Intermediate,9,,20033
,CHEMBL619763,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3257,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Intermediate,9,,20033
,CHEMBL617868,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3258,2116.0,14290,,1,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Intermediate,9,,20033
,CHEMBL617869,10141.0,D,BAO_0000357,Cavia porcellus,,,,3259,,15034,,1,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Intermediate,9,,20033
,CHEMBL882926,10141.0,D,BAO_0000249,Cavia porcellus,,,Striatum,3260,2435.0,5094,,1,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Intermediate,9,,20033
,CHEMBL617870,10141.0,D,BAO_0000249,Cavia porcellus,,,Striatum,3261,2435.0,5094,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Intermediate,9,,20033
,CHEMBL617871,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3262,2435.0,5399,,1,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Intermediate,9,,20033
,CHEMBL617872,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3263,2435.0,17394,,1,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Intermediate,9,,20033
,CHEMBL617873,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3264,2435.0,17394,,1,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Intermediate,9,,20033
,CHEMBL617874,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3265,2435.0,17394,,1,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Intermediate,9,,20033
,CHEMBL619067,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3266,2116.0,13961,,1,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL619068,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3267,2116.0,13961,,1,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Intermediate,9,,20033
,CHEMBL619069,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3268,2116.0,13961,,1,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Intermediate,9,,20033
,CHEMBL619070,10141.0,D,BAO_0000357,Cavia porcellus,,,,3269,,16946,,1,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Intermediate,9,,20033
,CHEMBL619071,10141.0,D,BAO_0000357,Cavia porcellus,,,,3270,,16946,,1,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Intermediate,9,,20033
,CHEMBL619072,10141.0,D,BAO_0000019,Cavia porcellus,,,,3271,,15034,,1,,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Intermediate,9,,20033
,CHEMBL619073,10141.0,D,BAO_0000019,Cavia porcellus,,,,3272,,15034,,1,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Intermediate,9,,20033
,CHEMBL619074,10141.0,D,BAO_0000019,Cavia porcellus,,,,3273,,12918,,1,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Intermediate,9,,20033
,CHEMBL619075,10141.0,D,BAO_0000357,Cavia porcellus,,,,3274,,16946,,1,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Intermediate,9,,20033
,CHEMBL619076,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3275,2435.0,17394,,1,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Intermediate,9,,20033
,CHEMBL619077,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3276,2435.0,15034,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Intermediate,9,,20033
,CHEMBL619078,10141.0,D,BAO_0000249,Cavia porcellus,,,Striatum,3277,2435.0,5094,,1,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Intermediate,9,,20033
,CHEMBL619079,10141.0,D,BAO_0000249,Cavia porcellus,,,Striatum,3278,2435.0,5094,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Intermediate,9,,20033
,CHEMBL619080,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3279,2116.0,17358,,1,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Intermediate,9,,20033
,CHEMBL619081,10141.0,D,BAO_0000357,Cavia porcellus,,,,3280,,12953,,1,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Expert,9,,20033
,CHEMBL619082,10141.0,D,BAO_0000357,Cavia porcellus,,,,3281,,12953,,1,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Intermediate,9,,20033
,CHEMBL619083,10141.0,D,BAO_0000357,Cavia porcellus,,,,3282,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Intermediate,9,,20033
,CHEMBL619084,10141.0,D,BAO_0000357,Cavia porcellus,,,,3283,,12953,,1,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Intermediate,9,,20033
,CHEMBL859397,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3284,2116.0,273,,1,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL619085,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3285,2116.0,12918,,1,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Intermediate,9,,20033
,CHEMBL619086,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3286,2116.0,12919,,1,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Intermediate,9,,20033
,CHEMBL619087,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3287,2116.0,273,,1,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Intermediate,9,,20033
,CHEMBL619088,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3288,2116.0,273,,1,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Intermediate,9,,20033
,CHEMBL619089,10141.0,D,BAO_0000357,Cavia porcellus,,,,3289,,13181,,1,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Intermediate,9,,20033
,CHEMBL619090,10141.0,H,BAO_0000357,Cavia porcellus,,,,3290,,13181,,1,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,168
,CHEMBL619091,10141.0,D,BAO_0000019,Cavia porcellus,,,,3291,,15034,,1,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Intermediate,9,,20033
,CHEMBL619092,10141.0,D,BAO_0000357,Cavia porcellus,,,,3292,,5033,,1,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Intermediate,9,,20033
,CHEMBL619093,10141.0,D,BAO_0000019,Cavia porcellus,,,,3293,,1980,,1,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Intermediate,9,,20033
,CHEMBL619094,10141.0,H,BAO_0000219,Cavia porcellus,,,,3294,,13181,,1,722.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,HEK293,Autocuration,8,,168
,CHEMBL619095,10141.0,D,BAO_0000019,Cavia porcellus,,,,3295,,14287,,1,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Intermediate,9,,20033
,CHEMBL857988,10141.0,D,BAO_0000357,Cavia porcellus,,,,3296,,1317,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Intermediate,9,,20033
,CHEMBL619096,10141.0,D,BAO_0000357,Cavia porcellus,,,,3297,,15316,,1,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Intermediate,9,,20033
,CHEMBL619097,10141.0,D,BAO_0000357,Cavia porcellus,,,Striatum,3298,2435.0,16429,,1,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Intermediate,9,,20033
,CHEMBL619098,10141.0,D,BAO_0000221,Cavia porcellus,,,Hippocampus,3299,10000000.0,14818,,1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Intermediate,9,,20033
,CHEMBL619751,10141.0,D,BAO_0000357,Cavia porcellus,,,,3300,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Intermediate,9,,20033
,CHEMBL619752,10141.0,D,BAO_0000357,Cavia porcellus,,,,3301,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Intermediate,9,,20033
,CHEMBL875096,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3302,2116.0,13961,,1,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Intermediate,9,,20033
,CHEMBL619004,,H,BAO_0000357,,,,,3303,,5486,,1,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,Autocuration,8,,108
,CHEMBL619005,,H,BAO_0000357,,,,,3304,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,168
,CHEMBL619006,,H,BAO_0000019,,,,,3305,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL619007,,H,BAO_0000219,,,,,3306,,4199,,1,308.0,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,HeLa,Autocuration,8,,168
,CHEMBL619008,,H,BAO_0000357,,,,,3307,,15146,,1,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL619009,,H,BAO_0000357,,,,,3308,,5213,,1,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL619010,,H,BAO_0000219,,,,,3309,,4829,,1,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,HeLa,Autocuration,8,,168
,CHEMBL619011,,H,BAO_0000357,,,,,3310,,17358,,1,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,Autocuration,8,,10622
,CHEMBL619012,,H,BAO_0000357,,,,,3311,,17358,,1,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,Autocuration,8,,10622
,CHEMBL619013,,H,BAO_0000219,,,,,3312,,16946,,1,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,Autocuration,8,,10622
,CHEMBL619014,,H,BAO_0000357,,,,,3313,,17358,,1,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,Autocuration,8,,10622
,CHEMBL857503,,H,BAO_0000019,,,,Cardiac atrium,3314,2081.0,268,,1,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,Autocuration,8,,11249
,CHEMBL619015,,H,BAO_0000019,,,,Cardiac atrium,3315,2081.0,268,,1,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,Autocuration,8,,11249
,CHEMBL619016,,H,BAO_0000357,,,,,3316,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,11249
,CHEMBL619017,,H,BAO_0000221,,,,Hippocampus,3317,10000000.0,14875,,1,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,11249
,CHEMBL619018,9823.0,H,BAO_0000221,Sus scrofa,,,Hippocampus,3318,10000000.0,13267,,1,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Autocuration,8,,168
,CHEMBL619019,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3319,,13047,,1,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Autocuration,8,,168
,CHEMBL619020,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3320,,1650,,1,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Expert,9,,10623
,CHEMBL619021,,H,BAO_0000019,,,,,3321,,567,,1,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,Autocuration,8,,10623
,CHEMBL619022,,H,BAO_0000357,,,,,3322,,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,Autocuration,8,,10623
,CHEMBL619023,,H,BAO_0000357,,,,,3323,,188,,1,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,Autocuration,8,,10623
,CHEMBL619024,,H,BAO_0000019,,,,,3324,,670,,1,,lntrinsic activity relative to 5-HT receptor,F,,,Autocuration,8,,10623
,CHEMBL619025,,H,BAO_0000019,,,,,3325,,204,,1,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,Autocuration,8,,10623
,CHEMBL619026,,H,BAO_0000019,,,,,3326,,1946,,1,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,Expert,8,,10623
,CHEMBL619027,,H,BAO_0000019,,,,,3327,,6398,,1,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,Autocuration,8,,10623
,CHEMBL619028,,H,BAO_0000019,,,,,3328,,6398,,1,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,Autocuration,8,,10623
,CHEMBL619029,,H,BAO_0000019,,,,,3329,,17358,,1,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,Autocuration,8,,10623
,CHEMBL619030,,H,BAO_0000019,,,,,3330,,6398,,1,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,Autocuration,8,,10623
,CHEMBL619031,,H,BAO_0000357,,,,,3331,,11752,,1,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,Expert,8,,10623
,CHEMBL619032,,H,BAO_0000019,,,,,3332,,809,,1,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,Autocuration,8,,10623
,CHEMBL619033,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3333,,14178,,1,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Expert,9,,10623
,CHEMBL619034,,H,BAO_0000357,,,,,3334,,567,,1,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,Autocuration,8,,10623
,CHEMBL619035,,H,BAO_0000357,,,,,3335,,1946,,1,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,Autocuration,8,,10623
,CHEMBL619036,,H,BAO_0000357,,,,,3336,,1946,,1,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,Autocuration,8,,10623
,CHEMBL619037,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3337,,13961,,1,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Expert,9,,10623
,CHEMBL619038,,H,BAO_0000249,,,,Striatum,3338,2435.0,6238,,1,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,Autocuration,8,,10623
,CHEMBL619039,,H,BAO_0000249,,,,,3339,,14290,,1,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,Autocuration,8,,10623
,CHEMBL619040,,H,BAO_0000249,,,,,3340,,14290,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,Expert,8,,10623
,CHEMBL619041,10116.0,D,BAO_0000019,Rattus norvegicus,,,Striatum,3341,2435.0,809,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Expert,9,,10623
,CHEMBL619042,,H,BAO_0000019,,,,Striatum,3342,2435.0,1578,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Autocuration,8,,10623
,CHEMBL619043,,H,BAO_0000249,,,,Striatum,3343,2435.0,16709,,1,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,Expert,8,,10623
,CHEMBL619044,,H,BAO_0000019,,,,Striatum,3344,2435.0,1946,,1,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,Expert,8,,10623
,CHEMBL619045,,H,BAO_0000249,,,,Striatum,3345,2435.0,15253,,1,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,Expert,8,,10623
,CHEMBL619046,,H,BAO_0000249,,,,Striatum,3346,2435.0,4535,,1,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,Expert,8,,10623
,CHEMBL619047,,H,BAO_0000249,,,,,3347,,13961,,1,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,Expert,8,,10623
,CHEMBL619048,,H,BAO_0000221,,,,Brain,3348,955.0,17358,,1,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,Autocuration,8,,10623
,CHEMBL859398,,H,BAO_0000019,,,,,3349,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,Autocuration,8,,10623
,CHEMBL619049,,H,BAO_0000019,,,,,3350,,15847,,1,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,Autocuration,8,,10623
,CHEMBL857886,,H,BAO_0000019,,,,,3351,,670,,1,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,Autocuration,8,,10623
,CHEMBL619050,,H,BAO_0000019,,,,,3352,,670,,1,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,Autocuration,8,,10623
,CHEMBL620591,,H,BAO_0000019,,,,,3353,,1317,,1,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Autocuration,8,,10623
,CHEMBL620592,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3354,,12936,,1,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Expert,9,,10623
,CHEMBL620593,,H,BAO_0000249,,,,Striatum,3355,2435.0,4535,,1,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,Expert,8,,10623
,CHEMBL620594,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3356,,14424,,1,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Expert,9,,10623
,CHEMBL875079,,H,BAO_0000019,,,,,3357,,14424,,1,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,Expert,8,,10623
,CHEMBL620595,,H,BAO_0000019,,,,,3358,,14424,,1,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,Expert,8,,10623
,CHEMBL620596,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3359,,14424,,1,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Expert,9,,10623
,CHEMBL620597,,H,BAO_0000019,,,,,3360,,14424,,1,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,Autocuration,8,,10623
,CHEMBL620598,,H,BAO_0000019,,,,,3361,,14424,,1,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,Expert,8,,10623
,CHEMBL620599,,H,BAO_0000218,,,,,3362,,14424,,1,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,Expert,8,,10623
,CHEMBL620600,,H,BAO_0000019,,,,,3363,,14424,,1,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,Autocuration,8,,10623
,CHEMBL620601,10116.0,H,BAO_0000019,Rattus norvegicus,,,,3364,,1980,,1,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Autocuration,8,,168
,CHEMBL620602,,H,BAO_0000019,,,,,3365,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,Autocuration,8,,168
,CHEMBL620603,,H,BAO_0000357,,,,,3366,,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL620604,,H,BAO_0000357,,,,,3367,,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,Autocuration,8,,168
,CHEMBL620605,,H,BAO_0000357,,,,,3368,,17358,,1,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,Autocuration,8,,168
,CHEMBL620606,,H,BAO_0000357,,,,,3369,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL620607,,H,BAO_0000019,,,,,3370,,17358,,1,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,Autocuration,8,,168
,CHEMBL620608,,H,BAO_0000357,,,,,3371,,16117,,1,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,Autocuration,8,,168
,CHEMBL620609,,H,BAO_0000019,,,,,3372,,17358,,1,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,Autocuration,8,,168
,CHEMBL620610,,H,BAO_0000019,,,,,3373,,17358,,1,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,Autocuration,8,,168
,CHEMBL620611,,H,BAO_0000357,,,,,3374,,17358,,1,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL620612,,H,BAO_0000357,,,,,3375,,17358,,1,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,Autocuration,8,,168
,CHEMBL620613,,H,BAO_0000357,,,,,3376,,17358,,1,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,Autocuration,8,,168
,CHEMBL620614,,H,BAO_0000357,,,,,3377,,17358,,1,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,Autocuration,8,,168
,CHEMBL620615,,H,BAO_0000357,,,,,3378,,1274,,1,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,Expert,8,,168
Brain membranes,CHEMBL857075,,H,BAO_0000249,,,,,3379,,10728,,1,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,Autocuration,6,,104698
Brain membranes,CHEMBL620616,,H,BAO_0000249,,,,,3380,,11695,,1,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,Autocuration,6,,104698
Brain membranes,CHEMBL619411,,H,BAO_0000249,,,,,3381,,11695,,1,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,Autocuration,6,,104698
,CHEMBL619412,,H,BAO_0000019,,,,,3382,,12490,,1,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,Autocuration,6,,104698
,CHEMBL619413,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3383,,11828,,1,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619414,,H,BAO_0000221,,,,Hippocampus,3384,10000000.0,12253,,1,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,Autocuration,6,,104698
,CHEMBL619415,,H,BAO_0000019,,,,,3385,,10561,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Autocuration,6,,104698
,CHEMBL619416,,H,BAO_0000019,,,,,3386,,10561,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,Autocuration,6,,104698
,CHEMBL619417,,H,BAO_0000019,,,,,3387,,14432,,1,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,Autocuration,6,,104698
,CHEMBL619418,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3388,,12936,,1,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619419,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3389,,1274,,1,,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619420,,H,BAO_0000019,,,,,3390,,1980,,1,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,Autocuration,6,,104698
,CHEMBL619421,,H,BAO_0000249,,,,,3391,,670,,1,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,Autocuration,6,,104698
,CHEMBL619422,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3392,,968,,1,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Autocuration,7,,104698
,CHEMBL619423,,H,BAO_0000019,,,,,3393,,14287,,1,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,Autocuration,6,,104698
,CHEMBL875080,,H,BAO_0000019,,,,,3394,,567,,1,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,Autocuration,6,,104698
,CHEMBL619424,,H,BAO_0000019,,,,,3395,,13267,,1,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,Autocuration,6,,104698
,CHEMBL619425,,H,BAO_0000249,,,,,3396,,14826,,1,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,Autocuration,6,,104698
,CHEMBL619426,,H,BAO_0000223,,,,,3397,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,Autocuration,6,,104698
,CHEMBL619427,,H,BAO_0000223,,,,,3398,,15194,,1,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,Autocuration,6,,104698
,CHEMBL619645,10116.0,D,BAO_0000223,Rattus norvegicus,,,,3399,,10394,,1,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Autocuration,7,,104698
,CHEMBL619646,,D,BAO_0000249,,,,,3400,,13657,,1,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,Expert,9,,10576
,CHEMBL619647,,H,BAO_0000221,,,,Brain,3401,955.0,1879,,1,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,Autocuration,8,,12020
,CHEMBL619648,,H,BAO_0000019,,,,,3402,,1879,,1,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,Autocuration,8,,12020
,CHEMBL619165,,H,BAO_0000019,,,,,3403,,1879,,1,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,Autocuration,8,,12020
,CHEMBL620719,,H,BAO_0000218,,,,,3404,,204,,1,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,Autocuration,8,,12020
,CHEMBL872924,,H,BAO_0000019,,,,,3405,,1879,,1,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,Autocuration,8,,12020
,CHEMBL620720,,H,BAO_0000357,,,,,3406,,1879,,1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,12020
,CHEMBL620721,,H,BAO_0000019,,,,,3407,,1879,,1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,Autocuration,8,,12020
,CHEMBL620722,,H,BAO_0000019,,,,,3408,,1879,,1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,Autocuration,8,,12020
,CHEMBL620723,,H,BAO_0000019,,,,,3409,,10641,,1,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,Autocuration,6,,104698
,CHEMBL620724,,H,BAO_0000019,,,,,3410,,773,,1,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,Autocuration,8,,12020
,CHEMBL620725,,H,BAO_0000249,,,,,3411,,11952,,1,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,Autocuration,6,,104698
,CHEMBL620726,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3412,,14145,,1,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Autocuration,9,,12020
,CHEMBL620727,,H,BAO_0000357,,,,,3413,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Expert,8,,144
,CHEMBL620728,,H,BAO_0000223,,,,,3414,,6398,,1,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,Autocuration,4,,104714
,CHEMBL620729,,U,BAO_0000019,,,,,3415,,10321,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,Autocuration,0,,22226
,CHEMBL858288,,H,BAO_0000019,,,,,3416,,511,,1,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,Autocuration,4,,104714
,CHEMBL620730,,H,BAO_0000223,,,,,3417,,4639,,1,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL620731,,H,BAO_0000223,,,,,3418,,4639,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL620732,10141.0,H,BAO_0000019,Cavia porcellus,,,,3419,,4639,,1,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Autocuration,4,,104714
,CHEMBL618042,10141.0,H,BAO_0000019,Cavia porcellus,,,,3420,,4639,,1,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Autocuration,4,,104714
,CHEMBL618043,10141.0,H,BAO_0000019,Cavia porcellus,,,,3421,,4639,,1,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Autocuration,4,,104714
,CHEMBL618044,,H,BAO_0000223,,,,,3422,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL618045,,H,BAO_0000019,,,,,3423,,268,,1,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,Autocuration,4,,104714
,CHEMBL618046,,H,BAO_0000223,,,,,3424,,2474,,1,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,Autocuration,4,,104714
,CHEMBL618047,,H,BAO_0000019,,,,,3425,,5067,,1,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,Autocuration,4,,104714
,CHEMBL875084,,H,BAO_0000019,,,,,3426,,5067,,1,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,Autocuration,4,,104714
,CHEMBL618048,,H,BAO_0000019,,,,,3427,,5067,,1,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,Autocuration,4,,104714
,CHEMBL618049,,H,BAO_0000223,,,,,3428,,5067,,1,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,Autocuration,4,,104714
,CHEMBL619764,,H,BAO_0000019,,,,,3429,,5067,,1,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,Autocuration,4,,104714
,CHEMBL619765,,H,BAO_0000019,,,,,3430,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,Autocuration,4,,104714
,CHEMBL619766,,H,BAO_0000019,,,,,3431,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,Autocuration,4,,104714
,CHEMBL619767,,H,BAO_0000223,,,,,3432,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,Autocuration,4,,104714
,CHEMBL619768,,H,BAO_0000223,,,,,3433,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,Autocuration,4,,104714
,CHEMBL619769,,H,BAO_0000019,,,,,3434,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,Autocuration,4,,104714
,CHEMBL619770,,H,BAO_0000223,,,,,3435,,5067,,1,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,Autocuration,4,,104714
,CHEMBL619771,,H,BAO_0000223,,,,,3436,,5067,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL619772,,H,BAO_0000219,,,,,3437,,14331,,1,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,Autocuration,4,,104714
,CHEMBL619773,,H,BAO_0000223,,,,,3438,,5067,,1,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,Autocuration,4,,104714
,CHEMBL619774,,H,BAO_0000219,,,,,3439,,6179,,1,433.0,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,NG108-15,Autocuration,4,,104714
,CHEMBL875083,,H,BAO_0000019,,,,,3440,,4265,,1,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,Autocuration,4,,104714
,CHEMBL620718,,H,BAO_0000219,,,,,3441,,4265,,1,433.0,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,NG108-15,Autocuration,4,,104714
,CHEMBL618127,,H,BAO_0000223,,,,,3442,,17358,,1,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,Autocuration,4,,104714
,CHEMBL618128,,H,BAO_0000223,,,,,3443,,17358,,1,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,Autocuration,4,,104714
,CHEMBL618129,,H,BAO_0000219,,,,,3444,,13628,,1,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,Autocuration,4,,104714
,CHEMBL618130,,H,BAO_0000223,,,,,3445,,4612,,1,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,Autocuration,4,,104714
,CHEMBL618131,,H,BAO_0000019,,,,,3446,,17358,,1,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,Autocuration,4,,104714
,CHEMBL618132,10141.0,H,BAO_0000019,Cavia porcellus,,,,3447,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Autocuration,4,,104714
,CHEMBL618133,10141.0,H,BAO_0000019,Cavia porcellus,,,,3448,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Autocuration,4,,104714
,CHEMBL618134,10141.0,H,BAO_0000019,Cavia porcellus,,,,3449,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Autocuration,4,,104714
,CHEMBL618135,10141.0,H,BAO_0000019,Cavia porcellus,,,,3450,,4639,,1,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Autocuration,4,,104714
,CHEMBL618136,,H,BAO_0000223,,,,,3451,,511,,1,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,Autocuration,4,,104714
,CHEMBL618137,,H,BAO_0000223,,,,,3452,,1479,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL618138,,H,BAO_0000223,,,,,3453,,1317,,1,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,Autocuration,4,,104714
,CHEMBL618139,,H,BAO_0000223,,,,,3454,,12146,,1,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,Autocuration,4,,104714
,CHEMBL618140,,H,BAO_0000223,,,,,3455,,12146,,1,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,Autocuration,4,,104714
,CHEMBL618141,,H,BAO_0000223,,,,,3456,,13969,,1,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,Autocuration,4,,104714
,CHEMBL873478,,H,BAO_0000357,,,,,3457,,13392,,1,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Expert,8,,108
,CHEMBL618142,,H,BAO_0000223,,,,,3458,,13392,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,6,,104698
,CHEMBL618143,,H,BAO_0000357,,,,,3459,,14159,,1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618144,,H,BAO_0000357,,,,,3460,,1558,,1,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618145,,H,BAO_0000357,,,,,3461,,16655,,1,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618146,,H,BAO_0000223,,,,,3462,,13020,,1,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,Autocuration,4,,104714
,CHEMBL618147,,H,BAO_0000223,,,,,3463,,13021,,1,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,Autocuration,4,,104714
,CHEMBL618148,,H,BAO_0000223,,,,,3464,,13020,,1,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,Autocuration,4,,104714
,CHEMBL618149,,H,BAO_0000019,,,,,3465,,10321,,1,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,Autocuration,8,,144
,CHEMBL872927,,H,BAO_0000357,,,,,3466,,15818,,1,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618150,,H,BAO_0000357,,,,,3467,,15818,,1,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618151,,H,BAO_0000357,,,,,3468,,17358,,1,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,Autocuration,8,,144
,CHEMBL875094,,H,BAO_0000357,,,,,3469,,2222,,1,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,Autocuration,8,,144
,CHEMBL618152,,H,BAO_0000019,,,,,3470,,10322,,1,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,Autocuration,8,,144
,CHEMBL618153,,H,BAO_0000357,,,,,3471,,16117,,1,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,Autocuration,8,,144
,CHEMBL618888,,H,BAO_0000357,,,,,3472,,17200,,1,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,Autocuration,8,,144
,CHEMBL618889,,H,BAO_0000019,,,,,3473,,17358,,1,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,Autocuration,8,,144
,CHEMBL618890,,H,BAO_0000357,,,,,3474,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,Autocuration,8,,144
,CHEMBL618891,,H,BAO_0000019,,,,,3475,,1980,,1,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,Autocuration,8,,144
,CHEMBL619054,,H,BAO_0000019,,,,,3476,,1980,,1,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,Autocuration,8,,144
,CHEMBL619055,,H,BAO_0000223,,,,,3477,,12409,,1,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,Autocuration,4,,104714
,CHEMBL619056,,H,BAO_0000357,,,,,3478,,4365,,1,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,Autocuration,8,,144
,CHEMBL619057,,H,BAO_0000019,,,,,3479,,4365,,1,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,Autocuration,8,,144
,CHEMBL619058,,H,BAO_0000357,,,,,3480,,4365,,1,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,Autocuration,8,,144
,CHEMBL619059,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3481,,6769,,1,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,Oocytes,Expert,9,,12020
,CHEMBL619060,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3482,,6769,,1,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,Oocytes,Expert,9,,12020
,CHEMBL875095,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3483,,6769,,1,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,Oocytes,Expert,9,,12020
,CHEMBL619061,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3484,2116.0,809,,1,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Intermediate,9,,20033
,CHEMBL619062,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3485,2116.0,809,,1,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Intermediate,9,,20033
,CHEMBL619063,10141.0,D,BAO_0000019,Cavia porcellus,,,,3486,,14290,,1,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Intermediate,9,,20033
,CHEMBL619064,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3487,2116.0,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Intermediate,9,,20033
,CHEMBL619065,10141.0,D,BAO_0000357,Cavia porcellus,,,,3488,,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Intermediate,9,,20033
,CHEMBL619066,10141.0,D,BAO_0000221,Cavia porcellus,,,Ileum,3489,2116.0,17358,,1,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Intermediate,9,,20033
,CHEMBL619775,,H,BAO_0000221,,,,Ileum,3490,2116.0,17386,,1,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,Autocuration,8,,10209
,CHEMBL619776,,H,BAO_0000357,,,,,3491,,3269,,1,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL619777,10141.0,H,BAO_0000224,Cavia porcellus,,,,3492,,7721,,1,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Autocuration,4,,104841
,CHEMBL619778,10141.0,H,BAO_0000224,Cavia porcellus,,,,3493,,7721,,1,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Autocuration,4,,104841
,CHEMBL619779,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,3494,2116.0,9117,,1,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Autocuration,4,,104841
,CHEMBL619780,10141.0,H,BAO_0000224,Cavia porcellus,,,,3495,,7721,,1,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Autocuration,4,,104841
,CHEMBL619166,10141.0,H,BAO_0000224,Cavia porcellus,,,,3496,,7721,,1,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Autocuration,4,,104841
,CHEMBL619167,10141.0,H,BAO_0000019,Cavia porcellus,,,,3497,,15796,,1,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Autocuration,4,,104841
,CHEMBL619168,10141.0,H,BAO_0000019,Cavia porcellus,,,,3498,,15796,,1,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Autocuration,4,,104841
,CHEMBL619169,9606.0,D,BAO_0000219,Homo sapiens,,,Cardiac atrium,3499,2081.0,15650,,1,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Expert,9,,168
,CHEMBL619170,9606.0,D,BAO_0000219,Homo sapiens,,,Cardiac atrium,3500,2081.0,15650,,1,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Expert,9,,168
,CHEMBL619171,9606.0,D,BAO_0000019,Homo sapiens,,,,3501,,6866,,1,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Autocuration,5,,104841
,CHEMBL619172,9606.0,D,BAO_0000219,Homo sapiens,,,Cardiac atrium,3502,2081.0,15650,,1,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Expert,9,,168
,CHEMBL619173,10090.0,U,BAO_0000019,Mus musculus,,,,3503,,10063,,1,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Autocuration,0,,22226
,CHEMBL619174,10090.0,U,BAO_0000019,Mus musculus,,,,3504,,12665,,1,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Autocuration,0,,22226
,CHEMBL619175,,H,BAO_0000019,,,,,3505,,7504,,1,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,Autocuration,4,,104705
,CHEMBL619176,,H,BAO_0000224,,,,,3506,,7504,,1,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,Autocuration,4,,104705
,CHEMBL619177,,H,BAO_0000019,,,,,3507,,7038,,1,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,Autocuration,4,,104705
,CHEMBL619178,,H,BAO_0000224,,,,,3508,,7626,,1,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,Autocuration,4,,104705
,CHEMBL619179,,H,BAO_0000224,,,,,3509,,7626,,1,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,Autocuration,4,,104705
,CHEMBL619180,,H,BAO_0000019,,,,Stomach,3510,945.0,7185,,1,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,Autocuration,4,,104705
,CHEMBL619181,,H,BAO_0000019,,,,Stomach,3511,945.0,7185,,1,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,Autocuration,4,,104705
,CHEMBL619182,,H,BAO_0000019,,,,,3512,,7185,,1,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,Autocuration,4,,104705
,CHEMBL619183,,H,BAO_0000224,,,,,3513,,6960,,1,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,Autocuration,4,,104705
,CHEMBL619184,,H,BAO_0000224,,,,,3514,,6960,,1,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,Autocuration,4,,104705
,CHEMBL619185,,H,BAO_0000221,,,,Hippocampus,3515,10000000.0,12416,,1,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,Autocuration,8,,10576
,CHEMBL619186,,H,BAO_0000357,,,,,3516,,15753,,1,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,Expert,8,,12198
,CHEMBL619187,,H,BAO_0000019,,,,,3517,,8062,,1,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,Autocuration,4,,104705
,CHEMBL619188,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3518,,9036,,1,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Autocuration,5,,104705
,CHEMBL619189,10116.0,D,BAO_0000224,Rattus norvegicus,,,,3519,,15067,,1,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Autocuration,5,,104705
,CHEMBL619190,10116.0,D,BAO_0000019,Rattus norvegicus,,,Brain,3520,955.0,15753,,1,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Expert,9,,12198
,CHEMBL619191,10116.0,D,BAO_0000221,Rattus norvegicus,,,Cerebellum,3521,2037.0,15753,,1,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Expert,9,,12198
,CHEMBL619192,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3522,,15295,,1,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Autocuration,5,,104705
,CHEMBL619193,10116.0,D,BAO_0000224,Rattus norvegicus,,,,3523,,6347,,1,,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Autocuration,5,,104705
,CHEMBL619194,,U,BAO_0000019,,,,,3524,,6763,,1,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,Autocuration,0,,22226
,CHEMBL619195,10116.0,D,BAO_0000224,Rattus norvegicus,,,,3525,,12092,,1,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Autocuration,5,,104705
,CHEMBL619196,10116.0,D,BAO_0000224,Rattus norvegicus,,,,3526,,1579,,1,,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Autocuration,5,,104705
,CHEMBL619197,10116.0,D,BAO_0000019,Rattus norvegicus,,,Stomach,3527,945.0,1579,,1,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Autocuration,5,,104705
,CHEMBL619198,9606.0,D,BAO_0000219,Homo sapiens,,,,3528,,5963,,1,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Expert,9,,121
,CHEMBL875081,9606.0,D,BAO_0000219,Homo sapiens,,,,3529,,5963,,1,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Expert,9,,121
,CHEMBL884712,,H,BAO_0000357,,,,,3530,,5030,,1,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,Autocuration,8,,18065
,CHEMBL884710,,H,BAO_0000357,,,,,3531,,15796,,1,,Inhibition of 5-hydroxytryptamine reuptake,B,,,Expert,8,,121
,CHEMBL619199,,H,BAO_0000019,,,,,3532,,15413,,1,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,Autocuration,8,,18065
,CHEMBL619200,,H,BAO_0000019,,,,,3533,,15413,,1,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,Autocuration,8,,18065
,CHEMBL619201,,H,BAO_0000019,,,,,3534,,15413,,1,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,Autocuration,8,,18065
,CHEMBL619202,,H,BAO_0000019,,,,,3535,,12409,,1,,Tested for 5-hydroxytryptamine receptor uptake,F,,,Autocuration,8,,18065
,CHEMBL619203,9606.0,D,BAO_0000219,Homo sapiens,,,,3536,,16909,,1,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,CHO,Expert,9,,51
,CHEMBL619204,9606.0,D,BAO_0000019,Homo sapiens,,,,3537,,16909,,1,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Expert,9,,51
,CHEMBL619205,9606.0,H,BAO_0000249,Homo sapiens,,,,3538,,15629,,1,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Autocuration,8,,10576
,CHEMBL619206,,H,BAO_0000357,,,,,3539,,15629,,1,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,Autocuration,8,,10576
,CHEMBL619207,,H,BAO_0000249,,,,,3540,,15629,,1,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,Expert,8,,10576
,CHEMBL619208,,H,BAO_0000019,,,,Striatum,3541,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619209,,H,BAO_0000019,,,,Striatum,3542,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619210,,H,BAO_0000019,,,,Striatum,3543,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619211,,H,BAO_0000019,,,,Striatum,3544,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619212,,H,BAO_0000019,,,,Striatum,3545,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620681,,H,BAO_0000019,,,,Striatum,3546,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620682,,H,BAO_0000019,,,,Striatum,3547,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620683,,H,BAO_0000019,,,,Striatum,3548,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620684,,H,BAO_0000019,,,,Striatum,3549,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620685,,H,BAO_0000019,,,,Striatum,3550,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620686,,H,BAO_0000019,,,,Striatum,3551,2435.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620687,,H,BAO_0000019,,,,Limbic system,3552,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620688,,H,BAO_0000019,,,,Limbic system,3553,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620689,,H,BAO_0000019,,,,Limbic system,3554,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620690,,H,BAO_0000019,,,,Limbic system,3555,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620691,,H,BAO_0000019,,,,Limbic system,3556,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620692,,H,BAO_0000019,,,,Limbic system,3557,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620693,,H,BAO_0000019,,,,Limbic system,3558,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL620694,,H,BAO_0000357,,,,,3559,,1274,,1,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,Expert,8,,168
,CHEMBL857986,,H,BAO_0000019,,,,,3560,,17358,,1,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,Autocuration,8,,168
,CHEMBL620695,,H,BAO_0000357,,,,,3561,,14532,,1,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,Autocuration,8,,168
,CHEMBL620696,,H,BAO_0000357,,,,,3562,,16989,,1,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,Expert,8,,168
,CHEMBL620697,,H,BAO_0000357,,,,,3563,,17200,,1,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,Autocuration,8,,168
,CHEMBL620698,,H,BAO_0000357,,,,,3564,,15779,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,Autocuration,8,,168
,CHEMBL620699,,H,BAO_0000357,,,,,3565,,15779,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,Autocuration,8,,168
,CHEMBL620700,,H,BAO_0000357,,,,,3566,,15779,,1,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,Autocuration,8,,168
,CHEMBL620701,,H,BAO_0000219,,,,,3567,,15650,,1,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,COS-7,Autocuration,8,,168
,CHEMBL875082,,H,BAO_0000219,,,,,3568,,15650,,1,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,COS-7,Autocuration,8,,168
,CHEMBL620702,,H,BAO_0000219,,,,,3569,,15650,,1,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,COS-7,Autocuration,8,,168
,CHEMBL620703,,H,BAO_0000219,,,,,3570,,15650,,1,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,COS-7,Autocuration,8,,168
,CHEMBL620704,,H,BAO_0000219,,,,,3571,,17046,,1,673.0,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,C6,Autocuration,8,,168
,CHEMBL620705,,H,BAO_0000219,,,,,3572,,17046,,1,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,C6,Expert,8,,168
,CHEMBL620706,,H,BAO_0000219,,,,,3573,,15650,,1,673.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,C6,Expert,8,,168
,CHEMBL620707,,H,BAO_0000219,,,,,3574,,17046,,1,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,C6,Expert,8,,168
,CHEMBL620708,,H,BAO_0000357,,,,,3575,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,Expert,8,,10624
,CHEMBL620709,,H,BAO_0000357,,,,,3576,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,Autocuration,8,,105
,CHEMBL620710,9606.0,D,BAO_0000357,Homo sapiens,,,,3577,,16146,,1,,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10624
,CHEMBL620711,,H,BAO_0000219,,,,,3578,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,10624
,CHEMBL620712,9606.0,D,BAO_0000357,Homo sapiens,,,,3579,,6491,,1,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Expert,9,,10624
,CHEMBL620713,9606.0,D,BAO_0000357,Homo sapiens,,,,3580,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10624
,CHEMBL620714,9606.0,D,BAO_0000357,Homo sapiens,,,,3581,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Expert,9,,10624
,CHEMBL620715,9606.0,D,BAO_0000357,Homo sapiens,,,,3582,,4234,,1,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10624
,CHEMBL620716,,H,BAO_0000357,,,,,3583,,6013,,1,,Binding affinity towards 5-HT5A receptor,B,,,Autocuration,8,,10624
,CHEMBL620717,,H,BAO_0000357,,,,,3584,,17175,,1,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,Expert,8,,10624
,CHEMBL618072,,H,BAO_0000357,,,,,3585,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Autocuration,8,,10624
,CHEMBL857987,,H,BAO_0000357,,,,,3586,,6166,,1,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,Autocuration,8,,10624
,CHEMBL618073,,H,BAO_0000219,,,,,3587,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,Autocuration,8,,10624
,CHEMBL618074,,H,BAO_0000219,,,,,3588,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,HEK293,Autocuration,8,,10624
,CHEMBL618075,,H,BAO_0000219,,,,,3589,,5213,,1,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,HEK293,Autocuration,8,,10624
,CHEMBL618076,10090.0,D,BAO_0000357,Mus musculus,,,,3590,,17066,,1,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10625
,CHEMBL618077,10090.0,D,BAO_0000357,Mus musculus,,,,3591,,17066,,1,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Expert,9,,10625
,CHEMBL618078,10090.0,D,BAO_0000357,Mus musculus,,,,3592,,17066,,1,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Expert,9,,10625
,CHEMBL881821,10090.0,D,BAO_0000357,Mus musculus,,,,3593,,17066,,1,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Expert,9,,10625
,CHEMBL618079,10090.0,D,BAO_0000357,Mus musculus,,,,3594,,17066,,1,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10625
,CHEMBL618080,,H,BAO_0000357,,,,,3595,,17175,,1,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,Expert,8,,10625
,CHEMBL618081,,H,BAO_0000219,,,,,3596,,16190,,1,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,HEK293,Autocuration,8,,10576
,CHEMBL618082,,H,BAO_0000219,,,,,3597,,16190,,1,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,HEK293,Autocuration,8,,10626
,CHEMBL618083,,H,BAO_0000357,,,,,3598,,4820,,1,,Binding affinity towards 5-HT5a receptor,B,,,Expert,8,,10624
,CHEMBL618084,9606.0,D,BAO_0000357,Homo sapiens,,,,3599,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Expert,9,,10624
,CHEMBL618085,,H,BAO_0000357,,,,,3600,,17066,,1,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,Expert,8,,10624
,CHEMBL618086,,H,BAO_0000357,,,,,3601,,17175,,1,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,Expert,8,,10624
,CHEMBL875092,,H,BAO_0000357,,,,,3602,,16633,,1,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,Autocuration,8,,10624
,CHEMBL618087,,H,BAO_0000357,,,,,3603,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,Autocuration,8,,10624
,CHEMBL872926,,H,BAO_0000357,,,,,3604,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,Autocuration,8,,10624
,CHEMBL618088,10141.0,H,BAO_0000019,Cavia porcellus,,,,3605,,4639,,1,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Autocuration,4,,104714
,CHEMBL618089,,H,BAO_0000223,,,,,3606,,5486,,1,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,Autocuration,4,,104714
,CHEMBL618090,9606.0,D,BAO_0000357,Homo sapiens,,,,3607,,16146,,1,,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL618091,9606.0,D,BAO_0000357,Homo sapiens,,,,3608,,17273,,1,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Expert,9,,10627
,CHEMBL618092,,H,BAO_0000357,,,,,3609,,17687,,1,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL618093,9606.0,D,BAO_0000357,Homo sapiens,,,,3610,,6491,,1,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Expert,9,,10627
,CHEMBL618094,,H,BAO_0000219,,,,,3611,,16190,,1,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,HeLa,Expert,8,,10627
,CHEMBL618095,9606.0,D,BAO_0000357,Homo sapiens,,,,3612,,17066,,1,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL875093,9606.0,D,BAO_0000357,Homo sapiens,,,,3613,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL618096,9606.0,D,BAO_0000357,Homo sapiens,,,,3614,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Expert,9,,10627
,CHEMBL618118,9606.0,D,BAO_0000357,Homo sapiens,,,,3615,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Expert,9,,10627
,CHEMBL618119,9606.0,D,BAO_0000357,Homo sapiens,,,,3616,,3555,,1,,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL618120,,H,BAO_0000357,,,,,3617,,5808,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Expert,8,,10627
,CHEMBL618121,,H,BAO_0000357,,,,,3618,,6013,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL618122,,H,BAO_0000219,,,,,3619,,15818,,1,722.0,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,HEK293,Expert,8,,10627
,CHEMBL618123,,H,BAO_0000357,,,,,3620,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,Autocuration,8,,10627
,CHEMBL618124,,H,BAO_0000219,,,,,3621,,3935,,1,722.0,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,HEK293,Expert,8,,10627
,CHEMBL618125,,H,BAO_0000357,,,,,3622,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL618126,9606.0,D,BAO_0000219,Homo sapiens,,,,3623,,3805,,1,722.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,HEK293,Expert,9,,10627
,CHEMBL618236,,H,BAO_0000019,,,,,3624,,16441,,1,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,Expert,8,,10627
,CHEMBL618237,,H,BAO_0000019,,,,,3625,,16441,,1,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,Expert,8,,10627
,CHEMBL618238,,H,BAO_0000219,,,,,3626,,6786,,1,643.0,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,COS-7,Expert,8,,10627
,CHEMBL618239,9606.0,D,BAO_0000357,Homo sapiens,,,,3627,,4234,,1,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL618240,,H,BAO_0000019,,,,,3628,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL618241,,H,BAO_0000357,,,,,3629,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,Autocuration,8,,10627
,CHEMBL859399,,H,BAO_0000219,,,,,3630,,17451,,1,722.0,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,HEK293,Autocuration,8,,10627
,CHEMBL618242,,H,BAO_0000019,,,,,3631,,3935,,1,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,Autocuration,8,,10627
,CHEMBL857991,,H,BAO_0000357,,,,,3632,,5033,,1,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL619951,,H,BAO_0000357,,,,,3633,,4540,,1,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,Expert,8,,10627
,CHEMBL619952,9606.0,D,BAO_0000219,Homo sapiens,,,,3634,,4540,,1,308.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,HeLa,Expert,9,,10627
,CHEMBL619953,9606.0,D,BAO_0000219,Homo sapiens,,,,3635,,4540,,1,308.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,HeLa,Expert,9,,10627
,CHEMBL619954,,H,BAO_0000219,,,,,3636,,17296,,1,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,HeLa,Autocuration,8,,10627
,CHEMBL619955,,H,BAO_0000219,,,,,3637,,17296,,1,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,HeLa,Autocuration,8,,10627
,CHEMBL619956,,H,BAO_0000219,,,,,3638,,17296,,1,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,HeLa,Autocuration,8,,10627
,CHEMBL619957,,H,BAO_0000219,,,,,3639,,15779,,1,449.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,Autocuration,8,,10627
,CHEMBL619958,,H,BAO_0000219,,,,,3640,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,Autocuration,8,,10627
,CHEMBL620627,,H,BAO_0000219,,,,,3641,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,HEK293,Autocuration,8,,10627
,CHEMBL620628,,H,BAO_0000219,,,,,3642,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,HEK293,Autocuration,8,,10627
,CHEMBL620629,,H,BAO_0000219,,,,,3643,,15779,,1,308.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,HeLa,Autocuration,8,,10627
,CHEMBL620630,,H,BAO_0000357,,,,,3644,,6166,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620782,,H,BAO_0000219,,,,,3645,,17451,,1,308.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,HeLa,Autocuration,8,,10627
,CHEMBL620783,,H,BAO_0000357,,,,,3646,,15316,,1,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620784,,H,BAO_0000357,,,,,3647,,4199,,1,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,Expert,8,,10627
,CHEMBL620785,,H,BAO_0000219,,,,,3648,,15146,,1,308.0,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,HeLa,Expert,8,,10627
,CHEMBL857992,,H,BAO_0000357,,,,,3649,,5213,,1,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,Autocuration,8,,10627
,CHEMBL620786,,H,BAO_0000219,,,,,3650,,16429,,1,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,Autocuration,8,,10627
,CHEMBL620787,,H,BAO_0000219,,,,,3651,,14818,,1,308.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,HeLa,Autocuration,8,,10627
,CHEMBL620788,,H,BAO_0000219,,,,,3652,,4829,,1,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,HeLa,Autocuration,8,,10627
,CHEMBL620789,,H,BAO_0000219,,,,,3653,,4829,,1,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,HeLa,Autocuration,8,,10627
,CHEMBL620790,,H,BAO_0000219,,,,,3654,,4829,,1,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,HeLa,Autocuration,8,,10627
,CHEMBL620791,,H,BAO_0000219,,,,,3655,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,10628
,CHEMBL620792,,H,BAO_0000019,,,,,3656,,14423,,1,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,Autocuration,8,,10628
,CHEMBL620793,,H,BAO_0000357,,,,,3657,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10628
,CHEMBL620794,,H,BAO_0000357,,,,,3658,,4342,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,Autocuration,8,,10628
,CHEMBL620795,9606.0,D,BAO_0000219,Homo sapiens,,,,3659,,16190,,1,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,HeLa,Autocuration,9,,10627
,CHEMBL620796,,H,BAO_0000357,,,,,3660,,4820,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Expert,8,,10627
,CHEMBL620797,,H,BAO_0000357,,,,,3661,,4639,,1,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,Autocuration,8,,10627
,CHEMBL620798,9606.0,D,BAO_0000019,Homo sapiens,,,,3662,,17066,,1,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Expert,9,,10627
,CHEMBL620799,,H,BAO_0000357,,,,,3663,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,Autocuration,8,,10627
,CHEMBL620800,,H,BAO_0000357,,,,,3664,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Expert,8,,10627
,CHEMBL620801,,H,BAO_0000357,,,,,3665,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,Autocuration,8,,10627
,CHEMBL875100,,H,BAO_0000357,,,,,3666,,5014,,1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620802,,H,BAO_0000357,,,,,3667,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,Autocuration,8,,10627
,CHEMBL620803,,H,BAO_0000019,,,,,3668,,17066,,1,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,Expert,8,,10627
,CHEMBL620804,,H,BAO_0000019,,,,,3669,,17066,,1,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Expert,8,,10627
,CHEMBL620805,,H,BAO_0000357,,,,,3670,,4373,,1,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,Autocuration,8,,10627
,CHEMBL620806,,H,BAO_0000357,,,,,3671,,4687,,1,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620807,,H,BAO_0000357,,,,,3672,,16946,,1,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,Autocuration,8,,10627
,CHEMBL620808,,H,BAO_0000357,,,,,3673,,16946,,1,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,Autocuration,8,,10627
,CHEMBL620809,,H,BAO_0000357,,,,,3674,,16633,,1,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620810,,H,BAO_0000357,,,,,3675,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620811,9606.0,D,BAO_0000357,Homo sapiens,,,,3676,,17066,,1,,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Expert,9,,10627
,CHEMBL620812,,H,BAO_0000357,,,,,3677,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,Autocuration,8,,10627
,CHEMBL620813,,H,BAO_0000357,,,,,3678,,3269,,1,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,Autocuration,8,,10627
,CHEMBL620814,,H,BAO_0000357,,,,,3679,,5486,,1,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,Autocuration,8,,10627
,CHEMBL620815,9606.0,D,BAO_0000357,Homo sapiens,,,,3680,,16146,,1,,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL620816,,H,BAO_0000219,,,,,3681,,5014,,1,722.0,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,HEK293,Autocuration,8,,10209
,CHEMBL620817,,H,BAO_0000357,,,,,3682,,15463,,1,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL620818,,H,BAO_0000357,,,,,3683,,3805,,1,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,Autocuration,8,,10209
,CHEMBL620819,,H,BAO_0000219,,,,,3684,,5014,,1,722.0,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,HEK293,Expert,8,,10209
,CHEMBL620820,9606.0,D,BAO_0000357,Homo sapiens,,,,3685,,6491,,1,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Expert,9,,10209
,CHEMBL620821,,H,BAO_0000219,,,,,3686,,16190,,1,449.0,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,CHO,Autocuration,8,,10209
,CHEMBL620822,9606.0,D,BAO_0000357,Homo sapiens,,,,3687,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL620823,9606.0,D,BAO_0000357,Homo sapiens,,,,3688,,17066,,1,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL620824,9606.0,D,BAO_0000357,Homo sapiens,,,,3689,,3555,,1,,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL620825,,H,BAO_0000219,,,,,3690,,6588,,1,449.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,CHO,Expert,8,,10209
,CHEMBL872930,,H,BAO_0000357,,,,,3691,,15463,,1,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,Autocuration,8,,10209
,CHEMBL620826,,H,BAO_0000357,,,,,3692,,6013,,1,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL620827,,H,BAO_0000357,,,,,3693,,16209,,1,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,10209
,CHEMBL620828,,H,BAO_0000357,,,,,3694,,3935,,1,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL620829,,H,BAO_0000357,,,,,3695,,15818,,1,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL620830,,H,BAO_0000219,,,,,3696,,5014,,1,722.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,HEK293,Expert,8,,10209
,CHEMBL620831,,H,BAO_0000019,,,,,3697,,16441,,1,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,Expert,8,,10209
,CHEMBL620832,,H,BAO_0000019,,,,,3698,,16441,,1,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,Expert,8,,10209
,CHEMBL621548,9606.0,D,BAO_0000357,Homo sapiens,,,,3699,,4234,,1,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL621549,,H,BAO_0000019,,,,,3700,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL621550,,H,BAO_0000357,,,,,3701,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,Autocuration,8,,10209
,CHEMBL621551,,H,BAO_0000219,,,,,3702,,17451,,1,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,CHO,Autocuration,8,,10209
,CHEMBL621552,,H,BAO_0000019,,,,,3703,,17085,,1,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,Autocuration,8,,10209
,CHEMBL857077,,H,BAO_0000357,,,,,3704,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL618158,,H,BAO_0000357,,,,,3705,,5104,,1,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,Autocuration,8,,10209
,CHEMBL618159,9606.0,D,BAO_0000219,Homo sapiens,,,,3706,,5033,,1,643.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,COS-7,Expert,9,,10209
,CHEMBL875101,,H,BAO_0000219,,,,,3707,,5486,,1,643.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,COS-7,Autocuration,8,,10209
,CHEMBL618160,9606.0,D,BAO_0000219,Homo sapiens,,,,3708,,4540,,1,722.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,HEK293,Expert,9,,10209
,CHEMBL618161,,H,BAO_0000357,,,,,3709,,6166,,1,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,Expert,8,,10209
,CHEMBL618162,,H,BAO_0000219,,,,,3710,,17342,,1,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,HEK293,Expert,8,,10209
,CHEMBL618163,,H,BAO_0000357,,,,,3711,,17342,,1,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,Expert,8,,10209
,CHEMBL618164,,H,BAO_0000357,,,,,3712,,17296,,1,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,Autocuration,8,,10209
,CHEMBL618165,,H,BAO_0000219,,,,,3713,,16429,,1,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,Expert,8,,10209
,CHEMBL618166,,H,BAO_0000219,,,,,3714,,15779,,1,722.0,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,HEK293,Autocuration,8,,10209
,CHEMBL857989,,H,BAO_0000219,,,,,3715,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,Autocuration,8,,10209
,CHEMBL619888,,H,BAO_0000219,,,,,3716,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,Autocuration,8,,10209
,CHEMBL619889,,H,BAO_0000219,,,,,3717,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,Autocuration,8,,10209
,CHEMBL619890,,H,BAO_0000219,,,,,3718,,15779,,1,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,Autocuration,8,,10209
,CHEMBL619891,,H,BAO_0000219,,,,,3719,,17451,,1,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,CHO,Autocuration,8,,10209
,CHEMBL619892,,H,BAO_0000219,,,,,3720,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,HEK293,Autocuration,8,,10209
,CHEMBL619893,,D,BAO_0000219,,,,,3721,,4199,,1,722.0,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,HEK293,Expert,9,,10209
,CHEMBL619894,,H,BAO_0000219,,,,,3722,,4199,,1,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,HEK293,Autocuration,8,,10209
,CHEMBL619895,,D,BAO_0000219,,,,,3723,,3680,,1,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,HEK293,Intermediate,9,,10209
,CHEMBL619896,,D,BAO_0000357,,,,,3724,,3680,,1,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,Intermediate,9,,10209
,CHEMBL619897,,H,BAO_0000219,,,,,3725,,15316,,1,643.0,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,COS-7,Autocuration,8,,10209
,CHEMBL619898,,H,BAO_0000219,,,,,3726,,15146,,1,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,HEK293,Autocuration,8,,10209
,CHEMBL619899,,H,BAO_0000219,,,,,3727,,5213,,1,722.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,HEK293,Expert,8,,10209
,CHEMBL619900,,H,BAO_0000219,,,,,3728,,5213,,1,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,HEK293,Autocuration,8,,10209
,CHEMBL619901,9606.0,D,BAO_0000219,Homo sapiens,,,,3729,,14818,,1,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,HEK293,Expert,9,,10209
,CHEMBL620580,,H,BAO_0000219,,,,,3730,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,HEK293,Autocuration,8,,10209
,CHEMBL620581,,H,BAO_0000219,,,,,3731,,14818,,1,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,HEK293,Autocuration,8,,10209
,CHEMBL620733,,H,BAO_0000219,,,,,3732,,4829,,1,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,HEK293,Autocuration,8,,10209
,CHEMBL620734,9606.0,D,BAO_0000357,Homo sapiens,,,,3733,,17200,,1,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Autocuration,9,,10209
,CHEMBL620735,10090.0,D,BAO_0000357,Mus musculus,,,,3734,,17066,,1,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Expert,9,,10022
,CHEMBL620736,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3735,,14025,,1,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Autocuration,8,,10209
,CHEMBL620737,,H,BAO_0000219,,,,,3736,,15250,,1,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,CHO,Autocuration,8,,11923
,CHEMBL620738,,H,BAO_0000219,,,,,3737,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620739,,H,BAO_0000219,,,,,3738,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620740,,H,BAO_0000219,,,,,3739,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620741,,H,BAO_0000219,,,,,3740,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,CHO,Autocuration,8,,11923
,CHEMBL620742,,H,BAO_0000219,,,,,3741,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,CHO,Autocuration,8,,11923
,CHEMBL620743,,H,BAO_0000219,,,,,3742,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,CHO,Autocuration,8,,11923
,CHEMBL620744,,H,BAO_0000219,,,,,3743,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620745,,H,BAO_0000219,,,,,3744,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620746,,H,BAO_0000219,,,,,3745,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,CHO,Autocuration,8,,11923
,CHEMBL620747,,H,BAO_0000219,,,,,3746,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,CHO,Autocuration,8,,11923
,CHEMBL620748,,H,BAO_0000219,,,,,3747,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,CHO,Autocuration,8,,11923
,CHEMBL620749,,H,BAO_0000219,,,,,3748,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,CHO,Autocuration,8,,11923
,CHEMBL620750,,H,BAO_0000357,,,,,3749,,17066,,1,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,11923
,CHEMBL620751,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3750,,17066,,1,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Expert,9,,11923
,CHEMBL620752,,H,BAO_0000357,,,,,3751,,17386,,1,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,11923
,CHEMBL872929,,H,BAO_0000019,,,,,3752,,14423,,1,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,Autocuration,8,,11923
,CHEMBL620753,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3753,,15874,,1,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Expert,9,,11923
,CHEMBL620754,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3754,,15874,,1,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,11923
,CHEMBL620755,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3755,,16372,,1,449.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,CHO,Expert,9,,11923
,CHEMBL620756,,H,BAO_0000357,,,,,3756,,4622,,1,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,Autocuration,8,,11923
,CHEMBL620757,,H,BAO_0000357,,,,,3757,,15086,,1,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,11923
,CHEMBL620758,,H,BAO_0000219,,,,,3758,,16372,,1,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,CHO,Autocuration,8,,11923
,CHEMBL620759,,H,BAO_0000219,,,,,3759,,16372,,1,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,CHO,Autocuration,8,,11923
,CHEMBL620760,,H,BAO_0000219,,,,,3760,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,CHO,Autocuration,8,,11923
,CHEMBL620761,,H,BAO_0000219,,,,,3761,,16372,,1,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,CHO,Autocuration,8,,11923
,CHEMBL620762,,H,BAO_0000221,,,,Ileum,3762,2116.0,17386,,1,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,Autocuration,8,,11923
,CHEMBL620763,,H,BAO_0000221,,,,Ileum,3763,2116.0,17386,,1,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,Autocuration,8,,11923
,CHEMBL620764,,H,BAO_0000221,,,,Ileum,3764,2116.0,17386,,1,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,Autocuration,8,,11923
Membranes,CHEMBL857990,10116.0,D,BAO_0000249,Rattus norvegicus,,,,3765,,5831,,1,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Expert,9,,11923
,CHEMBL620765,,H,BAO_0000357,,,,,3766,,4342,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,Autocuration,8,,11923
,CHEMBL620766,,H,BAO_0000357,,,,,3767,,17319,,1,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,Expert,8,,11923
,CHEMBL620767,,H,BAO_0000019,,,,Hypothalamus,3768,1898.0,17342,,1,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,Expert,8,,11923
,CHEMBL620768,,H,BAO_0000357,,,,,3769,,17342,,1,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,Autocuration,8,,11923
,CHEMBL619051,,H,BAO_0000249,,,,Hypothalamus,3770,1898.0,3680,,1,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,Expert,8,,11923
,CHEMBL619052,,H,BAO_0000357,,,,,3771,,3680,,1,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,11923
,CHEMBL619053,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3772,,17319,,1,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,HEK293,Expert,9,,11923
,CHEMBL619703,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3773,,17319,,1,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,HEK293,Expert,9,,11923
,CHEMBL619704,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3774,,17319,,1,722.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,HEK293,Autocuration,9,,11923
,CHEMBL619851,,H,BAO_0000357,,,,,3775,,4820,,1,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,10209
,CHEMBL619852,,H,BAO_0000357,,,,,3776,,4639,,1,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,Autocuration,8,,10209
,CHEMBL619853,,H,BAO_0000357,,,,,3777,,6011,,1,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,Autocuration,8,,10209
,CHEMBL619854,9606.0,D,BAO_0000357,Homo sapiens,,,,3778,,17066,,1,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Expert,9,,10209
,CHEMBL619855,,H,BAO_0000357,,,,,3779,,17066,,1,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,10209
,CHEMBL619856,,H,BAO_0000357,,,,,3780,,17515,,1,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,Autocuration,8,,10209
,CHEMBL619857,,H,BAO_0000357,,,,,3781,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,Autocuration,8,,10209
,CHEMBL619858,,H,BAO_0000019,,,,,3782,,17066,,1,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,Expert,8,,10209
,CHEMBL619859,,H,BAO_0000357,,,,,3783,,4373,,1,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,Autocuration,8,,10209
,CHEMBL619860,,H,BAO_0000357,,,,,3784,,4373,,1,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,Autocuration,8,,10209
,CHEMBL619861,,H,BAO_0000357,,,,,3785,,4687,,1,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL619862,,H,BAO_0000357,,,,,3786,,17342,,1,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,10209
,CHEMBL619863,,H,BAO_0000357,,,,,3787,,16946,,1,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,Autocuration,8,,10209
,CHEMBL619864,,H,BAO_0000357,,,,,3788,,16946,,1,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,Autocuration,8,,10209
,CHEMBL872928,,H,BAO_0000357,,,,,3789,,16633,,1,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL619865,,H,BAO_0000357,,,,,3790,,16633,,1,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,Autocuration,8,,10209
,CHEMBL619866,,H,BAO_0000357,,,,,3791,,17066,,1,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,Expert,8,,10209
,CHEMBL619867,,H,BAO_0000357,,,,,3792,,16700,,1,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,Autocuration,8,,10209
,CHEMBL619868,,H,BAO_0000221,,,,Ileum,3793,2116.0,17386,,1,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,Autocuration,8,,10209
,CHEMBL619869,,H,BAO_0000019,,,,,3794,,14080,,1,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,Autocuration,8,,55
,CHEMBL619870,9606.0,D,BAO_0000019,Homo sapiens,,,,3795,,14080,,1,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Expert,9,,55
,CHEMBL619871,,H,BAO_0000357,,,,,3796,,409,,1,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,Autocuration,8,,55
,CHEMBL619872,,H,BAO_0000357,,,,,3797,,409,,1,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,Autocuration,8,,55
,CHEMBL619873,,H,BAO_0000357,,,,,3798,,409,,1,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,Autocuration,8,,55
,CHEMBL619874,,H,BAO_0000357,,,,Blood,3799,178.0,11090,,1,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,Expert,8,,55
,CHEMBL619875,,H,BAO_0000357,,,,Blood,3800,178.0,11090,,1,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,Expert,8,,55
,CHEMBL619876,,H,BAO_0000357,,,,,3801,,948,,1,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,Autocuration,8,,55
,CHEMBL619877,,H,BAO_0000357,,,,,3802,,948,,1,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,Autocuration,8,,55
,CHEMBL619878,,H,BAO_0000219,,,,,3803,,13622,,1,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,Expert,8,,55
,CHEMBL619879,,H,BAO_0000019,,,,Blood,3804,178.0,13622,,1,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,Autocuration,8,,55
,CHEMBL619880,,H,BAO_0000357,,,,,3805,,9637,,1,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,Autocuration,8,,55
,CHEMBL619881,,H,BAO_0000357,,,,,3806,,11320,,1,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,Autocuration,8,,55
,CHEMBL619882,,H,BAO_0000357,,,,,3807,,11320,,1,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,Expert,8,,55
,CHEMBL619883,,H,BAO_0000357,,,,,3808,,6838,,1,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,Autocuration,8,,55
,CHEMBL619884,9606.0,D,BAO_0000357,Homo sapiens,,,Blood,3809,178.0,17667,,1,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Expert,9,,55
,CHEMBL619885,,H,BAO_0000357,,,,,3810,,12703,,1,,In vitro potency against human 5-Lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL619886,9606.0,D,BAO_0000019,Homo sapiens,,,,3811,,14312,,1,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Expert,9,,55
,CHEMBL619887,,H,BAO_0000019,,,,Blood,3812,178.0,14312,,1,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,Autocuration,8,,55
,CHEMBL875097,,H,BAO_0000019,,,,,3813,,5364,,1,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,Autocuration,8,,55
,CHEMBL618001,,H,BAO_0000219,,,,,3814,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,Autocuration,8,,55
,CHEMBL618002,,H,BAO_0000219,,,,,3815,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,Autocuration,8,,55
,CHEMBL618003,,H,BAO_0000219,,,,,3816,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,Autocuration,8,,55
,CHEMBL618004,,H,BAO_0000219,,,,,3817,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,Autocuration,8,,55
,CHEMBL618005,,H,BAO_0000219,,,,,3818,,12365,,1,,Inhibition of human 5-lipoxygenase in human cells,B,,,Autocuration,8,,55
,CHEMBL618006,,H,BAO_0000357,,,,,3819,,10603,,1,,Inhibition of human neutrophil 5-lipoxygenase,B,,,Expert,8,,55
,CHEMBL875086,,H,BAO_0000019,,,,,3820,,10501,,1,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,Autocuration,8,,55
,CHEMBL618007,,H,BAO_0000357,,,,Blood,3821,178.0,12281,,1,,Inhibition of 5-lipoxygenase from human whole blood,B,,,Expert,8,,55
,CHEMBL618008,,H,BAO_0000357,,,,,3822,,2567,,1,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,Autocuration,8,,55
,CHEMBL618009,,H,BAO_0000219,,,,,3823,,2567,,1,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,Autocuration,8,,55
,CHEMBL618010,,H,BAO_0000357,,,,,3824,,10193,,1,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,Expert,8,,55
,CHEMBL618011,,H,BAO_0000357,,,,,3825,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618012,,H,BAO_0000357,,,,,3826,,13623,,1,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,Expert,8,,55
,CHEMBL882927,,H,BAO_0000357,,,,,3827,,12780,,1,,Tested against 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618013,,H,BAO_0000357,,,,,3828,,12780,,1,,Tested for activity against 5-Lipoxygenase (5-LO),B,,,Autocuration,8,,55
,CHEMBL618014,,H,BAO_0000357,,,,,3829,,12780,,1,,Tested for activity against 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618015,,H,BAO_0000357,,,,,3830,,11966,,1,,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,Autocuration,8,,55
,CHEMBL618016,,H,BAO_0000019,,,,,3831,,5364,,1,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,Autocuration,8,,55
,CHEMBL618017,,H,BAO_0000357,,,,,3832,,13165,,1,,Inhibition of Human 5-lipoxygenase,B,,,Expert,8,,55
,CHEMBL618018,,H,BAO_0000019,,,,,3833,,5364,,1,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,Autocuration,8,,55
,CHEMBL875087,,H,BAO_0000219,,,,,3834,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,55
,CHEMBL618019,,H,BAO_0000219,,,,,3835,,11311,,1,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,55
,CHEMBL618020,,H,BAO_0000019,,,,,3836,,14863,,1,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,Autocuration,8,,55
,CHEMBL618021,,H,BAO_0000019,,,,,3837,,14863,,1,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,Autocuration,8,,55
,CHEMBL618022,,H,BAO_0000357,,,,Blood,3838,178.0,11087,,1,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,Autocuration,8,,55
,CHEMBL618023,,H,BAO_0000357,,,,,3839,,455,,1,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,Autocuration,8,,55
,CHEMBL618024,,H,BAO_0000357,,,,,3840,,13183,,1,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,Autocuration,8,,55
,CHEMBL873950,,H,BAO_0000019,,,,,3841,,10319,,1,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,Expert,8,,55
,CHEMBL618025,,H,BAO_0000357,,,,,3842,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618026,,H,BAO_0000219,,,,,3843,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618027,,H,BAO_0000219,,,,,3844,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,Autocuration,8,,55
,CHEMBL618028,,H,BAO_0000219,,,,,3845,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618029,,H,BAO_0000219,,,,,3846,,951,,1,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,Autocuration,8,,55
,CHEMBL618030,,H,BAO_0000357,,,,,3847,,9859,,1,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,Expert,8,,55
,CHEMBL618031,,H,BAO_0000357,,,,,3848,,9859,,1,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,Expert,8,,55
,CHEMBL618032,,H,BAO_0000357,,,,,3849,,9859,,1,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,Autocuration,8,,55
,CHEMBL618033,,H,BAO_0000357,,,,,3850,,2567,,1,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,Autocuration,8,,55
,CHEMBL618034,,H,BAO_0000357,,,,,3851,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,Autocuration,8,,55
,CHEMBL875088,,H,BAO_0000357,,,,,3852,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618035,,H,BAO_0000019,,,,,3853,,949,,1,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,Autocuration,8,,55
,CHEMBL618036,,H,BAO_0000019,,,,,3854,,949,,1,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,Autocuration,8,,55
,CHEMBL618037,,H,BAO_0000357,,,,,3855,,10603,,1,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,Expert,8,,55
,CHEMBL618038,,H,BAO_0000357,,,,,3856,,10603,,1,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,Expert,8,,55
,CHEMBL618761,,H,BAO_0000019,,,,,3857,,10603,,1,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,Autocuration,8,,55
,CHEMBL618762,,H,BAO_0000357,,,,,3858,,10603,,1,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,Expert,8,,55
,CHEMBL618763,,H,BAO_0000357,,,,,3859,,10603,,1,,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,Expert,8,,55
,CHEMBL618764,,H,BAO_0000357,,,,,3860,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,Autocuration,8,,55
,CHEMBL618765,9606.0,D,BAO_0000357,Homo sapiens,,,,3861,,14580,,1,,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Expert,9,,55
,CHEMBL618766,,H,BAO_0000357,,,,,3862,,11090,,1,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,Expert,8,,17087
,CHEMBL618767,,H,BAO_0000357,,,,,3863,,11090,,1,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,Expert,8,,17087
,CHEMBL619380,,H,BAO_0000357,,,,,3864,,6339,,1,,Inhibitory activity against lipoxygenase-2 in mice,B,,,Autocuration,8,,17087
,CHEMBL619381,,H,BAO_0000357,,,,,3865,,6339,,1,,Inhibitory activity against murine lipoxygenase-2.,B,,,Expert,8,,17087
,CHEMBL619382,10090.0,D,BAO_0000357,Mus musculus,,,,3866,,12281,,1,,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Expert,9,,17087
,CHEMBL619383,,H,BAO_0000357,,,,,3867,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,Autocuration,8,,17087
,CHEMBL619384,9823.0,H,BAO_0000019,Sus scrofa,,,,3868,,11089,,1,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Autocuration,8,,55
,CHEMBL619385,9823.0,H,BAO_0000019,Sus scrofa,,,,3869,,10091,,1,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Autocuration,8,,55
,CHEMBL882928,9986.0,H,BAO_0000019,Oryctolagus cuniculus,,,,3870,,14352,,1,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Autocuration,8,,55
,CHEMBL619386,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3871,,13329,,1,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Expert,9,,12166
,CHEMBL619387,,H,BAO_0000019,,,,,3872,,13329,,1,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,Autocuration,8,,12166
,CHEMBL619388,,H,BAO_0000019,,,,,3873,,13329,,1,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,Autocuration,8,,12166
,CHEMBL619389,,H,BAO_0000019,,,,,3874,,13329,,1,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,Autocuration,8,,12166
,CHEMBL619390,,H,BAO_0000019,,,,,3875,,13329,,1,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,Expert,8,,12166
,CHEMBL619391,,H,BAO_0000019,,,,,3876,,13329,,1,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,Expert,8,,12166
,CHEMBL619392,,H,BAO_0000019,,,,,3877,,13329,,1,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,Autocuration,8,,12166
,CHEMBL619393,,H,BAO_0000019,,,,,3878,,11311,,1,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,Autocuration,8,,12166
,CHEMBL619394,,H,BAO_0000019,,,,,3879,,11311,,1,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,Autocuration,8,,12166
,CHEMBL619395,,H,BAO_0000219,,,,,3880,,105,,1,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,RBL-1,Autocuration,8,,12166
,CHEMBL619396,,H,BAO_0000219,,,,,3881,,105,,1,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,RBL-1,Autocuration,8,,12166
,CHEMBL619397,,H,BAO_0000357,,,,,3882,,9138,,1,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,Autocuration,8,,12166
,CHEMBL619398,,H,BAO_0000357,,,,,3883,,9138,,1,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,Autocuration,8,,12166
,CHEMBL619399,,H,BAO_0000357,,,,,3884,,9138,,1,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,Autocuration,8,,12166
,CHEMBL619400,,H,BAO_0000357,,,,,3885,,14427,,1,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,Autocuration,8,,12166
,CHEMBL619401,,H,BAO_0000019,,,,,3886,,13329,,1,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,Autocuration,8,,12166
,CHEMBL619402,,H,BAO_0000019,,,,,3887,,13329,,1,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,Autocuration,8,,12166
,CHEMBL619403,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3888,,14427,,1,663.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,RBL-2H3,Expert,9,,12166
,CHEMBL619404,,H,BAO_0000357,,,,,3889,,14427,,1,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,Autocuration,8,,12166
,CHEMBL619405,,H,BAO_0000357,,,,,3890,,14427,,1,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,Autocuration,8,,12166
,CHEMBL619406,,H,BAO_0000219,,,,,3891,,10293,,1,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,RBL-1,Expert,8,,12166
,CHEMBL619407,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3892,,338,,1,702.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,RBL-1,Expert,9,,12166
,CHEMBL619408,,H,BAO_0000357,,,,,3893,,303,,1,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,Autocuration,8,,12166
,CHEMBL619409,,H,BAO_0000219,,,,,3894,,303,,1,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619410,,H,BAO_0000219,,,,,3895,,9247,,1,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,RBL-1,Expert,8,,12166
,CHEMBL619753,,H,BAO_0000219,,,,,3896,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619754,,H,BAO_0000219,,,,,3897,,137,,1,702.0,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619903,,H,BAO_0000357,,,,,3898,,11481,,1,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,Expert,8,,12166
,CHEMBL619904,,H,BAO_0000357,,,,,3899,,11481,,1,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,Expert,8,,12166
,CHEMBL619905,,H,BAO_0000357,,,,,3900,,9029,,1,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,Expert,8,,12166
,CHEMBL619906,,H,BAO_0000019,,,,,3901,,1701,,1,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,Autocuration,8,,12166
,CHEMBL619907,,H,BAO_0000019,,,,,3902,,1701,,1,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,Autocuration,8,,12166
,CHEMBL619908,,H,BAO_0000019,,,,,3903,,1701,,1,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,Autocuration,8,,12166
,CHEMBL619909,,H,BAO_0000019,,,,,3904,,1701,,1,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,Autocuration,8,,12166
,CHEMBL619910,,H,BAO_0000219,,,,,3905,,13358,,1,702.0,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,RBL-1,Expert,8,,12166
,CHEMBL882929,,H,BAO_0000219,,,,,3906,,1175,,1,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,RBL-1,Expert,8,,12166
,CHEMBL619911,,H,BAO_0000219,,,,,3907,,8797,,1,702.0,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,RBL-1,Expert,8,,12166
,CHEMBL619912,,H,BAO_0000019,,,,,3908,,8797,,1,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,Autocuration,8,,12166
,CHEMBL619913,10116.0,D,BAO_0000357,Rattus norvegicus,,,,3909,,577,,1,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Expert,9,,12166
,CHEMBL619914,,H,BAO_0000219,,,,,3910,,9295,,1,702.0,In vitro inhibitory activity against RBL-1 5-LO,B,,RBL-1,Expert,8,,12166
,CHEMBL619915,,H,BAO_0000219,,,,,3911,,9295,,1,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,RBL-1,Autocuration,8,,12166
,CHEMBL619916,,H,BAO_0000219,,,,,3912,,9295,,1,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,RBL-1,Autocuration,8,,12166
,CHEMBL619917,,H,BAO_0000218,,,,,3913,,9295,,1,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,Autocuration,8,,12166
,CHEMBL619918,,H,BAO_0000357,,,,,3914,,9295,,1,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,Autocuration,8,,12166
,CHEMBL619919,,H,BAO_0000218,,,,,3915,,216,,1,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,Autocuration,8,,12166
,CHEMBL883710,,H,BAO_0000219,,,,,3916,,11090,,1,702.0,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619920,,H,BAO_0000019,,,,Blood,3917,178.0,11090,,1,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,Autocuration,8,,12166
,CHEMBL619921,,H,BAO_0000357,,,,,3918,,10091,,1,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,Expert,8,,12166
,CHEMBL619922,,H,BAO_0000019,,,,,3919,,10274,,1,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,Autocuration,8,,12166
,CHEMBL619923,,H,BAO_0000219,,,,,3920,,13622,,1,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,Autocuration,8,,12166
,CHEMBL619924,,H,BAO_0000219,,,,,3921,,12118,,1,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,RBL-1,Expert,8,,12166
,CHEMBL619925,,H,BAO_0000357,,,,,3922,,12576,,1,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,Expert,8,,12166
,CHEMBL619926,,H,BAO_0000219,,,,,3923,,9546,,1,702.0,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,RBL-1,Expert,8,,12166
,CHEMBL619927,,H,BAO_0000219,,,,,3924,,9521,,1,702.0,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619928,,H,BAO_0000219,,,,,3925,,10626,,1,702.0,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,RBL-1,Expert,8,,12166
,CHEMBL619929,,H,BAO_0000219,,,,,3926,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase,B,,RBL-1,Autocuration,8,,12166
,CHEMBL875089,,H,BAO_0000219,,,,,3927,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619930,,H,BAO_0000219,,,,,3928,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619931,,H,BAO_0000219,,,,,3929,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619932,,H,BAO_0000219,,,,,3930,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619933,,H,BAO_0000219,,,,,3931,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619934,,H,BAO_0000219,,,,,3932,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619935,,H,BAO_0000219,,,,,3933,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619936,,H,BAO_0000219,,,,,3934,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619937,,H,BAO_0000219,,,,,3935,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619938,,H,BAO_0000219,,,,,3936,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619939,,H,BAO_0000219,,,,,3937,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619940,,H,BAO_0000219,,,,,3938,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,RBL-1,Autocuration,8,,12166
,CHEMBL875090,,H,BAO_0000219,,,,,3939,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619941,,H,BAO_0000219,,,,,3940,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619942,,H,BAO_0000219,,,,,3941,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,RBL-1,Autocuration,8,,12166
,CHEMBL883711,,H,BAO_0000219,,,,,3942,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619943,,H,BAO_0000219,,,,,3943,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619944,,H,BAO_0000219,,,,,3944,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619945,,H,BAO_0000219,,,,,3945,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619946,,H,BAO_0000219,,,,,3946,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619947,,H,BAO_0000219,,,,,3947,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619948,,H,BAO_0000219,,,,,3948,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619949,,H,BAO_0000219,,,,,3949,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619950,,H,BAO_0000019,,,,,3950,,9401,,1,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,Expert,8,,12166
,CHEMBL618050,,H,BAO_0000019,,,,,3951,,10325,,1,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,Autocuration,8,,12166
,CHEMBL875091,,H,BAO_0000219,,,,,3952,,1556,,1,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,RBL-2H3,Expert,8,,12166
,CHEMBL618051,,H,BAO_0000219,,,,,3953,,1556,,1,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,RBL-2H3,Expert,8,,12166
,CHEMBL618052,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3954,,961,,1,702.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,RBL-1,Expert,9,,12166
,CHEMBL618053,,H,BAO_0000019,,,,,3955,,6838,,1,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,Autocuration,8,,12166
,CHEMBL618054,,H,BAO_0000019,,,,,3956,,10325,,1,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,Expert,8,,12166
,CHEMBL618055,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3957,,9209,,1,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,Expert,9,,12166
,CHEMBL618056,,H,BAO_0000219,,,,,3958,,11520,,1,702.0,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,RBL-1,Expert,8,,12166
,CHEMBL618057,,H,BAO_0000357,,,,,3959,,137,,1,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,Autocuration,8,,12166
,CHEMBL618058,,H,BAO_0000219,,,,,3960,,4717,,1,702.0,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618059,,H,BAO_0000219,,,,,3961,,10636,,1,702.0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,RBL-1,Expert,8,,12166
,CHEMBL618060,10116.0,D,BAO_0000019,Rattus norvegicus,,,,3962,,14312,,1,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Expert,9,,12166
,CHEMBL618061,,H,BAO_0000219,,,,,3963,,1203,,1,702.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618062,,H,BAO_0000019,,,,,3964,,1203,,1,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,Autocuration,8,,12166
,CHEMBL618063,,H,BAO_0000219,,,,,3965,,13622,,1,702.0,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,RBL-1,Expert,8,,12166
,CHEMBL618064,,H,BAO_0000357,,,,,3966,,9793,,1,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,Autocuration,8,,12166
,CHEMBL618065,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3967,,1143,,1,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,RBL-1,Expert,9,,12166
,CHEMBL618066,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3968,,11854,,1,702.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,RBL-1,Expert,9,,12166
,CHEMBL618067,,H,BAO_0000219,,,,,3969,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,Autocuration,8,,12166
,CHEMBL618068,,H,BAO_0000219,,,,,3970,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,RBL-1,Autocuration,8,,12166
,CHEMBL618069,10116.0,D,BAO_0000219,Rattus norvegicus,,,,3971,,10501,,1,702.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,Expert,9,,12166
,CHEMBL618070,,H,BAO_0000219,,,,,3972,,12526,,1,702.0,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,Expert,8,,12166
,CHEMBL618071,,H,BAO_0000019,,,,Limbic system,3973,349.0,10034,,1,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619247,,H,BAO_0000019,,,,Limbic system,3974,349.0,10034,,1,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,Autocuration,8,,10825
,CHEMBL619248,,H,BAO_0000019,,,,,3975,,10034,,1,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,Autocuration,8,,10825
,CHEMBL619249,,H,BAO_0000221,,,,Hippocampus,3976,10000000.0,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,Autocuration,8,,10576
,CHEMBL619250,,H,BAO_0000221,,,,Hippocampus,3977,10000000.0,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,Autocuration,8,,10576
,CHEMBL619251,,H,BAO_0000019,,,,,3978,,10046,,1,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,Autocuration,8,,10577
,CHEMBL619252,9615.0,H,BAO_0000019,Canis lupus familiaris,,,Blood,3979,178.0,12079,,1,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Autocuration,8,,55
,CHEMBL619253,,H,BAO_0000019,,,,Blood,3980,178.0,12079,,1,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,Autocuration,8,,55
,CHEMBL619254,,H,BAO_0000219,,,,,3981,,11311,,1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,12166
,CHEMBL619255,,H,BAO_0000219,,,,,3982,,12338,,1,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,Expert,8,,17140
,CHEMBL619256,,H,BAO_0000219,,,,,3983,,12143,,1,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,Expert,8,,17140
,CHEMBL875418,,H,BAO_0000219,,,,,3984,,12143,,1,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,Autocuration,8,,17140
,CHEMBL619257,,H,BAO_0000219,,,,,3985,,12143,,1,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,Expert,8,,17140
,CHEMBL619258,,H,BAO_0000219,,,,,3986,,12143,,1,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,Autocuration,8,,17140
,CHEMBL619259,,H,BAO_0000357,,,,,3987,,12365,,1,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,Expert,8,,17140
,CHEMBL619260,,H,BAO_0000357,,,,,3988,,13500,,1,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,Expert,8,,17140
,CHEMBL619261,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3989,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619263,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3990,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619264,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3991,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619265,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3992,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619266,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3993,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619902,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3994,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620058,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3995,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620059,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3996,178.0,12832,,1,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620060,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3997,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620061,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3998,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620062,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,3999,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620063,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4000,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620064,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4001,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620065,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4002,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620066,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4003,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620067,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4004,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620068,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4005,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620069,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4006,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620070,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4007,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620071,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4008,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620072,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4009,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620036,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4010,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL857702,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4011,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620037,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4012,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620038,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4013,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620039,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4014,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620040,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4015,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620041,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4016,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620042,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4017,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620043,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4018,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620044,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4019,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620045,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4020,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620046,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4021,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620047,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4022,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620048,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4023,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL857703,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4024,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620049,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4025,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620050,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4026,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL620051,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4027,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619213,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4028,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619214,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4029,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619804,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4030,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619805,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4031,178.0,12832,,1,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619806,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4032,178.0,12832,,1,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619807,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4033,178.0,12832,,1,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619808,9615.0,H,BAO_0000218,Canis lupus familiaris,,,Blood,4034,178.0,12832,,1,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Autocuration,8,,55
,CHEMBL619809,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4035,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Autocuration,8,,55
,CHEMBL619810,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4036,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Autocuration,8,,55
,CHEMBL619811,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4037,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Autocuration,8,,55
,CHEMBL620769,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4038,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Autocuration,8,,55
,CHEMBL620770,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4039,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Autocuration,8,,55
,CHEMBL620771,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4040,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Autocuration,8,,55
,CHEMBL620772,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4041,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Autocuration,8,,55
,CHEMBL620773,9615.0,H,BAO_0000218,Canis lupus familiaris,,,,4042,,3595,,1,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Autocuration,8,,55
,CHEMBL620774,10141.0,H,BAO_0000357,Cavia porcellus,,,,4043,,9203,,1,,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Autocuration,8,,55
,CHEMBL620775,10141.0,H,BAO_0000357,Cavia porcellus,,,,4044,,82,,1,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Expert,8,,55
,CHEMBL620776,10141.0,H,BAO_0000357,Cavia porcellus,,,,4045,,11090,,1,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Autocuration,8,,55
,CHEMBL620777,10141.0,H,BAO_0000218,Cavia porcellus,,,Blood,4046,178.0,12832,,1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Autocuration,8,,55
,CHEMBL620778,10141.0,H,BAO_0000357,Cavia porcellus,,,,4047,,1065,,1,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Autocuration,8,,55
,CHEMBL620779,10141.0,H,BAO_0000357,Cavia porcellus,,,,4048,,1065,,1,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Autocuration,8,,55
,CHEMBL621500,10141.0,H,BAO_0000019,Cavia porcellus,,,,4049,,12832,,1,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Expert,8,,55
,CHEMBL621501,10141.0,H,BAO_0000019,Cavia porcellus,,,,4050,,12832,,1,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Expert,8,,55
,CHEMBL618098,10141.0,H,BAO_0000019,Cavia porcellus,,,,4051,,12832,,1,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Autocuration,8,,55
,CHEMBL618099,10141.0,H,BAO_0000019,Cavia porcellus,,,,4052,,10504,,1,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Autocuration,8,,55
,CHEMBL618100,10141.0,H,BAO_0000357,Cavia porcellus,,,,4053,,7788,,1,,Inhibitory activity against 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618101,10141.0,H,BAO_0000357,Cavia porcellus,,,,4054,,10001,,1,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Autocuration,8,,55
,CHEMBL618102,10141.0,H,BAO_0000357,Cavia porcellus,,,,4055,,10193,,1,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Autocuration,8,,55
,CHEMBL618103,10141.0,H,BAO_0000357,Cavia porcellus,,,,4056,,13243,,1,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618104,10141.0,H,BAO_0000357,Cavia porcellus,,,,4057,,13243,,1,,Inhibitory activity uM,B,,,Autocuration,8,,55
,CHEMBL883712,10141.0,H,BAO_0000219,Cavia porcellus,,,,4058,,969,,1,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Autocuration,8,,55
,CHEMBL618105,10141.0,H,BAO_0000357,Cavia porcellus,,,,4059,,10001,,1,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618106,10141.0,H,BAO_0000357,Cavia porcellus,,,,4060,,7788,,1,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Autocuration,8,,55
,CHEMBL618107,10141.0,H,BAO_0000357,Cavia porcellus,,,,4061,,10001,,1,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Autocuration,8,,55
,CHEMBL618108,10141.0,H,BAO_0000357,Cavia porcellus,,,,4062,,10193,,1,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618109,10141.0,H,BAO_0000357,Cavia porcellus,,,,4063,,13243,,1,,Inhibitory activity uM,B,,,Autocuration,8,,55
,CHEMBL618110,10141.0,H,BAO_0000357,Cavia porcellus,,,,4064,,13243,,1,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Autocuration,8,,55
,CHEMBL618111,10141.0,H,BAO_0000357,Cavia porcellus,,,,4065,,13243,,1,,Inhibitory activity uM,B,,,Expert,8,,55
,CHEMBL618112,10141.0,H,BAO_0000019,Cavia porcellus,,,,4066,,13243,,1,,Inhibitory activity uM,F,,,Autocuration,8,,55
,CHEMBL618113,10141.0,H,BAO_0000019,Cavia porcellus,,,,4067,,10504,,1,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Autocuration,8,,55
,CHEMBL618114,10141.0,H,BAO_0000357,Cavia porcellus,,,,4068,,7788,,1,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Autocuration,8,,55
,CHEMBL620871,10141.0,H,BAO_0000221,Cavia porcellus,,,Ileum,4069,2116.0,10546,,1,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Expert,8,,55
,CHEMBL620872,,H,BAO_0000357,,,,,4070,,13183,,1,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,Autocuration,8,,55
,CHEMBL620873,,H,BAO_0000357,,,,,4071,,13183,,1,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,Autocuration,8,,55
,CHEMBL620874,,H,BAO_0000357,,,,,4072,,2578,,1,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,Autocuration,8,,55
,CHEMBL620875,,H,BAO_0000357,,,,,4073,,12780,,1,,In vitro inhibition of human 5-Lipoxygenase.,B,,,Expert,8,,55
Microsomes,CHEMBL620876,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4074,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620877,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4075,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL857854,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4076,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620878,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4077,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620879,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4078,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620880,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4079,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620881,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4080,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620882,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4081,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620883,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4082,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620884,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4083,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620885,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4084,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620886,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4085,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620887,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4086,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618039,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4087,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618040,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4088,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618041,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4089,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618216,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4090,2107.0,7411,,1,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Autocuration,0,,22226
Microsomes,CHEMBL618217,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4091,2107.0,7411,,1,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Autocuration,0,,22226
Microsomes,CHEMBL618218,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4092,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618219,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4093,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618220,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4094,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618221,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4095,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618222,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4096,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618223,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4097,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618224,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4098,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618225,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4099,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618226,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4100,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618227,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4101,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618228,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4102,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618229,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4103,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618230,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4104,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618231,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4105,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618232,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4106,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618233,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4107,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618234,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4108,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618235,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4109,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618115,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4110,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618116,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4111,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL618117,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4112,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619968,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4113,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619969,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4114,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619970,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4115,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619971,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4116,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619972,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4117,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619973,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4118,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619974,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4119,2107.0,7411,,1,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619975,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4120,2107.0,7411,,1,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619976,10116.0,U,BAO_0000251,Rattus norvegicus,,,,4121,,7411,,1,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619977,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4122,2107.0,7411,,1,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Autocuration,0,,22226
Microsomes,CHEMBL619978,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4123,2107.0,7411,,1,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Autocuration,0,,22226
Microsomes,CHEMBL619979,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4124,2107.0,7411,,1,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Autocuration,0,,22226
Microsomes,CHEMBL619980,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4125,2107.0,7411,,1,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Autocuration,0,,22226
Microsomes,CHEMBL619981,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4126,2107.0,7411,,1,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Autocuration,0,,22226
,CHEMBL619982,9606.0,N,BAO_0000219,Homo sapiens,,,,4127,,10797,,1,741.0,In vitro inhibition of 7226/S myeloma cancer cell line,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619983,9606.0,N,BAO_0000219,Homo sapiens,,,,4128,,6881,,1,993.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,BEL-7404 tumor cell line,Intermediate,1,,80698
,CHEMBL620031,9606.0,N,BAO_0000219,Homo sapiens,,,,4129,,3838,,1,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL620032,9606.0,N,BAO_0000219,Homo sapiens,,,,4130,,3838,,1,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL620033,10029.0,N,BAO_0000219,Cricetulus griseus,,,,4131,,12981,,1,505.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,V79,Expert,1,,81264
,CHEMBL620034,10029.0,N,BAO_0000219,Cricetulus griseus,,,,4132,,12981,,1,505.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,V79,Expert,1,,81264
,CHEMBL620035,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4133,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL618318,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4134,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL618319,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4135,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL618320,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4136,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL618321,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4137,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL883118,10116.0,N,BAO_0000219,Rattus norvegicus,,,,4138,,7653,,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,7800C1 cell line,Intermediate,1,,80635
,CHEMBL883795,9606.0,N,BAO_0000219,Homo sapiens,,,,4139,,17229,,1,391.0,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,786-0,Intermediate,1,,80640
,CHEMBL618322,9606.0,N,BAO_0000219,Homo sapiens,,,,4140,,12858,,1,391.0,Cytotoxic activity against 786-0 Renal cancer cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL618323,9606.0,N,BAO_0000219,Homo sapiens,,,,4141,,16325,,1,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL618324,9606.0,N,BAO_0000219,Homo sapiens,,,,4142,,16325,,1,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL618325,9606.0,N,BAO_0000219,Homo sapiens,,,,4143,,5858,,1,391.0,In vitro antitumor activity against human renal 786-0 cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL875416,9606.0,N,BAO_0000219,Homo sapiens,,,,4144,,16325,,1,391.0,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,786-0,Intermediate,1,,80640
,CHEMBL618326,9606.0,N,BAO_0000219,Homo sapiens,,,,4145,,14696,,1,391.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,786-0,Intermediate,1,,80640
,CHEMBL618327,9606.0,N,BAO_0000219,Homo sapiens,,,,4146,,3786,,1,391.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,786-0,Intermediate,1,,80640
,CHEMBL619215,9606.0,N,BAO_0000219,Homo sapiens,,,,4147,,14696,,1,391.0,inhibition of the growth of renal cancer(786-0) cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619216,9606.0,N,BAO_0000219,Homo sapiens,,,,4148,,14769,,1,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,786-0,Intermediate,1,,80640
,CHEMBL619217,9606.0,N,BAO_0000219,Homo sapiens,,,,4149,,15354,,1,391.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619218,9606.0,N,BAO_0000219,Homo sapiens,,,,4150,,14255,,1,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,786-0,Intermediate,1,,80640
,CHEMBL619219,9606.0,N,BAO_0000219,Homo sapiens,,,,4151,,14255,,1,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,786-0,Intermediate,1,,80640
,CHEMBL619220,9606.0,N,BAO_0000219,Homo sapiens,,,,4152,,14255,,1,391.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,786-0,Intermediate,1,,80640
,CHEMBL619221,9606.0,N,BAO_0000219,Homo sapiens,,,,4153,,14696,,1,391.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,786-0,Intermediate,1,,80640
,CHEMBL619222,9606.0,N,BAO_0000219,Homo sapiens,,,,4154,,12016,,1,391.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL857454,9606.0,N,BAO_0000219,Homo sapiens,,,,4155,,2597,,1,391.0,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619223,,H,BAO_0000219,,,,,4156,,12526,,1,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619224,,H,BAO_0000219,,,,,4157,,12526,,1,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619225,,H,BAO_0000019,,,,,4158,,14799,,1,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Autocuration,8,,12166
,CHEMBL619226,,H,BAO_0000219,,,,,4159,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,Expert,8,,12166
,CHEMBL619227,,H,BAO_0000219,,,,,4160,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,RBL-1,Expert,8,,12166
,CHEMBL619228,,H,BAO_0000357,,,,,4161,,12767,,1,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL619229,,H,BAO_0000219,,,,,4162,,10997,,1,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,Autocuration,8,,12166
,CHEMBL619230,,H,BAO_0000219,,,,,4163,,11388,,1,702.0,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619231,,H,BAO_0000357,,,,,4164,,167,,1,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,Autocuration,8,,12166
,CHEMBL619232,,H,BAO_0000357,,,,,4165,,167,,1,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,Autocuration,8,,12166
,CHEMBL619233,,H,BAO_0000357,,,,,4166,,13744,,1,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,Expert,8,,12166
,CHEMBL619234,,H,BAO_0000357,,,,,4167,,1630,,1,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL619235,,H,BAO_0000357,,,,,4168,,1630,,1,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,Autocuration,8,,12166
,CHEMBL619236,10116.0,D,BAO_0000019,Rattus norvegicus,,,,4169,,969,,1,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Expert,9,,12166
,CHEMBL619237,,H,BAO_0000219,,,,,4170,,13621,,1,702.0,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619238,,H,BAO_0000357,,,,,4171,,10089,,1,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,Autocuration,8,,12166
,CHEMBL619239,,H,BAO_0000357,,,,,4172,,10193,,1,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,Expert,8,,12166
,CHEMBL619240,,H,BAO_0000357,,,,,4173,,11966,,1,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,Autocuration,8,,12166
,CHEMBL875417,,H,BAO_0000019,,,,,4174,,12251,,1,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,Autocuration,8,,12166
,CHEMBL619241,,H,BAO_0000219,,,,,4175,,211,,1,702.0,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,RBL-1,Autocuration,8,,12166
,CHEMBL619242,,H,BAO_0000019,,,,,4176,,12251,,1,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,Expert,8,,12166
,CHEMBL883796,,H,BAO_0000219,,,,,4177,,12495,,1,702.0,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619243,,H,BAO_0000357,,,,,4178,,414,,1,,Tested for its inhibitory activity against 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL619244,,H,BAO_0000357,,,,,4179,,414,,1,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,Autocuration,8,,12166
,CHEMBL619245,,H,BAO_0000019,,,,,4180,,10325,,1,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,Expert,8,,12166
,CHEMBL619246,,H,BAO_0000019,,,,,4181,,11966,,1,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,Expert,8,,12166
,CHEMBL619984,,H,BAO_0000219,,,,,4182,,165,,1,702.0,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,Expert,8,,12166
,CHEMBL619985,,H,BAO_0000219,,,,,4183,,165,,1,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619986,,H,BAO_0000219,,,,,4184,,165,,1,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619987,,H,BAO_0000219,,,,,4185,,165,,1,702.0,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,Expert,8,,12166
,CHEMBL619988,,H,BAO_0000218,,,,,4186,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,Autocuration,8,,12166
,CHEMBL619989,,H,BAO_0000219,,,,,4187,,11311,,1,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619990,,H,BAO_0000219,,,,,4188,,11311,,1,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL619991,,H,BAO_0000219,,,,,4189,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,12166
,CHEMBL619992,,H,BAO_0000219,,,,,4190,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,Autocuration,8,,12166
,CHEMBL619993,,H,BAO_0000218,,,,,4191,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,Autocuration,8,,12166
,CHEMBL619994,,H,BAO_0000219,,,,,4192,,11311,,1,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,RBL-2H3,Autocuration,8,,12166
,CHEMBL619995,,H,BAO_0000219,,,,,4193,,11311,,1,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,RBL-2H3,Autocuration,8,,12166
,CHEMBL619996,,H,BAO_0000019,,,,,4194,,11311,,1,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,Autocuration,8,,12166
,CHEMBL619997,,H,BAO_0000019,,,,,4195,,11732,,1,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL619998,,H,BAO_0000019,,,,,4196,,11732,,1,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,Expert,8,,12166
,CHEMBL619999,,H,BAO_0000019,,,,,4197,,11087,,1,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,Expert,8,,12166
,CHEMBL620000,,H,BAO_0000019,,,,,4198,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,Autocuration,8,,12166
,CHEMBL620001,,H,BAO_0000219,,,,,4199,,11087,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620002,10116.0,D,BAO_0000357,Rattus norvegicus,,,,4200,,11087,,1,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Expert,9,,12166
,CHEMBL620003,,H,BAO_0000219,,,,,4201,,496,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620004,,H,BAO_0000219,,,,,4202,,13986,,1,702.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,RBL-1,Expert,8,,12166
,CHEMBL874063,,H,BAO_0000357,,,,,4203,,11520,,1,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL620005,,H,BAO_0000219,,,,,4204,,10293,,1,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620006,,H,BAO_0000219,,,,,4205,,303,,1,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620007,,H,BAO_0000219,,,,,4206,,303,,1,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620008,,H,BAO_0000219,,,,,4207,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620009,10116.0,D,BAO_0000219,Rattus norvegicus,,,,4208,,9247,,1,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,RBL-1,Expert,9,,12166
,CHEMBL620010,,H,BAO_0000219,,,,,4209,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620011,,H,BAO_0000219,,,,,4210,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620677,,H,BAO_0000219,,,,,4211,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620678,,H,BAO_0000219,,,,,4212,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620679,,H,BAO_0000219,,,,,4213,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620680,,H,BAO_0000219,,,,,4214,,9247,,1,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620838,10116.0,D,BAO_0000357,Rattus norvegicus,,,,4215,,11481,,1,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Expert,9,,12166
,CHEMBL620839,,H,BAO_0000357,,,,,4216,,105,,1,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,Autocuration,8,,12166
,CHEMBL620840,,H,BAO_0000357,,,,,4217,,9029,,1,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,Expert,8,,12166
,CHEMBL620841,,H,BAO_0000219,,,,,4218,,1175,,1,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,RBL-1,Expert,8,,12166
,CHEMBL620842,,H,BAO_0000219,,,,,4219,,12118,,1,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620843,,H,BAO_0000219,,,,,4220,,12118,,1,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620844,,H,BAO_0000219,,,,,4221,,12118,,1,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620845,,H,BAO_0000219,,,,,4222,,9225,,1,702.0,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620846,,H,BAO_0000019,,,,,4223,,9401,,1,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,Autocuration,8,,12166
,CHEMBL873951,,H,BAO_0000357,,,,,4224,,137,,1,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,Autocuration,8,,12166
,CHEMBL620847,,H,BAO_0000357,,,,,4225,,137,,1,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,Autocuration,8,,12166
,CHEMBL620848,,H,BAO_0000219,,,,,4226,,4717,,1,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620849,,H,BAO_0000219,,,,,4227,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620850,,H,BAO_0000219,,,,,4228,,10501,,1,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620851,,H,BAO_0000219,,,,,4229,,10501,,1,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620852,,H,BAO_0000219,,,,,4230,,10501,,1,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,RBL-1,Autocuration,8,,12166
,CHEMBL875098,,H,BAO_0000219,,,,,4231,,12526,,1,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620853,10116.0,D,BAO_0000219,Rattus norvegicus,,,,4232,,14799,,1,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,RBL-1,Expert,9,,12166
,CHEMBL620854,,H,BAO_0000019,,,,,4233,,14799,,1,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,Autocuration,8,,12166
,CHEMBL620855,,H,BAO_0000219,,,,,4234,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL839884,,H,BAO_0000219,,,,,4235,,3595,,1,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,RBL-1,Expert,8,,12166
,CHEMBL620856,,H,BAO_0000219,,,,,4236,,12526,,1,702.0,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620857,,H,BAO_0000219,,,,,4237,,12526,,1,702.0,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620858,,H,BAO_0000019,,,,,4238,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,Autocuration,8,,12166
,CHEMBL620859,,H,BAO_0000019,,,,,4239,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,Autocuration,8,,12166
,CHEMBL620860,,H,BAO_0000019,,,,,4240,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,Autocuration,8,,12166
,CHEMBL620861,,H,BAO_0000019,,,,,4241,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,Autocuration,8,,12166
,CHEMBL620862,,H,BAO_0000357,,,,,4242,,9138,,1,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,Expert,8,,12166
,CHEMBL620863,,H,BAO_0000357,,,,,4243,,9138,,1,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,Autocuration,8,,12166
,CHEMBL620864,,H,BAO_0000019,,,,,4244,,11966,,1,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,Autocuration,8,,12166
,CHEMBL620865,,H,BAO_0000219,,,,,4245,,165,,1,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620866,,H,BAO_0000219,,,,,4246,,165,,1,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620867,,H,BAO_0000219,,,,,4247,,11311,,1,663.0,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,RBL-2H3,Autocuration,8,,12166
,CHEMBL620868,,H,BAO_0000219,,,,,4248,,11311,,1,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,RBL-2H3,Autocuration,8,,12166
,CHEMBL620869,,H,BAO_0000219,,,,,4249,,11311,,1,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,RBL-2H3,Autocuration,8,,12166
,CHEMBL873952,,H,BAO_0000019,,,,,4250,,11311,,1,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,Autocuration,8,,12166
,CHEMBL875099,,H,BAO_0000357,,,,,4251,,11311,,1,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL620870,,H,BAO_0000219,,,,,4252,,11311,,1,663.0,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,RBL-2H3,Autocuration,8,,12166
,CHEMBL618261,,H,BAO_0000019,,,,,4253,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,Autocuration,8,,12166
,CHEMBL618262,,H,BAO_0000019,,,,,4254,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,Autocuration,8,,12166
,CHEMBL619428,,H,BAO_0000019,,,,,4255,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,Autocuration,8,,12166
,CHEMBL619429,,H,BAO_0000019,,,,,4256,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,Autocuration,8,,12166
,CHEMBL619430,,H,BAO_0000019,,,,,4257,,11087,,1,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,Autocuration,8,,12166
,CHEMBL620017,,H,BAO_0000219,,,,,4258,,496,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620018,,H,BAO_0000219,,,,,4259,,496,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL620019,,H,BAO_0000219,,,,,4260,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620020,,H,BAO_0000219,,,,,4261,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620021,,H,BAO_0000219,,,,,4262,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620022,,H,BAO_0000219,,,,,4263,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620023,,H,BAO_0000219,,,,,4264,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620024,,H,BAO_0000219,,,,,4265,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620025,,H,BAO_0000219,,,,,4266,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620026,,H,BAO_0000219,,,,,4267,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620027,,H,BAO_0000219,,,,,4268,,13986,,1,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,RBL-1,Autocuration,8,,12166
,CHEMBL620028,10116.0,D,BAO_0000019,Rattus norvegicus,,,,4269,,13986,,1,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Expert,9,,12166
,CHEMBL620029,,H,BAO_0000357,,,,,4270,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,Autocuration,8,,12166
,CHEMBL620030,,H,BAO_0000357,,,,,4271,,9295,,1,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,Autocuration,8,,12166
,CHEMBL875415,,H,BAO_0000219,,,,,4272,,4717,,1,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618256,,H,BAO_0000219,,,,,4273,,4717,,1,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618257,,H,BAO_0000219,,,,,4274,,11854,,1,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618258,,H,BAO_0000219,,,,,4275,,11854,,1,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618259,,H,BAO_0000219,,,,,4276,,11854,,1,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618260,,H,BAO_0000019,,,,,4277,,10193,,1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,Autocuration,8,,12166
,CHEMBL618215,,H,BAO_0000219,,,,,4278,,9295,,1,702.0,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618390,,H,BAO_0000219,,,,,4279,,9295,,1,702.0,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618391,,H,BAO_0000219,,,,,4280,,9295,,1,702.0,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618392,,H,BAO_0000219,,,,,4281,,9295,,1,702.0,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618393,,H,BAO_0000219,,,,,4282,,165,,1,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618394,,H,BAO_0000219,,,,,4283,,11311,,1,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,Autocuration,8,,12166
,CHEMBL618395,9606.0,H,BAO_0000219,Homo sapiens,,,,4284,,10489,,1,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,RBL-1,Expert,8,,12166
,CHEMBL618396,10116.0,D,BAO_0000219,Rattus norvegicus,,,,4285,,10489,,1,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,RBL-1,Expert,9,,12166
,CHEMBL858253,10116.0,D,BAO_0000219,Rattus norvegicus,,,,4286,,10489,,1,702.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,RBL-1,Expert,9,,12166
,CHEMBL618397,10116.0,D,BAO_0000019,Rattus norvegicus,,,,4287,,14799,,1,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Autocuration,9,,12166
,CHEMBL618398,3847.0,H,BAO_0000357,Glycine max,,,,4288,,9295,,1,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Autocuration,8,,12054
,CHEMBL618399,,U,BAO_0000019,,,,,4289,,16811,,1,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,Autocuration,0,,22226
,CHEMBL618400,,H,BAO_0000357,,,,,4290,,168,,1,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,Expert,8,,55
,CHEMBL618401,,H,BAO_0000357,,,,,4291,,6309,,1,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,Autocuration,8,,55
,CHEMBL618402,,H,BAO_0000357,,,,,4292,,6309,,1,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,Autocuration,8,,55
,CHEMBL876400,,H,BAO_0000219,,,,,4293,,3092,,1,702.0,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,RBL-1,Autocuration,8,,55
,CHEMBL618403,,H,BAO_0000357,,,,,4294,,168,,1,,Inhibitory activity against 5-lipoxygenase.,B,,,Expert,8,,55
,CHEMBL618404,,H,BAO_0000357,,,,,4295,,168,,1,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,Autocuration,8,,55
,CHEMBL618405,,H,BAO_0000357,,,,,4296,,168,,1,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,Autocuration,8,,55
,CHEMBL618406,,H,BAO_0000357,,,,,4297,,168,,1,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,Autocuration,8,,55
,CHEMBL618407,,H,BAO_0000019,,,,,4298,,12338,,1,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,Expert,8,,55
,CHEMBL618408,,H,BAO_0000357,,,,,4299,,4501,,1,,Tested for the inhibitory activity against 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618409,,H,BAO_0000357,,,,,4300,,1132,,1,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,Autocuration,8,,55
,CHEMBL618410,,H,BAO_0000357,,,,,4301,,2117,,1,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,Autocuration,8,,55
,CHEMBL618411,,H,BAO_0000357,,,,,4302,,168,,1,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,Autocuration,8,,55
,CHEMBL618412,,H,BAO_0000357,,,,,4303,,168,,1,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,Autocuration,8,,55
,CHEMBL618413,,H,BAO_0000219,,,,,4304,,13575,,1,702.0,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,RBL-1,Autocuration,8,,12166
,CHEMBL618414,,H,BAO_0000357,,,,,4305,,11089,,1,,,B,,,Autocuration,8,,12166
,CHEMBL618415,,H,BAO_0000357,,,,,4306,,216,,1,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,Autocuration,8,,10102
,CHEMBL618416,,H,BAO_0000019,,,,,4307,,13165,,1,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,Autocuration,8,,10102
,CHEMBL876401,,H,BAO_0000357,,,,,4308,,3278,,1,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,Autocuration,8,,10102
,CHEMBL618417,,H,BAO_0000357,,,,,4309,,3278,,1,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,Expert,8,,10102
,CHEMBL618418,,H,BAO_0000357,,,,,4310,,11966,,1,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,Autocuration,8,,10102
,CHEMBL618419,,H,BAO_0000357,,,,,4311,,175,,1,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,Autocuration,8,,10102
,CHEMBL618420,,H,BAO_0000357,,,,,4312,,175,,1,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,Autocuration,8,,10102
,CHEMBL618421,,H,BAO_0000357,,,,,4313,,13449,,1,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,Autocuration,8,,10102
,CHEMBL618422,,H,BAO_0000019,,,,,4314,,12014,,1,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,Autocuration,8,,11238
,CHEMBL618423,,H,BAO_0000019,,,,,4315,,12014,,1,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,Autocuration,8,,11238
,CHEMBL618424,,H,BAO_0000019,,,,,4316,,12014,,1,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,Autocuration,8,,11238
,CHEMBL618425,,S,BAO_0000220,,,,,4317,,99,,1,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,Intermediate,2,,100284
,CHEMBL618426,9606.0,U,BAO_0000019,Homo sapiens,,,,4318,,4349,,1,,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Autocuration,0,,22226
,CHEMBL618427,9606.0,N,BAO_0000219,Homo sapiens,,,,4319,,4071,,1,390.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,Panel (56 tumour cell lines),Expert,1,,80623
,CHEMBL618428,9606.0,N,BAO_0000219,Homo sapiens,,,,4320,,17589,,1,345.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,5637,Expert,1,,80008
,CHEMBL618429,9606.0,N,BAO_0000219,Homo sapiens,,,,4321,,15002,,1,345.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,5637,Intermediate,1,,80008
,CHEMBL618430,9606.0,N,BAO_0000219,Homo sapiens,,,,4322,,13958,,1,345.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,5637,Intermediate,1,,80008
,CHEMBL618431,9606.0,N,BAO_0000219,Homo sapiens,,,,4323,,17589,,1,345.0,Growth inhibition against human 5637 cell lines,F,,5637,Expert,1,,80008
,CHEMBL883799,9606.0,N,BAO_0000219,Homo sapiens,,,,4324,,16748,,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells.,F,,5637,Expert,1,,80008
,CHEMBL618432,9606.0,N,BAO_0000219,Homo sapiens,,,,4325,,16747,,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,5637,Intermediate,1,,80008
,CHEMBL618433,9606.0,N,BAO_0000219,Homo sapiens,,,,4326,,16747,,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,5637,Intermediate,1,,80008
,CHEMBL618434,9913.0,D,BAO_0000357,Bos taurus,,,,4327,,15285,,1,,In vitro inhibition of bovine trypsin(Trp).,B,,,Expert,9,,10443
,CHEMBL618435,9527.0,H,BAO_0000219,Cercopithecidae,,,,4328,,3726,,1,407.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,CV-1,Expert,8,,240
,CHEMBL876402,,H,BAO_0000357,,,,,4329,,5033,,1,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,Autocuration,8,,10577
,CHEMBL618436,,H,BAO_0000019,,,,,4330,,11756,,1,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,Autocuration,6,,104698
,CHEMBL618437,,U,BAO_0000218,,,,,4331,,11953,,1,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,Autocuration,0,,22226
,CHEMBL618438,10141.0,D,BAO_0000357,Cavia porcellus,,,,4332,,5033,,1,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Intermediate,9,,20033
Microsomes,CHEMBL883800,10116.0,H,BAO_0000251,Rattus norvegicus,,,,4333,,11347,,1,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Expert,8,,17045
Microsomes,CHEMBL618439,10116.0,H,BAO_0000251,Rattus norvegicus,,,,4334,,11347,,1,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Expert,8,,17045
,CHEMBL618440,,U,BAO_0000019,,,,,4335,,1229,,1,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL618441,,U,BAO_0000019,,,,,4336,,1229,,1,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL618442,5691.0,H,BAO_0000019,Trypanosoma brucei,,,,4337,,17588,,1,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Expert,8,,11938
,CHEMBL618443,5691.0,H,BAO_0000019,Trypanosoma brucei,,,,4338,,17588,,1,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Autocuration,8,,11938
,CHEMBL619158,9940.0,H,BAO_0000019,Ovis aries,,,,4339,,17588,,1,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Expert,8,,11938
,CHEMBL620974,9940.0,H,BAO_0000019,Ovis aries,,,,4340,,17588,,1,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Autocuration,8,,11938
,CHEMBL620975,,H,BAO_0000357,,,,,4341,,16485,,1,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,Autocuration,8,,11938
,CHEMBL620976,9606.0,U,BAO_0000019,Homo sapiens,,,,4342,,4337,,1,,Average inhibitory concentration against 60 human cell lines was reported,F,,,Intermediate,0,,22226
,CHEMBL620977,9606.0,U,BAO_0000019,Homo sapiens,,,,4343,,4112,,1,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Expert,0,,22226
,CHEMBL620978,9606.0,N,BAO_0000219,Homo sapiens,,,,4344,,16160,,1,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,Panel NCI-60 (60 carcinoma cell lines),Intermediate,1,,80315
,CHEMBL620979,9606.0,N,BAO_0000219,Homo sapiens,,,,4345,,16160,,1,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,Panel NCI-60 (60 carcinoma cell lines),Intermediate,1,,80315
,CHEMBL620980,,N,BAO_0000219,,,,,4346,,17376,,1,542.0,In vitro mean growth inhibitory activity against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),Expert,1,,80315
,CHEMBL620981,,N,BAO_0000219,,,,,4347,,17376,,1,542.0,In vitro mean growth lethal concentration against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),Expert,1,,80315
,CHEMBL620982,,N,BAO_0000219,,,,,4348,,17376,,1,542.0,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),Expert,1,,80315
,CHEMBL620983,,N,BAO_0000219,,,,,4349,,17376,,1,542.0,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),Expert,1,,80315
,CHEMBL620984,,H,BAO_0000019,,,,,4350,,3241,,1,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,Autocuration,4,,104775
,CHEMBL620985,,H,BAO_0000019,,,,,4351,,3241,,1,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,Autocuration,4,,104775
,CHEMBL620986,,H,BAO_0000357,,,,,4352,,3725,,1,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,Expert,8,,275
,CHEMBL620987,5833.0,N,BAO_0000218,Plasmodium falciparum,,,,4353,,10805,,1,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Expert,1,,50425
,CHEMBL620988,5833.0,N,BAO_0000218,Plasmodium falciparum,,,,4354,,10805,,1,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Expert,1,,50425
,CHEMBL620989,5833.0,N,BAO_0000218,Plasmodium falciparum,,,,4355,,10805,,1,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Expert,1,,50425
,CHEMBL620990,5833.0,N,BAO_0000218,Plasmodium falciparum,,,,4356,,10805,,1,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Expert,1,,50425
,CHEMBL620991,5833.0,N,BAO_0000218,Plasmodium falciparum,,,,4357,,10805,,1,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Intermediate,1,,50425
,CHEMBL620992,10090.0,N,BAO_0000218,Mus musculus,,,,4358,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL620993,10090.0,N,BAO_0000218,Mus musculus,,,,4359,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL620994,10090.0,N,BAO_0000218,Mus musculus,,,,4360,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL620995,10090.0,N,BAO_0000218,Mus musculus,,,,4361,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL620996,10090.0,N,BAO_0000218,Mus musculus,,,,4362,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL875581,10090.0,N,BAO_0000218,Mus musculus,,,,4363,,10144,,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,6C3HED,Intermediate,1,,80628
,CHEMBL620997,10090.0,U,BAO_0000218,Mus musculus,,,,4364,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL620998,10090.0,U,BAO_0000218,Mus musculus,,,,4365,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL620999,10090.0,U,BAO_0000218,Mus musculus,,,,4366,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Autocuration,0,,22224
,CHEMBL621000,10090.0,U,BAO_0000218,Mus musculus,,,,4367,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL621001,10090.0,U,BAO_0000218,Mus musculus,,,,4368,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL621002,10090.0,U,BAO_0000218,Mus musculus,,,,4369,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL621003,10090.0,U,BAO_0000218,Mus musculus,,,,4370,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL621004,10090.0,U,BAO_0000218,Mus musculus,,,,4371,,10685,,1,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Autocuration,0,,22224
,CHEMBL621005,10090.0,U,BAO_0000218,Mus musculus,,,,4372,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Autocuration,0,,22224
,CHEMBL621006,10090.0,U,BAO_0000218,Mus musculus,,,,4373,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Autocuration,0,,22224
,CHEMBL621007,10090.0,U,BAO_0000218,Mus musculus,,,,4374,,10685,,1,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL621008,10090.0,U,BAO_0000218,Mus musculus,,,,4375,,10144,,1,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Autocuration,0,,22224
,CHEMBL621009,10090.0,U,BAO_0000218,Mus musculus,,,,4376,,10144,,1,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Autocuration,0,,22224
,CHEMBL857705,10090.0,U,BAO_0000218,Mus musculus,,,,4377,,10144,,1,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Autocuration,0,,22224
,CHEMBL619828,10090.0,U,BAO_0000218,Mus musculus,,,,4378,,10144,,1,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Autocuration,0,,22224
,CHEMBL619829,10090.0,U,BAO_0000218,Mus musculus,,,,4379,,10685,,1,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Autocuration,0,,22224
,CHEMBL619830,10090.0,U,BAO_0000218,Mus musculus,,,,4380,,10685,,1,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Autocuration,0,,22224
,CHEMBL619831,10090.0,U,BAO_0000218,Mus musculus,,,,4381,,10685,,1,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Autocuration,0,,22224
,CHEMBL619832,10090.0,U,BAO_0000218,Mus musculus,,,,4382,,10685,,1,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Autocuration,0,,22224
,CHEMBL619833,10090.0,U,BAO_0000218,Mus musculus,,,,4383,,10685,,1,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Autocuration,0,,22224
,CHEMBL619834,10090.0,U,BAO_0000218,Mus musculus,,,,4384,,10685,,1,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Autocuration,0,,22224
,CHEMBL619835,10090.0,U,BAO_0000218,Mus musculus,,,,4385,,10685,,1,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Autocuration,0,,22224
,CHEMBL619836,10090.0,U,BAO_0000218,Mus musculus,,,,4386,,10685,,1,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Autocuration,0,,22224
,CHEMBL619837,10090.0,N,BAO_0000218,Mus musculus,,,,4387,,8831,,1,850.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,6C3HED,Intermediate,1,,80628
,CHEMBL619838,,U,BAO_0000218,,,,,4388,,11704,,1,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,Autocuration,0,,22224
,CHEMBL619839,10090.0,N,BAO_0000218,Mus musculus,,,,4389,,11704,,1,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Intermediate,1,,50594
,CHEMBL619840,10090.0,N,BAO_0000218,Mus musculus,,,,4390,,10685,,1,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,6C3HED,Intermediate,1,,80628
,CHEMBL619841,10090.0,N,BAO_0000218,Mus musculus,,,,4391,,10685,,1,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,6C3HED,Intermediate,1,,80628
,CHEMBL857704,10090.0,N,BAO_0000218,Mus musculus,,,,4392,,11368,,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,6C3HED,Expert,1,,80628
,CHEMBL619842,10090.0,N,BAO_0000218,Mus musculus,,,,4393,,11368,,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,6C3HED,Intermediate,1,,80628
,CHEMBL619843,10090.0,N,BAO_0000218,Mus musculus,,,,4394,,11368,,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,6C3HED,Expert,1,,80628
,CHEMBL619844,1280.0,U,BAO_0000019,Staphylococcus aureus,,,,4395,,17763,,1,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Autocuration,0,,22226
Microsomes,CHEMBL857855,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4396,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619845,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4397,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619846,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4398,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619847,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4399,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL619848,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4400,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620893,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4401,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620894,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4402,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620895,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4403,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620896,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4404,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620897,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4405,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620898,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4406,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Autocuration,0,,22226
Microsomes,CHEMBL620899,10116.0,U,BAO_0000251,Rattus norvegicus,,,Liver,4407,2107.0,7411,,1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Autocuration,0,,22226
,CHEMBL620900,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4408,1969.0,347,,1,,The apparent total plasma clearance in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620901,9527.0,U,BAO_0000218,Cercopithecidae,,,,4409,,3341,,1,,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620902,9527.0,U,BAO_0000218,Cercopithecidae,,,,4410,,17853,,1,,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Autocuration,0,,22224
,CHEMBL620903,9527.0,U,BAO_0000218,Cercopithecidae,,,,4411,,4514,,1,,Plasma clearance in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620904,9527.0,U,BAO_0000218,Cercopithecidae,,,,4412,,6062,,1,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620905,9527.0,U,BAO_0000218,Cercopithecidae,,,,4413,,6821,,1,,Plasma clearance of compound was determined in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620906,9527.0,U,BAO_0000218,Cercopithecidae,,,,4414,,6057,,1,,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL875420,9527.0,U,BAO_0000218,Cercopithecidae,,,,4415,,5145,,1,,Plasma clearance in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620907,9527.0,U,BAO_0000218,Cercopithecidae,,,,4416,,6641,,1,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Autocuration,0,,22224
,CHEMBL620908,9527.0,U,BAO_0000218,Cercopithecidae,,,,4417,,5472,,1,,Plasma clearance was evaluated in rhesus,A,In vivo,,Autocuration,0,,22224
,CHEMBL620909,9527.0,U,BAO_0000218,Cercopithecidae,,,,4418,,4257,,1,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL620910,9527.0,U,BAO_0000218,Cercopithecidae,,,,4419,,5546,,1,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620911,9527.0,U,BAO_0000218,Cercopithecidae,,,,4420,,5334,,1,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL620912,9527.0,U,BAO_0000218,Cercopithecidae,,,,4421,,5334,,1,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL620913,9527.0,U,BAO_0000218,Cercopithecidae,,,,4422,,17509,,1,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL620914,9527.0,U,BAO_0000218,Cercopithecidae,,,,4423,,6535,,1,,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Autocuration,0,,22224
,CHEMBL620915,9527.0,U,BAO_0000218,Cercopithecidae,,,,4424,,5668,,1,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Autocuration,0,,22224
,CHEMBL620916,9527.0,U,BAO_0000218,Cercopithecidae,,,,4425,,5922,,1,,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620917,9527.0,U,BAO_0000218,Cercopithecidae,,,,4426,,5922,,1,,Cmax in cynomolgus monkey by po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620918,9527.0,U,BAO_0000218,Cercopithecidae,,,,4427,,6078,,1,,Cmax value evaluated in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620919,9527.0,U,BAO_0000218,Cercopithecidae,,,,4428,,2661,,1,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620920,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4429,1969.0,3249,,1,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620921,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4430,1969.0,3249,,1,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620922,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4431,1969.0,5553,,1,,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL620923,9527.0,U,BAO_0000218,Cercopithecidae,,,,4432,,1916,,1,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620924,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4433,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620925,9527.0,U,BAO_0000218,Cercopithecidae,,,,4434,,4809,,1,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620926,9527.0,U,BAO_0000218,Cercopithecidae,,,,4435,,5355,,1,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620927,9527.0,U,BAO_0000218,Cercopithecidae,,,,4436,,5355,,1,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620928,9527.0,U,BAO_0000218,Cercopithecidae,,,,4437,,5355,,1,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620929,9527.0,U,BAO_0000218,Cercopithecidae,,,,4438,,5355,,1,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL620930,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4439,1969.0,6221,,1,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL620931,9527.0,U,BAO_0000218,Cercopithecidae,,,,4440,,167,,1,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Autocuration,0,,22224
,CHEMBL620932,9527.0,U,BAO_0000218,Cercopithecidae,,,,4441,,167,,1,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Autocuration,0,,22224
,CHEMBL620933,9443.0,U,BAO_0000218,monkey,,,,4442,,4257,,1,,Absolute bioavailability was evaluated in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620934,9443.0,U,BAO_0000218,monkey,,,,4443,,6221,,1,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL620935,9443.0,U,BAO_0000218,monkey,,,,4444,,17667,,1,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620936,9544.0,U,BAO_0000218,Macaca mulatta,,,,4445,,17267,,1,,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620937,38020.0,U,BAO_0000218,marmosets,,,,4446,,4256,,1,,Bioavailability determined after oral administration in marmoset,A,In vivo,,Autocuration,0,,22224
,CHEMBL620938,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4447,,4256,,1,,Oral bioavailability in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620939,9443.0,U,BAO_0000218,monkey,,,,4448,,17853,,1,,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,Autocuration,0,,22224
,CHEMBL620940,9443.0,U,BAO_0000218,monkey,,,,4449,,16365,,1,,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620941,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4450,,1916,,1,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620942,9544.0,U,BAO_0000218,Macaca mulatta,,,,4451,,5334,,1,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL620943,9544.0,U,BAO_0000218,Macaca mulatta,,,,4452,,5334,,1,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL620944,9443.0,U,BAO_0000218,monkey,,,,4453,,17592,,1,,Bioavailability of the compound was determined in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620945,9521.0,U,BAO_0000218,Saimiri sciureus,,,,4454,,1399,,1,,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620946,9443.0,U,BAO_0000218,monkey,,,,4455,,4809,,1,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620947,9443.0,U,BAO_0000218,monkey,,,,4456,,3341,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620948,9521.0,U,BAO_0000218,Saimiri sciureus,,,,4457,,64,,1,,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620949,9544.0,U,BAO_0000218,Macaca mulatta,,,,4458,,5005,,1,,Oral bioavailability in Rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620950,9544.0,U,BAO_0000218,Macaca mulatta,,,,4459,,5005,,1,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Autocuration,0,,22224
,CHEMBL620951,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4460,,5237,,1,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620952,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4461,,5237,,1,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Autocuration,0,,22224
,CHEMBL875421,9443.0,U,BAO_0000218,monkey,,,,4462,,5302,,1,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620953,9443.0,U,BAO_0000218,monkey,,,,4463,,17667,,1,,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL873491,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4464,,6161,,1,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL620954,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4465,,6161,,1,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL620955,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4466,1969.0,3854,,1,,Plasma half life determined,A,,,Intermediate,1,,50588
,CHEMBL618097,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4467,1969.0,993,,1,,Plasma half life in dog,A,,,Intermediate,1,,50588
,CHEMBL618268,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4468,1969.0,4514,,1,,Plasma half-life in Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL618269,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4469,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL618270,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4470,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL618271,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4471,,1466,,1,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL873493,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4472,,1466,,1,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621031,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4473,,5313,,1,,Tested for the half life period in dog,A,,,Intermediate,1,,50588
,CHEMBL621032,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4474,,5313,,1,,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Intermediate,1,,50588
,CHEMBL621033,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4475,,3880,,1,,The compound was tested for half life in dog,A,,,Intermediate,1,,50588
,CHEMBL621034,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4476,1969.0,3639,,1,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Intermediate,1,,50588
,CHEMBL621035,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4477,,3880,,1,,The half life was determined,A,,,Intermediate,1,,50588
,CHEMBL621036,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4478,1969.0,3918,,1,,The plasma half-life in dogs,A,,,Intermediate,1,,50588
,CHEMBL621037,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,4479,1969.0,16452,,1,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Intermediate,1,,50588
,CHEMBL619812,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4480,,17796,,1,,Half life in dog,A,,,Intermediate,1,,50588
,CHEMBL619813,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4481,,5983,,1,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Intermediate,1,,50588
,CHEMBL873335,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4482,,1466,,1,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619814,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,4483,,16456,,1,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619815,9669.0,N,BAO_0000218,Mustela putorius furo,,,,4484,,6113,,1,,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Expert,1,,50506
,CHEMBL619816,9669.0,N,BAO_0000218,Mustela putorius furo,,,,4485,,6113,,1,,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Expert,1,,50506
,CHEMBL619817,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4486,,17796,,1,,Bioavailability in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619818,9541.0,N,BAO_0000218,Macaca fascicularis,,,,4487,,17796,,1,,Volume of distribution in cynomolgus,A,In vivo,,Intermediate,1,,100710
,CHEMBL619819,10141.0,U,BAO_0000218,Cavia porcellus,,,Plasma,4488,1969.0,5308,,1,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Autocuration,0,,22224
,CHEMBL619820,10141.0,U,BAO_0000218,Cavia porcellus,,,,4489,,4877,,1,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL875419,10141.0,U,BAO_0000218,Cavia porcellus,,,,4490,,4876,,1,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Autocuration,0,,22224
,CHEMBL619821,10141.0,U,BAO_0000218,Cavia porcellus,,,Plasma,4491,1969.0,4878,,1,,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL619822,10141.0,U,BAO_0000218,Cavia porcellus,,,,4492,,5308,,1,,Bioavailability in guinea pig was tested,A,In vivo,,Autocuration,0,,22224
,CHEMBL619823,10141.0,U,BAO_0000218,Cavia porcellus,,,,4493,,4877,,1,,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL619824,10141.0,U,BAO_0000218,Cavia porcellus,,,,4494,,4876,,1,,Tested for the oral bioavailability of the compound,A,In vivo,,Autocuration,0,,22224
,CHEMBL619825,10141.0,U,BAO_0000218,Cavia porcellus,,,,4495,,4876,,1,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Autocuration,0,,22224
,CHEMBL619826,10141.0,U,BAO_0000218,Cavia porcellus,,,,4496,,5308,,1,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Autocuration,0,,22224
,CHEMBL619827,10141.0,U,BAO_0000218,Cavia porcellus,,,Lung,4497,2048.0,4877,,1,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL618167,10141.0,U,BAO_0000218,Cavia porcellus,,,,4498,,4878,,1,,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL618168,10141.0,U,BAO_0000019,Cavia porcellus,,,Blood,4499,178.0,5689,,1,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618169,10141.0,U,BAO_0000019,Cavia porcellus,,,Brain,4500,955.0,5689,,1,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618170,10141.0,U,BAO_0000019,Cavia porcellus,,,,4501,,5689,,1,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618171,10141.0,U,BAO_0000019,Cavia porcellus,,,Intestine,4502,160.0,5689,,1,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618172,10141.0,U,BAO_0000019,Cavia porcellus,,,Kidney,4503,2113.0,5689,,1,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618173,10141.0,U,BAO_0000019,Cavia porcellus,,,Liver,4504,2107.0,5689,,1,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL618174,10141.0,U,BAO_0000019,Cavia porcellus,,,,4505,,5689,,1,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL875408,10141.0,U,BAO_0000019,Cavia porcellus,,,Spleen,4506,2106.0,5689,,1,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Autocuration,0,,22224
,CHEMBL839827,10141.0,U,BAO_0000218,Cavia porcellus,,,,4507,,14465,,1,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL618175,10141.0,U,BAO_0000019,Cavia porcellus,,,,4508,,5689,,1,,Partition coefficient was measured as -log (counts per min ),A,,,Autocuration,0,,22224
,CHEMBL618176,10141.0,U,BAO_0000218,Cavia porcellus,,,,4509,,611,,1,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Autocuration,0,,22224
,CHEMBL618177,10141.0,U,BAO_0000218,Cavia porcellus,,,,4510,,611,,1,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Autocuration,0,,22224
,CHEMBL618178,10141.0,U,BAO_0000218,Cavia porcellus,,,,4511,,14465,,1,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL618179,10141.0,U,BAO_0000218,Cavia porcellus,,,,4512,,4876,,1,,"Tested for the half life period of the compound, intravenously",A,In vivo,,Autocuration,0,,22224
,CHEMBL873489,10141.0,U,BAO_0000019,Cavia porcellus,,,,4513,,5689,,1,,Half-life was measured,A,,,Autocuration,0,,22224
,CHEMBL618180,10141.0,U,BAO_0000019,Cavia porcellus,,,,4514,,7515,,1,,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Autocuration,0,,22224
,CHEMBL618181,10141.0,U,BAO_0000218,Cavia porcellus,,,,4515,,17667,,1,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL618182,10141.0,U,BAO_0000218,Cavia porcellus,,,,4516,,17667,,1,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL618183,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4517,,4727,,1,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL618184,10090.0,N,BAO_0000218,Mus musculus,,,,4518,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618185,10090.0,N,BAO_0000218,Mus musculus,,,,4519,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618186,10090.0,N,BAO_0000218,Mus musculus,,,,4520,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618187,10090.0,N,BAO_0000218,Mus musculus,,,,4521,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618188,10090.0,N,BAO_0000218,Mus musculus,,,,4522,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL875409,10090.0,N,BAO_0000218,Mus musculus,,,,4523,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618189,10090.0,N,BAO_0000218,Mus musculus,,,,4524,,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618190,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4525,178.0,3655,,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618191,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4526,178.0,3655,,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618192,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4527,178.0,3655,,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618193,10090.0,N,BAO_0000218,Mus musculus,,,Bone,4528,10000001.0,3655,,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618194,10090.0,N,BAO_0000218,Mus musculus,,,Bone,4529,10000001.0,3655,,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618195,10090.0,N,BAO_0000218,Mus musculus,,,Bone,4530,10000001.0,3655,,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618196,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4531,955.0,3655,,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618197,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4532,955.0,3655,,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618198,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4533,955.0,3655,,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618199,10090.0,N,BAO_0000218,Mus musculus,,,Heart,4534,948.0,3655,,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618200,10090.0,N,BAO_0000218,Mus musculus,,,Heart,4535,948.0,3655,,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618201,10090.0,N,BAO_0000218,Mus musculus,,,Heart,4536,948.0,3655,,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618202,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,4537,160.0,3655,,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618203,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,4538,160.0,3655,,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618204,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,4539,160.0,3655,,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618205,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4540,2113.0,3655,,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618206,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4541,2113.0,3655,,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618207,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4542,2113.0,3655,,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618208,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4543,2107.0,3655,,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618932,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4544,2107.0,3655,,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618933,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4545,2107.0,3655,,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618934,10090.0,N,BAO_0000218,Mus musculus,,,Lung,4546,2048.0,3655,,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618935,10090.0,N,BAO_0000218,Mus musculus,,,Lung,4547,2048.0,3655,,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618936,10090.0,N,BAO_0000218,Mus musculus,,,Lung,4548,2048.0,3655,,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618937,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,4549,2385.0,3655,,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618938,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,4550,2385.0,3655,,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619104,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,4551,2385.0,3655,,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619105,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,4552,2106.0,3655,,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619106,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,4553,2106.0,3655,,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619107,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,4554,2106.0,3655,,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL875410,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,4555,945.0,3655,,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619108,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,4556,945.0,3655,,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619109,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,4557,945.0,3655,,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619110,10090.0,N,BAO_0000218,Mus musculus,,,,4558,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Intermediate,1,,50594
,CHEMBL619111,10090.0,N,BAO_0000218,Mus musculus,,,,4559,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Intermediate,1,,50594
,CHEMBL619112,10090.0,N,BAO_0000218,Mus musculus,,,,4560,,16597,,1,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL619113,10090.0,N,BAO_0000218,Mus musculus,,,,4561,,16597,,1,,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL619114,10090.0,N,BAO_0000218,Mus musculus,,,,4562,,17764,,1,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL619115,10090.0,N,BAO_0000218,Mus musculus,,,,4563,,17764,,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL619116,9606.0,N,BAO_0000219,Homo sapiens,,,,4564,,3830,,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,A2780,Intermediate,1,,81034
,CHEMBL619117,9606.0,N,BAO_0000219,Homo sapiens,,,,4565,,3829,,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,A2780,Intermediate,1,,81034
,CHEMBL619118,9606.0,N,BAO_0000219,Homo sapiens,,,,4566,,2040,,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL619119,9606.0,N,BAO_0000219,Homo sapiens,,,,4567,,15684,,1,478.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619120,9606.0,N,BAO_0000219,Homo sapiens,,,,4568,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619121,9606.0,N,BAO_0000219,Homo sapiens,,,,4569,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619122,9606.0,N,BAO_0000219,Homo sapiens,,,,4570,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619123,9606.0,N,BAO_0000219,Homo sapiens,,,,4571,,15684,,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619124,9606.0,N,BAO_0000219,Homo sapiens,,,,4572,,15684,,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619125,9606.0,N,BAO_0000219,Homo sapiens,,,,4573,,2859,,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL875411,9606.0,N,BAO_0000219,Homo sapiens,,,,4574,,5618,,1,478.0,In vitro inhibitory activity against human tumor cell line A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL619126,9606.0,N,BAO_0000219,Homo sapiens,,,,4575,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619127,9606.0,N,BAO_0000219,Homo sapiens,,,,4576,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619128,9606.0,N,BAO_0000219,Homo sapiens,,,,4577,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619129,9606.0,N,BAO_0000219,Homo sapiens,,,,4578,,15684,,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619130,9606.0,N,BAO_0000219,Homo sapiens,,,,4579,,2113,,1,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,A2780,Intermediate,1,,81034
,CHEMBL619131,9606.0,N,BAO_0000219,Homo sapiens,,,,4580,,2113,,1,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL619132,9606.0,N,BAO_0000219,Homo sapiens,,,,4581,,16745,,1,478.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,A2780,Intermediate,1,,81034
,CHEMBL619133,9606.0,N,BAO_0000218,Homo sapiens,,,,4582,,16597,,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,Expert,1,,81034
,CHEMBL619134,9606.0,N,BAO_0000219,Homo sapiens,,,,4583,,15684,,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619135,9606.0,N,BAO_0000219,Homo sapiens,,,,4584,,15684,,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619136,9606.0,N,BAO_0000219,Homo sapiens,,,,4585,,2040,,1,478.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL619137,9606.0,N,BAO_0000219,Homo sapiens,,,,4586,,2040,,1,478.0,Relative resistance factor in A2780 cisplatin-resistant line,F,,A2780,Intermediate,1,,81034
,CHEMBL883713,9606.0,N,BAO_0000219,Homo sapiens,,,,4587,,16165,,1,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,A2780,Intermediate,1,,81034
,CHEMBL875412,9606.0,N,BAO_0000219,Homo sapiens,,,,4588,,16165,,1,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,A2780,Intermediate,1,,81034
,CHEMBL619138,9606.0,N,BAO_0000218,Homo sapiens,,,,4589,,16597,,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,Expert,1,,81034
,CHEMBL619262,9606.0,N,BAO_0000218,Homo sapiens,,,,4590,,16597,,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,Expert,1,,81034
,CHEMBL619139,9606.0,N,BAO_0000219,Homo sapiens,,,,4591,,3992,,1,478.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,A2780,Intermediate,1,,81034
,CHEMBL619140,9606.0,N,BAO_0000219,Homo sapiens,,,,4592,,10553,,1,478.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,A2780,Intermediate,1,,81034
,CHEMBL619141,9606.0,N,BAO_0000219,Homo sapiens,,,,4593,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,A2780,Intermediate,1,,81034
,CHEMBL619142,9606.0,N,BAO_0000219,Homo sapiens,,,,4594,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,A2780,Intermediate,1,,81034
,CHEMBL619143,9606.0,N,BAO_0000219,Homo sapiens,,,,4595,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL619144,9606.0,N,BAO_0000219,Homo sapiens,,,,4596,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,A2780,Intermediate,1,,81034
,CHEMBL619145,9606.0,N,BAO_0000219,Homo sapiens,,,,4597,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,A2780,Intermediate,1,,81034
,CHEMBL619146,9606.0,N,BAO_0000219,Homo sapiens,,,,4598,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,A2780,Intermediate,1,,81034
,CHEMBL619147,9606.0,N,BAO_0000219,Homo sapiens,,,,4599,,15569,,1,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,A2780,Intermediate,1,,81034
,CHEMBL619148,9606.0,N,BAO_0000219,Homo sapiens,,,,4600,,17420,,1,478.0,Antiproliferative effect of compound on A2780/DX cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL619149,9606.0,N,BAO_0000219,Homo sapiens,,,,4601,,17420,,1,478.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,A2780,Intermediate,1,,81034
,CHEMBL619150,9606.0,N,BAO_0000219,Homo sapiens,,,,4602,,15099,,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,A2780,Intermediate,1,,81034
,CHEMBL619151,9606.0,N,BAO_0000219,Homo sapiens,,,,4603,,15099,,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,A2780,Intermediate,1,,81034
,CHEMBL883794,9606.0,N,BAO_0000219,Homo sapiens,,,,4604,,17672,,1,478.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,A2780,Intermediate,1,,81034
,CHEMBL619152,9606.0,N,BAO_0000219,Homo sapiens,,,,4605,,17672,,1,478.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,A2780,Intermediate,1,,81034
,CHEMBL619153,9606.0,N,BAO_0000219,Homo sapiens,,,,4606,,17270,,1,478.0,In vitro cytotoxicity against A2780ADR cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL619154,9606.0,N,BAO_0000219,Homo sapiens,,,,4607,,17270,,1,478.0,In vitro cytotoxicity against A2780CIS cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL619155,9606.0,N,BAO_0000219,Homo sapiens,,,,4608,,5574,,1,478.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,A2780,Intermediate,1,,81034
,CHEMBL619156,9606.0,N,BAO_0000219,Homo sapiens,,,,4609,,2113,,1,478.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL619157,9606.0,N,BAO_0000219,Homo sapiens,,,,4610,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL619797,9606.0,N,BAO_0000219,Homo sapiens,,,,4611,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL619798,9544.0,U,BAO_0000218,Macaca mulatta,,,,4612,,17839,,1,,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Autocuration,0,,22224
,CHEMBL619799,9443.0,U,BAO_0000218,monkey,,,,4613,,6821,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619800,9443.0,U,BAO_0000218,monkey,,,,4614,,6078,,1,,Oral bioavailability evaluated in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619801,9443.0,U,BAO_0000218,monkey,,,,4615,,6535,,1,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,Autocuration,0,,22224
,CHEMBL619802,9544.0,U,BAO_0000218,Macaca mulatta,,,,4616,,4449,,1,,Oral bioavailability in Rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619803,9544.0,U,BAO_0000218,Macaca mulatta,,,,4617,,6057,,1,,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619965,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4618,,5922,,1,,Oral bioavailability in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619966,9443.0,U,BAO_0000218,monkey,,,,4619,,5940,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619967,9443.0,U,BAO_0000218,monkey,,,,4620,,6265,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620073,9443.0,U,BAO_0000218,monkey,,,,4621,,6265,,1,,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620074,9443.0,U,BAO_0000218,monkey,,,,4622,,6265,,1,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620075,9443.0,U,BAO_0000218,monkey,,,,4623,,5940,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620076,9443.0,U,BAO_0000218,monkey,,,,4624,,5940,,1,,Oral bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620077,9544.0,U,BAO_0000218,Macaca mulatta,,,,4625,,4514,,1,,Oral bioavailability in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620078,9544.0,U,BAO_0000218,Macaca mulatta,,,,4626,,5546,,1,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620079,9521.0,U,BAO_0000218,Saimiri sciureus,,,,4627,,5553,,1,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620080,9443.0,U,BAO_0000218,monkey,,,,4628,,6641,,1,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Autocuration,0,,22224
,CHEMBL620081,9544.0,U,BAO_0000218,Macaca mulatta,,,,4629,,5472,,1,,Oral bioavailability in Rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620082,9544.0,U,BAO_0000218,Macaca mulatta,,,,4630,,5668,,1,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Autocuration,0,,22224
,CHEMBL620083,9443.0,U,BAO_0000218,monkey,,,,4631,,5711,,1,,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,Autocuration,0,,22224
,CHEMBL620084,9544.0,U,BAO_0000218,Macaca mulatta,,,,4632,,5145,,1,,Bioavailability in Rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620085,9527.0,U,BAO_0000218,Cercopithecidae,,,,4633,,3443,,1,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL874595,9527.0,U,BAO_0000218,Cercopithecidae,,,,4634,,3443,,1,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL873352,9527.0,U,BAO_0000218,Cercopithecidae,,,,4635,,3249,,1,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620086,9527.0,U,BAO_0000218,Cercopithecidae,,,,4636,,3249,,1,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620087,9527.0,U,BAO_0000218,Cercopithecidae,,,,4637,,5355,,1,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL620088,9527.0,U,BAO_0000218,Cercopithecidae,,,,4638,,5355,,1,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620089,9527.0,U,BAO_0000218,Cercopithecidae,,,,4639,,5355,,1,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL620090,9527.0,U,BAO_0000218,Cercopithecidae,,,,4640,,4809,,1,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620091,9527.0,U,BAO_0000218,Cercopithecidae,,,,4641,,4809,,1,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Autocuration,0,,22224
Microsomes,CHEMBL620092,9527.0,U,BAO_0000251,Cercopithecidae,,,,4642,,14294,,1,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620093,9527.0,U,BAO_0000251,Cercopithecidae,,,,4643,,14294,,1,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620094,9527.0,U,BAO_0000251,Cercopithecidae,,,,4644,,14294,,1,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620095,9527.0,U,BAO_0000251,Cercopithecidae,,,,4645,,14294,,1,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Autocuration,0,,22224
,CHEMBL620096,9527.0,U,BAO_0000218,Cercopithecidae,,,,4646,,3443,,1,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Autocuration,0,,22224
,CHEMBL620097,9527.0,U,BAO_0000218,Cercopithecidae,,,,4647,,3443,,1,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Autocuration,0,,22224
,CHEMBL620098,9527.0,U,BAO_0000019,Cercopithecidae,,,,4648,,11271,,1,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Autocuration,0,,22224
,CHEMBL620099,9527.0,U,BAO_0000218,Cercopithecidae,,,,4649,,3443,,1,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL620100,9527.0,U,BAO_0000218,Cercopithecidae,,,,4650,,3443,,1,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL620101,9527.0,U,BAO_0000019,Cercopithecidae,,,,4651,,6821,,1,,Elimination Half-life of compound was determined in monkey,A,,,Autocuration,0,,22224
,CHEMBL620102,9527.0,U,BAO_0000019,Cercopithecidae,,,,4652,,17267,,1,,Half life of compound was determined in rhesus monkey,A,,,Autocuration,0,,22224
,CHEMBL620103,9527.0,U,BAO_0000366,Cercopithecidae,,,Plasma,4653,1969.0,5819,,1,,Half life in monkey plasma,A,,,Autocuration,0,,22224
,CHEMBL620104,9527.0,U,BAO_0000366,Cercopithecidae,,,Plasma,4654,1969.0,5819,,1,,Half life in monkey plasma; Not detected,A,,,Autocuration,0,,22224
,CHEMBL874596,9527.0,U,BAO_0000218,Cercopithecidae,,,,4655,,1916,,1,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL873490,9527.0,U,BAO_0000218,Cercopithecidae,,,,4656,,17509,,1,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL620105,9527.0,U,BAO_0000019,Cercopithecidae,,,,4657,,1399,,1,,Terminal half life of the compound.,A,,,Autocuration,0,,22224
,CHEMBL620780,9527.0,U,BAO_0000218,Cercopithecidae,,,,4658,,1916,,1,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620781,9527.0,U,BAO_0000218,Cercopithecidae,,,,4659,,4809,,1,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620956,9527.0,U,BAO_0000218,Cercopithecidae,,,,4660,,5546,,1,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Autocuration,0,,22224
,CHEMBL620957,9527.0,U,BAO_0000218,Cercopithecidae,,,Urine,4661,1088.0,3443,,1,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL620958,9527.0,U,BAO_0000218,Cercopithecidae,,,Urine,4662,1088.0,3443,,1,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL620959,9527.0,U,BAO_0000218,Cercopithecidae,,,,4663,,4257,,1,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL620960,9527.0,U,BAO_0000218,Cercopithecidae,,,,4664,,6221,,1,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL620961,9527.0,U,BAO_0000218,Cercopithecidae,,,,4665,,5472,,1,,Volume of distribution was evaluated in rhesus,A,In vivo,,Autocuration,0,,22224
,CHEMBL620962,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4666,,4727,,1,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620963,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4667,,4727,,1,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620964,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4668,,4727,,1,,Bioavailability in hamster was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL620965,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4669,,4727,,1,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620966,10029.0,U,BAO_0000218,Cricetulus griseus,,,,4670,,4727,,1,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620967,10029.0,U,BAO_0000221,Cricetulus griseus,,,Blood,4671,178.0,4727,,1,,Half life of compound was determined in hamster blood,A,,,Autocuration,0,,22224
,CHEMBL620968,9823.0,U,BAO_0000019,Sus scrofa,,,,4672,,1452,,1,,Michaelis-Menten constant of the compound.,A,,,Autocuration,0,,22224
,CHEMBL874597,9823.0,U,BAO_0000019,Sus scrofa,,,,4673,,1452,,1,,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Autocuration,0,,22224
,CHEMBL620969,9823.0,U,BAO_0000019,Sus scrofa,,,,4674,,1452,,1,,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Autocuration,0,,22224
,CHEMBL620970,9823.0,U,BAO_0000019,Sus scrofa,,,,4675,,1452,,1,,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Autocuration,0,,22224
,CHEMBL620971,9606.0,D,BAO_0000357,Homo sapiens,,,,4676,,11706,,1,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Expert,9,,235
,CHEMBL620972,9606.0,U,BAO_0000218,Homo sapiens,,,,4677,,1916,,1,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Autocuration,0,,22224
,CHEMBL620973,9606.0,U,BAO_0000019,Homo sapiens,,,,4678,,17791,,1,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Autocuration,0,,22224
,CHEMBL618243,9606.0,U,BAO_0000019,Homo sapiens,,,,4679,,7766,,1,,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Autocuration,0,,22224
,CHEMBL618244,9606.0,U,BAO_0000019,Homo sapiens,,,,4680,,6567,,1,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Autocuration,0,,22224
,CHEMBL618245,9606.0,U,BAO_0000019,Homo sapiens,,,,4681,,6567,,1,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Autocuration,0,,22224
,CHEMBL618246,9606.0,U,BAO_0000019,Homo sapiens,,,,4682,,6567,,1,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Autocuration,0,,22224
,CHEMBL618247,9606.0,U,BAO_0000019,Homo sapiens,,,,4683,,6567,,1,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Autocuration,0,,22224
,CHEMBL618248,9606.0,U,BAO_0000218,Homo sapiens,,,,4684,,17791,,1,,Compound was evaluated for oral bioavailability in human,A,,,Autocuration,0,,22224
,CHEMBL618249,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4685,1088.0,7766,,1,,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Autocuration,0,,22224
,CHEMBL618250,9606.0,U,BAO_0000019,Homo sapiens,,,,4686,,6852,,1,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Autocuration,0,,22224
,CHEMBL874598,9606.0,U,BAO_0000019,Homo sapiens,,,,4687,,6852,,1,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Autocuration,0,,22224
,CHEMBL618251,9606.0,U,BAO_0000019,Homo sapiens,,,,4688,,6852,,1,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Autocuration,0,,22224
,CHEMBL618252,9606.0,U,BAO_0000019,Homo sapiens,,,,4689,,6852,,1,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Autocuration,0,,22224
,CHEMBL618253,9606.0,U,BAO_0000019,Homo sapiens,,,,4690,,6852,,1,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Autocuration,0,,22224
,CHEMBL618254,9606.0,U,BAO_0000019,Homo sapiens,,,,4691,,6852,,1,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Autocuration,0,,22224
,CHEMBL618255,9606.0,U,BAO_0000019,Homo sapiens,,,,4692,,6852,,1,,Percent of compound in healthy individuals (Group D),A,,,Autocuration,0,,22224
Microsomes,CHEMBL618983,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4693,2107.0,4397,,1,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Autocuration,0,,22224
,CHEMBL618984,9606.0,U,BAO_0000019,Homo sapiens,,,,4694,,17409,,1,,Binding towards human plasma protein at 10 uM,A,,,Autocuration,0,,22224
,CHEMBL618985,9606.0,U,BAO_0000019,Homo sapiens,,,,4695,,17409,,1,,Binding towards human plasma protein at 100 uM,A,,,Autocuration,0,,22224
,CHEMBL618986,9606.0,U,BAO_0000019,Homo sapiens,,,,4696,,17176,,1,,Human plasma protein binding activity was determined,A,,,Autocuration,0,,22224
,CHEMBL618987,9606.0,U,BAO_0000019,Homo sapiens,,,,4697,,15444,,1,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Autocuration,0,,22224
,CHEMBL618988,9606.0,U,BAO_0000019,Homo sapiens,,,,4698,,17267,,1,,Percent binding of compound towards human plasma protein was determined,A,,,Autocuration,0,,22224
Microsomes,CHEMBL618989,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4699,2107.0,5944,,1,,Plasma clearance in human liver microsomes,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618990,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4700,2107.0,5668,,1,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618991,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4701,2107.0,5669,,1,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL876725,9606.0,U,BAO_0000251,Homo sapiens,,,,4702,,5041,,1,,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618992,9606.0,U,BAO_0000251,Homo sapiens,,,,4703,,5041,,1,,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618993,9606.0,U,BAO_0000251,Homo sapiens,,,,4704,,5041,,1,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618994,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4705,2107.0,5676,,1,,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618995,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4706,2107.0,5944,,1,,Plasma clearance in human liver microsomes,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618996,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4707,2107.0,17538,,1,,In vitro clearance in human liver microsomes,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618997,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4708,2107.0,6331,,1,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618998,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4709,2107.0,5948,,1,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Autocuration,0,,22224
,CHEMBL618999,9606.0,U,BAO_0000218,Homo sapiens,,,,4710,,5965,,1,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Autocuration,0,,22224
,CHEMBL620223,9606.0,U,BAO_0000218,Homo sapiens,,,,4711,,1916,,1,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL620224,9606.0,U,BAO_0000218,Homo sapiens,,,,4712,,5965,,1,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Autocuration,0,,22224
,CHEMBL620225,9606.0,U,BAO_0000019,Homo sapiens,,,,4713,,1299,,1,,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Autocuration,0,,22224
,CHEMBL620226,9606.0,U,BAO_0000019,Homo sapiens,,,,4714,,1299,,1,,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Autocuration,0,,22224
,CHEMBL620227,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4715,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL876726,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4716,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL620228,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4717,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL620229,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4718,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL620230,10090.0,N,BAO_0000218,Mus musculus,,,,4719,,17764,,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620231,10090.0,N,BAO_0000218,Mus musculus,,,,4720,,17764,,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620232,10090.0,N,BAO_0000218,Mus musculus,,,,4721,,17764,,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620233,10090.0,N,BAO_0000218,Mus musculus,,,,4722,,17764,,1,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620234,10090.0,N,BAO_0000218,Mus musculus,,,,4723,,14294,,1,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Intermediate,1,,50594
,CHEMBL620235,10090.0,N,BAO_0000218,Mus musculus,,,,4724,,14294,,1,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Intermediate,1,,50594
,CHEMBL620236,10090.0,N,BAO_0000218,Mus musculus,,,,4725,,14294,,1,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Intermediate,1,,50594
,CHEMBL620237,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4726,2107.0,6251,,1,,In vitro metabolic potential in mouse liver microsomes,A,,,Intermediate,1,,50594
,CHEMBL620238,10090.0,N,BAO_0000218,Mus musculus,,,,4727,,17582,,1,,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Intermediate,1,,50594
,CHEMBL620239,10090.0,N,BAO_0000218,Mus musculus,,,Adrenal gland,4728,2369.0,17811,,1,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Intermediate,1,,50594
,CHEMBL620240,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4729,955.0,17811,,1,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Intermediate,1,,50594
,CHEMBL620241,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4730,955.0,17811,,1,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Intermediate,1,,50594
,CHEMBL876727,10090.0,N,BAO_0000218,Mus musculus,,,,4731,,17811,,1,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Intermediate,1,,50594
,CHEMBL620242,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4732,2113.0,17811,,1,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Intermediate,1,,50594
,CHEMBL620243,10090.0,N,BAO_0000218,Mus musculus,,,,4733,,17811,,1,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Intermediate,1,,50594
,CHEMBL620244,10090.0,N,BAO_0000218,Mus musculus,,,,4734,,5288,,1,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL620245,10090.0,N,BAO_0000218,Mus musculus,,,Serum,4735,1977.0,2717,,1,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Intermediate,1,,50594
,CHEMBL620246,10090.0,N,BAO_0000218,Mus musculus,,,Serum,4736,1977.0,2717,,1,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Intermediate,1,,50594
,CHEMBL620247,10090.0,N,BAO_0000218,Mus musculus,,,Serum,4737,1977.0,2717,,1,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Intermediate,1,,50594
,CHEMBL620248,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,4738,1969.0,17753,,1,,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL873497,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,4739,1969.0,17753,,1,,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620249,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,4740,1969.0,17753,,1,,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620250,10090.0,N,BAO_0000218,Mus musculus,,,,4741,,17764,,1,,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620251,10090.0,N,BAO_0000218,Mus musculus,,,,4742,,17764,,1,,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620252,10090.0,N,BAO_0000218,Mus musculus,,,,4743,,17764,,1,,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620253,10090.0,N,BAO_0000218,Mus musculus,,,,4744,,17764,,1,,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620254,10090.0,N,BAO_0000218,Mus musculus,,,,4745,,17764,,1,,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL620255,10090.0,N,BAO_0000218,Mus musculus,,,,4746,,17764,,1,,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620256,10090.0,N,BAO_0000218,Mus musculus,,,,4747,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Intermediate,1,,50594
,CHEMBL876728,10090.0,N,BAO_0000218,Mus musculus,,,,4748,,2675,,1,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL620257,10090.0,N,BAO_0000218,Mus musculus,,,,4749,,2675,,1,,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL620258,10090.0,N,BAO_0000218,Mus musculus,,,,4750,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Intermediate,1,,50594
,CHEMBL620259,10090.0,N,BAO_0000218,Mus musculus,,,,4751,,4890,,1,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Intermediate,1,,50594
,CHEMBL620260,10090.0,N,BAO_0000218,Mus musculus,,,,4752,,429,,1,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620261,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4753,178.0,17837,,1,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620262,10090.0,N,BAO_0000218,Mus musculus,,,,4754,,16597,,1,,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL620263,10090.0,N,BAO_0000218,Mus musculus,,,,4755,,16597,,1,,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL620264,10090.0,N,BAO_0000218,Mus musculus,,,,4756,,6619,,1,,Half life in ob/ob mice,A,,,Intermediate,1,,50594
,CHEMBL620265,10090.0,N,BAO_0000218,Mus musculus,,,,4757,,4066,,1,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL620266,10090.0,N,BAO_0000218,Mus musculus,,,,4758,,4239,,1,,Half-life was measured in mouse,A,,,Intermediate,1,,50594
,CHEMBL620267,10090.0,N,BAO_0000218,Mus musculus,,,,4759,,5969,,1,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL619364,10090.0,N,BAO_0000218,Mus musculus,,,,4760,,8999,,1,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Intermediate,1,,50594
,CHEMBL619365,10090.0,N,BAO_0000218,Mus musculus,,,,4761,,8999,,1,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Intermediate,1,,50594
,CHEMBL619366,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4762,955.0,17641,,1,,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL619367,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4763,2113.0,17641,,1,,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL619368,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4764,2107.0,17641,,1,,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL619369,10090.0,N,BAO_0000218,Mus musculus,,,Lung,4765,2048.0,17641,,1,,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL876729,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,4766,2106.0,17641,,1,,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL619370,10090.0,N,BAO_0000218,Mus musculus,,,,4767,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Intermediate,1,,50594
,CHEMBL619371,10090.0,N,BAO_0000218,Mus musculus,,,,4768,,4890,,1,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Intermediate,1,,50594
,CHEMBL619372,10090.0,N,BAO_0000218,Mus musculus,,,,4769,,429,,1,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620012,10090.0,N,BAO_0000218,Mus musculus,,,,4770,,429,,1,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL620013,10090.0,N,BAO_0000218,Mus musculus,,,,4771,,5969,,1,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620014,9606.0,N,BAO_0000219,Homo sapiens,,,,4772,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL620015,9606.0,N,BAO_0000219,Homo sapiens,,,,4773,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL621010,9606.0,N,BAO_0000219,Homo sapiens,,,,4774,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL621011,9606.0,N,BAO_0000219,Homo sapiens,,,,4775,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL621012,9606.0,N,BAO_0000219,Homo sapiens,,,,4776,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL621013,9606.0,N,BAO_0000219,Homo sapiens,,,,4777,,16913,,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,Intermediate,1,,81034
,CHEMBL621014,9606.0,N,BAO_0000219,Homo sapiens,,,,4778,,17270,,1,478.0,In vitro cytotoxicity against A2780TAX cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618154,9606.0,N,BAO_0000219,Homo sapiens,,,,4779,,5618,,1,481.0,In vitro inhibitory activity against human tumor cell line A2780cis,F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618155,9606.0,N,BAO_0000219,Homo sapiens,,,,4780,,17777,,1,478.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,A2780,Expert,1,,81034
,CHEMBL618156,9606.0,N,BAO_0000219,Homo sapiens,,,,4781,,16112,,1,481.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618157,9606.0,N,BAO_0000219,Homo sapiens,,,,4782,,15748,,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618328,9606.0,N,BAO_0000219,Homo sapiens,,,,4783,,6633,,1,478.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,A2780,Intermediate,1,,81034
,CHEMBL618329,9606.0,N,BAO_0000219,Homo sapiens,,,,4784,,16930,,1,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,A2780,Intermediate,1,,81034
,CHEMBL618330,9606.0,N,BAO_0000219,Homo sapiens,,,,4785,,17496,,1,478.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618331,9606.0,N,BAO_0000219,Homo sapiens,,,,4786,,12989,,1,478.0,In vitro antitumor activity against A2780cisR cell line.,F,,A2780,Expert,1,,81034
,CHEMBL618332,9606.0,N,BAO_0000219,Homo sapiens,,,,4787,,4840,,1,478.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,A2780,Intermediate,1,,81034
,CHEMBL618333,9606.0,N,BAO_0000219,Homo sapiens,,,,4788,,12989,,1,478.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,A2780,Expert,1,,81034
,CHEMBL618334,9606.0,N,BAO_0000219,Homo sapiens,,,,4789,,16745,,1,481.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618335,9606.0,N,BAO_0000219,Homo sapiens,,,,4790,,16597,,1,478.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,A2780,Expert,1,,81034
,CHEMBL618336,10116.0,D,BAO_0000019,Rattus norvegicus,,,,4791,,16547,,1,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Expert,9,,11736
,CHEMBL618337,,H,BAO_0000019,,,,,4792,,16547,,1,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Expert,8,,11736
,CHEMBL618338,10116.0,D,BAO_0000019,Rattus norvegicus,,,,4793,,16547,,1,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Expert,9,,11736
,CHEMBL618339,9606.0,D,BAO_0000219,Homo sapiens,,,,4794,,15856,,1,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,HEK293,Expert,9,,278
,CHEMBL618340,9606.0,D,BAO_0000219,Homo sapiens,,,,4795,,15856,,1,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,HEK293,Expert,9,,278
,CHEMBL618341,10090.0,D,BAO_0000019,Mus musculus,,,,4796,,16547,,1,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Expert,9,,11831
,CHEMBL618342,,H,BAO_0000019,,,,,4797,,16547,,1,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Expert,8,,11831
,CHEMBL618343,10090.0,D,BAO_0000019,Mus musculus,,,,4798,,16547,,1,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Expert,9,,11831
,CHEMBL621038,,H,BAO_0000357,,,,,4799,,17402,,1,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,Expert,8,,280
,CHEMBL621039,9606.0,U,BAO_0000219,Homo sapiens,,,,4800,,11746,,1,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,T-cells,Autocuration,0,,22226
,CHEMBL621040,9606.0,U,BAO_0000219,Homo sapiens,,,,4801,,11746,,1,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,T-cells,Autocuration,0,,22226
,CHEMBL621041,9606.0,N,BAO_0000219,Homo sapiens,,,,4802,,5455,,1,455.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,A-375,Intermediate,1,,80018
,CHEMBL621042,9606.0,N,BAO_0000219,Homo sapiens,,,,4803,,2068,,1,455.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,A-375,Intermediate,1,,80018
,CHEMBL621043,9606.0,N,BAO_0000219,Homo sapiens,,,,4804,,2683,,1,455.0,In vitro antitumor activity against A375cell line extracted form melanoma,F,,A-375,Intermediate,1,,80018
,CHEMBL621044,9606.0,N,BAO_0000219,Homo sapiens,,,,4805,,15313,,1,455.0,Inhibition of cell growth in (A375) melan cell line,F,,A-375,Expert,1,,80018
,CHEMBL621045,9606.0,N,BAO_0000219,Homo sapiens,,,,4806,,13739,,1,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,A-375,Intermediate,1,,80018
,CHEMBL621046,9606.0,N,BAO_0000219,Homo sapiens,,,,4807,,13739,,1,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,A-375,Intermediate,1,,80018
,CHEMBL621047,9606.0,N,BAO_0000219,Homo sapiens,,,,4808,,14750,,1,455.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,A-375,Intermediate,1,,80018
,CHEMBL621048,9606.0,N,BAO_0000219,Homo sapiens,,,,4809,,14777,,1,797.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,A-427,Intermediate,1,,80019
,CHEMBL883798,9606.0,N,BAO_0000219,Homo sapiens,,,,4810,,14777,,1,797.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,A-427,Intermediate,1,,80019
,CHEMBL621049,9606.0,N,BAO_0000219,Homo sapiens,,,,4811,,17672,,1,797.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,A-427,Intermediate,1,,80019
,CHEMBL621050,9606.0,N,BAO_0000219,Homo sapiens,,,,4812,,14368,,1,797.0,Inhibition of large cell lung carcinoma (A427),F,,A-427,Intermediate,1,,80019
,CHEMBL621051,9606.0,N,BAO_0000219,Homo sapiens,,,,4813,,14368,,1,797.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,A-427,Intermediate,1,,80019
,CHEMBL621052,9606.0,N,BAO_0000219,Homo sapiens,,,,4814,,13866,,1,797.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,A-427,Intermediate,1,,80019
,CHEMBL621053,9606.0,N,BAO_0000219,Homo sapiens,,,,4815,,2545,,1,797.0,Inhibitory concentration in human lung carcinoma A427 cell line,F,,A-427,Intermediate,1,,80019
,CHEMBL621054,9606.0,N,BAO_0000219,Homo sapiens,,,,4816,,2545,,1,797.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,A-427,Intermediate,1,,80019
,CHEMBL621055,9527.0,U,BAO_0000218,Cercopithecidae,,,,4817,,6062,,1,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL876398,9527.0,U,BAO_0000218,Cercopithecidae,,,,4818,,4578,,1,,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621056,9527.0,U,BAO_0000218,Cercopithecidae,,,,4819,,17592,,1,,Volume of distribution in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621057,9544.0,U,BAO_0000218,Macaca mulatta,,,,4820,,5005,,1,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Autocuration,0,,22224
,CHEMBL621058,9544.0,U,BAO_0000218,Macaca mulatta,,,,4821,,5005,,1,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Autocuration,0,,22224
,CHEMBL621059,9527.0,U,BAO_0000218,Cercopithecidae,,,,4822,,5922,,1,,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621060,9527.0,U,BAO_0000218,Cercopithecidae,,,,4823,,5355,,1,,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL621061,9527.0,U,BAO_0000218,Cercopithecidae,,,,4824,,5355,,1,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL621062,9527.0,U,BAO_0000218,Cercopithecidae,,,,4825,,5355,,1,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL621063,9527.0,U,BAO_0000218,Cercopithecidae,,,,4826,,6057,,1,,Volume displacement was calculated in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621064,9527.0,U,BAO_0000218,Cercopithecidae,,,,4827,,5145,,1,,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621065,9527.0,U,BAO_0000218,Cercopithecidae,,,,4828,,6821,,1,,Volume of distribution of compound was determined in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621066,9527.0,U,BAO_0000218,Cercopithecidae,,,,4829,,5334,,1,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL621067,9527.0,U,BAO_0000218,Cercopithecidae,,,,4830,,5334,,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL621068,9527.0,U,BAO_0000218,Cercopithecidae,,,,4831,,6641,,1,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Autocuration,0,,22224
,CHEMBL876399,9527.0,U,BAO_0000218,Cercopithecidae,,,,4832,,2661,,1,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621069,9527.0,U,BAO_0000218,Cercopithecidae,,,,4833,,6535,,1,,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Autocuration,0,,22224
,CHEMBL621070,9527.0,U,BAO_0000218,Cercopithecidae,,,,4834,,4809,,1,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL621071,9527.0,U,BAO_0000218,Cercopithecidae,,,,4835,,6062,,1,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL621072,9527.0,U,BAO_0000218,Cercopithecidae,,,,4836,,3443,,1,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Autocuration,0,,22224
,CHEMBL618209,9527.0,U,BAO_0000218,Cercopithecidae,,,,4837,,4578,,1,,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618210,9527.0,U,BAO_0000218,Cercopithecidae,,,,4838,,4809,,1,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL618211,9527.0,U,BAO_0000019,Cercopithecidae,,,,4839,,11271,,1,,Baboon plasma free fraction. ,A,,,Autocuration,0,,22224
,CHEMBL618212,9527.0,U,BAO_0000218,Cercopithecidae,,,,4840,,6057,,1,,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Autocuration,0,,22224
,CHEMBL618213,9527.0,U,BAO_0000019,Cercopithecidae,,,,4841,,6057,,1,,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Autocuration,0,,22224
,CHEMBL618214,9527.0,U,BAO_0000019,Cercopithecidae,,,,4842,,17853,,1,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Autocuration,0,,22224
,CHEMBL873492,9527.0,U,BAO_0000218,Cercopithecidae,,,,4843,,5302,,1,,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL618272,9527.0,U,BAO_0000218,Cercopithecidae,,,,4844,,4257,,1,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL618273,9527.0,U,BAO_0000218,Cercopithecidae,,,,4845,,4257,,1,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL618274,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4846,1969.0,13501,,1,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618275,9527.0,U,BAO_0000218,Cercopithecidae,,,,4847,,5394,,1,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL618276,9527.0,U,BAO_0000218,Cercopithecidae,,,,4848,,2661,,1,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618277,9527.0,U,BAO_0000019,Cercopithecidae,,,,4849,,3341,,1,,Compound was evaluated for terminal half life in monkey,A,,,Autocuration,0,,22224
,CHEMBL618278,9527.0,U,BAO_0000218,Cercopithecidae,,,,4850,,3045,,1,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618279,9544.0,U,BAO_0000218,Macaca mulatta,,,Plasma,4851,1969.0,5005,,1,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Autocuration,0,,22224
,CHEMBL618280,9527.0,U,BAO_0000019,Cercopithecidae,,,,4852,,4847,,1,,Half life of compound was determined in squirrel monkey,A,,,Autocuration,0,,22224
,CHEMBL618281,9541.0,U,BAO_0000218,Macaca fascicularis,,,,4853,,4256,,1,,Half life after iv administration in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618282,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,4854,1969.0,6535,,1,,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Autocuration,0,,22224
,CHEMBL618283,9527.0,U,BAO_0000019,Cercopithecidae,,,,4855,,6057,,1,,Half life was calculated in rhesus monkey,A,,,Autocuration,0,,22224
,CHEMBL618284,9527.0,U,BAO_0000019,Cercopithecidae,,,,4856,,17592,,1,,Half life in monkey,A,,,Autocuration,0,,22224
,CHEMBL618285,9527.0,U,BAO_0000218,Cercopithecidae,,,,4857,,6641,,1,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Autocuration,0,,22224
,CHEMBL618286,9527.0,U,BAO_0000019,Cercopithecidae,,,,4858,,5472,,1,,Half life was evaluated in rhesus,A,,,Autocuration,0,,22224
,CHEMBL618287,9527.0,U,BAO_0000218,Cercopithecidae,,,,4859,,6221,,1,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL618288,9527.0,U,BAO_0000218,Cercopithecidae,,,,4860,,5668,,1,,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Autocuration,0,,22224
,CHEMBL876393,9527.0,U,BAO_0000218,Cercopithecidae,,,,4861,,4809,,1,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL618289,9527.0,U,BAO_0000218,Cercopithecidae,,,,4862,,5546,,1,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL618290,9527.0,U,BAO_0000218,Cercopithecidae,,,,4863,,5553,,1,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL618291,9527.0,U,BAO_0000019,Cercopithecidae,,,,4864,,6078,,1,,Half-life was calculated in monkey,A,,,Autocuration,0,,22224
,CHEMBL618292,9527.0,U,BAO_0000019,Cercopithecidae,,,,4865,,5147,,1,,Half-life in Squirrel monkey,A,,,Autocuration,0,,22224
,CHEMBL618293,9527.0,U,BAO_0000019,Cercopithecidae,,,,4866,,5145,,1,,Half-life in rhesus monkey,A,,,Autocuration,0,,22224
,CHEMBL618294,9527.0,U,BAO_0000218,Cercopithecidae,,,,4867,,6062,,1,,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL618295,9527.0,U,BAO_0000218,Cercopithecidae,,,,4868,,5355,,1,,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL618296,9527.0,U,BAO_0000218,Cercopithecidae,,,,4869,,5355,,1,,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL618297,9527.0,U,BAO_0000218,Cercopithecidae,,,,4870,,5355,,1,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL618298,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4871,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL618299,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4872,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL618300,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4873,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL618301,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4874,1088.0,7766,,1,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Autocuration,0,,22224
,CHEMBL618302,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4875,1088.0,7766,,1,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Autocuration,0,,22224
,CHEMBL876394,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4876,1088.0,7766,,1,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Autocuration,0,,22224
,CHEMBL618303,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4877,1088.0,7766,,1,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Autocuration,0,,22224
,CHEMBL618304,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4878,1088.0,7766,,1,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Autocuration,0,,22224
,CHEMBL618305,9606.0,U,BAO_0000218,Homo sapiens,,,,4879,,1916,,1,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL618306,9606.0,U,BAO_0000218,Homo sapiens,,,,4880,,16643,,1,,Oral bioavailability in human,A,In vivo,,Autocuration,0,,22224
,CHEMBL618307,9606.0,U,BAO_0000019,Homo sapiens,,,,4881,,17248,,1,,Compound was tested for human plasma protein binding,A,,,Autocuration,0,,22224
,CHEMBL618308,9606.0,U,BAO_0000019,Homo sapiens,,,,4882,,17248,,1,,Compound was tested for human plasma protein binding; Not determined,A,,,Autocuration,0,,22224
,CHEMBL618309,9606.0,U,BAO_0000019,Homo sapiens,,,,4883,,6241,,1,,Protein binding activity of compound in human plasma; % Free,A,,,Autocuration,0,,22224
,CHEMBL618310,9606.0,U,BAO_0000019,Homo sapiens,,,,4884,,17716,,1,,Unbound fraction (plasma),A,,,Autocuration,0,,22224
,CHEMBL873353,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,4885,1969.0,17605,,1,,Half life for the hydrolysis of compound in human blood serum,A,,,Autocuration,0,,22224
,CHEMBL618311,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,4886,1969.0,17625,,1,,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Autocuration,0,,22224
,CHEMBL618312,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,4887,1969.0,17625,,1,,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Autocuration,0,,22224
,CHEMBL618313,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,4888,1969.0,17747,,1,,Half-life in human plasma was determined,A,,,Autocuration,0,,22224
,CHEMBL618314,9606.0,U,BAO_0000019,Homo sapiens,,,,4889,,15613,,1,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Autocuration,0,,22224
,CHEMBL618315,9606.0,U,BAO_0000019,Homo sapiens,,,,4890,,354,,1,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Autocuration,0,,22224
,CHEMBL618316,9606.0,U,BAO_0000019,Homo sapiens,,,,4891,,3741,,1,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Autocuration,0,,22224
,CHEMBL618317,9606.0,U,BAO_0000019,Homo sapiens,,,,4892,,3741,,1,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Autocuration,0,,22224
,CHEMBL620138,9606.0,U,BAO_0000019,Homo sapiens,,,,4893,,3741,,1,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Autocuration,0,,22224
,CHEMBL858280,9606.0,U,BAO_0000019,Homo sapiens,,,,4894,,17599,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL620139,9606.0,U,BAO_0000019,Homo sapiens,,,,4895,,5486,,1,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Autocuration,0,,22224
Microsomes,CHEMBL620140,9606.0,U,BAO_0000251,Homo sapiens,,,,4896,,5600,,1,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Autocuration,0,,22224
,CHEMBL620141,9606.0,U,BAO_0000019,Homo sapiens,,,,4897,,14294,,1,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Autocuration,0,,22224
,CHEMBL620142,9606.0,U,BAO_0000019,Homo sapiens,,,,4898,,14294,,1,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Autocuration,0,,22224
,CHEMBL620143,9606.0,U,BAO_0000019,Homo sapiens,,,,4899,,14294,,1,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620144,9606.0,U,BAO_0000251,Homo sapiens,,,,4900,,14294,,1,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620145,9606.0,U,BAO_0000251,Homo sapiens,,,,4901,,14294,,1,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL620146,9606.0,U,BAO_0000251,Homo sapiens,,,,4902,,14294,,1,,Metabolism of compound in human microsomes; Trace,A,,,Autocuration,0,,22224
Microsomes,CHEMBL620147,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4903,2107.0,6260,,1,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Autocuration,0,,22224
Microsomes,CHEMBL620148,9606.0,U,BAO_0000251,Homo sapiens,,,,4904,,6187,,1,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Autocuration,0,,22224
Microsomes,CHEMBL620149,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,4905,2107.0,6251,,1,,In vitro metabolic potential in human liver microsomes,A,,,Autocuration,0,,22224
,CHEMBL876412,9606.0,U,BAO_0000019,Homo sapiens,,,,4906,,3246,,1,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Autocuration,0,,22224
,CHEMBL619352,9606.0,U,BAO_0000019,Homo sapiens,,,,4907,,17313,,1,,Tested for human plasma protein binding of the compound; Not tested,A,,,Autocuration,0,,22224
,CHEMBL619353,9606.0,U,BAO_0000019,Homo sapiens,,,,4908,,6227,,1,,Compound was tested for percent protein binding (PB) in human,A,,,Autocuration,0,,22224
,CHEMBL619354,9606.0,U,BAO_0000019,Homo sapiens,,,Plasma,4909,1969.0,5530,,1,,Protein binding in human plasma,A,,,Autocuration,0,,22224
,CHEMBL619355,9606.0,U,BAO_0000019,Homo sapiens,,,,4910,,6108,,1,,Permeability coefficient (B to A) in Caco-2 cell,A,,,Autocuration,0,,22224
,CHEMBL619356,9606.0,U,BAO_0000019,Homo sapiens,,,,4911,,6108,,1,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Autocuration,0,,22224
,CHEMBL619357,9606.0,U,BAO_0000019,Homo sapiens,,,,4912,,2774,,1,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Autocuration,0,,22224
,CHEMBL619358,9606.0,U,BAO_0000019,Homo sapiens,,,,4913,,16643,,1,,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Autocuration,0,,22224
,CHEMBL619359,9606.0,U,BAO_0000219,Homo sapiens,,,,4914,,17582,,1,495.0,Cellular permeability of compound was determined in Caco-2 cells; High,A,,Caco-2,Autocuration,0,,22224
,CHEMBL619360,9606.0,U,BAO_0000219,Homo sapiens,,,,4915,,6838,,1,495.0,Permeability in Caco-2 cells of compound,A,,Caco-2,Autocuration,0,,22224
,CHEMBL619361,9606.0,U,BAO_0000019,Homo sapiens,,,,4916,,6108,,1,,Permeability coefficient (A to B) in Caco-2 cell,A,,,Autocuration,0,,22224
,CHEMBL619362,9606.0,U,BAO_0000019,Homo sapiens,,,,4917,,6108,,1,,Permeability coefficient (B to A) in Caco-2 cell,A,,,Autocuration,0,,22224
,CHEMBL619363,9606.0,U,BAO_0000019,Homo sapiens,,,,4918,,6108,,1,,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Autocuration,0,,22224
,CHEMBL618942,9606.0,U,BAO_0000019,Homo sapiens,,,,4919,,2146,,1,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Autocuration,0,,22224
,CHEMBL618943,9606.0,U,BAO_0000019,Homo sapiens,,,,4920,,4514,,1,,Compound was tested for protein binding in human plasma,A,,,Autocuration,0,,22224
,CHEMBL618944,9606.0,U,BAO_0000019,Homo sapiens,,,,4921,,6108,,1,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Autocuration,0,,22224
,CHEMBL618945,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,4922,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Autocuration,0,,22224
,CHEMBL618946,10090.0,N,BAO_0000218,Mus musculus,,,,4923,,5969,,1,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL876413,10090.0,N,BAO_0000218,Mus musculus,,,,4924,,3277,,1,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Intermediate,1,,50594
,CHEMBL618947,10090.0,N,BAO_0000218,Mus musculus,,,,4925,,3802,,1,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL618948,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,4926,1969.0,2862,,1,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL618949,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,4927,1969.0,6348,,1,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL618950,10090.0,N,BAO_0000218,Mus musculus,,,,4928,,17764,,1,,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Intermediate,1,,50594
,CHEMBL618951,10090.0,N,BAO_0000218,Mus musculus,,,,4929,,5781,,1,,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL618952,10090.0,N,BAO_0000218,Mus musculus,,,,4930,,17764,,1,,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618953,10090.0,N,BAO_0000218,Mus musculus,,,,4931,,4066,,1,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL618954,10090.0,N,BAO_0000218,Mus musculus,,,Brain,4932,955.0,17641,,1,,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618955,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4933,2113.0,17641,,1,,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618956,10090.0,N,BAO_0000218,Mus musculus,,,Liver,4934,2107.0,17641,,1,,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618957,10090.0,N,BAO_0000218,Mus musculus,,,Lung,4935,2048.0,17641,,1,,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618958,10090.0,N,BAO_0000218,Mus musculus,,,,4936,,17764,,1,,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL618959,10090.0,N,BAO_0000218,Mus musculus,,,,4937,,17764,,1,,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL618960,10090.0,N,BAO_0000218,Mus musculus,,,,4938,,17764,,1,,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL876723,10090.0,N,BAO_0000218,Mus musculus,,,,4939,,17764,,1,,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL618961,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,4940,2106.0,17641,,1,,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618962,10090.0,N,BAO_0000218,Mus musculus,,,,4941,,16597,,1,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL618963,10090.0,N,BAO_0000218,Mus musculus,,,,4942,,16597,,1,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL618964,10090.0,N,BAO_0000218,Mus musculus,,,,4943,,5951,,1,,Tmax value in IRC mice,A,,,Intermediate,1,,50594
,CHEMBL618965,10090.0,N,BAO_0000218,Mus musculus,,,,4944,,5506,,1,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL618966,10090.0,N,BAO_0000218,Mus musculus,,,,4945,,5506,,1,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL618967,10090.0,N,BAO_0000218,Mus musculus,,,Urine,4946,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Intermediate,1,,50594
,CHEMBL618968,10090.0,N,BAO_0000218,Mus musculus,,,Urine,4947,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Intermediate,1,,50594
,CHEMBL618969,10090.0,N,BAO_0000218,Mus musculus,,,Urine,4948,1088.0,4066,,1,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Intermediate,1,,50594
,CHEMBL618970,10090.0,N,BAO_0000218,Mus musculus,,,,4949,,17734,,1,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL618971,10090.0,N,BAO_0000218,Mus musculus,,,,4950,,17734,,1,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL618972,10090.0,N,BAO_0000218,Mus musculus,,,,4951,,6062,,1,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618973,10090.0,N,BAO_0000218,Mus musculus,,,,4952,,5969,,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618974,10090.0,N,BAO_0000218,Mus musculus,,,,4953,,5969,,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618975,10090.0,N,BAO_0000218,Mus musculus,,,,4954,,5969,,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL618976,10090.0,N,BAO_0000218,Mus musculus,,,,4955,,5980,,1,,Vd in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL618977,10090.0,N,BAO_0000218,Mus musculus,,,,4956,,17592,,1,,Volume of distribution in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL876724,10090.0,N,BAO_0000218,Mus musculus,,,,4957,,6348,,1,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL618978,10090.0,N,BAO_0000218,Mus musculus,,,,4958,,17753,,1,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618979,10090.0,N,BAO_0000218,Mus musculus,,,,4959,,17753,,1,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618980,10090.0,N,BAO_0000218,Mus musculus,,,,4960,,17753,,1,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL618981,10090.0,N,BAO_0000218,Mus musculus,,,,4961,,4239,,1,,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL618982,10090.0,N,BAO_0000218,Mus musculus,,,,4962,,2862,,1,,Value distribution upon iv administration in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL620150,10090.0,N,BAO_0000218,Mus musculus,,,,4963,,17734,,1,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL620151,10090.0,N,BAO_0000218,Mus musculus,,,,4964,,2675,,1,,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL620152,10090.0,N,BAO_0000218,Mus musculus,,,,4965,,2675,,1,,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL620153,10090.0,N,BAO_0000218,Mus musculus,,,,4966,,17837,,1,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL876395,10090.0,N,BAO_0000218,Mus musculus,,,,4967,,5727,,1,,Steady state volume of distribution was determined in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL620154,10090.0,N,BAO_0000218,Mus musculus,,,,4968,,17852,,1,,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL620155,10090.0,N,BAO_0000218,Mus musculus,,,,4969,,17764,,1,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620156,10090.0,N,BAO_0000218,Mus musculus,,,,4970,,16597,,1,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL620157,10090.0,N,BAO_0000218,Mus musculus,,,,4971,,6062,,1,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL620158,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,4972,2113.0,16438,,1,,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Intermediate,1,,50594
,CHEMBL620159,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4973,178.0,16438,,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Intermediate,1,,50594
,CHEMBL620160,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4974,178.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL620161,10090.0,N,BAO_0000218,Mus musculus,,,Blood,4975,178.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL620162,9606.0,N,BAO_0000219,Homo sapiens,,,,4976,,10708,,1,797.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,A-427,Intermediate,1,,80019
,CHEMBL620163,9606.0,N,BAO_0000219,Homo sapiens,,,,4977,,16597,,1,500.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,A-431,Expert,1,,80852
,CHEMBL620833,9606.0,N,BAO_0000219,Homo sapiens,,,,4978,,16062,,1,500.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,A-431,Expert,1,,80852
,CHEMBL876396,9606.0,N,BAO_0000219,Homo sapiens,,,,4979,,16062,,1,500.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,A-431,Expert,1,,80852
,CHEMBL620834,9606.0,N,BAO_0000219,Homo sapiens,,,,4980,,16958,,1,500.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,A-431,Expert,1,,80852
,CHEMBL620835,9606.0,N,BAO_0000219,Homo sapiens,,,,4981,,6700,,1,500.0,Inhibition of A431 human carcinoma cell proliferation,F,,A-431,Expert,1,,80852
,CHEMBL620836,9606.0,N,BAO_0000219,Homo sapiens,,,,4982,,17226,,1,500.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,A-431,Expert,1,,80852
,CHEMBL620837,9606.0,N,BAO_0000219,Homo sapiens,,,,4983,,6828,,1,500.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,A-431,Intermediate,1,,80852
,CHEMBL621017,9606.0,N,BAO_0000219,Homo sapiens,,,,4984,,12314,,1,500.0,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,A-431,Intermediate,1,,80852
,CHEMBL621018,9606.0,D,BAO_0000218,Homo sapiens,,,,4985,,13412,,1,500.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,A-431,Expert,9,,9
,CHEMBL621019,9606.0,N,BAO_0000219,Homo sapiens,,,,4986,,13299,,1,500.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,A-431,Intermediate,1,,80852
,CHEMBL621020,9606.0,N,BAO_0000219,Homo sapiens,,,,4987,,17420,,1,500.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,A-431,Intermediate,1,,80852
,CHEMBL621021,9606.0,N,BAO_0000219,Homo sapiens,,,,4988,,13678,,1,500.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,A-431,Intermediate,1,,80852
,CHEMBL621022,,H,BAO_0000219,,,,,4989,,14171,,1,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,A-431,Expert,8,,9
,CHEMBL621023,9606.0,N,BAO_0000219,Homo sapiens,,,,4990,,6333,,1,500.0,Tested for antiproliferative activity against human A431 cells,F,,A-431,Expert,1,,80852
,CHEMBL621024,9606.0,D,BAO_0000219,Homo sapiens,,,,4991,,2356,,1,500.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,A-431,Expert,9,,9
,CHEMBL621025,9606.0,N,BAO_0000219,Homo sapiens,,,,4992,,15578,,1,500.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,A-431,Expert,1,,80852
,CHEMBL621026,9606.0,N,BAO_0000219,Homo sapiens,,,,4993,,5126,,1,500.0,Inhibition of A431 cell proliferation,F,,A-431,Expert,1,,80852
,CHEMBL621027,9606.0,N,BAO_0000219,Homo sapiens,,,,4994,,6844,,1,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,A-431,Expert,1,,80852
,CHEMBL876397,9606.0,N,BAO_0000219,Homo sapiens,,,,4995,,6844,,1,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,A-431,Expert,1,,80852
,CHEMBL883797,9606.0,N,BAO_0000219,Homo sapiens,,,,4996,,4925,,1,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,A-431,Intermediate,1,,80852
,CHEMBL621028,9606.0,N,BAO_0000219,Homo sapiens,,,,4997,,4925,,1,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,A-431,Intermediate,1,,80852
,CHEMBL621029,9606.0,N,BAO_0000219,Homo sapiens,,,,4998,,13978,,1,500.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,A-431,Intermediate,1,,80852
,CHEMBL621030,9606.0,N,BAO_0000219,Homo sapiens,,,,4999,,16786,,1,500.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,A-431,Intermediate,1,,80852
,CHEMBL621147,,H,BAO_0000219,,,,,5000,,13412,,1,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,Expert,8,,9
,CHEMBL621148,9606.0,N,BAO_0000218,Homo sapiens,,,,5001,,17824,,1,500.0,In vivo antiproliferative activity against A431 cell line,F,,A-431,Intermediate,1,,80852
,CHEMBL621149,9606.0,D,BAO_0000219,Homo sapiens,,,,5002,,12751,,1,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,A-431,Expert,9,,9
,CHEMBL621150,9606.0,N,BAO_0000219,Homo sapiens,,,,5003,,12380,,1,500.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,A-431,Expert,1,,80852
,CHEMBL621151,9606.0,D,BAO_0000219,Homo sapiens,,,,5004,,4959,,1,500.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,A-431,Expert,9,,9
,CHEMBL621152,9606.0,N,BAO_0000219,Homo sapiens,,,,5005,,6333,,1,500.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,A-431,Intermediate,1,,80852
,CHEMBL621153,9606.0,N,BAO_0000219,Homo sapiens,,,,5006,,6333,,1,500.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,A-431,Intermediate,1,,80852
,CHEMBL884000,9606.0,N,BAO_0000219,Homo sapiens,,,,5007,,6333,,1,500.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,A-431,Intermediate,1,,80852
,CHEMBL621154,9606.0,D,BAO_0000019,Homo sapiens,,,,5008,,5296,,1,,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Expert,9,,9
,CHEMBL621155,9606.0,N,BAO_0000219,Homo sapiens,,,,5009,,12624,,1,500.0,Inhibition of A431 cell proliferation,F,,A-431,Expert,1,,80852
,CHEMBL621156,9606.0,D,BAO_0000219,Homo sapiens,,,,5010,,14926,,1,500.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,A-431,Expert,9,,9
,CHEMBL621157,9606.0,D,BAO_0000219,Homo sapiens,,,,5011,,14926,,1,500.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,A-431,Expert,9,,9
,CHEMBL621158,,H,BAO_0000219,,,,,5012,,14926,,1,500.0,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,A-431,Expert,8,,9
,CHEMBL621159,9606.0,N,BAO_0000219,Homo sapiens,,,,5013,,15144,,1,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,A-431,Intermediate,1,,80852
,CHEMBL621160,9606.0,N,BAO_0000219,Homo sapiens,,,,5014,,15144,,1,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,A-431,Intermediate,1,,80852
,CHEMBL621161,9606.0,N,BAO_0000219,Homo sapiens,,,,5015,,5245,,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,A-431,Intermediate,1,,80852
,CHEMBL621162,9606.0,N,BAO_0000219,Homo sapiens,,,,5016,,5245,,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,A-431,Intermediate,1,,80852
,CHEMBL621163,9606.0,N,BAO_0000219,Homo sapiens,,,,5017,,5245,,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,A-431,Intermediate,1,,80852
,CHEMBL621164,9606.0,N,BAO_0000219,Homo sapiens,,,,5018,,5245,,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,A-431,Intermediate,1,,80852
,CHEMBL621165,9606.0,N,BAO_0000219,Homo sapiens,,,,5019,,5245,,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,A-431,Intermediate,1,,80852
,CHEMBL619159,9527.0,U,BAO_0000019,Cercopithecidae,,,,5020,,5922,,1,,Half-life period in cynomolgus monkey,A,,,Autocuration,0,,22224
,CHEMBL619160,9527.0,U,BAO_0000366,Cercopithecidae,,,Plasma,5021,1969.0,1116,,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Autocuration,0,,22224
,CHEMBL619161,9527.0,U,BAO_0000218,Cercopithecidae,,,,5022,,17853,,1,,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Autocuration,0,,22224
,CHEMBL619162,9527.0,U,BAO_0000366,Cercopithecidae,,,Plasma,5023,1969.0,993,,1,,Plasma half life in monkey,A,,,Autocuration,0,,22224
,CHEMBL619163,9527.0,U,BAO_0000366,Cercopithecidae,,,Plasma,5024,1969.0,4514,,1,,Plasma half-life in rhesus monkey,A,,,Autocuration,0,,22224
,CHEMBL619164,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,5025,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL619320,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,5026,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL619321,9527.0,U,BAO_0000218,Cercopithecidae,,,,5027,,4578,,1,,Tested for half life upon iv administration to african green monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL873336,9527.0,U,BAO_0000218,Cercopithecidae,,,,5028,,2661,,1,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL619322,9527.0,U,BAO_0000218,Cercopithecidae,,,,5029,,5355,,1,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL619323,9527.0,U,BAO_0000218,Cercopithecidae,,,,5030,,5355,,1,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL619324,9527.0,U,BAO_0000218,Cercopithecidae,,,,5031,,5355,,1,,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL619325,9527.0,U,BAO_0000019,Cercopithecidae,,,,5032,,11271,,1,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL876411,9527.0,U,BAO_0000019,Cercopithecidae,,,,5033,,11271,,1,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619326,9527.0,U,BAO_0000019,Cercopithecidae,,,,5034,,11271,,1,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619327,9527.0,U,BAO_0000019,Cercopithecidae,,,,5035,,11271,,1,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619328,9527.0,U,BAO_0000019,Cercopithecidae,,,,5036,,11271,,1,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619329,9527.0,U,BAO_0000019,Cercopithecidae,,,,5037,,11271,,1,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619330,9527.0,U,BAO_0000019,Cercopithecidae,,,,5038,,11271,,1,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619331,9527.0,U,BAO_0000019,Cercopithecidae,,,,5039,,11271,,1,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619332,9527.0,U,BAO_0000019,Cercopithecidae,,,,5040,,11271,,1,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619333,9527.0,U,BAO_0000019,Cercopithecidae,,,,5041,,11271,,1,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619334,9527.0,U,BAO_0000019,Cercopithecidae,,,,5042,,11271,,1,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619335,9527.0,U,BAO_0000019,Cercopithecidae,,,,5043,,11271,,1,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619336,9527.0,U,BAO_0000019,Cercopithecidae,,,,5044,,11271,,1,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619337,9527.0,U,BAO_0000019,Cercopithecidae,,,,5045,,11271,,1,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619338,9527.0,U,BAO_0000019,Cercopithecidae,,,,5046,,11271,,1,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619339,9527.0,U,BAO_0000019,Cercopithecidae,,,,5047,,11271,,1,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Autocuration,0,,22224
,CHEMBL619340,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5048,,5809,,1,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL873496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,5049,1969.0,17720,,1,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL619341,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,5050,1969.0,3546,,1,,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL619342,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,5051,1969.0,3546,,1,,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL619343,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5052,,3546,,1,,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619344,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5053,,3546,,1,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619345,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5054,,3546,,1,,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619346,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5055,,3546,,1,,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL619347,10116.0,N,BAO_0000218,Rattus norvegicus,,,,5056,,3546,,1,,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619348,9557.0,U,BAO_0000019,Papio hamadryas,,,,5057,,10625,,1,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Autocuration,0,,22224
,CHEMBL619349,9557.0,U,BAO_0000019,Papio hamadryas,,,,5058,,10625,,1,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Autocuration,0,,22224
,CHEMBL619350,9557.0,U,BAO_0000019,Papio hamadryas,,,,5059,,10625,,1,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Autocuration,0,,22224
,CHEMBL619351,9557.0,U,BAO_0000019,Papio hamadryas,,,,5060,,10625,,1,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Autocuration,0,,22224
,CHEMBL875953,9557.0,U,BAO_0000019,Papio hamadryas,,,,5061,,10625,,1,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Autocuration,0,,22224
,CHEMBL621716,9557.0,U,BAO_0000019,Papio hamadryas,,,,5062,,10625,,1,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Autocuration,0,,22224
,CHEMBL621717,9557.0,U,BAO_0000019,Papio hamadryas,,,,5063,,10625,,1,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Autocuration,0,,22224
,CHEMBL621718,9557.0,U,BAO_0000019,Papio hamadryas,,,,5064,,10625,,1,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Autocuration,0,,22224
,CHEMBL621719,9615.0,U,BAO_0000019,beagle,,,,5065,,3510,,1,,Area under curve after 1 mpk peroral administration to beagles,A,,,Autocuration,0,,22224
,CHEMBL621720,9615.0,U,BAO_0000019,beagle,,,,5066,,3510,,1,,Area under curve after 2 mpk peroral administration to beagles,A,,,Autocuration,0,,22224
,CHEMBL621721,9615.0,U,BAO_0000218,beagle,,,,5067,,3510,,1,,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,Autocuration,0,,22224
,CHEMBL621722,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5068,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Autocuration,0,,22224
,CHEMBL621723,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5069,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Autocuration,0,,22224
,CHEMBL621724,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5070,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Autocuration,0,,22224
,CHEMBL623443,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5071,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Autocuration,0,,22224
,CHEMBL623444,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5072,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Autocuration,0,,22224
,CHEMBL623445,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5073,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Autocuration,0,,22224
,CHEMBL623446,9606.0,U,BAO_0000019,Homo sapiens,,,Urine,5074,1088.0,7766,,1,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Autocuration,0,,22224
Microsomes,CHEMBL623447,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5075,2107.0,16643,,1,,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Autocuration,0,,22224
,CHEMBL623448,9606.0,U,BAO_0000019,Homo sapiens,,,,5076,,6852,,1,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Autocuration,0,,22224
,CHEMBL623449,9606.0,U,BAO_0000019,Homo sapiens,,,,5077,,6852,,1,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Autocuration,0,,22224
,CHEMBL623450,9606.0,U,BAO_0000019,Homo sapiens,,,,5078,,6852,,1,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Autocuration,0,,22224
Microsomes,CHEMBL623451,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5079,2107.0,6567,,1,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Autocuration,0,,22224
,CHEMBL623452,9606.0,U,BAO_0000019,Homo sapiens,,,,5080,,6570,,1,,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Autocuration,0,,22224
,CHEMBL623453,9606.0,U,BAO_0000019,Homo sapiens,,,,5081,,6570,,1,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Autocuration,0,,22224
Microsomes,CHEMBL623454,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5082,2107.0,5237,,1,,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Autocuration,0,,22224
Microsomes,CHEMBL623455,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5083,2107.0,5237,,1,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Autocuration,0,,22224
Microsomes,CHEMBL624371,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5084,2107.0,5237,,1,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Autocuration,0,,22224
,CHEMBL624372,9606.0,U,BAO_0000218,Homo sapiens,,,,5085,,5202,,1,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Autocuration,0,,22224
,CHEMBL624373,9606.0,U,BAO_0000019,Homo sapiens,,,,5086,,5481,,1,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Autocuration,0,,22224
,CHEMBL624374,9606.0,U,BAO_0000019,Homo sapiens,,,,5087,,5481,,1,,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Autocuration,0,,22224
,CHEMBL624556,9606.0,U,BAO_0000019,Homo sapiens,,,,5088,,3956,,1,,The percent remaining in human plasma after 30 min was determined,A,,,Autocuration,0,,22224
,CHEMBL624557,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5089,1969.0,5074,,1,,Conversion rate of the prodrug in human plasma,A,,,Autocuration,0,,22224
,CHEMBL624558,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5090,1969.0,5074,,1,,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Autocuration,0,,22224
,CHEMBL624559,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5091,178.0,4727,,1,,Half life of compound was determined in human blood,A,,,Autocuration,0,,22224
,CHEMBL624560,9606.0,U,BAO_0000019,Homo sapiens,,,,5092,,5965,,1,,Half life of compound was determined in man with once daily dosing,A,,,Autocuration,0,,22224
Microsomes,CHEMBL624561,9606.0,U,BAO_0000251,Homo sapiens,,,,5093,,5732,,1,,Half life in human microsomes,A,In vitro,,Autocuration,0,,22224
,CHEMBL624562,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5094,1969.0,5819,,1,,Half life in human plasma,A,,,Autocuration,0,,22224
,CHEMBL624563,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5095,1969.0,5819,,1,,Half life in human plasma; Not detected,A,,,Autocuration,0,,22224
,CHEMBL624564,9606.0,U,BAO_0000218,Homo sapiens,,,,5096,,1916,,1,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
Microsomes,CHEMBL624565,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5097,2107.0,6597,,1,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Autocuration,0,,22224
,CHEMBL875152,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5098,1969.0,5229,,1,,Half-life in human plasma,A,,,Autocuration,0,,22224
,CHEMBL624566,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5099,1969.0,5229,,1,,Half-life of the parent prodrug in plasma,A,,,Autocuration,0,,22224
,CHEMBL873805,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5100,1969.0,2192,,1,,In vitro half life in human plasma was determined,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL624567,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5101,2107.0,3032,,1,,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Autocuration,0,,22224
,CHEMBL624568,9606.0,U,BAO_0000218,Homo sapiens,,,,5102,,1916,,1,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL624569,9606.0,U,BAO_0000218,Homo sapiens,,,,5103,,17716,,1,,Observed volume of distribution,A,In vivo,,Autocuration,0,,22224
,CHEMBL624570,9606.0,U,BAO_0000218,Homo sapiens,,,,5104,,15778,,1,,Oral bioavailability in human,A,In vivo,,Autocuration,0,,22224
,CHEMBL624571,9606.0,U,BAO_0000019,Homo sapiens,,,,5105,,17313,,1,,Tested for human plasma protein binding of the compound,A,,,Autocuration,0,,22224
,CHEMBL624572,9606.0,U,BAO_0000019,Homo sapiens,,,,5106,,4231,,1,,"First order rate constant, k was determined in human plasma",A,,,Autocuration,0,,22224
,CHEMBL624573,9606.0,U,BAO_0000019,Homo sapiens,,,,5107,,4755,,1,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL875153,9606.0,U,BAO_0000019,Homo sapiens,,,,5108,,4755,,1,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Autocuration,0,,22224
Microsomes,CHEMBL624574,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5109,2107.0,16907,,1,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Autocuration,0,,22224
,CHEMBL624575,9606.0,U,BAO_0000019,Homo sapiens,,,,5110,,10839,,1,,The compound was tested for the plasma binding in human,A,,,Autocuration,0,,22224
,CHEMBL624576,9606.0,U,BAO_0000019,Homo sapiens,,,,5111,,10839,,1,,Plasma protein binding (human),A,,,Autocuration,0,,22224
Microsomes,CHEMBL624577,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5112,2107.0,3199,,1,,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Autocuration,0,,22224
,CHEMBL624578,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5113,178.0,1345,,1,,Half life measured in vitro for its stability in human blood,A,In vitro,,Autocuration,0,,22224
,CHEMBL622796,9606.0,U,BAO_0000019,Homo sapiens,,,Serum,5114,1977.0,4297,,1,,Half life in human serum,A,,,Autocuration,0,,22224
,CHEMBL622797,9606.0,U,BAO_0000019,Homo sapiens,,,Serum,5115,1977.0,4297,,1,,Half life in human serum; ND=not determined,A,,,Autocuration,0,,22224
,CHEMBL622798,9606.0,U,BAO_0000019,Homo sapiens,,,,5116,,4297,,1,,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Autocuration,0,,22224
,CHEMBL622799,9606.0,U,BAO_0000019,Homo sapiens,,,,5117,,4297,,1,,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Autocuration,0,,22224
,CHEMBL622800,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5118,1969.0,4231,,1,,Half life of the in human plasma,A,,,Autocuration,0,,22224
S9,CHEMBL622801,9606.0,U,BAO_0000220,Homo sapiens,,,,5119,,5633,,1,,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL622802,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5120,2107.0,5633,,1,,Half life period in human liver microsome was determined,A,In vitro,,Autocuration,0,,22224
,CHEMBL622803,9606.0,U,BAO_0000019,Homo sapiens,,,,5121,,17791,,1,,Half life period was determined; 6-7,A,,,Autocuration,0,,22224
,CHEMBL875154,9606.0,U,BAO_0000019,Homo sapiens,,,,5122,,17791,,1,,Half life period was evaluated in human,A,,,Autocuration,0,,22224
,CHEMBL622804,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5123,1969.0,3160,,1,,Half life time in human plasma,A,,,Autocuration,0,,22224
,CHEMBL622805,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5124,955.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622611,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5125,948.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622612,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5126,948.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL875160,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5127,2113.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622613,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5128,2113.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622614,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5129,2113.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622615,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5130,2107.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622616,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5131,2107.0,16438,,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Intermediate,1,,50594
,CHEMBL622617,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5132,2107.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622618,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5133,2106.0,16438,,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Intermediate,1,,50594
,CHEMBL622619,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5134,2106.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622620,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5135,2106.0,16438,,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622621,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5136,955.0,16438,,1,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622622,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5137,178.0,16438,,1,,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Intermediate,1,,50594
,CHEMBL622623,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5138,178.0,16438,,1,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622624,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5139,178.0,16438,,1,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622625,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5140,178.0,16438,,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622626,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5141,178.0,16438,,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622627,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5142,178.0,16438,,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622628,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5143,955.0,16438,,1,,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL622629,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5144,955.0,16438,,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622630,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5145,955.0,16438,,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622631,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5146,955.0,16438,,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622632,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5147,955.0,16438,,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622633,10090.0,N,BAO_0000218,Mus musculus,,,Brain,5148,955.0,16438,,1,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622634,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5149,948.0,16438,,1,,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL622635,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5150,948.0,16438,,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL875161,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5151,948.0,16438,,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622636,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5152,948.0,16438,,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL623335,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5153,948.0,16438,,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL623336,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5154,948.0,16438,,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL623337,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5155,2113.0,16438,,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL623338,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5156,2113.0,16438,,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL623339,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5157,2113.0,16438,,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL623524,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5158,2113.0,16438,,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL623525,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5159,2113.0,16438,,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL623526,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5160,2107.0,16438,,1,,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Intermediate,1,,50594
,CHEMBL623527,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5161,2107.0,16438,,1,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL623528,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5162,2107.0,16438,,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL624615,9606.0,N,BAO_0000219,Homo sapiens,,,,5163,,5245,,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,A-431,Intermediate,1,,80852
,CHEMBL621672,9606.0,N,BAO_0000219,Homo sapiens,,,,5164,,5245,,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,A-431,Intermediate,1,,80852
,CHEMBL621673,,N,BAO_0000218,,,,,5165,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,A-431,Expert,1,,80852
,CHEMBL621674,,N,BAO_0000218,,,,,5166,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,A-431,Expert,1,,80852
,CHEMBL884002,9606.0,D,BAO_0000219,Homo sapiens,,,,5167,,16093,,1,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,Expert,9,,9
,CHEMBL621850,9606.0,N,BAO_0000219,Homo sapiens,,,,5168,,16825,,1,500.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,A-431,Intermediate,1,,80852
,CHEMBL621851,9606.0,N,BAO_0000219,Homo sapiens,,,,5169,,4848,,1,500.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,A-431,Intermediate,1,,80852
,CHEMBL621852,9606.0,D,BAO_0000219,Homo sapiens,,,,5170,,14827,,1,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,A-431,Expert,9,,9
,CHEMBL621853,9606.0,D,BAO_0000219,Homo sapiens,,,,5171,,14827,,1,500.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,A-431,Expert,9,,9
,CHEMBL621854,,N,BAO_0000218,,,,,5172,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,A-431,Expert,1,,80852
,CHEMBL621855,,N,BAO_0000218,,,,,5173,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,A-431,Expert,1,,80852
,CHEMBL623724,,N,BAO_0000218,,,,,5174,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,A-431,Expert,1,,80852
,CHEMBL623725,,N,BAO_0000218,,,,,5175,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,A-431,Expert,1,,80852
,CHEMBL623726,,N,BAO_0000218,,,,,5176,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,A-431,Expert,1,,80852
,CHEMBL623727,9606.0,D,BAO_0000219,Homo sapiens,,,,5177,,16289,,1,500.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,A-431,Expert,9,,9
,CHEMBL623728,,H,BAO_0000219,,,,,5178,,16289,,1,500.0,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,A-431,Expert,8,,9
,CHEMBL623729,,N,BAO_0000218,,,,,5179,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,A-431,Expert,1,,80852
,CHEMBL623730,,N,BAO_0000218,,,,,5180,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,A-431,Expert,1,,80852
,CHEMBL623731,,N,BAO_0000218,,,,,5181,,16289,,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,A-431,Expert,1,,80852
,CHEMBL623732,10090.0,N,BAO_0000218,Mus musculus,,,,5182,,14555,,1,500.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,Expert,1,,80852
,CHEMBL623733,10090.0,N,BAO_0000218,Mus musculus,,,,5183,,14555,,1,500.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,Expert,1,,80852
,CHEMBL623734,10090.0,N,BAO_0000218,Mus musculus,,,,5184,,14555,,1,500.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,Expert,1,,80852
,CHEMBL623735,10090.0,N,BAO_0000218,Mus musculus,,,,5185,,14555,,1,500.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,Expert,1,,80852
,CHEMBL623736,9606.0,N,BAO_0000219,Homo sapiens,,,,5186,,1937,,1,500.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,A-431,Expert,1,,80852
,CHEMBL623737,9606.0,N,BAO_0000219,Homo sapiens,,,,5187,,13739,,1,500.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,A-431,Intermediate,1,,80852
,CHEMBL623738,9606.0,N,BAO_0000219,Homo sapiens,,,,5188,,3558,,1,500.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,A-431,Intermediate,1,,80852
,CHEMBL875168,9606.0,N,BAO_0000219,Homo sapiens,,,,5189,,3558,,1,500.0,Dose giving a 50% decrease in the living cell number (A437 cells),F,,A-431,Intermediate,1,,80852
,CHEMBL623739,9606.0,N,BAO_0000219,Homo sapiens,,,,5190,,17686,,1,646.0,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,A549,Expert,1,,80682
,CHEMBL623740,9606.0,N,BAO_0000219,Homo sapiens,,,,5191,,5305,,1,646.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,A549,Intermediate,1,,80682
,CHEMBL624424,9606.0,N,BAO_0000219,Homo sapiens,,,,5192,,3614,,1,646.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,A549,Intermediate,1,,80682
,CHEMBL624425,9606.0,N,BAO_0000219,Homo sapiens,,,,5193,,17229,,1,624.0,In vitro antitumor activity against renal A498 tumor cell lines,F,,A498,Intermediate,1,,80021
,CHEMBL624426,9606.0,N,BAO_0000219,Homo sapiens,,,,5194,,15935,,1,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,A498,Intermediate,1,,80021
,CHEMBL624427,9606.0,N,BAO_0000219,Homo sapiens,,,,5195,,15935,,1,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,A498,Intermediate,1,,80021
,CHEMBL624428,9606.0,N,BAO_0000219,Homo sapiens,,,,5196,,15560,,1,624.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,A498,Intermediate,1,,80021
,CHEMBL624429,9606.0,N,BAO_0000219,Homo sapiens,,,,5197,,13891,,1,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624620,9606.0,N,BAO_0000219,Homo sapiens,,,,5198,,13891,,1,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,A498,Intermediate,1,,80021
,CHEMBL624621,9606.0,N,BAO_0000219,Homo sapiens,,,,5199,,13788,,1,624.0,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624622,9606.0,N,BAO_0000219,Homo sapiens,,,,5200,,15403,,1,624.0,Compound was evaluated against Human cell line renal A498,F,,A498,Intermediate,1,,80021
,CHEMBL624623,9606.0,N,BAO_0000219,Homo sapiens,,,,5201,,1009,,1,624.0,Compound was tested for inhibition of A498 human renal cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL874365,9606.0,N,BAO_0000219,Homo sapiens,,,,5202,,1043,,1,624.0,Growth inhibitory activity against A498 human cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624624,9606.0,N,BAO_0000219,Homo sapiens,,,,5203,,5858,,1,624.0,In vitro antitumor activity against human renal A498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624625,9606.0,N,BAO_0000219,Homo sapiens,,,,5204,,5958,,1,624.0,In vitro cytotoxic activity against renal (A498) cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624626,9606.0,N,BAO_0000219,Homo sapiens,,,,5205,,5506,,1,624.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,A498,Intermediate,1,,80021
,CHEMBL624627,9606.0,N,BAO_0000219,Homo sapiens,,,,5206,,12781,,1,624.0,Tested for cytostatic activity against renal A498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL883157,9606.0,N,BAO_0000219,Homo sapiens,,,,5207,,14399,,1,624.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,A498,Intermediate,1,,80021
,CHEMBL624628,9606.0,N,BAO_0000219,Homo sapiens,,,,5208,,5958,,1,624.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,A498,Expert,1,,80021
,CHEMBL624629,9615.0,U,BAO_0000218,beagle,,,,5209,,3510,,1,,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,Autocuration,0,,22224
,CHEMBL623551,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,5210,,3510,beagle,1,,Bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL623552,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,5211,,3510,beagle,1,,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Autocuration,0,,22224
,CHEMBL623553,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,5212,,3510,beagle,1,,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Autocuration,0,,22224
,CHEMBL623554,9913.0,U,BAO_0000019,Bos taurus,,,,5213,,3085,,1,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Autocuration,0,,22224
,CHEMBL623555,9913.0,U,BAO_0000019,Bos taurus,,,,5214,,3085,,1,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Autocuration,0,,22224
,CHEMBL623556,9913.0,U,BAO_0000019,Bos taurus,,,,5215,,3085,,1,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Autocuration,0,,22224
,CHEMBL623557,9913.0,U,BAO_0000019,Bos taurus,,,,5216,,9372,,1,,Solubility against bovine alpha-chymotrypsin,A,,,Autocuration,0,,22224
,CHEMBL623558,9913.0,U,BAO_0000019,Bos taurus,,,,5217,,3085,,1,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Autocuration,0,,22224
,CHEMBL623559,9913.0,U,BAO_0000019,Bos taurus,,,,5218,,3085,,1,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Autocuration,0,,22224
,CHEMBL623560,9913.0,U,BAO_0000221,Bos taurus,,,Spleen,5219,2106.0,1469,,1,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Autocuration,0,,22224
,CHEMBL623561,9913.0,U,BAO_0000019,Bos taurus,,,,5220,,4297,,1,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Autocuration,0,,22224
,CHEMBL623562,9913.0,U,BAO_0000019,Bos taurus,,,,5221,,4297,,1,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Autocuration,0,,22224
,CHEMBL623563,9913.0,U,BAO_0000019,Bos taurus,,,,5222,,17585,,1,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Autocuration,0,,22224
,CHEMBL623564,9913.0,U,BAO_0000221,Bos taurus,,,Spleen,5223,2106.0,1336,,1,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Autocuration,0,,22224
,CHEMBL873806,9913.0,U,BAO_0000019,Bos taurus,,,,5224,,3085,,1,,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Autocuration,0,,22224
,CHEMBL623565,9913.0,U,BAO_0000019,Bos taurus,,,,5225,,2857,,1,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Autocuration,0,,22224
,CHEMBL623566,9913.0,U,BAO_0000019,Bos taurus,,,,5226,,2857,,1,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Autocuration,0,,22224
,CHEMBL623567,9913.0,U,BAO_0000019,Bos taurus,,,,5227,,2857,,1,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Autocuration,0,,22224
,CHEMBL623568,9913.0,U,BAO_0000019,Bos taurus,,,,5228,,1540,,1,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Autocuration,0,,22224
,CHEMBL623569,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5229,1969.0,6316,,1,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL623570,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5230,1969.0,17594,,1,,AUC after administration at 100 mg/kg/day in dogs,A,,,Intermediate,1,,50588
,CHEMBL624254,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5231,1969.0,4953,,1,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Intermediate,1,,50588
,CHEMBL624255,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5232,1969.0,16907,,1,,AUC value after 15 mg/kg iv dose in Dogs,A,,,Intermediate,1,,50588
,CHEMBL624256,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5233,1969.0,16907,,1,,AUC value after 30 mg/kg po dose in Dogs,A,,,Intermediate,1,,50588
,CHEMBL624257,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5234,1969.0,2959,,1,,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Intermediate,1,,50588
,CHEMBL624258,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5235,1969.0,17594,,1,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Intermediate,1,,50588
,CHEMBL875277,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5236,,5356,,1,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Intermediate,1,,50588
,CHEMBL622667,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5237,,16807,,1,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Intermediate,1,,50588
,CHEMBL622668,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5238,,4527,,1,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Intermediate,1,,50588
,CHEMBL622669,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5239,,4527,,1,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Intermediate,1,,50588
,CHEMBL622670,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5240,,15660,,1,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL622671,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5241,,15660,,1,,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL622672,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5242,,5802,,1,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Intermediate,1,,50588
,CHEMBL622673,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5243,,3598,,1,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50588
,CHEMBL622674,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5244,,3598,,1,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50588
,CHEMBL622675,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5245,,5944,,1,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622676,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5246,,5944,,1,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Intermediate,1,,50588
,CHEMBL622677,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5247,,5944,,1,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622678,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5248,,5944,,1,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Intermediate,1,,50588
,CHEMBL622679,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5249,,4186,,1,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Intermediate,1,,50588
,CHEMBL622680,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5250,,5007,,1,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622681,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5251,,5668,,1,,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Intermediate,1,,50588
,CHEMBL875278,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5252,,5668,,1,,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Intermediate,1,,50588
,CHEMBL622682,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5253,,5006,,1,,Area under curve was determined,A,,,Intermediate,1,,50588
,CHEMBL622683,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5254,,5006,,1,,Area under curve in dogs,A,,,Intermediate,1,,50588
,CHEMBL622684,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5255,,3771,,1,,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Intermediate,1,,50588
,CHEMBL622685,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5256,,3771,,1,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Intermediate,1,,50588
,CHEMBL622686,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5257,,3771,,1,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Intermediate,1,,50588
,CHEMBL618344,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5258,,1916,,1,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Intermediate,1,,50588
,CHEMBL875582,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5259,,5302,,1,,Area under curve value in dog at a dose of 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL618345,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5260,,5600,,1,,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Intermediate,1,,50588
,CHEMBL618346,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5261,,5600,,1,,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Intermediate,1,,50588
,CHEMBL618347,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5262,,17764,,1,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Intermediate,1,,50588
,CHEMBL618348,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5263,,4368,,1,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL618349,9606.0,U,BAO_0000019,Homo sapiens,,,,5264,,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Autocuration,0,,22224
,CHEMBL618350,9606.0,U,BAO_0000019,Homo sapiens,,,,5265,,5318,,1,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Autocuration,0,,22224
,CHEMBL618351,9606.0,U,BAO_0000019,Homo sapiens,,,,5266,,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Autocuration,0,,22224
,CHEMBL618352,9606.0,U,BAO_0000019,Homo sapiens,,,,5267,,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Autocuration,0,,22224
,CHEMBL873494,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5268,178.0,14518,,1,,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Autocuration,0,,22224
,CHEMBL618353,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5269,1969.0,2209,,1,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Autocuration,0,,22224
,CHEMBL618354,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5270,1969.0,6787,,1,,Half life in human plasma,A,,,Autocuration,0,,22224
,CHEMBL875583,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5271,1969.0,4898,,1,,Half life in human plasma was reported,A,,,Autocuration,0,,22224
,CHEMBL618355,9606.0,U,BAO_0000019,Homo sapiens,,,Serum,5272,1977.0,6072,,1,,Half life in human serum,A,,,Autocuration,0,,22224
,CHEMBL618356,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5273,1969.0,16907,,1,,Half life upon exposure to human plasma,A,,,Autocuration,0,,22224
Microsomes,CHEMBL618357,9606.0,U,BAO_0000251,Homo sapiens,,,,5274,,5656,,1,,t1/2 in human microsomes,A,In vitro,,Autocuration,0,,22224
,CHEMBL618358,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5275,1969.0,4755,,1,,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL618359,9606.0,U,BAO_0000221,Homo sapiens,,,Zone of skin,5276,14.0,17503,,1,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Autocuration,0,,22224
,CHEMBL618360,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5277,1969.0,12357,,1,,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Autocuration,0,,22224
,CHEMBL618361,9606.0,U,BAO_0000019,Homo sapiens,,,,5278,,3076,,1,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Autocuration,0,,22224
Microsomes,CHEMBL618362,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5279,2107.0,6410,,1,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Autocuration,0,,22224
,CHEMBL618363,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5280,1969.0,3741,,1,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Autocuration,0,,22224
,CHEMBL618364,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5281,1969.0,3741,,1,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Autocuration,0,,22224
,CHEMBL875584,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5282,1969.0,3741,,1,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Autocuration,0,,22224
,CHEMBL618365,9606.0,U,BAO_0000019,Homo sapiens,,,,5283,,1540,,1,,Half-life in the CEM cell extracts,A,,,Autocuration,0,,22224
,CHEMBL873495,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5284,1969.0,2905,,1,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL618366,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5285,1969.0,2905,,1,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Autocuration,0,,22224
,CHEMBL618367,9606.0,U,BAO_0000019,Homo sapiens,,,,5286,,5523,,1,,Half-life was determined,A,,,Autocuration,0,,22224
,CHEMBL618368,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5287,178.0,1499,,1,,Half-life (human blood stability),A,,,Autocuration,0,,22224
,CHEMBL618369,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5288,178.0,1499,,1,,Half-life (human blood stability); no data,A,,,Autocuration,0,,22224
,CHEMBL618370,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5289,1969.0,17065,,1,,Half-life in human plasma,A,,,Autocuration,0,,22224
,CHEMBL618371,9606.0,U,BAO_0000019,Homo sapiens,,,,5290,,6861,,1,,CYP3A4 metabolism half-life (t1/2),A,,,Autocuration,0,,22224
,CHEMBL618372,9606.0,U,BAO_0000221,Homo sapiens,,,Blood,5291,178.0,1499,,1,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Autocuration,0,,22224
,CHEMBL618373,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5292,1969.0,530,,1,,In vitro half life in human plasma,A,In vitro,,Autocuration,0,,22224
,CHEMBL618374,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5293,1969.0,1116,,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Autocuration,0,,22224
,CHEMBL618375,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5294,1969.0,6695,,1,,In vitro hydrolysis in human plasma,A,In vitro,,Autocuration,0,,22224
,CHEMBL618376,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5295,1969.0,6695,,1,,In vitro hydrolysis in human plasma; no data,A,In vitro,,Autocuration,0,,22224
Microsomes,CHEMBL618377,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5296,2107.0,10,,1,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Autocuration,0,,22224
,CHEMBL618378,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5297,1969.0,993,,1,,Plasma half life in human,A,,,Autocuration,0,,22224
,CHEMBL618379,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5298,1969.0,15429,,1,,Stability after incubation with human plasma (at 37 degree C),A,,,Autocuration,0,,22224
,CHEMBL618380,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5299,1969.0,1675,,1,,T1/2 was evaluated in human plasma,A,,,Autocuration,0,,22224
,CHEMBL618381,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5300,1969.0,2209,,1,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Autocuration,0,,22224
,CHEMBL618382,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5301,1969.0,2209,,1,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Autocuration,0,,22224
,CHEMBL618383,9606.0,U,BAO_0000019,Homo sapiens,,,,5302,,5318,,1,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Autocuration,0,,22224
,CHEMBL618384,9606.0,U,BAO_0000019,Homo sapiens,,,,5303,,2412,,1,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Autocuration,0,,22224
,CHEMBL618385,9606.0,U,BAO_0000019,Homo sapiens,,,,5304,,2412,,1,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Autocuration,0,,22224
,CHEMBL619099,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5305,1969.0,2906,,1,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Autocuration,0,,22224
,CHEMBL619100,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,5306,1969.0,2906,,1,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Autocuration,0,,22224
,CHEMBL619101,9606.0,U,BAO_0000019,Homo sapiens,,,,5307,,5495,,1,,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Autocuration,0,,22224
,CHEMBL619102,9606.0,U,BAO_0000019,Homo sapiens,,,,5308,,5495,,1,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Autocuration,0,,22224
Microsomes,CHEMBL619103,9606.0,U,BAO_0000251,Homo sapiens,,,Liver,5309,2107.0,4397,,1,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Autocuration,0,,22224
,CHEMBL619268,10095.0,U,BAO_0000218,Mus sp.,,,,5310,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL619269,10095.0,U,BAO_0000218,Mus sp.,,,,5311,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL619270,10095.0,U,BAO_0000218,Mus sp.,,,,5312,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL619271,10095.0,U,BAO_0000218,Mus sp.,,,,5313,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL875585,10095.0,U,BAO_0000218,Mus sp.,,,,5314,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL619272,10095.0,U,BAO_0000218,Mus sp.,,,,5315,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Autocuration,0,,22224
,CHEMBL619273,9606.0,N,BAO_0000219,Homo sapiens,,,,5316,,6058,,1,391.0,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,786-0,Intermediate,1,,80640
,CHEMBL619274,9606.0,N,BAO_0000219,Homo sapiens,,,,5317,,17708,,1,391.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619275,9606.0,N,BAO_0000219,Homo sapiens,,,,5318,,14017,,1,391.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,786-0,Expert,1,,80640
,CHEMBL619276,9606.0,N,BAO_0000219,Homo sapiens,,,,5319,,16818,,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,786-0,Intermediate,1,,80640
,CHEMBL619277,9606.0,N,BAO_0000219,Homo sapiens,,,,5320,,16818,,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,786-0,Intermediate,1,,80640
,CHEMBL619278,9606.0,N,BAO_0000219,Homo sapiens,,,,5321,,16818,,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,786-0,Intermediate,1,,80640
,CHEMBL619279,9606.0,N,BAO_0000219,Homo sapiens,,,,5322,,11970,,1,391.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL858458,9606.0,N,BAO_0000219,Homo sapiens,,,,5323,,12400,,1,391.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,786-0,Intermediate,1,,80640
,CHEMBL619280,9606.0,N,BAO_0000219,Homo sapiens,,,,5324,,12888,,1,391.0,Cytotoxic effect on renal cancer line 786-0,F,,786-0,Expert,1,,80640
,CHEMBL619281,9606.0,N,BAO_0000219,Homo sapiens,,,,5325,,15300,,1,391.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,786-0,Intermediate,1,,80640
,CHEMBL619282,9606.0,N,BAO_0000219,Homo sapiens,,,,5326,,14769,,1,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,786-0,Intermediate,1,,80640
,CHEMBL619283,9606.0,N,BAO_0000219,Homo sapiens,,,,5327,,15895,,1,391.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,786-0,Intermediate,1,,80640
,CHEMBL619284,9606.0,N,BAO_0000219,Homo sapiens,,,,5328,,17376,,1,391.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619285,9606.0,N,BAO_0000219,Homo sapiens,,,,5329,,14882,,1,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,786-0,Intermediate,1,,80640
,CHEMBL619286,9606.0,N,BAO_0000219,Homo sapiens,,,,5330,,14882,,1,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,786-0,Intermediate,1,,80640
,CHEMBL619287,9606.0,N,BAO_0000219,Homo sapiens,,,,5331,,15176,,1,391.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,786-0,Intermediate,1,,80640
,CHEMBL857455,9606.0,N,BAO_0000219,Homo sapiens,,,,5332,,12696,,1,391.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,786-0,Intermediate,1,,80640
,CHEMBL883801,9606.0,N,BAO_0000219,Homo sapiens,,,,5333,,2496,,1,391.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,786-0,Intermediate,1,,80640
,CHEMBL619288,9606.0,N,BAO_0000219,Homo sapiens,,,,5334,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,791T cell line,Intermediate,1,,80641
,CHEMBL619289,9606.0,N,BAO_0000219,Homo sapiens,,,,5335,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619290,9606.0,N,BAO_0000219,Homo sapiens,,,,5336,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,791T cell line,Intermediate,1,,80641
,CHEMBL619291,9606.0,N,BAO_0000219,Homo sapiens,,,,5337,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619292,9606.0,N,BAO_0000219,Homo sapiens,,,,5338,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619293,9606.0,N,BAO_0000219,Homo sapiens,,,,5339,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,791T cell line,Intermediate,1,,80641
,CHEMBL619294,9606.0,N,BAO_0000219,Homo sapiens,,,,5340,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619295,9606.0,N,BAO_0000219,Homo sapiens,,,,5341,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619296,9606.0,N,BAO_0000219,Homo sapiens,,,,5342,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,791T cell line,Intermediate,1,,80641
,CHEMBL619297,9606.0,N,BAO_0000219,Homo sapiens,,,,5343,,11831,,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,791T cell line,Intermediate,1,,80641
,CHEMBL619298,9606.0,N,BAO_0000219,Homo sapiens,,,,5344,,12782,,1,391.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,786-0,Intermediate,1,,80640
,CHEMBL619299,,U,BAO_0000019,,,,,5345,,1229,,1,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL619300,9606.0,N,BAO_0000219,Homo sapiens,,,,5346,,15313,,1,741.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,RPMI-8226,Expert,1,,80433
,CHEMBL619301,9606.0,N,BAO_0000219,Homo sapiens,,,,5347,,15313,,1,741.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,RPMI-8226,Expert,1,,80433
,CHEMBL619302,9606.0,N,BAO_0000219,Homo sapiens,,,,5348,,11544,,1,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619303,9606.0,N,BAO_0000219,Homo sapiens,,,,5349,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619304,9606.0,N,BAO_0000219,Homo sapiens,,,,5350,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL857706,9606.0,N,BAO_0000219,Homo sapiens,,,,5351,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619305,9606.0,N,BAO_0000219,Homo sapiens,,,,5352,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619306,9606.0,N,BAO_0000219,Homo sapiens,,,,5353,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619307,9606.0,N,BAO_0000219,Homo sapiens,,,,5354,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619308,9606.0,N,BAO_0000219,Homo sapiens,,,,5355,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619309,9606.0,N,BAO_0000219,Homo sapiens,,,,5356,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619310,9606.0,N,BAO_0000219,Homo sapiens,,,,5357,,9424,,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL619311,9606.0,N,BAO_0000219,Homo sapiens,,,,5358,,14769,,1,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,A498,Intermediate,1,,80021
,CHEMBL619312,9606.0,N,BAO_0000219,Homo sapiens,,,,5359,,15354,,1,624.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619313,9606.0,N,BAO_0000219,Homo sapiens,,,,5360,,17445,,1,624.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,A498,Intermediate,1,,80021
,CHEMBL619314,9606.0,N,BAO_0000219,Homo sapiens,,,,5361,,4337,,1,624.0,In vitro inhibitory concentration against renal cancer cell line A498,F,,A498,Intermediate,1,,80021
,CHEMBL619959,9606.0,N,BAO_0000219,Homo sapiens,,,,5362,,15277,,1,624.0,Cytotoxicity against A 498 tumor cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619960,9606.0,N,BAO_0000219,Homo sapiens,,,,5363,,4812,,1,624.0,In vitro antitumor activity against A498 human cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619961,9606.0,N,BAO_0000219,Homo sapiens,,,,5364,,4812,,1,624.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,A498,Intermediate,1,,80021
,CHEMBL619962,9606.0,N,BAO_0000219,Homo sapiens,,,,5365,,4995,,1,624.0,Inhibitory dose required against A498 human tumor cell lines,F,,A498,Intermediate,1,,80021
,CHEMBL875586,9606.0,N,BAO_0000219,Homo sapiens,,,,5366,,5847,,1,624.0,Anticancer activity against one renal cancer (A498 cell line),F,,A498,Intermediate,1,,80021
,CHEMBL619963,9606.0,N,BAO_0000219,Homo sapiens,,,,5367,,6557,,1,624.0,In vitro cytotoxicity against melanoma A498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619964,9606.0,N,BAO_0000219,Homo sapiens,,,,5368,,2597,,1,624.0,Compound was tested for growth inhibitory activity against A498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL620108,9606.0,N,BAO_0000219,Homo sapiens,,,,5369,,6058,,1,624.0,Compound tested for growth inhibition of renal cancer cell line A498,F,,A498,Intermediate,1,,80021
,CHEMBL620109,9606.0,N,BAO_0000219,Homo sapiens,,,,5370,,17708,,1,624.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,A498,Intermediate,1,,80021
,CHEMBL620110,9606.0,N,BAO_0000219,Homo sapiens,,,,5371,,15176,,1,624.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,A498,Intermediate,1,,80021
,CHEMBL620111,9606.0,N,BAO_0000219,Homo sapiens,,,,5372,,15300,,1,624.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,A498,Intermediate,1,,80021
,CHEMBL620112,9606.0,N,BAO_0000219,Homo sapiens,,,,5373,,11970,,1,624.0,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,A498,Intermediate,1,,80021
,CHEMBL620113,9606.0,N,BAO_0000219,Homo sapiens,,,,5374,,12400,,1,624.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,A498,Intermediate,1,,80021
,CHEMBL620114,9606.0,N,BAO_0000219,Homo sapiens,,,,5375,,12888,,1,624.0,Cytotoxic effect on renal cancer lines A498,F,,A498,Expert,1,,80021
,CHEMBL620115,9606.0,N,BAO_0000219,Homo sapiens,,,,5376,,3030,,1,624.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,A498,Intermediate,1,,80021
,CHEMBL620116,9606.0,N,BAO_0000219,Homo sapiens,,,,5377,,14769,,1,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,A498,Intermediate,1,,80021
,CHEMBL620117,9606.0,N,BAO_0000219,Homo sapiens,,,,5378,,17376,,1,624.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL620118,9606.0,N,BAO_0000219,Homo sapiens,,,,5379,,16558,,1,624.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,A498,Intermediate,1,,80021
,CHEMBL620119,9606.0,N,BAO_0000219,Homo sapiens,,,,5380,,5194,,1,624.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,A498,Intermediate,1,,80021
,CHEMBL620120,9606.0,N,BAO_0000219,Homo sapiens,,,,5381,,10708,,1,624.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,A498,Intermediate,1,,80021
,CHEMBL620121,9606.0,N,BAO_0000219,Homo sapiens,,,,5382,,16880,,1,646.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL620122,9606.0,N,BAO_0000219,Homo sapiens,,,,5383,,10196,,1,646.0,Antitumor activity against A549 human lung carcinoma cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620123,9606.0,N,BAO_0000219,Homo sapiens,,,,5384,,10196,,1,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,A549,Intermediate,1,,80682
,CHEMBL620124,9606.0,N,BAO_0000219,Homo sapiens,,,,5385,,10196,,1,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,A549,Intermediate,1,,80682
,CHEMBL620125,9606.0,N,BAO_0000219,Homo sapiens,,,,5386,,12083,,1,646.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,A549,Intermediate,1,,80682
,CHEMBL620126,9606.0,N,BAO_0000219,Homo sapiens,,,,5387,,16464,,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,A549,Expert,1,,80682
,CHEMBL883027,9606.0,N,BAO_0000219,Homo sapiens,,,,5388,,16464,,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A549,Intermediate,1,,80682
,CHEMBL620127,9606.0,N,BAO_0000219,Homo sapiens,,,,5389,,16470,,1,646.0,In vitro cytotoxic activity against human lung A549 cell line,F,,A549,Expert,1,,80682
,CHEMBL620128,9606.0,N,BAO_0000219,Homo sapiens,,,,5390,,16470,,1,646.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,A549,Intermediate,1,,80682
,CHEMBL620129,9606.0,N,BAO_0000219,Homo sapiens,,,,5391,,16470,,1,646.0,In vitro cytotoxic activity against human lung A549 cell line),F,,A549,Intermediate,1,,80682
,CHEMBL620130,9606.0,N,BAO_0000219,Homo sapiens,,,,5392,,16470,,1,646.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,A549,Intermediate,1,,80682
,CHEMBL620131,9606.0,N,BAO_0000219,Homo sapiens,,,,5393,,16582,,1,646.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,A549,Expert,1,,80682
,CHEMBL620132,9606.0,N,BAO_0000219,Homo sapiens,,,,5394,,15935,,1,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,A549,Intermediate,1,,80682
,CHEMBL620133,9606.0,N,BAO_0000219,Homo sapiens,,,,5395,,15935,,1,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,A549,Intermediate,1,,80682
,CHEMBL620134,9606.0,N,BAO_0000219,Homo sapiens,,,,5396,,16597,,1,646.0,Inhibition of A549 human lung carcinoma cell proliferation,F,,A549,Expert,1,,80682
,CHEMBL620135,9606.0,N,BAO_0000219,Homo sapiens,,,,5397,,17376,,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620136,9606.0,N,BAO_0000219,Homo sapiens,,,,5398,,16496,,1,646.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL620137,9606.0,N,BAO_0000219,Homo sapiens,,,,5399,,16152,,1,646.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620268,9606.0,N,BAO_0000219,Homo sapiens,,,,5400,,16152,,1,646.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620269,9606.0,N,BAO_0000219,Homo sapiens,,,,5401,,16464,,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A549,Intermediate,1,,80682
,CHEMBL620270,9606.0,N,BAO_0000219,Homo sapiens,,,,5402,,2288,,1,646.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620271,9606.0,N,BAO_0000219,Homo sapiens,,,,5403,,17350,,1,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL620272,9606.0,N,BAO_0000219,Homo sapiens,,,,5404,,4090,,1,646.0,Inhibition of A549 cancer cell proliferation,F,,A549,Expert,1,,80682
,CHEMBL620273,9606.0,N,BAO_0000219,Homo sapiens,,,,5405,,4090,,1,646.0,Inhibition of A549 cancer cell proliferation (Not tested),F,,A549,Expert,1,,80682
,CHEMBL620274,9606.0,N,BAO_0000219,Homo sapiens,,,,5406,,17350,,1,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL620275,9606.0,N,BAO_0000219,Homo sapiens,,,,5407,,4197,,1,646.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,A549,Intermediate,1,,80682
,CHEMBL620276,9606.0,N,BAO_0000219,Homo sapiens,,,,5408,,17072,,1,646.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL620277,9606.0,N,BAO_0000219,Homo sapiens,,,,5409,,17072,,1,646.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,A549,Intermediate,1,,80682
,CHEMBL620278,9606.0,N,BAO_0000219,Homo sapiens,,,,5410,,5194,,1,646.0,Cytotoxicity against Renal cell lines A549 was determined,F,,A549,Intermediate,1,,80682
,CHEMBL620279,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5411,,4257,,1,,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Intermediate,1,,50588
,CHEMBL620280,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5412,,6123,,1,,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL620281,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5413,,1337,,1,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Intermediate,1,,50588
,CHEMBL620282,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5414,,1337,,1,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Intermediate,1,,50588
,CHEMBL621134,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5415,,8833,,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Intermediate,1,,50588
,CHEMBL621135,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5416,,8833,,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Intermediate,1,,50588
,CHEMBL621136,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5417,,8833,,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Intermediate,1,,50588
,CHEMBL621137,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5418,,8833,,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Intermediate,1,,50588
,CHEMBL621138,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5419,1969.0,17657,,1,,Area under plasma concentration time curve in dog upon oral administration,A,,,Intermediate,1,,50588
,CHEMBL875587,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5420,1969.0,17650,,1,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Intermediate,1,,50588
,CHEMBL621139,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5421,,1977,,1,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Intermediate,1,,50588
,CHEMBL621140,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5422,,1977,,1,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Intermediate,1,,50588
,CHEMBL621141,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5423,,3132,,1,,Area under the curve for the compound was obtained when tested in dog,A,,,Intermediate,1,,50588
,CHEMBL621142,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5424,,5473,,1,,Area under the curve at a dose of 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL621143,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5425,,5474,,1,,Area under the curve at a dose of 1 mg/kg (oral),A,,,Intermediate,1,,50588
,CHEMBL621144,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5426,,5474,,1,,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL621145,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5427,,6062,,1,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL621146,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5428,,4709,,1,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL622567,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5429,,2652,,1,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Intermediate,1,,50588
,CHEMBL622568,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5430,,2652,,1,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Intermediate,1,,50588
,CHEMBL622569,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5431,,2877,,1,,Compound was evaluated for area under the curve in dog blood.,A,,,Intermediate,1,,50588
,CHEMBL622570,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5432,,5444,,1,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Intermediate,1,,50588
,CHEMBL622571,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5433,1969.0,5130,,1,,AUC in dog after oral dose (1 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622572,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5434,,6265,,1,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL622573,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5435,,4657,,1,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Intermediate,1,,50588
,CHEMBL622574,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5436,,16367,,1,,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Intermediate,1,,50588
,CHEMBL622575,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5437,,16367,,1,,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Intermediate,1,,50588
,CHEMBL622576,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5438,,9579,,1,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Intermediate,1,,50588
,CHEMBL622577,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5439,,9579,,1,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Intermediate,1,,50588
,CHEMBL622578,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5440,,5983,,1,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Intermediate,1,,50588
,CHEMBL622579,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5441,,6241,,1,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL622580,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5442,,5313,,1,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Intermediate,1,,50588
,CHEMBL622581,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5443,,5313,,1,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Intermediate,1,,50588
,CHEMBL622582,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5444,,6642,,1,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Intermediate,1,,50588
,CHEMBL622583,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5445,,6642,,1,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Intermediate,1,,50588
,CHEMBL622584,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5446,,6641,,1,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Intermediate,1,,50588
,CHEMBL622585,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5447,,6642,,1,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Intermediate,1,,50588
,CHEMBL622586,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5448,,17791,,1,,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Intermediate,1,,50588
,CHEMBL623281,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5449,,17655,,1,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Intermediate,1,,50588
,CHEMBL623282,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5450,,17655,,1,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Intermediate,1,,50588
,CHEMBL623283,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5451,,6596,,1,,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Intermediate,1,,50588
,CHEMBL623284,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5452,,3880,,1,,Oral bioavailability in dog,A,,,Intermediate,1,,50588
,CHEMBL623285,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5453,,16367,,1,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Intermediate,1,,50588
,CHEMBL623463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5454,1969.0,17409,,1,,Plasma protein binding towards dog plasma at 10 uM,A,,,Intermediate,1,,50588
,CHEMBL875952,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5455,1969.0,17409,,1,,Plasma protein binding towards dog plasma at 100 uM,A,,,Intermediate,1,,50588
,CHEMBL621705,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5456,,2959,,1,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621706,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5457,,13501,,1,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621707,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5458,,4527,,1,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621708,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5459,,15145,,1,,Bioavailability in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621709,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5460,,4219,,1,,Bioavailability,A,In vivo,,Intermediate,1,,50588
,CHEMBL621710,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5461,,17538,,1,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621711,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5462,,17538,,1,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621712,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5463,,1466,,1,,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621713,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5464,,17650,,1,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621714,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5465,,3132,,1,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621715,10095.0,U,BAO_0000218,Mus sp.,,,,5466,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL623717,10095.0,U,BAO_0000218,Mus sp.,,,Liver,5467,2107.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL623718,10095.0,U,BAO_0000218,Mus sp.,,,Liver,5468,2107.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Autocuration,0,,22224
,CHEMBL623719,10095.0,U,BAO_0000218,Mus sp.,,,Liver,5469,2107.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL623720,10095.0,U,BAO_0000218,Mus sp.,,,,5470,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL623721,10095.0,U,BAO_0000218,Mus sp.,,,,5471,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL623722,10095.0,U,BAO_0000218,Mus sp.,,,Muscle tissue,5472,2385.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL623723,10095.0,U,BAO_0000218,Mus sp.,,,Muscle tissue,5473,2385.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Autocuration,0,,22224
,CHEMBL618543,10095.0,U,BAO_0000218,Mus sp.,,,Muscle tissue,5474,2385.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL618544,10095.0,U,BAO_0000218,Mus sp.,,,Spleen,5475,2106.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL875155,10095.0,U,BAO_0000218,Mus sp.,,,Spleen,5476,2106.0,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL618545,10095.0,U,BAO_0000218,Mus sp.,,,,5477,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Autocuration,0,,22224
,CHEMBL618546,10095.0,U,BAO_0000218,Mus sp.,,,,5478,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Autocuration,0,,22224
,CHEMBL623529,10095.0,U,BAO_0000218,Mus sp.,,,,5479,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL623530,10095.0,U,BAO_0000218,Mus sp.,,,,5480,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Autocuration,0,,22224
,CHEMBL621764,10095.0,U,BAO_0000218,Mus sp.,,,,5481,,2413,,1,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Autocuration,0,,22224
,CHEMBL621765,9527.0,U,BAO_0000019,Cercopithecidae,,,,5482,,17827,,1,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621766,9527.0,U,BAO_0000019,Cercopithecidae,,,Cerebellum,5483,2037.0,17827,,1,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621767,9527.0,U,BAO_0000019,Cercopithecidae,,,Frontal cortex,5484,1870.0,17827,,1,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621768,9527.0,U,BAO_0000019,Cercopithecidae,,,,5485,,17827,,1,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621769,9527.0,U,BAO_0000019,Cercopithecidae,,,Striatum,5486,2435.0,17827,,1,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621770,9527.0,U,BAO_0000019,Cercopithecidae,,,,5487,,17827,,1,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621771,9527.0,U,BAO_0000019,Cercopithecidae,,,Cerebellum,5488,2037.0,17827,,1,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621772,9527.0,U,BAO_0000019,Cercopithecidae,,,Frontal cortex,5489,1870.0,17827,,1,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621773,9527.0,U,BAO_0000019,Cercopithecidae,,,,5490,,17827,,1,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621774,9527.0,U,BAO_0000019,Cercopithecidae,,,Striatum,5491,2435.0,17827,,1,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Autocuration,0,,22224
,CHEMBL621775,9527.0,U,BAO_0000218,Cercopithecidae,,,,5492,,17791,,1,,Compound was evaluated for oral bioavailability in rats,A,,,Autocuration,0,,22224
,CHEMBL621776,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,5493,1969.0,17667,,1,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL621777,9527.0,U,BAO_0000019,Cercopithecidae,,,,5494,,17791,,1,,Half life period was evaluated in monkey,A,,,Autocuration,0,,22224
,CHEMBL875162,9527.0,U,BAO_0000218,Cercopithecidae,,,,5495,,110,,1,,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL621778,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,5496,1969.0,5781,,1,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Intermediate,1,,50594
,CHEMBL621779,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,5497,1969.0,17734,,1,,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL622479,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,5498,1969.0,17718,,1,,AUC value was determined after oral administration,A,,,Intermediate,1,,50594
,CHEMBL622480,10090.0,N,BAO_0000218,Mus musculus,,,,5499,,4573,,1,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Intermediate,1,,50594
,CHEMBL622481,10090.0,N,BAO_0000218,Mus musculus,,,,5500,,3277,,1,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Intermediate,1,,50594
,CHEMBL622482,10090.0,N,BAO_0000218,Mus musculus,,,,5501,,2862,,1,,Area under curve by ioral administration in mouse,A,,,Intermediate,1,,50594
,CHEMBL622483,10090.0,N,BAO_0000218,Mus musculus,,,,5502,,2862,,1,,Area under curve by iv administration in mouse,A,,,Intermediate,1,,50594
,CHEMBL622484,10090.0,N,BAO_0000218,Mus musculus,,,,5503,,5951,,1,,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Intermediate,1,,50594
,CHEMBL622641,10090.0,N,BAO_0000218,Mus musculus,,,,5504,,17729,,1,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622642,10090.0,N,BAO_0000218,Mus musculus,,,,5505,,17728,,1,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622643,10090.0,N,BAO_0000218,Mus musculus,,,,5506,,17728,,1,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622644,10090.0,N,BAO_0000218,Mus musculus,,,,5507,,17729,,1,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622645,9606.0,N,BAO_0000219,Homo sapiens,,,,5508,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL622646,9606.0,N,BAO_0000219,Homo sapiens,,,,5509,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL621238,9606.0,N,BAO_0000219,Homo sapiens,,,,5510,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL621239,9606.0,N,BAO_0000219,Homo sapiens,,,,5511,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL621240,9606.0,N,BAO_0000219,Homo sapiens,,,,5512,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL621241,9606.0,N,BAO_0000219,Homo sapiens,,,,5513,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL621242,9606.0,N,BAO_0000219,Homo sapiens,,,,5514,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620350,9606.0,N,BAO_0000219,Homo sapiens,,,,5515,,9424,,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620351,9606.0,N,BAO_0000219,Homo sapiens,,,,5516,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620352,9606.0,N,BAO_0000219,Homo sapiens,,,,5517,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620353,9606.0,N,BAO_0000219,Homo sapiens,,,,5518,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620354,9606.0,N,BAO_0000219,Homo sapiens,,,,5519,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620355,9606.0,N,BAO_0000219,Homo sapiens,,,,5520,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620356,9606.0,N,BAO_0000219,Homo sapiens,,,,5521,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620357,9606.0,N,BAO_0000219,Homo sapiens,,,,5522,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620358,9606.0,N,BAO_0000219,Homo sapiens,,,,5523,,9424,,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620359,9606.0,N,BAO_0000219,Homo sapiens,,,,5524,,9424,,1,741.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,RPMI-8226,Expert,1,,80433
,CHEMBL620360,9606.0,N,BAO_0000219,Homo sapiens,,,,5525,,11544,,1,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620361,9606.0,N,BAO_0000219,Homo sapiens,,,,5526,,17378,,1,741.0,Cytotoxicity of compound against 8226/DOX1V cells,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620362,9606.0,N,BAO_0000219,Homo sapiens,,,,5527,,17378,,1,741.0,Cytotoxicity of compound against 8226/S cells,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620363,9606.0,N,BAO_0000219,Homo sapiens,,,,5528,,17079,,1,741.0,Inhibitory concentration against 8226 myeloma cancer cell line,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620364,9606.0,N,BAO_0000219,Homo sapiens,,,,5529,,17079,,1,741.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,RPMI-8226,Intermediate,1,,80433
,CHEMBL620365,9606.0,N,BAO_0000219,Homo sapiens,,,,5530,,13466,,1,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,833K,Intermediate,1,,80647
,CHEMBL620366,9606.0,N,BAO_0000219,Homo sapiens,,,,5531,,13466,,1,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,833K,Intermediate,1,,80647
,CHEMBL620367,9606.0,N,BAO_0000219,Homo sapiens,,,,5532,,2392,,1,854.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,833K,Expert,1,,80647
,CHEMBL620368,9606.0,N,BAO_0000219,Homo sapiens,,,,5533,,2392,,1,854.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,833K,Intermediate,1,,80647
,CHEMBL620369,,U,BAO_0000019,,,,,5534,,6608,,1,,Inhibitory activity against caspase-1,B,,,Autocuration,0,,22226
,CHEMBL620370,1351.0,H,BAO_0000357,Enterococcus faecalis,,,,5535,,10199,,1,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Autocuration,8,,45
,CHEMBL620371,9606.0,N,BAO_0000219,Homo sapiens,,,,5536,,17749,,1,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,8701-BC,Intermediate,1,,80648
,CHEMBL620372,9606.0,N,BAO_0000219,Homo sapiens,,,,5537,,17749,,1,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,8701-BC,Intermediate,1,,80648
,CHEMBL876492,,U,BAO_0000019,,,,,5538,,1229,,1,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL620373,,U,BAO_0000019,,,,,5539,,1229,,1,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL620374,,U,BAO_0000019,,,,,5540,,1229,,1,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,Intermediate,0,,22226
,CHEMBL620375,,U,BAO_0000019,,,,,5541,,6390,,1,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,Autocuration,0,,22226
,CHEMBL857902,1314.0,U,BAO_0000019,Streptococcus pyogenes,,,,5542,,16219,,1,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Autocuration,0,,22226
,CHEMBL620376,1314.0,U,BAO_0000019,Streptococcus pyogenes,,,,5543,,16219,,1,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Autocuration,0,,22226
,CHEMBL620377,,H,BAO_0000357,,,,,5544,,17043,,1,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,Autocuration,8,,11922
,CHEMBL620378,9606.0,N,BAO_0000219,Homo sapiens,,,,5545,,6929,,1,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,KB ,Intermediate,1,,81115
,CHEMBL620379,9606.0,N,BAO_0000219,Homo sapiens,,,,5546,,6929,,1,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,KB ,Intermediate,1,,81115
,CHEMBL620380,9606.0,U,BAO_0000219,Homo sapiens,,,,5547,,7083,,1,,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Autocuration,0,,22226
,CHEMBL884006,10116.0,N,BAO_0000219,Rattus norvegicus,,,,5548,,12446,,1,392.0,Cytotoxic concentration against 9L cells was determined on day 3,F,,9L,Intermediate,1,,80653
,CHEMBL620381,10116.0,N,BAO_0000219,Rattus norvegicus,,,,5549,,15345,,1,392.0,Tested in vitro for anticancer activity against 9L cells,F,,9L,Expert,1,,80653
,CHEMBL620382,10116.0,N,BAO_0000219,Rattus norvegicus,,,,5550,,15345,,1,392.0,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,9L,Expert,1,,80653
,CHEMBL620383,9606.0,N,BAO_0000219,Homo sapiens,,,,5551,,6301,,1,646.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,A549,Intermediate,1,,80682
,CHEMBL876493,9606.0,N,BAO_0000219,Homo sapiens,,,,5552,,4833,,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL620384,9606.0,N,BAO_0000219,Homo sapiens,,,,5553,,4833,,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL620385,9606.0,N,BAO_0000219,Homo sapiens,,,,5554,,4833,,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL620386,9606.0,N,BAO_0000219,Homo sapiens,,,,5555,,13330,,1,646.0,Cytotoxicity against human lung carcinoma A549 cell line,F,,A549,Expert,1,,80682
,CHEMBL620387,9606.0,D,BAO_0000219,Homo sapiens,,,,5556,,17517,,1,646.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,A549,Expert,9,,25
,CHEMBL621404,9606.0,D,BAO_0000219,Homo sapiens,,,,5557,,17517,,1,646.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,A549,Expert,9,,25
,CHEMBL621405,9606.0,N,BAO_0000219,Homo sapiens,,,,5558,,14425,,1,646.0,"In vitro growth inhibition of A549, lung carcinoma",F,,A549,Intermediate,1,,80682
,CHEMBL621406,9606.0,N,BAO_0000219,Homo sapiens,,,,5559,,14425,,1,646.0,"In vitro growth inhibition of A549, lung carcinoma.",F,,A549,Intermediate,1,,80682
,CHEMBL621407,9606.0,N,BAO_0000219,Homo sapiens,,,,5560,,5228,,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL621408,9606.0,N,BAO_0000219,Homo sapiens,,,,5561,,5351,,1,646.0,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,A549,Intermediate,1,,80682
,CHEMBL885345,9606.0,N,BAO_0000219,Homo sapiens,,,,5562,,12198,,1,646.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,A549,Expert,1,,80682
,CHEMBL621409,9606.0,N,BAO_0000219,Homo sapiens,,,,5563,,13891,,1,646.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL876034,9606.0,N,BAO_0000219,Homo sapiens,,,,5564,,5677,,1,646.0,Cytotoxicity in A549 (human carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL621410,9606.0,N,BAO_0000219,Homo sapiens,,,,5565,,13788,,1,646.0,Cytotoxicity on lung carcinoma (A-549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621411,9606.0,N,BAO_0000219,Homo sapiens,,,,5566,,13384,,1,646.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,A549,Expert,1,,80682
,CHEMBL621412,9606.0,N,BAO_0000219,Homo sapiens,,,,5567,,6726,,1,646.0,Effective dose of compound against replication of A549 cell line was evaluated,F,,A549,Intermediate,1,,80682
,CHEMBL621413,9606.0,N,BAO_0000219,Homo sapiens,,,,5568,,3455,,1,646.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,A549,Expert,1,,80682
,CHEMBL621414,9606.0,N,BAO_0000219,Homo sapiens,,,,5569,,5726,,1,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,A549,Intermediate,1,,80682
,CHEMBL621415,9606.0,N,BAO_0000219,Homo sapiens,,,,5570,,5726,,1,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,A549,Intermediate,1,,80682
,CHEMBL621416,9606.0,N,BAO_0000219,Homo sapiens,,,,5571,,3936,,1,646.0,The compound was evaluated for antiproliferative activity against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621417,9606.0,N,BAO_0000219,Homo sapiens,,,,5572,,14991,,1,646.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,A549,Intermediate,1,,80682
,CHEMBL621418,9606.0,N,BAO_0000219,Homo sapiens,,,,5573,,5243,,1,646.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,A549,Intermediate,1,,80682
,CHEMBL621419,9606.0,N,BAO_0000219,Homo sapiens,,,,5574,,12858,,1,646.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621420,9606.0,N,BAO_0000219,Homo sapiens,,,,5575,,6776,,1,646.0,Growth inhibition against A549 cell line was evaluated,F,,A549,Intermediate,1,,80682
,CHEMBL875823,9606.0,N,BAO_0000219,Homo sapiens,,,,5576,,16558,,1,646.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL621421,9606.0,N,BAO_0000219,Homo sapiens,,,,5577,,4583,,1,646.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,A549,Expert,1,,80682
,CHEMBL621422,9606.0,N,BAO_0000219,Homo sapiens,,,,5578,,13514,,1,646.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,A549,Intermediate,1,,80682
,CHEMBL884014,9606.0,N,BAO_0000219,Homo sapiens,,,,5579,,15166,,1,646.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,A549,Expert,1,,80682
,CHEMBL621423,9606.0,N,BAO_0000219,Homo sapiens,,,,5580,,13873,,1,646.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,A549,Intermediate,1,,80682
,CHEMBL621424,9606.0,N,BAO_0000219,Homo sapiens,,,,5581,,6447,,1,646.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,A549,Expert,1,,80682
,CHEMBL621425,9606.0,N,BAO_0000219,Homo sapiens,,,,5582,,2068,,1,646.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,A549,Intermediate,1,,80682
,CHEMBL621426,9606.0,N,BAO_0000219,Homo sapiens,,,,5583,,1863,,1,646.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,A549,Expert,1,,80682
,CHEMBL621427,9606.0,N,BAO_0000219,Homo sapiens,,,,5584,,13873,,1,646.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,A549,Intermediate,1,,80682
,CHEMBL621428,9606.0,N,BAO_0000219,Homo sapiens,,,,5585,,13873,,1,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,A549,Intermediate,1,,80682
,CHEMBL621429,9606.0,N,BAO_0000219,Homo sapiens,,,,5586,,13873,,1,646.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,A549,Expert,1,,80682
,CHEMBL621430,9606.0,N,BAO_0000219,Homo sapiens,,,,5587,,579,,1,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,A549,Intermediate,1,,80682
,CHEMBL621431,9606.0,N,BAO_0000219,Homo sapiens,,,,5588,,579,,1,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,A549,Intermediate,1,,80682
,CHEMBL621432,9606.0,N,BAO_0000219,Homo sapiens,,,,5589,,4584,,1,646.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL621433,9606.0,N,BAO_0000219,Homo sapiens,,,,5590,,5421,,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,A549,Expert,1,,80682
,CHEMBL875824,9606.0,N,BAO_0000219,Homo sapiens,,,,5591,,5421,,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621434,9606.0,N,BAO_0000219,Homo sapiens,,,,5592,,5421,,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,A549,Intermediate,1,,80682
,CHEMBL621435,9606.0,N,BAO_0000219,Homo sapiens,,,,5593,,5421,,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,A549,Intermediate,1,,80682
,CHEMBL621436,9606.0,N,BAO_0000219,Homo sapiens,,,,5594,,14188,,1,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,A549,Intermediate,1,,80682
,CHEMBL621437,9606.0,N,BAO_0000219,Homo sapiens,,,,5595,,14188,,1,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,A549,Intermediate,1,,80682
,CHEMBL621438,9606.0,N,BAO_0000219,Homo sapiens,,,,5596,,15354,,1,646.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621439,9606.0,N,BAO_0000219,Homo sapiens,,,,5597,,14253,,1,646.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,A549,Expert,1,,80682
,CHEMBL621440,9606.0,N,BAO_0000219,Homo sapiens,,,,5598,,13873,,1,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,A549,Intermediate,1,,80682
,CHEMBL621441,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5599,,3043,,1,,Oral bioavailability in dog (conscious),A,In vivo,,Intermediate,1,,50588
,CHEMBL621442,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5600,,3045,,1,,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL621443,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5601,,3022,,1,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621444,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5602,,4453,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625133,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5603,,1696,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625134,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5604,,5045,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625135,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5605,,5356,,1,,Oral bioavailability in dog (fasted),A,In vivo,,Intermediate,1,,50588
,CHEMBL625136,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5606,,17764,,1,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625137,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5607,,6448,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625138,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5608,,1475,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625139,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5609,,3788,,1,,Percent bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL872264,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5610,,3639,,1,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625140,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5611,,13397,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624436,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5612,,2137,,1,,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Intermediate,1,,50588
,CHEMBL624437,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5613,,2959,,1,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL872261,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5614,,6448,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624438,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5615,,6084,,1,,8 hour trough Blood level in dog was measured after administration of compound,A,,,Intermediate,1,,50588
,CHEMBL624439,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5616,1969.0,3639,,1,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Intermediate,1,,50588
,CHEMBL624440,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5617,,6316,,1,,C24 after oral administration at 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL624441,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5618,,5238,,1,,Clearance after oral and iv dosing in dogs,A,,,Intermediate,1,,50588
,CHEMBL624442,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5619,1969.0,17796,,1,,Clearance of the drug was measured in the plasma of dog,A,,,Intermediate,1,,50588
,CHEMBL624443,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5620,,2652,,1,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Intermediate,1,,50588
,CHEMBL624444,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5621,,5654,,1,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624445,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5622,,6621,,1,,Clearance of compound was determined in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624446,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5623,,6505,,1,,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624447,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5624,,5802,,1,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624448,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5625,,17267,,1,,Plasma clearance in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624449,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5626,,4521,,1,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624450,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5627,,6535,,1,,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL875942,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5628,,6535,,1,,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL624451,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5629,,6535,,1,,Plasma clearance in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624452,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5630,,5542,,1,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624453,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5631,,5199,,1,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Intermediate,1,,50588
,CHEMBL624454,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5632,,16907,,1,,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624455,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5633,,16907,,1,,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624456,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5634,,16367,,1,,Plasma administration to dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624457,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5635,,5505,,1,,Plasma clearance was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624458,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5636,,6215,,1,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624459,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5637,,1466,,1,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
Microsomes,CHEMBL624460,9606.0,S,BAO_0000251,Homo sapiens,,,Liver,5638,2107.0,5007,,1,,Intrinsic clearance in human liver microsomes,A,In vitro,,Intermediate,2,,102164
Microsomes,CHEMBL624461,9606.0,S,BAO_0000251,Homo sapiens,,,Liver,5639,2107.0,5007,,1,,Intrinsic clearance in human liver microsomes,A,In vitro,,Intermediate,2,,102164
,CHEMBL875943,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5640,,16452,,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Intermediate,1,,50588
,CHEMBL624462,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5641,,16452,,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Intermediate,1,,50588
,CHEMBL624463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5642,,16452,,1,,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL624464,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5643,,6221,,1,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624465,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5644,,5007,,1,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL624466,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5645,,5668,,1,,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624467,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5646,,5668,,1,,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624468,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5647,,5668,,1,,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624469,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5648,,15660,,1,,Plasma clearance was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624470,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5649,,15660,,1,,Plasma clearance was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624471,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5650,,5983,,1,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Intermediate,1,,50588
,CHEMBL624472,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5651,,5600,,1,,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622775,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5652,,17764,,1,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622776,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5653,,6039,,1,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL622777,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5654,,6039,,1,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL622778,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5655,,6039,,1,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL622779,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5656,,4368,,1,,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622780,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5657,,4305,,1,,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622781,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5658,1969.0,1918,,1,,Clearance value was evaluated in dog plasma,A,In vivo,,Intermediate,1,,50588
,CHEMBL622782,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5659,,6005,,1,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622783,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5660,1969.0,4839,,1,,Compound was tested for plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622784,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5661,,4239,,1,,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622785,10090.0,N,BAO_0000218,Mus musculus,,,,5662,,17729,,1,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622786,10090.0,N,BAO_0000218,Mus musculus,,,,5663,,17728,,1,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL622787,10090.0,N,BAO_0000218,Mus musculus,,,,5664,,5302,,1,,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL875949,10090.0,N,BAO_0000218,Mus musculus,,,,5665,,5506,,1,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Intermediate,1,,50594
,CHEMBL622788,10090.0,N,BAO_0000218,Mus musculus,,,,5666,,5506,,1,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Intermediate,1,,50594
,CHEMBL622789,10090.0,N,BAO_0000218,Mus musculus,,,,5667,,17764,,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Intermediate,1,,50594
,CHEMBL622790,10090.0,N,BAO_0000218,Mus musculus,,,,5668,,17764,,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Intermediate,1,,50594
,CHEMBL622791,10090.0,N,BAO_0000218,Mus musculus,,,,5669,,17764,,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Intermediate,1,,50594
,CHEMBL622792,10090.0,N,BAO_0000218,Mus musculus,,,,5670,,17764,,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Intermediate,1,,50594
,CHEMBL622793,10090.0,N,BAO_0000218,Mus musculus,,,,5671,,17764,,1,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Intermediate,1,,50594
,CHEMBL622794,10090.0,N,BAO_0000218,Mus musculus,,,,5672,,17753,,1,,Area under curve was determined for the compound at 24 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL622795,10090.0,N,BAO_0000218,Mus musculus,,,,5673,,17753,,1,,Area under curve was determined for the compound at 40 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL621803,10090.0,N,BAO_0000218,Mus musculus,,,,5674,,17753,,1,,Area under curve was determined for the compound at 5 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL621804,10090.0,N,BAO_0000218,Mus musculus,,,,5675,,3132,,1,,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621805,10090.0,N,BAO_0000218,Mus musculus,,,,5676,,3132,,1,,Area under the curve for the compound was obtained when tested in mouse,A,,,Intermediate,1,,50594
,CHEMBL621806,10090.0,N,BAO_0000218,Mus musculus,,,,5677,,17837,,1,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621807,10090.0,N,BAO_0000218,Mus musculus,,,,5678,,17837,,1,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621808,10090.0,N,BAO_0000218,Mus musculus,,,,5679,,6062,,1,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621809,10090.0,N,BAO_0000218,Mus musculus,,,,5680,,4066,,1,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL621810,10090.0,N,BAO_0000218,Mus musculus,,,,5681,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Intermediate,1,,50594
,CHEMBL875164,10090.0,N,BAO_0000218,Mus musculus,,,,5682,,14239,,1,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL621811,10090.0,N,BAO_0000218,Mus musculus,,,,5683,,14239,,1,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL621812,10090.0,N,BAO_0000218,Mus musculus,,,,5684,,4890,,1,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Intermediate,1,,50594
,CHEMBL621813,10090.0,N,BAO_0000218,Mus musculus,,,,5685,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Intermediate,1,,50594
,CHEMBL621814,10090.0,N,BAO_0000218,Mus musculus,,,,5686,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Intermediate,1,,50594
,CHEMBL621815,10090.0,N,BAO_0000218,Mus musculus,,,,5687,,5969,,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621816,10090.0,N,BAO_0000218,Mus musculus,,,,5688,,5969,,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL621817,10090.0,N,BAO_0000218,Mus musculus,,,,5689,,5969,,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Intermediate,1,,50594
,CHEMBL621818,10090.0,N,BAO_0000218,Mus musculus,,,,5690,,6091,,1,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Intermediate,1,,50594
,CHEMBL621819,10090.0,N,BAO_0000218,Mus musculus,,,,5691,,6091,,1,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Intermediate,1,,50594
,CHEMBL621820,10090.0,N,BAO_0000218,Mus musculus,,,,5692,,6091,,1,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL621821,10090.0,N,BAO_0000218,Mus musculus,,,,5693,,6091,,1,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Intermediate,1,,50594
,CHEMBL621822,10090.0,N,BAO_0000218,Mus musculus,,,,5694,,6178,,1,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL619474,10090.0,N,BAO_0000218,Mus musculus,,,,5695,,6178,,1,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL619475,10090.0,N,BAO_0000218,Mus musculus,,,,5696,,6619,,1,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Intermediate,1,,50594
,CHEMBL619476,10090.0,N,BAO_0000218,Mus musculus,,,,5697,,6619,,1,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Intermediate,1,,50594
,CHEMBL619477,10090.0,N,BAO_0000218,Mus musculus,,,,5698,,3760,,1,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Intermediate,1,,50594
,CHEMBL619478,10090.0,N,BAO_0000218,Mus musculus,,,,5699,,3760,,1,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Intermediate,1,,50594
,CHEMBL619479,10090.0,N,BAO_0000218,Mus musculus,,,,5700,,3760,,1,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Intermediate,1,,50594
,CHEMBL619480,10090.0,N,BAO_0000218,Mus musculus,,,,5701,,3760,,1,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Intermediate,1,,50594
,CHEMBL619481,10090.0,N,BAO_0000218,Mus musculus,,,,5702,,3192,,1,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Intermediate,1,,50594
,CHEMBL619482,10090.0,N,BAO_0000218,Mus musculus,,,,5703,,3192,,1,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Intermediate,1,,50594
,CHEMBL619483,10090.0,N,BAO_0000218,Mus musculus,,,,5704,,2675,,1,,Area under the curve was evaluated in mice after intravenous administration,A,,,Intermediate,1,,50594
,CHEMBL619484,10090.0,N,BAO_0000218,Mus musculus,,,,5705,,2675,,1,,Area under the curve was evaluated in mice after oral administration,A,,,Intermediate,1,,50594
,CHEMBL619485,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,5706,1969.0,16597,,1,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Intermediate,1,,50594
,CHEMBL619486,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,5707,1969.0,16597,,1,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Intermediate,1,,50594
,CHEMBL619487,10090.0,N,BAO_0000218,Mus musculus,,,,5708,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Intermediate,1,,50594
,CHEMBL619488,10090.0,N,BAO_0000218,Mus musculus,,,,5709,,17734,,1,,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL620106,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5710,178.0,7767,,1,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620107,,N,BAO_0000219,,,,,5711,,15345,,1,392.0,The compound was tested in vitro for anticancer activity against 9L cells,F,,9L,Intermediate,1,,80653
,CHEMBL620283,10116.0,U,BAO_0000019,Rattus norvegicus,,,,5712,,2181,,1,,Anti proliferation activity determined; Weak effect,F,,,Autocuration,0,,22226
,CHEMBL875176,10116.0,U,BAO_0000219,Rattus norvegicus,,,,5713,,2181,,1,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Autocuration,0,,22226
,CHEMBL620284,10116.0,U,BAO_0000219,Rattus norvegicus,,,,5714,,2181,,1,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Autocuration,0,,22226
,CHEMBL623515,10116.0,U,BAO_0000219,Rattus norvegicus,,,,5715,,2181,,1,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Autocuration,0,,22226
,CHEMBL623516,10090.0,U,BAO_0000019,Mus musculus,,,,5716,,10486,,1,,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Autocuration,0,,22226
,CHEMBL623517,10090.0,U,BAO_0000019,Mus musculus,,,,5717,,10486,,1,,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Autocuration,0,,22226
,CHEMBL857878,,U,BAO_0000019,,,,,5718,,15508,,1,,Partition coefficient (logD6.5),A,,,Autocuration,0,,22224
,CHEMBL623518,9606.0,N,BAO_0000219,Homo sapiens,,,,5719,,5242,,1,478.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,A2780,Expert,1,,81034
,CHEMBL624195,9606.0,N,BAO_0000219,Homo sapiens,,,,5720,,16167,,1,455.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,A-375,Intermediate,1,,80018
,CHEMBL624196,9606.0,N,BAO_0000219,Homo sapiens,,,,5721,,4782,,1,500.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,A-431,Expert,1,,80852
,CHEMBL624197,9606.0,D,BAO_0000219,Homo sapiens,,,,5722,,16093,,1,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,Expert,9,,9
,CHEMBL624198,9606.0,N,BAO_0000219,Homo sapiens,,,,5723,,2596,,1,624.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL621287,9606.0,N,BAO_0000219,Homo sapiens,,,,5724,,2596,,1,624.0,in vitro cytotoxicity against A 498 cancer cell line,F,,A498,Intermediate,1,,80021
,CHEMBL621288,9606.0,N,BAO_0000219,Homo sapiens,,,,5725,,3239,,1,624.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,A498,Intermediate,1,,80021
,CHEMBL876496,9606.0,N,BAO_0000219,Homo sapiens,,,,5726,,1847,,1,624.0,Cytotoxic activity against A 498 renal cancer cell lines.,F,,A498,Intermediate,1,,80021
,CHEMBL621289,9606.0,N,BAO_0000219,Homo sapiens,,,,5727,,10553,,1,624.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,A498,Intermediate,1,,80021
,CHEMBL621290,1280.0,U,BAO_0000019,Staphylococcus aureus,,,,5728,,16219,,1,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Autocuration,0,,22226
,CHEMBL621291,1280.0,U,BAO_0000019,Staphylococcus aureus,,,,5729,,16219,,1,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Autocuration,0,,22226
,CHEMBL621292,1280.0,U,BAO_0000019,Staphylococcus aureus,,,,5730,,16219,,1,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Autocuration,0,,22226
,CHEMBL621293,1280.0,U,BAO_0000019,Staphylococcus aureus,,,,5731,,16219,,1,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Autocuration,0,,22226
,CHEMBL621294,9606.0,N,BAO_0000219,Homo sapiens,,,,5732,,4782,,1,646.0,Inhibitory concentration required against A 549 lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621295,9606.0,N,BAO_0000219,Homo sapiens,,,,5733,,11805,,1,646.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,A549,Intermediate,1,,80682
,CHEMBL884007,9606.0,N,BAO_0000219,Homo sapiens,,,,5734,,11805,,1,646.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,A549,Intermediate,1,,80682
,CHEMBL621296,9606.0,N,BAO_0000219,Homo sapiens,,,,5735,,2007,,1,646.0,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL621297,9606.0,N,BAO_0000219,Homo sapiens,,,,5736,,4594,,1,646.0,Compound was tested for its cytotoxicity against A 549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL839828,9606.0,N,BAO_0000219,Homo sapiens,,,,5737,,6018,,1,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,A549,Expert,1,,80682
,CHEMBL620397,9606.0,N,BAO_0000219,Homo sapiens,,,,5738,,6018,,1,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,A549,Intermediate,1,,80682
,CHEMBL620398,9606.0,N,BAO_0000219,Homo sapiens,,,,5739,,3599,,1,646.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,A549,Expert,1,,80682
,CHEMBL620399,9606.0,N,BAO_0000219,Homo sapiens,,,,5740,,2551,,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,A549,Intermediate,1,,80682
,CHEMBL620400,9606.0,N,BAO_0000219,Homo sapiens,,,,5741,,16132,,1,646.0,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,A549,Expert,1,,80682
,CHEMBL620401,9606.0,N,BAO_0000219,Homo sapiens,,,,5742,,16132,,1,646.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,A549,Intermediate,1,,80682
,CHEMBL620402,9606.0,N,BAO_0000219,Homo sapiens,,,,5743,,2551,,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,A549,Expert,1,,80682
,CHEMBL620403,9606.0,N,BAO_0000219,Homo sapiens,,,,5744,,2551,,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,A549,Expert,1,,80682
,CHEMBL620404,,U,BAO_0000218,,,,,5745,,11913,,1,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,Autocuration,0,,22226
,CHEMBL620405,,H,BAO_0000218,,,,,5746,,12621,,1,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,Autocuration,4,,104694
,CHEMBL620406,,H,BAO_0000218,,,,,5747,,12621,,1,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,Autocuration,4,,104694
,CHEMBL620407,,H,BAO_0000218,,,,,5748,,12621,,1,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,Autocuration,4,,104694
,CHEMBL620408,,H,BAO_0000218,,,,,5749,,12621,,1,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,Autocuration,4,,104694
,CHEMBL620409,,H,BAO_0000218,,,,,5750,,12621,,1,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,Autocuration,4,,104694
,CHEMBL620410,9606.0,N,BAO_0000219,Homo sapiens,,,,5751,,3600,,1,624.0,Inhibition of A-498 human Renal cell proliferation,F,,A498,Expert,1,,80021
,CHEMBL620411,10116.0,U,BAO_0000019,Rattus norvegicus,,,,5752,,1796,,1,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Autocuration,0,,22226
,CHEMBL620412,10116.0,U,BAO_0000019,Rattus norvegicus,,,,5753,,1796,,1,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Autocuration,0,,22226
,CHEMBL876596,10116.0,U,BAO_0000019,Rattus norvegicus,,,,5754,,1796,,1,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Autocuration,0,,22226
,CHEMBL620413,9606.0,N,BAO_0000219,Homo sapiens,,,,5755,,16464,,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,A 172,Expert,1,,80012
,CHEMBL620414,9606.0,N,BAO_0000219,Homo sapiens,,,,5756,,16464,,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A 172,Intermediate,1,,80012
,CHEMBL620415,9606.0,N,BAO_0000219,Homo sapiens,,,,5757,,16464,,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A 172,Intermediate,1,,80012
,CHEMBL620416,9606.0,N,BAO_0000219,Homo sapiens,,,,5758,,13617,,1,646.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,A549,Expert,1,,80682
,CHEMBL620417,9606.0,N,BAO_0000219,Homo sapiens,,,,5759,,4584,,1,646.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,A549,Intermediate,1,,80682
,CHEMBL620418,9606.0,N,BAO_0000219,Homo sapiens,,,,5760,,13799,,1,646.0,Cytotoxic activity evaluated against A549 tumor cells,F,,A549,Expert,1,,80682
,CHEMBL620419,9606.0,N,BAO_0000219,Homo sapiens,,,,5761,,16726,,1,646.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620420,9606.0,N,BAO_0000219,Homo sapiens,,,,5762,,16109,,1,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,A549,Intermediate,1,,80682
,CHEMBL620421,9606.0,N,BAO_0000219,Homo sapiens,,,,5763,,16109,,1,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,A549,Intermediate,1,,80682
,CHEMBL620422,9606.0,N,BAO_0000219,Homo sapiens,,,,5764,,15474,,1,646.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,A549,Intermediate,1,,80682
,CHEMBL620423,9606.0,N,BAO_0000219,Homo sapiens,,,,5765,,6851,,1,646.0,Cytotoxicity of compound against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620424,9606.0,N,BAO_0000219,Homo sapiens,,,,5766,,17534,,1,646.0,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,A549,Expert,1,,80682
,CHEMBL620425,9606.0,N,BAO_0000219,Homo sapiens,,,,5767,,2621,,1,646.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL620426,9606.0,N,BAO_0000219,Homo sapiens,,,,5768,,830,,1,646.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL620427,9606.0,N,BAO_0000219,Homo sapiens,,,,5769,,14255,,1,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,A549,Intermediate,1,,80682
,CHEMBL620428,9606.0,N,BAO_0000219,Homo sapiens,,,,5770,,14255,,1,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,A549,Intermediate,1,,80682
,CHEMBL620429,9606.0,N,BAO_0000219,Homo sapiens,,,,5771,,1590,,1,646.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,A549,Intermediate,1,,80682
,CHEMBL620430,9606.0,N,BAO_0000219,Homo sapiens,,,,5772,,6146,,1,646.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,A549,Expert,1,,80682
,CHEMBL839887,9606.0,N,BAO_0000219,Homo sapiens,,,,5773,,17427,,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL620431,9606.0,N,BAO_0000219,Homo sapiens,,,,5774,,5280,,1,646.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,A549,Intermediate,1,,80682
,CHEMBL884010,9606.0,N,BAO_0000219,Homo sapiens,,,,5775,,16786,,1,646.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,A549,Intermediate,1,,80682
,CHEMBL620538,9606.0,N,BAO_0000219,Homo sapiens,,,,5776,,5895,,1,646.0,In vitro cytotoxicity against A549 (human lung cancer),F,,A549,Intermediate,1,,80682
,CHEMBL620539,9606.0,N,BAO_0000219,Homo sapiens,,,,5777,,14297,,1,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL623373,9606.0,N,BAO_0000218,Homo sapiens,,,,5778,,17824,,1,646.0,In vivo antiproliferative activity against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623374,9606.0,N,BAO_0000219,Homo sapiens,,,,5779,,14368,,1,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,A549,Intermediate,1,,80682
,CHEMBL623375,9606.0,N,BAO_0000219,Homo sapiens,,,,5780,,14368,,1,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,A549,Intermediate,1,,80682
,CHEMBL623376,9606.0,N,BAO_0000219,Homo sapiens,,,,5781,,14254,,1,646.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,A549,Intermediate,1,,80682
,CHEMBL623377,9606.0,N,BAO_0000219,Homo sapiens,,,,5782,,15897,,1,646.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,A549,Intermediate,1,,80682
,CHEMBL623378,9606.0,N,BAO_0000219,Homo sapiens,,,,5783,,13866,,1,646.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,A549,Intermediate,1,,80682
,CHEMBL623379,9606.0,N,BAO_0000219,Homo sapiens,,,,5784,,13370,,1,646.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,A549,Intermediate,1,,80682
,CHEMBL623380,9606.0,N,BAO_0000219,Homo sapiens,,,,5785,,4862,,1,646.0,Inhibitory activity against A549 lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623381,9606.0,N,BAO_0000219,Homo sapiens,,,,5786,,4862,,1,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623382,9606.0,N,BAO_0000219,Homo sapiens,,,,5787,,4862,,1,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,A549,Intermediate,1,,80682
,CHEMBL623383,9606.0,N,BAO_0000219,Homo sapiens,,,,5788,,15970,,1,646.0,Inhibitory concentration against A549 (lung cancer) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623384,9606.0,N,BAO_0000219,Homo sapiens,,,,5789,,17713,,1,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL623385,9606.0,N,BAO_0000219,Homo sapiens,,,,5790,,4833,,1,646.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623386,9606.0,N,BAO_0000219,Homo sapiens,,,,5791,,13736,,1,646.0,Activity against A549 cancer cell line.,F,,A549,Expert,1,,80682
,CHEMBL884105,9606.0,N,BAO_0000219,Homo sapiens,,,,5792,,4312,,1,646.0,The compound was evaluated for cytotoxicity against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL623387,9606.0,N,BAO_0000219,Homo sapiens,,,,5793,,5421,,1,646.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,A549,Intermediate,1,,80682
,CHEMBL621568,9606.0,N,BAO_0000219,Homo sapiens,,,,5794,,5421,,1,646.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621569,9606.0,N,BAO_0000219,Homo sapiens,,,,5795,,14717,,1,646.0,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,A549,Intermediate,1,,80682
,CHEMBL621570,9606.0,N,BAO_0000219,Homo sapiens,,,,5796,,4634,,1,646.0,Inhibitory activity against A549 lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621571,9606.0,N,BAO_0000219,Homo sapiens,,,,5797,,1149,,1,646.0,Inhibitory activity against A549 cell line; inactive,F,,A549,Intermediate,1,,80682
,CHEMBL621572,9606.0,N,BAO_0000219,Homo sapiens,,,,5798,,5421,,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,A549,Expert,1,,80682
,CHEMBL621573,9606.0,N,BAO_0000219,Homo sapiens,,,,5799,,5421,,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,A549,Expert,1,,80682
,CHEMBL621574,9606.0,N,BAO_0000219,Homo sapiens,,,,5800,,5421,,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,A549,Intermediate,1,,80682
,CHEMBL621575,9606.0,N,BAO_0000219,Homo sapiens,,,,5801,,3320,,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,A549,Intermediate,1,,80682
,CHEMBL621576,9606.0,N,BAO_0000219,Homo sapiens,,,,5802,,3320,,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,A549,Intermediate,1,,80682
,CHEMBL621577,9606.0,N,BAO_0000219,Homo sapiens,,,,5803,,3320,,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,A549,Intermediate,1,,80682
,CHEMBL621578,9606.0,N,BAO_0000219,Homo sapiens,,,,5804,,3320,,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,A549,Intermediate,1,,80682
,CHEMBL621579,9606.0,N,BAO_0000219,Homo sapiens,,,,5805,,3320,,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,A549,Intermediate,1,,80682
,CHEMBL621580,9606.0,N,BAO_0000219,Homo sapiens,,,,5806,,5726,,1,646.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL621581,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5807,,17800,,1,,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621582,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5808,,5985,,1,,Plasma clearance was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621583,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5809,,5530,,1,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621584,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5810,,5530,,1,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621585,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5811,1969.0,4839,,1,,Tested for plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621586,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5812,,3639,,1,,The compound was tested for clearance in dog plasma.,A,In vivo,,Intermediate,1,,50588
,CHEMBL875835,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5813,,4838,,1,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Intermediate,1,,50588
,CHEMBL621587,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5814,,4137,,1,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621588,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5815,1969.0,5017,,1,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Intermediate,1,,50588
Microsomes,CHEMBL621589,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,5816,2107.0,17538,,1,,In vitro clearance in dog liver microsomes,A,In vitro,,Intermediate,1,,50588
,CHEMBL621590,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5817,,6161,,1,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621591,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5818,,6161,,1,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621592,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5819,,1696,,1,,Plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621593,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5820,,6762,,1,,Clearance rate in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621594,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5821,1969.0,5932,,1,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL621595,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5822,,6305,,1,,Clearance in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621596,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5823,,4942,,1,,Plasma clearance in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621597,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5824,,4219,,1,,Plasma clearance was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621598,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5825,,17853,,1,,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Intermediate,1,,50588
,CHEMBL621599,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5826,,4514,,1,,Plasma clearance in Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL875836,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5827,,6448,,1,,Plasma clearance (Clp) in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621600,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5828,,6227,,1,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621601,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5829,,6227,,1,,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL618474,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5830,,6062,,1,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL618475,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5831,,6821,,1,,Plasma clearance of compound was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624524,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5832,,4709,,1,,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624525,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5833,,4521,,1,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624526,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5834,,5374,,1,,Plasma clearance in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624527,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5835,,6057,,1,,Plasma clearance was calculated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624528,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5836,,4727,,1,,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624529,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5837,,5145,,1,,Plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624530,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5838,,17657,,1,,Plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624531,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5839,,17657,,1,,Plasma clearance in dog; Unable to calculate,A,In vivo,,Intermediate,1,,50588
,CHEMBL624532,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5840,,5145,,1,,Plasma clearance in rhesus monkey,A,In vivo,,Intermediate,1,,50588
,CHEMBL624533,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5841,,6642,,1,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Intermediate,1,,50588
,CHEMBL624534,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5842,,6641,,1,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624535,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5843,,6642,,1,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624536,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5844,,5472,,1,,Plasma clearance was evaluated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624537,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5845,,5472,,1,,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Intermediate,1,,50588
,CHEMBL624538,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5846,,5472,,1,,Plasma clearance was evaluated in rhesus,A,In vivo,,Intermediate,1,,50588
,CHEMBL624539,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5847,,5472,,1,,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Intermediate,1,,50588
,CHEMBL624540,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5848,,4257,,1,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL624541,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5849,,6679,,1,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624542,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5850,,5546,,1,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624543,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5851,,6348,,1,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624544,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5852,,5474,,1,,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Intermediate,1,,50588
,CHEMBL624545,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5853,1969.0,6316,,1,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624546,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5854,,17594,,1,,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL875957,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5855,,17594,,1,,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624547,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5856,,5802,,1,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624548,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5857,,6535,,1,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624549,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5858,,6535,,1,,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL624550,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,5859,1969.0,1466,,1,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621613,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5860,,6505,,1,,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621614,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5861,,5668,,1,,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623431,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5862,,5668,,1,,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623432,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5863,,5668,,1,,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623433,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5864,,5600,,1,,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623434,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5865,,17764,,1,,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623435,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5866,,6123,,1,,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623436,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5867,,6123,,1,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Intermediate,1,,50588
,CHEMBL875958,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5868,,6757,,1,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623437,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5869,,16907,,1,,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623438,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5870,178.0,7767,,1,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623439,10090.0,N,BAO_0000218,Mus musculus,,,Blood,5871,178.0,7767,,1,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623440,10090.0,N,BAO_0000218,Mus musculus,,,Bone,5872,10000001.0,7767,,1,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623441,10090.0,N,BAO_0000218,Mus musculus,,,Bone,5873,10000001.0,7767,,1,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623442,10090.0,N,BAO_0000218,Mus musculus,,,Bone,5874,10000001.0,7767,,1,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623469,10090.0,N,BAO_0000218,Mus musculus,,,,5875,,7767,,1,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623470,10090.0,N,BAO_0000218,Mus musculus,,,,5876,,7767,,1,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623471,10090.0,N,BAO_0000218,Mus musculus,,,,5877,,7767,,1,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623472,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5878,948.0,7767,,1,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623473,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5879,948.0,7767,,1,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623474,10090.0,N,BAO_0000218,Mus musculus,,,Heart,5880,948.0,7767,,1,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623475,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5881,2113.0,7767,,1,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623476,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5882,2113.0,7767,,1,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL623477,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,5883,2113.0,7767,,1,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621896,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5884,160.0,7767,,1,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621897,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5885,160.0,7767,,1,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621898,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5886,160.0,7767,,1,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621899,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5887,2107.0,7767,,1,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621900,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5888,2107.0,7767,,1,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621901,10090.0,N,BAO_0000218,Mus musculus,,,Liver,5889,2107.0,7767,,1,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621902,10090.0,N,BAO_0000218,Mus musculus,,,Lung,5890,2048.0,7767,,1,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL621903,10090.0,N,BAO_0000218,Mus musculus,,,Lung,5891,2048.0,7767,,1,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL622587,10090.0,N,BAO_0000218,Mus musculus,,,Lung,5892,2048.0,7767,,1,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620285,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,5893,2385.0,7767,,1,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL875285,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,5894,2385.0,7767,,1,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620286,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,5895,2385.0,7767,,1,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620287,10090.0,N,BAO_0000218,Mus musculus,,,,5896,,7767,,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620288,10090.0,N,BAO_0000218,Mus musculus,,,,5897,,7767,,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620289,10090.0,N,BAO_0000218,Mus musculus,,,,5898,,7767,,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620290,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5899,160.0,7767,,1,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620291,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5900,160.0,7767,,1,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620292,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,5901,160.0,7767,,1,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620293,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5902,2106.0,7767,,1,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL620294,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5903,2106.0,7767,,1,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL618614,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,5904,2106.0,7767,,1,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL618615,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,5905,945.0,7767,,1,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL618616,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,5906,945.0,7767,,1,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL618617,9606.0,N,BAO_0000219,Homo sapiens,,,,5907,,2036,,1,622.0,Cytotoxicity against A-172 human tumor cell lines,F,,A 172,Expert,1,,80012
,CHEMBL618618,9606.0,N,BAO_0000219,Homo sapiens,,,,5908,,2357,,1,622.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,A 172,Intermediate,1,,80012
,CHEMBL618619,9606.0,N,BAO_0000219,Homo sapiens,,,,5909,,1457,,1,623.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,A204,Intermediate,1,,80014
,CHEMBL618620,9606.0,N,BAO_0000219,Homo sapiens,,,,5910,,4379,,1,478.0,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618621,9606.0,N,BAO_0000219,Homo sapiens,,,,5911,,1093,,1,455.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,A-375,Intermediate,1,,80018
,CHEMBL618622,9606.0,N,BAO_0000219,Homo sapiens,,,,5912,,12152,,1,455.0,Tested in vitro against A-375 cell line human melanoma,F,,A-375,Intermediate,1,,80018
,CHEMBL618623,9606.0,N,BAO_0000219,Homo sapiens,,,,5913,,16464,,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,A-427,Expert,1,,80019
,CHEMBL618624,9606.0,N,BAO_0000219,Homo sapiens,,,,5914,,16464,,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A-427,Intermediate,1,,80019
,CHEMBL618625,9606.0,N,BAO_0000219,Homo sapiens,,,,5915,,16582,,1,797.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,A-427,Expert,1,,80019
,CHEMBL618626,9606.0,N,BAO_0000219,Homo sapiens,,,,5916,,16464,,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A-427,Intermediate,1,,80019
,CHEMBL618627,9606.0,N,BAO_0000219,Homo sapiens,,,,5917,,10413,,1,797.0,Antitumor activity on A-427 lung carcinoma cell lines,F,,A-427,Intermediate,1,,80019
,CHEMBL618628,9606.0,N,BAO_0000219,Homo sapiens,,,,5918,,6418,,1,797.0,Cytotoxic activity against human A-427 lung tumor cell line,F,,A-427,Intermediate,1,,80019
,CHEMBL618629,9606.0,N,BAO_0000219,Homo sapiens,,,,5919,,17134,,1,797.0,In vitro antitumor effects against human A-427 cell lines.,F,,A-427,Expert,1,,80019
,CHEMBL618630,9606.0,N,BAO_0000219,Homo sapiens,,,,5920,,16132,,1,797.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,A-427,Expert,1,,80019
,CHEMBL618631,9606.0,N,BAO_0000219,Homo sapiens,,,,5921,,16132,,1,797.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,A-427,Intermediate,1,,80019
,CHEMBL618632,9606.0,N,BAO_0000219,Homo sapiens,,,,5922,,16780,,1,797.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,A-427,Intermediate,1,,80019
,CHEMBL618633,9606.0,N,BAO_0000219,Homo sapiens,,,,5923,,4085,,1,500.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,A-431,Expert,1,,80852
,CHEMBL619315,9606.0,N,BAO_0000219,Homo sapiens,,,,5924,,1276,,1,624.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619316,9606.0,N,BAO_0000219,Homo sapiens,,,,5925,,3498,,1,624.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,A498,Expert,1,,80021
,CHEMBL619317,9606.0,N,BAO_0000219,Homo sapiens,,,,5926,,1169,,1,624.0,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,A498,Intermediate,1,,80021
,CHEMBL619318,9606.0,N,BAO_0000219,Homo sapiens,,,,5927,,4450,,1,624.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,A498,Intermediate,1,,80021
,CHEMBL619319,9606.0,N,BAO_0000219,Homo sapiens,,,,5928,,3311,,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,A498,Intermediate,1,,80021
,CHEMBL619739,9606.0,N,BAO_0000219,Homo sapiens,,,,5929,,4461,,1,624.0,Antitumor cytotoxic activity against A-498 cell line was determined,F,,A498,Intermediate,1,,80021
,CHEMBL619740,9606.0,N,BAO_0000219,Homo sapiens,,,,5930,,3311,,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,A498,Intermediate,1,,80021
,CHEMBL883158,9606.0,N,BAO_0000219,Homo sapiens,,,,5931,,3311,,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,A498,Intermediate,1,,80021
,CHEMBL884012,9606.0,N,BAO_0000219,Homo sapiens,,,,5932,,1457,,1,624.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,A498,Intermediate,1,,80021
,CHEMBL619741,9606.0,N,BAO_0000219,Homo sapiens,,,,5933,,3664,,1,624.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,A498,Intermediate,1,,80021
,CHEMBL619742,9606.0,N,BAO_0000219,Homo sapiens,,,,5934,,15895,,1,624.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,A498,Intermediate,1,,80021
,CHEMBL876610,9606.0,N,BAO_0000219,Homo sapiens,,,,5935,,11843,,1,646.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619743,9606.0,N,BAO_0000219,Homo sapiens,,,,5936,,11843,,1,646.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619744,9606.0,N,BAO_0000219,Homo sapiens,,,,5937,,17705,,1,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619745,9606.0,N,BAO_0000219,Homo sapiens,,,,5938,,17705,,1,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,A549,Intermediate,1,,80682
,CHEMBL619746,9606.0,N,BAO_0000219,Homo sapiens,,,,5939,,4369,,1,646.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL619747,9606.0,N,BAO_0000219,Homo sapiens,,,,5940,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL619748,9606.0,N,BAO_0000219,Homo sapiens,,,,5941,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,A549,Intermediate,1,,80682
,CHEMBL619749,9606.0,N,BAO_0000219,Homo sapiens,,,,5942,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL619750,9606.0,N,BAO_0000219,Homo sapiens,,,,5943,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,A549,Intermediate,1,,80682
,CHEMBL624014,9606.0,N,BAO_0000219,Homo sapiens,,,,5944,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,A549,Intermediate,1,,80682
,CHEMBL624015,9606.0,N,BAO_0000219,Homo sapiens,,,,5945,,4369,,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,A549,Intermediate,1,,80682
,CHEMBL885344,9606.0,N,BAO_0000219,Homo sapiens,,,,5946,,4787,,1,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,A549,Expert,1,,80682
,CHEMBL623224,9606.0,N,BAO_0000219,Homo sapiens,,,,5947,,4787,,1,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,A549,Intermediate,1,,80682
,CHEMBL623225,9606.0,N,BAO_0000219,Homo sapiens,,,,5948,,6513,,1,646.0,Cytotoxic activity against A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL622698,9606.0,N,BAO_0000219,Homo sapiens,,,,5949,,6690,,1,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,A549,Intermediate,1,,80682
,CHEMBL622699,9606.0,N,BAO_0000219,Homo sapiens,,,,5950,,6690,,1,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,A549,Intermediate,1,,80682
,CHEMBL622700,9606.0,N,BAO_0000219,Homo sapiens,,,,5951,,12263,,1,646.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,A549,Expert,1,,80682
,CHEMBL622701,9606.0,N,BAO_0000219,Homo sapiens,,,,5952,,1054,,1,646.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,A549,Intermediate,1,,80682
,CHEMBL622702,9606.0,N,BAO_0000219,Homo sapiens,,,,5953,,1359,,1,646.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,A549,Intermediate,1,,80682
,CHEMBL622703,9606.0,N,BAO_0000219,Homo sapiens,,,,5954,,3547,,1,646.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL622704,9606.0,N,BAO_0000219,Homo sapiens,,,,5955,,5771,,1,646.0,Cytotoxic activity towards A-549 cells,F,,A549,Expert,1,,80682
,CHEMBL622705,9606.0,N,BAO_0000219,Homo sapiens,,,,5956,,14425,,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,A549,Intermediate,1,,80682
,CHEMBL622706,9606.0,N,BAO_0000219,Homo sapiens,,,,5957,,14425,,1,646.0,"In vitro percent inhibition of A549, lung carcinoma",F,,A549,Intermediate,1,,80682
,CHEMBL622707,9606.0,N,BAO_0000219,Homo sapiens,,,,5958,,14425,,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,A549,Intermediate,1,,80682
,CHEMBL622708,9606.0,N,BAO_0000219,Homo sapiens,,,,5959,,14425,,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,A549,Intermediate,1,,80682
,CHEMBL622709,9606.0,N,BAO_0000219,Homo sapiens,,,,5960,,5280,,1,646.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,A549,Intermediate,1,,80682
,CHEMBL622710,9606.0,N,BAO_0000219,Homo sapiens,,,,5961,,15176,,1,646.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,A549,Intermediate,1,,80682
,CHEMBL622711,9606.0,N,BAO_0000219,Homo sapiens,,,,5962,,15300,,1,646.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,A549,Intermediate,1,,80682
,CHEMBL622712,9606.0,N,BAO_0000218,Homo sapiens,,,,5963,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,Intermediate,1,,80682
,CHEMBL622713,9606.0,N,BAO_0000218,Homo sapiens,,,,5964,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,Intermediate,1,,80682
,CHEMBL622714,9606.0,N,BAO_0000218,Homo sapiens,,,,5965,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,Intermediate,1,,80682
,CHEMBL622715,9606.0,N,BAO_0000218,Homo sapiens,,,,5966,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,Intermediate,1,,80682
,CHEMBL622716,9606.0,N,BAO_0000218,Homo sapiens,,,,5967,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,Intermediate,1,,80682
,CHEMBL622717,9606.0,N,BAO_0000219,Homo sapiens,,,,5968,,17824,,1,646.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,A549,Intermediate,1,,80682
,CHEMBL622718,9606.0,N,BAO_0000218,Homo sapiens,,,,5969,,17528,,1,646.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,A549,Intermediate,1,,80682
,CHEMBL622719,9606.0,N,BAO_0000219,Homo sapiens,,,,5970,,6870,,1,646.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,A549,Expert,1,,80682
,CHEMBL622720,9606.0,N,BAO_0000219,Homo sapiens,,,,5971,,6870,,1,646.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,A549,Intermediate,1,,80682
,CHEMBL622721,9606.0,N,BAO_0000219,Homo sapiens,,,,5972,,6870,,1,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,A549,Intermediate,1,,80682
,CHEMBL622722,9606.0,N,BAO_0000219,Homo sapiens,,,,5973,,6870,,1,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,A549,Intermediate,1,,80682
,CHEMBL876030,9606.0,N,BAO_0000219,Homo sapiens,,,,5974,,16726,,1,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL620206,9606.0,N,BAO_0000219,Homo sapiens,,,,5975,,6170,,1,646.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,A549,Intermediate,1,,80682
,CHEMBL620207,9606.0,N,BAO_0000219,Homo sapiens,,,,5976,,6583,,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,A549,Expert,1,,80682
,CHEMBL620208,9606.0,N,BAO_0000219,Homo sapiens,,,,5977,,6583,,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,A549,Expert,1,,80682
,CHEMBL620209,9606.0,N,BAO_0000219,Homo sapiens,,,,5978,,6583,,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,A549,Expert,1,,80682
,CHEMBL620210,9606.0,N,BAO_0000219,Homo sapiens,,,,5979,,6583,,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,A549,Expert,1,,80682
,CHEMBL621639,9606.0,N,BAO_0000219,Homo sapiens,,,,5980,,6583,,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,A549,Expert,1,,80682
,CHEMBL621640,9606.0,N,BAO_0000219,Homo sapiens,,,,5981,,17321,,1,646.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621641,9606.0,N,BAO_0000219,Homo sapiens,,,,5982,,17528,,1,646.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,A549,Expert,1,,80682
,CHEMBL621642,9606.0,N,BAO_0000219,Homo sapiens,,,,5983,,12888,,1,646.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,A549,Expert,1,,80682
,CHEMBL621643,9606.0,N,BAO_0000219,Homo sapiens,,,,5984,,4312,,1,646.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621644,9606.0,N,BAO_0000219,Homo sapiens,,,,5985,,4312,,1,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621645,9606.0,N,BAO_0000219,Homo sapiens,,,,5986,,4312,,1,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,A549,Intermediate,1,,80682
,CHEMBL621646,10090.0,N,BAO_0000219,Mus musculus,,,,5987,,17737,,1,646.0,In vitro antiproliferative activity against A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL621647,,N,BAO_0000219,,,,,5988,,6630,,1,646.0,Synergism with indomethacin in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621648,,N,BAO_0000219,,,,,5989,,6630,,1,646.0,Synergism with tolmetin in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621649,,N,BAO_0000219,,,,,5990,,6630,,1,646.0,Synergism with sulindac in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621650,,N,BAO_0000219,,,,,5991,,6630,,1,646.0,Antagonism of indomethacin in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621651,,N,BAO_0000219,,,,,5992,,6630,,1,646.0,Antagonism of sulindac in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621652,,N,BAO_0000219,,,,,5993,,6630,,1,646.0,Antagonism of tolmetin in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621653,,N,BAO_0000219,,,,,5994,,6630,,1,646.0,Synergism with indomethacin in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621654,,N,BAO_0000219,,,,,5995,,6630,,1,646.0,Synergism with sulindac in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL621655,,N,BAO_0000219,,,,,5996,,6630,,1,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,A549,Intermediate,1,,80682
,CHEMBL621656,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5997,,16907,,1,,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621657,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5998,,5944,,1,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621658,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,5999,,5944,,1,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621659,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6000,,5944,,1,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621660,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6001,,5944,,1,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621661,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6002,,2959,,1,,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621662,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6003,,6241,,1,,Cmax value in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621663,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6004,,6241,,1,,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621664,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6005,,2652,,1,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL621665,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6006,1969.0,1806,,1,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621666,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6007,1969.0,1806,,1,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621667,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6008,,1021,,1,,Concentration maxima after oral dosing in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL876738,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6009,,1021,,1,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Intermediate,1,,50588
,CHEMBL621668,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6010,,1021,,1,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Intermediate,1,,50588
,CHEMBL621669,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6011,,5444,,1,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Intermediate,1,,50588
,CHEMBL621670,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6012,,5444,,1,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Intermediate,1,,50588
,CHEMBL621671,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6013,,5444,,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622360,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6014,,5444,,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Intermediate,1,,50588
,CHEMBL622361,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6015,,5444,,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Intermediate,1,,50588
,CHEMBL622362,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6016,1969.0,5130,,1,,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL622363,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6017,1969.0,3249,,1,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622364,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6018,1969.0,5473,,1,,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622365,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6019,1969.0,5474,,1,,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Intermediate,1,,50588
,CHEMBL622533,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6020,1969.0,4657,,1,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Intermediate,1,,50588
,CHEMBL622534,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6021,,3031,,1,,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Intermediate,1,,50588
,CHEMBL622535,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6022,,4527,,1,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL876739,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6023,,4186,,1,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Intermediate,1,,50588
,CHEMBL622536,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6024,,5007,,1,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL622537,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6025,1969.0,3132,,1,,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL622538,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6026,,5006,,1,,Maximum concentration was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL627867,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6027,,4727,,1,,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL627868,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6028,,1916,,1,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL627869,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6029,1969.0,1918,,1,,Maximum concentration was evaluated in dog plasma,A,In vivo,,Intermediate,1,,50588
,CHEMBL627870,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6030,,3045,,1,,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL627871,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6031,1969.0,9579,,1,,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Intermediate,1,,50588
,CHEMBL627872,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6032,1969.0,9579,,1,,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Intermediate,1,,50588
,CHEMBL627873,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6033,1969.0,933,,1,,Maximum plasma concentration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL627874,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6034,1969.0,17839,,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL627875,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6035,1969.0,17839,,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL627876,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6036,1969.0,17839,,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL627877,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6037,1969.0,17839,,1,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL627878,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6038,1969.0,6348,,1,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL627879,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6039,1969.0,16367,,1,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL875355,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6040,1969.0,1337,,1,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL627880,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6041,1969.0,1337,,1,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL627881,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6042,1969.0,5199,,1,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Intermediate,1,,50588
,CHEMBL627882,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6043,1969.0,17650,,1,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL627883,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6044,1969.0,6679,,1,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL628526,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6045,1969.0,5356,,1,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Intermediate,1,,50588
,CHEMBL628527,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6046,1969.0,5356,,1,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Intermediate,1,,50588
,CHEMBL628528,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6047,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL628529,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6048,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL628530,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6049,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625243,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6050,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625244,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6051,1969.0,3598,,1,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50588
,CHEMBL625245,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6052,,4368,,1,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625246,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6053,,6265,,1,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625247,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,6054,945.0,7767,,1,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL625248,10090.0,N,BAO_0000218,Mus musculus,,,Urine,6055,1088.0,7767,,1,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Intermediate,1,,50594
,CHEMBL625249,10090.0,N,BAO_0000218,Mus musculus,,,Urine,6056,1088.0,7767,,1,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Intermediate,1,,50594
,CHEMBL625250,10090.0,N,BAO_0000218,Mus musculus,,,Urine,6057,1088.0,7767,,1,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Intermediate,1,,50594
,CHEMBL625251,10090.0,N,BAO_0000218,Mus musculus,,,,6058,,17811,,1,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Intermediate,1,,50594
,CHEMBL875356,10090.0,N,BAO_0000218,Mus musculus,,,,6059,,17811,,1,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Intermediate,1,,50594
,CHEMBL625252,10090.0,N,BAO_0000218,Mus musculus,,,,6060,,17827,,1,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625253,10090.0,N,BAO_0000218,Mus musculus,,,Blood,6061,178.0,17827,,1,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625254,10090.0,N,BAO_0000218,Mus musculus,,,,6062,,17827,,1,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625255,10090.0,N,BAO_0000218,Mus musculus,,,,6063,,17827,,1,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625256,10090.0,N,BAO_0000218,Mus musculus,,,,6064,,17827,,1,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625257,10090.0,N,BAO_0000218,Mus musculus,,,Blood,6065,178.0,17827,,1,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625258,10090.0,N,BAO_0000218,Mus musculus,,,Blood,6066,178.0,17827,,1,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625259,10090.0,N,BAO_0000218,Mus musculus,,,,6067,,17827,,1,,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625260,10090.0,N,BAO_0000218,Mus musculus,,,,6068,,17827,,1,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Intermediate,1,,50594
,CHEMBL625261,10090.0,N,BAO_0000218,Mus musculus,,,,6069,,17827,,1,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Intermediate,1,,50594
,CHEMBL625262,10090.0,N,BAO_0000218,Mus musculus,,,,6070,,17827,,1,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Intermediate,1,,50594
,CHEMBL622639,10090.0,N,BAO_0000218,Mus musculus,,,,6071,,17827,,1,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Intermediate,1,,50594
,CHEMBL622640,10090.0,N,BAO_0000218,Mus musculus,,,,6072,,17257,,1,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Intermediate,1,,50594
,CHEMBL622812,10090.0,N,BAO_0000218,Mus musculus,,,,6073,,17257,,1,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Intermediate,1,,50594
,CHEMBL622813,10090.0,N,BAO_0000218,Mus musculus,,,,6074,,17257,,1,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Intermediate,1,,50594
,CHEMBL622814,10090.0,N,BAO_0000218,Mus musculus,,,,6075,,17257,,1,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Intermediate,1,,50594
,CHEMBL622815,10090.0,N,BAO_0000218,Mus musculus,,,,6076,,17827,,1,,Time at maximum activity in mice (Radiolabeled compound),A,,,Intermediate,1,,50594
,CHEMBL625342,10090.0,N,BAO_0000218,Mus musculus,,,,6077,,3760,,1,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Intermediate,1,,50594
,CHEMBL625343,10090.0,N,BAO_0000218,Mus musculus,,,,6078,,3760,,1,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Intermediate,1,,50594
,CHEMBL877591,10090.0,N,BAO_0000218,Mus musculus,,,,6079,,17409,,1,,Binding towards mouse plasma protein at 10 uM,A,,,Intermediate,1,,50594
,CHEMBL625344,10090.0,N,BAO_0000218,Mus musculus,,,,6080,,17409,,1,,Binding towards mouse plasma protein at 100 uM,A,,,Intermediate,1,,50594
,CHEMBL625345,10090.0,N,BAO_0000218,Mus musculus,,,,6081,,2675,,1,,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL625346,10090.0,N,BAO_0000218,Mus musculus,,,,6082,,2675,,1,,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL625347,10090.0,N,BAO_0000218,Mus musculus,,,,6083,,3132,,1,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL625348,10090.0,N,BAO_0000218,Mus musculus,,,,6084,,3132,,1,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL625349,10090.0,N,BAO_0000218,Mus musculus,,,,6085,,16597,,1,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL625350,10090.0,N,BAO_0000218,Mus musculus,,,,6086,,2862,,1,,Oral bioavailability in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL882952,10090.0,N,BAO_0000218,Mus musculus,,,,6087,,17764,,1,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL625351,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6088,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL625352,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6089,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL877592,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6090,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL625353,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6091,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL625354,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6092,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626019,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6093,955.0,846,,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626020,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6094,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626021,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6095,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626022,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6096,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626192,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6097,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626193,9606.0,N,BAO_0000219,Homo sapiens,,,,6098,,1276,,1,646.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,A549,Intermediate,1,,80682
,CHEMBL626194,9606.0,N,BAO_0000219,Homo sapiens,,,,6099,,3498,,1,646.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,A549,Expert,1,,80682
,CHEMBL626195,9606.0,N,BAO_0000219,Homo sapiens,,,,6100,,1169,,1,646.0,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL626196,9606.0,N,BAO_0000219,Homo sapiens,,,,6101,,4450,,1,646.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL626197,9606.0,N,BAO_0000219,Homo sapiens,,,,6102,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,A549,Intermediate,1,,80682
,CHEMBL626198,9606.0,N,BAO_0000219,Homo sapiens,,,,6103,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,A549,Intermediate,1,,80682
,CHEMBL626199,9606.0,N,BAO_0000219,Homo sapiens,,,,6104,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,A549,Intermediate,1,,80682
,CHEMBL626200,9606.0,N,BAO_0000219,Homo sapiens,,,,6105,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,A549,Intermediate,1,,80682
,CHEMBL626201,9606.0,N,BAO_0000219,Homo sapiens,,,,6106,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,A549,Intermediate,1,,80682
,CHEMBL626202,9606.0,N,BAO_0000219,Homo sapiens,,,,6107,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,A549,Intermediate,1,,80682
,CHEMBL626203,9606.0,N,BAO_0000219,Homo sapiens,,,,6108,,358,,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,A549,Intermediate,1,,80682
,CHEMBL626204,9606.0,N,BAO_0000219,Homo sapiens,,,,6109,,15167,,1,646.0,In vitro cytotoxicity against A-549 human lung cancer cells,F,,A549,Intermediate,1,,80682
,CHEMBL624701,9606.0,N,BAO_0000219,Homo sapiens,,,,6110,,4139,,1,646.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL624702,9606.0,N,BAO_0000219,Homo sapiens,,,,6111,,833,,1,646.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL624703,9606.0,N,BAO_0000219,Homo sapiens,,,,6112,,15718,,1,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,Expert,1,,80682
,CHEMBL624704,9606.0,N,BAO_0000219,Homo sapiens,,,,6113,,12373,,1,646.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,A549,Intermediate,1,,80682
,CHEMBL624705,9606.0,N,BAO_0000219,Homo sapiens,,,,6114,,637,,1,646.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,A549,Intermediate,1,,80682
,CHEMBL624706,9606.0,N,BAO_0000219,Homo sapiens,,,,6115,,14867,,1,646.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,A549,Expert,1,,80682
,CHEMBL624707,9606.0,N,BAO_0000219,Homo sapiens,,,,6116,,4461,,1,646.0,Antitumor cytotoxic activity against A-549 cell line was determined,F,,A549,Intermediate,1,,80682
,CHEMBL624708,9606.0,N,BAO_0000219,Homo sapiens,,,,6117,,5406,,1,646.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,A549,Intermediate,1,,80682
,CHEMBL624709,9606.0,N,BAO_0000219,Homo sapiens,,,,6118,,4457,,1,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,A549,Intermediate,1,,80682
,CHEMBL884107,9606.0,N,BAO_0000219,Homo sapiens,,,,6119,,1386,,1,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL624710,9606.0,N,BAO_0000219,Homo sapiens,,,,6120,,3265,,1,646.0,Antitumoral activity was assayed against A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL624711,9606.0,N,BAO_0000219,Homo sapiens,,,,6121,,2359,,1,646.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,A549,Intermediate,1,,80682
,CHEMBL624712,9606.0,N,BAO_0000219,Homo sapiens,,,,6122,,4457,,1,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,A549,Intermediate,1,,80682
,CHEMBL624713,9606.0,N,BAO_0000219,Homo sapiens,,,,6123,,12454,,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL624714,9606.0,N,BAO_0000219,Homo sapiens,,,,6124,,1481,,1,646.0,Compound was tested for inhibition of cell growth of A-549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL624715,9606.0,N,BAO_0000219,Homo sapiens,,,,6125,,1750,,1,646.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,A549,Intermediate,1,,80682
,CHEMBL624716,9606.0,N,BAO_0000219,Homo sapiens,,,,6126,,5065,,1,646.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,A549,Intermediate,1,,80682
,CHEMBL619505,9606.0,N,BAO_0000219,Homo sapiens,,,,6127,,808,,1,646.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,A549,Expert,1,,80682
,CHEMBL619506,9606.0,N,BAO_0000219,Homo sapiens,,,,6128,,16364,,1,646.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,A549,Expert,1,,80682
,CHEMBL619507,9606.0,N,BAO_0000219,Homo sapiens,,,,6129,,1847,,1,646.0,Cytotoxic activity against A-549 cell lines.,F,,A549,Intermediate,1,,80682
,CHEMBL619508,9606.0,N,BAO_0000219,Homo sapiens,,,,6130,,1747,,1,646.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,A549,Expert,1,,80682
,CHEMBL619509,9606.0,N,BAO_0000219,Homo sapiens,,,,6131,,1003,,1,646.0,Cytotoxicity against human A549 non small cell lung cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL619510,9606.0,N,BAO_0000219,Homo sapiens,,,,6132,,15313,,1,646.0,Inhibition of cell growth in (A-549) lung cell line,F,,A549,Expert,1,,80682
,CHEMBL619511,9606.0,N,BAO_0000219,Homo sapiens,,,,6133,,3122,,1,646.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619512,9606.0,N,BAO_0000219,Homo sapiens,,,,6134,,16049,,1,646.0,In vitro antitumor activity against A-549 tumor cells.,F,,A549,Intermediate,1,,80682
,CHEMBL619513,9606.0,N,BAO_0000219,Homo sapiens,,,,6135,,17134,,1,646.0,In vitro antitumor effects against human A-549 cell lines.,F,,A549,Expert,1,,80682
,CHEMBL619514,9606.0,N,BAO_0000219,Homo sapiens,,,,6136,,6406,,1,646.0,In vitro cytotoxic activity of compound against A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619515,9606.0,N,BAO_0000219,Homo sapiens,,,,6137,,627,,1,646.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619516,9606.0,N,BAO_0000219,Homo sapiens,,,,6138,,12307,,1,646.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,A549,Intermediate,1,,80682
,CHEMBL884005,9606.0,N,BAO_0000219,Homo sapiens,,,,6139,,17861,,1,646.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,A549,Intermediate,1,,80682
,CHEMBL619517,9606.0,N,BAO_0000219,Homo sapiens,,,,6140,,6682,,1,646.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,A549,Expert,1,,80682
,CHEMBL619518,9606.0,N,BAO_0000219,Homo sapiens,,,,6141,,6663,,1,646.0,Inhibitory concentration of compound against A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619519,9606.0,N,BAO_0000219,Homo sapiens,,,,6142,,2454,,1,646.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,A549,Intermediate,1,,80682
,CHEMBL876489,9606.0,N,BAO_0000219,Homo sapiens,,,,6143,,14709,,1,646.0,cytotoxic activity against leukemia (A-549) cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619520,9606.0,N,BAO_0000219,Homo sapiens,,,,6144,,15718,,1,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,Expert,1,,80682
,CHEMBL619521,9606.0,N,BAO_0000219,Homo sapiens,,,,6145,,15718,,1,646.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619522,9606.0,N,BAO_0000219,Homo sapiens,,,,6146,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,A549,Intermediate,1,,80682
,CHEMBL619523,9606.0,N,BAO_0000219,Homo sapiens,,,,6147,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,A549,Intermediate,1,,80682
,CHEMBL619524,9606.0,N,BAO_0000219,Homo sapiens,,,,6148,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,A549,Intermediate,1,,80682
,CHEMBL619525,9606.0,N,BAO_0000219,Homo sapiens,,,,6149,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,A549,Intermediate,1,,80682
,CHEMBL619526,,N,BAO_0000219,,,,,6150,,6630,,1,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,A549,Intermediate,1,,80682
,CHEMBL619527,9606.0,N,BAO_0000219,Homo sapiens,,,,6151,,16726,,1,646.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,A549,Intermediate,1,,80682
,CHEMBL619528,9606.0,N,BAO_0000219,Homo sapiens,,,,6152,,17846,,1,646.0,Cytotoxicity against A549 cells; No cytotoxicity,F,,A549,Intermediate,1,,80682
,CHEMBL619529,9606.0,N,BAO_0000219,Homo sapiens,,,,6153,,3415,,1,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,A549,Expert,1,,80682
,CHEMBL619530,9606.0,N,BAO_0000219,Homo sapiens,,,,6154,,3415,,1,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,A549,Expert,1,,80682
,CHEMBL876490,9606.0,N,BAO_0000219,Homo sapiens,,,,6155,,5609,,1,646.0,In vitro anticancer activity against human lung (A549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619531,9606.0,N,BAO_0000219,Homo sapiens,,,,6156,,17206,,1,646.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619532,9606.0,N,BAO_0000219,Homo sapiens,,,,6157,,17206,,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619533,9606.0,N,BAO_0000219,Homo sapiens,,,,6158,,17206,,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619534,9606.0,N,BAO_0000219,Homo sapiens,,,,6159,,17206,,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL620164,9606.0,N,BAO_0000219,Homo sapiens,,,,6160,,17206,,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL620165,9606.0,N,BAO_0000219,Homo sapiens,,,,6161,,17206,,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL620166,9606.0,N,BAO_0000219,Homo sapiens,,,,6162,,16295,,1,646.0,Inhibition of A549 human lung tumor cell proliferation,F,,A549,Expert,1,,80682
,CHEMBL620167,9606.0,N,BAO_0000219,Homo sapiens,,,,6163,,16825,,1,646.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,A549,Intermediate,1,,80682
,CHEMBL620168,9606.0,N,BAO_0000219,Homo sapiens,,,,6164,,3439,,1,646.0,In vitro cytotoxicity against human tumor cell line A549,F,,A549,Expert,1,,80682
,CHEMBL620338,9606.0,N,BAO_0000219,Homo sapiens,,,,6165,,10870,,1,646.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,A549,Intermediate,1,,80682
,CHEMBL620339,9606.0,N,BAO_0000219,Homo sapiens,,,,6166,,4845,,1,646.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620340,9606.0,N,BAO_0000219,Homo sapiens,,,,6167,,5822,,1,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL620341,9606.0,N,BAO_0000219,Homo sapiens,,,,6168,,5822,,1,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL876491,9606.0,N,BAO_0000219,Homo sapiens,,,,6169,,5822,,1,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,A549,Intermediate,1,,80682
,CHEMBL620342,9606.0,N,BAO_0000219,Homo sapiens,,,,6170,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL620343,9606.0,N,BAO_0000219,Homo sapiens,,,,6171,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL620344,9606.0,N,BAO_0000219,Homo sapiens,,,,6172,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL620345,9606.0,N,BAO_0000219,Homo sapiens,,,,6173,,5609,,1,646.0,In vitro anticancer activity against human lung (A549) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620346,9606.0,N,BAO_0000219,Homo sapiens,,,,6174,,4644,,1,646.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,A549,Intermediate,1,,80682
,CHEMBL620347,9606.0,N,BAO_0000219,Homo sapiens,,,,6175,,4644,,1,646.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,A549,Intermediate,1,,80682
,CHEMBL620348,9606.0,N,BAO_0000219,Homo sapiens,,,,6176,,4644,,1,646.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,A549,Intermediate,1,,80682
,CHEMBL620349,9606.0,N,BAO_0000219,Homo sapiens,,,,6177,,4644,,1,646.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,A549,Intermediate,1,,80682
,CHEMBL618667,9606.0,N,BAO_0000219,Homo sapiens,,,,6178,,5822,,1,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,A549,Intermediate,1,,80682
,CHEMBL618668,9606.0,N,BAO_0000219,Homo sapiens,,,,6179,,3415,,1,646.0,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,A549,Expert,1,,80682
,CHEMBL876031,9606.0,N,BAO_0000219,Homo sapiens,,,,6180,,16726,,1,646.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,A549,Intermediate,1,,80682
,CHEMBL618759,9606.0,N,BAO_0000219,Homo sapiens,,,,6181,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,A549,Intermediate,1,,80682
,CHEMBL618760,9606.0,N,BAO_0000219,Homo sapiens,,,,6182,,17206,,1,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,A549,Intermediate,1,,80682
,CHEMBL619000,9606.0,N,BAO_0000219,Homo sapiens,,,,6183,,17206,,1,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,A549,Intermediate,1,,80682
,CHEMBL619001,9606.0,N,BAO_0000219,Homo sapiens,,,,6184,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,A549,Intermediate,1,,80682
,CHEMBL619002,9606.0,N,BAO_0000219,Homo sapiens,,,,6185,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,A549,Intermediate,1,,80682
,CHEMBL619003,9606.0,N,BAO_0000219,Homo sapiens,,,,6186,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,A549,Intermediate,1,,80682
,CHEMBL619597,9606.0,N,BAO_0000219,Homo sapiens,,,,6187,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,A549,Intermediate,1,,80682
,CHEMBL619598,9606.0,N,BAO_0000219,Homo sapiens,,,,6188,,17206,,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,A549,Intermediate,1,,80682
,CHEMBL619599,9606.0,N,BAO_0000219,Homo sapiens,,,,6189,,17206,,1,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619600,9606.0,N,BAO_0000219,Homo sapiens,,,,6190,,17206,,1,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619601,9606.0,N,BAO_0000219,Homo sapiens,,,,6191,,16726,,1,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,A549,Intermediate,1,,80682
,CHEMBL619602,9606.0,N,BAO_0000219,Homo sapiens,,,,6192,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619603,9606.0,N,BAO_0000219,Homo sapiens,,,,6193,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619604,9606.0,N,BAO_0000219,Homo sapiens,,,,6194,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619605,9606.0,N,BAO_0000219,Homo sapiens,,,,6195,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619606,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6196,,6084,,1,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL876032,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6197,,6084,,1,,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619607,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6198,,4809,,1,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL619608,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6199,,5983,,1,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619609,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6200,,6251,,1,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619610,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6201,1969.0,5932,,1,,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL619611,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,6202,178.0,4273,,1,,Tested for the peak blood level in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619612,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6203,,5313,,1,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Intermediate,1,,50588
,CHEMBL619613,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6204,,5313,,1,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Intermediate,1,,50588
,CHEMBL619614,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,6205,178.0,6221,,1,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL619615,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6206,,4709,,1,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL619616,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6207,,167,,1,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Intermediate,1,,50588
,CHEMBL619617,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6208,1969.0,6241,,1,,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL619618,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6209,,344,,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Intermediate,1,,50588
,CHEMBL876033,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6210,,344,,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Intermediate,1,,50588
,CHEMBL619619,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6211,,344,,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Intermediate,1,,50588
,CHEMBL619620,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6212,,2189,,1,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Intermediate,1,,50588
,CHEMBL619621,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,6213,1088.0,2189,,1,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Intermediate,1,,50588
,CHEMBL619622,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,6214,1088.0,2189,,1,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Intermediate,1,,50588
,CHEMBL618874,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,6215,1088.0,2189,,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Intermediate,1,,50588
,CHEMBL618875,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6216,,4257,,1,,Absolute bioavailability was evaluated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618876,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6217,,6221,,1,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL618877,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6218,,6215,,1,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618878,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6219,,17267,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618879,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6220,,6621,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618880,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6221,,3854,,1,,Bioavailability after intravenous administration in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618881,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6222,,3854,,1,,Bioavailability after peroral administration in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618882,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6223,,5007,,1,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL624226,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6224,,4333,,1,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Intermediate,1,,50588
,CHEMBL624227,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6225,1969.0,4333,,1,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624228,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6226,,5006,,1,,Bioavailability,A,In vivo,,Intermediate,1,,50588
,CHEMBL624229,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6227,,5199,,1,,Bioavailability,A,In vivo,,Intermediate,1,,50588
,CHEMBL624230,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6228,,4368,,1,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624231,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6229,,3771,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624232,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6230,,4953,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625127,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6231,,5064,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625128,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6232,,17657,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621675,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6233,,17796,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621676,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6234,,17853,,1,,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Intermediate,1,,50588
,CHEMBL621677,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6235,,4521,,1,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621678,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6236,,4521,,1,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621679,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6237,,5006,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621680,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6238,,16365,,1,,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621681,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6239,,1916,,1,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL876740,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6240,,1918,,1,,Bioavailability was evaluated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621682,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6241,,4239,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621683,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6242,,6505,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621684,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6243,,5334,,1,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL621685,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6244,,5334,,1,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL621686,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6245,,4809,,1,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621687,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6246,,6348,,1,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621688,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6247,,6005,,1,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621689,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6248,,17804,,1,,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621690,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6249,,3184,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621691,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6250,,1806,,1,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL875941,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6251,,1806,,1,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621692,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6252,,1806,,1,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Intermediate,1,,50588
,CHEMBL621693,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6253,,4839,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621694,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6254,,5017,,1,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621695,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6255,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL621696,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6256,948.0,846,,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL621697,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6257,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL621698,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6258,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623420,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6259,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623421,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6260,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623422,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6261,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623423,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6262,2113.0,846,,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623424,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6263,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623425,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6264,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623426,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6265,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623427,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6266,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623428,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6267,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL875947,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6268,2107.0,846,,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623429,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6269,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL623430,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6270,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL622588,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6271,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL622589,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6272,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL622751,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6273,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL622752,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6274,2048.0,846,,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Intermediate,1,,50594
,CHEMBL622753,10090.0,N,BAO_0000218,Mus musculus,,,,6275,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622647,10090.0,N,BAO_0000218,Mus musculus,,,,6276,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL875163,10090.0,N,BAO_0000218,Mus musculus,,,,6277,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622648,10090.0,N,BAO_0000218,Mus musculus,,,,6278,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622649,10090.0,N,BAO_0000218,Mus musculus,,,,6279,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622650,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6280,955.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622651,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6281,955.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622652,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6282,955.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622653,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6283,955.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622654,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6284,955.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622655,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6285,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622656,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6286,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622657,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6287,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622658,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6288,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL622659,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6289,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624630,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6290,2113.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624631,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6291,2113.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624632,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6292,2113.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624633,9606.0,N,BAO_0000219,Homo sapiens,,,,6293,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,A549,Intermediate,1,,80682
,CHEMBL624634,9606.0,N,BAO_0000219,Homo sapiens,,,,6294,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,A549,Intermediate,1,,80682
,CHEMBL624635,9606.0,N,BAO_0000219,Homo sapiens,,,,6295,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,A549,Intermediate,1,,80682
,CHEMBL624636,9606.0,N,BAO_0000219,Homo sapiens,,,,6296,,17130,,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,A549,Intermediate,1,,80682
,CHEMBL857055,9606.0,N,BAO_0000219,Homo sapiens,,,,6297,,3263,,1,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL624637,9606.0,N,BAO_0000219,Homo sapiens,,,,6298,,6663,,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,A549,Expert,1,,80682
,CHEMBL624638,9606.0,N,BAO_0000219,Homo sapiens,,,,6299,,6663,,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,A549,Expert,1,,80682
,CHEMBL874366,9606.0,N,BAO_0000219,Homo sapiens,,,,6300,,6663,,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,A549,Expert,1,,80682
,CHEMBL624639,9606.0,N,BAO_0000219,Homo sapiens,,,,6301,,6663,,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,A549,Expert,1,,80682
,CHEMBL624640,9606.0,N,BAO_0000219,Homo sapiens,,,,6302,,6663,,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,A549,Expert,1,,80682
,CHEMBL624641,9606.0,N,BAO_0000219,Homo sapiens,,,,6303,,6663,,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,A549,Intermediate,1,,80682
,CHEMBL624642,9606.0,N,BAO_0000219,Homo sapiens,,,,6304,,6663,,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,A549,Intermediate,1,,80682
,CHEMBL624643,9606.0,N,BAO_0000219,Homo sapiens,,,,6305,,6663,,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,A549,Intermediate,1,,80682
,CHEMBL624644,9606.0,N,BAO_0000219,Homo sapiens,,,,6306,,6663,,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,A549,Intermediate,1,,80682
,CHEMBL624645,9606.0,N,BAO_0000219,Homo sapiens,,,,6307,,6663,,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,A549,Intermediate,1,,80682
,CHEMBL619445,9606.0,N,BAO_0000219,Homo sapiens,,,,6308,,3983,,1,646.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,A549,Intermediate,1,,80682
,CHEMBL839886,9606.0,N,BAO_0000219,Homo sapiens,,,,6309,,11141,,1,646.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,A549,Expert,1,,80682
,CHEMBL619446,9606.0,N,BAO_0000219,Homo sapiens,,,,6310,,5076,,1,646.0,Cytotoxic activity of compound against A-549 tumor cell line.,F,,A549,Intermediate,1,,80682
,CHEMBL619447,9606.0,N,BAO_0000219,Homo sapiens,,,,6311,,3311,,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,A549,Intermediate,1,,80682
,CHEMBL619448,9606.0,N,BAO_0000219,Homo sapiens,,,,6312,,3311,,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,A549,Intermediate,1,,80682
,CHEMBL619449,9606.0,N,BAO_0000219,Homo sapiens,,,,6313,,3311,,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,A549,Intermediate,1,,80682
,CHEMBL619450,9606.0,N,BAO_0000219,Homo sapiens,,,,6314,,5076,,1,646.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL619451,9606.0,N,BAO_0000219,Homo sapiens,,,,6315,,4150,,1,646.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,A549,Intermediate,1,,80682
,CHEMBL619452,9606.0,N,BAO_0000219,Homo sapiens,,,,6316,,2150,,1,646.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,A549,Expert,1,,80682
,CHEMBL619453,9606.0,N,BAO_0000219,Homo sapiens,,,,6317,,4644,,1,646.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,A549,Intermediate,1,,80682
,CHEMBL874367,9606.0,N,BAO_0000219,Homo sapiens,,,,6318,,263,,1,646.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,A549,Intermediate,1,,80682
,CHEMBL619454,9606.0,N,BAO_0000219,Homo sapiens,,,,6319,,11333,,1,646.0,Cytotoxic concentration against A-549 tumor cells.,F,,A549,Intermediate,1,,80682
,CHEMBL619455,9606.0,N,BAO_0000219,Homo sapiens,,,,6320,,11333,,1,646.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,A549,Intermediate,1,,80682
,CHEMBL619456,9606.0,N,BAO_0000219,Homo sapiens,,,,6321,,15895,,1,646.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,A549,Intermediate,1,,80682
,CHEMBL619457,470.0,N,BAO_0000218,Acinetobacter baumannii,,,,6322,,16677,,1,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Expert,1,,50191
,CHEMBL619458,471.0,N,BAO_0000218,Acinetobacter calcoaceticus,,,,6323,,10624,,1,,Activity against Acinetobacter calcoaceticus (AC54),F,,,Intermediate,1,,50192
,CHEMBL619459,5059.0,N,BAO_0000218,Aspergillus flavus,,,,6324,,16717,,1,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Expert,1,,50274
,CHEMBL619460,5059.0,N,BAO_0000218,Aspergillus flavus,,,,6325,,16717,,1,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Expert,1,,50274
,CHEMBL619461,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6326,,5513,,1,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Intermediate,1,,50416
,CHEMBL619462,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6327,,15962,,1,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Intermediate,1,,50416
,CHEMBL620388,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6328,,15962,,1,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Intermediate,1,,50416
,CHEMBL620389,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6329,,15962,,1,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Intermediate,1,,50416
,CHEMBL620390,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6330,,15962,,1,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Intermediate,1,,50416
,CHEMBL620391,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6331,,16717,,1,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Expert,1,,50416
,CHEMBL621073,746128.0,N,BAO_0000218,Aspergillus fumigatus,,,,6332,,16717,,1,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Expert,1,,50416
,CHEMBL621074,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6333,,8117,,1,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Intermediate,1,,50296
,CHEMBL621075,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6334,,8117,,1,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Intermediate,1,,50366
,CHEMBL619554,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6335,,15472,,1,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Intermediate,1,,50535
,CHEMBL619555,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6336,,15472,,1,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Intermediate,1,,50535
,CHEMBL619556,714.0,N,BAO_0000218,Aggregatibacter actinomycetemcomitans,,,,6337,,16443,,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Intermediate,1,,50169
,CHEMBL619557,714.0,N,BAO_0000218,Aggregatibacter actinomycetemcomitans,,,,6338,,16443,,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Intermediate,1,,50169
,CHEMBL619558,714.0,N,BAO_0000218,Aggregatibacter actinomycetemcomitans,,,,6339,,16443,,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Intermediate,1,,50169
,CHEMBL619559,9606.0,N,BAO_0000219,Homo sapiens,,,,6340,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619560,9606.0,N,BAO_0000219,Homo sapiens,,,,6341,,17206,,1,646.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619561,9606.0,N,BAO_0000219,Homo sapiens,,,,6342,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL619562,9606.0,N,BAO_0000219,Homo sapiens,,,,6343,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL619563,9606.0,N,BAO_0000219,Homo sapiens,,,,6344,,16381,,1,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,A549,Intermediate,1,,80682
,CHEMBL857457,9606.0,N,BAO_0000219,Homo sapiens,,,,6345,,16381,,1,646.0,GI values against A549 cells (lung cancer),F,,A549,Intermediate,1,,80682
,CHEMBL619564,9606.0,N,BAO_0000219,Homo sapiens,,,,6346,,17206,,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,A549,Intermediate,1,,80682
,CHEMBL619565,9606.0,N,BAO_0000219,Homo sapiens,,,,6347,,16325,,1,646.0,Inhibitory activity against A549 human adenocarcinoma,F,,A549,Intermediate,1,,80682
,CHEMBL619566,9606.0,N,BAO_0000218,Homo sapiens,,,,6348,,10708,,1,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,A549,Intermediate,1,,80682
,CHEMBL619567,9606.0,N,BAO_0000218,Homo sapiens,,,,6349,,10708,,1,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,A549,Intermediate,1,,80682
,CHEMBL619568,9606.0,N,BAO_0000219,Homo sapiens,,,,6350,,17376,,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619569,9606.0,N,BAO_0000219,Homo sapiens,,,,6351,,17376,,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,A549,Intermediate,1,,80682
,CHEMBL619570,9606.0,N,BAO_0000219,Homo sapiens,,,,6352,,17488,,1,646.0,Cytotoxicity against human A549 lung cells,F,,A549,Intermediate,1,,80682
,CHEMBL619571,9606.0,N,BAO_0000218,Homo sapiens,,,,6353,,17404,,1,646.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,A549,Intermediate,1,,80682
,CHEMBL619572,9606.0,N,BAO_0000219,Homo sapiens,,,,6354,,10958,,1,646.0,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,A549,Expert,1,,80682
,CHEMBL619573,9606.0,N,BAO_0000219,Homo sapiens,,,,6355,,17099,,1,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,A549,Expert,1,,80682
,CHEMBL619574,9606.0,N,BAO_0000219,Homo sapiens,,,,6356,,17099,,1,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,A549,Intermediate,1,,80682
,CHEMBL619575,9606.0,N,BAO_0000219,Homo sapiens,,,,6357,,4096,,1,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,A549,Intermediate,1,,80682
,CHEMBL619576,9606.0,N,BAO_0000219,Homo sapiens,,,,6358,,4096,,1,646.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,A549,Expert,1,,80682
,CHEMBL619577,9606.0,N,BAO_0000219,Homo sapiens,,,,6359,,4096,,1,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,A549,Intermediate,1,,80682
,CHEMBL619578,9606.0,N,BAO_0000219,Homo sapiens,,,,6360,,2525,,1,646.0,In vitro inhibitory activity against A549 tumor cell culture,F,,A549,Intermediate,1,,80682
,CHEMBL884009,9606.0,N,BAO_0000219,Homo sapiens,,,,6361,,2525,,1,646.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,A549,Intermediate,1,,80682
,CHEMBL619579,9606.0,N,BAO_0000219,Homo sapiens,,,,6362,,5302,,1,646.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,A549,Intermediate,1,,80682
,CHEMBL619580,9606.0,N,BAO_0000219,Homo sapiens,,,,6363,,16325,,1,646.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,A549,Intermediate,1,,80682
,CHEMBL619581,9606.0,N,BAO_0000219,Homo sapiens,,,,6364,,16939,,1,646.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619582,9606.0,N,BAO_0000219,Homo sapiens,,,,6365,,17229,,1,646.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL619583,9606.0,N,BAO_0000219,Homo sapiens,,,,6366,,17380,,1,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,A549,Intermediate,1,,80682
,CHEMBL876502,9606.0,N,BAO_0000219,Homo sapiens,,,,6367,,17380,,1,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,A549,Intermediate,1,,80682
,CHEMBL619584,9606.0,N,BAO_0000219,Homo sapiens,,,,6368,,1903,,1,646.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,A549,Intermediate,1,,80682
,CHEMBL619585,9606.0,N,BAO_0000219,Homo sapiens,,,,6369,,3838,,1,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,A549,Intermediate,1,,80682
,CHEMBL619586,9606.0,N,BAO_0000219,Homo sapiens,,,,6370,,14696,,1,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619587,9606.0,N,BAO_0000219,Homo sapiens,,,,6371,,3838,,1,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,A549,Intermediate,1,,80682
,CHEMBL619588,9606.0,N,BAO_0000219,Homo sapiens,,,,6372,,1522,,1,646.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,A549,Intermediate,1,,80682
,CHEMBL619589,9606.0,N,BAO_0000219,Homo sapiens,,,,6373,,12400,,1,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL619590,9606.0,N,BAO_0000219,Homo sapiens,,,,6374,,14696,,1,646.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,A549,Intermediate,1,,80682
,CHEMBL619591,9606.0,N,BAO_0000219,Homo sapiens,,,,6375,,14769,,1,646.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,A549,Intermediate,1,,80682
,CHEMBL619592,9606.0,N,BAO_0000219,Homo sapiens,,,,6376,,14696,,1,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,A549,Intermediate,1,,80682
,CHEMBL619593,9606.0,N,BAO_0000219,Homo sapiens,,,,6377,,1888,,1,646.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,A549,Intermediate,1,,80682
,CHEMBL620217,9606.0,N,BAO_0000219,Homo sapiens,,,,6378,,12016,,1,646.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620218,9606.0,N,BAO_0000219,Homo sapiens,,,,6379,,6058,,1,646.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,A549,Intermediate,1,,80682
,CHEMBL620219,9606.0,N,BAO_0000219,Homo sapiens,,,,6380,,17708,,1,646.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,A549,Intermediate,1,,80682
,CHEMBL620220,9606.0,N,BAO_0000219,Homo sapiens,,,,6381,,12301,,1,646.0,Antitumor activity against A549/ATCC cell line,F,,A549,Intermediate,1,,80682
,CHEMBL625141,9606.0,N,BAO_0000219,Homo sapiens,,,,6382,,11970,,1,646.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,A549,Intermediate,1,,80682
,CHEMBL625142,9606.0,N,BAO_0000219,Homo sapiens,,,,6383,,11818,,1,646.0,In vitro cytotoxicity against A549/ATCC cell line.,F,,A549,Expert,1,,80682
,CHEMBL625143,9606.0,N,BAO_0000219,Homo sapiens,,,,6384,,12400,,1,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,A549,Intermediate,1,,80682
,CHEMBL625144,9606.0,N,BAO_0000219,Homo sapiens,,,,6385,,3381,,1,646.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,A549,Intermediate,1,,80682
,CHEMBL622474,9606.0,N,BAO_0000219,Homo sapiens,,,,6386,,17376,,1,646.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,A549,Intermediate,1,,80682
,CHEMBL884104,9606.0,N,BAO_0000219,Homo sapiens,,,,6387,,10708,,1,646.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,A549,Intermediate,1,,80682
,CHEMBL622475,9606.0,U,BAO_0000219,Homo sapiens,,,,6388,,2964,,1,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Autocuration,0,,22226
,CHEMBL622476,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,6389,,5005,,1,,Compound was tested for oral bioavailability in dogs,A,In vivo,,Intermediate,0,,22224
,CHEMBL875831,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6390,,6229,,1,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Intermediate,1,,50588
,CHEMBL622477,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6391,,6229,,1,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Intermediate,1,,50588
,CHEMBL622478,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6392,,5374,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623172,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6393,,5374,,1,,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Intermediate,1,,50588
,CHEMBL623173,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6394,,6265,,1,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL623174,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6395,,5654,,1,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623175,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6396,,5654,,1,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623340,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6397,,16456,,1,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL623341,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6398,,5302,,1,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL623342,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6399,,3624,,1,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Intermediate,1,,50588
,CHEMBL623343,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6400,,16452,,1,,Oral bioavailability of active FTIs in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623344,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6401,,5802,,1,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL623345,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6402,,3598,,1,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50588
,CHEMBL875832,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6403,,17839,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623346,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6404,,6762,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623347,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6405,,6821,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623348,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6406,,6821,,1,,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Intermediate,1,,50588
,CHEMBL623349,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6407,,5210,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623350,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6408,,6227,,1,,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623351,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6409,,761,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50588
,CHEMBL623352,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6410,,761,,1,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Intermediate,1,,50588
,CHEMBL623353,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6411,,761,,1,,Oral bioavailability administered in solution in rats,A,In vivo,,Intermediate,1,,50588
,CHEMBL875833,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6412,,16907,,1,,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623354,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6413,,5474,,1,,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623355,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6414,,6535,,1,,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL623356,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6415,,6535,,1,,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623357,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6416,,3352,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623358,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6417,,6168,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623359,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6418,,5988,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623360,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6419,,4942,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623361,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6420,,4942,,1,,Oral bioavailability in dogs; No data,A,In vivo,,Intermediate,1,,50588
,CHEMBL623362,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6421,,14541,,1,,Oral bioavailability measured in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623363,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6422,,4449,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623364,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6423,,6057,,1,,Oral bioavailability was calculated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL875834,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6424,,5600,,1,,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623365,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6425,,5542,,1,,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Intermediate,1,,50588
,CHEMBL623366,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6426,,5542,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623367,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6427,,5546,,1,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL623368,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6428,,4514,,1,,Oral bioavailability in Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623369,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6429,,3624,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623370,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6430,,3854,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623371,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6431,,5836,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623372,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6432,,5940,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621351,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6433,,6168,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621352,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6434,,6227,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621353,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6435,,6251,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621354,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6436,,6448,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621355,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6437,,6647,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621356,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6438,,5940,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621357,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6439,,933,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621358,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6440,,5210,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621359,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6441,,6642,,1,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Intermediate,1,,50588
,CHEMBL621360,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6442,,6641,,1,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621361,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6443,,6642,,1,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621362,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6444,,5472,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621363,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6445,,5985,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621364,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6446,,15660,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621166,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6447,,5530,,1,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621167,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6448,,5530,,1,,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL621168,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6449,,6305,,1,,Oral bioavailability (F) in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL621169,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6450,,5210,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL875950,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6451,,5238,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621170,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6452,,5668,,1,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621171,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6453,,5668,,1,,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621172,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6454,,5668,,1,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621173,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6455,,6084,,1,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621174,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6456,2113.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621175,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6457,2113.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621176,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6458,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621177,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6459,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621178,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6460,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621179,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6461,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621180,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6462,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL875951,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6463,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621181,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6464,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621182,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6465,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621183,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6466,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621184,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6467,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621185,10090.0,N,BAO_0000218,Mus musculus,,,,6468,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621186,10090.0,N,BAO_0000218,Mus musculus,,,,6469,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621187,10090.0,N,BAO_0000218,Mus musculus,,,,6470,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621188,10090.0,N,BAO_0000218,Mus musculus,,,,6471,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621189,10090.0,N,BAO_0000218,Mus musculus,,,,6472,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621190,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6473,2106.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL618520,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6474,2106.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621739,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6475,2106.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621740,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6476,2106.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621741,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6477,2106.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621742,10090.0,N,BAO_0000218,Mus musculus,,,,6478,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621743,10090.0,N,BAO_0000218,Mus musculus,,,,6479,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621744,10090.0,N,BAO_0000218,Mus musculus,,,,6480,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621745,10090.0,N,BAO_0000218,Mus musculus,,,,6481,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621746,10090.0,N,BAO_0000218,Mus musculus,,,,6482,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621747,10090.0,N,BAO_0000218,Mus musculus,,,,6483,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621748,10090.0,N,BAO_0000218,Mus musculus,,,,6484,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621749,10090.0,N,BAO_0000218,Mus musculus,,,,6485,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621750,10090.0,N,BAO_0000218,Mus musculus,,,,6486,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621751,10090.0,N,BAO_0000218,Mus musculus,,,,6487,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621752,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6488,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621753,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6489,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL875955,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6490,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621754,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6491,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621755,10090.0,N,BAO_0000218,Mus musculus,,,Heart,6492,948.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL621756,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6493,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624199,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6494,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624200,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6495,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624375,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6496,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624376,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6497,2107.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624377,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6498,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624378,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6499,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL857901,107673.0,N,BAO_0000218,aeinetobacter anitrotap,,,,6500,,12269,,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Intermediate,1,,50067
,CHEMBL875274,107673.0,N,BAO_0000218,Acinetobacter calcoaceticus subsp. anitratus,,,,6501,,12269,,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Intermediate,1,,50067
,CHEMBL624379,107673.0,N,BAO_0000218,Acinetobacter calcoaceticus subsp. anitratus,,,,6502,,12269,,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Intermediate,1,,50067
,CHEMBL624380,107673.0,N,BAO_0000218,aeinetobacter anitrotap,,,,6503,,12269,,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Intermediate,1,,50067
,CHEMBL624381,471.0,N,BAO_0000218,Acinetobacter calcoaceticus,,,,6504,,10624,,1,,Activity against Acinetobacter calcoaceticus (AC54),F,,,Intermediate,1,,50192
,CHEMBL624382,28377.0,N,BAO_0000218,Anolis carolinensis,,,,6505,,17216,,1,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Intermediate,1,,50714
,CHEMBL624383,28377.0,N,BAO_0000218,Anolis carolinensis,,,,6506,,17216,,1,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Intermediate,1,,50714
,CHEMBL624384,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6507,,9560,,1,,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Intermediate,1,,50296
,CHEMBL624385,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6508,,9560,,1,,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Intermediate,1,,50296
,CHEMBL624386,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6509,,9560,,1,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Intermediate,1,,50296
,CHEMBL624387,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6510,,9560,,1,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Intermediate,1,,50296
,CHEMBL624388,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6511,,9560,,1,,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Intermediate,1,,50296
,CHEMBL624389,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6512,,9560,,1,,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Intermediate,1,,50296
,CHEMBL624390,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6513,,9560,,1,,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Intermediate,1,,50296
,CHEMBL875275,1655.0,N,BAO_0000218,Actinomyces naeslundii,,,,6514,,9560,,1,,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Intermediate,1,,50296
,CHEMBL624391,85549.0,N,BAO_0000218,Artemia salina,,,,6515,,114,,1,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Intermediate,1,,50056
,CHEMBL623636,85549.0,N,BAO_0000218,Artemia salina,,,,6516,,114,,1,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Intermediate,1,,50056
,CHEMBL623637,6253.0,N,BAO_0000218,Ascaris suum,,,,6517,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Intermediate,1,,50532
,CHEMBL623638,6253.0,N,BAO_0000218,Ascaris suum,,,,6518,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Intermediate,1,,50532
,CHEMBL623639,6253.0,N,BAO_0000218,Ascaris suum,,,,6519,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Intermediate,1,,50532
,CHEMBL623640,6253.0,N,BAO_0000218,Ascaris suum,,,,6520,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Intermediate,1,,50532
,CHEMBL623641,6253.0,N,BAO_0000218,Ascaris suum,,,,6521,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Intermediate,1,,50532
,CHEMBL623642,6253.0,N,BAO_0000218,Ascaris suum,,,,6522,,10841,,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Intermediate,1,,50532
,CHEMBL623643,6253.0,N,BAO_0000218,Ascaris suum,,,,6523,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Intermediate,1,,50532
,CHEMBL623644,6253.0,N,BAO_0000218,Ascaris suum,,,,6524,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Intermediate,1,,50532
,CHEMBL623645,6253.0,N,BAO_0000218,Ascaris suum,,,,6525,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Intermediate,1,,50532
,CHEMBL623646,6253.0,N,BAO_0000218,Ascaris suum,,,,6526,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Intermediate,1,,50532
,CHEMBL623647,6253.0,N,BAO_0000218,Ascaris suum,,,,6527,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Intermediate,1,,50532
,CHEMBL623648,6253.0,N,BAO_0000218,Ascaris suum,,,,6528,,10841,,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Intermediate,1,,50532
,CHEMBL623649,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6529,,8117,,1,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Intermediate,1,,50366
,CHEMBL623650,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6530,,8117,,1,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Intermediate,1,,50366
,CHEMBL623651,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6531,,9560,,1,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Intermediate,1,,50366
,CHEMBL623652,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6532,,9560,,1,,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Expert,1,,50366
,CHEMBL623653,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6533,,9560,,1,,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Intermediate,1,,50366
,CHEMBL623654,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6534,,9560,,1,,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Intermediate,1,,50366
,CHEMBL623655,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6535,,9560,,1,,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Intermediate,1,,50366
,CHEMBL623656,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6536,,9560,,1,,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Intermediate,1,,50366
,CHEMBL623657,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6537,,9560,,1,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Expert,1,,50366
,CHEMBL623658,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6538,,9560,,1,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Intermediate,1,,50366
,CHEMBL623659,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6539,,9560,,1,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Intermediate,1,,50366
,CHEMBL623660,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6540,,9560,,1,,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Intermediate,1,,50366
,CHEMBL623661,1656.0,N,BAO_0000218,Actinomyces viscosus,,,,6541,,9560,,1,,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Intermediate,1,,50366
,CHEMBL875281,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6542,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL623662,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6543,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL623663,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6544,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL623664,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6545,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL623665,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6546,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL621856,9606.0,N,BAO_0000219,Homo sapiens,,,,6547,,10708,,1,165.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,A673,Intermediate,1,,80023
,CHEMBL620432,9606.0,N,BAO_0000219,Homo sapiens,,,,6548,,10708,,1,645.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,A704,Intermediate,1,,80661
,CHEMBL620433,10116.0,U,BAO_0000219,Rattus norvegicus,,,,6549,,416,,1,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Autocuration,0,,22226
,CHEMBL620434,10090.0,N,BAO_0000219,Mus musculus,,,,6550,,14354,,1,625.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,A9,Intermediate,1,,80024
,CHEMBL620435,10090.0,N,BAO_0000219,Mus musculus,,,,6551,,14354,,1,625.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,A9,Intermediate,1,,80024
,CHEMBL620436,9606.0,N,BAO_0000219,Homo sapiens,,,,6552,,5116,,1,625.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,A9,Intermediate,1,,80024
,CHEMBL876597,9606.0,N,BAO_0000219,Homo sapiens,,,,6553,,5116,,1,625.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,A9,Intermediate,1,,80024
,CHEMBL620437,9606.0,N,BAO_0000219,Homo sapiens,,,,6554,,15694,,1,874.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,Human ovarian carcinoma cell line,Expert,1,,81037
,CHEMBL620438,10090.0,N,BAO_0000219,Mus musculus,,,,6555,,13038,,1,625.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,A9,Expert,1,,80024
,CHEMBL620439,10090.0,N,BAO_0000219,Mus musculus,,,,6556,,13038,,1,625.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,A9,Expert,1,,80024
,CHEMBL619657,10090.0,N,BAO_0000219,Mus musculus,,,,6557,,10923,,1,625.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,A9,Expert,1,,80024
,CHEMBL619658,10090.0,N,BAO_0000219,Mus musculus,,,,6558,,10923,,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,A9,Intermediate,1,,80024
,CHEMBL619659,10090.0,N,BAO_0000219,Mus musculus,,,,6559,,10923,,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,A9,Intermediate,1,,80024
,CHEMBL619660,,H,BAO_0000019,,,,,6560,,10923,,1,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,Expert,8,,10649
,CHEMBL619661,10090.0,N,BAO_0000219,Mus musculus,,,,6561,,10923,,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,A9,Intermediate,1,,80024
,CHEMBL619662,10090.0,N,BAO_0000219,Mus musculus,,,,6562,,10923,,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,A9,Intermediate,1,,80024
,CHEMBL619663,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6563,,8158,,1,975.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,AA6,Intermediate,1,,80663
,CHEMBL619664,9606.0,U,BAO_0000219,Homo sapiens,,,,6564,,15494,,1,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Autocuration,0,,22226
,CHEMBL619665,9606.0,U,BAO_0000219,Homo sapiens,,,,6565,,15494,,1,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Autocuration,0,,22226
,CHEMBL883244,9606.0,N,BAO_0000219,Homo sapiens,,,,6566,,12348,,1,974.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,AA5,Intermediate,1,,80662
,CHEMBL884011,9606.0,N,BAO_0000219,Homo sapiens,,,,6567,,12348,,1,974.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,AA5,Intermediate,1,,80662
,CHEMBL619666,9606.0,N,BAO_0000219,Homo sapiens,,,,6568,,2726,,1,974.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,AA5,Intermediate,1,,80662
,CHEMBL619667,9606.0,N,BAO_0000219,Homo sapiens,,,,6569,,2726,,1,379.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,U-937,Intermediate,1,,80566
,CHEMBL619668,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6570,,10747,,1,274.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,UV4,Intermediate,1,,80578
,CHEMBL619669,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6571,,11005,,1,185.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,CHO-AA8,Expert,1,,80089
,CHEMBL876608,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6572,,12687,,1,185.0,Average intracellular compound concentration when the hypoxic SER=1.6,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619670,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6573,,12687,,1,185.0,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619671,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6574,,12687,,1,185.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619672,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6575,,12687,,1,185.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619673,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6576,,12687,,1,185.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619674,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6577,,13436,,1,185.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619675,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6578,,13435,,1,185.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619676,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6579,,13302,,1,185.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619677,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6580,,12687,,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619678,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6581,,12687,,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619679,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6582,,12687,,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL619680,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6583,,12878,,1,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,CHO-AA8,Expert,1,,80089
,CHEMBL621457,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6584,,12878,,1,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL876609,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6585,,14367,,1,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,CHO-AA8,Expert,1,,80089
,CHEMBL621458,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6586,,14367,,1,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL621459,36483.0,N,BAO_0000219,hampster,,,,6587,,12398,,1,185.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,CHO-AA8,Expert,1,,80089
,CHEMBL621460,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6588,,12878,,1,185.0,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,CHO-AA8,Expert,1,,80089
,CHEMBL621461,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6589,,13820,,1,185.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,CHO-AA8,Expert,1,,80089
,CHEMBL621462,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6590,,13436,,1,185.0,Inhibition of growth under aerobic conditions in AA8 cells,F,,CHO-AA8,Expert,1,,80089
,CHEMBL621463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6591,,6084,,1,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621464,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6592,,5711,,1,,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Intermediate,1,,50588
,CHEMBL621465,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6593,,4353,,1,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621466,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6594,,4353,,1,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621467,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6595,,17800,,1,,Oral bioavailability in dog (mongrel),A,In vivo,,Intermediate,1,,50588
,CHEMBL621468,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6596,,3994,,1,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL876734,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6597,,3994,,1,,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Intermediate,1,,50588
,CHEMBL618476,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6598,,5145,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618477,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6599,,16452,,1,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL618478,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6600,,16452,,1,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Intermediate,1,,50588
,CHEMBL618479,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6601,,5983,,1,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL618480,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6602,,4273,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618481,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6603,,12500,,1,,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL618482,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6604,1969.0,12500,,1,,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Intermediate,1,,50588
,CHEMBL618483,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6605,,3639,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618484,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6606,,3880,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618485,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6607,,4838,,1,,Bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618486,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6608,,15600,,1,,oral bioavailability was measured in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618487,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6609,,17248,,1,,Compound was tested for plasma protein binding in dog; Not determined,A,,,Intermediate,1,,50588
,CHEMBL618488,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6610,,17248,,1,,Compound was tested for plasma protein binding of dog,A,,,Intermediate,1,,50588
,CHEMBL876735,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6611,,17248,,1,,Compound was tested for plasma protein binding of dog; Not determined,A,,,Intermediate,1,,50588
,CHEMBL618489,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6612,,17443,,1,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Intermediate,1,,50588
,CHEMBL618490,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6613,,4186,,1,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Intermediate,1,,50588
,CHEMBL618491,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6614,,3749,,1,,Half life was determined,A,,,Intermediate,1,,50588
,CHEMBL618492,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6615,,3249,,1,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL873354,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6616,,3022,,1,,Half life was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL618493,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6617,,3749,,1,,Half life was determined,A,,,Intermediate,1,,50588
,CHEMBL618494,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6618,,2517,,1,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL618495,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Heart,6619,948.0,2517,,1,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL618496,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Kidney,6620,2113.0,2517,,1,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL618497,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,6621,2107.0,2517,,1,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL618498,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Lung,6622,2048.0,2517,,1,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL618499,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Spleen,6623,2106.0,2517,,1,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Intermediate,1,,50588
,CHEMBL876736,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6624,,3639,,1,,LogP in dog,A,,,Intermediate,1,,50588
,CHEMBL618500,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6625,,6227,,1,,Partition coefficient (logP),A,,,Intermediate,1,,50588
,CHEMBL857831,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6626,,6227,,1,,Partition coefficient in dog,A,,,Intermediate,1,,50588
,CHEMBL618501,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6627,,17764,,1,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL618502,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6628,,4809,,1,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL618503,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6629,,5600,,1,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Intermediate,1,,50588
,CHEMBL618504,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6630,,14294,,1,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Intermediate,1,,50588
,CHEMBL618505,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6631,,14294,,1,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Intermediate,1,,50588
,CHEMBL618506,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6632,,14294,,1,,Metabolism of compound in dog S9 microsomes; Trace,A,,,Intermediate,1,,50588
,CHEMBL618507,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,6633,2107.0,6251,,1,,In vitro metabolic potential in dog liver microsomes,A,,,Intermediate,1,,50588
,CHEMBL876737,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6634,,3748,,1,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618508,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6635,,2713,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618509,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6636,,6512,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618510,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6637,,6679,,1,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL618511,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6638,,3749,,1,,The compound was tested for bioavailability in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618512,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6639,,3749,,1,,The compound was tested for oral bioavailability in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618513,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6640,,6742,,1,,Oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618514,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6641,,6227,,1,,Compound was tested for percent protein binding (PB) in dog,A,,,Intermediate,1,,50588
,CHEMBL620052,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6642,,6874,,1,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Intermediate,1,,50588
,CHEMBL620053,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6643,1969.0,2877,,1,,Compound was evaluated for plasma clearance.,A,In vivo,,Intermediate,1,,50588
,CHEMBL620054,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6644,1969.0,12500,,1,,The compound was tested for plasma clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL620055,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6645,1969.0,12500,,1,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Intermediate,1,,50588
,CHEMBL620056,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6646,,4709,,1,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL620057,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,6647,2107.0,5542,,1,,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Intermediate,1,,50588
,CHEMBL618939,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6648,,17594,,1,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618940,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6649,,2652,,1,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Intermediate,1,,50588
,CHEMBL618941,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6650,,17764,,1,,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624473,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6651,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624474,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6652,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624475,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6653,2048.0,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL624476,10090.0,N,BAO_0000218,Mus musculus,,,,6654,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL623478,10090.0,N,BAO_0000218,Mus musculus,,,,6655,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL623479,10090.0,N,BAO_0000218,Mus musculus,,,,6656,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL623480,10090.0,N,BAO_0000218,Mus musculus,,,,6657,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL623481,10090.0,N,BAO_0000218,Mus musculus,,,,6658,,6599,,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,Intermediate,1,,50594
,CHEMBL623482,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6659,955.0,17641,,1,,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL623483,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6660,2113.0,17641,,1,,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL623484,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6661,2107.0,17641,,1,,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL623485,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6662,2048.0,17641,,1,,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL623486,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6663,2106.0,17641,,1,,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL623487,10090.0,N,BAO_0000218,Mus musculus,,,,6664,,17852,,1,,Plasma clearance in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL623488,10090.0,N,BAO_0000218,Mus musculus,,,,6665,,17764,,1,,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623489,10090.0,N,BAO_0000218,Mus musculus,,,,6666,,17837,,1,,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL875157,10090.0,N,BAO_0000218,Mus musculus,,,,6667,,2675,,1,,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL623490,10090.0,N,BAO_0000218,Mus musculus,,,,6668,,2675,,1,,Clearance was evaluated in mice after oral administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL623491,10090.0,N,BAO_0000218,Mus musculus,,,,6669,,4239,,1,,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL623492,10090.0,N,BAO_0000218,Mus musculus,,,,6670,,17753,,1,,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623493,10090.0,N,BAO_0000218,Mus musculus,,,,6671,,17753,,1,,Plasma clearance of at 24 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623494,10090.0,N,BAO_0000218,Mus musculus,,,,6672,,17753,,1,,Plasma clearance at 24 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623495,10090.0,N,BAO_0000218,Mus musculus,,,,6673,,17753,,1,,Plasma clearance at 5 mg/Kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623496,10090.0,N,BAO_0000218,Mus musculus,,,,6674,,5727,,1,,Plasma clearance in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623497,10090.0,N,BAO_0000218,Mus musculus,,,,6675,,2862,,1,,Plasma clearance value upon iv administration in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL623498,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6676,1969.0,5980,,1,,Total plasma clearance in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623499,10090.0,N,BAO_0000218,Mus musculus,,,,6677,,17592,,1,,Clearance in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL623500,10090.0,N,BAO_0000218,Mus musculus,,,,6678,,17718,,1,,Clearance value was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL623501,10090.0,N,BAO_0000218,Mus musculus,,,,6679,,16597,,1,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL875158,,U,BAO_0000100,,,,,6680,,17384,,1,,Calculated partition coefficient (clogP),P,,,Intermediate,0,,22229
,CHEMBL623502,10090.0,N,BAO_0000218,Mus musculus,,,,6681,,6062,,1,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623503,10090.0,N,BAO_0000218,Mus musculus,,,,6682,,17734,,1,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623504,10090.0,N,BAO_0000218,Mus musculus,,,,6683,,6348,,1,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL623505,10090.0,N,BAO_0000218,Mus musculus,,,,6684,,5969,,1,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623506,10090.0,N,BAO_0000218,Mus musculus,,,,6685,,5969,,1,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623507,10090.0,N,BAO_0000218,Mus musculus,,,,6686,,5969,,1,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL623508,10090.0,N,BAO_0000218,Mus musculus,,,,6687,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Intermediate,1,,50594
,CHEMBL623509,10090.0,N,BAO_0000218,Mus musculus,,,,6688,,5781,,1,,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL875159,10090.0,N,BAO_0000218,Mus musculus,,,,6689,,17764,,1,,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623510,10090.0,N,BAO_0000218,Mus musculus,,,Brain,6690,955.0,17641,,1,,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623511,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,6691,2113.0,17641,,1,,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623512,10090.0,N,BAO_0000218,Mus musculus,,,Liver,6692,2107.0,17641,,1,,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623513,10090.0,N,BAO_0000218,Mus musculus,,,Lung,6693,2048.0,17641,,1,,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623514,10090.0,N,BAO_0000218,Mus musculus,,,,6694,,17764,,1,,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL622609,10090.0,N,BAO_0000218,Mus musculus,,,,6695,,17764,,1,,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL622610,10090.0,N,BAO_0000218,Mus musculus,,,,6696,,17764,,1,,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL621823,10090.0,N,BAO_0000218,Mus musculus,,,,6697,,17764,,1,,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL621824,10090.0,N,BAO_0000218,Mus musculus,,,,6698,,17764,,1,,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Intermediate,1,,50594
,CHEMBL621825,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,6699,2106.0,17641,,1,,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL621826,10090.0,N,BAO_0000218,Mus musculus,,,,6700,,16597,,1,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL621827,10090.0,N,BAO_0000218,Mus musculus,,,,6701,,16597,,1,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL621828,10090.0,N,BAO_0000218,Mus musculus,,,,6702,,5727,,1,,Cmax value was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL621829,10090.0,N,BAO_0000218,Mus musculus,,,,6703,,5951,,1,,Cmax value in IRC mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL621830,10090.0,N,BAO_0000218,Mus musculus,,,,6704,,5506,,1,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL621831,10090.0,N,BAO_0000218,Mus musculus,,,,6705,,5506,,1,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL621832,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6706,1969.0,14239,,1,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL624579,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6707,1969.0,4890,,1,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Intermediate,1,,50594
,CHEMBL624580,10090.0,N,BAO_0000218,Mus musculus,,,,6708,,429,,1,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL624581,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6709,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL624582,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6710,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL624583,6277.0,N,BAO_0000218,Acanthocheilonema viteae,,,,6711,,10986,,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Intermediate,1,,50535
,CHEMBL624584,9606.0,N,BAO_0000219,Homo sapiens,,,,6712,,13227,,1,455.0,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,A-375,Intermediate,1,,80018
Brain membranes,CHEMBL624585,10116.0,D,BAO_0000249,Rattus norvegicus,,,,6713,,4481,,1,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Expert,9,,12512
,CHEMBL875165,9606.0,D,BAO_0000019,Homo sapiens,,,,6714,,16931,,1,,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Expert,9,,114
,CHEMBL619490,,H,BAO_0000219,,,,,6715,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL619491,,H,BAO_0000219,,,,,6716,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,CHO,Autocuration,8,,114
,CHEMBL619492,,H,BAO_0000219,,,,,6717,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,CHO,Expert,8,,114
,CHEMBL619493,,H,BAO_0000219,,,,,6718,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,CHO,Expert,8,,114
,CHEMBL619494,,H,BAO_0000219,,,,,6719,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,CHO,Autocuration,8,,114
,CHEMBL619495,,H,BAO_0000219,,,,,6720,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,CHO,Autocuration,8,,114
,CHEMBL619496,,H,BAO_0000219,,,,,6721,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL619497,9606.0,D,BAO_0000219,Homo sapiens,,,,6722,,3850,,1,449.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,CHO,Expert,9,,114
,CHEMBL619498,,H,BAO_0000219,,,,,6723,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,CHO,Autocuration,8,,114
,CHEMBL619499,,H,BAO_0000219,,,,,6724,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL619500,,H,BAO_0000219,,,,,6725,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,CHO,Expert,8,,114
,CHEMBL619501,,H,BAO_0000219,,,,,6726,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL619502,,H,BAO_0000219,,,,,6727,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,CHO,Expert,8,,114
,CHEMBL619503,,H,BAO_0000219,,,,,6728,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,CHO,Autocuration,8,,114
,CHEMBL619504,,H,BAO_0000219,,,,,6729,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,CHO,Autocuration,8,,114
,CHEMBL621298,,H,BAO_0000219,,,,,6730,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL621299,,H,BAO_0000219,,,,,6731,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,CHO,Expert,8,,114
,CHEMBL621300,,H,BAO_0000219,,,,,6732,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,CHO,Autocuration,8,,114
,CHEMBL621301,,H,BAO_0000219,,,,,6733,,3850,,1,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,Autocuration,8,,114
,CHEMBL621302,,H,BAO_0000219,,,,,6734,,3850,,1,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,CHO,Expert,8,,114
,CHEMBL621303,9986.0,N,BAO_0000219,Oryctolagus cuniculus,,,,6735,,12680,,1,164.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,A10,Intermediate,1,,80013
,CHEMBL621304,10116.0,U,BAO_0000219,Rattus norvegicus,,,,6736,,1313,,1,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,A10,Autocuration,0,,22226
,CHEMBL621305,10116.0,U,BAO_0000219,Rattus norvegicus,,,,6737,,1313,,1,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,A10,Autocuration,0,,22226
,CHEMBL621306,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6738,,17567,,1,164.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,A10,Intermediate,1,,80013
,CHEMBL618444,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6739,,17567,,1,164.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,A10,Intermediate,1,,80013
,CHEMBL618445,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6740,,11819,,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,A10,Intermediate,1,,80013
,CHEMBL618446,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6741,,13436,,1,185.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618447,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6742,,12687,,1,185.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618448,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6743,,12651,,1,185.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618449,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6744,,13300,,1,185.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618637,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6745,,15296,,1,185.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618638,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6746,,15328,,1,185.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618639,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6747,,13302,,1,185.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618640,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6748,,14367,,1,185.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,CHO-AA8,Expert,1,,80089
,CHEMBL618641,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6749,,17002,,1,185.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,CHO-AA8,Expert,1,,80089
,CHEMBL618642,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6750,,13436,,1,185.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL618643,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6751,,13435,,1,185.0,Inhibitory activity against aerobic growth of AA8 cells.,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL884013,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6752,,10503,,1,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622723,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6753,,10503,,1,185.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,CHO-AA8,Expert,1,,80089
,CHEMBL622724,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6754,,10503,,1,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622725,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6755,,15090,,1,185.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,CHO-AA8,Expert,1,,80089
,CHEMBL622726,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6756,,10368,,1,185.0,Cytotoxicity against AA8 cell line,F,,CHO-AA8,Expert,1,,80089
,CHEMBL622727,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6757,,12651,,1,185.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622728,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6758,,12687,,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622729,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6759,,12687,,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622730,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6760,,12687,,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622731,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6761,,1890,,1,185.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622732,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6762,,10747,,1,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622733,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6763,,10747,,1,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,CHO-AA8,Intermediate,1,,80089
,CHEMBL622734,10029.0,U,BAO_0000218,Cricetulus griseus,,,,6764,,11616,,1,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Autocuration,0,,22224
,CHEMBL622735,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6765,,11616,,1,185.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,CHO-AA8,Expert,1,,80089
,CHEMBL618746,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6766,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618747,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6767,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL620540,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6768,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL620541,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6769,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL620542,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6770,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL620543,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6771,,3471,,1,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618832,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6772,,3471,,1,185.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618833,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6773,,11616,,1,185.0,Concentration required to reduce AA8 cell survival by 10%,F,,CHO-AA8,Expert,1,,80089
,CHEMBL618834,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6774,,2656,,1,185.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618835,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6775,,10518,,1,185.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618836,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6776,,10518,,1,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618837,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6777,,10518,,1,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618838,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6778,,10518,,1,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618839,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6779,,16156,,1,185.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618840,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6780,,2656,,1,185.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618841,10029.0,U,BAO_0000019,Cricetulus griseus,,,,6781,,11005,,1,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Autocuration,0,,22224
,CHEMBL618842,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6782,,11942,,1,185.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618843,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6783,,2128,,1,185.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL618844,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6784,,16907,,1,,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618845,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6785,,16907,,1,,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618846,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6786,,9579,,1,,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Intermediate,1,,50588
,CHEMBL618847,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6787,,9579,,1,,Half life was measured in dog after oral 17b administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL618848,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6788,,9579,,1,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Intermediate,1,,50588
,CHEMBL618849,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6789,,9579,,1,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Intermediate,1,,50588
,CHEMBL618850,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6790,,16907,,1,,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618851,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6791,,16907,,1,,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL873815,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6792,,3184,,1,,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618852,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6793,1969.0,5017,,1,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL618853,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6794,,6821,,1,,Elimination Half-life of compound was determined in dog,A,,,Intermediate,1,,50588
,CHEMBL618854,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6795,,17839,,1,,Half life of compound in dog following oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL618855,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6796,,17267,,1,,Half life of compound was determined in dog,A,,,Intermediate,1,,50588
,CHEMBL618856,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,6797,178.0,4727,,1,,Half life of compound was determined in dog blood,A,,,Intermediate,1,,50588
,CHEMBL875827,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6798,,5238,,1,,Half life after oral and iv dosing in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL618857,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6799,,4942,,1,,Half life in dogs in hours,A,,,Intermediate,1,,50588
,CHEMBL618858,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6800,,6505,,1,,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618859,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6801,,5130,,1,,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL618860,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6802,,1475,,1,,Half life was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL618861,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6803,,17804,,1,,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622539,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6804,,17804,,1,,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622540,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6805,,6084,,1,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL873803,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6806,,6084,,1,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL873804,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6807,,5542,,1,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624311,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6808,,5542,,1,,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624312,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6809,,6084,,1,,Half life period in dog,A,,,Intermediate,1,,50588
,CHEMBL624313,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6810,,6241,,1,,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624314,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6811,,1916,,1,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624315,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6812,,6621,,1,,Half-life of compound was determined in dogs,A,,,Intermediate,1,,50588
,CHEMBL624316,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6813,1969.0,1696,,1,,Half-life in dog plasma,A,,,Intermediate,1,,50588
,CHEMBL624317,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6814,,17800,,1,,Half-life in mongrel dogs was determined,A,,,Intermediate,1,,50588
,CHEMBL624318,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6815,,17657,,1,,Half-life in dog upon oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624319,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6816,,17657,,1,,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Intermediate,1,,50588
,CHEMBL624496,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6817,,4239,,1,,Half-life was measured in dog,A,,,Intermediate,1,,50588
,CHEMBL624497,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6818,,5985,,1,,Half-life was measured in dog,A,,,Intermediate,1,,50588
,CHEMBL624498,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6819,,9932,,1,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Intermediate,1,,50588
,CHEMBL624499,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6820,,5199,,1,,Oral half life was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624500,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6821,1969.0,5199,,1,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Intermediate,1,,50588
,CHEMBL624501,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6822,1969.0,1475,,1,,Plasma half life was evaluated,A,,,Intermediate,1,,50588
,CHEMBL623666,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6823,1969.0,1475,,1,,Plasma half life was evaluated in Dog,A,,,Intermediate,1,,50588
,CHEMBL623667,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6824,1969.0,1475,,1,,Plasma half life was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL623668,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6825,,6316,,1,,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623669,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6826,,4883,,1,,Tested for the half life value in dog,A,,,Intermediate,1,,50588
,CHEMBL623670,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6827,,4727,,1,,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623671,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6828,,1916,,1,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL875945,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,6829,178.0,1337,,1,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL623672,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,6830,178.0,1337,,1,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL623673,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6831,,6265,,1,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623674,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6832,,4809,,1,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL623675,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6833,,5983,,1,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Intermediate,1,,50588
,CHEMBL872526,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6834,,5313,,1,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Intermediate,1,,50588
,CHEMBL623676,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6835,,5313,,1,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Intermediate,1,,50588
,CHEMBL623677,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6836,1969.0,17650,,1,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623678,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6837,1969.0,5199,,1,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Intermediate,1,,50588
,CHEMBL623679,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6838,1969.0,933,,1,,Time taken for maximum plasma concentration in dog,A,,,Intermediate,1,,50588
,CHEMBL623680,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6839,,16367,,1,,Time to reach Cmax after oral administration to dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL623681,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,6840,1969.0,6348,,1,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL623682,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6841,,6316,,1,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL623683,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6842,,6215,,1,,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623684,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6843,,3598,,1,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50588
,CHEMBL622745,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6844,,4527,,1,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL622746,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6845,,17764,,1,,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622747,10090.0,N,BAO_0000218,Mus musculus,,,,6846,,5969,,1,,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL622748,10090.0,N,BAO_0000218,Mus musculus,,,,6847,,5969,,1,,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL622749,10090.0,N,BAO_0000218,Mus musculus,,,,6848,,4573,,1,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL622750,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6849,1969.0,3277,,1,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Intermediate,1,,50594
,CHEMBL623411,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6850,1969.0,17734,,1,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL875946,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6851,1969.0,3132,,1,,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL623412,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6852,1969.0,3132,,1,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623413,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6853,1969.0,6348,,1,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL623414,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6854,1969.0,17729,,1,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623415,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6855,1969.0,17729,,1,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623416,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6856,1969.0,17729,,1,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623417,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6857,1969.0,17728,,1,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL623418,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6858,1969.0,17728,,1,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL623419,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6859,1969.0,17728,,1,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL622816,10090.0,N,BAO_0000218,Mus musculus,,,,6860,,4066,,1,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623313,10090.0,N,BAO_0000218,Mus musculus,,,,6861,,6178,,1,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623314,10090.0,N,BAO_0000218,Mus musculus,,,,6862,,6178,,1,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL876788,10090.0,N,BAO_0000218,Mus musculus,,,,6863,,3760,,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623315,10090.0,N,BAO_0000218,Mus musculus,,,,6864,,3760,,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623316,10090.0,N,BAO_0000218,Mus musculus,,,,6865,,3760,,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623317,10090.0,N,BAO_0000218,Mus musculus,,,,6866,,3760,,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623319,10090.0,N,BAO_0000218,Mus musculus,,,,6868,,5961,,1,,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL623320,10090.0,N,BAO_0000218,Mus musculus,,,,6869,,6137,,1,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Intermediate,1,,50594
,CHEMBL623321,10090.0,N,BAO_0000218,Mus musculus,,,,6870,,3802,,1,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL623322,10090.0,N,BAO_0000218,Mus musculus,,,,6871,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Intermediate,1,,50594
,CHEMBL623323,10090.0,N,BAO_0000218,Mus musculus,,,,6872,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Intermediate,1,,50594
,CHEMBL623324,10090.0,N,BAO_0000218,Mus musculus,,,,6873,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Intermediate,1,,50594
,CHEMBL623325,10090.0,N,BAO_0000218,Mus musculus,,,,6874,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Intermediate,1,,50594
,CHEMBL623326,10090.0,N,BAO_0000218,Mus musculus,,,,6875,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Intermediate,1,,50594
,CHEMBL623327,10090.0,N,BAO_0000218,Mus musculus,,,,6876,,3535,,1,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Intermediate,1,,50594
,CHEMBL623328,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6877,1969.0,2862,,1,,Maximum concentration in plasma upon oral administration in mouse,A,,,Intermediate,1,,50594
,CHEMBL623329,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6878,1969.0,2675,,1,,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Intermediate,1,,50594
,CHEMBL623330,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,6879,1969.0,2675,,1,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL876789,10090.0,N,BAO_0000218,Mus musculus,,,,6880,,5399,,1,,Dose at which the compound induced fecal excretion in mice,A,,,Intermediate,1,,50594
,CHEMBL623333,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6893,,11819,,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,A10,Expert,1,,80013
,CHEMBL623334,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6894,,11819,,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,A10,Expert,1,,80013
,CHEMBL627536,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6895,,11819,,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,A10,Expert,1,,80013
,CHEMBL627537,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6896,,11819,,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,A10,Expert,1,,80013
,CHEMBL627538,10116.0,N,BAO_0000219,Rattus norvegicus,,,,6897,,16361,,1,164.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,A10,Intermediate,1,,80013
,CHEMBL884106,9606.0,N,BAO_0000219,Homo sapiens,,,,6898,,2288,,1,393.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,A121,Intermediate,1,,80655
,CHEMBL625294,9606.0,N,BAO_0000219,Homo sapiens,,,,6899,,10404,,1,393.0,Anticancer activity against human ovarian carcinoma A121 cells,F,,A121,Intermediate,1,,80655
,CHEMBL625295,9606.0,N,BAO_0000219,Homo sapiens,,,,6900,,14790,,1,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,A121,Intermediate,1,,80655
,CHEMBL625296,9606.0,N,BAO_0000219,Homo sapiens,,,,6901,,14790,,1,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,A121,Intermediate,1,,80655
,CHEMBL625297,9606.0,N,BAO_0000219,Homo sapiens,,,,6902,,14253,,1,393.0,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,A121,Expert,1,,80655
,CHEMBL625298,9606.0,N,BAO_0000219,Homo sapiens,,,,6903,,13617,,1,393.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,A121,Expert,1,,80655
,CHEMBL625960,9606.0,N,BAO_0000219,Homo sapiens,,,,6904,,1003,,1,393.0,Cytotoxicity against human A121 ovarian cells,F,,A121,Intermediate,1,,80655
,CHEMBL625961,9606.0,N,BAO_0000219,Homo sapiens,,,,6905,,830,,1,393.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,A121,Intermediate,1,,80655
,CHEMBL625962,9606.0,N,BAO_0000219,Homo sapiens,,,,6906,,12307,,1,393.0,In vitro cytotoxicity against human ovarian carcinoma A21,F,,A121,Intermediate,1,,80655
,CHEMBL624717,9606.0,N,BAO_0000219,Homo sapiens,,,,6907,,14254,,1,393.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,A121,Intermediate,1,,80655
,CHEMBL624718,9606.0,N,BAO_0000219,Homo sapiens,,,,6908,,13370,,1,393.0,Inhibitory activity of compound against human A121 ovarian cell line.,F,,A121,Intermediate,1,,80655
,CHEMBL624719,9606.0,N,BAO_0000219,Homo sapiens,,,,6909,,14790,,1,393.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,A121,Intermediate,1,,80655
,CHEMBL624720,9606.0,N,BAO_0000219,Homo sapiens,,,,6910,,3614,,1,393.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,A121,Intermediate,1,,80655
,CHEMBL624721,9606.0,N,BAO_0000219,Homo sapiens,,,,6911,,2664,,1,622.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,A 172,Intermediate,1,,80012
,CHEMBL624722,9606.0,N,BAO_0000219,Homo sapiens,,,,6912,,2037,,1,622.0,In vitro cytotoxicity against A172 human tumor cell lines.,F,,A 172,Expert,1,,80012
,CHEMBL877597,9606.0,N,BAO_0000219,Homo sapiens,,,,6913,,14539,,1,622.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,A 172,Intermediate,1,,80012
,CHEMBL624723,9606.0,N,BAO_0000219,Homo sapiens,,,,6914,,2836,,1,622.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,A 172,Intermediate,1,,80012
,CHEMBL624724,9606.0,N,BAO_0000219,Homo sapiens,,,,6915,,10708,,1,622.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,A 172,Intermediate,1,,80012
,CHEMBL624725,9615.0,H,BAO_0000224,Canis lupus familiaris,,,,6916,,8975,,1,,Association constant against A2 adenosine receptor,B,,,Autocuration,4,,104729
,CHEMBL624726,,N,BAO_0000219,fish,,,,6917,,7645,,1,1085.0,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,A2,Intermediate,1,,80656
,CHEMBL857535,10116.0,D,BAO_0000224,Rattus norvegicus,,,,6918,,11377,,1,,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Autocuration,5,,104713
,CHEMBL624727,9606.0,N,BAO_0000219,Homo sapiens,,,,6919,,13528,,1,623.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,A204,Expert,1,,80014
,CHEMBL624728,9606.0,N,BAO_0000219,Homo sapiens,,,,6920,,10160,,1,623.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,A204,Expert,1,,80014
,CHEMBL624729,9606.0,N,BAO_0000219,Homo sapiens,,,,6921,,15144,,1,404.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,A2058,Intermediate,1,,80015
,CHEMBL624730,9606.0,N,BAO_0000219,Homo sapiens,,,,6922,,13160,,1,973.0,Growth inhibition against Human squamous cell line(A 253),F,,A253 cell line,Intermediate,1,,80657
,CHEMBL624731,9606.0,N,BAO_0000219,Homo sapiens,,,,6923,,12898,,1,973.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,A253 cell line,Intermediate,1,,80657
,CHEMBL624732,9606.0,N,BAO_0000219,Homo sapiens,,,,6924,,13069,,1,973.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,A253 cell line,Intermediate,1,,80657
,CHEMBL883245,9606.0,N,BAO_0000219,Homo sapiens,,,,6925,,15984,,1,973.0,Growth inhibition of A253 cell lines.,F,,A253 cell line,Intermediate,1,,80657
,CHEMBL624733,9606.0,N,BAO_0000219,Homo sapiens,,,,6926,,15564,,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,A253 cell line,Intermediate,1,,80657
,CHEMBL624734,9606.0,N,BAO_0000219,Homo sapiens,,,,6927,,15564,,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,A253 cell line,Intermediate,1,,80657
,CHEMBL624735,9606.0,N,BAO_0000219,Homo sapiens,,,,6928,,15564,,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,A253 cell line,Intermediate,1,,80657
,CHEMBL621780,9606.0,N,BAO_0000219,Homo sapiens,,,,6929,,4720,,1,478.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL877598,9606.0,N,BAO_0000219,Homo sapiens,,,,6930,,16112,,1,478.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL621781,9606.0,N,BAO_0000219,Homo sapiens,,,,6931,,16597,,1,478.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,A2780,Expert,1,,81034
,CHEMBL621782,9606.0,N,BAO_0000219,Homo sapiens,,,,6932,,16378,,1,478.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,A2780,Intermediate,1,,81034
,CHEMBL621783,9606.0,N,BAO_0000219,Homo sapiens,,,,6933,,16085,,1,478.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,A2780,Expert,1,,81034
,CHEMBL621784,9606.0,N,BAO_0000219,Homo sapiens,,,,6934,,16317,,1,478.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,A2780,Intermediate,1,,81034
,CHEMBL621785,9606.0,N,BAO_0000219,Homo sapiens,,,,6935,,15748,,1,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,A2780,Intermediate,1,,81034
,CHEMBL621968,9606.0,N,BAO_0000219,Homo sapiens,,,,6936,,16597,,1,478.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,A2780,Expert,1,,81034
,CHEMBL621969,9606.0,N,BAO_0000219,Homo sapiens,,,,6937,,16597,,1,478.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,A2780,Expert,1,,81034
,CHEMBL621970,9606.0,N,BAO_0000219,Homo sapiens,,,,6938,,16597,,1,478.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,A2780,Expert,1,,81034
,CHEMBL621971,9606.0,N,BAO_0000219,Homo sapiens,,,,6939,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,A2780,Intermediate,1,,81034
,CHEMBL621972,9606.0,N,BAO_0000219,Homo sapiens,,,,6940,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,A2780,Intermediate,1,,81034
,CHEMBL884108,9606.0,N,BAO_0000219,Homo sapiens,,,,6941,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,A2780,Intermediate,1,,81034
,CHEMBL623826,10029.0,U,BAO_0000019,Cricetulus griseus,,,,6942,,15296,,1,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Autocuration,0,,22224
,CHEMBL623827,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6943,,10251,,1,185.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623828,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6944,,10251,,1,185.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623829,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6945,,10251,,1,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623830,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6946,,10251,,1,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623831,10029.0,U,BAO_0000019,Cricetulus griseus,,,,6947,,11858,,1,,Growth inhibition against CHO-derived cell line AA8,F,,,Autocuration,0,,22224
,CHEMBL623832,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6948,,11858,,1,185.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623833,36483.0,N,BAO_0000219,hampster,,,,6949,,11616,,1,185.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,CHO-AA8,Expert,1,,80089
,CHEMBL623834,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6950,,11616,,1,185.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,CHO-AA8,Expert,1,,80089
,CHEMBL623835,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6951,,10518,,1,185.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623836,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6952,,11396,,1,185.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623837,10029.0,U,BAO_0000219,Cricetulus griseus,,,,6953,,10518,,1,185.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,CHO-AA8,Autocuration,0,,22224
,CHEMBL623838,10029.0,N,BAO_0000219,Cricetulus griseus,,,,6954,,11616,,1,185.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,CHO-AA8,Expert,1,,80089
,CHEMBL623839,,H,BAO_0000019,,,,,6955,,14837,,1,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,Autocuration,8,,12675
,CHEMBL623840,,H,BAO_0000019,,,,,6956,,14837,,1,,Number of binding sites (n) of isolated serum protein AAG,F,,,Autocuration,8,,12675
,CHEMBL623841,,M,BAO_0000225,,,,,6957,,16037,,1,,Association constant for binding to AATT duplex,B,,,Intermediate,3,,22222
,CHEMBL623842,9606.0,N,BAO_0000219,Homo sapiens,,,,6958,,16597,,1,416.0,Inhibition of ABAE human fibroblast cell proliferation,F,,ABAE,Expert,1,,100090
,CHEMBL623843,10090.0,N,BAO_0000218,Mus musculus,,,,6959,,8831,,1,1064.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,AC755,Intermediate,1,,80668
,CHEMBL618669,9986.0,D,BAO_0000218,Oryctolagus cuniculus,,,,6960,,13419,,1,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Expert,9,,102444
,CHEMBL618670,9986.0,D,BAO_0000218,Oryctolagus cuniculus,,,,6961,,13419,,1,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Expert,9,,102444
,CHEMBL618671,,H,BAO_0000357,,,,,6962,,15778,,1,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,Autocuration,8,,69
,CHEMBL618672,,H,BAO_0000357,,,,,6963,,15778,,1,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,Autocuration,8,,69
,CHEMBL618673,9606.0,N,BAO_0000219,Homo sapiens,,,,6964,,12988,,1,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,ACH-2 cell line,Intermediate,1,,80669
,CHEMBL618674,9606.0,N,BAO_0000219,Homo sapiens,,,,6965,,12988,,1,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,ACH-2 cell line,Intermediate,1,,80669
,CHEMBL618675,11676.0,U,BAO_0000219,Human immunodeficiency virus 1,,,,6966,,12988,,1,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,T cell line,Autocuration,0,,22224
,CHEMBL618676,11676.0,U,BAO_0000219,Human immunodeficiency virus 1,,,,6967,,12988,,1,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,T cell line,Autocuration,0,,22224
,CHEMBL618677,11676.0,U,BAO_0000219,Human immunodeficiency virus 1,,,,6968,,12988,,1,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,T cell line,Autocuration,0,,22224
,CHEMBL618678,9606.0,N,BAO_0000219,Homo sapiens,,,,6969,,11843,,1,626.0,Inhibition of growth of renal cancer ACHN cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL618679,9606.0,N,BAO_0000219,Homo sapiens,,,,6970,,16939,,1,626.0,Inhibition of growth of ACHN renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL618680,9606.0,N,BAO_0000219,Homo sapiens,,,,6971,,4782,,1,626.0,Inhibitory concentration required against ACHN renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL618681,9606.0,N,BAO_0000219,Homo sapiens,,,,6972,,6310,,1,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,ACHN,Expert,1,,80025
,CHEMBL618682,9606.0,N,BAO_0000219,Homo sapiens,,,,6973,,6310,,1,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,ACHN,Intermediate,1,,80025
,CHEMBL618683,9606.0,N,BAO_0000219,Homo sapiens,,,,6974,,12858,,1,626.0,Cytotoxic activity against ACHN Renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL618684,9606.0,N,BAO_0000219,Homo sapiens,,,,6975,,17380,,1,626.0,Cytotoxicity evaluation against ACHN renal cancer cells,F,,ACHN,Intermediate,1,,80025
,CHEMBL618685,9606.0,N,BAO_0000219,Homo sapiens,,,,6976,,5858,,1,626.0,In vitro antitumor activity against human renal ACHN cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL876499,9606.0,N,BAO_0000219,Homo sapiens,,,,6977,,3838,,1,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,ACHN,Intermediate,1,,80025
,CHEMBL618686,9606.0,N,BAO_0000219,Homo sapiens,,,,6978,,3838,,1,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,ACHN,Intermediate,1,,80025
,CHEMBL618687,9606.0,N,BAO_0000219,Homo sapiens,,,,6979,,5406,,1,626.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,ACHN,Intermediate,1,,80025
,CHEMBL618688,9606.0,N,BAO_0000219,Homo sapiens,,,,6980,,4071,,1,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,ACHN,Intermediate,1,,80025
,CHEMBL618689,9606.0,N,BAO_0000219,Homo sapiens,,,,6981,,4071,,1,626.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,ACHN,Expert,1,,80025
,CHEMBL618690,9606.0,N,BAO_0000219,Homo sapiens,,,,6982,,4071,,1,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,ACHN,Intermediate,1,,80025
,CHEMBL618691,9606.0,N,BAO_0000219,Homo sapiens,,,,6983,,15002,,1,626.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,ACHN,Intermediate,1,,80025
,CHEMBL619373,9606.0,N,BAO_0000219,Homo sapiens,,,,6984,,14769,,1,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,ACHN,Intermediate,1,,80025
,CHEMBL884008,9606.0,N,BAO_0000219,Homo sapiens,,,,6985,,13958,,1,626.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,ACHN,Intermediate,1,,80025
,CHEMBL619374,9606.0,N,BAO_0000219,Homo sapiens,,,,6986,,1665,,1,626.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,ACHN,Intermediate,1,,80025
,CHEMBL619375,9606.0,N,BAO_0000219,Homo sapiens,,,,6987,,15354,,1,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL619376,9606.0,N,BAO_0000219,Homo sapiens,,,,6988,,15354,,1,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,ACHN,Intermediate,1,,80025
,CHEMBL619377,9606.0,N,BAO_0000219,Homo sapiens,,,,6989,,13978,,1,626.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL619378,9606.0,N,BAO_0000219,Homo sapiens,,,,6990,,6798,,1,626.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL872527,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6991,,2959,,1,,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL876500,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6992,,9932,,1,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Intermediate,1,,50588
,CHEMBL619379,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6993,,5546,,1,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Intermediate,1,,50588
,CHEMBL619538,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6994,,16907,,1,,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL619539,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6995,,16907,,1,,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL619540,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6996,,4257,,1,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL619541,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6997,,4305,,1,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619542,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6998,,5472,,1,,Volume of distribution was evaluated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619543,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,6999,,6062,,1,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619544,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7000,,3598,,1,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50588
,CHEMBL619545,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7001,,12500,,1,,The compound was tested for volume of distribution in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619546,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7002,,12500,,1,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619547,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7003,,6227,,1,,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Intermediate,1,,50588
,CHEMBL619548,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7004,,6227,,1,,Vd in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619549,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7005,,4219,,1,,Volume distribution was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL619550,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7006,,1696,,1,,Volume of distribution in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL876501,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7007,,5542,,1,,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL619551,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7008,,5199,,1,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Intermediate,1,,50588
,CHEMBL619552,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7009,,6348,,1,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL619553,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7010,,4727,,1,,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618722,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7011,,16367,,1,,Steady state volume of distribution was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL618723,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7012,,2652,,1,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL618724,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7013,,16452,,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Intermediate,1,,50588
,CHEMBL618725,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7014,,16452,,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Intermediate,1,,50588
,CHEMBL618726,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7015,,16452,,1,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL618727,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7016,,5334,,1,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL624233,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7017,,4239,,1,,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624234,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7018,,4709,,1,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624235,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7019,,5600,,1,,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624236,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7020,,6057,,1,,Volume displacement was calculated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624237,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7021,,5654,,1,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624238,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7022,,5505,,1,,Volume distribution constant was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624239,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7023,,4527,,1,,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL875829,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7024,,4521,,1,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624240,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7025,,4521,,1,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624241,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7026,,15660,,1,,Volume distribution (Vdss) was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624242,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7027,,15660,,1,,Volume distribution (Vdss) was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624243,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7028,,6679,,1,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL624244,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7029,,5145,,1,,Volume of distribution in steady state was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624245,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7030,,6821,,1,,Volume of distribution of compound was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624246,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7031,,4137,,1,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624247,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7032,,5334,,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Intermediate,1,,50588
,CHEMBL624248,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7033,,15660,,1,,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624249,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7034,,6642,,1,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Intermediate,1,,50588
,CHEMBL624250,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7035,,6641,,1,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624251,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7036,,6642,,1,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624252,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7037,,11659,,1,,Maximum rate of depolarization of the upstroke of the action potential,A,,,Intermediate,1,,50588
,CHEMBL624253,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7038,,6448,,1,,Steady state volume distribution in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624950,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7039,,5474,,1,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Intermediate,1,,50588
,CHEMBL624951,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7040,,1466,,1,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL875830,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7041,,6535,,1,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624952,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7042,,6535,,1,,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL624953,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7043,,17764,,1,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624954,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7044,,6215,,1,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624955,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7045,,6505,,1,,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624956,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7046,,3639,,1,,Vss was determined,A,,,Intermediate,1,,50588
,CHEMBL625129,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7047,,3639,,1,,Vss in dog,A,,,Intermediate,1,,50588
,CHEMBL625130,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7048,,6062,,1,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625131,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7049,,4942,,1,,Volume distribution in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625132,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7050,,17796,,1,,Volume of distribution in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL872263,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7051,,4883,,1,,Tested for the oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624336,10090.0,N,BAO_0000218,Mus musculus,,,,7060,,17837,,1,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL624337,10090.0,N,BAO_0000218,Mus musculus,,,,7061,,17729,,1,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL624338,10090.0,N,BAO_0000218,Mus musculus,,,,7062,,17729,,1,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL624339,10090.0,N,BAO_0000218,Mus musculus,,,,7063,,4239,,1,,Bioavailability was measured in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL624340,10090.0,N,BAO_0000218,Mus musculus,,,,7064,,17592,,1,,Bioavailability in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL624341,10090.0,N,BAO_0000218,Mus musculus,,,,7065,,6348,,1,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL624342,10090.0,N,BAO_0000218,Mus musculus,,,,7066,,2801,,1,,Bioavailability in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL624343,10090.0,N,BAO_0000218,Mus musculus,,,,7067,,2801,,1,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL624344,10090.0,N,BAO_0000218,Mus musculus,,,,7068,,17718,,1,,Oral bioavailability in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL624345,10090.0,N,BAO_0000218,Mus musculus,,,,7069,,5727,,1,,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL624346,10090.0,N,BAO_0000218,Mus musculus,,,,7070,,5302,,1,,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50594
,CHEMBL624347,10090.0,N,BAO_0000218,Mus musculus,,,,7071,,3598,,1,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50594
,CHEMBL624348,10090.0,N,BAO_0000218,Mus musculus,,,,7072,,5961,,1,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Intermediate,1,,50594
,CHEMBL622754,10090.0,N,BAO_0000218,Mus musculus,,,,7074,,6091,,1,,Oral bioavailability in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL622755,10090.0,N,BAO_0000218,Mus musculus,,,,7075,,6091,,1,,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL622756,10090.0,N,BAO_0000218,Mus musculus,,,,7076,,5711,,1,,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Intermediate,1,,50594
,CHEMBL622757,10090.0,N,BAO_0000218,Mus musculus,,,,7077,,17728,,1,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Intermediate,1,,50594
,CHEMBL622758,10090.0,N,BAO_0000218,Mus musculus,,,,7078,,17728,,1,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Intermediate,1,,50594
,CHEMBL622759,10090.0,N,BAO_0000218,Mus musculus,,,,7079,,3802,,1,,Tested for bioavailability of the compound,A,In vivo,,Intermediate,1,,50594
,CHEMBL622760,10090.0,N,BAO_0000218,Mus musculus,,,,7080,,3802,,1,,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Intermediate,1,,50594
,CHEMBL622761,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7081,1969.0,14029,,1,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Intermediate,1,,50594
,CHEMBL622762,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7082,1969.0,14029,,1,,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Intermediate,1,,50594
,CHEMBL622763,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7083,1969.0,14029,,1,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Intermediate,1,,50594
,CHEMBL622764,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7084,1969.0,14029,,1,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Intermediate,1,,50594
,CHEMBL622765,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7085,1969.0,14029,,1,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Intermediate,1,,50594
,CHEMBL622766,10090.0,N,BAO_0000218,Mus musculus,,,,7086,,17753,,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Intermediate,1,,50594
,CHEMBL622767,10090.0,N,BAO_0000218,Mus musculus,,,,7087,,17753,,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL622768,10090.0,N,BAO_0000218,Mus musculus,,,,7088,,17753,,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Intermediate,1,,50594
,CHEMBL875948,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7089,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622769,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7090,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622770,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7091,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622771,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7092,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622772,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7093,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622773,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7094,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL622774,10090.0,N,BAO_0000218,Mus musculus,,,Blood,7095,178.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621725,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7096,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621726,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7097,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621727,9606.0,N,BAO_0000219,Homo sapiens,,,,7098,,15608,,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,A2780,Intermediate,1,,81034
,CHEMBL622413,9606.0,N,BAO_0000219,Homo sapiens,,,,7099,,3290,,1,478.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,Expert,1,,81034
,CHEMBL622414,9606.0,N,BAO_0000219,Homo sapiens,,,,7100,,2859,,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL622415,9606.0,N,BAO_0000219,Homo sapiens,,,,7101,,15688,,1,478.0,Inhibition of A2780 cell clonogenic assay,F,,A2780,Expert,1,,81034
,CHEMBL884001,9606.0,N,BAO_0000219,Homo sapiens,,,,7102,,5642,,1,478.0,Cytotoxic effect on ovarian cancer cell line (A2780),F,,A2780,Expert,1,,81034
,CHEMBL622416,9606.0,N,BAO_0000219,Homo sapiens,,,,7103,,6633,,1,478.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,A2780,Intermediate,1,,81034
,CHEMBL622417,9606.0,N,BAO_0000219,Homo sapiens,,,,7104,,3906,,1,478.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,A2780,Intermediate,1,,81034
,CHEMBL622590,9606.0,N,BAO_0000219,Homo sapiens,,,,7105,,6788,,1,478.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,A2780,Expert,1,,81034
,CHEMBL622591,9606.0,N,BAO_0000219,Homo sapiens,,,,7106,,17582,,1,478.0,Antiproliferative activity against human A2780 cells,F,,A2780,Expert,1,,81034
,CHEMBL622592,9606.0,N,BAO_0000219,Homo sapiens,,,,7107,,17764,,1,478.0,Inhibition of human A2780 cell proliferation,F,,A2780,Expert,1,,81034
,CHEMBL622593,9606.0,N,BAO_0000219,Homo sapiens,,,,7108,,17764,,1,478.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,A2780,Expert,1,,81034
,CHEMBL622594,9606.0,N,BAO_0000219,Homo sapiens,,,,7109,,17764,,1,478.0,Inhibition of human A2780 cell proliferation (No data),F,,A2780,Expert,1,,81034
,CHEMBL622595,9606.0,N,BAO_0000219,Homo sapiens,,,,7110,,2815,,1,478.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL622596,9606.0,N,BAO_0000219,Homo sapiens,,,,7111,,16930,,1,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL622597,9606.0,N,BAO_0000219,Homo sapiens,,,,7112,,17777,,1,478.0,Growth inhibition against A2780 wild-type ovarian cell lines,F,,A2780,Expert,1,,81034
,CHEMBL622598,9606.0,N,BAO_0000219,Homo sapiens,,,,7113,,17777,,1,478.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,A2780,Intermediate,1,,81034
,CHEMBL622599,9606.0,D,BAO_0000019,Homo sapiens,,,,7114,,16936,,1,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Autocuration,5,,104766
,CHEMBL622600,9606.0,N,BAO_0000219,Homo sapiens,,,,7115,,13759,,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL622601,9606.0,N,BAO_0000219,Homo sapiens,,,,7116,,13759,,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,A2780,Intermediate,1,,81034
,CHEMBL622602,9606.0,N,BAO_0000219,Homo sapiens,,,,7117,,13759,,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL622603,9606.0,N,BAO_0000219,Homo sapiens,,,,7118,,13759,,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,A2780,Intermediate,1,,81034
,CHEMBL622604,9606.0,N,BAO_0000219,Homo sapiens,,,,7119,,15292,,1,478.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,A2780,Intermediate,1,,81034
,CHEMBL622605,9606.0,N,BAO_0000219,Homo sapiens,,,,7120,,15292,,1,478.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,A2780,Intermediate,1,,81034
,CHEMBL622606,9606.0,N,BAO_0000219,Homo sapiens,,,,7121,,15069,,1,478.0,In vitro inhibition of human ovarian cell line A2780,F,,A2780,Expert,1,,81034
,CHEMBL619463,9606.0,N,BAO_0000219,Homo sapiens,,,,7122,,15069,,1,478.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,A2780,Expert,1,,81034
,CHEMBL619464,9606.0,N,BAO_0000219,Homo sapiens,,,,7123,,14073,,1,478.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,A2780,Intermediate,1,,81034
,CHEMBL619465,9606.0,N,BAO_0000219,Homo sapiens,,,,7124,,14553,,1,478.0,Concentration required to inhibit A2780-cell growth by 50%,F,,A2780,Expert,1,,81034
,CHEMBL619466,9606.0,N,BAO_0000219,Homo sapiens,,,,7125,,13040,,1,478.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,A2780,Expert,1,,81034
,CHEMBL619467,9606.0,N,BAO_0000219,Homo sapiens,,,,7126,,6891,,1,478.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,A2780,Expert,1,,81034
,CHEMBL619468,9606.0,N,BAO_0000219,Homo sapiens,,,,7127,,15569,,1,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,A2780,Intermediate,1,,81034
,CHEMBL619469,9606.0,N,BAO_0000219,Homo sapiens,,,,7128,,14190,,1,478.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,A2780,Expert,1,,81034
,CHEMBL619470,9606.0,N,BAO_0000219,Homo sapiens,,,,7129,,15014,,1,478.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,Expert,1,,81034
,CHEMBL619471,9606.0,N,BAO_0000219,Homo sapiens,,,,7130,,15014,,1,478.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,Intermediate,1,,81034
,CHEMBL619472,9606.0,N,BAO_0000219,Homo sapiens,,,,7131,,17496,,1,478.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL619473,9606.0,N,BAO_0000219,Homo sapiens,,,,7132,,13617,,1,478.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,A2780,Intermediate,1,,81034
,CHEMBL874368,9606.0,N,BAO_0000219,Homo sapiens,,,,7133,,13617,,1,478.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,A2780,Intermediate,1,,81034
,CHEMBL884003,9606.0,N,BAO_0000219,Homo sapiens,,,,7134,,13617,,1,478.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,A2780,Intermediate,1,,81034
,CHEMBL622690,9606.0,N,BAO_0000219,Homo sapiens,,,,7135,,13617,,1,478.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,A2780,Intermediate,1,,81034
,CHEMBL622691,9606.0,N,BAO_0000219,Homo sapiens,,,,7136,,17672,,1,478.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,A2780,Intermediate,1,,81034
,CHEMBL622692,9606.0,N,BAO_0000219,Homo sapiens,,,,7137,,4544,,1,478.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,A2780,Intermediate,1,,81034
,CHEMBL623406,9606.0,N,BAO_0000219,Homo sapiens,,,,7138,,4544,,1,478.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,A2780,Intermediate,1,,81034
,CHEMBL884004,9606.0,N,BAO_0000219,Homo sapiens,,,,7139,,16317,,1,478.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,A2780,Intermediate,1,,81034
,CHEMBL623407,9606.0,N,BAO_0000219,Homo sapiens,,,,7140,,15099,,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL623408,9606.0,N,BAO_0000219,Homo sapiens,,,,7141,,13978,,1,478.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL623409,9606.0,N,BAO_0000219,Homo sapiens,,,,7142,,12989,,1,478.0,In vitro antitumor activity against A2780 cell line.,F,,A2780,Expert,1,,81034
,CHEMBL623410,9606.0,N,BAO_0000219,Homo sapiens,,,,7143,,5574,,1,478.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,A2780,Intermediate,1,,81034
,CHEMBL623576,9606.0,N,BAO_0000219,Homo sapiens,,,,7144,,13528,,1,478.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,A2780,Expert,1,,81034
,CHEMBL623577,9606.0,N,BAO_0000219,Homo sapiens,,,,7145,,12782,,1,626.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,ACHN,Intermediate,1,,80025
,CHEMBL623578,9606.0,N,BAO_0000219,Homo sapiens,,,,7146,,14255,,1,626.0,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,ACHN,Intermediate,1,,80025
,CHEMBL623579,9606.0,N,BAO_0000219,Homo sapiens,,,,7147,,16364,,1,626.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,ACHN,Intermediate,1,,80025
,CHEMBL623580,9606.0,N,BAO_0000219,Homo sapiens,,,,7148,,17376,,1,626.0,In vitro lethal concentration against most sensitive ACHN cell line,F,,ACHN,Expert,1,,80025
,CHEMBL623581,9606.0,N,BAO_0000219,Homo sapiens,,,,7149,,12016,,1,626.0,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL857456,9606.0,N,BAO_0000219,Homo sapiens,,,,7150,,6058,,1,626.0,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,ACHN,Intermediate,1,,80025
,CHEMBL623582,9606.0,N,BAO_0000219,Homo sapiens,,,,7151,,17708,,1,626.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL623583,9606.0,N,BAO_0000219,Homo sapiens,,,,7152,,15176,,1,626.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,ACHN,Intermediate,1,,80025
,CHEMBL623584,9606.0,N,BAO_0000219,Homo sapiens,,,,7153,,2806,,1,626.0,In vitro anticancer activity against ACHN renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL623585,9606.0,N,BAO_0000219,Homo sapiens,,,,7154,,15300,,1,626.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,ACHN,Intermediate,1,,80025
,CHEMBL623586,9606.0,N,BAO_0000219,Homo sapiens,,,,7155,,16364,,1,626.0,Percent selectivity was evaluated in renal ACHN cell lines,F,,ACHN,Intermediate,1,,80025
,CHEMBL623587,9606.0,N,BAO_0000219,Homo sapiens,,,,7156,,13859,,1,626.0,In vitro inhibitory activity against renal ACHN cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL875279,9606.0,N,BAO_0000219,Homo sapiens,,,,7157,,11970,,1,626.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,ACHN,Intermediate,1,,80025
,CHEMBL623588,9606.0,N,BAO_0000219,Homo sapiens,,,,7158,,2450,,1,626.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL623589,9606.0,N,BAO_0000219,Homo sapiens,,,,7159,,12696,,1,626.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,ACHN,Intermediate,1,,80025
,CHEMBL623590,9606.0,N,BAO_0000219,Homo sapiens,,,,7160,,12400,,1,626.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,ACHN,Intermediate,1,,80025
,CHEMBL623591,9606.0,N,BAO_0000219,Homo sapiens,,,,7161,,12888,,1,626.0,Cytotoxic effect on renal cancer line ACHN,F,,ACHN,Expert,1,,80025
,CHEMBL623592,9606.0,N,BAO_0000219,Homo sapiens,,,,7162,,3156,,1,626.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL623593,9606.0,N,BAO_0000219,Homo sapiens,,,,7163,,3381,,1,626.0,In vitro inhibition of Renal Cancer ACHN cell lines,F,,ACHN,Intermediate,1,,80025
,CHEMBL623594,9606.0,N,BAO_0000219,Homo sapiens,,,,7164,,16747,,1,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,ACHN,Intermediate,1,,80025
,CHEMBL621833,9606.0,N,BAO_0000219,Homo sapiens,,,,7165,,16748,,1,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,ACHN,Expert,1,,80025
,CHEMBL621834,9606.0,N,BAO_0000219,Homo sapiens,,,,7166,,12062,,1,626.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,ACHN,Intermediate,1,,80025
,CHEMBL621835,9606.0,N,BAO_0000219,Homo sapiens,,,,7167,,14769,,1,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,ACHN,Intermediate,1,,80025
,CHEMBL621836,9606.0,N,BAO_0000219,Homo sapiens,,,,7168,,15895,,1,626.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,ACHN,Intermediate,1,,80025
,CHEMBL621837,9606.0,N,BAO_0000219,Homo sapiens,,,,7169,,17376,,1,626.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,ACHN,Intermediate,1,,80025
,CHEMBL875280,9606.0,N,BAO_0000219,Homo sapiens,,,,7170,,14882,,1,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,ACHN,Intermediate,1,,80025
,CHEMBL621838,9606.0,N,BAO_0000219,Homo sapiens,,,,7171,,14882,,1,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,ACHN,Intermediate,1,,80025
,CHEMBL621839,9606.0,N,BAO_0000219,Homo sapiens,,,,7172,,15661,,1,626.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,ACHN,Intermediate,1,,80025
,CHEMBL621840,,U,BAO_0000019,,,,,7173,,9680,,1,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL621841,,H,BAO_0000019,,,,,7174,,14579,,1,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,Autocuration,8,,10647
,CHEMBL622979,10358.0,N,BAO_0000218,Cytomegalovirus,,,,7175,,17290,,1,468.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,HEL,Expert,1,,50529
,CHEMBL876595,10358.0,N,BAO_0000218,Cytomegalovirus,,,,7176,,17290,,1,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Intermediate,1,,50529
,CHEMBL620221,,H,BAO_0000357,,,,,7177,,15891,,1,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,Autocuration,8,,12159
,CHEMBL620222,,H,BAO_0000357,,,,,7178,,15890,,1,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,Autocuration,8,,12159
,CHEMBL620506,9913.0,N,BAO_0000219,Bos taurus,,,,7179,,3801,,1,979.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,ADDP cell line,Intermediate,1,,80670
,CHEMBL620507,10090.0,N,BAO_0000219,Mus musculus,,,,7180,,9222,,1,980.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620508,10090.0,N,BAO_0000219,Mus musculus,,,,7181,,9222,,1,980.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620509,10090.0,N,BAO_0000219,Mus musculus,,,,7182,,7257,,1,980.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620510,10090.0,N,BAO_0000219,Mus musculus,,,,7183,,7257,,1,980.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620511,10090.0,N,BAO_0000219,Mus musculus,,,,7184,,7257,,1,980.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620512,10090.0,N,BAO_0000219,Mus musculus,,,,7185,,8084,,1,980.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,ADJ/PC6,Intermediate,1,,80671
,CHEMBL620513,10090.0,U,BAO_0000019,Mus musculus,,,,7186,,14943,,1,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Autocuration,0,,22224
,CHEMBL620514,10090.0,U,BAO_0000019,Mus musculus,,,,7187,,14943,,1,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Autocuration,0,,22224
,CHEMBL620515,10090.0,U,BAO_0000019,Mus musculus,,,,7188,,14943,,1,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Autocuration,0,,22224
,CHEMBL620516,1423.0,U,BAO_0000218,Bacillus subtilis,,,,7189,,10524,,1,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620517,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7190,1969.0,3546,,1,,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL620518,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7191,1969.0,3546,,1,,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL620519,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7192,,3546,,1,,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621386,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7193,,3546,,1,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621387,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7194,,3546,,1,,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621388,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7195,,3184,,1,,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621389,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7196,,16456,,1,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621390,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7197,,4809,,1,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621391,,U,BAO_0000100,,,,,7198,,4219,,1,,Calculated partition coefficient (clogP),P,,,Intermediate,0,,22229
,CHEMBL621392,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7199,,3748,,1,,Half life in dog,A,,,Intermediate,1,,50588
,CHEMBL621393,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7200,,3132,,1,,Time taken for EC90 was determined when tested in dog,A,,,Intermediate,1,,50588
,CHEMBL621394,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7201,,4219,,1,,Half life (iv) was determined,A,,,Intermediate,1,,50588
,CHEMBL621395,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,7202,2107.0,16907,,1,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Intermediate,1,,50588
,CHEMBL621396,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7203,,6057,,1,,Area under the curve was calculated in dog after iv administration,A,,,Intermediate,1,,50588
,CHEMBL621397,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7204,,6057,,1,,Area under the curve was calculated in dog after peroral administration,A,,,Intermediate,1,,50588
,CHEMBL621398,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7205,,17853,,1,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Intermediate,1,,50588
,CHEMBL618818,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7206,,3639,,1,,pKa was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL618819,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7207,,14541,,1,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Intermediate,1,,50588
,CHEMBL618820,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7208,,16456,,1,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL873810,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7209,,16456,,1,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL876606,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7210,,2652,,1,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Intermediate,1,,50588
,CHEMBL618821,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7211,,3624,,1,,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Intermediate,1,,50588
,CHEMBL618822,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,7212,178.0,1337,,1,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL618823,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,7213,178.0,1337,,1,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Intermediate,1,,50588
,CHEMBL618824,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7214,,4709,,1,,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL618825,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7215,,15660,,1,,Half life was measured in dog,A,,,Intermediate,1,,50588
,CHEMBL618826,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7216,,5302,,1,,Half life period in dog after 5 mg/kg dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL618827,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7217,,17791,,1,,Half life period was evaluated in dog; 4-4.8,A,,,Intermediate,1,,50588
,CHEMBL618828,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7218,,6348,,1,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL618829,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7219,,4257,,1,,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL618830,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7220,,3771,,1,,Half-life was determined,A,,,Intermediate,1,,50588
,CHEMBL618831,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7221,,6305,,1,,Half life in dogs,A,,,Intermediate,1,,50588
,CHEMBL619489,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7222,1969.0,13501,,1,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619649,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7223,,17594,,1,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL876607,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7224,,3045,,1,,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL619650,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7225,,3043,,1,,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL619651,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7226,,4839,,1,,Compound was tested for half life in dog,A,,,Intermediate,1,,50588
,CHEMBL619652,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7227,,4839,,1,,Compound was tested for its half life in dog,A,,,Intermediate,1,,50588
,CHEMBL619653,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7228,,5802,,1,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL619654,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7229,,17839,,1,,Half life of compound in dog was determined,A,,,Intermediate,1,,50588
,CHEMBL619655,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7230,,4219,,1,,Half life (iv) was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL619656,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,7231,178.0,13966,,1,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Intermediate,1,,50588
,CHEMBL873812,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7232,1969.0,3994,,1,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621365,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7233,1969.0,3994,,1,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Intermediate,1,,50588
,CHEMBL621366,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7234,,4453,,1,,Half life in dog,A,,,Intermediate,1,,50588
,CHEMBL621367,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7235,1969.0,6535,,1,,Half life in dog plasma,A,,,Intermediate,1,,50588
,CHEMBL621368,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7236,1969.0,6535,,1,,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL621369,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7237,1969.0,6535,,1,,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Intermediate,1,,50588
,CHEMBL621370,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7238,1969.0,3132,,1,,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621371,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7239,,5374,,1,,Half life in dog was determined,A,,,Intermediate,1,,50588
,CHEMBL621372,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7240,,5007,,1,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL621373,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7241,1969.0,16907,,1,,Half life upon exposure to human plasma,A,,,Intermediate,1,,50588
,CHEMBL621374,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7242,,6057,,1,,Half life was calculated in dog,A,,,Intermediate,1,,50588
,CHEMBL621375,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7243,,5006,,1,,Half life was determined,A,,,Intermediate,1,,50588
,CHEMBL621376,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7244,,5473,,1,,Half life was determined,A,,,Intermediate,1,,50588
,CHEMBL619624,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7245,,4368,,1,,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL875840,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7246,,6448,,1,,Half life in dog,A,,,Intermediate,1,,50588
,CHEMBL619625,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7247,,4353,,1,,Half life in dog after intra venous administration of the compound,A,,,Intermediate,1,,50588
,CHEMBL619626,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7248,,4353,,1,,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Intermediate,1,,50588
,CHEMBL619627,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7249,,4353,,1,,Half life in dog after po administration of the compound,A,In vivo,,Intermediate,1,,50588
,CHEMBL873817,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7250,,4353,,1,,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL619628,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7251,,6265,,1,,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL619629,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7252,,5006,,1,,Half life in dogs,A,,,Intermediate,1,,50588
,CHEMBL619630,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7253,,5356,,1,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Intermediate,1,,50588
,CHEMBL619631,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7254,,405,,1,,Half life in rat,A,,,Intermediate,1,,50588
,CHEMBL619632,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7255,,6642,,1,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Intermediate,1,,50588
,CHEMBL619633,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7256,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL875841,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7257,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619634,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7258,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619635,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7259,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619636,10090.0,N,BAO_0000218,Mus musculus,,,Bone,7260,10000001.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619637,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7261,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619638,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7262,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619639,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7263,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619640,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7264,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619641,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7265,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619642,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7266,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619643,10090.0,N,BAO_0000218,Mus musculus,,,Gut,7267,10000004.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL619644,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7268,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621112,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7269,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621113,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7270,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621114,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7271,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621115,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7272,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621116,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7273,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621117,10090.0,N,BAO_0000218,Mus musculus,,,Heart,7274,948.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621118,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7275,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621119,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7276,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621120,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7277,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621757,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7278,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621758,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7279,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621759,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7280,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621760,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,7281,2113.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621761,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7282,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621762,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7283,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL621763,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7284,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624502,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7285,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624503,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7286,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624504,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7287,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624505,10090.0,N,BAO_0000218,Mus musculus,,,Liver,7288,2107.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624506,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7289,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624507,9606.0,N,BAO_0000219,Homo sapiens,,,,7290,,5895,,1,478.0,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,A2780,Intermediate,1,,81034
,CHEMBL624508,9606.0,N,BAO_0000219,Homo sapiens,,,,7291,,6338,,1,478.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,A2780,Intermediate,1,,81034
,CHEMBL624509,9606.0,N,BAO_0000219,Homo sapiens,,,,7292,,15163,,1,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,A2780,Intermediate,1,,81034
,CHEMBL624510,9606.0,N,BAO_0000219,Homo sapiens,,,,7293,,15163,,1,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,A2780,Intermediate,1,,81034
,CHEMBL875956,9606.0,N,BAO_0000219,Homo sapiens,,,,7294,,15000,,1,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,A2780,Expert,1,,81034
,CHEMBL839885,9606.0,N,BAO_0000219,Homo sapiens,,,,7295,,15000,,1,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,A2780,Expert,1,,81034
,CHEMBL624511,9606.0,N,BAO_0000219,Homo sapiens,,,,7296,,14729,,1,478.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,A2780,Expert,1,,81034
,CHEMBL624512,9606.0,N,BAO_0000219,Homo sapiens,,,,7297,,17270,,1,478.0,In vitro cytotoxicity against A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL624513,9606.0,N,BAO_0000219,Homo sapiens,,,,7298,,5685,,1,478.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,A2780,Intermediate,1,,81034
,CHEMBL624514,9606.0,N,BAO_0000219,Homo sapiens,,,,7299,,3563,,1,478.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618547,9606.0,N,BAO_0000218,Homo sapiens,,,,7300,,17753,,1,478.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,A2780,Intermediate,1,,81034
,CHEMBL618548,9606.0,N,BAO_0000219,Homo sapiens,,,,7301,,16317,,1,478.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,A2780,Intermediate,1,,81034
,CHEMBL618549,9606.0,N,BAO_0000219,Homo sapiens,,,,7302,,16936,,1,478.0,Inhibition of tubulin polymerization in analogy of ca.,F,,A2780,Intermediate,1,,81034
,CHEMBL618550,9606.0,N,BAO_0000219,Homo sapiens,,,,7303,,3801,,1,478.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,A2780,Intermediate,1,,81034
,CHEMBL618551,9606.0,N,BAO_0000219,Homo sapiens,,,,7304,,6181,,1,478.0,Cytotoxic effect in ovarian cancer cell line (A2780),F,,A2780,Expert,1,,81034
,CHEMBL618552,9606.0,N,BAO_0000219,Homo sapiens,,,,7305,,5318,,1,478.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,A2780,Intermediate,1,,81034
,CHEMBL618553,9606.0,N,BAO_0000219,Homo sapiens,,,,7306,,4840,,1,478.0,Tested for the cytotoxicity in A2780 ovarian cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618554,9606.0,N,BAO_0000219,Homo sapiens,,,,7307,,15748,,1,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,A2780,Intermediate,1,,81034
,CHEMBL618555,9606.0,N,BAO_0000219,Homo sapiens,,,,7308,,15748,,1,478.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,A2780,Intermediate,1,,81034
,CHEMBL618556,,N,BAO_0000219,,,,,7309,,15748,,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618557,,N,BAO_0000219,,,,,7310,,15748,,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618558,,N,BAO_0000219,,,,,7311,,15748,,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618559,,N,BAO_0000219,,,,,7312,,15748,,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,A2780cisR,Intermediate,1,,80017
,CHEMBL618560,9606.0,N,BAO_0000218,Homo sapiens,,,,7313,,17753,,1,478.0,In vivo log of cells killed after administration of compound in A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618561,9606.0,N,BAO_0000218,Homo sapiens,,,,7314,,17753,,1,478.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,A2780,Intermediate,1,,81034
,CHEMBL618562,9606.0,N,BAO_0000219,Homo sapiens,,,,7315,,16936,,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,A2780,Intermediate,1,,81034
,CHEMBL618563,9606.0,N,BAO_0000219,Homo sapiens,,,,7316,,16936,,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,A2780,Intermediate,1,,81034
,CHEMBL618564,9606.0,N,BAO_0000219,Homo sapiens,,,,7317,,16936,,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,A2780,Intermediate,1,,81034
,CHEMBL618565,9606.0,N,BAO_0000219,Homo sapiens,,,,7318,,16936,,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,A2780,Intermediate,1,,81034
,CHEMBL618566,9606.0,N,BAO_0000218,Homo sapiens,,,,7319,,17528,,1,478.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,A2780,Intermediate,1,,81034
,CHEMBL618567,9606.0,N,BAO_0000219,Homo sapiens,,,,7320,,6633,,1,478.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL618568,9606.0,N,BAO_0000219,Homo sapiens,,,,7321,,15000,,1,478.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,A2780,Expert,1,,81034
,CHEMBL618569,9606.0,N,BAO_0000219,Homo sapiens,,,,7322,,17528,,1,478.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,A2780,Expert,1,,81034
,CHEMBL621857,9606.0,N,BAO_0000219,Homo sapiens,,,,7323,,16936,,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL621858,9606.0,N,BAO_0000219,Homo sapiens,,,,7324,,16936,,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,A2780,Intermediate,1,,81034
,CHEMBL621859,9606.0,N,BAO_0000219,Homo sapiens,,,,7325,,16936,,1,478.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,A2780,Intermediate,1,,81034
,CHEMBL621860,9606.0,N,BAO_0000219,Homo sapiens,,,,7326,,16936,,1,478.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,A2780,Intermediate,1,,81034
,CHEMBL621861,9606.0,N,BAO_0000219,Homo sapiens,,,,7327,,16936,,1,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,A2780,Intermediate,1,,81034
,CHEMBL621862,9606.0,N,BAO_0000219,Homo sapiens,,,,7328,,16936,,1,478.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,A2780,Expert,1,,81034
,CHEMBL621863,9606.0,N,BAO_0000219,Homo sapiens,,,,7329,,16936,,1,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,Intermediate,1,,81034
,CHEMBL621864,9606.0,N,BAO_0000219,Homo sapiens,,,,7330,,16936,,1,478.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,Intermediate,1,,81034
,CHEMBL621865,9606.0,N,BAO_0000219,Homo sapiens,,,,7331,,16936,,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,Intermediate,1,,81034
,CHEMBL621866,10090.0,N,BAO_0000219,Mus musculus,,,,7332,,17737,,1,478.0,In vitro antiproliferative activity against A2780 cell line,F,,A2780,Intermediate,1,,81034
,CHEMBL621867,10090.0,N,BAO_0000219,Mus musculus,,,,7333,,17764,,1,478.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,A2780,Expert,1,,81034
,CHEMBL621868,9606.0,N,BAO_0000219,Homo sapiens,,,,7334,,3830,,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,A2780,Intermediate,1,,81034
,CHEMBL875282,9606.0,N,BAO_0000219,Homo sapiens,,,,7335,,3829,,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,A2780,Intermediate,1,,81034
,CHEMBL621869,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7336,,3546,,1,,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL621870,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7337,,3546,,1,,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621871,9527.0,U,BAO_0000019,Cercopithecidae,,,,7338,,5668,,1,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Autocuration,0,,22224
,CHEMBL621243,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,7339,1969.0,3443,,1,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL621244,9527.0,U,BAO_0000218,Cercopithecidae,,,Plasma,7340,1969.0,3443,,1,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Autocuration,0,,22224
,CHEMBL621245,9541.0,U,BAO_0000218,Macaca fascicularis,,,,7341,,4256,,1,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621246,9541.0,U,BAO_0000218,Macaca fascicularis,,,,7342,,4256,,1,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621247,9541.0,U,BAO_0000218,Macaca fascicularis,,,,7343,,4256,,1,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618386,10116.0,U,BAO_0000218,Rattus norvegicus,,,,7344,,4256,,1,,Oral Bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL618387,9527.0,U,BAO_0000218,Cercopithecidae,,,,7345,,1916,,1,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Autocuration,0,,22224
,CHEMBL618388,9527.0,U,BAO_0000218,Cercopithecidae,,,,7346,,5302,,1,,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL618389,9527.0,U,BAO_0000218,Cercopithecidae,,,,7347,,4257,,1,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Autocuration,0,,22224
,CHEMBL618574,9527.0,U,BAO_0000019,Cercopithecidae,,,,7348,,5355,,1,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Autocuration,0,,22224
,CHEMBL618575,9527.0,U,BAO_0000019,Cercopithecidae,,,,7349,,5355,,1,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Autocuration,0,,22224
,CHEMBL618576,9527.0,U,BAO_0000019,Cercopithecidae,,,,7350,,5355,,1,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Autocuration,0,,22224
,CHEMBL618577,9527.0,U,BAO_0000218,Cercopithecidae,,,,7351,,6078,,1,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL876487,9527.0,U,BAO_0000218,Cercopithecidae,,,,7352,,6078,,1,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL618578,9527.0,U,BAO_0000218,Cercopithecidae,,,,7353,,6062,,1,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL618579,9527.0,U,BAO_0000218,Cercopithecidae,,,,7354,,2661,,1,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Autocuration,0,,22224
,CHEMBL618580,9527.0,U,BAO_0000019,Cercopithecidae,,,,7355,,2661,,1,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Autocuration,0,,22224
,CHEMBL618581,9527.0,U,BAO_0000218,Cercopithecidae,,,,7356,,5394,,1,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL618582,9527.0,U,BAO_0000218,Cercopithecidae,,,,7357,,4397,,1,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Autocuration,0,,22224
,CHEMBL618583,9527.0,U,BAO_0000218,Cercopithecidae,,,,7358,,17509,,1,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Autocuration,0,,22224
,CHEMBL618584,9527.0,U,BAO_0000218,Cercopithecidae,,,,7359,,17509,,1,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Autocuration,0,,22224
,CHEMBL618585,9527.0,U,BAO_0000218,Cercopithecidae,,,,7360,,6641,,1,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Autocuration,0,,22224
,CHEMBL618586,9527.0,U,BAO_0000218,Cercopithecidae,,,,7361,,5355,,1,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Autocuration,0,,22224
,CHEMBL618587,9527.0,U,BAO_0000218,Cercopithecidae,,,,7362,,3443,,1,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Autocuration,0,,22224
,CHEMBL618588,9527.0,U,BAO_0000218,Cercopithecidae,,,,7363,,3443,,1,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Autocuration,0,,22224
,CHEMBL618589,9527.0,U,BAO_0000019,Cercopithecidae,,,,7364,,17409,,1,,Binding towards monkey plasma protein at 10 uM,A,,,Autocuration,0,,22224
,CHEMBL618590,9527.0,U,BAO_0000019,Cercopithecidae,,,,7365,,17409,,1,,Binding towards monkey plasma protein at 100 uM,A,,,Autocuration,0,,22224
,CHEMBL872262,9527.0,U,BAO_0000218,Cercopithecidae,,,,7366,,1052,,1,,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL618591,9527.0,U,BAO_0000218,Cercopithecidae,,,,7367,,13501,,1,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618592,9443.0,U,BAO_0000218,monkey,,,,7368,,17509,,1,,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL876488,9527.0,U,BAO_0000218,Cercopithecidae,,,,7369,,5394,,1,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL618593,9527.0,U,BAO_0000218,Cercopithecidae,,,,7370,,2661,,1,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL618594,9443.0,U,BAO_0000218,monkey,,,,7371,,11219,,1,,Bioavailability in monkey (i.d. dosing),A,In vivo,,Autocuration,0,,22224
,CHEMBL618595,9527.0,U,BAO_0000218,Cercopithecidae,,,,7372,,3045,,1,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL621469,9527.0,U,BAO_0000019,Cercopithecidae,,,,7373,,17796,,1,,Clearance of the drug was measured in cynomolgus,A,,,Autocuration,0,,22224
,CHEMBL621470,9527.0,U,BAO_0000218,Cercopithecidae,,,,7374,,1399,,1,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL621471,9527.0,U,BAO_0000218,Cercopithecidae,,,,7375,,2661,,1,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621472,9544.0,U,BAO_0000218,Macaca mulatta,,,Plasma,7376,1969.0,5005,,1,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Autocuration,0,,22224
,CHEMBL621473,9527.0,U,BAO_0000218,Cercopithecidae,,,,7377,,17267,,1,,Plasma clearance in rhesus monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL621474,9527.0,U,BAO_0000218,Cercopithecidae,,,,7378,,6535,,1,,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Autocuration,0,,22224
,CHEMBL621475,9527.0,U,BAO_0000218,Cercopithecidae,,,,7379,,5922,,1,,Plasma clearance in cynomolgus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL621476,9527.0,U,BAO_0000218,Cercopithecidae,,,,7380,,6221,,1,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL624290,9527.0,U,BAO_0000218,Cercopithecidae,,,,7381,,5668,,1,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Autocuration,0,,22224
,CHEMBL624291,9527.0,U,BAO_0000218,Cercopithecidae,,,,7382,,5355,,1,,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL624292,9527.0,U,BAO_0000218,Cercopithecidae,,,,7383,,5355,,1,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL624293,9527.0,U,BAO_0000218,Cercopithecidae,,,,7384,,5355,,1,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Autocuration,0,,22224
,CHEMBL624294,9527.0,U,BAO_0000218,Cercopithecidae,,,,7385,,4578,,1,,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL624295,9527.0,U,BAO_0000218,Cercopithecidae,,,,7386,,17592,,1,,Clearance in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL624296,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7387,,6641,,1,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624297,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7388,,6642,,1,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Intermediate,1,,50588
,CHEMBL624298,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7389,,16367,,1,,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL624299,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7390,,5472,,1,,Half life was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL624300,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7391,,5474,,1,,Half life was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL624301,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7392,,5654,,1,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624302,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7393,,6227,,1,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Intermediate,1,,50588
,CHEMBL876026,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7394,,6227,,1,,Half life period after intravenous administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624303,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7395,,6221,,1,,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624304,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7396,,4527,,1,,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Intermediate,1,,50588
,CHEMBL624305,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7397,,5668,,1,,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624306,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7398,,5668,,1,,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL624307,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7399,,3854,,1,,Half life period was determined,A,,,Intermediate,1,,50588
,CHEMBL624308,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7400,,5505,,1,,Half life period was determined,A,,,Intermediate,1,,50588
,CHEMBL624309,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7401,,6251,,1,,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL624310,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7402,,1918,,1,,Half life period was evaluated in dog,A,,,Intermediate,1,,50588
,CHEMBL625003,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7403,,5546,,1,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL625004,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7404,,4809,,1,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL625005,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7405,,6215,,1,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL873813,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7406,,4527,,1,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL625006,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7407,,17594,,1,,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625007,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7408,,17839,,1,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL876027,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7409,,17839,,1,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625008,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7410,,17839,,1,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625009,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7411,,17839,,1,,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625010,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7412,1969.0,5210,,1,,Half-life of compound in plasma of dog was determined,A,,,Intermediate,1,,50588
,CHEMBL625011,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7413,,5210,,1,,Half-life of compound was determined in dogs,A,,,Intermediate,1,,50588
,CHEMBL621553,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7414,,2959,,1,,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621554,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7415,,4137,,1,,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL621555,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7416,,5064,,1,,Half-life in Dog,A,,,Intermediate,1,,50588
,CHEMBL621556,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7417,,5147,,1,,Half-life in Dog,A,,,Intermediate,1,,50588
,CHEMBL621557,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7418,,5145,,1,,Half-life in dog,A,,,Intermediate,1,,50588
,CHEMBL621558,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7419,,6123,,1,,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621559,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7420,,6123,,1,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL621560,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7421,,4333,,1,,Half-life in dogs,A,,,Intermediate,1,,50588
,CHEMBL876028,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7422,,4333,,1,,Half-life in dogs; ND indicates not determined,A,,,Intermediate,1,,50588
,CHEMBL621561,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7423,1969.0,12500,,1,,Half-life in plasma of dog,A,,,Intermediate,1,,50588
,CHEMBL621562,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7424,1969.0,12500,,1,,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Intermediate,1,,50588
,CHEMBL621563,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7425,,6005,,1,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621564,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7426,,6062,,1,,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621565,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7427,,17650,,1,,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621566,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7428,,5530,,1,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL621567,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7429,,5530,,1,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL622978,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7430,,5600,,1,,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL873814,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7431,,6039,,1,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623219,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7432,,6039,,1,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624477,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7433,,6039,,1,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL624478,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7434,,6227,,1,,t1/2 in dog,A,,,Intermediate,1,,50588
,CHEMBL624479,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7435,,14541,,1,,Half-life period measured in dogs,A,,,Intermediate,1,,50588
,CHEMBL624480,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7436,,4521,,1,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL623595,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7437,,4521,,1,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623596,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7438,,6679,,1,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL623597,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7439,1969.0,1116,,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Intermediate,1,,50588
,CHEMBL623598,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7440,,5444,,1,,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623599,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7441,,5444,,1,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Intermediate,1,,50588
,CHEMBL623600,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7442,,17853,,1,,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Intermediate,1,,50588
,CHEMBL623601,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7443,,4353,,1,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL623602,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7444,,16452,,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Intermediate,1,,50588
,CHEMBL623603,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7445,,16452,,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Intermediate,1,,50588
,CHEMBL623604,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7446,,16452,,1,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50588
,CHEMBL623605,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7447,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623606,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7448,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623607,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7449,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623608,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7450,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623609,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7451,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623610,10090.0,N,BAO_0000218,Mus musculus,,,Lung,7452,2048.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623611,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7453,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623612,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7454,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623613,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7455,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623614,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7456,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623615,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7457,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623616,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7458,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623617,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,7459,2385.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL875944,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7460,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623618,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7461,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623619,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7462,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623620,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7463,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623621,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7464,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623622,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7465,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623623,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,7466,14.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL623624,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7467,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618521,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7468,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618522,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7469,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618523,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7470,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618524,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7471,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL618525,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7472,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624586,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,7473,2106.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624587,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7474,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624588,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7475,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624589,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7476,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624590,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7477,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624591,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7478,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624592,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7479,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624593,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,7480,945.0,10107,,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Intermediate,1,,50594
,CHEMBL624594,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7481,,4689,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624595,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7482,,4950,,1,,Tested for the bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624596,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7483,,5328,,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL624597,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7484,,406,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624598,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7485,,12500,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624599,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7486,,12500,,1,,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL875166,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7487,,5247,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624600,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7488,1969.0,4186,,1,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL624601,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7489,1969.0,4186,,1,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL624602,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7490,,6647,,1,,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624603,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7491,,6484,,1,,Half life was determined,A,,,Intermediate,1,,50597
,CHEMBL624604,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7492,,3249,,1,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624605,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7493,1969.0,6281,,1,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Intermediate,1,,50597
,CHEMBL624606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7494,,3307,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL624607,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7495,178.0,12058,,1,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7496,,8833,,1,,Hill coefficient of the compound,A,,,Intermediate,1,,50597
,CHEMBL624609,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7497,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Intermediate,1,,50597
,CHEMBL624610,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7498,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Intermediate,1,,50597
,CHEMBL624611,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7499,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Intermediate,1,,50597
,CHEMBL624612,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7500,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Intermediate,1,,50597
,CHEMBL875167,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7501,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Intermediate,1,,50597
,CHEMBL624613,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7502,178.0,3193,,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Intermediate,1,,50597
,CHEMBL624614,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7503,178.0,3193,,1,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Intermediate,1,,50597
,CHEMBL624392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7504,,5960,,1,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Intermediate,1,,50597
,CHEMBL624393,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7505,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624394,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7506,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624395,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7507,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624396,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7508,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624397,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7509,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624398,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7510,2046.0,13950,,1,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624399,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7511,2046.0,13950,,1,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624400,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7512,2046.0,13950,,1,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624401,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7513,2046.0,13950,,1,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624402,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7514,2046.0,13950,,1,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624403,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7515,178.0,9866,,1,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL624404,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7516,178.0,9866,,1,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL624405,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7517,178.0,9866,,1,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL624406,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7518,10000001.0,9866,,1,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL624407,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7519,10000001.0,9866,,1,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL624408,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7520,10000001.0,9866,,1,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618644,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7521,948.0,9866,,1,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618645,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7522,948.0,9866,,1,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL618646,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7523,948.0,9866,,1,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618647,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7524,2113.0,9866,,1,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618648,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7525,2113.0,9866,,1,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL618649,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7526,2113.0,9866,,1,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618650,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7527,2107.0,9866,,1,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618651,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7528,2107.0,9866,,1,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL876497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7529,2107.0,9866,,1,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618652,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7530,2048.0,9866,,1,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618653,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7531,2048.0,9866,,1,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL618654,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7532,2048.0,9866,,1,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618655,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7533,,6351,,1,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,,,Intermediate,1,,50597
,CHEMBL618656,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7534,,1465,,1,,Compound was tested for solubility in water,A,,,Intermediate,1,,50597
,CHEMBL618657,,U,BAO_0000100,,,,,7535,,5182,,1,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,Intermediate,0,,22229
,CHEMBL618658,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7536,,17847,,1,,Solubility was determined,A,,,Intermediate,1,,50597
,CHEMBL618659,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7537,,15339,,1,,solubility in water (ug/mL) at 37 degree C.,A,,,Intermediate,1,,50597
,CHEMBL618660,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7538,,5202,,1,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,,,Intermediate,1,,50597
,CHEMBL618661,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7539,,1088,,1,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,,,Intermediate,1,,50597
,CHEMBL873807,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7540,,3169,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL618662,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7541,,5353,,1,,Half life in Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL618663,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7542,,2864,,1,,Half life period after 3 mg/kg iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618664,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7543,,2864,,1,,Half life period after 3 mg/kg iv administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618665,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7544,,2864,,1,,Half life period after 3 mg/kg iv administration in the rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL876498,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7545,,6362,,1,,Half life period in female Sprague-Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618666,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7546,,6249,,1,,Half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL620440,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7547,,3169,,1,,Half-life in rats was determined,A,,,Intermediate,1,,50597
,CHEMBL620441,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7548,,3169,,1,,Half-life in rats with metabolic oxidation,A,,,Intermediate,1,,50597
,CHEMBL620442,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7549,,3169,,1,,Half-life in rats,A,,,Intermediate,1,,50597
,CHEMBL620443,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7550,,17260,,1,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620444,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7551,,17260,,1,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620445,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7552,,17260,,1,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620446,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7553,,17260,,1,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620447,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7554,1969.0,2879,,1,,Biological half-life measured in plasma of rat,A,,,Intermediate,1,,50597
,CHEMBL621129,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7555,1969.0,2879,,1,,Biological half-life measured in plasma of rat; 22-25,A,,,Intermediate,1,,50597
,CHEMBL621130,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7556,1969.0,2879,,1,,Biological half-life measured in plasma of rat; 9-16,A,,,Intermediate,1,,50597
,CHEMBL873808,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7557,,3184,,1,,Compound was evaluated for its half life when administered intravenously in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL876598,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7558,,4891,,1,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,In vivo,,Intermediate,1,,50597
,CHEMBL621131,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7559,,429,,1,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621132,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7560,,5656,,1,,Half life (T1/2) after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621133,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7561,,4413,,1,,Half life of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7562,,3598,,1,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL621313,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7563,,17267,,1,,Half life of compound was determined in rat,A,,,Intermediate,1,,50597
,CHEMBL621314,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7564,178.0,4727,,1,,Half life of compound was determined in rat blood,A,,,Intermediate,1,,50597
,CHEMBL621315,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7565,,17651,,1,,Half life at 1 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621316,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7566,,17651,,1,,Half life at 10 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621317,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7567,,401,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL621318,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7568,,4942,,1,,Half life in rats in hours,A,,,Intermediate,1,,50597
,CHEMBL621319,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7569,,17735,,1,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621377,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7570,,6056,,1,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621378,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7571,,5213,,1,,Half life was determined,A,,,Intermediate,1,,50597
,CHEMBL876599,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7572,,6616,,1,,Half life after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621379,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7573,,5937,,1,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621380,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7574,1969.0,5819,,1,,Half life in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL621381,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7575,1969.0,5819,,1,,Half life in rat plasma; Not detected,A,,,Intermediate,1,,50597
,CHEMBL618515,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7576,,6803,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL618516,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7577,,17804,,1,,Half life period of compound was determined after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618517,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7578,,17804,,1,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618518,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7579,,5948,,1,,Half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL618519,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7580,,1916,,1,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618698,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7581,,1916,,1,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618862,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7582,,1916,,1,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,In vivo,,Intermediate,1,,50597
,CHEMBL618863,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7583,,4890,,1,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618864,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7584,,17764,,1,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618865,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7585,,4727,,1,,Half life time in rat the dose of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618866,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7586,,17509,,1,,Half-life 24 hr after 10 mg/kg iv administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618867,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7587,,17509,,1,,Half-life 24 hr after 2 mg/kg iv administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL875828,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7588,,6597,,1,,Half-life consistent with the observed metabolic steady state in rats,A,,,Intermediate,1,,50597
,CHEMBL618868,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7589,,17735,,1,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618869,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7590,,6597,,1,,Half-life for oxidative metabolic stability was determined using male human,A,,,Intermediate,1,,50597
,CHEMBL618870,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7591,,17670,,1,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL618871,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7592,1969.0,1696,,1,,Half-life in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL618872,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7593,1969.0,1742,,1,,Half-life in rat plasma was determined,A,,,Intermediate,1,,50597
,CHEMBL873816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7594,,17800,,1,,Half-life in rats was determined,A,,,Intermediate,1,,50597
,CHEMBL618873,,U,BAO_0000218,,,,,7595,,12923,,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,Autocuration,0,,22224
,CHEMBL621602,,U,BAO_0000019,,,,,7596,,11954,,1,,Area under curve after oral dose of 0.1 mg//kg,A,,,Autocuration,0,,22224
,CHEMBL621603,,U,BAO_0000218,,,,,7597,,11954,,1,,Area under curve after oral dose of 0.3 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621604,,U,BAO_0000218,,,,,7598,,11954,,1,,Area under curve after oral dose of 1 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621605,,U,BAO_0000218,,,,,7599,,11954,,1,,Area under curve after oral dose of 10 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621606,,U,BAO_0000218,,,,,7600,,11954,,1,,Area under curve after oral dose of 23.4 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621607,,U,BAO_0000218,,,,,7601,,11954,,1,,Area under curve after oral dose of 3 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621608,,U,BAO_0000218,,,,,7602,,11954,,1,,Area under curve after oral dose of 3.87 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621609,,U,BAO_0000019,,,,,7603,,5237,,1,,Area under curve was determined,A,,,Autocuration,0,,22224
,CHEMBL621610,,U,BAO_0000218,,,,,7604,,4026,,1,,Area under curve at a dose of 10 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7605,,5237,,1,,Area under curve was determined; ND=No data,A,,,Intermediate,1,,50597
,CHEMBL621612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7606,,14793,,1,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622308,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7607,,14793,,1,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622309,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7608,,14793,,1,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622310,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7609,,14793,,1,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622311,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7610,,14793,,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7611,,14793,,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,,,Intermediate,1,,50597
,CHEMBL622931,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7612,,14793,,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622932,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7613,,14793,,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,,,Intermediate,1,,50597
,CHEMBL622736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7614,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7615,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622738,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7616,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622739,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7617,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622740,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7618,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622741,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7619,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622742,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7620,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Intermediate,1,,50597
,CHEMBL622743,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7621,1969.0,14793,,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,,,Intermediate,1,,50597
,CHEMBL622744,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,7622,1969.0,11637,,1,,AUC in mice,A,,,Intermediate,1,,50594
,CHEMBL624134,,U,BAO_0000019,,,,,7623,,11149,,1,,Area under curve was measured from the graph obtained from concentration Vs time,A,,,Autocuration,0,,22224
,CHEMBL624135,,U,BAO_0000019,,,,,7624,,10016,,1,,Area under curve value of compound per hour after oral administration,A,,,Autocuration,0,,22224
,CHEMBL624136,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7625,,17796,,1,,Area under curve was determined after oral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL624137,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7626,,17796,,1,,Area under curve was determined after oral administration in rats; No data,A,,,Intermediate,1,,50597
,CHEMBL624320,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7627,,17796,,1,,Area under curve was determined after oral administration in rats;No data,A,,,Intermediate,1,,50597
,CHEMBL624321,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7628,,12923,,1,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Intermediate,1,,50588
,CHEMBL624322,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7629,,15372,,1,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL624323,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7630,,15372,,1,,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,,,Intermediate,1,,50597
,CHEMBL624324,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7631,,15372,,1,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL624325,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7632,,15372,,1,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL624326,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7633,,15372,,1,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL624327,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7634,,15372,,1,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL624328,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7635,,15372,,1,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL627848,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7636,,14169,,1,,Area under curve was determined in Dogs after peroral administration,A,,,Intermediate,1,,50588
,CHEMBL627849,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7637,,14169,,1,,Area under curve was determined in Rats after peroral administration,A,,,Intermediate,1,,50597
,CHEMBL627850,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7638,,14258,,1,,Area under curve was determined in carotid blood of rat when administered intradermally,A,,,Intermediate,1,,50597
,CHEMBL627851,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7639,,14258,,1,,Area under curve was determined in portal blood of rat when administered intradermally,A,,,Intermediate,1,,50597
,CHEMBL627852,10090.0,N,BAO_0000218,Mus musculus,,,,7640,,15011,,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL627853,10090.0,N,BAO_0000218,Mus musculus,,,,7641,,15011,,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL627854,10090.0,N,BAO_0000218,Mus musculus,,,,7642,,15011,,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,,,Intermediate,1,,50594
,CHEMBL627855,10090.0,N,BAO_0000218,Mus musculus,,,,7643,,15011,,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL627856,10090.0,N,BAO_0000218,Mus musculus,,,,7644,,15011,,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Intermediate,1,,50594
,CHEMBL875339,10090.0,N,BAO_0000218,Mus musculus,,,,7645,,15011,,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL627857,10090.0,N,BAO_0000218,Mus musculus,,,,7646,,15011,,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,,,Intermediate,1,,50594
,CHEMBL627858,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7647,2106.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627859,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7648,178.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627860,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7649,955.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627019,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7650,948.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627020,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7651,2107.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627021,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7652,2048.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627022,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7653,2385.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627023,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7654,,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627024,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7655,2106.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627025,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7656,2046.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627026,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7657,2113.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627027,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7658,178.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627028,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7659,955.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627029,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7660,948.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627030,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7661,2113.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627031,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7662,2107.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627032,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7663,2048.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627033,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7664,2385.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627034,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7665,,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627035,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7666,2106.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627036,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7667,2046.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL875340,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7668,178.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627037,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7669,948.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627038,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7670,2113.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627039,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7671,2107.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL627040,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7672,2385.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL624663,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7673,2106.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL625963,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,7674,2046.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL876799,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7675,955.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL626133,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,7676,2048.0,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL626134,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7677,,10130,,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,,,Intermediate,1,,50597
,CHEMBL626135,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7678,,6295,,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626136,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7679,,6296,,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626137,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7680,,6296,,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,,,Intermediate,1,,50597
,CHEMBL626138,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7681,,6295,,1,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626139,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7682,,6296,,1,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626140,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7683,,17260,,1,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626141,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7684,,17260,,1,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626142,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7685,,17686,,1,,C24h in rat p.o. at 20 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL627930,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7686,2385.0,9866,,1,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627931,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7687,2385.0,9866,,1,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL627932,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,7688,2385.0,9866,,1,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627933,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7689,2106.0,9866,,1,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627934,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7690,2106.0,9866,,1,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL627935,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,7691,2106.0,9866,,1,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627936,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7692,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627937,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7693,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627938,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7694,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627939,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7695,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL627940,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7696,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627941,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7697,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL876800,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7698,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627942,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7699,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627943,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7700,178.0,9866,,1,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627944,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7701,178.0,9866,,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627945,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7702,178.0,9866,,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL628584,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7703,178.0,9866,,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL628585,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7704,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628586,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7705,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL628587,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7706,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628588,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7707,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL628589,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7708,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625304,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7709,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625305,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7710,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL625306,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7711,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL625307,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7712,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625308,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7713,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627740,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7714,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627741,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7715,178.0,9866,,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL627742,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7716,178.0,9866,,1,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627743,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7717,178.0,9866,,1,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL627744,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,7718,178.0,9866,,1,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL627745,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7719,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627746,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7720,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627747,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7721,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL876810,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7722,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL627748,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7723,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627749,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7724,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL627750,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7725,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL618728,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7726,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL618729,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7727,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL618730,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7728,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618731,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7729,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618732,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7730,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618733,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7731,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618734,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7732,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618735,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7733,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL876602,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7734,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7735,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7736,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618738,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7737,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618739,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7738,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL618740,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7739,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL618741,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7740,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL618742,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7741,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL618743,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,7742,10000001.0,9866,,1,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL618744,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7743,1969.0,17752,,1,,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618745,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7744,,5610,,1,,Half-life in male rat,A,,,Intermediate,1,,50597
,CHEMBL620479,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7745,,5939,,1,,Half-life in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620480,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7746,,5939,,1,,Half-life in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620481,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7747,,17771,,1,,Half-life in rat at a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620482,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7748,,1974,,1,,Half-life was evaluated in rats,A,,,Intermediate,1,,50597
,CHEMBL876603,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7749,,4239,,1,,Half-life was measured in rat,A,,,Intermediate,1,,50597
,CHEMBL620483,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7750,,6681,,1,,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL620484,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7751,,17752,,1,,Half-life period in rats after intravenous administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620485,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7752,,6046,,1,,Half-life period in rat at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620486,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7753,,6685,,1,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL620487,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7754,,6685,,1,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL620488,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7755,,6685,,1,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL620489,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7756,,4727,,1,,Half-life time in rat the dose of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620490,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7757,,1088,,1,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620491,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7758,,5610,,1,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL876604,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7759,1969.0,3032,,1,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Intermediate,1,,50597
,CHEMBL620492,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7760,,5199,,1,,Oral half life was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620493,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7761,,14941,,1,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Intermediate,1,,50597
,CHEMBL620494,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7762,,4408,,1,,Pharmacokinetic property (t1/2) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7763,1969.0,2552,,1,,Plasma elimination half-life was determined,A,,,Intermediate,1,,50597
,CHEMBL620496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7764,1969.0,5199,,1,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Intermediate,1,,50597
,CHEMBL620497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7765,1969.0,15662,,1,,Plasma half life was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620498,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7766,1969.0,1465,,1,,Plasma half-life was determined,A,,,Intermediate,1,,50597
,CHEMBL620499,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7767,1969.0,1446,,1,,Plasma half-life following oral administration in Fisher rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620500,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7768,1969.0,6824,,1,,Plasma half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL873809,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7769,1969.0,17533,,1,,Plasmatic Half-life after intravenous administration to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620501,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7770,,5979,,1,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620502,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7771,,4689,,1,,Terminal half life after intravenous administration (1 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620503,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7772,,4689,,1,,Terminal half life in Rat at a oral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620504,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7773,,2463,,1,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL876605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7774,,4883,,1,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620505,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7775,,4883,,1,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL873811,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7776,1969.0,15662,,1,,plasma half life was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624016,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7777,,3598,,1,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL624017,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7778,,4576,,1,,Half life of compound determined in rat,A,,,Intermediate,1,,50597
,CHEMBL624018,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7779,,4576,,1,,Mean residence time determined in rat,A,,,Intermediate,1,,50597
,CHEMBL624019,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7780,,4576,,1,,Plasma half life determined in rat,A,,,Intermediate,1,,50597
,CHEMBL624020,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,7781,955.0,4910,,1,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624201,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7782,,4891,,1,,Compound was evaluated for pharmacokinetic parameter maximum time period,A,In vivo,,Intermediate,1,,50597
,CHEMBL872528,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7783,,429,,1,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624202,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7784,,5974,,1,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624203,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7785,,5974,,1,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624350,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7786,,5974,,1,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621320,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7787,,5974,,1,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621321,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7788,,17582,,1,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621322,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7789,,4026,,1,,Maximum time (Tmax) required to reach Cmax in rats,A,,,Intermediate,1,,50597
,CHEMBL621323,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7790,,4890,,1,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621324,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7791,,6571,,1,,Maximum time of clearance of compound in rats after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621325,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7792,,4727,,1,,Maximum time at the dose of 2 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL875837,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7793,1969.0,17651,,1,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621326,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7794,1969.0,17651,,1,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621327,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7795,,14465,,1,,Tmax in Guinea pig (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL621328,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7796,,14941,,1,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Intermediate,1,,50597
,CHEMBL621329,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7797,,5960,,1,,Pharmacokinetic parameter (Tmax) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621330,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7798,,5022,,1,,Pharmacokinetic parameter (Tmax) was estimated,A,In vivo,,Intermediate,1,,50597
,CHEMBL621331,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7799,,4408,,1,,Pharmacokinetic property (Tmax) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621332,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7800,,5983,,1,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621333,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7801,,4689,,1,,T max in Rat at a oral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621334,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7802,,2792,,1,,T max was determined at 10 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621335,10090.0,N,BAO_0000218,Mus musculus,,,,7803,,15011,,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Intermediate,1,,50594
,CHEMBL621336,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7804,,14180,,1,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,,,Intermediate,1,,50588
,CHEMBL621337,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7805,,14180,,1,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,,,Intermediate,1,,50597
,CHEMBL621338,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7806,,14599,,1,,Area under curve was measured after i.v. administration into Beagle dog.,A,,,Intermediate,1,,50588
,CHEMBL875838,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7807,,14599,,1,,Area under curve was measured after iv administration into Beagle dog,A,,,Intermediate,1,,50588
,CHEMBL621339,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7808,,14599,,1,,Area under curve was measured after po administration into Beagle dog,A,,,Intermediate,1,,50588
,CHEMBL621340,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7809,,14599,,1,,Area under curve was measured after po administration into Beagle dog.,A,,,Intermediate,1,,50588
,CHEMBL621341,,U,BAO_0000218,,,,,7810,,15675,,1,,Area under curve was measured at peroral dose of 3 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621342,,U,BAO_0000019,,,,,7811,,12706,,1,,Area under curve was measured by using concentration Vs time,A,,,Autocuration,0,,22224
,CHEMBL621343,,U,BAO_0000019,,,,,7812,,12706,,1,,Area under curve was measured by using concentration Vs time; not tested,A,,,Autocuration,0,,22224
,CHEMBL621344,10090.0,N,BAO_0000218,Mus musculus,,,,7813,,9750,,1,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,,,Intermediate,1,,50594
,CHEMBL621345,10090.0,N,BAO_0000218,Mus musculus,,,,7814,,9750,,1,,Area under curve(AUC) was measured in mice after oral administration.,A,,,Intermediate,1,,50594
,CHEMBL621346,,U,BAO_0000019,,,,,7815,,14691,,1,,Area under curve(AUC) value of the compound,A,,,Autocuration,0,,22224
,CHEMBL621347,,U,BAO_0000218,,,,,7816,,14691,,1,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,Autocuration,0,,22224
,CHEMBL621348,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7817,,14691,,1,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,,,Intermediate,1,,50588
,CHEMBL621349,,U,BAO_0000019,,,,Blood,7818,178.0,2939,,1,,Area under curve(carotid artery) was determined by the availability in blood,A,,,Autocuration,0,,22224
,CHEMBL621350,,U,BAO_0000019,,,,Blood,7819,178.0,2939,,1,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,,Autocuration,0,,22224
,CHEMBL875839,,U,BAO_0000019,,,,Blood,7820,178.0,2939,,1,,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,,Autocuration,0,,22224
,CHEMBL620211,,U,BAO_0000019,,,,Blood,7821,178.0,2939,,1,,Area under curve(portal vein) was determined by the availability in blood,A,,,Autocuration,0,,22224
,CHEMBL620212,,U,BAO_0000019,,,,Blood,7822,178.0,2939,,1,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,,Autocuration,0,,22224
,CHEMBL620213,,U,BAO_0000019,,,,Blood,7823,178.0,2939,,1,,Area under curve(portal vein) was determined by the availability in blood; No data,A,,,Autocuration,0,,22224
,CHEMBL620214,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,7824,1969.0,9552,,1,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Intermediate,1,,50797
,CHEMBL620215,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,7825,1969.0,9552,,1,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Intermediate,1,,50797
,CHEMBL620216,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,7826,1969.0,9552,,1,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,,,Intermediate,1,,50797
,CHEMBL620888,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7827,1969.0,9552,,1,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,,,Intermediate,1,,50588
,CHEMBL620889,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,7828,1969.0,9552,,1,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,,,Intermediate,1,,50588
,CHEMBL620890,,U,BAO_0000019,,,,Plasma,7829,1969.0,9552,,1,,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,,Autocuration,0,,22224
,CHEMBL620891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7830,1969.0,11911,,1,,Area under plasma time curve determined in male rat,A,,,Intermediate,1,,50597
,CHEMBL620892,,U,BAO_0000019,,,,,7831,,16618,,1,,Area under the MAP curve measured over 5 min.,A,,,Autocuration,0,,22224
,CHEMBL621079,10090.0,N,BAO_0000218,Mus musculus,,,,7832,,14387,,1,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,,,Intermediate,1,,50594
,CHEMBL621080,10090.0,N,BAO_0000218,Mus musculus,,,,7833,,14387,,1,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,,,Intermediate,1,,50594
,CHEMBL621081,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7834,,12836,,1,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,,,Intermediate,1,,50588
,CHEMBL621082,10026.0,N,BAO_0000218,Cricetinae,,,,7835,,12836,,1,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,,,Intermediate,1,,100712
,CHEMBL621083,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7836,,12836,,1,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,,,Intermediate,1,,50597
,CHEMBL621084,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7837,,14339,,1,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,,,Intermediate,1,,50588
,CHEMBL621085,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7838,,14339,,1,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,,,Intermediate,1,,50588
,CHEMBL621086,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7839,,14339,,1,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,,,Intermediate,1,,50588
,CHEMBL621087,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7840,,10524,,1,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622607,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7841,,9994,,1,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL622608,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7842,,11325,,1,,Serum AUC in marmosets (IV dose),A,,,Intermediate,1,,50588
,CHEMBL624481,,U,BAO_0000019,,,,,7843,,12536,,1,,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL624482,,U,BAO_0000019,,,,,7844,,12536,,1,,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL624483,,U,BAO_0000019,,,,,7845,,12536,,1,,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL624484,,U,BAO_0000019,,,,,7846,,12536,,1,,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL624485,,U,BAO_0000019,,,,,7847,,12536,,1,,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL624486,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7848,,15556,,1,,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,,,Intermediate,1,,50597
,CHEMBL624487,,U,BAO_0000019,,,,,7849,,2809,,1,,Area under the curve for the compound was calculated.,A,,,Autocuration,0,,22224
,CHEMBL624488,,U,BAO_0000019,,,,,7850,,9511,,1,,Area under the curve in concentration/ time,A,,,Autocuration,0,,22224
,CHEMBL624489,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7851,,12818,,1,,Area under the curve administered intraintestinal in rats.,A,,,Intermediate,1,,50597
,CHEMBL625184,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7852,,12818,,1,,Area under the curve administered intravenously in rats.,A,,,Intermediate,1,,50597
,CHEMBL625185,,U,BAO_0000019,,,,,7853,,15118,,1,,Area under the curve during intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL875954,,U,BAO_0000019,,,,,7854,,15118,,1,,Area under the curve during intravenous administration; Not determined,A,,,Autocuration,0,,22224
,CHEMBL625186,,U,BAO_0000019,,,,,7855,,15118,,1,,Area under the curve during systemic administration,A,,,Autocuration,0,,22224
,CHEMBL625187,,U,BAO_0000019,,,,,7856,,15118,,1,,Area under the curve during systemic administration; Not determined,A,,,Autocuration,0,,22224
,CHEMBL625188,,U,BAO_0000019,,,,,7857,,2632,,1,,Area under the curve was calculated for the compound.,A,,,Autocuration,0,,22224
,CHEMBL625189,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7858,,14346,,1,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL625190,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,7859,,14346,,1,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL621733,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7860,,14346,,1,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL621734,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7861,,14346,,1,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL621735,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7862,,11149,,1,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,,,Intermediate,1,,50597
,CHEMBL621736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7863,1969.0,17796,,1,,Clearance of the drug was measured in the plasma of rat; No data,A,,,Intermediate,1,,50597
,CHEMBL621737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7864,1969.0,5247,,1,,The pharmacokinetic parameter plasma clearance in vivo in rats,A,,,Intermediate,1,,50597
,CHEMBL621738,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7865,,4727,,1,,Plasma clearance at the dose of 2 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL622806,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7866,,5654,,1,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623519,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7867,,5654,,1,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623520,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7868,,17260,,1,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623521,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7869,,17065,,1,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623522,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7870,,17671,,1,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623523,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7871,,6672,,1,,Clearance rate in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623690,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7872,,6673,,1,,Clearance rate in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623691,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7873,,5978,,1,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623692,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7874,,5978,,1,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623693,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7875,,5978,,1,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623694,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7876,,5978,,1,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623695,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7877,,4413,,1,,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623696,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7878,,2661,,1,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623697,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7879,,2661,,1,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623698,9544.0,U,BAO_0000218,Macaca mulatta,,,Plasma,7880,1969.0,5005,,1,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Intermediate,0,,22224
,CHEMBL623699,10116.0,U,BAO_0000218,Rattus norvegicus,,,Plasma,7881,1969.0,5005,,1,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,In vivo,,Intermediate,0,,22224
,CHEMBL623700,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7882,,15765,,1,,Mean (%CV) PK parameters for CL(mL/min/kg).,A,In vivo,,Intermediate,1,,50597
,CHEMBL623701,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7883,,3747,,1,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623702,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7884,1969.0,16366,,1,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,In vivo,,Intermediate,1,,50597
,CHEMBL623703,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7885,,4199,,1,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623704,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7886,,17267,,1,,Plasma clearance in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623705,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7887,,6535,,1,,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL623706,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7888,,6535,,1,,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL623707,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7889,,5041,,1,,Plasma clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623708,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7890,,5960,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623709,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7891,,5937,,1,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623710,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7892,,5871,,1,,Plasma clearance in rat by iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623711,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7893,,5874,,1,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623712,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7894,,6504,,1,,Plasma clearance in rat p.o.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623713,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7895,,6803,,1,,Plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623714,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7896,,5041,,1,,Plasma clearance was determined; ND denotes no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL623715,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7897,,5041,,1,,Plasma clearance was determined; ND denotes not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623716,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7898,,1916,,1,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622980,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7899,,5199,,1,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Intermediate,1,,50597
,CHEMBL622981,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7900,,16367,,1,,Plasma administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622982,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7901,,6362,,1,,Plasma clearance of the compound in female Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622983,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7902,,15662,,1,,Plasma clearance was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622984,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7903,,6215,,1,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622985,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7904,,1466,,1,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623631,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7905,1969.0,15662,,1,,plasma clearance was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623632,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7906,,4723,,1,,In vivo CL/F determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623633,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7907,1969.0,2792,,1,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623634,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7908,1969.0,2792,,1,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623635,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7909,,5213,,1,,Compound was tested for the lower blood clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621195,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7910,,4687,,1,,Evaluated for the low clearance in rat (in vivo),A,In vivo,,Intermediate,1,,50597
,CHEMBL621196,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7911,,3371,,1,,Pharmacokinetic property (CLb)of the compound was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL875287,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7912,,4690,,1,,Rapid clearance after intravenous administration in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621197,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7913,,5702,,1,,Clearance measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621198,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7914,1969.0,740,,1,,Compound was evaluated for plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621199,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7915,1969.0,4853,,1,,Low plasma clearance was calculated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621200,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7916,,5789,,1,,Pharmacokinetic property (Clp) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621201,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7917,,4527,,1,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621202,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7918,,4527,,1,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621203,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7919,,6518,,1,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621204,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7920,,6518,,1,,Plasma clearance after IV dosing at 1 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7921,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7922,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621207,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7923,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621208,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7924,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621209,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7925,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL876484,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7926,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621210,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7927,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621211,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7928,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621212,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7929,948.0,9866,,1,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621213,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7930,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621214,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7931,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621215,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7932,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621216,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7933,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621217,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7934,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621218,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7935,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621219,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7936,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621220,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7937,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621221,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7938,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621222,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7939,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621223,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7940,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL876485,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7941,948.0,9866,,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621224,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7942,948.0,9866,,1,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621225,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7943,948.0,9866,,1,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL621226,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,7944,948.0,9866,,1,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL621227,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7945,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621228,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7946,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621229,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7947,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621230,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7948,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL621231,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7949,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621232,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7950,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621233,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7951,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621234,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7952,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621235,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7953,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621236,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7954,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621237,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7955,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL876486,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,7956,2113.0,9866,,1,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL622436,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,7957,160.0,9866,,1,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622437,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,7958,160.0,9866,,1,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622438,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,7959,160.0,9866,,1,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622439,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7960,2107.0,9866,,1,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622440,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7961,2107.0,9866,,1,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL622441,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7962,2107.0,9866,,1,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL622442,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7963,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622443,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7964,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622444,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7965,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622445,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7966,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622446,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7967,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622447,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7968,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622448,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7969,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL622449,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7970,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL622450,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7971,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622451,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7972,2107.0,9866,,1,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622452,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7973,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622453,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7974,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL622454,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7975,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622455,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7976,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL876024,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,7977,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622456,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7978,,2792,,1,,T max was determined at 3 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622457,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7979,,15078,,1,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL622458,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7980,,15078,,1,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL622459,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7981,,15022,,1,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL873343,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7982,,15022,,1,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL622460,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7983,,15022,,1,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL622461,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7984,1969.0,4576,,1,,Time for maximum plasma concentration determined in rat,A,,,Intermediate,1,,50597
,CHEMBL622462,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7985,1969.0,6681,,1,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL622463,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7986,,16365,,1,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622464,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7987,,16365,,1,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622465,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7988,,16365,,1,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622466,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7989,,16365,,1,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622467,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7990,,16365,,1,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622468,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7991,1969.0,6824,,1,,Time of maximum plasma concentration in rat,A,,,Intermediate,1,,50597
,CHEMBL876025,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7992,1969.0,6685,,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622469,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7993,1969.0,6685,,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Intermediate,1,,50597
,CHEMBL622470,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7994,1969.0,6685,,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,,,Intermediate,1,,50597
,CHEMBL622471,10116.0,N,BAO_0000218,Rattus norvegicus,,,,7995,,15662,,1,,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622472,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7996,1969.0,1742,,1,,Time required to reach maximum concentration in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL622473,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7997,1969.0,2774,,1,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624282,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7998,1969.0,5199,,1,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624283,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,7999,1969.0,12873,,1,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624284,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8000,1969.0,12873,,1,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624285,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8001,1969.0,1916,,1,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624286,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8002,,16367,,1,,Time to reach Cmax after oral administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624287,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8003,,16366,,1,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL624288,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8004,,216,,1,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,,,Intermediate,1,,50597
,CHEMBL624289,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8005,1969.0,6410,,1,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Intermediate,1,,50597
,CHEMBL873344,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8006,1969.0,6410,,1,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619623,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8007,,6215,,1,,Tmax after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621399,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8008,,3598,,1,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL621400,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8009,,4527,,1,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621401,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8010,,17670,,1,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL621402,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8011,,1465,,1,,Tmax was determined,A,,,Intermediate,1,,50597
,CHEMBL621403,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8012,,2552,,1,,Tmax was determined,A,,,Intermediate,1,,50597
,CHEMBL621121,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8013,,5656,,1,,Tmax after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL872525,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8014,,17764,,1,,Tmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621122,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8015,,5610,,1,,Tmax in male rat,A,,,Intermediate,1,,50597
,CHEMBL621123,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8016,,6046,,1,,Tmax in rat at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621124,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8017,,5874,,1,,Tmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621125,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8018,,17596,,1,,Tmax in rats,A,,,Intermediate,1,,50597
,CHEMBL621126,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8019,,17804,,1,,Tmax was measured in rats after peroral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621127,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8020,,1908,,1,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621128,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8021,,2959,,1,,Tmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618263,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8022,,6757,,1,,Tmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8023,,6757,,1,,Tmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618265,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8024,,6757,,1,,Tmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8025,1969.0,4186,,1,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL618267,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8026,,15662,,1,,time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618450,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,8027,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,,,Intermediate,1,,50597
,CHEMBL618451,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,8028,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,,,Intermediate,1,,50597
,CHEMBL618452,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8029,,5546,,1,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,,,Intermediate,1,,50597
,CHEMBL618453,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,8030,1088.0,3173,,1,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,,,Intermediate,1,,50597
,CHEMBL618454,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,8031,1088.0,3173,,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,,,Intermediate,1,,50597
,CHEMBL618455,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,8032,1088.0,3173,,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,,,Intermediate,1,,50597
,CHEMBL618456,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8033,,4257,,1,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618457,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8034,,6011,,1,,Compound distribution in rat tissues was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618458,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8035,,5472,,1,,Volume of distribution was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618459,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8036,,14346,,1,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL876733,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8037,,14346,,1,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618460,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,8038,,14346,,1,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL618461,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8039,,14346,,1,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618462,,U,BAO_0000019,,,,,8040,,15469,,1,,Area under the curve was determined after oral administration (300 uM/Kg),A,,,Autocuration,0,,22224
,CHEMBL618463,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8041,,14346,,1,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618464,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8042,,14346,,1,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618465,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8043,,14346,,1,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618466,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8044,,14346,,1,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618467,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8045,,14346,,1,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL618468,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8046,,15372,,1,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL618469,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,8047,1969.0,12935,,1,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL618470,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,8048,1969.0,12935,,1,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL618471,,U,BAO_0000218,,,,,8049,,14813,,1,,Plasma drug AUC in rat (PO dose),A,,,Autocuration,0,,22224
,CHEMBL618472,10090.0,N,BAO_0000218,Mus musculus,,,,8050,,15792,,1,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,,,Intermediate,1,,50594
,CHEMBL618473,,U,BAO_0000218,,,,,8051,,3579,,1,,Area under was determined at a dose of 30 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL621699,9669.0,N,BAO_0000218,Mustela putorius furo,,,,8052,,12487,,1,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,,,Intermediate,1,,50506
,CHEMBL621700,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8053,,12487,,1,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,,,Intermediate,1,,50597
,CHEMBL621701,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8054,,12487,,1,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,,,Intermediate,1,,50597
,CHEMBL621702,9669.0,N,BAO_0000218,Mustela putorius furo,,,,8055,,12487,,1,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,,,Intermediate,1,,50506
,CHEMBL621703,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,8056,,12487,,1,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Intermediate,1,,50588
,CHEMBL621704,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,8057,,12487,,1,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,,,Intermediate,1,,50588
,CHEMBL624259,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8058,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624260,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8059,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624430,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8060,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624431,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8061,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624432,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8062,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624433,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8063,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624434,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8064,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL624435,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8065,,12902,,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,,,Intermediate,1,,50597
,CHEMBL618570,10090.0,N,BAO_0000218,Mus musculus,,,,8066,,12745,,1,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL618571,10090.0,N,BAO_0000218,Mus musculus,,,,8067,,12745,,1,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Intermediate,1,,50594
,CHEMBL618572,10090.0,N,BAO_0000218,Mus musculus,,,,8068,,12745,,1,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL618573,10090.0,N,BAO_0000218,Mus musculus,,,,8069,,12745,,1,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Intermediate,1,,50594
,CHEMBL619267,10090.0,N,BAO_0000218,Mus musculus,,,,8070,,12745,,1,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL619431,10090.0,N,BAO_0000218,Mus musculus,,,,8071,,12745,,1,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Intermediate,1,,50594
,CHEMBL619432,10090.0,N,BAO_0000218,Mus musculus,,,,8072,,12745,,1,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL619433,10090.0,N,BAO_0000218,Mus musculus,,,,8073,,12745,,1,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Intermediate,1,,50594
,CHEMBL619434,,U,BAO_0000218,,,,Plasma,8074,1969.0,13298,,1,,AUC in mice after oral dose (50 mg/kg),A,,,Autocuration,0,,22224
,CHEMBL619435,10090.0,N,BAO_0000218,Mus musculus,,,Serum,8075,1977.0,12226,,1,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,,,Intermediate,1,,50594
,CHEMBL619436,,U,BAO_0000019,,,,Plasma,8076,1969.0,12634,,1,,AUC (0-4 hr) ug/ml/h,A,,,Autocuration,0,,22224
,CHEMBL619437,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8077,,14810,,1,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,,,Intermediate,1,,50597
,CHEMBL619438,,U,BAO_0000218,,,,,8078,,13889,,1,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,Autocuration,0,,22224
,CHEMBL619439,10090.0,N,BAO_0000218,Mus musculus,,,,8079,,10018,,1,,Compound was evaluated for Area under curve in mice,A,,,Intermediate,1,,50594
,CHEMBL619440,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8080,,8758,,1,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Intermediate,1,,50597
,CHEMBL619441,,U,BAO_0000218,,,,,8081,,8758,,1,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,Autocuration,0,,22224
,CHEMBL619442,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8082,,8758,,1,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Intermediate,1,,50597
,CHEMBL875156,,U,BAO_0000019,,,,,8083,,2249,,1,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,Autocuration,0,,22224
,CHEMBL619443,,U,BAO_0000019,,,,,8084,,2249,,1,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,Autocuration,0,,22224
,CHEMBL619444,,U,BAO_0000019,,,,,8085,,2249,,1,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,Autocuration,0,,22224
,CHEMBL623464,,U,BAO_0000019,,,,,8086,,2249,,1,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,Autocuration,0,,22224
,CHEMBL623465,10090.0,N,BAO_0000218,Mus musculus,,,,8087,,15115,,1,,Compound was evaluated for area under curve when administered through oral route in mouse,A,,,Intermediate,1,,50594
,CHEMBL623466,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8088,,6518,,1,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL623467,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8089,,6518,,1,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL623468,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8090,,6249,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622660,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8091,,2463,,1,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622661,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8092,,4969,,1,,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622662,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8093,,17720,,1,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Intermediate,1,,50597
,CHEMBL622663,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8094,,3457,,1,,Pharmacokinetic property (total body clearance) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622664,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8095,,5983,,1,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL622665,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8096,,6295,,1,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622666,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8097,,6296,,1,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL621615,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8098,,17686,,1,,Cl in rat i.v. at 2 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621616,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8099,,17764,,1,,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621617,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8100,,5503,,1,,Clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621618,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8101,,4368,,1,,Clearance by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621619,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8102,,6005,,1,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621620,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8103,,5031,,1,,Clearance rate after i.v. administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621786,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8104,,4890,,1,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621787,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8105,,5182,,1,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621788,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8106,,5979,,1,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621789,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8107,,5656,,1,,Clearance (Cl) after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621790,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8108,,17804,,1,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621791,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8109,1969.0,4839,,1,,Compound was tested for plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
Microsomes,CHEMBL621792,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8110,,5041,,1,,In vitro microsome metabolism clearance in rat was determined,A,In vitro,,Intermediate,1,,50597
Microsomes,CHEMBL621793,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8111,,5041,,1,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,In vitro,,Intermediate,1,,50597
,CHEMBL621794,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8112,,5974,,1,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621795,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8113,1969.0,5496,,1,,In vivo plasma clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8114,,5739,,1,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621797,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8115,2107.0,5676,,1,401.0,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,In vivo,Hepatocyte,Intermediate,1,,50597
,CHEMBL621798,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8116,,4239,,1,,Pharmacokinetic property (Plasma clearance) was measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621799,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8117,,5676,,1,,Pharmacokinetic property (clearance) in rat i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621800,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8118,,1918,,1,,"Plasma Clearance was evaluated in rats, iv",A,In vivo,,Intermediate,1,,50597
,CHEMBL621801,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8119,,17800,,1,,Plasma clearance (in vivo) in rats was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621802,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8120,,6056,,1,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618596,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8121,,5496,,1,,Plasma clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618597,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8122,,5939,,1,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618598,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8123,,5939,,1,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618599,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8124,,17752,,1,,Plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618600,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8125,,4576,,1,,Plasma clearance rate determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618601,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8126,,6011,,1,,Plasma clearance was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618602,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8127,,5510,,1,,Plasma clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618603,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8128,,5948,,1,,Plasma clearance value in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618604,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8129,2107.0,6125,,1,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Intermediate,1,,50597
,CHEMBL618605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8130,,4839,,1,,Clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8131,,17686,,1,,Total body clearance in rat i.v. at 2 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618607,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8132,,6571,,1,,Clearance of compound in rats after intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8133,,3364,,1,,Clearance after iv administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618609,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8134,,13569,,1,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618610,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8135,,13569,,1,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8136,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8137,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618613,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8138,,13569,,1,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621076,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8139,,13569,,1,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621077,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8140,,13569,,1,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621078,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8141,,17670,,1,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL621251,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8142,,5970,,1,,Clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621252,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8143,,6495,,1,,Clearance in rat after oral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621253,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8144,,4590,,1,,Clearance in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621254,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8145,,6193,,1,,Clearance rate following an oral dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621255,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8146,,2832,,1,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621256,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8147,1969.0,1052,,1,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,In vivo,,Intermediate,1,,50597
,CHEMBL621257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8148,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8149,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621259,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8150,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621260,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8151,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL876494,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8152,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8153,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621262,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8154,2107.0,9866,,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621263,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8155,2107.0,9866,,1,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621264,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8156,2107.0,9866,,1,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL621265,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8157,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8158,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL621267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8159,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621268,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8160,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621269,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8161,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621270,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8162,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621271,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8163,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621272,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8164,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621273,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8165,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8166,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL876495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8167,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621275,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8168,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8169,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL621277,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8170,2385.0,9866,,1,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL621278,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8171,160.0,9866,,1,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621279,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8172,160.0,9866,,1,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621280,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8173,160.0,9866,,1,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,In vivo,,Intermediate,1,,50597
,CHEMBL621281,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8174,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621282,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8175,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621283,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8176,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621284,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8177,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Intermediate,1,,50597
,CHEMBL621285,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8178,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL621286,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8179,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL623220,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8180,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL623221,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8181,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,In vivo,,Intermediate,1,,50597
,CHEMBL876029,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8182,2106.0,9866,,1,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,In vivo,,Intermediate,1,,50597
,CHEMBL623222,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8183,945.0,9866,,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623223,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8184,945.0,9866,,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621445,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8185,945.0,9866,,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621446,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8186,178.0,13950,,1,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621447,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8187,178.0,13950,,1,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619681,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8188,178.0,13950,,1,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619682,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8189,178.0,13950,,1,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619683,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8190,178.0,13950,,1,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619684,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8191,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619685,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8192,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619686,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8193,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619687,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8194,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619688,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8195,955.0,13950,,1,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619689,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8196,948.0,13950,,1,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619690,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8197,948.0,13950,,1,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619691,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8198,948.0,13950,,1,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619692,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8199,,6062,,1,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL619693,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8200,,3598,,1,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50597
,CHEMBL619694,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8201,,1908,,1,,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL619695,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8202,,17596,,1,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL619696,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8203,,4891,,1,,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,In vivo,,Intermediate,1,,50597
,CHEMBL619697,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8204,,740,,1,,Compound was evaluated for volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL619698,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8205,,16366,,1,,Steady state volume distribution was determined; steady state(ss),A,In vivo,,Intermediate,1,,50597
,CHEMBL619699,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8206,,3364,,1,,Steady state volume of distribution after iv administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL619700,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8207,,2552,,1,,Steady state volume of distribution dosing at 3 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL619701,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8208,,406,,1,,The compound was evaluated for volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL619702,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8209,,12500,,1,,The compound was tested for volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620335,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8210,,12500,,1,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620336,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8211,,5656,,1,,Volume distribution (VD) after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620337,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8212,,17671,,1,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620520,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8213,,1094,,1,,Volume distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620521,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8214,,5833,,1,,Volume distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL875825,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8215,,5939,,1,,Volume distribution in rat after peroral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620522,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8216,,5939,,1,,Volume distribution in rat after peroral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620523,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8217,,6005,,1,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620524,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8218,,1696,,1,,Volume of distribution in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620525,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8219,,6672,,1,,Volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620526,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8220,,6673,,1,,Volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620527,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8221,,5871,,1,,Volume of distribution in rat by iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620528,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8222,,6803,,1,,Volume of distribution in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620529,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8223,,5199,,1,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Intermediate,1,,50597
,CHEMBL620530,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8224,,4727,,1,,Volume distribution at the dose of 2 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL620531,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8225,,16367,,1,,Steady state volume of distribution was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620532,9544.0,U,BAO_0000218,Macaca mulatta,,,,8226,,5005,,1,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Intermediate,0,,22224
,CHEMBL620533,10116.0,U,BAO_0000218,Rattus norvegicus,,,,8227,,5005,,1,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,In vivo,,Intermediate,0,,22224
,CHEMBL620534,10116.0,U,BAO_0000218,Rattus norvegicus,,,,8228,,5005,,1,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,In vivo,,Intermediate,0,,22224
,CHEMBL620535,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8229,,15765,,1,,Mean (%CV) PK parameters for Vdss(mL/kg).,A,In vivo,,Intermediate,1,,50597
,CHEMBL875826,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8230,,2792,,1,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620536,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8231,,2792,,1,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620537,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8232,,5334,,1,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618526,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8233,,5334,,1,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618527,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8234,,5739,,1,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618528,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8235,,5789,,1,,Pharmacokinetic property (Vdss) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618529,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8236,,4239,,1,,Pharmacokinetic property (vdss) was measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618530,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8237,,4709,,1,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618531,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8238,,6642,,1,,Volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618532,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8239,,5247,,1,,The pharmacokinetic parameter volume of distribution in vivo in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618533,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8240,,17720,,1,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Intermediate,1,,50597
,CHEMBL618534,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8241,,17686,,1,,Vdss in rat i.v. at 2 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618535,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8242,,4689,,1,,Volume distribution after intravenous administration (1 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618536,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8243,,5654,,1,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618537,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8244,,5654,,1,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618538,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8245,,4527,,1,,Volume distribution at a dose of 10 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618539,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8246,,4521,,1,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8247,,6057,,1,,Volume distribution was calculated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618541,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8248,,5510,,1,,Volume distribution was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618542,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8249,,2938,,1,,Volume of distribution after intravenous administration was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622544,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8250,,6679,,1,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622545,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8251,,6685,,1,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL622546,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8252,,6685,,1,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL622547,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8253,,6685,,1,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL622548,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8254,,5145,,1,,Volume of distribution in steady state was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622549,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8255,,6467,,1,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622550,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8256,,6467,,1,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622551,10090.0,N,BAO_0000218,Mus musculus,,,,8257,,15115,,1,,Compound was evaluated for area under curve when administered through oral route to mouse,A,,,Intermediate,1,,50594
,CHEMBL622552,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8258,,8758,,1,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Intermediate,1,,50597
,CHEMBL622553,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8259,,8758,,1,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Intermediate,1,,50597
,CHEMBL622554,,U,BAO_0000218,,,,,8260,,8267,,1,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,In vivo,,Autocuration,0,,22224
,CHEMBL622555,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,8261,,8267,,1,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL622556,10090.0,N,BAO_0000218,Mus musculus,,,,8262,,14239,,1,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL622557,10090.0,N,BAO_0000218,Mus musculus,,,,8263,,14239,,1,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL622558,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8264,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,,,Intermediate,1,,50594
,CHEMBL622559,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8265,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,,,Intermediate,1,,50594
,CHEMBL622560,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,8266,,10754,,1,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,,,Intermediate,1,,50588
,CHEMBL622561,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8267,,14681,,1,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Intermediate,1,,50597
,CHEMBL622562,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8268,,14681,,1,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,,,Intermediate,1,,50597
,CHEMBL622563,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8269,,14681,,1,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Intermediate,1,,50597
,CHEMBL622564,,U,BAO_0000019,,,,,8270,,13118,,1,,Concentration of compound in Central nervous system,A,,,Autocuration,0,,22224
,CHEMBL622565,,U,BAO_0000019,,,,,8271,,13118,,1,,Concentration of compound in Central nervous system; Not detectable,A,,,Autocuration,0,,22224
,CHEMBL622566,10090.0,N,BAO_0000218,Mus musculus,,,,8272,,13318,,1,,"Concentration of diester in the blood, following oral administration in mice",A,,,Intermediate,1,,50594
,CHEMBL624515,10090.0,N,BAO_0000218,Mus musculus,,,,8273,,13318,,1,,"Concentration of monoester in the blood, following oral administration in mice",A,,,Intermediate,1,,50594
,CHEMBL624516,10090.0,N,BAO_0000218,Mus musculus,,,,8274,,13318,,1,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,,,Intermediate,1,,50594
,CHEMBL624517,,U,BAO_0000019,,,,,8275,,15692,,1,,Evaluated for Pharmacokinetic property: Area under the curve,A,,,Autocuration,0,,22224
,CHEMBL624518,10090.0,N,BAO_0000218,Mus musculus,,,,8276,,14839,,1,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,,,Intermediate,1,,50594
,CHEMBL624519,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8277,,14839,,1,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,,,Intermediate,1,,100710
,CHEMBL624520,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8278,,14839,,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,100710
,CHEMBL624521,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8279,,14839,,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,100710
,CHEMBL624522,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8280,,14839,,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,100710
,CHEMBL624523,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8281,,14839,,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,100710
,CHEMBL624409,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8282,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL624410,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8283,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL624411,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8284,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL623531,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8285,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL623532,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8286,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL623533,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8287,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL623534,9541.0,N,BAO_0000218,Macaca fascicularis,,,,8288,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Intermediate,1,,100710
,CHEMBL623535,10090.0,N,BAO_0000218,Mus musculus,,,,8289,,14839,,1,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623536,10090.0,N,BAO_0000218,Mus musculus,,,,8290,,14839,,1,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623537,10090.0,N,BAO_0000218,Mus musculus,,,,8291,,14839,,1,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623538,10090.0,N,BAO_0000218,Mus musculus,,,,8292,,14839,,1,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623539,10090.0,N,BAO_0000218,Mus musculus,,,,8293,,14839,,1,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623540,10090.0,N,BAO_0000218,Mus musculus,,,,8294,,14839,,1,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Intermediate,1,,50594
,CHEMBL623541,10090.0,N,BAO_0000218,Mus musculus,,,,8295,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,,,Intermediate,1,,50594
,CHEMBL623542,10090.0,N,BAO_0000218,Mus musculus,,,,8296,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL623543,10090.0,N,BAO_0000218,Mus musculus,,,,8297,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,,,Intermediate,1,,50594
,CHEMBL623544,10090.0,N,BAO_0000218,Mus musculus,,,,8298,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,,,Intermediate,1,,50594
,CHEMBL623545,10090.0,N,BAO_0000218,Mus musculus,,,,8299,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL623546,10090.0,N,BAO_0000218,Mus musculus,,,,8300,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,,,Intermediate,1,,50594
,CHEMBL623547,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8301,1969.0,5408,,1,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623548,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8302,,6827,,1,,High i.v. clearance in Dawley rats,A,In vivo,,Intermediate,1,,50597
Microsomes,CHEMBL623549,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8303,2107.0,17538,,1,,In vitro clearance in rat liver microsomes,A,In vitro,,Intermediate,1,,50597
Microsomes,CHEMBL623550,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8304,2107.0,6331,,1,,Intrinsic clearance in rat liver microsomes was determined,A,In vitro,,Intermediate,1,,50597
,CHEMBL875276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8305,2107.0,5948,,1,401.0,Intrinsic clearance in rat hepatocytes was determined,A,In vitro,Hepatocyte,Intermediate,1,,50597
,CHEMBL621872,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8306,,4026,,1,,Plasma Clearance was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621873,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8307,,6647,,1,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621874,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8308,,1696,,1,,Plasma clearance in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621875,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8309,,6597,,1,,Plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621876,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8310,,347,,1,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621877,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8311,,16423,,1,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621878,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8312,,2879,,1,,Plasma clearance was measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621879,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8313,,4883,,1,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621880,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8314,1969.0,5328,,1,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,In vivo,,Intermediate,1,,50597
,CHEMBL621881,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8315,,5160,,1,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621882,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8316,,17582,,1,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL875283,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8317,,17651,,1,,Total clearance at 1 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621883,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8318,,17651,,1,,Total clearance at 10 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621884,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8319,,6596,,1,,Clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621885,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8320,,4796,,1,,Plasma clearance rate determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621886,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8321,,6850,,1,,Clearance of compound in rat was evaluated,A,In vivo,,Intermediate,1,,50597
,CHEMBL621887,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8322,1969.0,5932,,1,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL621888,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8323,,3371,,1,,Pharmacokinetic property (blood clearance) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621889,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8324,,2083,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621890,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8325,,4942,,1,,Plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
Microsomes,CHEMBL621891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8326,2107.0,6838,,1,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,In vitro,,Intermediate,1,,50597
,CHEMBL621892,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8327,,5353,,1,,Clearance in Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621893,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8328,,6641,,1,,Clearance rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621894,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8329,,6641,,1,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,In vivo,,Intermediate,1,,50597
,CHEMBL621895,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8330,,6641,,1,,Clearance rat; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL875284,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8331,,6444,,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL618699,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8332,,6444,,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618700,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8333,,6444,,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618701,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8334,,6211,,1,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL876600,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8335,1969.0,12873,,1,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Intermediate,1,,50597
,CHEMBL618702,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8336,,6570,,1,,Clearance of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618703,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8337,,3341,,1,,Compound was evaluated for Hepatic clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618704,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8338,,4891,,1,,In vivo clearance after 5 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618705,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8339,1969.0,1094,,1,,Compound was tested for plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618706,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8340,,2938,,1,,Hepatic clearance after intravenous administration was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618707,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8341,,17853,,1,,Lower clearance in rat (i.v.) at 0.5 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL618708,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8342,1969.0,6049,,1,,Pharmacokinetic parameter expressed as plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618709,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8343,,5789,,1,,Pharmacokinetic property (Clp) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618710,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8344,,4514,,1,,Plasma clearance in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618711,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8345,,6448,,1,,Plasma clearance (Clp) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618712,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8346,,6062,,1,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618713,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8347,,5710,,1,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL618714,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8348,,4709,,1,,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618715,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8349,,4521,,1,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618716,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8350,,1742,,1,,Plasma clearance in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL876601,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8351,,6057,,1,,Plasma clearance measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618717,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8352,,6057,,1,,Plasma clearance was calculated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618718,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8353,,5145,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618719,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8354,,5833,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618720,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8355,,6453,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618721,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8356,,6640,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621477,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8357,,6305,,1,,Plasma clearance in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621478,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8358,,6642,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621479,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8359,,5472,,1,,Plasma clearance was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621480,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8360,,5472,,1,,Plasma clearance was evaluated in rat; Not tested,A,In vivo,,Intermediate,1,,50597
,CHEMBL621481,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8361,,5144,,1,,Plasma clearance rate was determined for the compound in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621482,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8362,,6685,,1,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL621483,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8363,,6685,,1,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL621484,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8364,,6685,,1,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL621485,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8365,948.0,13950,,1,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621486,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8366,948.0,13950,,1,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621487,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8367,160.0,13950,,1,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621488,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8368,160.0,13950,,1,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8369,160.0,13950,,1,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621490,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8370,160.0,13950,,1,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621491,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,8371,160.0,13950,,1,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621492,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8372,2113.0,13950,,1,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621493,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8373,2113.0,13950,,1,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621494,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8374,2113.0,13950,,1,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8375,2113.0,13950,,1,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8376,2113.0,13950,,1,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8377,2107.0,13950,,1,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621498,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8378,2107.0,13950,,1,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL621499,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8379,2107.0,13950,,1,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL618634,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8380,2107.0,13950,,1,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL618635,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8381,2107.0,13950,,1,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL618636,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8382,2048.0,13950,,1,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8383,2048.0,13950,,1,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619738,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8384,2048.0,13950,,1,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624329,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8385,2048.0,13950,,1,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8386,2048.0,13950,,1,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624331,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8387,2385.0,13950,,1,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624332,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8388,2385.0,13950,,1,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624333,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8389,2385.0,13950,,1,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624334,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8390,2385.0,13950,,1,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL624335,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8391,2385.0,13950,,1,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620016,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8392,2106.0,13950,,1,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620169,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8393,2106.0,13950,,1,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620170,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8394,2106.0,13950,,1,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8395,2106.0,13950,,1,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,8396,2106.0,13950,,1,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620173,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8397,945.0,13950,,1,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620174,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8398,945.0,13950,,1,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620175,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8399,945.0,13950,,1,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620176,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8400,945.0,13950,,1,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620177,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,8401,945.0,13950,,1,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL620178,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8402,2037.0,13950,,1,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620179,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8403,2037.0,13950,,1,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620180,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8404,,13950,,1,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620181,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8405,,6570,,1,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620182,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8406,,6571,,1,,Volume of distribution of compound in rats after intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620183,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8407,,6453,,1,,Volume of distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620184,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8408,,6444,,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620185,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8409,,6444,,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620186,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8410,,6444,,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620187,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8411,,5353,,1,,Volume of distribution was determined in Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620188,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8412,,5334,,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620189,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8413,,5334,,1,,Volume of distribution was reported in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620190,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8414,,6641,,1,,Volumes of distribution in rat after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620191,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8415,,6641,,1,,Volumes of distribution in rat after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620192,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8416,,6641,,1,,Volumes of distribution in rat after po administration; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620193,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8417,,5676,,1,,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620194,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8418,,6410,,1,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,In vivo,,Intermediate,1,,50597
,CHEMBL876730,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8419,,17670,,1,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL620195,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8420,,6495,,1,,Volume distribution in rat after oral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620196,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8421,,5408,,1,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620197,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8422,,4883,,1,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620198,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8423,,6647,,1,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL620199,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8424,,6495,,1,,Volume of distribution in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620200,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8425,,2661,,1,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620201,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8426,,2661,,1,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620202,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8427,,5974,,1,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620203,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8428,,5974,,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620204,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8429,,5974,,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,In vivo,,Intermediate,1,,50597
,CHEMBL620205,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8430,,5974,,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624664,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8431,,5960,,1,,Pharmacokinetic parameter (Vss) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624665,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8432,,5676,,1,,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624666,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8433,,5948,,1,,Pharmacokinetic property (Vss) in rat,A,,,Intermediate,1,,50597
,CHEMBL624667,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8434,,5979,,1,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624668,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8435,,5978,,1,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624669,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8436,,5978,,1,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624670,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8437,,5978,,1,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624671,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8438,,5978,,1,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624672,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8439,,6448,,1,,Steady state volume distribution in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624673,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8440,1969.0,12873,,1,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,In vivo,,Intermediate,1,,50597
,CHEMBL624674,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8441,,4576,,1,,Steady state volume of distribution determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624675,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8442,,17582,,1,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621728,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8443,,1466,,1,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621729,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8444,,5182,,1,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,,,Intermediate,1,,50597
,CHEMBL621730,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8445,,5182,,1,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,,,Intermediate,1,,50597
,CHEMBL621731,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8446,,6535,,1,,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL621732,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8447,,6535,,1,,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL621908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8448,,5041,,1,,Volume in steady state distribution value was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL875347,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8449,,5041,,1,,Volume in steady state distribution value was determined; ND denotes no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL621909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8450,,5041,,1,,Volume in steady state distribution value was determined; ND denotes not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8451,,17065,,1,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621911,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8452,,6597,,1,,Volume of distribution at steady state was evaluated in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621912,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8453,,15662,,1,,Volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621913,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8454,,6485,,1,,Volume of distribution in steady state was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621914,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8455,,17655,,1,,Volume of distribution in steady state was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621915,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8456,,6616,,1,,Volume of distribution after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621916,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8457,,1916,,1,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621917,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8458,2107.0,16438,,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL621918,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8459,2107.0,16438,,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL621919,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8460,2106.0,16438,,1,,Biodistribution of compound (oxidized form) in spleen tissue,A,In vivo,,Intermediate,1,,50594
,CHEMBL621920,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8461,2106.0,16438,,1,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL621921,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8462,2106.0,16438,,1,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622401,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8463,2106.0,16438,,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL875348,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8464,2106.0,16438,,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Intermediate,1,,50594
,CHEMBL622402,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8465,2106.0,16438,,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Intermediate,1,,50594
,CHEMBL622403,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8466,178.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,In vivo,,Intermediate,1,,50594
,CHEMBL622404,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8467,178.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622405,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8468,955.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,In vivo,,Intermediate,1,,50594
,CHEMBL622406,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8469,955.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622407,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8470,955.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622408,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8471,948.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,In vivo,,Intermediate,1,,50594
,CHEMBL622409,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8472,948.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622410,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8473,948.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL622411,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8474,2113.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,In vivo,,Intermediate,1,,50594
,CHEMBL627864,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8475,2113.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL627865,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8476,2113.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL627866,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8477,2107.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,In vivo,,Intermediate,1,,50594
,CHEMBL627751,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8478,2107.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL627752,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8479,2106.0,16438,,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,In vivo,,Intermediate,1,,50594
,CHEMBL627753,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8480,2106.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL627754,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8481,2106.0,16438,,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Intermediate,1,,50594
,CHEMBL627755,10090.0,N,BAO_0000218,Mus musculus,,,,8482,,12467,,1,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,,,Intermediate,1,,50594
,CHEMBL627756,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8483,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627757,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8484,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627758,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8485,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627759,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8486,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627760,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8487,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627761,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8488,955.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL876811,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8489,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627762,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8490,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627763,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8491,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627764,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8492,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627765,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8493,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627766,10090.0,N,BAO_0000218,Mus musculus,,,Heart,8494,948.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627767,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8495,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627768,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8496,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL628422,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8497,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL628423,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8498,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL628424,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8499,,5089,,1,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL628425,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8500,,5089,,1,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL628426,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8501,,4257,,1,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL628427,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8502,,6679,,1,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626938,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8503,,5546,,1,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626939,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8504,,6141,,1,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626940,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8505,,5334,,1,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626941,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8506,,5334,,1,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626942,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8507,,5334,,1,,Plasma clearance was reported in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL876812,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8508,,4689,,1,,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626943,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8509,,6848,,1,,Plasma clearance of compound in rats was evaluated,A,In vivo,,Intermediate,1,,50597
,CHEMBL626944,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8510,,6848,,1,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL626945,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8511,,6467,,1,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8512,,6467,,1,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL626856,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8513,,4956,,1,,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626857,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8514,,5529,,1,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL626858,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8515,1969.0,406,,1,,The compound was evaluated for plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627018,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8516,1969.0,17655,,1,,Total plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625331,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8517,178.0,3293,,1,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625332,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8518,178.0,4075,,1,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL877590,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8519,,2792,,1,,C max was determined at 10 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625333,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8520,,2792,,1,,C max was determined at 3 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625334,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8521,,17594,,1,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625335,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8522,,17594,,1,,Cmax after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625336,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8523,,4762,,1,,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625337,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8524,,17509,,1,,Cmax 24 hr after 10 mg/kg oral administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625338,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8525,,17509,,1,,Cmax 24 hr after 2 mg/kg oral administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625339,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8526,1969.0,1466,,1,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625340,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8527,,6535,,1,,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL625341,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8528,,6535,,1,,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL622687,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8529,,3169,,1,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622688,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8530,1969.0,6515,,1,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622689,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8531,178.0,11149,,1,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620295,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8532,178.0,11149,,1,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620296,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8533,,17858,,1,,Cmax after 10 mg/kg oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620297,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8534,,6518,,1,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL620298,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8535,,6518,,1,,Cmax after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL620299,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8536,,4426,,1,,Cmax after oral administration at 20 mpk in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620300,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8537,,4426,,1,,Cmax after oral administration at 20 mpk in rats; Not performed.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620301,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8538,,4426,,1,,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620302,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8539,,5656,,1,,Cmax after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620303,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8540,,6518,,1,,Cmax after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620304,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8541,,6518,,1,,Cmax after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620305,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8542,,6113,,1,,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL620306,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8543,,17764,,1,,Cmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620307,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8544,,4756,,1,,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620308,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8545,,4756,,1,,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620309,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8546,,6402,,1,,Cmax by administering at 20 mg/kg p.o. in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620310,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8547,,5610,,1,,Cmax in male rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620311,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8548,,5207,,1,,Cmax in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8549,,6011,,1,,Cmax in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620313,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8550,,6504,,1,,Cmax in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620314,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8551,,6046,,1,,Cmax in rat at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620315,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8552,,6504,,1,,Cmax in rat at the dose of 1 mg/kg i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620316,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8553,,5874,,1,,Cmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620317,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8554,,17686,,1,,Cmax in rat p.o. at 20 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620318,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8555,,5836,,1,,Cmax in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620319,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8556,,17596,,1,,Cmax in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL620320,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8557,,16423,,1,,Cmax was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL620321,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8558,,17804,,1,,Cmax was measured in rats after peroral administration at 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620322,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8559,,1908,,1,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL620323,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8560,,13950,,1,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620324,10116.0,N,BAO_0000218,Rattus norvegicus,,,Frontal cortex,8561,1870.0,13950,,1,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620325,10116.0,N,BAO_0000218,Rattus norvegicus,,,Frontal cortex,8562,1870.0,13950,,1,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620326,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8563,10000000.0,13950,,1,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620327,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8564,10000000.0,13950,,1,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620328,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8565,,13950,,1,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620329,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8566,,13950,,1,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Midbrain,8567,1891.0,13950,,1,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL875286,10116.0,N,BAO_0000218,Rattus norvegicus,,,Midbrain,8568,1891.0,13950,,1,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620331,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8569,,13950,,1,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620332,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8570,,13950,,1,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620333,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8571,2435.0,13950,,1,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL620334,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8572,2435.0,13950,,1,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Intermediate,1,,50597
,CHEMBL621015,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8573,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621016,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8574,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8575,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621192,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8576,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621193,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8577,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621194,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8578,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624204,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8579,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8580,178.0,16434,,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8581,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624207,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8582,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624208,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8583,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624209,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8584,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624210,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8585,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624211,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8586,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624212,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8587,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624213,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8588,178.0,16435,,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL876611,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8589,178.0,16434,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624214,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8590,178.0,16434,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624215,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8591,178.0,16434,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624216,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8592,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624217,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8593,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624218,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8594,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624219,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8595,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624220,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8596,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624221,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8597,178.0,16435,,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624222,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8598,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624223,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8599,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624224,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8600,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624225,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8601,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622420,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8602,,17764,,1,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622421,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8603,,5031,,1,,Volume of steady state distribution after i.v. administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622422,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8604,,6215,,1,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622423,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8605,,17671,,1,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622424,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8606,,17752,,1,,Vss was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622425,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8607,,6596,,1,,Vss in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL876612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8608,,16423,,1,,Vss was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622426,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8609,,15662,,1,,volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622427,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8610,,6062,,1,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622428,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8611,,5874,,1,,Pharmacokinetic (PK) parameter Vz in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622429,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8612,,4942,,1,,Volume distribution in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622430,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8613,,17796,,1,,Volume of distribution in rat; No data,A,In vivo,,Intermediate,1,,50597
,CHEMBL622431,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8614,,4890,,1,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622432,10116.0,N,BAO_0000218,Rattus norvegicus,,,Ileum,8615,2116.0,15765,,1,,% absorption predicted from in vitro rat ileum transport studies,A,,,Intermediate,1,,50597
,CHEMBL622433,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8616,,13569,,1,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622434,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8617,,13569,,1,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622435,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8618,,13569,,1,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618748,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8619,,13569,,1,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618749,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8620,,13569,,1,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618750,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8621,,13569,,1,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618751,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8622,,13569,,1,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618752,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8623,,13569,,1,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618753,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8624,,4576,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618754,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8625,1969.0,750,,1,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,In vivo,,Intermediate,1,,50597
,CHEMBL618755,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8626,,750,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618756,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8627,,4590,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618757,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8628,,1716,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618758,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8629,,1974,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621088,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8630,,4502,,1,,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL621089,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8631,,3371,,1,,Pharmacokinetic property (cLogP) in rat,A,,,Intermediate,1,,50597
,CHEMBL621090,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8632,178.0,9099,,1,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,,,Intermediate,1,,50597
,CHEMBL621091,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8633,178.0,9099,,1,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,,,Intermediate,1,,50597
,CHEMBL876731,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8634,,4590,,1,,Clearance in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621092,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8635,,3184,,1,,Compound was evaluated for its clearance when administered intravenously in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621093,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8636,,16456,,1,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621094,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8637,,4199,,1,,Blood: Brain distribution ratio is determined in rat,A,,,Intermediate,1,,50597
,CHEMBL621095,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8638,,4199,,1,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,,,Intermediate,1,,50597
,CHEMBL621096,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8639,,4199,,1,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,,,Intermediate,1,,50597
,CHEMBL621097,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8640,2113.0,8677,,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL621098,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8641,,7449,,1,,Percent dose excreted in 0-48 hours administered ip to male rat,F,,,Intermediate,1,,50597
,CHEMBL621099,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8642,2037.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621100,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8643,2037.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621101,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8644,2037.0,11977,,1,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Intermediate,1,,50597
,CHEMBL621102,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8645,2037.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL876732,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,8646,2037.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621103,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8647,,11977,,1,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621104,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8648,,11977,,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621105,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8649,,11977,,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Intermediate,1,,50597
,CHEMBL621106,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8650,,11977,,1,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621107,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8651,,11977,,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621108,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8652,,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621109,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8653,,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL621110,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8654,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL621111,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,8655,2113.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL622541,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8656,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL622542,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8657,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL622543,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8658,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624412,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8659,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624413,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8660,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624414,10090.0,N,BAO_0000218,Mus musculus,,,Liver,8661,2107.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624415,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8662,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624416,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8663,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624417,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8664,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624418,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8665,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624419,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8666,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624420,10090.0,N,BAO_0000218,Mus musculus,,,Lung,8667,2048.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624421,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8668,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624422,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8669,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL624423,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8670,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL625123,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8671,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL625124,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8672,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL625125,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,8673,2385.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL625126,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8674,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626947,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8675,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626948,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8676,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626949,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8677,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626950,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8678,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626951,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,8679,14.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626952,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8680,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626953,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8681,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626954,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8682,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626955,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8683,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626956,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8684,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626957,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,8685,2106.0,17208,,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626958,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8686,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626959,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8687,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626960,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8688,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL626961,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8689,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627589,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8690,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627590,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8691,178.0,17208,,1,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Intermediate,1,,50594
,CHEMBL627591,10090.0,N,BAO_0000218,Mus musculus,,,,8692,,3132,,1,,Time taken for EC90 was determined when tested in mouse,A,,,Intermediate,1,,50594
,CHEMBL627592,10090.0,N,BAO_0000218,Mus musculus,,,,8693,,3132,,1,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,,,Intermediate,1,,50594
,CHEMBL627593,10090.0,N,BAO_0000218,Mus musculus,,,,8694,,16597,,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Intermediate,1,,50594
,CHEMBL627594,10090.0,N,BAO_0000218,Mus musculus,,,,8695,,5727,,1,,Half life in mice,A,,,Intermediate,1,,50594
,CHEMBL876813,10090.0,N,BAO_0000218,Mus musculus,,,,8696,,5302,,1,,Half life period in mouse after 10 mg/Kg dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627595,10090.0,N,BAO_0000218,Mus musculus,,,,8697,,5302,,1,,Half life period in mouse after 10 mg/kg dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627596,10090.0,N,BAO_0000218,Mus musculus,,,,8698,,6348,,1,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL627597,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8699,,5964,,1,,Cmax value at 5 mg/kg po was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627598,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8700,,6078,,1,,Cmax value evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627599,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8701,955.0,5206,,1,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,In vivo,,Intermediate,1,,50597
,CHEMBL627600,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8702,,2959,,1,,Cmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627601,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8703,,5964,,1,,Cmax value at 1 mg/kg po in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627776,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8704,,5964,,1,,Cmax value at 5 mg/kg po in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627777,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8705,,6757,,1,,Cmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627778,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8706,,6757,,1,,Cmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627779,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8707,,6757,,1,,Cmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL876814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8708,,17617,,1,,Cmax value in rats at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627780,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8709,,1445,,1,,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627781,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8710,,6082,,1,,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627782,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8711,,1446,,1,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Intermediate,1,,50597
,CHEMBL627783,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8712,1969.0,5407,,1,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627784,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8713,1969.0,2690,,1,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627785,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8714,,2661,,1,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627786,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8715,,2661,,1,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627787,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8716,1969.0,4891,,1,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627788,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8717,1969.0,2807,,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL626579,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8718,1969.0,2807,,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL626580,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8719,1969.0,2807,,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL876815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8720,,3634,,1,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626581,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8721,1969.0,1881,,1,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL626582,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8722,1969.0,1881,,1,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL626583,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8723,,429,,1,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626205,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8724,,5974,,1,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626206,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8725,,5974,,1,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626207,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8726,,5974,,1,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623882,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8727,,5974,,1,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623883,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8728,,17582,,1,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623884,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8729,,17582,,1,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623885,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8730,1969.0,3032,,1,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Intermediate,1,,50597
,CHEMBL623886,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8731,1969.0,6295,,1,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623887,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8732,,6619,,1,,Maximal concentration in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623888,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8733,,6616,,1,,Maximal concentration after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623889,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8734,1969.0,3249,,1,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623890,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8735,1969.0,17791,,1,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8736,1969.0,17791,,1,,Cmax in rat plasma after oral dose (50 mg/Kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623892,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8737,1969.0,1360,,1,,Maximal plasma concentration was determined.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623893,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8738,1969.0,2552,,1,,Maximal plasma drug concentration was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL877616,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8739,,6571,,1,,Maximal concentration in rats after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623894,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8740,,6570,,1,,Maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623895,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8741,1969.0,6567,,1,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,In vivo,,Intermediate,1,,50597
,CHEMBL623896,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8742,,3031,,1,,Maximum concentration of compound in rat was evaluated.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623897,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8743,,3436,,1,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623898,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8744,,3436,,1,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623899,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8745,,2083,,1,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623900,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8746,,3436,,1,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623901,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8747,,4527,,1,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623902,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8748,,1974,,1,,Maximum concentration was evaluated in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623903,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebrospinal fluid,8749,1359.0,3307,,1,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623904,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8750,1969.0,3307,,1,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL877617,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8751,1969.0,1916,,1,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623905,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8752,,1500,,1,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623906,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8753,,1500,,1,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623907,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8754,1969.0,4186,,1,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL623908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8755,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL623909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8756,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8757,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL623911,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8758,,16434,,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL623912,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8759,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624616,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8760,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624617,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8761,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624618,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8762,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624619,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8763,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624794,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8764,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624795,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8765,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL623921,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8766,,16435,,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL623922,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8767,,16434,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623923,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8768,,16434,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623924,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8769,,16434,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623925,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8770,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623926,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8771,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623927,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8772,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623928,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8773,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623929,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8774,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623930,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8775,,16435,,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623931,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8776,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622165,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8777,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621249,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8778,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621250,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8779,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621448,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8780,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621449,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8781,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621450,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8782,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621451,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8783,955.0,16434,,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621452,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8784,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621453,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8785,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621454,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8786,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621455,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8787,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621456,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8788,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625145,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8789,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL875847,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8790,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL625146,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8791,955.0,16435,,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL625147,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8792,955.0,16434,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL625148,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8793,955.0,16434,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL625149,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8794,955.0,16434,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL625150,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8795,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL625151,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8796,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL625152,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8797,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL625153,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8798,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL625154,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8799,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL625155,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8800,955.0,16435,,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL625156,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8801,,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Intermediate,1,,50597
,CHEMBL624354,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8802,,11977,,1,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624355,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8803,10000000.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624356,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8804,10000000.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624357,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8805,10000000.0,11977,,1,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624358,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,8806,10000000.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624359,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8807,2435.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624360,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8808,2435.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624361,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8809,2435.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Intermediate,1,,50597
,CHEMBL624362,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8810,2435.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624363,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,8811,2435.0,11977,,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Intermediate,1,,50597
,CHEMBL624364,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8812,178.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624365,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8813,178.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624366,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8814,178.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624367,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8815,178.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624368,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8816,955.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624369,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8817,955.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL624370,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8818,955.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625069,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8819,955.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625070,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8820,955.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626051,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8821,948.0,11977,,1,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626052,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8822,948.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626053,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8823,948.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626054,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8824,948.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626055,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8825,948.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626056,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8826,2113.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626057,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8827,2113.0,11977,,1,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625193,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8828,2113.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625194,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8829,2113.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625195,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8830,2107.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625196,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8831,2107.0,11977,,1,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625197,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8832,2107.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625198,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8833,2107.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627929,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,8834,2107.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627074,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8835,2048.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627075,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8836,2048.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627076,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8837,2048.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627077,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8838,2048.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627078,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,8839,2048.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL627079,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8840,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL873824,10090.0,N,BAO_0000218,Mus musculus,,,,8841,,4573,,1,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL627080,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,8842,1969.0,3132,,1,,Half life in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL627081,10090.0,N,BAO_0000218,Mus musculus,,,,8843,,17718,,1,,Half life was determined,A,,,Intermediate,1,,50594
,CHEMBL627082,10090.0,N,BAO_0000218,Mus musculus,,,,8844,,17728,,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL627083,10090.0,N,BAO_0000218,Mus musculus,,,,8845,,5961,,1,,Half-life in male mice after 1 mg/kg intravenous dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627085,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,8847,1969.0,17731,,1,,Half life in mice plasma,A,,,Intermediate,1,,50594
,CHEMBL627086,10090.0,N,BAO_0000218,Mus musculus,,,,8848,,17592,,1,,Half life in mouse,A,,,Intermediate,1,,50594
,CHEMBL627087,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,8849,1969.0,3132,,1,,Half life in mouse plasma at dose 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL627088,10090.0,N,BAO_0000218,Mus musculus,,,,8850,,17729,,1,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL627089,10090.0,N,BAO_0000218,Mus musculus,,,,8851,,17729,,1,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL627090,10090.0,N,BAO_0000218,Mus musculus,,,,8852,,17729,,1,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL627091,10090.0,N,BAO_0000218,Mus musculus,,,,8853,,3277,,1,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Intermediate,1,,50594
,CHEMBL627092,10090.0,N,BAO_0000218,Mus musculus,,,,8854,,3760,,1,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Intermediate,1,,50594
,CHEMBL876785,10090.0,N,BAO_0000218,Mus musculus,,,,8855,,3760,,1,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Intermediate,1,,50594
,CHEMBL627093,10090.0,N,BAO_0000218,Mus musculus,,,,8856,,2862,,1,,Half-life by iv administration in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL627094,10090.0,N,BAO_0000218,Mus musculus,,,,8857,,2862,,1,,Half-life by oral administration in mouse,A,In vivo,,Intermediate,1,,50594
,CHEMBL627095,10090.0,N,BAO_0000218,Mus musculus,,,,8858,,5980,,1,,Half-life in mice,A,,,Intermediate,1,,50594
,CHEMBL627096,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8859,955.0,6159,,1,,Half-life using mouse brain homogenate,A,,,Intermediate,1,,50594
,CHEMBL627097,10090.0,N,BAO_0000218,Mus musculus,,,,8860,,6254,,1,,Half-life was measured in mice,A,,,Intermediate,1,,50594
,CHEMBL627098,10090.0,N,BAO_0000218,Mus musculus,,,,8861,,6062,,1,,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL627099,10090.0,N,BAO_0000218,Mus musculus,,,Blood,8862,178.0,1574,,1,,Half-life period was determined in mouse blood,A,,,Intermediate,1,,50594
,CHEMBL627100,10090.0,N,BAO_0000218,Mus musculus,,,Brain,8863,955.0,56,,1,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,,,Intermediate,1,,50594
,CHEMBL627101,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,8864,1969.0,993,,1,,Plasma half life in mouse,A,,,Intermediate,1,,50594
,CHEMBL627102,10090.0,N,BAO_0000218,Mus musculus,,,,8865,,6652,,1,,Stability of the peptide in the presence of mouse serum,A,,,Intermediate,1,,50594
,CHEMBL627103,10090.0,N,BAO_0000218,Mus musculus,,,,8866,,17852,,1,,Terminal half life of compound was determined in mouse,A,,,Intermediate,1,,50594
,CHEMBL627104,10090.0,N,BAO_0000218,Mus musculus,,,,8867,,2675,,1,,Terminal half life was evaluated in mice after intravenous administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL627105,10090.0,N,BAO_0000218,Mus musculus,,,,8868,,2675,,1,,Terminal half life was evaluated in mice after oral administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL876786,10090.0,N,BAO_0000218,Mus musculus,,,,8869,,499,,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,,,Intermediate,1,,50594
,CHEMBL873825,10090.0,N,BAO_0000218,Mus musculus,,,,8870,,499,,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,,,Intermediate,1,,50594
,CHEMBL627106,10090.0,N,BAO_0000218,Mus musculus,,,,8871,,499,,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,,,Intermediate,1,,50594
,CHEMBL626336,10090.0,N,BAO_0000218,Mus musculus,,,,8872,,14239,,1,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL877462,10090.0,N,BAO_0000218,Mus musculus,,,,8873,,5506,,1,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,In vivo,,Intermediate,1,,50594
,CHEMBL626337,10090.0,N,BAO_0000218,Mus musculus,,,,8874,,5506,,1,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,In vivo,,Intermediate,1,,50594
,CHEMBL626338,10090.0,N,BAO_0000218,Mus musculus,,,,8875,,17734,,1,,Half life after intraperitoneal administration of 100 mg/kg in mice,A,,,Intermediate,1,,50594
,CHEMBL626339,10090.0,N,BAO_0000218,Mus musculus,,,,8876,,17728,,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL626340,10090.0,N,BAO_0000218,Mus musculus,,,,8877,,17728,,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL625377,10090.0,N,BAO_0000218,Mus musculus,,,,8878,,17728,,1,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL625378,10090.0,N,BAO_0000218,Mus musculus,,,,8879,,17728,,1,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,In vivo,,Intermediate,1,,50594
,CHEMBL625379,10090.0,N,BAO_0000218,Mus musculus,,,,8880,,17728,,1,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,In vivo,,Intermediate,1,,50594
Microsomes,CHEMBL625380,9823.0,U,BAO_0000251,Sus scrofa,,,,8881,,14294,,1,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL625381,9823.0,U,BAO_0000251,Sus scrofa,,,,8882,,14294,,1,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,,,Autocuration,0,,22224
,CHEMBL625382,9823.0,U,BAO_0000019,Sus scrofa,,,,8883,,6056,,1,,Stability to porcine renal DHP-I,A,,,Autocuration,0,,22224
,CHEMBL873828,9823.0,U,BAO_0000218,Sus scrofa,,,,8884,,1317,,1,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625383,9823.0,U,BAO_0000218,Sus scrofa,,,,8885,,1317,,1,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625384,9823.0,U,BAO_0000019,Sus scrofa,,,,8886,,5229,,1,,Half-life of the parent prodrug in porcine esterase solution,A,,,Autocuration,0,,22224
,CHEMBL625385,9823.0,U,BAO_0000019,Sus scrofa,,,,8887,,4231,,1,,"First order rate constant, k was determined in in pig liver Esterase",A,,,Autocuration,0,,22224
,CHEMBL625386,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8888,2107.0,4231,,1,,Half life of the in pig liver Esterase,A,,,Autocuration,0,,22224
,CHEMBL623571,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8889,2107.0,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,,,Autocuration,0,,22224
,CHEMBL623572,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8890,2107.0,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,,,Autocuration,0,,22224
,CHEMBL623573,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8891,2107.0,5318,,1,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,,,Autocuration,0,,22224
,CHEMBL623574,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8892,2107.0,3305,,1,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,,,Autocuration,0,,22224
,CHEMBL623575,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8893,2107.0,3305,,1,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,,,Autocuration,0,,22224
,CHEMBL623749,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8894,2107.0,2842,,1,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,,,Autocuration,0,,22224
,CHEMBL623750,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8895,2107.0,2842,,1,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,,,Autocuration,0,,22224
,CHEMBL623751,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8896,2107.0,889,,1,,Half-life in vitro in pig liver,A,In vitro,,Autocuration,0,,22224
,CHEMBL623752,9823.0,U,BAO_0000221,Sus scrofa,,,Liver,8897,2107.0,1904,,1,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,,,Autocuration,0,,22224
,CHEMBL623753,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8898,1969.0,4186,,1,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL623754,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8899,1969.0,2774,,1,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623755,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8900,1969.0,1742,,1,,Maximum concentration in rat plasma was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623756,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8901,,3169,,1,,Maximum concentration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623757,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8902,,3169,,1,,Maximum concentration in rats at 1-2 hours,A,In vivo,,Intermediate,1,,50597
,CHEMBL623758,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8903,,2081,,1,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,In vivo,,Intermediate,1,,50597
,CHEMBL623759,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,8904,955.0,3307,,1,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623760,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8905,,4727,,1,,Maximum concentration at the dose of 2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623761,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8906,,6597,,1,,Maximum concentration was evaluated in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623762,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8907,1969.0,16365,,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL877594,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8908,1969.0,16365,,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623763,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8909,1969.0,16365,,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623764,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8910,1969.0,16365,,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623765,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8911,1969.0,16365,,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623766,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8912,178.0,2591,,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623767,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8913,178.0,2591,,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623768,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,8914,178.0,2591,,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623769,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8915,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623770,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8916,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623771,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8917,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623772,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8918,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623773,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8919,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623774,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8920,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623775,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8921,1969.0,5978,,1,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623776,10116.0,N,BAO_0000218,Rattus norvegicus,,,,8922,,14465,,1,,Cmax in rat (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL622191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8923,1969.0,4723,,1,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622192,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8924,1969.0,4723,,1,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622193,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8925,1969.0,4576,,1,,Maximum plasma concentration determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622194,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8926,1969.0,12873,,1,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622195,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8927,1969.0,12873,,1,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622196,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8928,1969.0,6824,,1,,Maximum plasma concentration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622197,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8929,1969.0,17065,,1,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622198,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8930,1969.0,2932,,1,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622199,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8931,1969.0,2932,,1,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622200,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8932,1969.0,2879,,1,,Maximum plasma concentration of compound was measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622201,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8933,1969.0,2864,,1,,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623990,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8934,1969.0,16367,,1,,Maximum plasma concentration after oral administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623991,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8935,1969.0,17717,,1,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL623992,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8936,1969.0,17717,,1,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL623993,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8937,1969.0,17717,,1,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL623994,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8938,1969.0,17717,,1,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Intermediate,1,,50597
,CHEMBL623995,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8939,1969.0,17720,,1,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,In vivo,,Intermediate,1,,50597
,CHEMBL623996,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8940,1969.0,17720,,1,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Intermediate,1,,50597
,CHEMBL623997,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8941,1969.0,17720,,1,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,In vivo,,Intermediate,1,,50597
,CHEMBL623998,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8942,1969.0,4516,,1,,Maximum plasma concentration dosed orally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623999,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8943,1969.0,4516,,1,,Maximum plasma concentration dosed orally in rats after 6 hours,A,In vivo,,Intermediate,1,,50597
,CHEMBL624000,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8944,1969.0,4516,,1,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,In vivo,,Intermediate,1,,50597
,CHEMBL624001,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8945,1969.0,5199,,1,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624002,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8946,1969.0,17538,,1,,Maximum plasma concentration in rat after po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624003,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8947,1969.0,6685,,1,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL624004,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,8948,1969.0,6685,,1,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL624005,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8949,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624006,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8950,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624007,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8951,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624008,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8952,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624009,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8953,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL874387,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8954,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624010,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8955,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624011,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8956,948.0,16434,,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624012,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8957,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624013,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8958,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL624736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8959,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL624737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8960,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL624738,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8961,948.0,16434,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624739,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8962,948.0,16434,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624740,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8963,948.0,16434,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624896,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8964,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624897,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8965,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624108,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8966,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624109,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8967,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL624110,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8968,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL624111,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8969,948.0,16435,,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL624112,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8970,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL624113,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8971,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL619709,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8972,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL619710,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,8973,948.0,16435,,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL619711,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8974,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL619712,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8975,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL619713,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8976,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL619714,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8977,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL619715,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8978,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL619716,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8979,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL619717,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8980,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL619718,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8981,2113.0,16434,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL619719,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8982,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL875329,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8983,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL619720,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8984,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL619721,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8985,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL619722,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8986,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL619723,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8987,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL619724,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8988,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL619725,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8989,2113.0,16435,,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL619726,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8990,2113.0,16434,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL619727,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8991,2113.0,16434,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL619728,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8992,2113.0,16434,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL619729,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,8993,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL619730,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8994,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL619731,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8995,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL619732,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8996,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL619733,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8997,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL619734,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,8998,2385.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL619735,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,8999,14.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL875330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9000,14.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628465,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9001,14.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628466,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9002,14.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628467,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9003,14.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628468,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9004,2106.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628469,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9005,2106.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628470,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9006,2106.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628471,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9007,2106.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL628472,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9008,2106.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9009,2046.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL625192,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9010,2046.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL875337,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9011,2046.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626341,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9012,2046.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL626342,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9013,2046.0,11977,,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL621943,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9014,2107.0,11977,,1,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Intermediate,1,,50597
,CHEMBL621944,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9015,,3748,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL621945,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9016,,15765,,1,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,,,Intermediate,1,,50597
,CHEMBL621946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9017,,4871,,1,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,,,Intermediate,1,,50597
,CHEMBL621947,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9018,,4871,,1,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Intermediate,1,,50597
,CHEMBL621948,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9019,,4872,,1,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,,,Intermediate,1,,50597
,CHEMBL621949,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9020,,4872,,1,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Intermediate,1,,50597
,CHEMBL621950,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9021,,5413,,1,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,,,Intermediate,1,,50597
,CHEMBL621951,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9022,,5413,,1,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,,,Intermediate,1,,50597
,CHEMBL621952,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9023,178.0,15272,,1,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL621953,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9024,2107.0,4689,,1,,Stability (%) in rat liver microsomes,A,,,Intermediate,1,,50597
,CHEMBL621954,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9025,,6057,,1,,Area under curve was calculated after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL621955,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9026,,6057,,1,,Area under the curve was calculated after iv administration in rat,A,,,Intermediate,1,,50597
,CHEMBL621956,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9027,,6057,,1,,Area under the curve was calculated in rat after peroral administration,A,,,Intermediate,1,,50597
,CHEMBL621957,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9028,,6211,,1,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL621958,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9029,,5710,,1,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL621959,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9030,,5710,,1,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL621960,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9031,,17853,,1,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,,,Intermediate,1,,50597
,CHEMBL621961,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9032,,17853,,1,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,,,Intermediate,1,,50597
,CHEMBL621962,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9033,,15765,,1,,p value of the compound,A,,,Intermediate,1,,50597
,CHEMBL876787,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9034,,15765,,1,,p value of the compound,F,,,Intermediate,1,,50597
,CHEMBL621963,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9035,,15765,,1,,p value of the compound,A,,,Intermediate,1,,50597
,CHEMBL622637,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9036,945.0,6175,,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL622638,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9037,945.0,6175,,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL626561,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9038,945.0,6175,,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL626562,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,9039,,7991,,1,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,,,Autocuration,0,,22224
,CHEMBL626563,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9040,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,,,Autocuration,0,,22224
,CHEMBL626564,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9041,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,,,Autocuration,0,,22224
,CHEMBL626565,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9042,,6253,,1,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Autocuration,0,,22224
,CHEMBL626566,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9043,,6253,,1,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Autocuration,0,,22224
,CHEMBL626567,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9044,,3615,,1,,Clearance rate in rabbits,A,In vivo,,Autocuration,0,,22224
,CHEMBL626568,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9045,,4059,,1,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Autocuration,0,,22224
,CHEMBL626569,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9046,,5124,,1,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626570,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9047,,5124,,1,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626571,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9048,,5124,,1,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626572,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9049,,429,,1,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626573,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Plasma,9050,1969.0,4059,,1,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Autocuration,0,,22224
Microsomes,CHEMBL626574,9986.0,U,BAO_0000251,Oryctolagus cuniculus,,,Liver,9051,2107.0,9659,,1,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,,,Autocuration,0,,22224
Microsomes,CHEMBL626575,9986.0,U,BAO_0000251,Oryctolagus cuniculus,,,Liver,9052,2107.0,9659,,1,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,,,Autocuration,0,,22224
,CHEMBL626576,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9053,,3639,,1,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,,,Autocuration,0,,22224
,CHEMBL626577,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9054,,3639,,1,,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,,,Autocuration,0,,22224
,CHEMBL626578,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9055,,3639,,1,,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,In vivo,,Autocuration,0,,22224
,CHEMBL625263,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9056,,5124,,1,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625264,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9057,,5124,,1,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625265,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9058,,5124,,1,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Autocuration,0,,22224
Microsomes,CHEMBL625266,9986.0,U,BAO_0000251,Oryctolagus cuniculus,,,,9059,,14294,,1,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,,,Autocuration,0,,22224
Microsomes,CHEMBL876796,9986.0,U,BAO_0000251,Oryctolagus cuniculus,,,,9060,,14294,,1,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,,,Autocuration,0,,22224
,CHEMBL625267,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9061,,429,,1,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625268,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Plasma,9062,1969.0,5124,,1,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625269,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Plasma,9063,1969.0,5124,,1,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL624689,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Plasma,9064,1969.0,5124,,1,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL624690,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9065,,429,,1,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL624691,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Urine,9066,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,,,Autocuration,0,,22224
,CHEMBL624692,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Urine,9067,1088.0,429,,1,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,,,Autocuration,0,,22224
,CHEMBL624693,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9068,,4059,,1,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Autocuration,0,,22224
,CHEMBL624694,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9069,,4137,,1,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL877596,9986.0,U,BAO_0000221,Oryctolagus cuniculus,,,,9070,,11672,,1,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,In vitro,,Autocuration,0,,22224
,CHEMBL624695,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,9071,,12886,,1,,Time within which only 10% of the drug was degraded,A,,,Autocuration,0,,22224
,CHEMBL624696,9986.0,U,BAO_0000221,Oryctolagus cuniculus,,,Liver,9072,2107.0,3853,,1,,Half life period in rabbit liver homogenate,A,,,Autocuration,0,,22224
,CHEMBL624697,9986.0,U,BAO_0000019,Oryctolagus cuniculus,,,,9073,,3615,,1,,Half life value in rabbits,A,,,Autocuration,0,,22224
,CHEMBL624698,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Blood,9074,178.0,6253,,1,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Autocuration,0,,22224
,CHEMBL624699,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,Blood,9075,178.0,6253,,1,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Autocuration,0,,22224
,CHEMBL624700,9986.0,U,BAO_0000218,Oryctolagus cuniculus,,,,9076,,6077,,1,,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL622903,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9077,1969.0,17617,,1,,AUC 0-8 hr value in rats at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622904,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9078,1969.0,17594,,1,,AUC after administration at 2000 mg/kg/day in rats,A,,,Intermediate,1,,50597
,CHEMBL622905,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9079,1969.0,6149,,1,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,,,Intermediate,1,,50597
,CHEMBL622906,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9080,1969.0,17260,,1,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,,,Intermediate,1,,50597
,CHEMBL622907,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9081,1969.0,17260,,1,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,,,Intermediate,1,,50597
,CHEMBL622908,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9082,1969.0,6644,,1,,AUC in rat after oral administration at 10.5 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL622909,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9083,1969.0,6644,,1,,AUC in rat after oral administration at 11.2 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL622910,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9084,1969.0,6644,,1,,AUC in rat after oral administration at 9.7 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL622911,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9085,955.0,6495,,1,,AUC in rat brain after oral administration at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622912,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9086,1969.0,6504,,1,,AUC in rat p.o.,A,,,Intermediate,1,,50597
,CHEMBL622913,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9087,1969.0,17686,,1,,AUC in rat p.o. at 20 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL622914,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9088,1969.0,6495,,1,,AUC in rat plasma after oral administration at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622915,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9089,1969.0,216,,1,,AUC in rats,A,,,Intermediate,1,,50597
,CHEMBL622916,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9090,1969.0,1908,,1,,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,,,Intermediate,1,,50597
,CHEMBL622917,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9091,1969.0,1908,,1,,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,,,Intermediate,1,,50597
,CHEMBL622918,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9092,1969.0,6685,,1,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL622919,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9093,1969.0,216,,1,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,In vivo,,Intermediate,1,,50597
,CHEMBL622920,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9094,1969.0,6049,,1,,Maximum plasma concentration was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622921,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9095,1969.0,2463,,1,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622922,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9096,1969.0,6679,,1,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622923,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9097,1969.0,6681,,1,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL877604,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9098,1969.0,4890,,1,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622924,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9099,1969.0,6410,,1,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622925,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9100,1969.0,6410,,1,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622926,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9101,1969.0,16366,,1,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL623625,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9102,1969.0,6227,,1,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623626,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9103,1969.0,3598,,1,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL623627,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9104,1969.0,1465,,1,,Maximum plasma drug concentration was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623628,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9105,,4368,,1,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623629,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9106,1969.0,15662,,1,,Mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623630,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9107,1969.0,15662,,1,,Mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623804,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9108,,5355,,1,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623805,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9109,,5355,,1,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623806,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9110,1969.0,1567,,1,,Peak oral plasma concentration was determined in rats by oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623807,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9111,1969.0,4026,,1,,Peak plasma concentration (Cmax) was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623808,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9112,1969.0,6193,,1,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623809,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9113,1969.0,4026,,1,,Peak plasma concentration (Cmax) in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623810,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9114,1969.0,6485,,1,,Peak plasma concentration at 1 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623811,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9115,1969.0,17655,,1,,Peak plasma concentration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623812,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9116,1969.0,14941,,1,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Intermediate,1,,50597
,CHEMBL877605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9117,,5394,,1,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623813,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9118,,4408,,1,,Pharmacokinetic property (Cmax) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9119,,5983,,1,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9120,,4878,,1,,Cmax in rat after 3mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9121,,5862,Sprague-Dawley,1,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623145,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9122,,4517,,1,,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623146,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9123,1969.0,5932,,1,,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623147,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9124,1969.0,5436,,1,,Plasma concentration after oral administration of 100 mg/kg to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623042,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9125,955.0,4910,,1,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623043,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9126,,4950,,1,,Tested for the Cmax in rat at 10 mg/kg per orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL623044,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9127,,15078,,1,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL623045,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9128,,15078,,1,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL623046,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9129,,3360,,1,,Bioavailability as oral Cmax in rats at 30 mins,A,In vivo,,Intermediate,1,,50597
,CHEMBL623226,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9130,,3360,,1,,Bioavailability as oral Cmax in rats at 6hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL623227,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9131,,15022,,1,,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623228,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9132,,15022,,1,,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623229,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9133,,15022,,1,,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623230,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9134,1969.0,5160,,1,,The maximum plasma levels for the compounds were determined by LC-MS.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623231,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9135,1969.0,15662,,1,,mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623232,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9136,1969.0,15662,,1,,mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623233,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9137,,4709,,1,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL623234,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9138,,3535,,1,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,,,Intermediate,1,,50597
,CHEMBL623235,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9139,,3535,,1,,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,,,Intermediate,1,,50597
,CHEMBL623236,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9140,,3535,,1,,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,,,Intermediate,1,,50597
,CHEMBL623237,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9141,,3535,,1,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,,,Intermediate,1,,50597
,CHEMBL623238,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9142,,3535,,1,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,,,Intermediate,1,,50597
,CHEMBL623239,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9143,,3535,,1,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,,,Intermediate,1,,50597
,CHEMBL623240,10116.0,U,BAO_0000218,Rattus norvegicus,,,Plasma,9144,1969.0,5005,,1,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,In vivo,,Intermediate,0,,22224
,CHEMBL623241,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,9145,1898.0,6326,,1,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,,,Intermediate,1,,50597
,CHEMBL623242,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,9146,1898.0,6326,,1,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,,,Intermediate,1,,50597
,CHEMBL874394,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9147,,6326,,1,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,,,Intermediate,1,,50597
,CHEMBL623243,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9148,,6326,,1,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,,,Intermediate,1,,50597
,CHEMBL623244,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9149,,17411,,1,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL623245,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9150,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623246,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9151,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623247,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9152,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623248,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9153,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623249,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9154,2113.0,16435,,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL625072,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9155,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625073,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9156,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL625074,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9157,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL625075,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9158,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL625076,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9159,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625077,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9160,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL625078,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9161,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL874395,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9162,2107.0,16434,,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL625079,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9163,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625080,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9164,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL625081,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9165,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL625082,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9166,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL625083,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9167,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL625084,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9168,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL625085,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9169,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL625086,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9170,2107.0,16435,,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625087,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9171,2107.0,16434,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL625088,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9172,2107.0,16434,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9173,2107.0,16434,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9174,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622207,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9175,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622366,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9176,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622367,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9177,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL875331,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9178,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622368,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9179,2107.0,16435,,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622369,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9180,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622370,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9181,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622371,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9182,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622372,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9183,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622373,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9184,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622374,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9185,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622375,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9186,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622376,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9187,2048.0,16434,,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622377,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9188,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622378,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9189,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622379,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9190,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622380,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9191,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622381,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9192,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622382,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9193,2048.0,16435,,1,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622383,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9194,2048.0,16434,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL875332,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9195,945.0,6175,,1,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL622384,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9196,945.0,6175,,1,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL622385,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9197,945.0,6175,,1,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL622386,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9198,945.0,6175,,1,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Intermediate,1,,50597
,CHEMBL622387,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9199,,10839,,1,,The compound was tested for the plasma binding in rat,A,,,Intermediate,1,,50597
,CHEMBL622388,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9200,,16459,,1,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,,,Intermediate,1,,50597
,CHEMBL622389,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9201,,16459,,1,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,,,Intermediate,1,,50597
,CHEMBL622390,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9202,,16459,,1,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,,,Intermediate,1,,50597
,CHEMBL622391,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9203,,16459,,1,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,,,Intermediate,1,,50597
,CHEMBL622392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9204,,16459,,1,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,,,Intermediate,1,,50597
,CHEMBL622393,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9205,,16459,,1,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,,,Intermediate,1,,50597
,CHEMBL622394,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9206,,3278,,1,,Plasma level at 2 hr after administration of the compound,A,,,Intermediate,1,,50597
,CHEMBL622395,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9207,,3278,,1,,plasma level at 2 hr after administration of the compound,A,,,Intermediate,1,,50597
,CHEMBL622396,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9208,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 1 min,A,,,Intermediate,1,,50597
,CHEMBL624894,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9209,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 10 min,A,,,Intermediate,1,,50597
,CHEMBL624895,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9210,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 10 mins,A,,,Intermediate,1,,50597
,CHEMBL624058,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9211,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 2 hr,A,,,Intermediate,1,,50597
,CHEMBL624059,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9212,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 3 min,A,,,Intermediate,1,,50597
,CHEMBL624060,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9213,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 3 mins,A,,,Intermediate,1,,50597
,CHEMBL624061,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9214,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 5 min,A,,,Intermediate,1,,50597
,CHEMBL624062,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9215,1977.0,4684,,1,,Stability in rat serum measured as % recovery at 5 mins,A,,,Intermediate,1,,50597
,CHEMBL624063,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9216,,16456,,1,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624064,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9217,,16456,,1,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624065,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9218,1969.0,723,,1,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,,,Intermediate,1,,50597
,CHEMBL624066,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9219,1969.0,723,,1,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,,,Intermediate,1,,50597
,CHEMBL877490,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9220,,5160,,1,,Half life tested in mature male rat at a dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL874442,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9221,,4709,,1,,Half life after intravenous administration of 1 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626890,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9222,,5633,,1,,Half life period after administration (30 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626891,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9223,,5302,,1,,Half life period in rat after 5 mg/Kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626892,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9224,,5302,,1,,Half life period in rat after 5 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626893,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9225,,17791,,1,,Half life period was determined,A,,,Intermediate,1,,50597
,CHEMBL626894,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9226,,17791,,1,,Half life period was evaluated in rat,A,,,Intermediate,1,,50597
,CHEMBL626895,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9227,,17791,,1,,Half life period was evaluated in rat; 0.5-1.0,A,,,Intermediate,1,,50597
,CHEMBL626896,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9228,,17791,,1,,Half life period was evaluated in rat; 5.9-7.5,A,,,Intermediate,1,,50597
,CHEMBL626897,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9229,1969.0,14512,,1,,Half-life in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL626898,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9230,,6230,,1,,Half-life time in rat was determined,A,,,Intermediate,1,,50597
,CHEMBL626899,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9231,,3364,,1,,Terminal half-life after iv administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626900,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9232,,6874,,1,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626901,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9233,,857,,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626902,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9234,,858,,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,In vivo,,Intermediate,1,,50597
,CHEMBL626903,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9235,,858,,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,In vivo,,Intermediate,1,,50597
,CHEMBL874443,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9236,,5355,,1,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626904,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9237,,5355,,1,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626905,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9238,,6305,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL873830,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9239,1969.0,13501,,1,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626906,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9240,,17594,,1,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL631076,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9241,1969.0,4186,,1,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Intermediate,1,,50597
,CHEMBL631077,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9242,1969.0,2932,,1,,Biological half-life was measured in plasma of rats,A,,,Intermediate,1,,50597
,CHEMBL631078,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9243,,17065,,1,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL631079,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9244,,15765,,1,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL631080,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9245,,2713,,1,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL631081,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9246,,2661,,1,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL631239,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9247,,2661,,1,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL631240,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9248,1969.0,740,,1,,Compound was evaluated for plasma half life in rat,A,,,Intermediate,1,,50597
,CHEMBL631241,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9249,1969.0,6597,,1,,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,,,Intermediate,1,,50597
,CHEMBL631242,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9250,1969.0,2959,,1,,AUC value after administration of 20 mg/Kg oral dose in rat,A,,,Intermediate,1,,50597
,CHEMBL631243,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9251,1969.0,17594,,1,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL874444,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9252,1969.0,17596,,1,,AUC0-96 after administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631244,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9253,1969.0,17594,,1,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL631245,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9254,,3293,,1,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,,,Intermediate,1,,50597
,CHEMBL627162,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9255,,6757,,1,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,,,Intermediate,1,,50597
,CHEMBL627163,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9256,,6757,,1,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,,,Intermediate,1,,50597
,CHEMBL627164,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9257,,6757,,1,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,,,Intermediate,1,,50597
,CHEMBL627165,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9258,2113.0,5979,,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,,,Intermediate,1,,50597
,CHEMBL627166,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9259,,5979,,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,,,Intermediate,1,,50597
,CHEMBL627167,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9260,,5979,,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,,,Intermediate,1,,50597
,CHEMBL627822,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9261,,4026,,1,,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL627823,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9262,,5355,,1,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL627824,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9263,,5355,,1,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL627825,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9264,,5355,,1,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL627826,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9265,,5633,,1,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,,,Intermediate,1,,50597
,CHEMBL627827,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9266,,1716,,1,,Area under curve (Pharmacokinetic property) was determined,A,,,Intermediate,1,,50597
,CHEMBL627828,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9267,,1716,,1,,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,,,Intermediate,1,,50597
,CHEMBL627829,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9268,,4689,,1,,Area under curve after intravenous administration (1 mg/kg) in rat,A,,,Intermediate,1,,50597
,CHEMBL627830,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9269,,4527,,1,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,,,Intermediate,1,,50597
,CHEMBL627831,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9270,,4527,,1,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,,,Intermediate,1,,50597
,CHEMBL627832,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9271,,15662,,1,,Area under curve in male SD rats was observed after oral administration in rat,A,,,Intermediate,1,,50597
,CHEMBL627833,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9272,,4413,,1,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,,,Intermediate,1,,50597
,CHEMBL627834,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9273,,3598,,1,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50597
,CHEMBL628004,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9274,,3598,,1,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,,,Expert,1,,50597
,CHEMBL628005,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9275,,5964,,1,,Area under curve at 5 mg/kg po was determined in rat,A,,,Intermediate,1,,50597
,CHEMBL628006,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9276,,4689,,1,,Area under curve in Rat at a oral dose of 5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL628007,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9277,,4186,,1,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,,Intermediate,1,,50597
,CHEMBL625676,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9278,,5510,,1,,Area under curve was determined,A,,,Intermediate,1,,50597
,CHEMBL631309,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9279,,17858,,1,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,,,Intermediate,1,,50597
,CHEMBL631310,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9280,,17804,,1,,Area under curve after intravenous administration at 3 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631311,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9281,,6106,,1,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,,,Intermediate,1,,50597
,CHEMBL631312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9282,,5964,,1,,Area under curve at 4 hr in rat,A,,,Intermediate,1,,50597
,CHEMBL631313,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9283,,4026,,1,,Area under curve at a dose of 30 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631314,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9284,,4756,,1,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,,,Intermediate,1,,50597
,CHEMBL631315,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9285,,4756,,1,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,,,Intermediate,1,,50597
,CHEMBL631316,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9286,,5862,,1,,Area under curve for a 2-mpk po dose in SD rats,A,,,Intermediate,1,,50597
,CHEMBL631317,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9287,,5862,,1,,Area under curve in SD rats,A,,,Intermediate,1,,50597
,CHEMBL874471,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9288,,6644,,1,,Area under curve in rat after oral administration at 13 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL631318,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9289,,5871,,1,,Area under curve in rat by po administration at 0-24 hr,A,,,Intermediate,1,,50597
,CHEMBL631319,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9290,1969.0,5919,,1,,Area under curve in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL631320,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9291,,5939,,1,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631321,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9292,,5939,,1,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631322,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9293,,10,,1,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,,,Intermediate,1,,50597
,CHEMBL631323,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9294,,11149,,1,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,,,Intermediate,1,,50597
,CHEMBL631324,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9295,,5302,,1,,Area under curve value in rat at a dose of 5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL631325,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9296,,17796,,1,,Area under curve was determined after oral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL631326,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9297,,4890,,1,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL631327,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9298,,6011,,1,,Area under curve was determined after peroral administration in rat,A,,,Intermediate,1,,50597
,CHEMBL631328,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9299,,5375,,1,,Area under curve was determined at a dose 30 mpk administered orally.,A,,,Intermediate,1,,50597
,CHEMBL631329,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9300,,17764,,1,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,,,Intermediate,1,,50597
,CHEMBL627217,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9301,,4368,,1,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL626352,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9302,,5610,,1,,Area under curve was determined in male rat,A,,,Intermediate,1,,50597
,CHEMBL626353,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9303,,5833,,1,,Area under curve was determined in rat after PO administration,A,,,Intermediate,1,,50597
,CHEMBL626354,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9304,,4257,,1,,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,,,Intermediate,1,,50597
,CHEMBL626355,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9305,,5937,,1,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626356,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9306,,5932,,1,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626357,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9307,,5932,,1,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,,,Intermediate,1,,50597
,CHEMBL626358,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9308,,17411,,1,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626359,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9309,,17411,,1,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626360,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9310,1969.0,17771,,1,,Peak plasma concentration in rat at a dose of 3 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626361,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9311,,1628,,1,,Plasma concentration at 2 hr in rats was evaluated.,A,,,Intermediate,1,,50597
,CHEMBL626362,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9312,,1628,,1,,Plasma concentration at 2 hr in rats was evaluated; Not available,A,,,Intermediate,1,,50597
,CHEMBL626363,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9313,,17411,,1,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626970,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9314,,4910,,1,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL626971,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9315,,4910,,1,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL626972,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9316,1969.0,4910,,1,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL626973,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9317,1969.0,4910,,1,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL626974,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9318,1969.0,4910,,1,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL874592,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9319,1969.0,4910,,1,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL626975,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9320,,5510,,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,,,Intermediate,1,,50597
,CHEMBL626976,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9321,,5510,,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,,,Intermediate,1,,50597
,CHEMBL626977,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9322,,5510,,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,,,Intermediate,1,,50597
,CHEMBL626978,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9323,,5510,,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,,,Intermediate,1,,50597
,CHEMBL626979,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9324,,16427,,1,,PK study was carried to determine the relative absorption ranking in rat.,A,,,Intermediate,1,,50597
,CHEMBL626980,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9325,1969.0,4689,,1,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626981,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9326,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL626982,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9327,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL626983,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9328,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622522,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9329,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,,,Intermediate,1,,50597
,CHEMBL622523,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9330,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622524,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9331,178.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622525,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9332,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622526,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9333,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL619849,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9334,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL619850,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9335,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623864,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9336,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623865,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9337,955.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623866,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9338,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623867,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9339,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL877615,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9340,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623868,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9341,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623869,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9342,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623870,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9343,948.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL623871,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9344,2048.0,16434,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623872,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9345,2048.0,16434,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622129,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9346,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622130,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9347,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622131,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9348,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622132,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9349,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622133,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9350,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622134,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9351,2048.0,16435,,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622135,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9352,2048.0,16435,,1,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622136,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9353,2048.0,16435,,1,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622137,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9354,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622138,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9355,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623017,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9356,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL623018,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9357,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL623019,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9358,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL623020,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9359,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623021,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9360,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL623022,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9361,2385.0,16434,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL623023,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9362,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL623024,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9363,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623025,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9364,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL620545,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9365,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL620546,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9366,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL620547,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9367,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL620548,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9368,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL620549,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9369,2385.0,16435,,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL620550,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9370,2385.0,16434,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL620551,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9371,2385.0,16434,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL620552,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9372,2385.0,16434,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL620553,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9373,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL620554,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9374,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL875845,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9375,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL620555,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9376,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL620556,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9377,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL620557,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9378,2385.0,16435,,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL620558,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9379,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL620559,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9380,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622939,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9381,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622940,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9382,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622941,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9383,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622942,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9384,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622943,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9385,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622944,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9386,,16434,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622945,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9387,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9388,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622947,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9389,,3341,,1,,Compound was evaluated for terminal half life in rat,A,,,Intermediate,1,,50597
,CHEMBL622948,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9390,1969.0,3634,,1,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,In vivo,,Intermediate,1,,50597
,CHEMBL622949,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9391,1969.0,3634,,1,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,In vivo,,Intermediate,1,,50597
,CHEMBL622950,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9392,,4839,,1,,Compound was tested for its half life in rat,A,,,Intermediate,1,,50597
,CHEMBL622951,9544.0,U,BAO_0000218,Macaca mulatta,,,Plasma,9393,1969.0,5005,,1,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Intermediate,0,,22224
,CHEMBL622952,10116.0,U,BAO_0000366,Rattus norvegicus,,,Plasma,9394,1969.0,5005,,1,,Compound was tested for its plasma half life in Sprague Dawley rats,A,,,Intermediate,0,,22224
,CHEMBL622953,10116.0,U,BAO_0000366,Rattus norvegicus,,,Plasma,9395,1969.0,5005,,1,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,,,Intermediate,0,,22224
,CHEMBL873818,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9396,1969.0,1094,,1,,Compound was tested for plasma half-life period in rat,A,,,Intermediate,1,,50597
,CHEMBL622954,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9397,,5031,,1,,Elimination half life after i.v. administration of compound in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622955,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9398,,6518,,1,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL875229,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9399,,6518,,1,,Elimination half-life after IV dosing at 1 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622956,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9400,,6518,,1,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622957,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9401,,6518,,1,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622958,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9402,955.0,5408,,1,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622959,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9403,1969.0,5408,,1,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Intermediate,1,,50597
,CHEMBL622960,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9404,955.0,5408,,1,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,In vivo,,Intermediate,1,,50597
,CHEMBL622961,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9405,1969.0,5408,,1,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Intermediate,1,,50597
,CHEMBL622962,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9406,,4687,,1,,Evaluated for the half life in rat (in vivo),A,In vivo,,Intermediate,1,,50597
,CHEMBL622963,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9407,,6640,,1,,Hafl life in rat,A,,,Intermediate,1,,50597
,CHEMBL622964,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9408,,6640,,1,,Hafl life rat,A,,,Intermediate,1,,50597
,CHEMBL622965,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9409,,6641,,1,,Hafl life rat,A,,,Intermediate,1,,50597
,CHEMBL622966,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9410,,6640,,1,,Hafl life rat; Not determined,A,,,Intermediate,1,,50597
,CHEMBL622967,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9411,,6641,,1,,Hafl life rat; Not determined,A,,,Intermediate,1,,50597
,CHEMBL622968,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9412,2113.0,17411,,1,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622969,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9413,2107.0,17411,,1,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL875327,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9414,2048.0,17411,,1,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL628638,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9415,,6570,,1,,Half life in rat after 1 mg/kg i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL628639,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9416,,6570,,1,,Half life in rat after 2 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625840,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9417,,17411,,1,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625841,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9418,,4722,,1,,Half life of 10 mg/kg oral dose determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625842,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9419,,5978,,1,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625843,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9420,,5978,,1,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625844,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9421,,5978,,1,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL873822,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9422,,5978,,1,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9423,,5978,,1,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9424,,5978,,1,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9425,,5978,,1,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627061,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9426,,5978,,1,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627709,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9427,,4762,,1,,Half life of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627710,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9428,,5327,,1,,Half life of compound determined after intravenous administration to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627711,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9429,,4847,,1,,Half life of compound was determined in rat,A,,,Intermediate,1,,50597
,CHEMBL627712,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9430,1969.0,17720,,1,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627713,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9431,,4723,,1,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627714,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9432,,4723,,1,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627889,9541.0,U,BAO_0000218,Macaca fascicularis,,,,9433,,4256,,1,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Intermediate,0,,22224
,CHEMBL627890,10116.0,U,BAO_0000218,Rattus norvegicus,,,,9434,,4256,,1,,Half life determined in rat by intravenous administration,A,In vivo,,Intermediate,0,,22224
,CHEMBL627891,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9435,,4722,,1,,Half life determined in rats after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627892,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9436,1969.0,6535,,1,,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL627893,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9437,1969.0,6535,,1,,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Intermediate,1,,50597
,CHEMBL627894,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9438,1969.0,1435,,1,,Half life in rat plasma was determined,A,,,Intermediate,1,,50597
,CHEMBL627895,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9439,1969.0,1435,,1,,Half life in rat plasma was determined; NA means not applicable,A,,,Intermediate,1,,50597
,CHEMBL627896,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9440,,5206,,1,,Half life in rat was tested,A,,,Intermediate,1,,50597
,CHEMBL627897,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9441,1969.0,6080,,1,,Half life measured in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL627898,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9442,,4449,,1,,Half life recorded in rats,A,,,Intermediate,1,,50597
,CHEMBL627899,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9443,,6057,,1,,Half life was calculated,A,,,Intermediate,1,,50597
,CHEMBL873823,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9444,,6057,,1,,Half life was calculated in rat,A,,,Intermediate,1,,50597
,CHEMBL627900,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9445,,3747,,1,,Half life was determined,A,,,Intermediate,1,,50597
,CHEMBL627901,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9446,,17858,,1,,Half life after 10 mg/kg oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627902,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9447,,16365,,1,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627903,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9448,,16365,,1,,Half life after administering orally a dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627904,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9449,,5031,,1,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,,,Intermediate,1,,50597
,CHEMBL627905,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9450,,4722,,1,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,,,Intermediate,1,,50597
,CHEMBL627906,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9451,,6078,,1,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL627907,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9452,,6078,,1,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL876783,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9453,,6078,,1,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL627908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9454,,6078,,1,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,,,Intermediate,1,,50597
,CHEMBL627909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9455,,17065,,1,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,,,Intermediate,1,,50597
,CHEMBL627910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9456,,1353,,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,,,Intermediate,1,,50597
,CHEMBL627911,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9457,,1353,,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,,,Intermediate,1,,50597
,CHEMBL627912,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9458,,1353,,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,,,Intermediate,1,,50597
,CHEMBL627913,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9459,,1353,,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,,,Intermediate,1,,50597
,CHEMBL627914,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9460,,1353,,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,,,Intermediate,1,,50597
,CHEMBL627915,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9461,,16423,,1,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,,,Intermediate,1,,50597
,CHEMBL627916,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9462,,16423,,1,,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,,,Intermediate,1,,50597
,CHEMBL627917,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9463,,6062,,1,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL627918,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9464,,6056,,1,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL627919,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9465,,5182,,1,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,,,Intermediate,1,,50597
,CHEMBL627920,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9466,,6410,,1,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL627921,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9467,,6410,,1,,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL627922,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9468,,4723,,1,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL876784,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9469,,4723,,1,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL627923,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9470,,4723,,1,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL626208,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9471,,4723,,1,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL626209,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9472,,4723,,1,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL626210,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9473,,4723,,1,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Intermediate,1,,50597
,CHEMBL627994,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9474,1969.0,2463,,1,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,,,Intermediate,1,,50597
,CHEMBL627995,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9475,,4709,,1,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL627996,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9476,,4075,,1,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,,,Intermediate,1,,50597
,CHEMBL627997,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9477,,5394,,1,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,,,Intermediate,1,,50597
,CHEMBL627998,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9478,,2661,,1,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,,,Intermediate,1,,50597
,CHEMBL628640,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9479,,2661,,1,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,,,Intermediate,1,,50597
,CHEMBL628641,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9480,,2661,,1,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,,,Intermediate,1,,50597
,CHEMBL628642,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9481,,2661,,1,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,,,Intermediate,1,,50597
,CHEMBL628643,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9482,,17791,,1,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Intermediate,1,,50597
,CHEMBL628644,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9483,,2591,,1,,Compound was tested for area under curve in rat,A,,,Intermediate,1,,50597
,CHEMBL628645,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9484,,6567,,1,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,,,Intermediate,1,,50597
,CHEMBL628646,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9485,,6211,,1,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628647,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9486,,5529,,1,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,,,Intermediate,1,,50597
,CHEMBL628648,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9487,,5408,,1,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,,,Intermediate,1,,50597
,CHEMBL625358,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9488,,5408,,1,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,,,Intermediate,1,,50597
,CHEMBL625359,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9489,,5408,,1,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,,,Intermediate,1,,50597
,CHEMBL625360,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9490,,5408,,1,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,,,Intermediate,1,,50597
,CHEMBL625361,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9491,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,,,Intermediate,1,,50597
,CHEMBL625362,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9492,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,,,Intermediate,1,,50597
,CHEMBL625363,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9493,,429,,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,,,Intermediate,1,,50597
,CHEMBL625364,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9494,,4796,,1,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Intermediate,1,,50597
,CHEMBL625365,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9495,,5974,,1,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL625366,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9496,,5974,,1,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL625367,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9497,,5974,,1,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL625368,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9498,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625369,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9499,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625370,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9500,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625371,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9501,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625372,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9502,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625373,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9503,2113.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625374,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9504,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL877593,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9505,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625375,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9506,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL625376,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9507,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL621973,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9508,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL621974,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9509,2107.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL621975,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9510,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622166,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9511,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622167,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9512,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622168,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9513,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,,,Intermediate,1,,50597
,CHEMBL622169,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9514,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622170,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9515,2048.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9516,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9517,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622173,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9518,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622174,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9519,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622175,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9520,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622176,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9521,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622177,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9522,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622178,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9523,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622179,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9524,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622180,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9525,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622181,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9526,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622182,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9527,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622183,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9528,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622184,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9529,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622185,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9530,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622186,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9531,,16435,,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622187,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9532,,16434,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL625002,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9533,,16434,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622090,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9534,,16434,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622091,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9535,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622092,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9536,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622093,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9537,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622094,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9538,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622095,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9539,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL622264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9540,,16435,,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL622265,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9541,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9542,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9543,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622268,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9544,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622269,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9545,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL625071,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9546,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621621,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9547,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621622,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9548,2106.0,16434,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621623,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9549,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621624,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9550,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL621625,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9551,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621626,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9552,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621627,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9553,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL621628,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9554,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL875328,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9555,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL621629,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9556,2106.0,16435,,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL621630,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9557,2106.0,16434,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL621631,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9558,2106.0,16434,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL621632,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9559,2106.0,16434,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL621633,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9560,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL621634,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9561,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL621635,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9562,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL621636,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9563,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL621637,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9564,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL621638,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9565,2106.0,16435,,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL618883,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9566,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL618884,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9567,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL628627,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9568,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL628628,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9569,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL628629,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9570,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL628630,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9571,,16365,,1,,Half life after administering orally a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL628631,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9572,,16365,,1,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL628632,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9573,,16365,,1,,Half life after administering intravenously a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL628633,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9574,,526,,1,,Half life after oral dosing in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL628634,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9575,,16365,,1,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627789,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9576,,4368,,1,,Half life by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627790,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9577,,3371,,1,,Half life in rat,A,,,Intermediate,1,,50597
,CHEMBL627791,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9578,,6448,,1,,Half life in rat,A,,,Intermediate,1,,50597
,CHEMBL627792,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9579,,6453,,1,,Half life in rat,A,,,Intermediate,1,,50597
,CHEMBL627793,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9580,,4353,,1,,Half life in rat after intravenous administration of the compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL627794,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9581,1969.0,4353,,1,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Intermediate,1,,50597
,CHEMBL627795,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9582,,4353,,1,,Half life in rat after po administration of the compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL627796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9583,,4353,,1,,Half life in rat after po administration of the compound; ND means Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL875335,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9584,1969.0,4353,,1,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,In vivo,,Intermediate,1,,50597
,CHEMBL627797,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9585,1969.0,4353,,1,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Intermediate,1,,50597
,CHEMBL627798,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9586,,5789,,1,,Half life in rat i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627799,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9587,,17686,,1,,Half life in rat i.v. at 2 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627800,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9588,,6495,,1,,Half life in rats,A,,,Intermediate,1,,50597
,CHEMBL627801,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9589,,484,,1,,Half life in rats after intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627802,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9590,,6467,,1,,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627803,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9591,,6642,,1,,Half life in rat,A,,,Expert,1,,50597
,CHEMBL873820,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9592,,16367,,1,,Half life was evaluated after intravenous administration to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627804,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9593,,1369,,1,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,,,Intermediate,1,,50597
,CHEMBL627805,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9594,,5472,,1,,Half life was evaluated in rat,A,,,Intermediate,1,,50597
,CHEMBL627806,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9595,,6049,,1,,Half life was evaluated in rat,A,,,Intermediate,1,,50597
,CHEMBL627107,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9596,,5472,,1,,Half life was evaluated in rat; Not tested,A,,,Intermediate,1,,50597
,CHEMBL627108,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9597,,16366,,1,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627109,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9598,,11149,,1,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627110,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9599,178.0,11149,,1,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627111,9443.0,U,BAO_0000218,Primates,,,,9600,,2891,,1,,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Intermediate,0,,22224
,CHEMBL627112,9443.0,U,BAO_0000218,Primates,,,,9601,,2891,,1,,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Intermediate,0,,22224
,CHEMBL627113,10116.0,U,BAO_0000218,Rattus norvegicus,,,,9602,,2891,,1,,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,In vivo,,Intermediate,0,,22224
,CHEMBL627114,10116.0,U,BAO_0000218,Rattus norvegicus,,,,9603,,2891,,1,,Half life was measured in rat at dose of 30 mg/kg by po administration,A,In vivo,,Intermediate,0,,22224
,CHEMBL627115,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9604,,4026,,1,,Half life (t1/2) was determined,A,,,Intermediate,1,,50597
,CHEMBL627116,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9605,,4527,,1,,Half life period at a dose of 10 uM/kg in rat was determined,A,,,Intermediate,1,,50597
,CHEMBL627117,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9606,,4527,,1,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL627118,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9607,,5503,,1,,Half life period was determined,A,,,Intermediate,1,,50597
,CHEMBL627119,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9608,,4426,,1,,Half life period after intravenous administration at 20 mpk in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627120,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9609,,4426,,1,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626922,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9610,,6109,,1,,Half life period after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626923,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9611,,5654,,1,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626924,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9612,,5654,,1,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626925,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9613,1969.0,4755,,1,,Half life period in 80% rat plasma at 37 degree Centigrade,A,,,Intermediate,1,,50597
,CHEMBL626926,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9614,,5862,,1,,Half life period in SD rats,A,,,Intermediate,1,,50597
,CHEMBL626927,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9615,1969.0,1515,,1,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,,,Intermediate,1,,50597
,CHEMBL626928,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9616,1969.0,1515,,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,,,Intermediate,1,,50597
,CHEMBL626929,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9617,1969.0,1515,,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Intermediate,1,,50597
,CHEMBL626930,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9618,1969.0,1515,,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Intermediate,1,,50597
,CHEMBL626931,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9619,,5960,,1,,Half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL626932,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9620,,6103,,1,,Half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL626933,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9621,,6317,,1,,Half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL873826,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9622,,6644,,1,,Half life period in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626934,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9623,,6644,,1,,Half life period in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626935,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9624,,6644,,1,,Half life period in rat after oral administration at 13 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626936,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9625,,6644,,1,,Half life period in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626937,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9626,,5974,,1,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL625906,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9627,,6295,,1,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL625907,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9628,,6296,,1,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL625908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9629,,16427,,1,,PK study was carried to determine AUC (area under curve) value in rat,A,,,Intermediate,1,,50597
,CHEMBL625909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9630,,16367,,1,,Pharmacokinetic parameter AUC after intravenous administration to rats,A,,,Intermediate,1,,50597
,CHEMBL625910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9631,,16367,,1,,Pharmacokinetic parameter AUC after oral administration to rats,A,,,Intermediate,1,,50597
,CHEMBL625911,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9632,,16365,,1,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL625912,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9633,,16365,,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,,,Intermediate,1,,50597
,CHEMBL626538,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9634,,16365,,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,,,Intermediate,1,,50597
,CHEMBL876794,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9635,,16365,,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,,,Intermediate,1,,50597
,CHEMBL626539,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9636,,16365,,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,,,Intermediate,1,,50597
,CHEMBL626540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9637,,16365,,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,,,Intermediate,1,,50597
,CHEMBL626541,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9638,,5394,,1,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626542,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9639,,5394,,1,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626543,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9640,,2792,,1,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,,,Intermediate,1,,50597
,CHEMBL626544,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9641,,2792,,1,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,,,Intermediate,1,,50597
,CHEMBL626545,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9642,,2792,,1,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,,,Intermediate,1,,50597
,CHEMBL626546,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9643,,2792,,1,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,,,Intermediate,1,,50597
,CHEMBL626547,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9644,,5334,,1,,Pharmacokinetic parameter area under curve was reported,A,,,Intermediate,1,,50597
,CHEMBL626548,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9645,,4408,,1,,Pharmacokinetic property (AUC) in rat,A,,,Intermediate,1,,50597
,CHEMBL626549,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9646,,5983,,1,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,,,Intermediate,1,,50597
,CHEMBL626550,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9647,,4397,,1,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,,,Intermediate,1,,50597
,CHEMBL626551,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9648,,4397,,1,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,,,Intermediate,1,,50597
,CHEMBL623777,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9649,,5491,,1,,Pharmacokinetic property was determined,A,,,Intermediate,1,,50597
,CHEMBL623778,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9650,,5491,,1,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL623779,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9651,,5491,,1,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,,,Intermediate,1,,50597
,CHEMBL623780,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9652,1969.0,4199,,1,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622015,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9653,1969.0,4199,,1,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622016,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9654,1969.0,4199,,1,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622017,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9655,,5173,,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,,,Intermediate,1,,50597
,CHEMBL622018,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9656,,5173,,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,,,Intermediate,1,,50597
,CHEMBL622019,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9657,,5173,,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,,,Intermediate,1,,50597
,CHEMBL622020,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9658,,5173,,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,,,Intermediate,1,,50597
,CHEMBL622021,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9659,,16366,,1,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,,,Intermediate,1,,50597
,CHEMBL622022,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9660,,16366,,1,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,,,Intermediate,1,,50597
,CHEMBL622023,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9661,,5327,,1,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,,,Intermediate,1,,50597
,CHEMBL622024,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9662,,6681,,1,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL622693,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9663,,12873,,1,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,,,Intermediate,1,,50597
,CHEMBL622694,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9664,,12873,,1,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,,,Intermediate,1,,50597
,CHEMBL622695,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9665,,6685,,1,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622696,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9666,,6685,,1,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Intermediate,1,,50597
,CHEMBL622697,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9667,,6685,,1,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,,,Intermediate,1,,50597
,CHEMBL622874,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9668,,6619,,1,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,,,Intermediate,1,,50597
,CHEMBL622875,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9669,,6619,,1,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,,,Intermediate,1,,50597
,CHEMBL622876,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9670,,10363,,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Intermediate,1,,50597
,CHEMBL622877,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9671,,4796,,1,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Intermediate,1,,50597
,CHEMBL622878,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9672,,4910,,1,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL622879,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9673,1969.0,4910,,1,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL877602,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9674,,4839,,1,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,,,Intermediate,1,,50597
,CHEMBL622880,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9675,,15078,,1,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622881,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9676,,15078,,1,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622882,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9677,,15078,,1,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622883,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9678,,15078,,1,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL622884,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9679,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,,,Intermediate,1,,50597
,CHEMBL622885,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9680,2046.0,11450,,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,,,Intermediate,1,,50597
,CHEMBL622886,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9681,,8151,,1,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Intermediate,1,,50597
,CHEMBL622887,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9682,,8151,,1,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL622888,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9683,1088.0,8151,,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL622889,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9684,178.0,8677,,1,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622890,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9685,178.0,8677,,1,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9686,178.0,8677,,1,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL877603,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9687,178.0,8677,,1,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622892,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9688,955.0,8677,,1,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622893,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9689,955.0,8677,,1,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622894,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9690,955.0,8677,,1,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622895,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9691,955.0,8677,,1,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622896,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9692,955.0,8677,,1,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL622897,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9693,948.0,8677,,1,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622898,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9694,948.0,8677,,1,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622899,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9695,948.0,8677,,1,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622900,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9696,2113.0,8677,,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624114,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9697,2113.0,8677,,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624115,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9698,2113.0,8677,,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624116,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9699,2113.0,8677,,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624117,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9700,2107.0,8677,,1,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624118,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9701,2107.0,8677,,1,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624119,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9702,2107.0,8677,,1,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624120,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9703,2107.0,8677,,1,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624121,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9704,2048.0,8677,,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624122,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9705,2048.0,8677,,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624123,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9706,2048.0,8677,,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624124,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9707,2048.0,8677,,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624125,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9708,2385.0,8677,,1,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624126,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9709,2385.0,8677,,1,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624127,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9710,2385.0,8677,,1,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624128,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9711,2385.0,8677,,1,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624129,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9712,14.0,8677,,1,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624130,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9713,14.0,8677,,1,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622340,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9714,14.0,8677,,1,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622341,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,9715,14.0,8677,,1,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622342,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,9716,160.0,8677,,1,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622343,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,9717,160.0,8677,,1,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622344,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,9718,160.0,8677,,1,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622345,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,9719,160.0,8677,,1,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622346,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9720,2106.0,8677,,1,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622347,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9721,2106.0,8677,,1,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622348,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9722,2106.0,8677,,1,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622349,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9723,2106.0,8677,,1,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622350,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9724,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622351,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9725,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622352,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9726,,16434,,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622353,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9727,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622354,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9728,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622355,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9729,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL622356,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9730,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622357,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9731,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL622358,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9732,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL622359,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9733,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL874393,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9734,,16435,,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL622872,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9735,,16434,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL622873,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9736,,16434,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623047,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9737,,16434,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623048,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9738,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623049,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9739,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL623050,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9740,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL623051,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9741,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Intermediate,1,,50597
,CHEMBL623052,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9742,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL626343,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9743,,16435,,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL626344,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9744,,16434,,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Intermediate,1,,50597
,CHEMBL626345,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9745,,16434,,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Intermediate,1,,50597
,CHEMBL626346,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9746,,16434,,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Intermediate,1,,50597
,CHEMBL626347,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9747,,16434,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Intermediate,1,,50597
,CHEMBL626348,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9748,,16434,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Intermediate,1,,50597
,CHEMBL626349,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9749,,16434,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Intermediate,1,,50597
,CHEMBL626350,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9750,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,,,Intermediate,1,,50597
,CHEMBL626351,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9751,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL627650,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9752,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL627651,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9753,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,,,Intermediate,1,,50597
,CHEMBL627652,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9754,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Intermediate,1,,50597
,CHEMBL627653,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9755,,16435,,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Intermediate,1,,50597
,CHEMBL627654,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9756,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL627835,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9757,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL627836,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9758,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627837,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9759,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627838,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9760,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL875338,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9761,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL627839,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9762,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627840,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9763,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627841,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9764,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL627842,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9765,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL627843,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9766,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627844,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9767,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL627845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9768,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL627846,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9769,,5874,,1,,Half life period in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627847,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9770,1969.0,1515,,1,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,,,Intermediate,1,,50597
,CHEMBL873821,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9771,1969.0,1515,,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,,,Intermediate,1,,50597
,CHEMBL626079,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9772,1969.0,1515,,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Intermediate,1,,50597
,CHEMBL626080,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9773,1969.0,1515,,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Intermediate,1,,50597
,CHEMBL626081,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9774,1969.0,5491,,1,,Half life period was evaluated in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL875344,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9775,1969.0,5491,,1,,Half life period was evaluated in rat plasma; Not tested,A,,,Intermediate,1,,50597
,CHEMBL626082,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9776,,1918,,1,,Half life period was evaluated in rats,A,,,Intermediate,1,,50597
,CHEMBL626250,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9777,,1918,,1,,"Half life period was evaluated in rats, iv",A,In vivo,,Intermediate,1,,50597
,CHEMBL626251,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9778,,6113,,1,,Half life period after intravenous administration at 5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626252,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9779,,5546,,1,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626253,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9780,,5553,,1,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626254,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9781,1969.0,4188,,1,,Half life stability of compound was evaluated in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL626255,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9782,,6215,,1,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626256,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9783,,6141,,1,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626257,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9784,,5182,,1,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626258,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9785,,5182,,1,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,In vivo,,Intermediate,1,,50597
,CHEMBL626259,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9786,,5710,,1,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626260,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9787,,5789,,1,,Half in rat i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL875345,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9788,,6011,,1,,Half period in rat after intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626261,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9789,,17594,,1,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626262,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9790,2107.0,12357,,1,,Half-life measured in in vitro Cathepsin B assay in rat liver,A,In vitro,,Intermediate,1,,50597
,CHEMBL626263,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9791,,5210,,1,,Half-life of compound was determined in rats,A,,,Intermediate,1,,50597
,CHEMBL625270,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9792,,17596,,1,,Half-life at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625271,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9793,,6672,,1,,Half-life determined in rat,A,,,Intermediate,1,,50597
,CHEMBL625272,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9794,,6673,,1,,Half-life determined in rat,A,,,Intermediate,1,,50597
,CHEMBL625273,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9795,955.0,4910,,1,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9796,1969.0,3741,,1,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,,,Intermediate,1,,50597
,CHEMBL625275,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9797,,17671,,1,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9798,1969.0,4910,,1,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625277,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9799,1969.0,17537,,1,,Half-life in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL625278,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9800,1969.0,4965,,1,,Half-life in rat plasma was determined,A,,,Intermediate,1,,50597
,CHEMBL625279,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9801,1969.0,17537,,1,,Half-life in rat plasma; Not tested,A,,,Intermediate,1,,50597
,CHEMBL625280,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9802,1977.0,6124,,1,,Half-life in rat serum,A,,,Intermediate,1,,50597
,CHEMBL876797,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,9803,1977.0,6124,,1,,Half-life in rat serum; na is not available,A,,,Intermediate,1,,50597
,CHEMBL625281,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9804,,6078,,1,,Half-life was calculated in rat,A,,,Intermediate,1,,50597
,CHEMBL873827,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9805,1969.0,17668,,1,,Half-life was calculated in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL625282,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9806,,3185,,1,,Half-life was determined,A,,,Intermediate,1,,50597
,CHEMBL625283,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9807,,4883,,1,,Half-life was determined,A,,,Intermediate,1,,50597
,CHEMBL625284,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9808,,2959,,1,,Half-life after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625285,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9809,,4029,,1,,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625286,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9810,,4029,,1,,Half-life after intravenous administration in female rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625287,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9811,,4029,,1,,Half-life after intravenous administration in male rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625288,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9812,,6180,,1,,Half-life after intravenous dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625289,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9813,2107.0,1557,,1,,Half-life in a rat liver homogenate preparation,A,,,Intermediate,1,,50597
,CHEMBL625290,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9814,1969.0,12500,,1,,Half-life in plasma of rat,A,,,Intermediate,1,,50597
,CHEMBL876798,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9815,1969.0,12500,,1,,Half-life in plasma of rat at dose of 3-10 mgkg,A,,,Intermediate,1,,50597
,CHEMBL625291,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9816,,5064,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL625292,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9817,,5145,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL625293,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9818,,5147,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL622832,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9819,,5833,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL622833,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9820,,6596,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL622834,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9821,,17655,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL622835,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9822,,6495,,1,,Half-life in rat after oral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622836,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9823,,17538,,1,,Half-life in rat after po administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622837,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9824,,17538,,1,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622838,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9825,,10,,1,,Half-life in rat at 3 mg/kg dose administered intravenously,A,In vivo,,Intermediate,1,,50597
,CHEMBL622839,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9826,955.0,17669,,1,,Half-life in rat brain homogenate,A,,,Intermediate,1,,50597
,CHEMBL622840,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9827,1969.0,17065,,1,,Half-life in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL622841,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9828,,4333,,1,,Half-life in rats,A,,,Intermediate,1,,50597
,CHEMBL622842,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9829,,6827,,1,,Half-life in Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL622843,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9830,1969.0,889,,1,,Half-life in vitro in rat plasma,A,In vitro,,Intermediate,1,,50597
,CHEMBL622844,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9831,1969.0,889,,1,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,In vitro,,Intermediate,1,,50597
,CHEMBL622845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9832,,3747,,1,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,,,Intermediate,1,,50597
,CHEMBL622846,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9833,,15022,,1,,The area under the curve of compound was measured at the dose of 100 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL622847,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9834,,15022,,1,,The area under the curve of compound was measured at the dose of 300 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL622848,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9835,,15022,,1,,The area under the curve of compound was measured at the dose of 30 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL622849,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9836,,3360,,1,,Bioavailability as oral AUC in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622850,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9837,1969.0,5334,,1,,The plasma concentration versus time curve (AUC) was determined,A,,,Intermediate,1,,50597
,CHEMBL876807,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9838,,17411,,1,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622851,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9839,,17411,,1,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622852,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9840,,17411,,1,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622853,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9841,,6570,,1,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,,,Intermediate,1,,50597
,CHEMBL622854,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9842,,6570,,1,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,,,Intermediate,1,,50597
,CHEMBL622855,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9843,,17411,,1,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622856,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9844,1969.0,14941,,1,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,,,Intermediate,1,,50597
,CHEMBL622857,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9845,1969.0,14941,,1,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,,,Intermediate,1,,50597
,CHEMBL622858,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9846,1969.0,17538,,1,,AUC in rat after po administration at a dose of 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622859,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9847,1969.0,17752,,1,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622860,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9848,,17509,,1,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622861,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9849,,17509,,1,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622862,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9850,,17509,,1,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,,,Intermediate,1,,50597
,CHEMBL622863,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9851,,17509,,1,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL623817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9852,,17509,,1,,Area under curve value 6 hr after po administration in rat,A,,,Intermediate,1,,50597
,CHEMBL623818,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9853,,17717,,1,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Intermediate,1,,50597
,CHEMBL623819,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9854,,17717,,1,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,,,Intermediate,1,,50597
,CHEMBL623820,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9855,,17717,,1,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Intermediate,1,,50597
,CHEMBL623821,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9856,,17717,,1,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,,,Intermediate,1,,50597
,CHEMBL623822,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9857,1969.0,6642,,1,,AUC normalized for dose (AUCN) in rat,A,,,Intermediate,1,,50597
,CHEMBL623823,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9858,,6640,,1,,Area under curve in rat after p.o. administration,A,,,Intermediate,1,,50597
,CHEMBL623824,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9859,,6641,,1,,Area under curve in rat after p.o. administration,A,,,Intermediate,1,,50597
,CHEMBL623825,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9860,,6641,,1,,Area under curve in rat after p.o. administration; Not determined,A,,,Intermediate,1,,50597
,CHEMBL622070,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9861,,6641,,1,,Area under curve in rat after peroral administration,A,,,Intermediate,1,,50597
,CHEMBL622071,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9862,,3603,,1,,Area under curve (carotid artery) value of the compound,A,,,Intermediate,1,,50597
,CHEMBL622072,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9863,,3550,,1,,Bioavailability expressed as the area under curve of rat carotid artery,A,,,Intermediate,1,,50597
,CHEMBL622073,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9864,,15662,,1,,Area under curve in male SD rats was observed after intravenous administration in rat,A,,,Intermediate,1,,50597
,CHEMBL622074,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9865,,17720,,1,,Area under curve of the compound was determined,A,,,Intermediate,1,,50597
,CHEMBL622075,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9866,,5407,,1,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,,,Intermediate,1,,50597
,CHEMBL622076,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9867,1969.0,17752,,1,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622077,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9868,1969.0,17752,,1,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL622078,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9869,,3603,,1,,Area under curve (portal vein) value of the compound,A,,,Intermediate,1,,50597
,CHEMBL622079,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9870,,3550,,1,,Bioavailability expressed as the area under curve of rat portal vein,A,,,Intermediate,1,,50597
,CHEMBL622080,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9871,1969.0,17655,,1,,Area Under plasma concentration time curve in rat upon peroral administration,A,,,Intermediate,1,,50597
,CHEMBL877612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9872,,17582,,1,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL622081,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9873,,17582,,1,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL622082,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9874,,17791,,1,,Compound was evaluated for oral bioavailability in rats,A,,,Intermediate,1,,50597
,CHEMBL622083,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9875,,17791,,1,,Compound was evaluated for oral bioavailability in rats after iv administration,A,,,Intermediate,1,,50597
,CHEMBL622084,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9876,,17791,,1,,Compound was evaluated for oral bioavailability in rats; 30-80,A,,,Intermediate,1,,50597
,CHEMBL622085,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9877,,17791,,1,,Compound was evaluated for oral bioavailability in rats; 50-60,A,,,Intermediate,1,,50597
,CHEMBL622086,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9878,,17791,,1,,Compound was evaluated for oral bioavailability in rats; no data,A,,,Intermediate,1,,50597
,CHEMBL622087,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9879,,17791,,1,,Compound was evaluated for oral bioavailability in rats; peptide,A,,,Intermediate,1,,50597
,CHEMBL622088,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9880,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,,,Intermediate,1,,50597
,CHEMBL622089,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9881,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,,,Intermediate,1,,50597
,CHEMBL623685,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9882,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,,,Intermediate,1,,50597
,CHEMBL623686,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9883,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,,,Intermediate,1,,50597
,CHEMBL623687,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9884,945.0,8677,,1,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL623688,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9885,945.0,8677,,1,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL623689,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9886,945.0,8677,,1,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622485,10116.0,N,BAO_0000218,Rattus norvegicus,,,Stomach,9887,945.0,8677,,1,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622486,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9888,2046.0,8677,,1,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL877613,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9889,2046.0,8677,,1,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622487,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9890,2046.0,8677,,1,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622488,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,9891,2046.0,8677,,1,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9892,948.0,8677,,1,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Intermediate,1,,50597
,CHEMBL622490,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9893,1088.0,6899,,1,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Intermediate,1,,50597
,CHEMBL622491,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9894,1088.0,6899,,1,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Intermediate,1,,50597
,CHEMBL622492,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9895,2107.0,6899,,1,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,,,Intermediate,1,,50597
,CHEMBL622493,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9896,1088.0,6899,,1,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Intermediate,1,,50597
,CHEMBL622494,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9897,1088.0,6899,,1,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Intermediate,1,,50597
,CHEMBL622495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9898,2385.0,8677,,1,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,,,Intermediate,1,,50597
,CHEMBL622496,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9899,,6899,,1,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,,,Intermediate,1,,50597
,CHEMBL622497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9900,1088.0,6899,,1,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Intermediate,1,,50597
,CHEMBL622498,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9901,,2189,,1,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,,,Intermediate,1,,50597
,CHEMBL624918,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9902,1088.0,2189,,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,,,Intermediate,1,,50597
,CHEMBL624919,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9903,1088.0,2189,,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,,,Intermediate,1,,50597
,CHEMBL624920,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9904,178.0,10839,,1,,Biodistribution of compound in rat blood after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624921,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,9905,178.0,10839,,1,,Biodistribution of compound in rat blood after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624922,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,9906,955.0,10839,,1,,Biodistribution of compound in rat brain after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624923,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9907,948.0,10839,,1,,Biodistribution of compound in rat heart after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624924,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9908,948.0,10839,,1,,Biodistribution of compound in rat heart after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624925,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9909,2113.0,10839,,1,,Biodistribution of compound in rat kidney after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624926,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9910,2113.0,10839,,1,,Biodistribution of compound in rat kidney after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624927,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9911,2107.0,10839,,1,,Biodistribution of compound in rat liver after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL874402,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9912,2107.0,10839,,1,,Biodistribution of compound in rat liver after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624928,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9913,2048.0,10839,,1,,Biodistribution of compound in rat lung after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624929,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,9914,2048.0,10839,,1,,Biodistribution of compound in rat lung after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624930,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9915,2385.0,10839,,1,,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624931,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9916,2385.0,10839,,1,,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL624932,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9917,948.0,4043,,1,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624933,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,9918,948.0,4043,,1,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624934,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9919,2107.0,4043,,1,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624935,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9920,2107.0,4043,,1,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624936,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9921,,4043,,1,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624937,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9922,,4043,,1,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624938,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9923,2106.0,4043,,1,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624939,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,9924,2106.0,4043,,1,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624940,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9925,,4043,,1,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL874403,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9926,,4043,,1,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Intermediate,1,,50597
,CHEMBL624941,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9927,,1446,,1,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,,,Intermediate,1,,50597
,CHEMBL624942,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9928,1088.0,9971,,1,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL624943,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,9929,1088.0,9971,,1,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,,,Intermediate,1,,50597
,CHEMBL624944,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9930,,5765,,1,,% Bioavailability after 1 day of the drug administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624945,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9931,,5765,,1,,% Bioavailability after 4 day of the drug administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9932,,4257,,1,,Absolute bioavailability was evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624947,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9933,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL624948,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9934,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624949,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9935,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL622025,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9936,2113.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL622026,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9937,2113.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL622027,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9938,2113.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL622028,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,9939,2113.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL622029,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9940,2107.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL622208,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9941,2107.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL622209,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9942,2107.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL622210,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,9943,2107.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL622211,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9944,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL622212,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9945,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL622213,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9946,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL874404,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9947,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL620452,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9948,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL620453,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9949,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL620454,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9950,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624067,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9951,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624068,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9952,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL624069,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,9953,992.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL624070,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,9954,992.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624071,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,9955,992.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624072,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,9956,995.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL624073,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,9957,995.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL624788,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,9958,995.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624789,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,9959,995.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624790,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9960,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL624791,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9961,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL624792,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9962,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624793,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9963,,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL877491,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9964,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,,,Intermediate,1,,50597
,CHEMBL624957,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9965,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,,,Intermediate,1,,50597
,CHEMBL624958,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9966,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624959,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,9967,2385.0,13091,,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,,,Intermediate,1,,50597
,CHEMBL624960,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9968,,11977,,1,,Dissociation constant was determined,A,,,Intermediate,1,,50597
,CHEMBL624961,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9969,,14941,,1,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,,,Intermediate,1,,50597
,CHEMBL624962,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9970,,15078,,1,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL624963,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9971,,15078,,1,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL624964,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9972,,4755,,1,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,,,Intermediate,1,,50597
,CHEMBL624965,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9973,,589,,1,,LogP value was evaluated in the in situ rat gut perfusion assay,A,,,Intermediate,1,,50597
,CHEMBL624966,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9974,,17582,,1,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624967,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9975,,5031,,1,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624968,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9976,,17764,,1,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624969,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9977,,17720,,1,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,,Intermediate,1,,50597
,CHEMBL624970,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9978,,2862,,1,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,,,Expert,1,,50597
,CHEMBL624971,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9979,,16423,,1,,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,,,Intermediate,1,,50597
,CHEMBL624972,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9980,,16423,,1,,Half-life was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624973,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9981,,6005,,1,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624974,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9982,1969.0,2938,,1,,Half-life was evaluated in plasma of rat,A,,,Intermediate,1,,50597
,CHEMBL624975,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9983,,6410,,1,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL877492,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9984,,6410,,1,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624976,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9985,,6062,,1,,Half-life was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624977,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9986,,6571,,1,,Half-life period of compound in rats after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626848,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9987,1969.0,3136,,1,,Half-life period of compound was measured in rat plasma.,A,,,Intermediate,1,,50597
,CHEMBL626849,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9988,1969.0,3136,,1,,Half-life period of compound was measured in rat plasma; ND is not determined,A,,,Intermediate,1,,50597
,CHEMBL626850,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,9989,1969.0,3136,,1,,Half-life period of compound was measured in rat plasma; not determined,A,,,Intermediate,1,,50597
,CHEMBL626851,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9990,,4521,,1,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626852,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9991,,5871,,1,,Half-life period in rat by iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626853,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9992,,6077,,1,,Half-life period in rats following intravenous administration at 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626854,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9993,,6679,,1,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627486,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9994,,5144,,1,,Half-life period was determined for the compound in rat,A,,,Intermediate,1,,50597
,CHEMBL627487,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9995,,4498,,1,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL627488,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9996,,4498,,1,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Intermediate,1,,50597
,CHEMBL627489,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9997,,1908,,1,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627490,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9998,,6211,,1,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL873829,10116.0,N,BAO_0000218,Rattus norvegicus,,,,9999,,5529,,1,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL627655,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10000,,6444,,1,,Half-life was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625994,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10001,,6444,,1,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL625995,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10002,,6444,,1,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL625996,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10003,,5207,,1,,Half-life in rat,A,,,Intermediate,1,,50597
,CHEMBL625850,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10004,1969.0,530,,1,,In vitro half life in rat plasma,A,In vitro,,Intermediate,1,,50597
,CHEMBL625851,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10005,1969.0,1116,,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,In vitro,,Intermediate,1,,50597
,CHEMBL625852,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10006,,3219,,1,,In vitro half life in rat,A,In vitro,,Intermediate,1,,50597
,CHEMBL625853,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10007,,6109,,1,,In vivo half life period after intravenous administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625854,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10008,,17582,,1,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL874450,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10009,,17582,,1,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625855,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10010,,5974,,1,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625856,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10011,,5974,,1,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625857,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10012,,5974,,1,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL873831,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10013,,5974,,1,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625858,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10014,,17853,,1,,Longer half-life in rat (i.v.) at 0.5 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL625859,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10015,,17853,,1,,Longer half-life in rat (p.o.) at 2.0 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL625860,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10016,,3457,,1,,Pharmacokinetic property (half life) in rat,A,,,Intermediate,1,,50597
,CHEMBL625861,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10017,,2792,,1,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625862,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10018,,2792,,1,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625863,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10019,,2792,,1,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625864,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10020,,2792,,1,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625865,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10021,,5739,,1,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625866,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10022,,15765,,1,,Pharmacokinetic half time was determined intravenously in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625867,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10023,1969.0,6567,,1,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,In vivo,,Intermediate,1,,50597
,CHEMBL625868,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10024,1969.0,2448,,1,,Plasma half life of hydrolysis of the compound,A,,,Intermediate,1,,50597
,CHEMBL625869,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10025,1969.0,5423,,1,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL874451,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10026,1969.0,4853,,1,,Plasma half life period was calculated in rat,A,,,Intermediate,1,,50597
,CHEMBL625870,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10027,1969.0,4514,,1,,Plasma half-life in Sprague-Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL625871,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10028,1969.0,4514,,1,,Plasma half-life in Sprague-Dawley rats; Not determined,A,,,Intermediate,1,,50597
,CHEMBL625872,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10029,1969.0,1500,,1,,Plasma half-life in rats,A,,,Intermediate,1,,50597
,CHEMBL625873,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10030,1969.0,1500,,1,,Plasma half-life in rats; <MQL,A,,,Intermediate,1,,50597
,CHEMBL625874,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10031,1969.0,5334,,1,,Plasma half-life period (0-8 h) was determined,A,,,Intermediate,1,,50597
,CHEMBL625875,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10032,1969.0,5334,,1,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,,,Intermediate,1,,50597
,CHEMBL625876,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10033,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10034,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631259,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10035,1969.0,4956,,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,,,Intermediate,1,,50597
,CHEMBL631260,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10036,1969.0,4956,,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,,,Intermediate,1,,50597
,CHEMBL631261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10037,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,,,Intermediate,1,,50597
,CHEMBL631262,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10038,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,,,Intermediate,1,,50597
,CHEMBL631263,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10039,178.0,7768,,1,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,,,Intermediate,1,,50597
,CHEMBL631264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10040,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,,,Intermediate,1,,50597
,CHEMBL631265,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10041,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,,,Intermediate,1,,50597
,CHEMBL631266,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10042,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,,,Intermediate,1,,50597
,CHEMBL631267,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10043,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,,,Intermediate,1,,50597
,CHEMBL631268,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10044,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,,,Intermediate,1,,50597
,CHEMBL631269,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10045,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,,,Intermediate,1,,50597
,CHEMBL631270,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10046,,7768,,1,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,,,Intermediate,1,,50597
,CHEMBL631271,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10047,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Intermediate,1,,50597
,CHEMBL631272,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10048,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,,,Intermediate,1,,50597
,CHEMBL631273,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10049,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,,,Intermediate,1,,50597
,CHEMBL631274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10050,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,,,Intermediate,1,,50597
,CHEMBL631275,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10051,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,,,Intermediate,1,,50597
,CHEMBL626984,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10052,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,,,Intermediate,1,,50597
,CHEMBL626985,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10053,948.0,7768,,1,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,,,Intermediate,1,,50597
,CHEMBL626986,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10054,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Intermediate,1,,50597
,CHEMBL626987,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10055,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,,,Intermediate,1,,50597
,CHEMBL626988,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10056,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,,,Intermediate,1,,50597
,CHEMBL626989,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10057,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,,,Intermediate,1,,50597
,CHEMBL626990,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10058,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,,,Intermediate,1,,50597
,CHEMBL626991,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10059,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,,,Intermediate,1,,50597
,CHEMBL626992,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10060,2107.0,7768,,1,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,,,Intermediate,1,,50597
,CHEMBL626993,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10061,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,,,Intermediate,1,,50597
,CHEMBL874593,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10062,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,,,Intermediate,1,,50597
,CHEMBL626994,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10063,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,,,Intermediate,1,,50597
,CHEMBL626995,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10064,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,,,Intermediate,1,,50597
,CHEMBL626190,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10065,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,,,Intermediate,1,,50597
,CHEMBL626191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10066,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,,,Intermediate,1,,50597
,CHEMBL626364,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10067,2048.0,7768,,1,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,,,Intermediate,1,,50597
,CHEMBL626365,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10068,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,,,Intermediate,1,,50597
,CHEMBL626366,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10069,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,,,Intermediate,1,,50597
,CHEMBL626367,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10070,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,,,Intermediate,1,,50597
,CHEMBL626368,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10071,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,,,Intermediate,1,,50597
,CHEMBL626369,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10072,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,,,Intermediate,1,,50597
,CHEMBL626370,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10073,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,,,Intermediate,1,,50597
,CHEMBL626371,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10074,,4498,,1,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Intermediate,1,,50597
,CHEMBL626372,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10075,,4498,,1,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Intermediate,1,,50597
,CHEMBL626373,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10076,,3603,,1,,Bioavailability after a dose of 10 mg/kg p.o.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626374,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10077,,6215,,1,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626375,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10078,,5710,,1,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626376,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10079,,5710,,1,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL626377,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10080,,5676,,1,,Bioavailability in rat po was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL626378,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10081,,17667,,1,,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626379,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10082,,17667,,1,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626380,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10083,,6848,,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL626381,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10084,,6848,,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL626382,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10085,,17267,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626383,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10086,,6362,,1,,Bioavailability in rat (Sprague-Dawley) (female),A,In vivo,,Intermediate,1,,50597
,CHEMBL874652,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10087,,17671,,1,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626384,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10088,,17671,,1,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL626385,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10089,,4333,,1,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL626386,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10090,,6077,,1,,Bioavailability in rat at an oral dose of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626387,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10091,,3278,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626388,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10092,,5964,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626389,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10093,,4884,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626390,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10094,,4905,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626391,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10095,,4884,,1,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,In vivo,,Intermediate,1,,50597
,CHEMBL626392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10096,,6850,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626393,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10097,,2864,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623026,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10098,,5780,,1,,Bioavailability was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623027,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10099,,1465,,1,,Bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623028,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10100,,5199,,1,,Bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623029,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10101,,5765,,1,,Bioavailability in rat after 1 day dosing,A,In vivo,,Intermediate,1,,50597
,CHEMBL623030,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10102,,5765,,1,,Bioavailability in rat after 4 day dosing,A,In vivo,,Intermediate,1,,50597
,CHEMBL623031,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10103,,6518,,1,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL623032,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10104,,6518,,1,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Intermediate,1,,50597
,CHEMBL623033,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10105,,6518,,1,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623034,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10106,,6518,,1,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623035,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10107,,2083,,1,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623036,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10108,,17260,,1,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623037,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10109,,4956,,1,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623038,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10110,,4368,,1,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL874385,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10111,1969.0,17752,,1,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623039,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10112,,1446,,1,,Bioavailability in rat (Fisher) (fasted),A,In vivo,,Intermediate,1,,50597
,CHEMBL623040,9443.0,U,BAO_0000218,Primates,,,,10113,,2891,,1,,Bioavailability in monkey after po administration of 10 mg/kg dose,A,In vivo,,Intermediate,0,,22224
,CHEMBL623041,9443.0,U,BAO_0000218,Primates,,,,10114,,2891,,1,,Oral bioavailability in monkey (dose 10 mg/kg),A,In vivo,,Intermediate,0,,22224
,CHEMBL623741,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10115,,6672,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623742,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10116,,6673,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623743,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10117,,17655,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623744,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10118,,17796,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623745,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10119,,17853,,1,,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623746,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10120,,4521,,1,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623747,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10121,,4940,,1,,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623748,10116.0,U,BAO_0000218,Rattus norvegicus,,,,10122,,2891,,1,,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Intermediate,0,,22224
,CHEMBL623916,10116.0,U,BAO_0000218,Rattus norvegicus,,,,10123,,2891,,1,,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Intermediate,0,,22224
,CHEMBL623917,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10124,,4521,,1,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623918,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10125,,17686,,1,,Bioavailability in rat (dose 2 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL874386,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10126,,17796,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623919,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10127,1969.0,17796,,1,,Bioavailability in rat; Only traces detected in rat plasma,A,In vivo,,Intermediate,1,,50597
,CHEMBL623920,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10128,,5064,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623148,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10129,,5147,,1,,Bioavailability upon oral administration of compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL623149,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10130,,1916,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623150,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10131,,6049,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623151,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10132,,1445,,1,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,In vivo,,Intermediate,1,,50597
,CHEMBL623152,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10133,,1445,,1,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,In vivo,,Intermediate,1,,50597
,CHEMBL623153,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10134,,2862,,1,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,,,Expert,1,,50597
,CHEMBL623154,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10135,,2862,,1,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,,,Expert,1,,50597
,CHEMBL623155,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10136,,4194,,1,,In vitro and metabolic stability was determined,A,,,Intermediate,1,,50597
,CHEMBL623156,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10137,,4194,,1,,In vitro metabolic stability in rat hepatocytes,A,,,Intermediate,1,,50597
,CHEMBL623157,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10138,,5486,,1,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,,,Intermediate,1,,50597
,CHEMBL623158,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10139,2107.0,17582,,1,401.0,Metabolic rate for compound was observed in rat hepatocytes,A,In vitro,Hepatocyte,Intermediate,1,,50597
,CHEMBL623159,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10140,,5600,,1,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,,,Intermediate,1,,50597
,CHEMBL874390,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10141,,14294,,1,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,,,Intermediate,1,,50597
,CHEMBL623160,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10142,,14294,,1,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,,,Intermediate,1,,50597
,CHEMBL623161,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10143,,14294,,1,,Metabolism of compound in rat S9 microsomes; Trace,A,,,Intermediate,1,,50597
,CHEMBL623162,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10144,,17847,,1,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,,,Intermediate,1,,50597
,CHEMBL623163,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10145,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL623164,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10146,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,,,Intermediate,1,,50597
,CHEMBL623165,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10147,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,,,Intermediate,1,,50597
,CHEMBL623166,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10148,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,,,Intermediate,1,,50597
,CHEMBL624983,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10149,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,,,Intermediate,1,,50597
,CHEMBL624984,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10150,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,,,Intermediate,1,,50597
,CHEMBL624985,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10151,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL622970,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10152,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,,,Intermediate,1,,50597
,CHEMBL622971,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10153,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL622972,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10154,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL622973,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10155,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL622974,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10156,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL622975,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10157,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL622976,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10158,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL622977,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10159,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,,,Intermediate,1,,50597
,CHEMBL624351,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10160,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL624352,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10161,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Intermediate,1,,50597
,CHEMBL624353,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10162,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Intermediate,1,,50597
,CHEMBL622397,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10163,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Intermediate,1,,50597
,CHEMBL622398,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10164,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Intermediate,1,,50597
,CHEMBL622399,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10165,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,,,Intermediate,1,,50597
,CHEMBL622400,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10166,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Intermediate,1,,50597
,CHEMBL628428,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10167,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL628590,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10168,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,,,Intermediate,1,,50597
,CHEMBL628591,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10169,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL628592,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10170,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL628593,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10171,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL875333,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10172,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL628594,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10173,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL628595,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10174,1969.0,4969,,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,,,Intermediate,1,,50597
,CHEMBL628596,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10175,1969.0,6737,,1,,Stability in rat plasma was determined,A,,,Intermediate,1,,50597
,CHEMBL628597,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10176,1969.0,6737,,1,,Stability in rat plasma was determined; ND= no data,A,,,Intermediate,1,,50597
,CHEMBL628598,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10177,1969.0,5089,,1,,Tested for plasma half life period in rat (0-8 hr),A,,,Intermediate,1,,50597
,CHEMBL628599,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10178,1969.0,5089,,1,,Tested for plasma half life period in rat (0-8 hr); Not determined,A,,,Intermediate,1,,50597
,CHEMBL628600,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10179,,1466,,1,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL628601,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10180,,1466,,1,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL628602,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10181,,4950,,1,,Tested for the half life in rat,A,,,Intermediate,1,,50597
,CHEMBL628603,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10182,,2412,,1,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,In vitro,,Intermediate,1,,50597
,CHEMBL628604,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10183,,2412,,1,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,In vitro,,Intermediate,1,,50597
,CHEMBL628605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10184,,2412,,1,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,In vitro,,Intermediate,1,,50597
,CHEMBL628606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10185,,2412,,1,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,In vitro,,Intermediate,1,,50597
,CHEMBL628607,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10186,,2412,,1,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,In vitro,,Intermediate,1,,50597
,CHEMBL628608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10187,,15022,,1,,The biological half life the compound was measured at the dose of 100 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL628609,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10188,,15022,,1,,The biological half life the compound was measured at the dose of 30 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL628610,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10189,1969.0,406,,1,,The compound was evaluated for plasma half life period in rat,A,,,Intermediate,1,,50597
,CHEMBL873819,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10190,,15078,,1,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL628611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10191,,15078,,1,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL628612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10192,,5247,,1,,The pharmacokinetic parameter half-life period in vivo in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL628613,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10193,,5041,,1,,"The pharmacokinetic property, Half-life was determined",A,In vivo,,Intermediate,1,,50597
,CHEMBL628614,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10194,,5041,,1,,"The pharmacokinetic property, Half-life in rat in vivo",A,In vivo,,Intermediate,1,,50597
,CHEMBL628615,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10195,,5041,,1,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,In vivo,,Intermediate,1,,50597
,CHEMBL628616,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10196,,5041,,1,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,In vivo,,Intermediate,1,,50597
,CHEMBL627924,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10197,1969.0,3918,,1,,The plasma half life period in rats,A,,,Intermediate,1,,50597
,CHEMBL627925,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10198,2107.0,2906,,1,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,,,Intermediate,1,,50597
,CHEMBL627926,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10199,,6467,,1,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL627927,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10200,,5510,,1,,t1/2 (apparent elimination)of the compound was determined,A,,,Intermediate,1,,50597
,CHEMBL627928,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10201,,3788,,1,,t1/2 value in rat,A,,,Intermediate,1,,50597
,CHEMBL627539,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10202,,17796,,1,,Half life in rat,A,,,Intermediate,1,,50597
,CHEMBL876790,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10203,1969.0,12873,,1,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Intermediate,1,,50597
,CHEMBL858186,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10204,,5983,,1,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10205,,15765,,1,,Half-life period in fasted rats,A,,,Intermediate,1,,50597
,CHEMBL627541,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10206,,2661,,1,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627715,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10207,,2661,,1,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627716,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10208,,429,,1,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627717,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10209,,17655,,1,,Maximum time required to achieve Cmax was determined in rat,A,,,Intermediate,1,,50597
,CHEMBL627718,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10210,,17717,,1,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL627719,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10211,,17717,,1,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL627720,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10212,,17717,,1,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Intermediate,1,,50597
,CHEMBL627721,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10213,,6570,,1,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627722,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10214,,6570,,1,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,In vivo,,Intermediate,1,,50597
,CHEMBL627723,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10215,,5978,,1,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626058,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10216,,5978,,1,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10217,,5978,,1,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10218,,5978,,1,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626061,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10219,1969.0,17720,,1,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL876791,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10220,,4723,,1,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626062,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10221,,4723,,1,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626063,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10222,,4756,,1,,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626064,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10223,,4756,,1,,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626065,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10224,1969.0,17720,,1,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626066,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10225,1969.0,17720,,1,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626067,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10226,,1466,,1,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626068,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10227,,7449,,1,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,,,Intermediate,1,,50597
,CHEMBL626069,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10228,,7449,,1,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,,,Intermediate,1,,50597
,CHEMBL626070,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10229,,7449,,1,,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,,,Intermediate,1,,50597
,CHEMBL626071,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10230,,7449,,1,,Percent total excretion of N-methoxyacetaminophen glucuronide,F,,,Intermediate,1,,50597
,CHEMBL626072,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10231,,7449,,1,,Percent total excretion of N-methoxyacetaminophen sulfate,F,,,Intermediate,1,,50597
,CHEMBL626073,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10232,,7449,,1,,Percent total excretion of acetaminophen,F,,,Intermediate,1,,50597
,CHEMBL626741,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,10233,2046.0,7768,,1,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,,,Intermediate,1,,50597
,CHEMBL626742,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10234,,17655,,1,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,,,Intermediate,1,,50597
,CHEMBL626743,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10235,,17735,,1,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,,,Intermediate,1,,50597
,CHEMBL876792,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10236,,5960,,1,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Intermediate,1,,50597
,CHEMBL626744,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10237,,17735,,1,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,,,Intermediate,1,,50597
,CHEMBL626745,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10238,,7116,,1,,Compound was tested for antidiuretic activity in rats,A,,,Intermediate,1,,50597
,CHEMBL626746,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10239,1969.0,4878,,1,,AUC in rat after 3mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626747,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10240,,5939,,1,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626748,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10241,,5939,,1,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626749,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10242,,16367,,1,,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,,,Intermediate,1,,50597
,CHEMBL626750,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10243,,16366,,1,,Oral Bioavailability was determined,A,,,Intermediate,1,,50597
,CHEMBL626751,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10244,,4426,,1,,Oral bioavailability in rat,A,,,Intermediate,1,,50597
,CHEMBL626913,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10245,,4426,,1,,Oral bioavailability in rat; Not performed.,A,,,Intermediate,1,,50597
,CHEMBL626914,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10246,,5041,,1,,Bioavailability,A,,,Intermediate,1,,50597
,CHEMBL626915,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10247,,5041,,1,,Bioavailability was determined; ND denotes no data,A,,,Intermediate,1,,50597
,CHEMBL626916,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10248,,1500,,1,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL626917,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10249,,1500,,1,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL626918,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10250,,17409,,1,,Binding towards rat plasma protein at 10 uM,A,,,Intermediate,1,,50597
,CHEMBL626919,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10251,,17409,,1,,Binding towards rat plasma protein at 100 uM,A,,,Intermediate,1,,50597
,CHEMBL626920,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10252,,2959,,1,,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL621976,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10253,,13501,,1,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL877599,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10254,,6567,,1,,Bioavailability in rat after 5 mg/kg oral gavage,A,In vivo,,Intermediate,1,,50597
,CHEMBL621977,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10255,,6571,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621978,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10256,,6715,,1,,Bioavailability in rat (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL621979,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10257,,6715,,1,,Bioavailability in rat (dose 3 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL621980,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10258,,2932,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621981,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10259,,4171,,1,,Bioavailability of the compound in rats after administration of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621982,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10260,,17509,,1,,Bioavailability after administration of 10 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL882953,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10261,,17509,,1,,Bioavailability after administration of 2 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621983,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10262,,4527,,1,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621984,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10263,,4026,,1,,Bioavailability in dogs was determined; high,A,In vivo,,Intermediate,1,,50597
,CHEMBL621985,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10264,,6659,,1,,Bioavailability in monkey after intravenous administration at 1 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL621986,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10265,,6659,,1,,Bioavailability in monkey after peroral administration at 10 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL621987,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10266,,6659,,1,,Bioavailability in rat after intravenous administration at 1 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL877600,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10267,,6659,,1,,Bioavailability in rat after intravenous administration at 2 mpk,F,In vivo,,Intermediate,1,,50597
,CHEMBL621988,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10268,,6659,,1,,Bioavailability in rat after peroral administration at 30 mpk,A,In vivo,,Intermediate,1,,50597
,CHEMBL621989,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10269,,6659,,1,,Bioavailability in rat after peroral administration at at 100 mpk,F,In vivo,,Intermediate,1,,50597
,CHEMBL621990,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10270,,6597,,1,,Bioavailability in rats was evaluated,A,In vivo,,Intermediate,1,,50597
,CHEMBL621991,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10271,,1202,,1,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621992,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10272,,1202,,1,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621993,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10273,,1202,,1,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621994,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10274,,1202,,1,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,In vivo,,Intermediate,1,,50597
,CHEMBL621995,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10275,,5207,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621996,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10276,,5970,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621997,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10277,,17538,,1,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL621998,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10278,,17538,,1,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL621999,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10279,,1466,,1,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622000,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10280,,2879,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622001,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10281,,2879,,1,,Bioavailability was measured in rat after oral administration; 2-4,A,In vivo,,Intermediate,1,,50597
,CHEMBL622002,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10282,,2879,,1,,Bioavailability was measured in rat after oral administration; 3-7,A,In vivo,,Intermediate,1,,50597
,CHEMBL622003,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10283,,3777,,1,,Bioavailability in rat (intraduodenal administration),A,In vivo,,Intermediate,1,,50597
,CHEMBL877601,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10284,,3777,,1,,Bioavailability in rat (intraduodenal administration),A,In vivo,,Intermediate,1,,50597
,CHEMBL624871,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10285,,3777,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622004,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10286,,3777,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL882954,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10287,,5423,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622005,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10288,,16365,,1,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL622006,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10289,,16365,,1,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622007,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10290,,4239,,1,,Bioavailability was measured in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622008,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10291,,5438,,1,,Bioavailability was reported,A,In vivo,,Intermediate,1,,50597
,CHEMBL622009,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10292,,5334,,1,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622010,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10293,,5334,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622011,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10294,,4199,,1,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622012,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10295,,4199,,1,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622013,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10296,,4199,,1,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,In vivo,,Intermediate,1,,50597
,CHEMBL622014,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10297,,4890,,1,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624749,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10298,,2792,,1,,Bioavailability was determined at 3 mg/kg po dose in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624750,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10299,,5529,,1,,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL624751,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10300,,6685,,1,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL624752,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10301,,6685,,1,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL624753,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10302,,6685,,1,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Intermediate,1,,50597
,CHEMBL624754,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10303,,6005,,1,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624755,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10304,,6410,,1,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Intermediate,1,,50597
,CHEMBL624756,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10305,,6410,,1,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624757,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10306,,6103,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624758,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10307,,6410,,1,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Intermediate,1,,50597
,CHEMBL622270,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10308,,6410,,1,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622271,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10309,,5353,,1,,Bioavailability in rat (Sprague-Dawley),A,In vivo,,Intermediate,1,,50597
,CHEMBL622272,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10310,,4727,,1,,Bioavailability in rat at the dose of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622273,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10311,,17804,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622274,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10312,,5809,,1,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622275,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10313,,17804,,1,,Bioavailability value of compound in rats was determined after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622276,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10314,,3634,,1,,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622277,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10315,,3341,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622278,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10316,,2690,,1,,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622279,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10317,,3184,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622280,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10318,,740,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624083,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10319,,1806,,1,,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,In vivo,,Intermediate,1,,50597
,CHEMBL624084,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10320,,4891,,1,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,In vivo,,Intermediate,1,,50597
,CHEMBL624085,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10321,,3634,,1,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,In vivo,,Intermediate,1,,50597
,CHEMBL624086,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10322,,64,,1,,Compound was tested for bioavailability in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624087,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10323,,4839,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624088,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10324,,1094,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624089,9544.0,U,BAO_0000218,Macaca mulatta,,,,10325,,5005,,1,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,In vivo,,Intermediate,0,,22224
,CHEMBL624090,10116.0,U,BAO_0000218,Rattus norvegicus,,,,10326,,5005,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Intermediate,0,,22224
,CHEMBL624091,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10327,,4687,,1,,Evaluated for the bioavailability in rat (in vivo),A,In vivo,,Intermediate,1,,50597
,CHEMBL624092,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10328,,17804,,1,,F value of compound in rats was determined after peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624093,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10329,,5974,,1,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624094,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10330,,5974,,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624095,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10331,,5974,,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624096,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10332,,5974,,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624097,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10333,,1088,,1,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,In vivo,,Intermediate,1,,50597
,CHEMBL624098,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10334,,1742,,1,,Maximum fall in carotid flow in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL874392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10335,,4689,,1,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624099,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10336,,2463,,1,,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL624100,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10337,,5654,,1,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624101,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10338,,5654,,1,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL624102,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10339,,6874,,1,,Oral bioavailability in rat (male Wistar),A,In vivo,,Intermediate,1,,50597
,CHEMBL624103,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10340,,5633,,1,,Oral bioavailability after administration (30 mg/kg) in rat; good,A,In vivo,,Intermediate,1,,50597
,CHEMBL624104,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10341,,5496,,1,,Oral bioavailability at the dose of 2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL624105,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10342,,2358,,1,,Oral bioavailability determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624106,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10343,,16456,,1,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL624107,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10344,,5302,,1,,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623943,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10345,,5302,,1,,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623944,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10346,,5302,,1,,Oral bioavailability in rat (dose 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623945,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10347,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL623946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10348,,11020,,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,,,Intermediate,1,,50597
,CHEMBL623947,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10349,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL623948,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10350,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,,,Intermediate,1,,50597
,CHEMBL623949,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10351,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,,,Intermediate,1,,50597
,CHEMBL623950,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10352,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,,,Intermediate,1,,50597
,CHEMBL874398,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10353,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,,,Intermediate,1,,50597
,CHEMBL623951,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10354,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,,,Intermediate,1,,50597
,CHEMBL623952,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10355,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL623953,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10356,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,,,Intermediate,1,,50597
,CHEMBL623954,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10357,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL623955,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10358,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL623956,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10359,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL627807,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10360,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL627808,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10361,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL627809,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10362,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,,,Intermediate,1,,50597
,CHEMBL627810,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10363,,11020,,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,,,Intermediate,1,,50597
,CHEMBL627811,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10364,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,,,Intermediate,1,,50597
,CHEMBL627812,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10365,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,,,Intermediate,1,,50597
,CHEMBL627813,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10366,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,,,Intermediate,1,,50597
,CHEMBL627814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10367,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,,,Intermediate,1,,50597
,CHEMBL875336,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10368,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,,,Intermediate,1,,50597
,CHEMBL627815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10369,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,,,Intermediate,1,,50597
,CHEMBL627816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10370,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,,,Intermediate,1,,50597
,CHEMBL627817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10371,,11020,,1,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,,,Intermediate,1,,50597
,CHEMBL627818,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10372,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,,,Intermediate,1,,50597
,CHEMBL627819,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10373,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,,,Intermediate,1,,50597
,CHEMBL627820,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10374,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,,,Intermediate,1,,50597
,CHEMBL627821,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10375,,11020,,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,,,Intermediate,1,,50597
,CHEMBL628464,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10376,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL626239,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10377,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Intermediate,1,,50597
,CHEMBL626240,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10378,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,,,Intermediate,1,,50597
,CHEMBL626241,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10379,,11020,,1,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Intermediate,1,,50597
,CHEMBL626242,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10380,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Intermediate,1,,50597
,CHEMBL626243,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10381,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,,,Intermediate,1,,50597
,CHEMBL626244,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10382,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Intermediate,1,,50597
,CHEMBL626907,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10383,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL626908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10384,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL626909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10385,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL626910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10386,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Intermediate,1,,50597
,CHEMBL875342,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10387,,7449,,1,,Percent total excretion of acetaminophen cysteine conjugate,F,,,Intermediate,1,,50597
,CHEMBL626911,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10388,,7449,,1,,Percent total excretion of acetaminophen glucuronide,F,,,Intermediate,1,,50597
,CHEMBL626912,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10389,,7449,,1,,Percent total excretion of acetaminophen sulfate,F,,,Intermediate,1,,50597
,CHEMBL627065,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10390,,7449,,1,,Percent total excretion of acetaminophen-mercapturic acid,F,,,Intermediate,1,,50597
,CHEMBL627066,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,10391,1088.0,3172,,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,,,Intermediate,1,,50597
,CHEMBL627067,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10392,,16456,,1,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL627068,8656.0,U,BAO_0000218,ratrat,,,Muscle tissue,10393,2385.0,10839,,1,,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL627069,8656.0,U,BAO_0000218,ratrat,,,Muscle tissue,10394,2385.0,10839,,1,,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Autocuration,0,,22224
,CHEMBL627070,9940.0,U,BAO_0000218,Ovis aries,,,,10395,,5334,,1,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL627071,9940.0,U,BAO_0000218,Ovis aries,,,,10396,,5334,,1,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL627072,9940.0,U,BAO_0000218,Ovis aries,,,,10397,,5334,,1,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL627073,9940.0,U,BAO_0000218,Ovis aries,,,,10398,,5334,,1,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL625387,9940.0,U,BAO_0000218,Ovis aries,,,,10399,,5334,,1,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL625388,9940.0,U,BAO_0000218,Ovis aries,,,,10400,,5334,,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL625389,9940.0,U,BAO_0000218,Ovis aries,,,Plasma,10401,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL875343,9940.0,U,BAO_0000218,Ovis aries,,,Plasma,10402,1969.0,5334,,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Autocuration,0,,22224
,CHEMBL876795,8570.0,N,BAO_0000218,Serpentes,,,,10403,,1735,,1,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,,,Intermediate,1,,50497
,CHEMBL626552,8570.0,N,BAO_0000218,Serpentes,,,,10404,,1469,,1,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,,,Intermediate,1,,50497
,CHEMBL626553,8570.0,N,BAO_0000218,Serpentes,,,,10405,,1336,,1,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,,,Intermediate,1,,50497
,CHEMBL626554,9606.0,U,BAO_0000366,Homo sapiens,,,Plasma,10406,1969.0,12403,,1,,The human biological plasma half life of the compound,A,,,Autocuration,0,,22224
,CHEMBL626555,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,10407,1088.0,8151,,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL626556,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10408,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Intermediate,1,,50597
,CHEMBL626557,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10409,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL626558,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10410,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Intermediate,1,,50597
,CHEMBL626559,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10411,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL626560,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10412,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL876803,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10413,,8004,,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627964,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10414,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Intermediate,1,,50597
,CHEMBL627965,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10415,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627966,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10416,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Intermediate,1,,50597
,CHEMBL627967,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10417,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627968,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10418,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627969,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10419,,8004,,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627970,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10420,,8004,,1,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627971,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10421,178.0,8004,,1,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL627972,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10422,178.0,8004,,1,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,,,Intermediate,1,,50597
,CHEMBL856029,9606.0,D,BAO_0000357,Homo sapiens,,,,10423,,15917,,1,,Dissociation constant against binding to human cyclophilin A,B,,,Expert,9,,180
,CHEMBL627973,9913.0,H,BAO_0000019,Bos taurus,,,,10424,,12396,,1,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,,,Expert,8,,11591
,CHEMBL627974,,U,BAO_0000019,,,,,10425,,7065,,1,,-Log C was determined by performing the electroshock minimum test,A,,,Autocuration,0,,22224
,CHEMBL627975,,U,BAO_0000019,,,,,10426,,7065,,1,,-Log C was determined by performing the foot shock test,A,,,Autocuration,0,,22224
,CHEMBL627976,,U,BAO_0000019,,,,,10427,,7065,,1,,-Log C was determined by performing the incl screen test,A,,,Autocuration,0,,22224
,CHEMBL627977,,U,BAO_0000019,,,,,10428,,7065,,1,,-Log C was determined by performing the maximum electroshock test,A,,,Autocuration,0,,22224
,CHEMBL627978,,U,BAO_0000019,,,,,10429,,7065,,1,,-Log C was determined by performing the pentylenetetrazole test,A,,,Autocuration,0,,22224
,CHEMBL627979,,U,BAO_0000019,,,,,10430,,12415,,1,,Tested for experimental arotinoid inhibitory dose,A,,,Autocuration,0,,22224
,CHEMBL876804,,U,BAO_0000019,,,,,10431,,10256,,1,,Negative log transformed activity,A,,,Autocuration,0,,22224
,CHEMBL627980,,U,BAO_0000019,,,,,10432,,7991,,1,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,,,Autocuration,0,,22224
,CHEMBL627981,10141.0,N,BAO_0000218,Cavia porcellus,,,,10433,,14342,,1,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,,,Intermediate,1,,50512
,CHEMBL627982,10141.0,N,BAO_0000218,Cavia porcellus,,,,10434,,14342,,1,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,,,Intermediate,1,,50512
,CHEMBL627983,10141.0,N,BAO_0000218,Cavia porcellus,,,,10435,,14342,,1,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,,,Intermediate,1,,50512
,CHEMBL627984,10141.0,N,BAO_0000218,Cavia porcellus,,,Ileum,10436,2116.0,14342,,1,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,,,Intermediate,1,,50512
,CHEMBL627985,,U,BAO_0000100,,,,,10437,,6047,,1,,Solubility in water was determined; values expressed as -log,P,,,Autocuration,0,,22229
,CHEMBL627986,,U,BAO_0000019,,,,,10438,,17269,,1,,Ratio of Kcat to that of Km was determined,A,,,Autocuration,0,,22224
,CHEMBL627987,,U,BAO_0000019,,,,,10439,,10026,,1,,Observed first order rate constant,A,,,Autocuration,0,,22224
,CHEMBL627988,,U,BAO_0000019,,,,,10440,,14583,,1,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,,,Autocuration,0,,22224
,CHEMBL627989,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10441,,2661,,1,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627990,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10442,,2661,,1,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL876805,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10443,,4029,,1,,Oral Bioavailability after administration of 10 mg/kg in male rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627991,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10444,,17735,,1,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL627992,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10445,,4576,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627993,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10446,,17582,,1,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10447,,17651,,1,,Oral bioavailability at 1 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622818,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10448,,17651,,1,,Oral bioavailability at 10 mg/kg was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622819,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10449,,17670,,1,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,In vivo,,Intermediate,1,,50597
,CHEMBL872267,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10450,,5045,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622820,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10451,,1696,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622821,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10452,,17764,,1,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622822,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10453,,6448,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622823,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10454,,6596,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622824,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10455,,17547,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622825,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10456,,17771,,1,,Oral bioavailability in rat at a dose of 3 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622901,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10457,,6495,,1,,Oral bioavailability in rat after oral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622902,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10458,,4558,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621844,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10459,,17596,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10460,,6827,,1,,Oral bioavailability in Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL621846,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10461,,4026,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL621847,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10462,,10,,1,,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL877609,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10463,,17717,,1,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL621848,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10464,,17717,,1,,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL621849,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10465,,17717,,1,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL622030,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10466,,17717,,1,,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622031,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10467,,4796,,1,,Percent oral bioavailability determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622032,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10468,,4883,,1,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622033,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10469,,2137,,1,,The compound was evaluated for bioavailability in rats; 32-51,A,In vivo,,Intermediate,1,,50597
,CHEMBL622034,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10470,,2959,,1,,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622035,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10471,,1361,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL882966,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10472,,4727,,1,,Bioavailability percent in rat at the dose of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622036,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10473,,16423,,1,,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622037,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10474,,5206,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622038,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10475,,6448,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622039,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10476,,17723,,1,,Bioavailability in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622040,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10477,178.0,17738,,1,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622041,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10478,178.0,17738,,1,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622042,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10479,178.0,17738,,1,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622043,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10480,178.0,17738,,1,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622044,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10481,178.0,17738,,1,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622045,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,10482,10000001.0,17738,,1,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622046,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,10483,10000001.0,17738,,1,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622047,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,10484,10000001.0,17738,,1,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL877610,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,10485,10000001.0,17738,,1,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622048,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10486,955.0,17738,,1,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622049,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10487,955.0,17738,,1,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622050,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10488,955.0,17738,,1,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622051,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10489,955.0,17738,,1,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622052,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10490,,17738,,1,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622053,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10491,,17738,,1,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622054,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10492,,17738,,1,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622055,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10493,,17738,,1,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622056,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10494,,5237,,1,,Oral bioavailability in rats was determined; High,A,In vivo,,Intermediate,1,,50597
,CHEMBL622057,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10495,,5503,,1,,Oral bioavailability in the rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL628008,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10496,,15765,,1,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL622058,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10497,,15660,,1,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL622059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10498,,5978,,1,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10499,,5978,,1,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622061,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10500,,5978,,1,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622062,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10501,,5978,,1,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622063,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10502,,5656,,1,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL877611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10503,,3598,,1,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL622064,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10504,,4216,,1,,Oral bioavailability of compound in Sprague Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622065,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10505,,17839,,1,,Oral bioavailability of compound in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622066,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10506,,6570,,1,,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622067,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10507,,5334,,1,,Oral bioavailability of compound in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622068,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10508,,6886,,1,,Oral bioavailability of compound in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622069,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10509,,5210,,1,,Oral bioavailability of compound was determined in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10510,,4170,,1,,Oral bioavailability at a dose of 30 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL624797,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10511,,6028,,1,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623053,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10512,,6028,,1,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623054,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10513,,6078,,1,,Oral bioavailability evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623055,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10514,,6168,,1,,Oral bioavailability in fasted rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623056,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10515,,6168,,1,,Oral bioavailability in fed rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623057,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10516,,5160,,1,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623058,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10517,,6057,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10518,,6535,,1,,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10519,,6535,,1,,Oral bioavailability in rat after administration of 10 mg/kg po,A,In vivo,,Intermediate,1,,50597
,CHEMBL623061,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10520,,4194,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623062,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10521,,6230,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623063,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10522,,6619,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623064,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10523,,17607,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623065,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10524,,4942,,1,,Oral bioavailability in ratrs,A,In vivo,,Intermediate,1,,50597
,CHEMBL623066,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10525,,4942,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623067,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10526,,6646,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623068,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10527,,5237,,1,,Oral bioavailability in rats was determined; High,A,In vivo,,Intermediate,1,,50597
,CHEMBL623069,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10528,,6646,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623070,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10529,,4449,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623071,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10530,,6057,,1,,Oral bioavailability was calculated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623072,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10531,,2552,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623073,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10532,,5496,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623074,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10533,,6484,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623075,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10534,,6485,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL623076,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10535,,6616,,1,,Oral bioavailability after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623077,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10536,,4969,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623078,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10537,,5862,,1,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Intermediate,1,,50597
,CHEMBL623079,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10538,,4514,,1,,Oral bioavailability in Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623080,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10539,,4514,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623081,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10540,,4514,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL623082,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10541,,5546,,1,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL874400,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10542,,6168,,1,,Oral bioavailability in fasted rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623083,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10543,,6168,,1,,Oral bioavailability in fed rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623084,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10544,,3624,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623085,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10545,,5213,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623086,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10546,,5496,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623087,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10547,,5553,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623088,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10548,,5833,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623089,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10549,,5836,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623090,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10550,,5865,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623091,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10551,,5960,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623092,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10552,,6249,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623093,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10553,,6448,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL874401,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10554,,6453,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623094,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10555,,6640,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623095,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10556,,17607,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623096,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10557,,5939,,1,,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624913,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10558,,5939,,1,,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624914,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10559,,6281,,1,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL624915,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10560,,5874,,1,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL624916,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10561,,5213,,1,,Oral bioavailability in rat; Not measured,A,In vivo,,Intermediate,1,,50597
,CHEMBL624917,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10562,,4964,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625157,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10563,,11020,,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,,,Intermediate,1,,50597
,CHEMBL625158,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10564,2107.0,6251,,1,,In vitro metabolic potential in rat liver microsomes,A,,,Intermediate,1,,50597
,CHEMBL625159,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10565,,1568,,1,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,In vivo,,Intermediate,1,,50597
,CHEMBL625160,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10566,,3032,,1,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Intermediate,1,,50597
,CHEMBL625161,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10567,,3748,,1,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625162,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10568,,401,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625163,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10569,,6512,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625164,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10570,,17617,,1,,Oral bioavailability in rats at 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625165,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10571,,6679,,1,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625166,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10572,,6742,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625167,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10573,,589,,1,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,,,Intermediate,1,,50597
,CHEMBL625168,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10574,,589,,1,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,,,Intermediate,1,,50597
,CHEMBL625169,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10575,,3185,,1,,Plasma clearance of the compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL626264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10576,,17596,,1,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626265,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10577,,2713,,1,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10578,1969.0,12500,,1,,The compound was tested for plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10579,1969.0,12500,,1,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626268,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10580,,2713,,1,,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,,,Intermediate,1,,50597
,CHEMBL626269,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10581,,1446,,1,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,,,Intermediate,1,,50597
,CHEMBL626270,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10582,,6227,,1,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,,,Intermediate,1,,50597
,CHEMBL626271,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10583,,4709,,1,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL626272,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10584,,5510,,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,,,Intermediate,1,,50597
,CHEMBL626273,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10585,,5510,,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Intermediate,1,,50597
,CHEMBL875346,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10586,,5510,,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Intermediate,1,,50597
,CHEMBL626274,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10587,,5510,,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,,,Intermediate,1,,50597
,CHEMBL626275,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10588,,4514,,1,,Compound was tested for protein binding in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL624646,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10589,,2713,,1,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,,,Intermediate,1,,50597
,CHEMBL624647,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10590,,2713,,1,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,,,Intermediate,1,,50597
,CHEMBL624648,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10591,2107.0,5340,,1,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,,,Intermediate,1,,50597
,CHEMBL624649,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10592,,12058,,1,,Area under curve ratio was determined (po/iv) in rat,A,,,Intermediate,1,,50597
,CHEMBL624650,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10593,,11195,,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,,,Intermediate,1,,50597
,CHEMBL624651,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10594,,11195,,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,,,Intermediate,1,,50597
,CHEMBL624652,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10595,,11195,,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,,,Intermediate,1,,50597
,CHEMBL624653,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10596,,6495,,1,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624654,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10597,,6078,,1,,Ratio of AUCbrain to AUCplasma,A,,,Intermediate,1,,50597
,CHEMBL624655,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10598,,5656,,1,,Ratio of brain to plasma,A,,,Intermediate,1,,50597
,CHEMBL624656,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10599,,4910,,1,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,,,Intermediate,1,,50597
,CHEMBL624657,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10600,,4910,,1,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Intermediate,1,,50597
,CHEMBL624658,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10601,,4910,,1,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Intermediate,1,,50597
,CHEMBL624659,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10602,,10130,,1,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,,,Intermediate,1,,50597
,CHEMBL624660,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10603,,10130,,1,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,,,Intermediate,1,,50597
,CHEMBL624661,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10604,,10130,,1,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,,,Intermediate,1,,50597
,CHEMBL624662,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10605,,5213,,1,,Steady state brain :blood ratio was determined,A,,,Intermediate,1,,50597
,CHEMBL625199,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10606,,4910,,1,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL625200,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10607,,4910,,1,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Intermediate,1,,50597
,CHEMBL625201,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10608,,4910,,1,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Intermediate,1,,50597
,CHEMBL625202,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10609,,4910,,1,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Intermediate,1,,50597
,CHEMBL625203,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10610,,2083,,1,,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,,,Intermediate,1,,50597
,CHEMBL625204,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10611,,2082,,1,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Intermediate,1,,50597
,CHEMBL625205,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10612,,2082,,1,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Intermediate,1,,50597
,CHEMBL625206,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10613,,6351,,1,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,,,Intermediate,1,,50597
,CHEMBL625207,,U,BAO_0000019,,,,,10614,,14583,,1,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,,,Autocuration,0,,22224
,CHEMBL625208,,U,BAO_0000019,,,,,10615,,14583,,1,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,,,Autocuration,0,,22224
,CHEMBL625209,9606.0,N,BAO_0000218,Homo sapiens,,,,10616,,4608,,1,495.0,In vivo absorption in Caco-2 cell line monolayers was determined,A,,Caco-2,Intermediate,1,,50587
,CHEMBL625210,,U,BAO_0000100,,,,,10617,,13668,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625211,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10618,,5669,,1,,Area under curve was determine after peroral administration at 10 mpk in Rat,A,,,Intermediate,1,,50597
,CHEMBL625212,9544.0,N,BAO_0000218,Macaca mulatta,,,,10619,,5669,,1,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Intermediate,1,,50797
,CHEMBL625213,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10620,,5669,,1,,Area under curve was determine after peroral administration at 160 mpk in Rat,A,,,Intermediate,1,,50597
,CHEMBL625214,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10621,,5669,,1,,Area under curve was determine after peroral administration at 20 mpk in Rat,A,,,Intermediate,1,,50597
,CHEMBL874542,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10622,,5669,,1,,Area under curve was determine after peroral administration at 50 mpk in Rat,A,,,Intermediate,1,,50597
,CHEMBL625215,,U,BAO_0000100,,,,,10623,,6472,,1,,Calculated partition coefficient (clogP) (AlogP),P,,,Autocuration,0,,22229
,CHEMBL625216,,U,BAO_0000019,,,,,10624,,15106,,1,,Activated partial thromboplastin time measured,A,,,Autocuration,0,,22224
,CHEMBL625217,,U,BAO_0000100,,,,,10625,,15207,,1,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,,,Autocuration,0,,22224
,CHEMBL625218,,U,BAO_0000100,,,,,10626,,15207,,1,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,,,Autocuration,0,,22224
,CHEMBL622864,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,10627,1969.0,13941,,1,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL622865,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10628,1969.0,13941,,1,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,,,Intermediate,1,,50597
,CHEMBL622866,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10629,1969.0,13941,,1,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,,,Intermediate,1,,50597
,CHEMBL622867,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,10630,1969.0,13941,,1,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL876808,10141.0,N,BAO_0000218,Cavia porcellus,,,Plasma,10631,1969.0,15240,,1,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,,,Intermediate,1,,50512
,CHEMBL627725,,U,BAO_0000019,,,,Brain,10632,955.0,10655,,1,,AUC in brain,A,,,Autocuration,0,,22224
,CHEMBL627726,,U,BAO_0000019,,,,Serum,10633,1977.0,10655,,1,,AUC in serum,A,,,Autocuration,0,,22224
,CHEMBL627727,,U,BAO_0000019,,,,Plasma,10634,1969.0,6504,,1,,AUC was determined,A,,,Autocuration,0,,22224
,CHEMBL627728,,U,BAO_0000019,,,,Plasma,10635,1969.0,10615,,1,,AUC of the compound.,A,,,Autocuration,0,,22224
,CHEMBL627729,,U,BAO_0000019,,,,Plasma,10636,1969.0,10353,,1,,AUC value (0-4 hr),A,,,Autocuration,0,,22224
,CHEMBL627730,,U,BAO_0000019,,,,Plasma,10637,1969.0,14907,,1,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,,,Autocuration,0,,22224
,CHEMBL627731,,U,BAO_0000019,,,,Plasma,10638,1969.0,14907,,1,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,,,Autocuration,0,,22224
,CHEMBL627732,,U,BAO_0000019,,,,Plasma,10639,1969.0,14907,,1,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,,,Autocuration,0,,22224
,CHEMBL627733,,U,BAO_0000019,,,,Plasma,10640,1969.0,14907,,1,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,,,Autocuration,0,,22224
,CHEMBL627734,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10641,1969.0,16359,,1,,AUC(area under curve) was determined after intravenous administration in rats,A,,,Intermediate,1,,50597
,CHEMBL627735,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10642,1969.0,16359,,1,,AUC(area under curve) was determined after oral administration in rats,A,,,Intermediate,1,,50597
,CHEMBL627736,10141.0,N,BAO_0000218,Cavia porcellus,,,Plasma,10643,1969.0,15240,,1,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,,,Intermediate,1,,50512
,CHEMBL876809,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10644,1969.0,15240,,1,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,,,Intermediate,1,,50597
,CHEMBL627737,,U,BAO_0000019,,,,,10645,,15469,,1,,Area Under Curve after oral dosing of 100 uM/Kg,A,,,Autocuration,0,,22224
,CHEMBL627738,,U,BAO_0000019,,,,,10646,,15469,,1,,Area Under Curve after oral dosing of 30 uM/Kg,A,,,Autocuration,0,,22224
,CHEMBL627739,,U,BAO_0000019,,,,,10647,,13520,,1,,Area Under Curve was measured by ploting the graph between concentration verses time,A,,,Autocuration,0,,22224
,CHEMBL626143,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10648,,17025,,1,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,,,Intermediate,1,,50588
,CHEMBL626144,314293.0,U,BAO_0000218,Simiiformes,,,,10649,,17025,,1,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL626145,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,10650,,17025,,1,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,,,Intermediate,1,,50592
,CHEMBL626146,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10651,,17025,,1,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,,,Intermediate,1,,50597
,CHEMBL626147,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10652,178.0,12032,,1,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,,,Intermediate,1,,50597
,CHEMBL626148,,U,BAO_0000019,,,,,10653,,10291,,1,,Area under curve (AUC) was determined,A,,,Autocuration,0,,22224
,CHEMBL626149,,U,BAO_0000218,,,,,10654,,5767,,1,,Area under curve (AUC) following ip administration at 1 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL626150,,U,BAO_0000019,,,,,10655,,1434,,1,,Area under curve (AUC) was determined; ND is Not determined,A,,,Autocuration,0,,22224
,CHEMBL626151,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10656,,14925,,1,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,,,Intermediate,1,,50588
,CHEMBL626152,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10657,,14925,,1,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,,,Intermediate,1,,50588
,CHEMBL626153,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10658,,14925,,1,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,,,Intermediate,1,,50588
,CHEMBL626154,,U,BAO_0000019,,,,,10659,,1434,,1,,Area under curve (AUR) was determined,A,,,Autocuration,0,,22224
,CHEMBL626155,,U,BAO_0000019,,,,,10660,,11883,,1,,Area under curve at 1 uM/dg administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626156,,U,BAO_0000019,,,,,10661,,11883,,1,,Area under curve at 10 uM/dg administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626157,,U,BAO_0000019,,,,,10662,,11883,,1,,Area under curve at 2 uM/dg administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626158,,U,BAO_0000019,,,,,10663,,11883,,1,,Area under curve at 20 uM/dg administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626159,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10664,,15233,,1,,Area under curve at a peroral dose of 3 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL626160,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10665,,15233,,1,,Area under curve at a peroral dose of 3 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL626161,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10666,,15233,,1,,Area under curve at an iv dose of 1 mg/kg in dog,A,,,Intermediate,1,,50588
,CHEMBL626162,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10667,,15233,,1,,Area under curve at an iv dose of 1 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL626163,,U,BAO_0000019,,,,,10668,,12978,,1,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,,,Autocuration,0,,22224
,CHEMBL626164,,U,BAO_0000019,,,,,10669,,12978,,1,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,,,Autocuration,0,,22224
,CHEMBL626165,10090.0,N,BAO_0000218,Mus musculus,,,,10670,,11355,,1,,Area under curve measured as conc vs time after intravenous administration to mice.,A,,,Intermediate,1,,50594
,CHEMBL626166,10090.0,N,BAO_0000218,Mus musculus,,,,10671,,11355,,1,,Area under curve measured as conc vs time after peroral administration to mice.,A,,,Intermediate,1,,50594
,CHEMBL626167,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10672,,12923,,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Intermediate,1,,50588
,CHEMBL626168,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10673,,12923,,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,,,Intermediate,1,,50588
,CHEMBL877463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10674,,12923,,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,,,Intermediate,1,,50588
,CHEMBL626169,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10675,,12923,,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,,,Intermediate,1,,50588
,CHEMBL626170,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10676,948.0,17738,,1,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10677,948.0,17738,,1,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10678,948.0,17738,,1,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626173,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10679,948.0,17738,,1,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626174,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10680,2113.0,17738,,1,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626175,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10681,2113.0,17738,,1,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626176,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10682,2113.0,17738,,1,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL626177,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10683,2113.0,17738,,1,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622499,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10684,2113.0,17738,,1,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622500,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10685,2107.0,17738,,1,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622501,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10686,2107.0,17738,,1,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622502,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10687,2107.0,17738,,1,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL622503,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10688,2107.0,17738,,1,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL877614,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10689,2107.0,17738,,1,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624839,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10690,2048.0,17738,,1,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624840,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10691,2048.0,17738,,1,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624841,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10692,2048.0,17738,,1,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624842,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10693,2048.0,17738,,1,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624843,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10694,2385.0,17738,,1,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624844,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10695,2385.0,17738,,1,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL624845,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10696,2385.0,17738,,1,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL621904,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10697,2385.0,17738,,1,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL621905,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10698,178.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL874382,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10699,178.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621906,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,10700,178.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL621907,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10701,955.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622096,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10702,955.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622097,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,10703,955.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622098,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10704,948.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622099,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10705,948.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622100,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10706,948.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622101,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10707,2113.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622102,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10708,2113.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622103,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10709,2113.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622104,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10710,2107.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622105,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10711,2107.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622106,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10712,2107.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622107,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10713,2048.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622108,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10714,2048.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622109,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,10715,2048.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622110,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10716,2385.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622111,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10717,2385.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL874383,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,10718,2385.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622112,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,10719,14.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622113,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,10720,14.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622114,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,10721,14.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622115,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,10722,2106.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622116,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,10723,2106.0,11195,,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622117,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10724,,6193,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622118,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10725,,6803,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622119,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10726,,6647,,1,,Oral bioavailability in rats at 6 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622120,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10727,,6647,,1,,Oral bioavailability in rat (dose 6 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL622121,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10728,,6647,,1,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,In vivo,,Intermediate,1,,50597
,CHEMBL622122,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10729,,6640,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622123,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10730,,6641,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622124,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10731,,6641,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622125,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10732,,6642,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622126,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10733,,5472,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL620455,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10734,,6141,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL620456,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10735,,4390,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620457,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10736,,5472,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620458,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10737,,5472,,1,,Oral bioavailability was evaluated; Not tested,A,In vivo,,Intermediate,1,,50597
,CHEMBL620459,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10738,,5438,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL620460,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10739,,4883,,1,,Oral bioavailability in rat by oral dosing,A,In vivo,,Intermediate,1,,50597
,CHEMBL620461,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10740,,1908,,1,,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL620462,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10741,,4853,,1,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Intermediate,1,,50597
,CHEMBL620463,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10742,,4853,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL620464,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10743,,4853,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL620465,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10744,,4853,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL620466,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10745,,4853,,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL620467,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10746,,4853,,1,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620468,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10747,,4853,,1,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL620469,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10748,,12873,,1,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,In vivo,,Intermediate,1,,50597
,CHEMBL620470,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10749,,12873,,1,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,In vivo,,Intermediate,1,,50597
,CHEMBL620471,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10750,,3169,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620472,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10751,,6305,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620473,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10752,,4762,,1,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620474,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10753,,17847,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620475,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10754,,6211,,1,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL620476,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10755,,6011,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620477,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10756,,6317,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL620478,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10757,,6644,,1,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618768,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10758,,6644,,1,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618769,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10759,,6644,,1,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618770,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10760,,6644,,1,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL618771,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10761,,6113,,1,,Oral bioavailability (dose 20 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618772,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10762,,5937,,1,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618773,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10763,,5711,,1,,Oral bioavailability in rat at 10 mg/kg of the compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL875842,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10764,,17717,,1,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL618774,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10765,,17717,,1,,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618775,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10766,,17717,,1,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Intermediate,1,,50597
,CHEMBL618776,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10767,,17717,,1,,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618777,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10768,,4722,,1,,Percent bioavailability (F) in rats after iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL618778,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10769,,4722,,1,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618779,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10770,,4353,,1,,Bioavailability in rat (dose 5 uM/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618780,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10771,,15662,,1,,Oral bioavailability,A,In vivo,,Intermediate,1,,50597
,CHEMBL618781,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10772,,4756,,1,,Bioavailability in rat (dose 2 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL618782,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10773,,4756,,1,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL618783,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10774,,3436,,1,,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL618784,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10775,,17800,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618785,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10776,,15762,,1,,Percent oral bioavailability evaluated in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618786,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10777,,5089,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618787,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10778,,5089,,1,,Percent oral bioavailability in rat; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL618788,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10779,,3185,,1,,Oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618789,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10780,,5145,,1,,Bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL618790,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10781,,3457,,1,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,In vivo,,Intermediate,1,,50597
,CHEMBL618791,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10782,,3457,,1,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,In vivo,,Intermediate,1,,50597
,CHEMBL875843,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10783,,5983,,1,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL618792,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10784,,5739,,1,,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Intermediate,1,,50597
,CHEMBL623395,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10785,,3579,,1,,Cmax at a dose of 30 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623396,314293.0,U,BAO_0000218,Simiiformes,,,,10786,,17788,,1,,Cmax in monkeys at a dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL623397,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10787,,14956,,1,,Cmax in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623398,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10788,,17788,,1,,Cmax in rats at a dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623399,10090.0,N,BAO_0000218,Mus musculus,,,,10789,,9750,,1,,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,In vivo,,Intermediate,1,,50594
,CHEMBL623400,,U,BAO_0000218,,,,,10790,,12767,,1,,"Cmax value at a dose of 12.7 uM/kg, po",A,In vivo,,Autocuration,0,,22224
,CHEMBL623401,,U,BAO_0000218,,,,,10791,,12767,,1,,"Cmax value at a dose of 6.3 uM/kg, iv",A,In vivo,,Autocuration,0,,22224
,CHEMBL623402,,U,BAO_0000218,,,,,10792,,12767,,1,,"Cmax value at a dose of 7.1 uM/kg, iv",A,In vivo,,Autocuration,0,,22224
,CHEMBL623403,,U,BAO_0000218,,,,,10793,,12703,,1,,Cmax value of compound was determined after 1 hr,A,In vivo,,Autocuration,0,,22224
,CHEMBL623404,,U,BAO_0000218,,,,,10794,,15778,,1,,Cmax value of the compound,A,In vivo,,Autocuration,0,,22224
,CHEMBL625997,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10795,,12818,,1,,Cmax value administered intraintestinal in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625998,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10796,,14964,,1,,Cmax value administered perorally was determined in rat; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL625999,,U,BAO_0000218,,,,,10797,,15808,,1,,Cmax value at the dose of 2.3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626000,,U,BAO_0000218,,,,,10798,,15808,,1,,Cmax value at the dose of 5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626001,,U,BAO_0000218,,,,,10799,,15778,,1,,Cmax value in the period of 8 hr after dosing. ,A,In vivo,,Autocuration,0,,22224
,CHEMBL626002,,U,BAO_0000218,,,,,10800,,3715,,1,,Cmax value at a oral dose of 20 mg/kg; Not tested,A,In vivo,,Autocuration,0,,22224
,CHEMBL626003,,U,BAO_0000218,,,,,10801,,3715,,1,,Cmax value at a oral dose of 20 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626004,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10802,,1446,,1,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Intermediate,1,,50597
,CHEMBL626005,10141.0,N,BAO_0000218,Cavia porcellus,,,,10803,,15240,,1,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Intermediate,1,,50512
,CHEMBL626006,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10804,,15240,,1,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626007,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10805,1969.0,14810,,1,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,In vivo,,Intermediate,1,,50597
,CHEMBL626008,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10806,1969.0,14239,,1,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL626009,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,10807,2107.0,12555,,1,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,In vivo,,Intermediate,1,,50588
,CHEMBL626010,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10808,,10754,,1,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626011,10090.0,N,BAO_0000218,Mus musculus,,,Blood,10809,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL626012,10090.0,N,BAO_0000218,Mus musculus,,,Blood,10810,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL626013,10090.0,N,BAO_0000218,Mus musculus,,,Blood,10811,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL626014,10090.0,N,BAO_0000218,Mus musculus,,,Blood,10812,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL877496,10090.0,N,BAO_0000218,Mus musculus,,,Blood,10813,178.0,10754,,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL626015,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10814,,14600,,1,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Intermediate,1,,50588
,CHEMBL626016,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10815,,14600,,1,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Intermediate,1,,50588
,CHEMBL626017,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10816,,14600,,1,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Intermediate,1,,50588
,CHEMBL626018,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,10817,1969.0,13543,,1,,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626692,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,10818,1969.0,13543,,1,,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626693,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10819,1969.0,13543,,1,,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626694,10116.0,U,BAO_0000218,Rattus norvegicus,,,Plasma,10820,1969.0,13543,,1,,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Autocuration,0,,22224
,CHEMBL626695,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10821,178.0,14600,,1,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626696,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10822,178.0,14600,,1,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626697,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10823,178.0,14600,,1,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626859,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10824,178.0,14600,,1,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,In vivo,,Intermediate,1,,50588
,CHEMBL626860,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10825,178.0,14600,,1,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626861,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,10826,178.0,14600,,1,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626296,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10827,,14681,,1,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626297,,U,BAO_0000218,,,,,10828,,15905,,1,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626298,,U,BAO_0000218,,,,Plasma,10829,1969.0,15905,,1,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,In vivo,,Autocuration,0,,22224
,CHEMBL626299,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10830,1969.0,13304,,1,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,In vivo,,Intermediate,1,,50597
,CHEMBL626300,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10831,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626301,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10832,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626962,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10833,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626963,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10834,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626964,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10835,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626965,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,10836,1969.0,14839,,1,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,In vivo,,Intermediate,1,,100710
,CHEMBL626966,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10837,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL626967,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10838,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL626968,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,10839,1969.0,14839,,1,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,In vivo,,Intermediate,1,,100710
,CHEMBL626969,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10840,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,,,Intermediate,1,,50597
,CHEMBL627126,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10841,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,,,Intermediate,1,,50597
,CHEMBL631276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10842,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,,,Intermediate,1,,50597
,CHEMBL631277,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10843,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,,,Intermediate,1,,50597
,CHEMBL631278,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10844,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,,,Intermediate,1,,50597
,CHEMBL874457,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10845,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,,,Intermediate,1,,50597
,CHEMBL631279,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10846,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,,,Intermediate,1,,50597
,CHEMBL631280,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10847,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,,,Intermediate,1,,50597
,CHEMBL631281,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10848,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,,,Intermediate,1,,50597
,CHEMBL631968,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10849,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,,,Intermediate,1,,50597
,CHEMBL631969,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10850,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,,,Intermediate,1,,50597
,CHEMBL631970,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10851,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,,,Intermediate,1,,50597
,CHEMBL631971,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10852,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,,,Intermediate,1,,50597
,CHEMBL631972,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10853,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,,,Intermediate,1,,50597
,CHEMBL630435,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10854,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,,,Intermediate,1,,50597
,CHEMBL630436,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10855,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,,,Intermediate,1,,50597
,CHEMBL630437,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10856,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,,,Intermediate,1,,50597
,CHEMBL630438,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10857,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,,,Intermediate,1,,50597
,CHEMBL630439,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,10858,948.0,8418,,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,,,Intermediate,1,,50597
,CHEMBL630440,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10859,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,,,Intermediate,1,,50597
,CHEMBL630441,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10860,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,,,Intermediate,1,,50597
,CHEMBL630442,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10861,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,,,Intermediate,1,,50597
,CHEMBL625234,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10862,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,,,Intermediate,1,,50597
,CHEMBL625235,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10863,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,,,Intermediate,1,,50597
,CHEMBL625236,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10864,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,,,Intermediate,1,,50597
,CHEMBL625237,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10865,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,,,Intermediate,1,,50597
,CHEMBL626125,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10866,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,,,Intermediate,1,,50597
,CHEMBL626126,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10867,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,,,Intermediate,1,,50597
,CHEMBL626127,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10868,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,,,Intermediate,1,,50597
,CHEMBL626128,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10869,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,,,Intermediate,1,,50597
,CHEMBL626129,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10870,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,,,Intermediate,1,,50597
,CHEMBL626130,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10871,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,,,Intermediate,1,,50597
,CHEMBL626131,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10872,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,,,Intermediate,1,,50597
,CHEMBL626132,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10873,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,,,Intermediate,1,,50597
,CHEMBL626752,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10874,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,,,Intermediate,1,,50597
,CHEMBL626753,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10875,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,,,Intermediate,1,,50597
,CHEMBL626754,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10876,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,,,Intermediate,1,,50597
,CHEMBL626755,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,10877,2113.0,8418,,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,,,Intermediate,1,,50597
,CHEMBL626756,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10878,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,,,Intermediate,1,,50597
,CHEMBL626757,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10879,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,,,Intermediate,1,,50597
,CHEMBL626758,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10880,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,,,Intermediate,1,,50597
,CHEMBL626759,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10881,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,,,Intermediate,1,,50597
,CHEMBL626760,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,10882,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,,,Intermediate,1,,50597
,CHEMBL626394,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10883,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL626395,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10884,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL626396,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10885,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL626397,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10886,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL626398,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10887,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL626399,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10888,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL874653,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10889,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL626400,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10890,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL626401,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10891,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL626402,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10892,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL626403,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10893,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL626404,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10894,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL626405,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10895,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL625529,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10896,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625530,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10897,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625531,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10898,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL625532,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10899,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL625533,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10900,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL875474,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10901,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL625534,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10902,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625535,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10903,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625536,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10904,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL625537,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10905,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL625538,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10906,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625539,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10907,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL625540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10908,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625541,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10909,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625542,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10910,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL625543,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10911,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL625544,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10912,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL625545,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10913,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL625546,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10914,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625547,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10915,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL625548,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10916,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625549,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10917,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625550,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10918,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625551,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10919,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL875475,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10920,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625552,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10921,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625553,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10922,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL625554,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10923,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL625555,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10924,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL625556,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10925,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624986,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10926,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL624987,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10927,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624988,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10928,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL624989,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10929,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,In vivo,,Intermediate,1,,50588
,CHEMBL624990,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10930,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,In vivo,,Intermediate,1,,50588
,CHEMBL874391,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10931,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,In vivo,,Intermediate,1,,50588
,CHEMBL624991,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10932,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,In vivo,,Intermediate,1,,50588
,CHEMBL624992,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10933,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,In vivo,,Intermediate,1,,50588
,CHEMBL624993,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10934,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,In vivo,,Intermediate,1,,50588
,CHEMBL624994,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10935,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,In vivo,,Intermediate,1,,50588
,CHEMBL624995,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10936,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,In vivo,,Intermediate,1,,50588
,CHEMBL624996,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10937,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,In vivo,,Intermediate,1,,50588
,CHEMBL624997,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10938,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,In vivo,,Intermediate,1,,50588
,CHEMBL624998,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10939,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,In vivo,,Intermediate,1,,50588
,CHEMBL624999,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10940,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,In vivo,,Intermediate,1,,50588
,CHEMBL882955,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10941,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,In vivo,,Intermediate,1,,50588
,CHEMBL625000,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10942,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,In vivo,,Intermediate,1,,50588
,CHEMBL625001,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10943,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,In vivo,,Intermediate,1,,50588
,CHEMBL625089,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10944,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,In vivo,,Intermediate,1,,50588
,CHEMBL625090,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10945,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,In vivo,,Intermediate,1,,50588
,CHEMBL625091,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10946,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,In vivo,,Intermediate,1,,50588
,CHEMBL625092,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10947,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,In vivo,,Intermediate,1,,50588
,CHEMBL625093,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10948,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,In vivo,,Intermediate,1,,50588
,CHEMBL625094,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10949,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,In vivo,,Intermediate,1,,50588
,CHEMBL625095,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,10950,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,In vivo,,Intermediate,1,,50588
,CHEMBL625096,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10951,,2249,,1,,Compound was evaluated for its bioavailability in the dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625097,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10952,,2249,,1,,Compound was evaluated for its bioavailability in the rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL882956,,U,BAO_0000218,,,,,10953,,17515,,1,,Compound was evaluated for oral bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL625098,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10954,,14541,,1,,Compound was evaluated for percentage of Oral bioavailability in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625099,10141.0,U,BAO_0000218,Cavia porcellus,,,,10955,,12797,,1,,Bioavailability in guinea pig,A,In vivo,,Autocuration,0,,22224
,CHEMBL625100,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10956,,12797,,1,,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625101,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10957,,12797,,1,,Compound was evaluated for the oral bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL874396,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10958,,12797,,1,,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625102,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,10959,,11727,,1,,Bioavailability in dog (dosed i.v.),F,In vivo,,Autocuration,0,,22224
,CHEMBL625103,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,10960,,13249,,1,,Compound was tested for in vivo bioavailability in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625104,10026.0,N,BAO_0000218,Cricetinae,,,,10961,,13249,,1,,Compound was tested for in vivo bioavailability in hamsters,A,In vivo,,Intermediate,1,,100712
,CHEMBL625105,314293.0,U,BAO_0000218,Simiiformes,,,,10962,,13249,,1,,Compound was tested for in vivo bioavailability in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL625106,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10963,,13249,,1,,Compound was tested for in vivo bioavailability in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625107,10090.0,U,BAO_0000218,Mus musculus,,,,10964,,9552,,1,,Oral bioavailability in mouse,A,In vivo,,Autocuration,0,,22224
,CHEMBL625108,10090.0,N,BAO_0000218,Mus musculus,,,,10965,,9552,,1,,Compound was tested for percent of oral bioavailability in mice; 56-74,A,In vivo,,Intermediate,1,,50594
,CHEMBL625109,10090.0,U,BAO_0000218,Mus musculus,,,,10966,,14839,,1,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL625110,9541.0,U,BAO_0000218,Macaca fascicularis,,,,10967,,14839,,1,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625111,9541.0,U,BAO_0000218,Macaca fascicularis,,,,10968,,14839,,1,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625112,10090.0,N,BAO_0000218,Mus musculus,,,,10969,,14839,,1,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,In vivo,,Intermediate,1,,50594
,CHEMBL875334,10090.0,N,BAO_0000218,Mus musculus,,,,10970,,14839,,1,,Oral bioavailability in nude mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL628617,9443.0,U,BAO_0000218,Primates,,,,10971,,11219,,1,,Bioavailability in monkey (i.d. dosing),A,In vivo,,Autocuration,0,,22224
,CHEMBL628618,10116.0,U,BAO_0000218,Rattus norvegicus,,,,10972,,9552,,1,,Bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL628619,,U,BAO_0000218,,,,,10973,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,In vivo,,Autocuration,0,,22224
,CHEMBL628620,,U,BAO_0000218,,,,,10974,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,In vivo,,Autocuration,0,,22224
,CHEMBL628621,9541.0,N,BAO_0000218,Macaca fascicularis,,,,10975,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Intermediate,1,,100710
,CHEMBL628622,9541.0,N,BAO_0000218,Macaca fascicularis,,,,10976,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Intermediate,1,,100710
,CHEMBL628623,9541.0,N,BAO_0000218,Macaca fascicularis,,,,10977,,14839,,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Intermediate,1,,100710
,CHEMBL628624,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,10978,1969.0,14839,,1,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,100710
,CHEMBL628625,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10979,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL628626,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,10980,1969.0,14839,,1,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,In vivo,,Intermediate,1,,100710
,CHEMBL627041,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10981,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627042,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10982,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627043,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10983,1969.0,14839,,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50594
,CHEMBL627044,,U,BAO_0000218,,,,Plasma,10984,1969.0,13932,,1,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL627045,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,10985,1969.0,11637,,1,,Cmax in mouse plasma,A,In vivo,,Intermediate,1,,50594
,CHEMBL627046,,U,BAO_0000218,,,,Plasma,10986,1969.0,11637,,1,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,In vivo,,Autocuration,0,,22224
,CHEMBL627047,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10987,1969.0,13960,,1,,Maximal plasma concentration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627048,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,10988,1969.0,15905,,1,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627049,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10989,,14062,,1,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627050,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10990,,14062,,1,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627051,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10991,,14062,,1,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627052,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10992,,14062,,1,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627053,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10993,,14062,,1,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627054,10116.0,N,BAO_0000218,Rattus norvegicus,,,,10994,,14062,,1,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627055,10090.0,N,BAO_0000218,Mus musculus,,,,10995,,15011,,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL627056,10090.0,N,BAO_0000218,Mus musculus,,,,10996,,15011,,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL627057,10090.0,N,BAO_0000218,Mus musculus,,,,10997,,15011,,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Intermediate,1,,50594
,CHEMBL627058,10090.0,N,BAO_0000218,Mus musculus,,,,10998,,15011,,1,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL626211,10090.0,N,BAO_0000218,Mus musculus,,,,10999,,15011,,1,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL626212,,U,BAO_0000218,,,,,11000,,10291,,1,,Maximum Concentration of the compound.,A,In vivo,,Autocuration,0,,22224
,CHEMBL626213,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11001,,14599,,1,,Maximum Concentration was measured after iv administration into Beagle dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626214,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11002,,14599,,1,,Maximum Concentration was measured after iv administration into Beagle dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626215,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11003,,14599,,1,,Maximum Concentration was measured after po administration into Beagle dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626216,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11004,,14599,,1,,Maximum Concentration was measured after po administration into Beagle dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626217,,U,BAO_0000218,,,,Blood,11005,178.0,12767,,1,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626218,,U,BAO_0000218,,,,Blood,11006,178.0,12767,,1,,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626219,,U,BAO_0000218,,,,Blood,11007,178.0,12767,,1,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,In vivo,,Autocuration,0,,22224
,CHEMBL626220,,U,BAO_0000218,,,,Blood,11008,178.0,12767,,1,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,In vivo,,Autocuration,0,,22224
,CHEMBL626221,,U,BAO_0000218,,,,Blood,11009,178.0,12767,,1,,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626222,,U,BAO_0000218,,,,Blood,11010,178.0,12767,,1,,Maximum blood level reached at dose of 10.6 uM/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626223,10141.0,N,BAO_0000218,Cavia porcellus,,,,11011,,14706,,1,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,In vivo,,Intermediate,1,,50512
,CHEMBL626224,10141.0,N,BAO_0000218,Cavia porcellus,,,,11012,,14706,,1,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,In vivo,,Intermediate,1,,50512
,CHEMBL626225,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11013,955.0,14793,,1,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626226,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11014,955.0,14793,,1,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626227,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11015,955.0,14793,,1,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626228,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11016,955.0,14793,,1,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626229,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11017,,14793,,1,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626921,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11018,,14793,,1,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL876793,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11019,,14793,,1,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625309,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11020,,14793,,1,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625310,1423.0,N,BAO_0000218,Bacillus subtilis,,,,11021,,10524,,1,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Intermediate,1,,50278
,CHEMBL625311,314293.0,U,BAO_0000218,Simiiformes,,,,11022,,11871,,1,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11023,,11871,,1,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625313,,U,BAO_0000218,,,,,11024,,3437,,1,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL625314,10090.0,N,BAO_0000218,Mus musculus,,,,11025,,12038,,1,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL625315,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11026,,12038,,1,,Maximum concentration in male rats after iv administration of 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625316,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11027,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,,,Intermediate,1,,50597
,CHEMBL625317,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11028,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,,,Intermediate,1,,50597
,CHEMBL625318,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11029,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,,,Intermediate,1,,50597
,CHEMBL625319,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11030,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,,,Intermediate,1,,50597
,CHEMBL625320,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11031,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,,,Intermediate,1,,50597
,CHEMBL625321,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11032,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,,,Intermediate,1,,50597
,CHEMBL625322,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11033,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,,,Intermediate,1,,50597
,CHEMBL876801,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11034,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,,,Intermediate,1,,50597
,CHEMBL625323,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11035,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,,,Intermediate,1,,50597
,CHEMBL625324,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11036,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,,,Intermediate,1,,50597
,CHEMBL625325,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11037,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,,,Intermediate,1,,50597
,CHEMBL625326,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11038,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,,,Intermediate,1,,50597
,CHEMBL625327,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11039,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,,,Intermediate,1,,50597
,CHEMBL625328,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11040,2107.0,8418,,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,,,Intermediate,1,,50597
,CHEMBL625329,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11041,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,,,Intermediate,1,,50597
,CHEMBL625330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11042,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,,,Intermediate,1,,50597
,CHEMBL627774,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11043,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,,,Intermediate,1,,50597
,CHEMBL627775,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11044,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,,,Intermediate,1,,50597
,CHEMBL627949,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11045,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,,,Intermediate,1,,50597
,CHEMBL627950,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11046,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,,,Intermediate,1,,50597
,CHEMBL627951,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11047,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,,,Intermediate,1,,50597
,CHEMBL627952,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11048,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,,,Intermediate,1,,50597
,CHEMBL627953,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11049,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,,,Intermediate,1,,50597
,CHEMBL627954,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11050,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,,,Intermediate,1,,50597
,CHEMBL627955,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11051,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,,,Intermediate,1,,50597
,CHEMBL627956,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11052,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,,,Intermediate,1,,50597
,CHEMBL876802,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11053,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,,,Intermediate,1,,50597
,CHEMBL627957,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11054,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,,,Intermediate,1,,50597
,CHEMBL627958,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11055,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,,,Intermediate,1,,50597
,CHEMBL627959,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11056,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,,,Intermediate,1,,50597
,CHEMBL627960,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11057,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,,,Intermediate,1,,50597
,CHEMBL627961,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11058,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,,,Intermediate,1,,50597
,CHEMBL627962,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11059,2048.0,8418,,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,,,Intermediate,1,,50597
,CHEMBL627963,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11060,,9796,,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624759,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11061,,9796,,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624760,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11062,,9796,,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624761,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11063,,9796,,1,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL877607,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11064,,9796,,1,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624762,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11065,2107.0,9796,,1,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624763,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11066,2107.0,9796,,1,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624764,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11067,2107.0,9796,,1,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624765,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11068,2107.0,9796,,1,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624766,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11069,2107.0,9796,,1,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL624767,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11070,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624768,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11071,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL624769,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11072,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624770,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11073,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL624771,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11074,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL624772,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11075,,6996,,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624773,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11076,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL624774,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11077,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624775,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11078,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624776,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11079,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL624777,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11080,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL624778,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11081,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624779,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11082,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL624780,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11083,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL624781,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11084,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL877608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11085,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624782,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11086,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624783,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11087,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624784,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11088,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL624785,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11089,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624786,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11090,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL624787,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11091,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL628676,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11092,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL621842,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11093,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL621843,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11094,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL623873,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11095,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL623874,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11096,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL623875,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11097,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL623876,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11098,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL623877,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11099,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL623878,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11100,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623879,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11101,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL623880,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11102,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623881,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11103,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623957,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11104,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623958,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11105,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623959,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11106,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623960,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11107,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623961,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11108,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL623962,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11109,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL624676,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11110,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL624677,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11111,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624678,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11112,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL624679,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11113,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624680,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11114,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL624849,,U,BAO_0000218,,,,,11115,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,In vivo,,Autocuration,0,,22224
,CHEMBL624850,,U,BAO_0000218,,,,,11116,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,In vivo,,Autocuration,0,,22224
,CHEMBL874399,,U,BAO_0000218,,,,,11117,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,In vivo,,Autocuration,0,,22224
,CHEMBL624851,,U,BAO_0000218,,,,,11118,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,In vivo,,Autocuration,0,,22224
,CHEMBL624852,,U,BAO_0000218,,,,,11119,,11732,,1,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,In vivo,,Autocuration,0,,22224
,CHEMBL624853,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11120,,13359,,1,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL624854,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11121,,16618,,1,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Autocuration,0,,22224
,CHEMBL624855,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11122,,13960,,1,,Oral bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL624856,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11123,,13917,,1,,Oral bioavailability in rats was determined in vivo,A,In vivo,,Autocuration,0,,22224
,CHEMBL882957,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11124,,14266,,1,,Oral bioavailability in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL624857,314293.0,U,BAO_0000218,Simiiformes,,,,11125,,12359,,1,,Oral bioavailability of compound in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL622202,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11126,,12359,,1,,Oral bioavailability of compound in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622203,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11127,,12359,,1,,Bioavailability in rat of PMEA prodrug,A,In vivo,,Autocuration,0,,22224
,CHEMBL625522,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11128,,12359,,1,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,In vivo,,Intermediate,1,,50597
,CHEMBL622868,9544.0,U,BAO_0000218,Macaca mulatta,,,,11129,,10791,,1,,Serum conc at 3 hours following 25 mg/kg dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL622869,9544.0,U,BAO_0000218,Macaca mulatta,,,Urine,11130,1088.0,10791,,1,,Urine conc 0-5 hours following 25 mg/kg dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL622870,9544.0,U,BAO_0000218,Macaca mulatta,,,Urine,11131,1088.0,10791,,1,,Urine conc 0-24 hours following 25 mg/kg dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL622871,9534.0,U,BAO_0000218,Chlorocebus aethiops,,,,11132,,138,,1,,Oral bioavailability in African green monkeys; 20-25,A,In vivo,,Autocuration,0,,22224
,CHEMBL620560,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11133,,14521,,1,,Oral bioavailability in cynomolgus monkey.,A,In vivo,,Intermediate,1,,100710
,CHEMBL620561,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11134,,13953,,1,,Oral bioavailability in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL620562,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11135,,12836,,1,,Oral bioavailability in dog at 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL620563,10026.0,N,BAO_0000218,Cricetinae,,,,11136,,12836,,1,,Oral bioavailability in hamster at 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,100712
,CHEMBL620564,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11137,,12836,,1,,Oral bioavailability in rat at 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL872265,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11138,,14521,,1,,Oral bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL620565,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11139,,13953,,1,,Oral bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL620566,9347.0,U,BAO_0000218,Eutheria,,,,11140,,6799,,1,,Oral bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL620567,,U,BAO_0000218,,,,,11141,,11311,,1,,Oral bioavailability was determined; range 49-102%,A,In vivo,,Autocuration,0,,22224
,CHEMBL620568,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11142,,4013,,1,,Oral bioavailability was determined in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL620569,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11143,,4013,,1,,Oral bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL620570,9347.0,U,BAO_0000218,Eutheria,,,,11144,,17591,,1,,Oral bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL620571,,U,BAO_0000218,,,,,11145,,17591,,1,,Oral bioavailability was determined; Not orally available,A,In vivo,,Autocuration,0,,22224
,CHEMBL620572,10090.0,N,BAO_0000218,Mus musculus,,,,11146,,15011,,1,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Intermediate,1,,50594
,CHEMBL620573,10090.0,U,BAO_0000218,Mus musculus,,,,11147,,15011,,1,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL620574,10090.0,U,BAO_0000218,Mus musculus,,,,11148,,15011,,1,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL620575,9544.0,U,BAO_0000218,Macaca mulatta,,,,11149,,9552,,1,,Oral bioavailability in Rhesus monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL620576,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11150,,9552,,1,,Oral bioavailability in dog (female mongrel),A,In vivo,,Autocuration,0,,22224
,CHEMBL875846,,U,BAO_0000218,,,,,11151,,3639,,1,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,In vivo,,Autocuration,0,,22224
,CHEMBL620577,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11152,,13397,,1,,Oral bioavailability in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL620578,,U,BAO_0000218,,,,,11153,,3031,,1,,Percentage Bioavailability was evaluated.,A,In vivo,,Autocuration,0,,22224
,CHEMBL620579,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11154,,12818,,1,,Bioavailability in rat administered i.d.,A,In vivo,,Autocuration,0,,22224
,CHEMBL621248,9347.0,U,BAO_0000218,Eutheria,,,,11155,,4847,,1,,Bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL625390,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11156,,12421,,1,,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL625391,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11157,,11966,,1,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,In vivo,,Autocuration,0,,22224
,CHEMBL872266,9443.0,U,BAO_0000218,Primates,,,,11158,,11218,,1,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625392,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11159,,13129,,1,,Oral bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL625393,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11160,,12350,,1,,The oral bioavailability was measured on rats after oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625394,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11161,,2231,,1,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625395,9544.0,N,BAO_0000218,Macaca mulatta,,,,11162,,2231,,1,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50797
,CHEMBL625396,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11163,,12187,,1,,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625397,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,11164,,12421,,1,,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL625398,10090.0,N,BAO_0000218,Mus musculus,,,,11165,,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625399,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11166,178.0,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL626074,10090.0,N,BAO_0000218,Mus musculus,,,Cerebellum,11167,2037.0,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL626075,10090.0,N,BAO_0000218,Mus musculus,,,,11168,,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL626076,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11169,1969.0,2231,,1,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626077,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,11170,1969.0,2231,,1,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Intermediate,1,,50797
,CHEMBL626078,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11171,178.0,12178,,1,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL625846,,U,BAO_0000218,,,,Blood,11172,178.0,12178,,1,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL625847,,U,BAO_0000218,,,,Blood,11173,178.0,12178,,1,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL625848,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11174,,15633,,1,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,In vivo,,Expert,1,,50597
,CHEMBL625849,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11175,1969.0,14258,,1,,Maximum concentration of compound in plasma administered orally to rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626023,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11176,1969.0,14224,,1,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,In vivo,,Intermediate,1,,50588
,CHEMBL626024,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11177,1969.0,14224,,1,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,In vivo,,Intermediate,1,,50588
,CHEMBL626025,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11178,1969.0,14224,,1,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,In vivo,,Intermediate,1,,50588
,CHEMBL626026,,U,BAO_0000218,,,,,11179,,5566,,1,,Maximum concentration after 10 mg/kg by oral administration,A,In vivo,,Autocuration,0,,22224
,CHEMBL626027,,U,BAO_0000218,,,,,11180,,16935,,1,,Maximum concentration at a dose of 1.5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626028,,U,BAO_0000218,,,,,11181,,16935,,1,,Maximum concentration at a dose of 2.0 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626029,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11182,1969.0,14224,,1,,Maximum concentration in dog plasma,A,In vivo,,Intermediate,1,,50588
,CHEMBL626030,,U,BAO_0000218,,,,Plasma,11183,1969.0,12536,,1,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626031,,U,BAO_0000218,,,,Plasma,11184,1969.0,12536,,1,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626032,,U,BAO_0000218,,,,Plasma,11185,1969.0,12536,,1,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626033,,U,BAO_0000218,,,,Plasma,11186,1969.0,12536,,1,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626034,,U,BAO_0000218,,,,Plasma,11187,1969.0,12536,,1,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626035,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11188,1969.0,9994,,1,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL626036,,U,BAO_0000218,,,,Plasma,11189,1969.0,1434,,1,,Maximum concentration in plasma at Tmax,A,In vivo,,Autocuration,0,,22224
,CHEMBL626037,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11190,1969.0,12836,,1,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,In vivo,,Expert,1,,50588
,CHEMBL626038,10026.0,N,BAO_0000218,Cricetinae,,,Plasma,11191,1969.0,12836,,1,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,100712
,CHEMBL626039,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11192,1969.0,12836,,1,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626040,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11193,1969.0,12545,,1,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626041,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Plasma,11194,1969.0,13856,,1,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,In vivo,,Intermediate,1,,50592
,CHEMBL626042,,U,BAO_0000218,,,,,11195,,3550,,1,,Maximum concentration was calculated,A,In vivo,,Autocuration,0,,22224
,CHEMBL626043,,U,BAO_0000218,,,,,11196,,2632,,1,,Maximum concentration was calculated.,A,In vivo,,Autocuration,0,,22224
,CHEMBL626044,,U,BAO_0000218,,,,,11197,,5566,,1,,Maximum concentration at a peroral dose of 10 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626045,,U,BAO_0000218,,,,,11198,,11883,,1,,Maximum concentration of the drug at 10 uM/dg administered perorally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626046,,U,BAO_0000218,,,,,11199,,11883,,1,,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626047,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11200,1969.0,14122,,1,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Intermediate,1,,50588
,CHEMBL626048,10026.0,N,BAO_0000218,Cricetinae,,,Plasma,11201,1969.0,14122,,1,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Intermediate,1,,100712
,CHEMBL626049,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11202,1969.0,14122,,1,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Intermediate,1,,50597
,CHEMBL626050,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11203,1969.0,12542,,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL874541,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11204,1969.0,12542,,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL622826,10026.0,N,BAO_0000218,Cricetinae,,,Plasma,11205,1969.0,12542,,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,In vivo,,Intermediate,1,,100712
,CHEMBL622827,10026.0,N,BAO_0000218,Cricetinae,,,Plasma,11206,1969.0,12542,,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,In vivo,,Intermediate,1,,100712
,CHEMBL622828,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11207,1969.0,12542,,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL622829,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11208,1969.0,14080,,1,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,In vivo,,Intermediate,1,,50597
,CHEMBL876806,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11209,,11911,,1,,Maximum concentration reached following intravenous administration in male rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622830,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11210,,13204,,1,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622831,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11211,,13204,,1,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626794,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11212,,14346,,1,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626795,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11213,,14346,,1,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11214,,14346,,1,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626797,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11215,,14346,,1,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626798,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11216,,14127,,1,,Maximum drug concentration is determined after oral dosing in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626799,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11217,,14339,,1,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626800,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11218,,14339,,1,,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626801,,U,BAO_0000218,,,,Plasma,11219,1969.0,13494,,1,,Maximum plasma concentration,A,In vivo,,Autocuration,0,,22224
,CHEMBL876816,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11220,1969.0,14925,,1,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,In vivo,,Intermediate,1,,50597
,CHEMBL626802,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11221,1969.0,14474,,1,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626803,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11222,1969.0,14474,,1,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626804,,U,BAO_0000218,,,,Plasma,11223,1969.0,13917,,1,,Maximum plasma concentration following oral administration of 30 umol/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626805,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11224,1969.0,9796,,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,,,Intermediate,1,,50597
,CHEMBL626309,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11225,1969.0,9796,,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626310,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11226,1969.0,9796,,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626311,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11227,1969.0,9796,,1,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626312,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11228,1969.0,9796,,1,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626313,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11229,995.0,9796,,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626314,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11230,995.0,9796,,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626315,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11231,995.0,9796,,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626316,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11232,995.0,9796,,1,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626317,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11233,995.0,9796,,1,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Intermediate,1,,50597
,CHEMBL626318,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11234,,8363,,1,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL626319,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11235,,8363,,1,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626320,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11236,,8363,,1,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL875053,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11237,,8363,,1,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626321,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11238,,8363,,1,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL626322,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11239,,8363,,1,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626323,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11240,,8363,,1,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL626324,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11241,,8363,,1,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626325,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11242,,8363,,1,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL626326,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11243,,8363,,1,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626327,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11244,,8363,,1,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Intermediate,1,,50597
,CHEMBL626328,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11245,,8363,,1,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Intermediate,1,,50597
,CHEMBL626329,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11246,178.0,8684,,1,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11247,178.0,8684,,1,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626331,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11248,178.0,8684,,1,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626332,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11249,178.0,8684,,1,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626333,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11250,178.0,8684,,1,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626334,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11251,178.0,8684,,1,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL626335,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11252,178.0,8684,,1,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624798,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11253,178.0,8684,,1,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624799,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11254,955.0,8684,,1,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624800,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11255,955.0,8684,,1,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624801,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11256,955.0,8684,,1,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624802,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11257,955.0,8684,,1,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624803,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11258,955.0,8684,,1,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624804,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11259,955.0,8684,,1,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624805,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11260,955.0,8684,,1,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624806,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11261,955.0,8684,,1,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624807,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11262,,8684,,1,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624808,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11263,,8684,,1,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624809,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11264,,8684,,1,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624810,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11265,,8684,,1,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL877618,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11266,,8684,,1,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624811,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11267,,8684,,1,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624812,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11268,,8684,,1,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624813,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11269,,8684,,1,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11270,,8684,,1,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11271,,8684,,1,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11272,,8684,,1,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11273,,8684,,1,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624818,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11274,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624819,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11275,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL624820,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11276,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624821,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11277,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL624822,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11278,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL624823,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11279,,6996,,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL624824,562.0,N,BAO_0000218,Escherichia coli,,,,11280,,15599,,1,,Observed diffusion coefficient in organic solvent for Escherichia coli,A,,,Intermediate,1,,50212
,CHEMBL624825,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11281,178.0,9614,,1,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624826,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11282,178.0,9614,,1,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL876817,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cardiac atrium,11283,2081.0,9614,,1,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624827,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cardiac atrium,11284,2081.0,9614,,1,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624828,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11285,,9614,,1,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624829,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11286,,9614,,1,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624830,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11287,2107.0,9614,,1,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624831,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11288,2107.0,9614,,1,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624832,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cardiac atrium,11289,2081.0,9614,,1,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624833,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cardiac atrium,11290,2081.0,9614,,1,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624834,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11291,,9614,,1,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624835,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11292,,9614,,1,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624836,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11293,2106.0,9614,,1,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Intermediate,1,,50597
,CHEMBL624837,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11294,2106.0,9614,,1,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Intermediate,1,,50597
,CHEMBL624838,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11295,178.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL622188,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11296,178.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL622189,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11297,948.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL622190,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11298,948.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,,,Intermediate,1,,50597
,CHEMBL625170,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11299,948.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11300,2113.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11301,2113.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625173,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11302,2113.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625174,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11303,2107.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625175,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11304,2107.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625176,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11305,2107.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,,,Intermediate,1,,50597
,CHEMBL625177,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11306,2048.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625178,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11307,2048.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625179,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11308,2048.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,,,Intermediate,1,,50597
,CHEMBL625180,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11309,2048.0,9071,,1,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Intermediate,1,,50597
,CHEMBL625181,,U,BAO_0000218,,,,,11310,,10677,,1,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,,,Autocuration,0,,22224
,CHEMBL625182,10090.0,N,BAO_0000218,Mus musculus,,,Urine,11311,1088.0,9750,,1,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,,,Intermediate,1,,50594
,CHEMBL625183,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11312,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL875848,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11313,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL622260,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11314,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL622261,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11315,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL622262,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11316,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL622263,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11317,2113.0,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL622418,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11318,2113.0,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL622419,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11319,2107.0,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL623388,10090.0,N,BAO_0000218,Mus musculus,,,,11320,,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623389,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11321,2107.0,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623390,10090.0,N,BAO_0000218,Mus musculus,,,,11322,,13256,,1,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623391,10090.0,N,BAO_0000218,Mus musculus,,,,11323,,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623392,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11324,178.0,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623393,10090.0,N,BAO_0000218,Mus musculus,,,Cerebellum,11325,2037.0,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL623394,10090.0,N,BAO_0000218,Mus musculus,,,,11326,,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL618885,10090.0,N,BAO_0000218,Mus musculus,,,,11327,,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL618886,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11328,2107.0,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL618887,10090.0,N,BAO_0000218,Mus musculus,,,,11329,,13256,,1,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619535,10090.0,N,BAO_0000218,Mus musculus,,,,11330,,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619536,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11331,178.0,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619537,10090.0,N,BAO_0000218,Mus musculus,,,Cerebellum,11332,2037.0,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619705,10090.0,N,BAO_0000218,Mus musculus,,,,11333,,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619706,10090.0,N,BAO_0000218,Mus musculus,,,,11334,,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619707,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11335,2107.0,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL619708,10090.0,N,BAO_0000218,Mus musculus,,,,11336,,13256,,1,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625219,10090.0,N,BAO_0000218,Mus musculus,,,,11337,,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625220,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11338,178.0,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625221,10090.0,N,BAO_0000218,Mus musculus,,,Cerebellum,11339,2037.0,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625222,10090.0,N,BAO_0000218,Mus musculus,,,,11340,,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625223,10090.0,N,BAO_0000218,Mus musculus,,,,11341,,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625224,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11342,2107.0,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625225,10090.0,N,BAO_0000218,Mus musculus,,,,11343,,13256,,1,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Intermediate,1,,50594
,CHEMBL625226,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11344,178.0,8829,,1,,Biodistribution in Rat blood after 24 hours of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625227,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11345,178.0,8829,,1,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625228,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11346,178.0,8829,,1,,Biodistribution in Rat blood after 30 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL875354,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11347,178.0,8829,,1,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625229,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11348,178.0,8829,,1,,Biodistribution in Rat blood after 5 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625230,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11349,178.0,8829,,1,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625231,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11350,948.0,8829,,1,,Biodistribution in Rat heart after 24 hours of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625900,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11351,948.0,8829,,1,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625901,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11352,948.0,8829,,1,,Biodistribution in Rat heart after 30 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625902,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11353,948.0,8829,,1,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625903,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11354,948.0,8829,,1,,Biodistribution in Rat heart after 5 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625904,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11355,948.0,8829,,1,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625905,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11356,2107.0,8829,,1,,Biodistribution in Rat liver after 24 hours of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627861,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11357,2107.0,8829,,1,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL627862,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11358,2107.0,8829,,1,,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627863,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11359,2107.0,8829,,1,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL627769,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11360,2107.0,8829,,1,,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL627770,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11361,1969.0,13249,,1,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,In vivo,,Intermediate,1,,50588
,CHEMBL627771,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11362,,13622,,1,,Cmax in cynomolgus monkey (PO dose),A,In vivo,,Intermediate,1,,100710
,CHEMBL627772,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11363,,13622,,1,,Cmax in rat (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL627773,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11364,,13622,,1,,Cmax in rat (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL621922,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11365,1969.0,13494,,1,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621923,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11366,1969.0,12170,,1,,Cmax in rat plasma after oral dose (10 mg/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL621924,,U,BAO_0000218,,,,Plasma,11367,1969.0,12170,,1,,Cmax in plasma after oral dose (10 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL621925,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11368,1969.0,17025,,1,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,In vivo,,Intermediate,1,,50588
,CHEMBL621926,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11369,1969.0,17025,,1,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621927,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Plasma,11370,1969.0,17025,,1,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,In vivo,,Intermediate,1,,50592
,CHEMBL621928,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11371,1969.0,17025,,1,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL621929,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11372,1969.0,14187,,1,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL621930,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11373,1969.0,14816,,1,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL621931,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11374,1969.0,17820,,1,,Maximum plasma concentration after oral dosing in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL621932,,U,BAO_0000218,,,,Plasma,11375,1969.0,14380,,1,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621933,,U,BAO_0000218,,,,Plasma,11376,1969.0,14380,,1,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621934,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11377,1969.0,14691,,1,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621935,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11378,1969.0,14691,,1,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL621936,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11379,1969.0,13375,,1,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL621937,,U,BAO_0000218,,,,Plasma,11380,1969.0,6236,,1,,Maximum plasma concentration was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL621938,,U,BAO_0000218,,,,Plasma,11381,1969.0,14380,,1,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621939,,U,BAO_0000218,,,,Plasma,11382,1969.0,14380,,1,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621940,,U,BAO_0000218,,,,Plasma,11383,1969.0,14380,,1,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621941,,U,BAO_0000218,,,,Plasma,11384,1969.0,14380,,1,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL621942,,U,BAO_0000218,,,,Plasma,11385,1969.0,14380,,1,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626178,,U,BAO_0000218,,,,Plasma,11386,1969.0,14380,,1,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626179,,U,BAO_0000218,,,,Plasma,11387,1969.0,14380,,1,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626180,,U,BAO_0000218,,,,Plasma,11388,1969.0,14380,,1,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626181,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11389,1969.0,13622,,1,,Plasma Cmax in rat (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL626182,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11390,,15372,,1,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626183,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11391,,15372,,1,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626184,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11392,,15372,,1,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626185,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11393,,15372,,1,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626186,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11394,1969.0,14925,,1,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,In vivo,,Intermediate,1,,50588
,CHEMBL877589,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11395,1969.0,14925,,1,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626187,,U,BAO_0000218,,,,,11396,,11883,,1,,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL626188,,U,BAO_0000218,,,,,11397,,11883,,1,,Maximum concentration of the drug at 20 uM/dg administered perorally,A,In vivo,,Autocuration,0,,22224
,CHEMBL626189,,U,BAO_0000218,,,,,11398,,13391,,1,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626855,,U,BAO_0000218,,,,Blood,11399,178.0,13391,,1,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,Autocuration,0,,22224
,CHEMBL623781,,U,BAO_0000218,,,,Blood,11400,178.0,13391,,1,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,Autocuration,0,,22224
,CHEMBL623782,,U,BAO_0000218,,,,Blood,11401,178.0,13391,,1,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,Autocuration,0,,22224
,CHEMBL623783,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11402,1969.0,16360,,1,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623784,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11403,1969.0,3673,,1,,Cmax in dog plasma after 1mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL623785,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11404,1969.0,14431,,1,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL623786,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11405,1969.0,14431,,1,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL623787,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11406,,14964,,1,,Oral maximum concentration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623788,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11407,,14964,,1,,Oral maximum concentration in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623789,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11408,1969.0,14209,,1,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,In vivo,,Intermediate,1,,50594
,CHEMBL623790,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11409,178.0,11355,,1,,Peak concentration in blood after intravenous administration to mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623791,10090.0,N,BAO_0000218,Mus musculus,,,Blood,11410,178.0,11355,,1,,Peak concentration in blood after peroral administration to mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL623792,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11411,1969.0,11966,,1,,Peak concentration in rat plasma was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL623793,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11412,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL623794,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11413,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL623795,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11414,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL623796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11415,,8684,,1,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623797,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11416,,8684,,1,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623798,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11417,,8684,,1,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623799,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11418,,8684,,1,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624490,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11419,160.0,8684,,1,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624491,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11420,160.0,8684,,1,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624492,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11421,160.0,8684,,1,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624493,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11422,160.0,8684,,1,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL877595,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11423,160.0,8684,,1,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624494,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11424,160.0,8684,,1,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11425,160.0,8684,,1,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624681,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,11426,160.0,8684,,1,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624682,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11427,,8684,,1,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624683,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11428,,8684,,1,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624684,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11429,,8684,,1,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624685,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11430,,8684,,1,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624686,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11431,,8684,,1,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624687,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11432,,8684,,1,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624688,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11433,,8684,,1,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL627161,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11434,,8684,,1,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL622127,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11435,,8684,,1,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL622128,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11436,,8684,,1,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL874384,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11437,,8684,,1,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624898,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11438,,8684,,1,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624899,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11439,,8684,,1,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624900,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11440,,8684,,1,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624901,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11441,,8684,,1,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624902,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11442,,8684,,1,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624903,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11443,,8684,,1,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624904,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11444,,8684,,1,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624905,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11445,,8684,,1,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624906,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11446,,8684,,1,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624907,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11447,,8684,,1,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624908,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11448,,8684,,1,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624909,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11449,,8684,,1,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624910,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11450,,8684,,1,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624911,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11451,2385.0,8684,,1,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL874388,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11452,2385.0,8684,,1,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL624912,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11453,2385.0,8684,,1,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL622930,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11454,2385.0,8684,,1,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623121,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11455,2385.0,8684,,1,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623122,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11456,2385.0,8684,,1,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623123,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11457,2385.0,8684,,1,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623124,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11458,2385.0,8684,,1,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623125,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11459,,8684,,1,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623126,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11460,,8684,,1,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623127,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11461,,8684,,1,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623128,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11462,,8684,,1,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623129,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11463,,8684,,1,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623130,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11464,,8684,,1,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623131,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11465,,8684,,1,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623132,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11466,,8684,,1,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL623133,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11467,2107.0,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623134,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11468,,8319,,1,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL874389,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11469,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623135,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11470,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL623136,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11471,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623137,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11472,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL623138,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11473,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623139,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11474,2113.0,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL623140,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11475,2113.0,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623141,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11476,2107.0,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL623142,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11477,2107.0,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623143,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11478,,8319,,1,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL623144,10090.0,N,BAO_0000218,Mus musculus,,,Urine,11479,1088.0,14571,,1,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,,,Intermediate,1,,50594
,CHEMBL623405,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,11480,1088.0,14571,,1,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,,,Intermediate,1,,50597
,CHEMBL624074,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11481,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624075,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11482,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624076,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11483,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624077,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11484,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624078,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11485,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624079,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11486,2113.0,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11487,2113.0,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624262,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11488,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624263,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11489,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11490,,8319,,1,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624265,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11491,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624266,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11492,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624267,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11493,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624268,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11494,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL875227,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11495,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624269,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11496,2113.0,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624270,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11497,2113.0,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624271,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11498,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Intermediate,1,,50597
,CHEMBL624272,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11499,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624273,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11500,,8319,,1,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Intermediate,1,,50597
,CHEMBL624274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,11501,1088.0,12064,,1,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624275,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,11502,1088.0,12064,,1,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,11503,1088.0,12064,,1,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624277,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,11504,1088.0,12038,,1,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624278,,U,BAO_0000019,,,,,11505,,14314,,1,,% dose converted to 2-amino-5-chlorophenyl sulfate,A,,,Autocuration,0,,22224
,CHEMBL624279,,U,BAO_0000019,,,,,11506,,14314,,1,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,,,Autocuration,0,,22224
,CHEMBL624280,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,11507,1988.0,11488,,1,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Intermediate,1,,50597
,CHEMBL624281,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,11508,1988.0,11488,,1,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Intermediate,1,,50597
,CHEMBL622933,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,11509,1988.0,11488,,1,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Intermediate,1,,50597
,CHEMBL622934,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,11510,1988.0,11488,,1,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Intermediate,1,,50597
,CHEMBL622935,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11511,2107.0,8829,,1,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL622936,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11512,2107.0,8829,,1,,Biodistribution in Rat liver after 5 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL875228,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11513,2107.0,8829,,1,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL622937,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11514,2048.0,8829,,1,,Biodistribution in Rat lung after 24 hours of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL622938,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11515,2048.0,8829,,1,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL619736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11516,2048.0,8829,,1,,Biodistribution in Rat lung after 30 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625117,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11517,2048.0,8829,,1,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625118,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11518,2048.0,8829,,1,,Biodistribution in Rat lung after 5 minutes of iv administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625119,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11519,2048.0,8829,,1,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,In vivo,,Intermediate,1,,50597
,CHEMBL625120,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,11520,2037.0,14972,,1,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,In vivo,,Intermediate,1,,50597
,CHEMBL625121,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11521,,14972,,1,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,In vivo,,Intermediate,1,,50597
,CHEMBL625122,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thalamus,11522,10000006.0,14972,,1,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,In vivo,,Intermediate,1,,50597
,CHEMBL622204,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11523,178.0,14608,,1,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL877503,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11524,178.0,14608,,1,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627127,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11525,178.0,14608,,1,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627128,,U,BAO_0000218,,,,Hippocampus,11526,10000000.0,14608,,1,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Autocuration,0,,22224
,CHEMBL627129,,U,BAO_0000218,,,,Hippocampus,11527,10000000.0,14608,,1,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Autocuration,0,,22224
,CHEMBL627130,,U,BAO_0000218,,,,Hippocampus,11528,10000000.0,14608,,1,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Autocuration,0,,22224
,CHEMBL627131,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11529,955.0,14608,,1,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627132,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11530,955.0,14608,,1,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627133,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11531,955.0,14608,,1,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627134,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,11532,2037.0,14608,,1,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627135,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,11533,2037.0,14608,,1,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL627136,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,11534,2037.0,14608,,1,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628435,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11535,,14608,,1,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628436,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11536,,14608,,1,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628437,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11537,,14608,,1,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628438,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11538,948.0,14608,,1,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628439,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11539,948.0,14608,,1,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628440,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,11540,948.0,14608,,1,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628441,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,11541,10000000.0,14608,,1,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628442,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,11542,10000000.0,14608,,1,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628443,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,11543,10000000.0,14608,,1,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628444,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11544,2113.0,14608,,1,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628445,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11545,2113.0,14608,,1,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL877504,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11546,2113.0,14608,,1,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL628446,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11547,2107.0,14608,,1,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626874,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11548,2107.0,14608,,1,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626875,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11549,2107.0,14608,,1,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626876,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11550,2048.0,14608,,1,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626877,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11551,2048.0,14608,,1,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626878,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11552,2048.0,14608,,1,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626879,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11553,2385.0,14608,,1,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL626880,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11554,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL626881,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11555,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Intermediate,1,,50594
,CHEMBL626882,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11556,1969.0,8918,,1,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626883,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11557,1969.0,14470,,1,,Peak plasma concentration was measured in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL626884,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11558,,14393,,1,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626885,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11559,,14886,,1,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626886,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11560,,14886,,1,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626887,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11561,,14886,,1,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL626888,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11562,,14393,,1,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL626889,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11563,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626761,314293.0,U,BAO_0000218,Simiiformes,,,,11564,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL626762,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11565,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626763,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11566,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626764,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11567,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626765,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11568,,13465,,1,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626766,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11569,,13465,,1,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626767,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11570,,13465,,1,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626768,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11571,,13465,,1,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,In vivo,,Intermediate,1,,50597
,CHEMBL626769,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11572,,13465,,1,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL874463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11573,,13465,,1,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL626770,314293.0,U,BAO_0000218,Simiiformes,,,,11574,,13465,,1,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL626771,314293.0,U,BAO_0000218,Simiiformes,,,,11575,,13465,,1,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,In vivo,,Autocuration,0,,22224
,CHEMBL626772,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11576,,13465,,1,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL626773,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11577,,14731,,1,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,In vivo,,Intermediate,1,,100710
,CHEMBL626774,10090.0,N,BAO_0000218,Mus musculus,,,,11578,,14731,,1,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,In vivo,,Intermediate,1,,50594
,CHEMBL626775,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11579,,13376,,1,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL626776,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11580,,13376,,1,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL626777,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11581,,14443,,1,,Maximum concentration (Cmax) in rat when administered orally,A,In vivo,,Intermediate,1,,50597
,CHEMBL626778,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11582,1969.0,13465,,1,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL626779,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11583,,16359,,1,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,In vivo,,Autocuration,0,,22224
,CHEMBL626780,10116.0,U,BAO_0000218,Rattus norvegicus,,,,11584,,16359,,1,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,In vivo,,Autocuration,0,,22224
,CHEMBL626781,,U,BAO_0000218,,,,Plasma,11585,1969.0,15618,,1,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,In vivo,,Autocuration,0,,22224
,CHEMBL632164,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11586,,14554,,1,,Pharmacokinetic profile Cmax was evaluated in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL632165,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11587,,11537,,1,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL632166,10090.0,N,BAO_0000218,Mus musculus,,,,11588,,11537,,1,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,In vivo,,Intermediate,1,,50594
,CHEMBL632167,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11589,,11537,,1,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,In vivo,,Intermediate,1,,50588
,CHEMBL632168,10090.0,N,BAO_0000218,Mus musculus,,,,11590,,11537,,1,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,In vivo,,Intermediate,1,,50594
,CHEMBL632169,10116.0,U,BAO_0000218,Rattus norvegicus,,,Plasma,11591,1969.0,2021,,1,,Cmax in rat plasma,A,In vivo,,Autocuration,0,,22224
,CHEMBL632170,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11592,1969.0,5932,,1,,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL632171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11593,1969.0,5932,,1,,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL632172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11594,1969.0,17320,,1,,Plasma level in rats at 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL632173,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11595,1969.0,15831,,1,,Tested for maximum plasma concentration in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL632174,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11596,,15078,,1,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Intermediate,1,,50597
,CHEMBL632175,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11597,,14941,,1,,The Cmax values in female wistar rats.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632176,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11598,1969.0,15343,,1,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL632177,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11599,1969.0,15343,,1,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL632178,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11600,1969.0,14856,,1,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632179,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11601,,13129,,1,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632180,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11602,178.0,13098,,1,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632181,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11603,178.0,13098,,1,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632182,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11604,178.0,13098,,1,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL632183,10090.0,U,BAO_0000218,Mus musculus,,,Blood,11605,178.0,15478,,1,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,In vivo,,Autocuration,0,,22224
,CHEMBL632184,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11606,,15341,,1,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,In vivo,,Intermediate,1,,50588
,CHEMBL874470,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11607,,15341,,1,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL631302,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11608,,8684,,1,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631303,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11609,,8684,,1,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631304,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11610,,8684,,1,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631305,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11611,,8684,,1,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631306,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11612,,8684,,1,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631307,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11613,,8684,,1,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL631308,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11614,,8684,,1,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625557,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11615,,8684,,1,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625558,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11616,2106.0,8684,,1,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625559,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11617,2106.0,8684,,1,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625560,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11618,2106.0,8684,,1,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625561,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11619,2106.0,8684,,1,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625562,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11620,2106.0,8684,,1,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL875320,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11621,2106.0,8684,,1,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625563,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11622,2106.0,8684,,1,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625564,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11623,2106.0,8684,,1,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625565,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11624,995.0,8684,,1,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625566,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11625,995.0,8684,,1,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625567,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11626,995.0,8684,,1,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL625568,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11627,995.0,8684,,1,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL628217,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11628,995.0,8684,,1,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL628218,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11629,995.0,8684,,1,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL628219,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11630,995.0,8684,,1,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL628220,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,11631,995.0,8684,,1,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,,,Intermediate,1,,50597
,CHEMBL628221,,U,BAO_0000019,,,,,11632,,8926,,1,,Distribution in the blood after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628222,,U,BAO_0000019,,,,,11633,,8926,,1,,Distribution in the blood after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628223,,U,BAO_0000019,,,,,11634,,8926,,1,,Distribution in the blood after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628224,,U,BAO_0000019,,,,,11635,,8926,,1,,Distribution in the blood after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628225,,U,BAO_0000019,,,,,11636,,8926,,1,,Distribution in the blood after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628226,,U,BAO_0000019,,,,,11637,,8926,,1,,Distribution in the blood after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628227,,U,BAO_0000019,,,,,11638,,8926,,1,,Distribution in the bone after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL875481,,U,BAO_0000019,,,,,11639,,8926,,1,,Distribution in the bone after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628228,,U,BAO_0000019,,,,,11640,,8926,,1,,Distribution in the bone after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628229,,U,BAO_0000019,,,,,11641,,8926,,1,,Distribution in the bone after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628230,,U,BAO_0000019,,,,,11642,,8926,,1,,Distribution in the bone after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628231,,U,BAO_0000019,,,,,11643,,8926,,1,,Distribution in the bone after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628232,,U,BAO_0000019,,,,,11644,,8926,,1,,Distribution in the heart after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628233,,U,BAO_0000019,,,,,11645,,8926,,1,,Distribution in the heart after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628234,,U,BAO_0000019,,,,,11646,,8926,,1,,Distribution in the heart after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628235,,U,BAO_0000019,,,,,11647,,8926,,1,,Distribution in the heart after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628236,,U,BAO_0000019,,,,,11648,,8926,,1,,Distribution in the heart after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628237,,U,BAO_0000019,,,,,11649,,8926,,1,,Distribution in the heart after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628238,,U,BAO_0000019,,,,,11650,,8926,,1,,Distribution in the kidneys after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628239,,U,BAO_0000019,,,,,11651,,8926,,1,,Distribution in the kidneys after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628240,,U,BAO_0000019,,,,,11652,,8926,,1,,Distribution in the kidneys after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628241,,U,BAO_0000019,,,,,11653,,8926,,1,,Distribution in the kidneys after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628242,,U,BAO_0000019,,,,,11654,,8926,,1,,Distribution in the kidneys after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL875482,,U,BAO_0000019,,,,,11655,,8926,,1,,Distribution in the kidneys after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628243,,U,BAO_0000019,,,,,11656,,8926,,1,,Distribution in the liver after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628244,,U,BAO_0000019,,,,,11657,,8926,,1,,Distribution in the liver after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628245,,U,BAO_0000019,,,,,11658,,8926,,1,,Distribution in the liver after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628246,,U,BAO_0000019,,,,,11659,,8926,,1,,Distribution in the liver after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628247,,U,BAO_0000019,,,,,11660,,8926,,1,,Distribution in the liver after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628248,,U,BAO_0000019,,,,,11661,,8926,,1,,Distribution in the liver after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628249,,U,BAO_0000019,,,,,11662,,8926,,1,,Distribution in the lung after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL625452,10090.0,N,BAO_0000218,Mus musculus,,,,11663,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL625453,10090.0,N,BAO_0000218,Mus musculus,,,,11664,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL625454,10090.0,N,BAO_0000218,Mus musculus,,,,11665,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL623844,10090.0,N,BAO_0000218,Mus musculus,,,,11666,,14839,,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,,,Intermediate,1,,50594
,CHEMBL623845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11667,,12178,,1,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Intermediate,1,,50597
,CHEMBL623846,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11668,,12178,,1,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Intermediate,1,,50597
,CHEMBL623847,,U,BAO_0000218,,,,,11669,,12178,,1,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,,,Autocuration,0,,22224
,CHEMBL623848,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11670,,12186,,1,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Intermediate,1,,100710
,CHEMBL623849,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11671,,12186,,1,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Intermediate,1,,100710
,CHEMBL623850,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11672,,12186,,1,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Intermediate,1,,100710
,CHEMBL623851,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11673,,12186,,1,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Intermediate,1,,100710
,CHEMBL623852,314293.0,U,BAO_0000218,Simiiformes,,,,11674,,12187,,1,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL624551,9669.0,N,BAO_0000218,Mustela putorius furo,,,,11675,,12187,,1,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Intermediate,1,,50506
,CHEMBL624552,9669.0,N,BAO_0000218,Mustela putorius furo,,,,11676,,12187,,1,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Intermediate,1,,50506
,CHEMBL624553,314293.0,U,BAO_0000218,Simiiformes,,,,11677,,12187,,1,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL624554,314293.0,U,BAO_0000218,Simiiformes,,,,11678,,12187,,1,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,,,Autocuration,0,,22224
,CHEMBL624555,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11679,,12187,,1,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL624741,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11680,,12187,,1,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Intermediate,1,,50597
,CHEMBL624742,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11681,,14122,,1,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Intermediate,1,,50588
,CHEMBL624743,10026.0,N,BAO_0000218,Cricetinae,,,,11682,,14122,,1,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Intermediate,1,,100712
,CHEMBL877606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11683,,14122,,1,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Intermediate,1,,50597
,CHEMBL624744,,U,BAO_0000218,,,,,11684,,13391,,1,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL624745,,U,BAO_0000218,,,,Blood,11685,178.0,13391,,1,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,Autocuration,0,,22224
,CHEMBL624746,,U,BAO_0000218,,,,Blood,11686,178.0,13391,,1,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,,Autocuration,0,,22224
,CHEMBL624747,,U,BAO_0000218,,,,Blood,11687,178.0,13391,,1,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,Autocuration,0,,22224
,CHEMBL624748,,U,BAO_0000019,,,,,11688,,16360,,1,,Oral absorption expressed as Area under curve was determined,A,,,Autocuration,0,,22224
,CHEMBL622504,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11689,,3673,,1,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,,,Intermediate,1,,50588
,CHEMBL622505,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11690,,14122,,1,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Intermediate,1,,50588
,CHEMBL622506,10026.0,N,BAO_0000218,Cricetinae,,,,11691,,14122,,1,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Intermediate,1,,100712
,CHEMBL622507,10026.0,N,BAO_0000218,Cricetinae,,,,11692,,14122,,1,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Intermediate,1,,100712
,CHEMBL622508,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11693,,14122,,1,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Intermediate,1,,50597
,CHEMBL622509,,U,BAO_0000019,,,,,11694,,13889,,1,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,,,Autocuration,0,,22224
,CHEMBL622510,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11695,,14393,,1,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Intermediate,1,,50597
,CHEMBL622511,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11696,,17279,,1,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,,,Intermediate,1,,50597
,CHEMBL622512,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11697,,14548,,1,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,,,Intermediate,1,,100710
,CHEMBL622513,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11698,,14548,,1,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,,,Intermediate,1,,100710
,CHEMBL622514,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11699,,14548,,1,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,,,Intermediate,1,,100710
,CHEMBL622515,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11700,,14548,,1,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,,,Intermediate,1,,50588
,CHEMBL622516,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11701,,14548,,1,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,,,Intermediate,1,,50588
,CHEMBL622517,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11702,,14548,,1,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL622518,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11703,,14548,,1,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL622519,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11704,,14548,,1,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL622520,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11705,2385.0,14608,,1,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL622521,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11706,2385.0,14608,,1,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625113,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,11707,14.0,14608,,1,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50594
,CHEMBL625114,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,11708,14.0,14608,,1,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL874397,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,11709,14.0,14608,,1,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625115,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11710,2106.0,14608,,1,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL625116,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11711,2106.0,14608,,1,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623932,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,11712,2106.0,14608,,1,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623933,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,11713,2435.0,14608,,1,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623934,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,11714,2435.0,14608,,1,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623935,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,11715,2435.0,14608,,1,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623936,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,11716,2046.0,14608,,1,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623937,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,11717,2046.0,14608,,1,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623938,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,11718,2046.0,14608,,1,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Intermediate,1,,50597
,CHEMBL623939,10090.0,N,BAO_0000218,Mus musculus,,,,11719,,15383,,1,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL623940,10090.0,N,BAO_0000218,Mus musculus,,,,11720,,15383,,1,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Intermediate,1,,50594
,CHEMBL623941,10090.0,N,BAO_0000218,Mus musculus,,,,11721,,15383,,1,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Intermediate,1,,50594
,CHEMBL627216,10090.0,N,BAO_0000218,Mus musculus,,,,11722,,15383,,1,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL623942,10090.0,N,BAO_0000218,Mus musculus,,,,11723,,15383,,1,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618793,10090.0,N,BAO_0000218,Mus musculus,,,Brain,11724,955.0,15383,,1,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL618794,10090.0,N,BAO_0000218,Mus musculus,,,Brain,11725,955.0,15383,,1,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618795,10090.0,N,BAO_0000218,Mus musculus,,,Brain,11726,955.0,15383,,1,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618796,10090.0,N,BAO_0000218,Mus musculus,,,,11727,,15383,,1,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618797,10090.0,N,BAO_0000218,Mus musculus,,,,11728,,15383,,1,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618798,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11729,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Intermediate,1,,50594
,CHEMBL618799,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11730,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL618800,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11731,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618801,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11732,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618802,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11733,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618803,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,11734,2113.0,15383,,1,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618804,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11735,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Intermediate,1,,50594
,CHEMBL618805,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11736,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL618806,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11737,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618807,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11738,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618808,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11739,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618809,10090.0,N,BAO_0000218,Mus musculus,,,Liver,11740,2107.0,15383,,1,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618810,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11741,2385.0,15383,,1,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL618811,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11742,2385.0,15383,,1,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Intermediate,1,,50594
,CHEMBL875844,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11743,2385.0,15383,,1,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618812,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11744,2385.0,15383,,1,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618813,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11745,2385.0,15383,,1,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618814,10090.0,N,BAO_0000218,Mus musculus,,,,11746,,15383,,1,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL618815,10090.0,N,BAO_0000218,Mus musculus,,,,11747,,15383,,1,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618816,10090.0,N,BAO_0000218,Mus musculus,,,,11748,,15383,,1,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL618817,10090.0,N,BAO_0000218,Mus musculus,,,,11749,,15383,,1,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL620544,10090.0,N,BAO_0000218,Mus musculus,,,,11750,,15383,,1,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL626230,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11751,,15341,,1,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626231,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11752,,15341,,1,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626232,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11753,,15341,,1,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626233,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11754,1969.0,14906,,1,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626234,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11755,1969.0,14906,,1,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL875341,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11756,1969.0,14906,,1,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL626235,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,11757,1969.0,14215,,1,,The maximum plasma concentration (100 mg/kg) administered orally in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL626236,9481.0,U,BAO_0000218,Callithrix,,,Plasma,11758,1969.0,14215,,1,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,In vivo,,Autocuration,0,,22224
,CHEMBL626237,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11759,1969.0,14215,,1,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL626238,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11760,1969.0,14215,,1,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622412,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,11761,1969.0,14215,,1,,The maximum plasma concentration (200 mg/kg) administered orally in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL623114,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11762,1969.0,14215,,1,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623115,9481.0,U,BAO_0000218,Callithrix,,,Plasma,11763,1969.0,14215,,1,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,In vivo,,Autocuration,0,,22224
,CHEMBL623116,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11764,1969.0,14215,,1,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL623117,9615.0,U,BAO_0000218,Canis lupus familiaris,,,Plasma,11765,1969.0,14215,,1,,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL623118,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,11766,1969.0,14215,,1,,The maximum plasma concentration (400 mg/kg) administered orally in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL623119,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11767,1969.0,14215,,1,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623120,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11768,1969.0,14215,,1,,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623286,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,11769,1969.0,14215,,1,,The maximum plasma concentration (800 mg/kg) administered orally in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL623287,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11770,1969.0,14067,,1,,The maximum plasma concentration was measured on rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623288,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11771,1969.0,12350,,1,,The maximum plasma concentration was measured on rats after oral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623289,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11772,1969.0,14813,,1,,Plasma drug Cmax in rat (PO dose),A,In vivo,,Intermediate,1,,50597
,CHEMBL623290,,U,BAO_0000218,,,,,11773,,12536,,1,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,In vivo,,Autocuration,0,,22224
,CHEMBL623291,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11774,1969.0,14169,,1,,maximum Plasma concentration in Dog was determined after Peroral administration,A,In vivo,,Intermediate,1,,50588
,CHEMBL623292,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11775,1969.0,14169,,1,,maximum Plasma concentration in Rats was determined after Peroral administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL623293,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,11776,1969.0,15604,,1,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623294,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,11777,1969.0,15604,,1,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL623295,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11778,1969.0,15604,,1,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623296,10090.0,N,BAO_0000218,Mus musculus,,,,11779,,14387,,1,,maximum concentration was measured when administered through oral route in mice,A,In vivo,,Intermediate,1,,50594
,CHEMBL875349,10090.0,N,BAO_0000218,Mus musculus,,,,11780,,15115,,1,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,,,Intermediate,1,,50594
,CHEMBL623297,314293.0,U,BAO_0000019,Simiiformes,,,,11781,,15115,,1,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,,,Autocuration,0,,22224
,CHEMBL623298,314293.0,U,BAO_0000019,Simiiformes,,,,11782,,15115,,1,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,,,Autocuration,0,,22224
,CHEMBL623299,314293.0,U,BAO_0000019,Simiiformes,,,,11783,,15115,,1,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,,,Autocuration,0,,22224
,CHEMBL623300,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11784,,16359,,1,,Pharmacokinetic parameter was evaluated in rats,A,,,Intermediate,1,,50597
,CHEMBL623301,10090.0,N,BAO_0000218,Mus musculus,,,,11785,,12829,,1,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Intermediate,1,,50594
,CHEMBL623302,10090.0,N,BAO_0000218,Mus musculus,,,,11786,,12829,,1,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,,,Intermediate,1,,50594
,CHEMBL623303,10090.0,N,BAO_0000218,Mus musculus,,,,11787,,12829,,1,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Intermediate,1,,50594
,CHEMBL623304,10090.0,N,BAO_0000218,Mus musculus,,,,11788,,12829,,1,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,,,Intermediate,1,,50594
,CHEMBL623305,10090.0,N,BAO_0000218,Mus musculus,,,,11789,,12829,,1,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,,,Intermediate,1,,50594
,CHEMBL623306,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11790,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623307,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11791,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623308,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,11792,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,,,Intermediate,1,,50597
,CHEMBL623309,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,11793,1969.0,15137,,1,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,,,Intermediate,1,,50594
,CHEMBL623310,10090.0,N,BAO_0000218,Mus musculus,,,,11794,,13509,,1,,Plasma Concentration after 120 min of oral administration to mice,A,,,Intermediate,1,,50594
,CHEMBL623311,10090.0,N,BAO_0000218,Mus musculus,,,,11795,,13509,,1,,Plasma Concentration after 30 min of oral administration to mice,A,,,Intermediate,1,,50594
,CHEMBL623312,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11796,,13509,,1,,Plasma Concentration after 60 min of oral administration to mice,A,,,Intermediate,1,,100710
,CHEMBL875350,10090.0,N,BAO_0000218,Mus musculus,,,,11797,,13509,,1,,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,,,Intermediate,1,,50594
,CHEMBL628635,10090.0,N,BAO_0000218,Mus musculus,,,,11798,,13509,,1,,Plasma Concentration after 90 min of oral administration to mice,A,,,Intermediate,1,,50594
,CHEMBL628636,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11799,,12064,,1,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL628637,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11800,,12064,,1,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL628058,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11801,,12064,,1,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL628059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11802,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,,,Intermediate,1,,50597
,CHEMBL628060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11803,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,,,Intermediate,1,,50597
,CHEMBL628061,,U,BAO_0000019,,,,,11804,,8926,,1,,Distribution in the lung after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628062,,U,BAO_0000019,,,,,11805,,8926,,1,,Distribution in the lung after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628063,,U,BAO_0000019,,,,,11806,,8926,,1,,Distribution in the lung after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628064,,U,BAO_0000019,,,,,11807,,8926,,1,,Distribution in the lung after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628065,,U,BAO_0000019,,,,,11808,,8926,,1,,Distribution in the lung after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628066,,U,BAO_0000019,,,,Muscle tissue,11809,2385.0,8926,,1,,Distribution in the muscle after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628067,,U,BAO_0000019,,,,Muscle tissue,11810,2385.0,8926,,1,,Distribution in the muscle after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL874646,10090.0,N,BAO_0000218,Mus musculus,,,Muscle tissue,11811,2385.0,8926,,1,,Distribution in the muscle after 30 min of intravenous administration,A,,,Intermediate,1,,50594
,CHEMBL628068,,U,BAO_0000019,,,,Muscle tissue,11812,2385.0,8926,,1,,Distribution in the muscle after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628069,,U,BAO_0000019,,,,Muscle tissue,11813,2385.0,8926,,1,,Distribution in the muscle after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628070,,U,BAO_0000019,,,,Muscle tissue,11814,2385.0,8926,,1,,Distribution in the muscle after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628071,,U,BAO_0000019,,,,Spleen,11815,2106.0,8926,,1,,Distribution in the spleen after 120 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628072,,U,BAO_0000019,,,,Spleen,11816,2106.0,8926,,1,,Distribution in the spleen after 15 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628073,,U,BAO_0000019,,,,Spleen,11817,2106.0,8926,,1,,Distribution in the spleen after 30 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628074,,U,BAO_0000019,,,,Spleen,11818,2106.0,8926,,1,,Distribution in the spleen after 5 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628075,,U,BAO_0000019,,,,Spleen,11819,2106.0,8926,,1,,Distribution in the spleen after 60 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628076,,U,BAO_0000019,,,,Spleen,11820,2106.0,8926,,1,,Distribution in the spleen after 90 min of intravenous administration,A,,,Autocuration,0,,22224
,CHEMBL628077,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal cortex,11821,1235.0,7570,,1,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628078,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11822,178.0,7570,,1,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628079,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11823,2107.0,7570,,1,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628080,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,11824,992.0,7570,,1,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628081,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,11825,2046.0,7570,,1,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL628082,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal cortex,11826,1235.0,7570,,1,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL874647,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11827,178.0,7570,,1,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL626406,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11828,2107.0,7570,,1,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL626407,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,11829,992.0,7570,,1,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL626408,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,11830,2046.0,7570,,1,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Intermediate,1,,50597
,CHEMBL626409,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11831,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,,,Intermediate,1,,50597
,CHEMBL626410,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11832,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,,,Intermediate,1,,50597
,CHEMBL626411,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11833,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,,,Intermediate,1,,50597
,CHEMBL626412,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11834,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,,,Intermediate,1,,50597
,CHEMBL626413,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11835,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,,,Intermediate,1,,50597
,CHEMBL626414,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11836,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,,,Intermediate,1,,50597
,CHEMBL626415,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11837,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,,,Intermediate,1,,50597
,CHEMBL626416,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11838,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,,,Intermediate,1,,50597
,CHEMBL627062,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11839,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,,,Intermediate,1,,50597
,CHEMBL627063,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11840,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,,,Intermediate,1,,50597
,CHEMBL627064,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11841,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,,,Intermediate,1,,50597
,CHEMBL627227,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11842,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,,,Intermediate,1,,50597
,CHEMBL627228,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11843,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,,,Intermediate,1,,50597
,CHEMBL627229,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11844,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,,,Intermediate,1,,50597
,CHEMBL625792,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11845,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,,,Intermediate,1,,50597
,CHEMBL625793,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11846,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,,,Intermediate,1,,50597
,CHEMBL625794,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11847,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,,,Intermediate,1,,50597
,CHEMBL625795,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11848,178.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,,,Intermediate,1,,50597
,CHEMBL625796,10090.0,N,BAO_0000218,Mus musculus,,,,11849,,13792,,1,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,,,Intermediate,1,,50594
,CHEMBL625797,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11850,,13376,,1,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL625798,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,11851,,13376,,1,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL875613,,U,BAO_0000218,,,,,11852,,14380,,1,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625799,,U,BAO_0000218,,,,,11853,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625800,,U,BAO_0000218,,,,,11854,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625801,,U,BAO_0000218,,,,,11855,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625802,,U,BAO_0000218,,,,,11856,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625803,,U,BAO_0000218,,,,,11857,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL625804,,U,BAO_0000019,,,,,11858,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,,,Autocuration,0,,22224
,CHEMBL622530,,U,BAO_0000218,,,,,11859,,14380,,1,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,,,Autocuration,0,,22224
,CHEMBL622531,10090.0,N,BAO_0000218,Mus musculus,,,,11860,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,,,Intermediate,1,,50594
,CHEMBL622532,10090.0,N,BAO_0000218,Mus musculus,,,,11861,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL623176,10090.0,N,BAO_0000218,Mus musculus,,,,11862,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL623177,10090.0,N,BAO_0000218,Mus musculus,,,,11863,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL623178,10090.0,N,BAO_0000218,Mus musculus,,,,11864,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL623179,10090.0,N,BAO_0000218,Mus musculus,,,,11865,,13701,,1,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,,,Intermediate,1,,50594
,CHEMBL623180,10090.0,N,BAO_0000218,Mus musculus,,,,11866,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL623181,10090.0,N,BAO_0000218,Mus musculus,,,,11867,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL624131,10090.0,N,BAO_0000218,Mus musculus,,,,11868,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL624132,10090.0,N,BAO_0000218,Mus musculus,,,,11869,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL624133,10090.0,N,BAO_0000218,Mus musculus,,,,11870,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL624846,10090.0,N,BAO_0000218,Mus musculus,,,,11871,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,,,Intermediate,1,,50594
,CHEMBL624847,10090.0,N,BAO_0000218,Mus musculus,,,,11872,,13701,,1,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL624848,10090.0,N,BAO_0000218,Mus musculus,,,,11873,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625012,10090.0,N,BAO_0000218,Mus musculus,,,,11874,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625013,10090.0,N,BAO_0000218,Mus musculus,,,,11875,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625014,10090.0,N,BAO_0000218,Mus musculus,,,,11876,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,,,Intermediate,1,,50594
,CHEMBL625015,10090.0,N,BAO_0000218,Mus musculus,,,,11877,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625016,10090.0,N,BAO_0000218,Mus musculus,,,,11878,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625017,10090.0,N,BAO_0000218,Mus musculus,,,,11879,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,,,Intermediate,1,,50594
,CHEMBL625018,10090.0,N,BAO_0000218,Mus musculus,,,,11880,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625019,10090.0,N,BAO_0000218,Mus musculus,,,,11881,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625020,10090.0,N,BAO_0000218,Mus musculus,,,,11882,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL625021,10090.0,N,BAO_0000218,Mus musculus,,,,11883,,13701,,1,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,,,Intermediate,1,,50594
,CHEMBL625022,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11884,,14393,,1,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Intermediate,1,,50597
,CHEMBL625023,10090.0,N,BAO_0000218,Mus musculus,,,,11885,,14731,,1,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,,,Intermediate,1,,50594
,CHEMBL625024,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11886,,14731,,1,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,,,Intermediate,1,,100710
,CHEMBL627626,9541.0,N,BAO_0000218,Macaca fascicularis,,,,11887,,14731,,1,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,,,Intermediate,1,,100710
,CHEMBL627627,,U,BAO_0000218,,,,Brain,11888,955.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,Autocuration,0,,22224
,CHEMBL627628,,U,BAO_0000218,,,,Serum,11889,1977.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,,,Autocuration,0,,22224
,CHEMBL627629,,U,BAO_0000218,,,,Brain,11890,955.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,Autocuration,0,,22224
,CHEMBL627630,,U,BAO_0000218,,,,Serum,11891,1977.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,,,Autocuration,0,,22224
,CHEMBL627631,,U,BAO_0000019,,,,,11892,,16359,,1,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,,,Autocuration,0,,22224
,CHEMBL629515,,U,BAO_0000218,,,,,11893,,16359,,1,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,,,Autocuration,0,,22224
,CHEMBL629516,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,11894,2106.0,15383,,1,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL629517,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,11895,2106.0,15383,,1,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL629518,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,11896,2106.0,15383,,1,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL877499,10090.0,N,BAO_0000218,Mus musculus,,,,11897,,15383,,1,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Intermediate,1,,50594
,CHEMBL629519,10090.0,N,BAO_0000218,Mus musculus,,,,11898,,15383,,1,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Intermediate,1,,50594
,CHEMBL629520,10090.0,N,BAO_0000218,Mus musculus,,,,11899,,15383,,1,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Intermediate,1,,50594
,CHEMBL629521,10090.0,N,BAO_0000218,Mus musculus,,,,11900,,15383,,1,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Intermediate,1,,50594
,CHEMBL629522,10090.0,N,BAO_0000218,Mus musculus,,,,11901,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,,,Intermediate,1,,50594
,CHEMBL629523,10090.0,N,BAO_0000218,Mus musculus,,,,11902,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,,,Intermediate,1,,50594
,CHEMBL629524,10090.0,N,BAO_0000218,Mus musculus,,,,11903,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,,,Intermediate,1,,50594
,CHEMBL629525,10090.0,N,BAO_0000218,Mus musculus,,,,11904,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,,,Intermediate,1,,50594
,CHEMBL629526,10090.0,N,BAO_0000218,Mus musculus,,,,11905,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,,,Intermediate,1,,50594
,CHEMBL629527,10090.0,N,BAO_0000218,Mus musculus,,,,11906,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,,,Intermediate,1,,50594
,CHEMBL629528,10090.0,N,BAO_0000218,Mus musculus,,,,11907,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,,,Intermediate,1,,50594
,CHEMBL629529,10090.0,N,BAO_0000218,Mus musculus,,,,11908,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,,,Intermediate,1,,50594
,CHEMBL629530,10090.0,N,BAO_0000218,Mus musculus,,,,11909,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,,,Intermediate,1,,50594
,CHEMBL629531,10090.0,N,BAO_0000218,Mus musculus,,,,11910,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,,,Intermediate,1,,50594
,CHEMBL628656,10090.0,N,BAO_0000218,Mus musculus,,,,11911,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,,,Intermediate,1,,50594
,CHEMBL628657,10090.0,N,BAO_0000218,Mus musculus,,,,11912,,14439,,1,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,,,Intermediate,1,,50594
,CHEMBL628658,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11913,,13751,,1,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628659,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11914,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL877500,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11915,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628660,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11916,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628661,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11917,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628662,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11918,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628663,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11919,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628664,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11920,,13751,,1,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628665,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11921,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628666,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11922,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628667,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11923,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628668,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11924,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628669,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11925,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628670,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11926,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628671,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11927,178.0,13751,,1,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL628672,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,11928,10000001.0,13751,,1,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL630300,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,11929,10000001.0,13751,,1,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629787,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,11930,10000001.0,13751,,1,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629788,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,11931,10000001.0,13751,,1,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629789,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11932,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629790,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11933,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629791,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11934,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629792,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11935,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629793,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11936,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629794,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11937,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL874459,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11938,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,,,Intermediate,1,,50597
,CHEMBL629795,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11939,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,,,Intermediate,1,,50597
,CHEMBL629796,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11940,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,,,Intermediate,1,,50597
,CHEMBL629797,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11941,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,,,Intermediate,1,,50597
,CHEMBL629798,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11942,,10677,,1,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,,,Intermediate,1,,50597
,CHEMBL629799,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal gland,11943,2369.0,10911,,1,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629800,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal gland,11944,2369.0,10911,,1,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629801,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal gland,11945,2369.0,10911,,1,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629802,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal gland,11946,2369.0,10911,,1,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,In vivo,,Intermediate,1,,50597
,CHEMBL629803,10116.0,N,BAO_0000218,Rattus norvegicus,,,Adrenal gland,11947,2369.0,10911,,1,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629804,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11948,178.0,10911,,1,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629805,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11949,178.0,10911,,1,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629806,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11950,178.0,10911,,1,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629807,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11951,178.0,10911,,1,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629808,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,11952,178.0,10911,,1,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629809,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11953,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629810,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11954,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629811,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11955,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629812,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11956,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629813,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11957,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL874460,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,11958,955.0,10911,,1,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11959,,10911,,1,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11960,,10911,,1,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11961,,10911,,1,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL629817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11962,,10911,,1,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626643,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11963,2113.0,10911,,1,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626644,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11964,2113.0,10911,,1,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626806,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11965,2113.0,10911,,1,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626807,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,11966,2113.0,10911,,1,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11967,2107.0,10911,,1,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627262,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11968,2107.0,10911,,1,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627263,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11969,2107.0,10911,,1,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627264,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,11970,2107.0,10911,,1,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627265,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11971,2048.0,10911,,1,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11972,2048.0,10911,,1,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11973,2048.0,10911,,1,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627268,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,11974,2048.0,10911,,1,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627269,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11975,2385.0,10911,,1,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627270,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,11976,2385.0,10911,,1,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627271,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11977,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,,,Intermediate,1,,50597
,CHEMBL627946,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11978,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,,,Intermediate,1,,50597
,CHEMBL875472,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11979,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,,,Intermediate,1,,50597
,CHEMBL627947,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11980,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,,,Intermediate,1,,50597
,CHEMBL627948,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11981,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,,,Intermediate,1,,50597
,CHEMBL628113,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11982,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,,,Intermediate,1,,50597
,CHEMBL628114,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11983,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,,,Intermediate,1,,50597
,CHEMBL628115,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11984,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,,,Intermediate,1,,50597
,CHEMBL628116,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11985,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,,,Intermediate,1,,50597
,CHEMBL628117,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11986,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,,,Intermediate,1,,50597
,CHEMBL628118,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11987,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,,,Intermediate,1,,50597
,CHEMBL628119,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11988,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,,,Intermediate,1,,50597
,CHEMBL628120,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11989,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,,,Intermediate,1,,50597
,CHEMBL628121,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11990,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,,,Intermediate,1,,50597
,CHEMBL628122,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11991,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,,,Intermediate,1,,50597
,CHEMBL627297,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11992,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,,,Intermediate,1,,50597
,CHEMBL627298,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11993,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,,,Intermediate,1,,50597
,CHEMBL627299,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11994,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,,,Intermediate,1,,50597
,CHEMBL627300,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11995,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,,,Intermediate,1,,50597
,CHEMBL627301,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11996,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,,,Intermediate,1,,50597
,CHEMBL627302,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11997,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,,,Intermediate,1,,50597
,CHEMBL627303,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11998,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,,,Intermediate,1,,50597
,CHEMBL627304,10116.0,N,BAO_0000218,Rattus norvegicus,,,,11999,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,,,Intermediate,1,,50597
,CHEMBL627305,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12000,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,,,Intermediate,1,,50597
,CHEMBL627306,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12001,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Intermediate,1,,50597
,CHEMBL623982,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12002,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,,,Intermediate,1,,50597
,CHEMBL623983,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12003,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,,,Intermediate,1,,50597
,CHEMBL623984,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12004,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,,,Intermediate,1,,50597
,CHEMBL623985,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12005,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,,,Intermediate,1,,50597
,CHEMBL623986,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12006,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,,,Intermediate,1,,50597
,CHEMBL623987,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12007,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,,,Intermediate,1,,50597
,CHEMBL623988,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12008,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,,,Intermediate,1,,50597
,CHEMBL623989,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12009,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,,,Intermediate,1,,50597
,CHEMBL622215,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12010,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,,,Intermediate,1,,50597
,CHEMBL622216,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12011,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,,,Intermediate,1,,50597
,CHEMBL877481,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12012,,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,,,Intermediate,1,,50597
,CHEMBL622217,,U,BAO_0000218,,,,,12013,,16359,,1,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,,,Autocuration,0,,22224
,CHEMBL622218,10090.0,N,BAO_0000218,Mus musculus,,,,12014,,13701,,1,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Intermediate,1,,50594
,CHEMBL622219,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12015,,14554,,1,,Pharmacokinetic profile AUC was evaluated in rats,A,,,Intermediate,1,,50597
,CHEMBL622220,,U,BAO_0000019,,,,,12016,,6241,,1,,Pharmacokinetic property (Area under curve),A,,,Autocuration,0,,22224
,CHEMBL622221,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12017,,11537,,1,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,,,Intermediate,1,,50588
,CHEMBL622222,10090.0,N,BAO_0000218,Mus musculus,,,,12018,,11537,,1,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,,,Intermediate,1,,50594
,CHEMBL622223,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12019,,11537,,1,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,,,Intermediate,1,,50588
,CHEMBL622224,10090.0,N,BAO_0000218,Mus musculus,,,,12020,,11537,,1,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,,,Intermediate,1,,50594
,CHEMBL622225,,U,BAO_0000019,,,,,12021,,13118,,1,,Plasma concentration (AUC) was determined,A,,,Autocuration,0,,22224
,CHEMBL622226,,U,BAO_0000019,,,,,12022,,13118,,1,,Plasma concentration (AUC) was determined; Not detectable,A,,,Autocuration,0,,22224
,CHEMBL624154,10141.0,N,BAO_0000218,Cavia porcellus,,,,12023,,9562,,1,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,,,Intermediate,1,,50512
,CHEMBL624155,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12024,,10363,,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624156,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12025,,10363,,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Intermediate,1,,50597
,CHEMBL624157,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12026,,10363,,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624158,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12027,,10363,,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL624159,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12028,,12504,,1,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,,,Intermediate,1,,50597
,CHEMBL624160,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12029,,12504,,1,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,,,Intermediate,1,,50597
,CHEMBL624161,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12030,,12504,,1,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,,,Intermediate,1,,50597
,CHEMBL624162,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12031,,12504,,1,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,,,Intermediate,1,,50597
,CHEMBL624163,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12032,,13317,,1,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,,,Intermediate,1,,50588
,CHEMBL624164,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12033,,15078,,1,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL624165,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12034,,14941,,1,,The AUC(0-infinity) values in female wistar rats.,A,,,Intermediate,1,,50597
,CHEMBL624166,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12035,,15078,,1,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL624167,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12036,,15078,,1,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,,,Intermediate,1,,50597
,CHEMBL624168,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12037,,14941,,1,,The AUC(0-t)values in female wistar rats.,A,,,Intermediate,1,,50597
,CHEMBL624169,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12038,,14067,,1,,The Area under the concentration time curve of compound was measured on rats,A,,,Intermediate,1,,50597
,CHEMBL624170,9606.0,N,BAO_0000218,Homo sapiens,,,,12039,,14215,,1,,The area under curve (100 mg/kg) administered orally in humans,A,,,Intermediate,1,,50587
,CHEMBL624171,9481.0,U,BAO_0000218,Callithrix,,,,12040,,14215,,1,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,,,Autocuration,0,,22224
,CHEMBL624172,314293.0,U,BAO_0000218,Simiiformes,,,,12041,,14215,,1,,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,,,Autocuration,0,,22224
,CHEMBL624173,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12042,,14215,,1,,The area under curve (15 mg/kg) administered intravenously in dog,A,,,Intermediate,1,,50588
,CHEMBL877488,9606.0,N,BAO_0000218,Homo sapiens,,,,12043,,14215,,1,,The area under curve (200 mg/kg) administered orally in humans,A,,,Intermediate,1,,50587
,CHEMBL624174,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12044,,14215,,1,,The area under curve (25 mg/kg) administered intravenously in rat,A,,,Intermediate,1,,50597
,CHEMBL624175,9481.0,U,BAO_0000218,Callithrix,,,,12045,,14215,,1,,The area under curve (25 mg/kg) administered orally in marmoset,A,,,Autocuration,0,,22224
,CHEMBL624176,314293.0,U,BAO_0000218,Simiiformes,,,,12046,,14215,,1,,The area under curve (25 mg/kg) administered orally in monkey,A,,,Autocuration,0,,22224
,CHEMBL624177,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12047,,14215,,1,,The area under curve (30 mg/kg) administered orally in dog,A,,,Intermediate,1,,50588
,CHEMBL624178,9606.0,N,BAO_0000218,Homo sapiens,,,,12048,,14215,,1,,The area under curve (400 mg/kg) administered orally in humans,A,,,Intermediate,1,,50587
,CHEMBL624179,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12049,,14215,,1,,The area under curve (50 mg/kg) administered orally in fasted rat,A,,,Intermediate,1,,50597
,CHEMBL627689,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12050,,14215,,1,,The area under curve (50 mg/kg) administered orally in rat,A,,,Intermediate,1,,50597
,CHEMBL627690,9606.0,N,BAO_0000218,Homo sapiens,,,,12051,,14215,,1,,The area under curve (800 mg/kg) administered orally in humans,A,,,Intermediate,1,,50587
,CHEMBL627691,,U,BAO_0000019,,,,,12052,,11324,,1,,The compound was evaluated for area under the curve,A,,,Autocuration,0,,22224
,CHEMBL627692,9481.0,U,BAO_0000019,Callithrix,,,,12053,,11324,,1,,The compound was evaluated for area under the curve in marmosets,A,,,Autocuration,0,,22224
,CHEMBL627693,9481.0,U,BAO_0000019,Callithrix,,,,12054,,11324,,1,,The compound was evaluated for area under the curve in marmosets,A,,,Autocuration,0,,22224
,CHEMBL627694,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12055,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Intermediate,1,,50597
,CHEMBL627695,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12056,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Intermediate,1,,50597
,CHEMBL627696,,U,BAO_0000218,,,,,12057,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,,,Autocuration,0,,22224
,CHEMBL627697,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12058,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Intermediate,1,,50597
,CHEMBL627698,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12059,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Intermediate,1,,50597
,CHEMBL627699,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12060,,13875,,1,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Intermediate,1,,50597
,CHEMBL627700,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12061,,13807,,1,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,,,Intermediate,1,,50597
,CHEMBL627701,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12062,,14127,,1,,Total drug exposure is determined after oral dosing in rats.,A,,,Intermediate,1,,50597
,CHEMBL627702,,U,BAO_0000218,,,,,12063,,15116,,1,,Total drug exposure (5 mg/kg) when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL627703,,U,BAO_0000218,,,,,12064,,15116,,1,,Total drug exposure (5 mg/kg) when administered orally,A,,,Autocuration,0,,22224
,CHEMBL626873,314293.0,U,BAO_0000218,Simiiformes,,,,12065,,15604,,1,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,,,Autocuration,0,,22224
,CHEMBL629583,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12066,,15604,,1,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,,,Intermediate,1,,50597
,CHEMBL629584,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12067,,15604,,1,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,,,Intermediate,1,,50588
,CHEMBL629585,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12068,,15604,,1,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,,,Intermediate,1,,50588
,CHEMBL629586,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,12069,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629587,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,12070,955.0,13751,,1,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629588,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12071,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629589,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12072,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629590,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12073,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629591,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12074,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629592,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12075,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629593,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12076,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629594,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12077,,13751,,1,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL629595,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12078,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL630290,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12079,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627137,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12080,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627138,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12081,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627139,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12082,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627140,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12083,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627141,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12084,948.0,13751,,1,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627142,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12085,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627143,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12086,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL874449,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12087,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627144,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12088,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627145,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12089,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627146,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12090,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627147,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12091,2113.0,13751,,1,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627148,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12092,2107.0,13751,,1,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627149,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12093,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL632160,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12094,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL632161,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12095,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL632162,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12096,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL632163,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12097,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL874469,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12098,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627182,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12099,2048.0,13751,,1,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627183,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12100,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627184,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12101,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627185,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12102,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627186,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12103,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627187,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12104,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627188,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12105,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627189,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12106,2385.0,13751,,1,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627190,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12107,,13751,,1,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12108,2107.0,13751,,1,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627192,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12109,2107.0,13751,,1,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL627193,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12110,2107.0,13751,,1,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL874590,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12111,2385.0,10911,,1,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627194,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12112,2385.0,10911,,1,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627195,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12113,2385.0,10911,,1,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627196,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,12114,992.0,10911,,1,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627197,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,12115,992.0,10911,,1,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627198,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,12116,992.0,10911,,1,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627199,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,12117,992.0,10911,,1,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,In vivo,,Intermediate,1,,50597
,CHEMBL627200,10116.0,N,BAO_0000218,Rattus norvegicus,,,Female gonad,12118,992.0,10911,,1,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627201,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12119,1969.0,10911,,1,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627202,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12120,1969.0,10911,,1,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627203,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12121,1969.0,10911,,1,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627204,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12122,1969.0,10911,,1,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12123,2106.0,10911,,1,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12124,2106.0,10911,,1,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627207,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12125,2106.0,10911,,1,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627208,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12126,2106.0,10911,,1,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627209,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12127,2046.0,10911,,1,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627210,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12128,2046.0,10911,,1,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627211,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12129,2046.0,10911,,1,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627212,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12130,2046.0,10911,,1,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627213,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12131,995.0,10911,,1,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626599,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12132,995.0,10911,,1,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626600,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12133,995.0,10911,,1,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL626601,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12134,995.0,10911,,1,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Intermediate,1,,50597
,CHEMBL627484,,U,BAO_0000019,,,,,12135,,8081,,1,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,,,Autocuration,0,,22224
,CHEMBL627485,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,12136,1969.0,17248,,1,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,,,Intermediate,1,,100710
,CHEMBL628147,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,12137,1969.0,17248,,1,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,,,Intermediate,1,,100710
,CHEMBL628148,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,12138,1969.0,17248,,1,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,,,Intermediate,1,,100710
,CHEMBL628149,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12139,1969.0,17248,,1,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,,,Intermediate,1,,50588
,CHEMBL628150,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12140,1969.0,17248,,1,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,,,Intermediate,1,,50588
,CHEMBL628318,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12141,1969.0,17248,,1,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,,,Intermediate,1,,50588
,CHEMBL628319,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12142,1969.0,17248,,1,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,,,Intermediate,1,,50588
,CHEMBL875609,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12143,,15592,,1,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Intermediate,1,,50588
,CHEMBL628320,,U,BAO_0000019,,,,,12144,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,,,Autocuration,0,,22224
,CHEMBL628321,,U,BAO_0000019,,,,,12145,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,,,Autocuration,0,,22224
,CHEMBL628322,,U,BAO_0000019,,,,,12146,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,,,Autocuration,0,,22224
,CHEMBL628323,,U,BAO_0000019,,,,,12147,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,,,Autocuration,0,,22224
,CHEMBL628324,,U,BAO_0000019,,,,,12148,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,,,Autocuration,0,,22224
,CHEMBL628325,,U,BAO_0000019,,,,,12149,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,,,Autocuration,0,,22224
,CHEMBL628326,,U,BAO_0000019,,,,,12150,,7040,,1,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,,,Autocuration,0,,22224
,CHEMBL628327,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12151,1236.0,9614,,1,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL628328,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12152,1236.0,9614,,1,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL628329,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,12153,178.0,9614,,1,,"Concentration of compound in blood of dog 1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL628330,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12154,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,,,Intermediate,1,,50597
,CHEMBL628331,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12155,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,,,Intermediate,1,,50597
,CHEMBL628332,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12156,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,,,Intermediate,1,,50597
,CHEMBL628333,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12157,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,,,Intermediate,1,,50597
,CHEMBL628334,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12158,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,,,Intermediate,1,,50597
,CHEMBL628335,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12159,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,,,Intermediate,1,,50597
,CHEMBL628336,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12160,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,,,Intermediate,1,,50597
,CHEMBL628337,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12161,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Intermediate,1,,50597
,CHEMBL628338,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12162,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,,,Intermediate,1,,50597
,CHEMBL875610,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12163,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,,,Intermediate,1,,50597
,CHEMBL628339,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12164,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,,,Intermediate,1,,50597
,CHEMBL628340,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12165,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,,,Intermediate,1,,50597
,CHEMBL628341,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12166,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,,,Intermediate,1,,50597
,CHEMBL622214,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12167,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,,,Intermediate,1,,50597
,CHEMBL623167,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12168,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,,,Intermediate,1,,50597
,CHEMBL623168,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12169,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,,,Intermediate,1,,50597
,CHEMBL623169,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12170,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,,,Intermediate,1,,50597
,CHEMBL623170,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12171,2107.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,,,Intermediate,1,,50597
,CHEMBL627224,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12172,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,,,Intermediate,1,,50597
,CHEMBL875634,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12173,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,,,Intermediate,1,,50597
,CHEMBL627225,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12174,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,,,Intermediate,1,,50597
,CHEMBL627226,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12175,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,,,Intermediate,1,,50597
,CHEMBL626083,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12176,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,,,Intermediate,1,,50597
,CHEMBL626084,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12177,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,,,Intermediate,1,,50597
,CHEMBL626085,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12178,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,,,Intermediate,1,,50597
,CHEMBL626086,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12179,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,,,Intermediate,1,,50597
,CHEMBL626087,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12180,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,,,Intermediate,1,,50597
,CHEMBL626088,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12181,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,,,Intermediate,1,,50597
,CHEMBL626089,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12182,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,,,Intermediate,1,,50597
,CHEMBL626090,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12183,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,,,Intermediate,1,,50597
,CHEMBL626091,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12184,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,,,Intermediate,1,,50597
,CHEMBL626092,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12185,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,,,Intermediate,1,,50597
,CHEMBL626093,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12186,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,,,Intermediate,1,,50597
,CHEMBL626094,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12187,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,,,Intermediate,1,,50597
,CHEMBL626095,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12188,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,,,Intermediate,1,,50597
,CHEMBL626096,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12189,2048.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,,,Intermediate,1,,50597
,CHEMBL626097,314293.0,U,BAO_0000218,Simiiformes,,,,12190,,15604,,1,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,,,Autocuration,0,,22224
,CHEMBL626098,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12191,,15604,,1,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,,,Intermediate,1,,50597
,CHEMBL626099,,U,BAO_0000218,,,,Plasma,12192,1969.0,1806,,1,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,,,Autocuration,0,,22224
,CHEMBL626100,,U,BAO_0000218,,,,Plasma,12193,1969.0,1806,,1,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,,,Autocuration,0,,22224
,CHEMBL626101,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12194,1969.0,17237,,1,,AUC 0-inf in dog,A,,,Intermediate,1,,50588
,CHEMBL626102,10141.0,N,BAO_0000218,Cavia porcellus,,,Plasma,12195,1969.0,17237,,1,,AUC 0-inf in guinea pig,A,,,Intermediate,1,,50512
,CHEMBL626103,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12196,1969.0,17237,,1,,AUC 0-t in dog,A,,,Intermediate,1,,50588
,CHEMBL628391,10141.0,N,BAO_0000218,Cavia porcellus,,,Plasma,12197,1969.0,17237,,1,,AUC 0-t in guinea pig,A,,,Intermediate,1,,50512
,CHEMBL628392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12198,,15194,,1,,The compound was tested for brain to plasma partition in rat,A,,,Intermediate,1,,50597
,CHEMBL628393,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12199,,15194,,1,,The compound was tested for brain to plasma partition in rat.,A,,,Intermediate,1,,50597
,CHEMBL628394,,U,BAO_0000019,,,,Blood,12200,178.0,8787,,1,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,,,Autocuration,0,,22224
,CHEMBL628395,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12201,,17025,,1,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50588
,CHEMBL628396,314293.0,U,BAO_0000218,Simiiformes,,,,12202,,17025,,1,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,,,Autocuration,0,,22224
,CHEMBL628397,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12203,,17025,,1,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50592
,CHEMBL628398,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12204,,17025,,1,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50597
,CHEMBL628399,9544.0,N,BAO_0000218,Macaca mulatta,,,,12205,,4236,,1,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Intermediate,1,,50797
,CHEMBL628400,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12206,,15343,,1,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,,,Intermediate,1,,50588
,CHEMBL874907,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12207,,15343,,1,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL628401,,U,BAO_0000019,,,,,12208,,17720,,1,,Area under curve of the compound was determined,A,,,Autocuration,0,,22224
,CHEMBL628402,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,12209,1969.0,17788,,1,,AUC in monkeys at a dose of 1 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL628403,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12210,1969.0,17788,,1,,AUC in rats at a dose of 1 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL628404,,U,BAO_0000019,,,,,12211,,8778,,1,,Compound was evaluated for the overall absorbance loss at pH of 2,A,,,Autocuration,0,,22224
,CHEMBL628405,,U,BAO_0000019,,,,,12212,,8778,,1,,Compound was evaluated for the overall absorbance loss at pH of 4,A,,,Autocuration,0,,22224
,CHEMBL628406,,U,BAO_0000019,,,,,12213,,8778,,1,,Compound was evaluated for the overall absorbance loss at pH of 7,A,,,Autocuration,0,,22224
,CHEMBL628407,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12214,,2249,,1,,Compound was evaluated for its absorption in the rats,A,,,Intermediate,1,,50597
,CHEMBL628408,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,12215,1088.0,8881,,1,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Intermediate,1,,50597
,CHEMBL629171,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,12216,1088.0,8881,,1,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,,,Intermediate,1,,50597
,CHEMBL629172,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,12217,1088.0,8881,,1,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Intermediate,1,,50597
,CHEMBL629173,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,12218,1088.0,8881,,1,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,,,Intermediate,1,,50597
,CHEMBL629174,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12219,,15286,,1,,In vitro percent permeability into rat ileum,A,,,Intermediate,1,,50597
,CHEMBL629175,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12220,,15286,,1,,In vitro percent permeability into rat ileum; Range is 10-17,A,,,Intermediate,1,,50597
,CHEMBL629176,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12221,,15286,,1,,In vitro percent permeability into rat ileum; Range is 10-18,A,,,Intermediate,1,,50597
,CHEMBL629177,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12222,,15286,,1,,In vitro percent permeability into rat ileum; Range is 10-19,A,,,Intermediate,1,,50597
,CHEMBL629178,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12223,,15286,,1,,In vitro percent permeability into rat ileum; Range is 12-15,A,,,Intermediate,1,,50597
,CHEMBL631869,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12224,,15286,,1,,In vitro percent permeability into rat ileum; Range is 13-19,A,,,Intermediate,1,,50597
,CHEMBL631870,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12225,,15286,,1,,In vitro percent permeability into rat ileum; Range is 14-17,A,,,Intermediate,1,,50597
,CHEMBL631871,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12226,,15286,,1,,In vitro percent permeability into rat ileum; Range is 15-18,A,,,Intermediate,1,,50597
,CHEMBL631872,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12227,,15286,,1,,In vitro percent permeability into rat ileum; Range is 2-5,A,,,Intermediate,1,,50597
,CHEMBL875775,,U,BAO_0000221,,,,Ileum,12228,2116.0,15286,,1,,In vitro percent permeability into rat ileum; Range is 23-42,A,,,Autocuration,0,,22224
,CHEMBL631873,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12229,,15286,,1,,In vitro percent permeability into rat ileum; Range is 28-36,A,,,Intermediate,1,,50597
,CHEMBL631874,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12230,,15286,,1,,In vitro percent permeability into rat ileum; Range is 29-35,A,,,Intermediate,1,,50597
,CHEMBL631875,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12231,,15286,,1,,In vitro percent permeability into rat ileum; Range is 46-66,A,,,Intermediate,1,,50597
,CHEMBL631876,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12232,,15286,,1,,In vitro percent permeability into rat ileum; Range is 50-68,A,,,Intermediate,1,,50597
,CHEMBL631877,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12233,,15286,,1,,In vitro percent permeability into rat ileum; Range is 78-81,A,,,Intermediate,1,,50597
,CHEMBL631878,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12234,,15286,,1,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,,,Intermediate,1,,50597
,CHEMBL631879,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12235,,15286,,1,,In vitro percent permeability into rat ileum; nd indicates not detected,A,,,Intermediate,1,,50597
,CHEMBL631880,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12236,,15286,,1,,In vitro percent permeability into rat ileum; nt indicates not detected,A,,,Intermediate,1,,50597
,CHEMBL631881,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12237,,15286,,1,,In vitro percent permeability into rat ileum; nt indicates not tested,A,,,Intermediate,1,,50597
,CHEMBL631882,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12238,,13770,,1,,Compound was tested for oral absorption in bile-duct cannulated rats,A,,,Intermediate,1,,50597
,CHEMBL630749,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12239,,13770,,1,,Compound was tested for oral absorption in bile-duct cannulated rats.,A,,,Intermediate,1,,50597
,CHEMBL630750,9606.0,N,BAO_0000218,Homo sapiens,,,,12240,,5202,,1,,Oral absorption using Caco-2 cell monolayers.,A,,,Intermediate,1,,50587
,CHEMBL630253,9606.0,N,BAO_0000218,Homo sapiens,,,,12241,,14920,,1,,Percent of the drug absorbed after administration to humans was determined,A,,,Intermediate,1,,50587
,CHEMBL630254,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12242,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Intermediate,1,,50597
,CHEMBL630255,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12243,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Intermediate,1,,50597
,CHEMBL630256,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12244,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Intermediate,1,,50597
,CHEMBL875781,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12245,2107.0,13751,,1,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL630257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12246,2107.0,13751,,1,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL630258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12247,2107.0,13751,,1,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Intermediate,1,,50597
,CHEMBL630259,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12248,,15807,,1,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,,,Intermediate,1,,50597
,CHEMBL630260,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,12249,2435.0,15807,,1,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Intermediate,1,,50597
,CHEMBL630261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,12250,2435.0,15807,,1,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Intermediate,1,,50597
,CHEMBL630262,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12251,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,,,Intermediate,1,,50597
,CHEMBL630263,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12252,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL630264,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12253,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,,,Intermediate,1,,50597
,CHEMBL630265,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12254,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,,,Intermediate,1,,50597
,CHEMBL630266,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12255,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,,,Intermediate,1,,50597
,CHEMBL630267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12256,2113.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,,,Intermediate,1,,50597
,CHEMBL630268,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12257,2113.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,,,Intermediate,1,,50597
,CHEMBL630269,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12258,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL630270,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12259,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,,,Intermediate,1,,50597
,CHEMBL630141,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12260,2048.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL630142,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12261,2048.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,,,Intermediate,1,,50597
,CHEMBL630143,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12262,2385.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,,,Intermediate,1,,50597
,CHEMBL630144,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12263,2385.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,,,Intermediate,1,,50597
,CHEMBL630145,10116.0,N,BAO_0000218,Rattus norvegicus,,,Prostate gland,12264,2367.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,,,Intermediate,1,,50597
,CHEMBL630146,10116.0,N,BAO_0000218,Rattus norvegicus,,,Prostate gland,12265,2367.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,,,Intermediate,1,,50597
,CHEMBL630147,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12266,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,,,Intermediate,1,,50597
,CHEMBL630148,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12267,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,,,Intermediate,1,,50597
,CHEMBL630149,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12268,,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,,,Intermediate,1,,50597
,CHEMBL630150,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12269,2106.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL630151,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,12270,2106.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,,,Intermediate,1,,50597
,CHEMBL632031,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12271,2046.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,,,Intermediate,1,,50597
,CHEMBL632032,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12272,2046.0,14950,,1,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,,,Intermediate,1,,50597
,CHEMBL632033,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12273,,14950,,1,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL632034,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12274,,14950,,1,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL632035,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12275,2385.0,14950,,1,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL632036,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12276,,14950,,1,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL632037,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12277,2046.0,14950,,1,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,,,Intermediate,1,,50597
,CHEMBL632038,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12278,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Intermediate,1,,50597
,CHEMBL632039,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12279,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL632040,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12280,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL632041,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12281,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Intermediate,1,,50597
,CHEMBL632042,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Blood,12282,178.0,9614,,1,,"Concentration of compound in blood of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632043,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12283,,9614,,1,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632044,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12284,,9614,,1,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632045,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,12285,2107.0,9614,,1,,"Concentration of compound in liver of dog 1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632046,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,12286,2107.0,9614,,1,,"Concentration of compound in liver of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632047,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Lung,12287,2048.0,9614,,1,,"Concentration of compound in lung of dog 1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632048,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Lung,12288,2048.0,9614,,1,,"Concentration of compound in lung of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632049,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Muscle tissue,12289,2385.0,9614,,1,,"Concentration of compound in muscle of dog 1, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL876418,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Muscle tissue,12290,2385.0,9614,,1,,"Concentration of compound in muscle of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632050,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Spleen,12291,2106.0,9614,,1,,"Concentration of compound in spleen of dog 1,after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632051,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Spleen,12292,2106.0,9614,,1,,"Concentration of compound in spleen of dog 2, after administering intravenously",A,,,Intermediate,1,,50588
,CHEMBL632052,,U,BAO_0000218,,,,,12293,,10353,,1,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,,,Autocuration,0,,22224
,CHEMBL632053,,U,BAO_0000218,,,,,12294,,10353,,1,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,,,Autocuration,0,,22224
,CHEMBL632054,,U,BAO_0000218,,,,,12295,,10353,,1,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,,,Autocuration,0,,22224
,CHEMBL632055,,U,BAO_0000218,,,,,12296,,10353,,1,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,,,Autocuration,0,,22224
,CHEMBL631181,,U,BAO_0000218,,,,,12297,,10353,,1,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,,,Autocuration,0,,22224
,CHEMBL631182,,U,BAO_0000218,,,,,12298,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL631183,,U,BAO_0000218,,,,,12299,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL631184,,U,BAO_0000218,,,,,12300,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL629774,,U,BAO_0000218,,,,,12301,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL629775,,U,BAO_0000218,,,,,12302,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL876549,,U,BAO_0000218,,,,,12303,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628172,,U,BAO_0000218,,,,,12304,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628173,,U,BAO_0000218,,,,,12305,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628174,,U,BAO_0000218,,,,,12306,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628175,,U,BAO_0000218,,,,,12307,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628176,,U,BAO_0000218,,,,,12308,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628177,,U,BAO_0000218,,,,,12309,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628178,,U,BAO_0000218,,,,,12310,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628179,,U,BAO_0000218,,,,,12311,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628180,,U,BAO_0000218,,,,,12312,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,Autocuration,0,,22224
,CHEMBL628181,,U,BAO_0000218,,,,,12313,,9196,,1,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628182,,U,BAO_0000218,,,,,12314,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628183,,U,BAO_0000218,,,,,12315,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628184,,U,BAO_0000218,,,,,12316,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL628185,,U,BAO_0000218,,,,,12317,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL875617,,U,BAO_0000218,,,,,12318,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628186,,U,BAO_0000218,,,,,12319,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL628187,,U,BAO_0000218,,,,,12320,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628188,,U,BAO_0000218,,,,,12321,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628189,,U,BAO_0000218,,,,,12322,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628190,,U,BAO_0000218,,,,,12323,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL628191,,U,BAO_0000218,,,,,12324,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626513,,U,BAO_0000218,,,,,12325,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL626514,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12326,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,,,Intermediate,1,,50597
,CHEMBL626515,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12327,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,,,Intermediate,1,,50597
,CHEMBL626516,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12328,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,,,Intermediate,1,,50597
,CHEMBL626517,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12329,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,,,Intermediate,1,,50597
,CHEMBL626518,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12330,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,,,Intermediate,1,,50597
,CHEMBL626519,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12331,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,,,Intermediate,1,,50597
,CHEMBL626520,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12332,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,,,Intermediate,1,,50597
,CHEMBL626521,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12333,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,,,Intermediate,1,,50597
,CHEMBL626522,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12334,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,,,Intermediate,1,,50597
,CHEMBL626523,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12335,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,,,Intermediate,1,,50597
,CHEMBL626524,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12336,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,,,Intermediate,1,,50597
,CHEMBL626688,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12337,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,,,Intermediate,1,,50597
,CHEMBL626689,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12338,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,,,Intermediate,1,,50597
,CHEMBL626690,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12339,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,,,Intermediate,1,,50597
,CHEMBL626691,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12340,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,,,Intermediate,1,,50597
,CHEMBL627319,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12341,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,,,Intermediate,1,,50597
,CHEMBL624052,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12342,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,,,Intermediate,1,,50597
,CHEMBL624053,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12343,2046.0,8608,,1,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,,,Intermediate,1,,50597
,CHEMBL624054,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12344,,8085,,1,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL624055,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12345,,8085,,1,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL624056,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12346,,8085,,1,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL624057,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12347,995.0,8085,,1,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622281,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12348,995.0,8085,,1,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622282,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12349,995.0,8085,,1,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622283,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12350,995.0,8085,,1,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622284,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12351,995.0,8085,,1,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622285,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12352,995.0,8085,,1,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622286,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,12353,995.0,8085,,1,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Intermediate,1,,50597
,CHEMBL622287,,U,BAO_0000100,,,,,12354,,7657,,1,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,,,Autocuration,0,,22224
,CHEMBL622288,10090.0,N,BAO_0000218,Mus musculus,,,,12355,,8935,,1,,Partition coefficient (logD7.4),A,,,Intermediate,1,,50594
,CHEMBL622289,10090.0,N,BAO_0000218,Mus musculus,,,,12356,,13792,,1,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Intermediate,1,,50594
,CHEMBL622290,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12357,955.0,13792,,1,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Intermediate,1,,50594
,CHEMBL622291,10090.0,N,BAO_0000218,Mus musculus,,,,12358,,13792,,1,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Intermediate,1,,50594
,CHEMBL622292,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12359,955.0,13792,,1,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Intermediate,1,,50594
,CHEMBL622293,10090.0,N,BAO_0000218,Mus musculus,,,,12360,,13792,,1,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Intermediate,1,,50594
,CHEMBL622294,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12361,955.0,13792,,1,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Intermediate,1,,50594
,CHEMBL622295,10090.0,N,BAO_0000218,Mus musculus,,,,12362,,13792,,1,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Intermediate,1,,50594
,CHEMBL622296,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,12363,955.0,13792,,1,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Intermediate,1,,50597
,CHEMBL874409,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12364,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622297,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12365,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622298,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12366,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622299,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12367,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622300,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12368,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622301,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12369,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622302,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12370,1969.0,14103,,1,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622303,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12371,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622304,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12372,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Intermediate,1,,50597
,CHEMBL622305,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12373,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL622306,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12374,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Intermediate,1,,50597
,CHEMBL626864,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12375,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL626865,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12376,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Intermediate,1,,50597
,CHEMBL626866,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12377,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL626867,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12378,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Intermediate,1,,50597
,CHEMBL626868,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12379,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Intermediate,1,,50597
,CHEMBL626869,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12380,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL626870,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12381,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Intermediate,1,,50597
,CHEMBL626871,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12382,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL626872,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12383,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Intermediate,1,,50597
,CHEMBL632185,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12384,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Intermediate,1,,50597
,CHEMBL632186,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12385,1969.0,14103,,1,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,,,Intermediate,1,,50597
,CHEMBL629310,,U,BAO_0000019,,,,,12386,,12904,,1,,Amount of acetic acid produced by the compound,A,,,Autocuration,0,,22224
,CHEMBL629311,,U,BAO_0000019,,,,,12387,,12904,,1,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,,,Autocuration,0,,22224
,CHEMBL629312,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12388,,9663,,1,,Log of (Cbrain/Cblood) in rats,A,,,Intermediate,1,,50597
,CHEMBL629313,,U,BAO_0000221,,,,,12389,,7652,,1,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629314,,U,BAO_0000221,,,,,12390,,7652,,1,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629315,,U,BAO_0000221,,,,,12391,,7652,,1,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629316,,U,BAO_0000219,,,,,12392,,7652,,1,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,,,Autocuration,0,,22224
,CHEMBL629317,,U,BAO_0000221,,,,,12393,,7652,,1,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629318,,U,BAO_0000019,,,,,12394,,7652,,1,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL877497,,U,BAO_0000019,,,,,12395,,7652,,1,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629319,,U,BAO_0000019,,,,,12396,,7652,,1,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629320,,U,BAO_0000019,,,,,12397,,7652,,1,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629496,,U,BAO_0000019,,,,,12398,,7652,,1,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629497,,U,BAO_0000019,,,,,12399,,7652,,1,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629498,,U,BAO_0000019,,,,,12400,,7652,,1,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629499,,U,BAO_0000019,,,,,12401,,7652,,1,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629500,,U,BAO_0000019,,,,,12402,,7652,,1,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629501,,U,BAO_0000019,,,,,12403,,7652,,1,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629502,,U,BAO_0000019,,,,,12404,,7652,,1,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,,,Autocuration,0,,22224
,CHEMBL629503,,U,BAO_0000218,,,,,12405,,8267,,1,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,In vivo,,Autocuration,0,,22224
,CHEMBL629504,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12406,,8267,,1,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,,,Intermediate,1,,50588
,CHEMBL629505,,U,BAO_0000019,,,,,12407,,14479,,1,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,,,Autocuration,0,,22224
,CHEMBL629506,,U,BAO_0000019,,,,,12408,,17515,,1,,Compound was evaluated for total body clearance,A,,,Autocuration,0,,22224
,CHEMBL629507,,U,BAO_0000019,,,,,12409,,17515,,1,,Compound was evaluated for volume of distribution at steady state,A,,,Autocuration,0,,22224
,CHEMBL877498,,U,BAO_0000019,,,,,12410,,8142,,1,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,,,Autocuration,0,,22224
,CHEMBL629508,,U,BAO_0000019,,,,,12411,,14849,,1,,Percentage of the diamine which is monoprotonated at pH 7.4,A,,,Autocuration,0,,22224
,CHEMBL629509,,U,BAO_0000019,,,,,12412,,7653,,1,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,,,Autocuration,0,,22224
,CHEMBL629510,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12413,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL629511,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12414,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Intermediate,1,,50597
,CHEMBL629512,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12415,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL629513,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12416,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL629514,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12417,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Intermediate,1,,50597
,CHEMBL628447,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12418,178.0,8631,,1,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL628448,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12419,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Intermediate,1,,50597
,CHEMBL628449,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12420,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL631119,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12421,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL631120,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12422,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Intermediate,1,,50597
,CHEMBL631121,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12423,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL874458,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12424,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,,,Intermediate,1,,50597
,CHEMBL631122,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12425,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL631123,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12426,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL631124,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12427,178.0,8631,,1,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL631125,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12428,178.0,8631,,1,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Intermediate,1,,50597
,CHEMBL631290,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12429,178.0,8631,,1,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL631291,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12430,178.0,8631,,1,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL631292,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12431,178.0,8631,,1,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL631293,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12432,178.0,8631,,1,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Intermediate,1,,50597
,CHEMBL631294,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12433,178.0,8631,,1,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Intermediate,1,,50597
,CHEMBL631295,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12434,178.0,8631,,1,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Intermediate,1,,50597
,CHEMBL631296,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12435,178.0,8631,,1,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Intermediate,1,,50597
,CHEMBL631297,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12436,178.0,8631,,1,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Intermediate,1,,50597
,CHEMBL631298,,U,BAO_0000218,,,,,12437,,10263,,1,,Maximum biodistribution (Bmax) was determined.,A,,,Autocuration,0,,22224
,CHEMBL631299,10090.0,N,BAO_0000218,Mus musculus,,,,12438,,12364,,1,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,,,Intermediate,1,,50594
,CHEMBL631300,10090.0,N,BAO_0000218,Mus musculus,,,,12439,,12364,,1,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,,,Intermediate,1,,50594
,CHEMBL631301,10090.0,N,BAO_0000218,Mus musculus,,,,12440,,12364,,1,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,,,Intermediate,1,,50594
,CHEMBL630291,10090.0,N,BAO_0000218,Mus musculus,,,,12441,,12364,,1,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,,,Intermediate,1,,50594
,CHEMBL630292,,U,BAO_0000218,,,,,12442,,14793,,1,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,Autocuration,0,,22224
,CHEMBL630293,,U,BAO_0000218,,,,,12443,,14793,,1,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL630294,,U,BAO_0000218,,,,,12444,,14793,,1,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL630295,,U,BAO_0000218,,,,,12445,,14793,,1,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,,,Autocuration,0,,22224
,CHEMBL630296,,U,BAO_0000218,,,,,12446,,14793,,1,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626782,,U,BAO_0000218,,,,,12447,,14793,,1,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626783,,U,BAO_0000218,,,,,12448,,14793,,1,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626784,,U,BAO_0000218,,,,,12449,,14793,,1,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,Autocuration,0,,22224
,CHEMBL626785,,U,BAO_0000218,,,,,12450,,14793,,1,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626786,,U,BAO_0000218,,,,,12451,,14793,,1,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626787,,U,BAO_0000218,,,,,12452,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626788,,U,BAO_0000218,,,,,12453,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL625927,,U,BAO_0000218,,,,,12454,,9196,,1,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL625928,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12455,178.0,8374,,1,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL625929,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12456,178.0,8374,,1,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL625930,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12457,178.0,8374,,1,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Intermediate,1,,50597
,CHEMBL625931,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12458,178.0,8374,,1,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,,,Intermediate,1,,50597
,CHEMBL627230,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12459,178.0,8374,,1,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,,,Intermediate,1,,50597
,CHEMBL627231,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12460,178.0,8374,,1,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627232,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12461,178.0,8374,,1,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL627233,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12462,178.0,8374,,1,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Intermediate,1,,50597
,CHEMBL875470,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12463,178.0,8374,,1,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627234,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12464,178.0,8374,,1,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627235,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12465,178.0,8374,,1,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627236,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12466,178.0,8374,,1,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627237,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12467,178.0,8374,,1,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627238,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12468,178.0,8374,,1,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627239,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12469,178.0,8374,,1,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627240,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12470,178.0,8374,,1,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627241,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12471,178.0,8374,,1,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627242,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12472,178.0,8374,,1,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627243,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12473,178.0,8374,,1,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL627244,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12474,178.0,8374,,1,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL627245,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12475,178.0,8374,,1,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627246,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12476,178.0,8374,,1,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627247,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12477,178.0,8374,,1,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627248,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12478,178.0,8374,,1,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627249,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12479,178.0,8374,,1,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL625569,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12480,178.0,8374,,1,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL625570,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12481,178.0,8374,,1,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL625571,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12482,178.0,8374,,1,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL625572,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12483,178.0,8374,,1,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL625573,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12484,178.0,8374,,1,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL625574,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12485,178.0,8374,,1,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626245,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12486,178.0,8374,,1,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Intermediate,1,,50597
,CHEMBL626246,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12487,178.0,8374,,1,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL626247,,U,BAO_0000218,,,,,12488,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL626248,,U,BAO_0000218,,,,,12489,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626249,,U,BAO_0000218,,,,,12490,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL626420,,U,BAO_0000218,,,,,12491,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626421,,U,BAO_0000218,,,,,12492,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL626422,,U,BAO_0000218,,,,,12493,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL626423,,U,BAO_0000218,,,,,12494,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626424,,U,BAO_0000218,,,,,12495,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626425,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12496,,12023,,1,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,,,Intermediate,1,,50588
,CHEMBL875476,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12497,,12023,,1,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,,,Intermediate,1,,50597
,CHEMBL626426,9541.0,N,BAO_0000218,Macaca fascicularis,,,,12498,,12023,,1,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,,,Intermediate,1,,100710
,CHEMBL626427,,U,BAO_0000100,,,,,12499,,10580,,1,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,Autocuration,0,,22224
,CHEMBL626428,,U,BAO_0000100,,,,,12500,,10580,,1,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,Autocuration,0,,22224
,CHEMBL626429,,U,BAO_0000019,,,,,12501,,16032,,1,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL625025,,U,BAO_0000019,,,,Urine,12502,1088.0,16032,,1,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,,,Autocuration,0,,22224
,CHEMBL625026,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12503,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL625027,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12504,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL874410,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12505,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL625028,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12506,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL625029,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12507,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL625030,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12508,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL625031,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12509,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL625032,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12510,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL625033,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12511,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL625034,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12512,178.0,8594,,1,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624872,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12513,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624873,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12514,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624874,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12515,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624875,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12516,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624876,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12517,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624877,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12518,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624878,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12519,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624879,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12520,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624880,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12521,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624881,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12522,948.0,8594,,1,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624882,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12523,948.0,8594,,1,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,,,Intermediate,1,,50597
,CHEMBL624883,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12524,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624884,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12525,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624885,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12526,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624886,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12527,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624887,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12528,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624888,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12529,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624889,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12530,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624890,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12531,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL621964,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12532,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL621965,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12533,2113.0,8594,,1,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL621966,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12534,2107.0,8594,,1,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL621967,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12535,2107.0,8594,,1,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL622164,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12536,2107.0,8594,,1,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL623097,,U,BAO_0000019,,,,,12537,,7653,,1,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,,,Autocuration,0,,22224
,CHEMBL623098,,U,BAO_0000019,,,,,12538,,7653,,1,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,,,Autocuration,0,,22224
,CHEMBL623099,,U,BAO_0000019,,,,,12539,,7653,,1,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,,,Autocuration,0,,22224
,CHEMBL623100,,U,BAO_0000019,,,,,12540,,7653,,1,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,,,Autocuration,0,,22224
,CHEMBL628673,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12541,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,,,Intermediate,1,,50597
,CHEMBL628674,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12542,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,,,Intermediate,1,,50597
,CHEMBL628675,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12543,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,,,Intermediate,1,,50597
,CHEMBL627644,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12544,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Intermediate,1,,50597
,CHEMBL627645,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12545,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,,,Intermediate,1,,50597
,CHEMBL627646,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12546,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,,,Intermediate,1,,50597
,CHEMBL627647,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12547,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Intermediate,1,,50597
,CHEMBL627648,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12548,,9104,,1,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,,,Intermediate,1,,50597
,CHEMBL627649,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12549,,12902,,1,,Free level in rat plasma,A,,,Intermediate,1,,50597
,CHEMBL628313,,U,BAO_0000019,,,,,12550,,6614,,1,,Level reaching in blood plasma of rat or human was determined,A,,,Autocuration,0,,22224
,CHEMBL628314,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12551,,9663,,1,,Log (Cbrain/Cblood) in rats,A,,,Intermediate,1,,50597
,CHEMBL628315,,U,BAO_0000019,,,,,12552,,17658,,1,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,,,Autocuration,0,,22224
,CHEMBL628316,,U,BAO_0000019,,,,,12553,,17658,,1,,Mean percentage of compound transport through membrane; expressed as membrane transport,A,,,Autocuration,0,,22224
,CHEMBL628317,,U,BAO_0000218,,,,,12554,,14314,,1,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,,,Autocuration,0,,22224
,CHEMBL628473,,U,BAO_0000019,,,,,12555,,7385,,1,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,,,Autocuration,0,,22224
,CHEMBL628474,,U,BAO_0000019,,,,,12556,,7385,,1,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,,,Autocuration,0,,22224
,CHEMBL628475,,U,BAO_0000019,,,,,12557,,7385,,1,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,,,Autocuration,0,,22224
,CHEMBL628476,,U,BAO_0000019,,,,,12558,,1329,,1,,Net water uptake by a carrier mediated transport (%cm) mechanism,A,,,Autocuration,0,,22224
,CHEMBL628477,314293.0,U,BAO_0000218,Simiiformes,,,,12559,,12187,,1,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL628478,9669.0,N,BAO_0000218,Mustela putorius furo,,,,12560,,12187,,1,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Intermediate,1,,50506
,CHEMBL628479,9669.0,N,BAO_0000218,Mustela putorius furo,,,,12561,,12187,,1,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Intermediate,1,,50506
,CHEMBL628480,314293.0,U,BAO_0000218,Simiiformes,,,,12562,,12187,,1,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL628481,314293.0,U,BAO_0000218,Simiiformes,,,,12563,,12187,,1,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,,,Autocuration,0,,22224
,CHEMBL628482,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12564,,12187,,1,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Intermediate,1,,50597
,CHEMBL628483,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12565,,12187,,1,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Intermediate,1,,50597
,CHEMBL628484,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12566,1969.0,9278,,1,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Intermediate,1,,50597
,CHEMBL628485,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12567,1969.0,9278,,1,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Intermediate,1,,50597
,CHEMBL628486,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,12568,1969.0,9278,,1,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,,,Intermediate,1,,100710
,CHEMBL628487,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,12569,1969.0,9278,,1,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,,,Intermediate,1,,50587
,CHEMBL628488,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12570,1969.0,9278,,1,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Intermediate,1,,50597
,CHEMBL628489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12571,1969.0,9278,,1,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Intermediate,1,,50597
,CHEMBL628490,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12572,1969.0,9278,,1,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Intermediate,1,,50597
,CHEMBL628491,9541.0,N,BAO_0000218,Macaca fascicularis,,,,12573,,12186,,1,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Intermediate,1,,100710
,CHEMBL877507,9541.0,N,BAO_0000218,Macaca fascicularis,,,,12574,,12186,,1,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Intermediate,1,,100710
,CHEMBL628492,,U,BAO_0000218,,,,,12575,,12186,,1,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Autocuration,0,,22224
,CHEMBL628493,314293.0,U,BAO_0000019,Simiiformes,,,,12576,,12041,,1,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,,,Autocuration,0,,22224
,CHEMBL628494,314293.0,U,BAO_0000019,Simiiformes,,,,12577,,12041,,1,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,,,Autocuration,0,,22224
,CHEMBL628495,314293.0,U,BAO_0000019,Simiiformes,,,,12578,,12041,,1,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,,,Autocuration,0,,22224
,CHEMBL628496,9606.0,N,BAO_0000218,Homo sapiens,,,,12579,,6737,,1,,Permeability in Caco-2 assay at 10E-6,A,,,Intermediate,1,,50587
,CHEMBL628497,,U,BAO_0000218,,,,Brain,12580,955.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,Autocuration,0,,22224
,CHEMBL628498,,U,BAO_0000218,,,,Brain,12581,955.0,13758,,1,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,Autocuration,0,,22224
,CHEMBL628499,,U,BAO_0000019,,,,,12582,,5676,,1,,Plasma protein binding was determined,A,,,Autocuration,0,,22224
,CHEMBL627656,,U,BAO_0000218,,,,,12583,,14793,,1,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL627657,,U,BAO_0000218,,,,,12584,,14793,,1,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,Autocuration,0,,22224
,CHEMBL626808,,U,BAO_0000218,,,,,12585,,14793,,1,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626809,,U,BAO_0000218,,,,,12586,,14793,,1,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626810,,U,BAO_0000218,,,,,12587,,14793,,1,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626811,,U,BAO_0000218,,,,,12588,,14793,,1,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,Autocuration,0,,22224
,CHEMBL874465,,U,BAO_0000218,,,,,12589,,14793,,1,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,,,Autocuration,0,,22224
,CHEMBL626812,,U,BAO_0000218,,,,,12590,,14793,,1,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626813,,U,BAO_0000218,,,,,12591,,14793,,1,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626814,,U,BAO_0000218,,,,,12592,,14793,,1,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,,,Autocuration,0,,22224
,CHEMBL626815,,U,BAO_0000019,,,,,12593,,14000,,1,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,,,Autocuration,0,,22224
,CHEMBL628566,,U,BAO_0000019,,,,,12594,,5948,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL628567,,U,BAO_0000100,,,,,12595,,13824,,1,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,Autocuration,0,,22229
,CHEMBL628568,,U,BAO_0000100,,,,,12596,,10778,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL628569,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12597,,17237,,1,,C max in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL628570,10141.0,N,BAO_0000218,Cavia porcellus,,,,12598,,17237,,1,,C max in guinea pig,A,In vivo,,Intermediate,1,,50512
,CHEMBL628571,,U,BAO_0000218,,,,,12599,,2809,,1,,C max value was evaluated,A,In vivo,,Autocuration,0,,22224
,CHEMBL628572,,U,BAO_0000218,,,,,12600,,11954,,1,,Cmax value after oral dose of 0.1 mg//kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628573,,U,BAO_0000218,,,,,12601,,11954,,1,,Cmax value after oral dose of 0.3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628574,,U,BAO_0000218,,,,,12602,,11954,,1,,Cmax value after oral dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628575,,U,BAO_0000218,,,,,12603,,11954,,1,,Cmax value after oral dose of 10 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628576,,U,BAO_0000218,,,,,12604,,11954,,1,,Cmax value after oral dose of 23.4 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628577,,U,BAO_0000218,,,,,12605,,11954,,1,,Cmax value after oral dose of 3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL628578,,U,BAO_0000218,,,,,12606,,11954,,1,,Cmax value after oral dose of 3.87 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL874466,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12607,,12768,,1,,Cmax value in female Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL628579,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12608,,12768,,1,,Cmax value in male rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL628580,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12609,1969.0,12780,,1,,Cmax value in rat plasma when administered 20 mg/kg perorally,A,In vivo,,Intermediate,1,,50597
,CHEMBL628581,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12610,1969.0,15592,,1,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Intermediate,1,,50588
,CHEMBL628582,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12611,1969.0,15592,,1,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Intermediate,1,,50588
,CHEMBL628583,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12612,,17025,,1,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50588
,CHEMBL625782,314293.0,U,BAO_0000218,Simiiformes,,,,12613,,17025,,1,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,,,Autocuration,0,,22224
,CHEMBL625783,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12614,,17025,,1,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50592
,CHEMBL625784,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12615,,17025,,1,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,,,Intermediate,1,,50597
,CHEMBL625785,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,12616,1969.0,4236,,1,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Intermediate,1,,50797
,CHEMBL625786,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12617,,15791,,1,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL874467,,U,BAO_0000019,,,,,12618,,11149,,1,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,,,Autocuration,0,,22224
,CHEMBL625787,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12619,,15592,,1,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Intermediate,1,,50588
,CHEMBL625964,12721.0,N,BAO_0000218,Human immunodeficiency virus,,,,12620,,15778,,1,,cytotoxicity against HIV protease enzyme.,A,,,Intermediate,1,,50677
,CHEMBL625965,10090.0,N,BAO_0000218,Mus musculus,,,,12621,,12745,,1,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL625966,10090.0,N,BAO_0000218,Mus musculus,,,,12622,,12745,,1,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,,,Intermediate,1,,50594
,CHEMBL625967,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12623,1969.0,13941,,1,,The plasma clearance in dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625968,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12624,1969.0,13941,,1,,The plasma clearance in rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625969,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12625,1969.0,16449,,1,,Clearance from plasma in male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625970,9541.0,N,BAO_0000218,Macaca fascicularis,,,Plasma,12626,1969.0,16449,,1,,Clearance from plasma in male cynomolgus monkeys,A,In vivo,,Intermediate,1,,100710
,CHEMBL625971,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12627,1969.0,14224,,1,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,In vivo,,Intermediate,1,,50588
,CHEMBL625972,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12628,1969.0,14224,,1,,Clearance of compound in dog plasma,A,In vivo,,Intermediate,1,,50588
,CHEMBL625973,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,12629,1969.0,14224,,1,,Clearance of compound in human plasma,A,In vivo,,Intermediate,1,,50587
,CHEMBL625974,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12630,,14317,,1,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625975,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12631,,14317,,1,,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625976,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12632,1969.0,14224,,1,,"Clearance (10 mg/kg, intravenously) in dog plasma",A,In vivo,,Intermediate,1,,50588
,CHEMBL625977,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12633,,17237,,1,,Clearance value in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625978,10141.0,N,BAO_0000218,Cavia porcellus,,,,12634,,17237,,1,,Clearance value in guinea pig,A,In vivo,,Intermediate,1,,50512
,CHEMBL874468,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12635,,14187,,1,,Clearance values in rats after iv administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625421,,U,BAO_0000218,,,,Plasma,12636,1969.0,4806,,1,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,In vivo,,Autocuration,0,,22224
,CHEMBL625422,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12637,,15025,,1,,In vivo clearance (5 mg/kg) was determined in rabbits,A,In vivo,,Intermediate,1,,50592
,CHEMBL625423,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12638,,13197,,1,,Plasma Clearance rate was determined for the compound in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625424,9520.0,U,BAO_0000218,Saimiri,,,,12639,,13197,,1,,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL625425,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12640,,13960,,1,,Plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625426,,U,BAO_0000218,,,,,12641,,17820,,1,,Plasma clearance of the compound,A,In vivo,,Autocuration,0,,22224
,CHEMBL625427,10141.0,N,BAO_0000218,Cavia porcellus,,,,12642,,14706,,1,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,In vivo,,Intermediate,1,,50512
,CHEMBL625428,10141.0,N,BAO_0000218,Cavia porcellus,,,,12643,,14706,,1,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,In vivo,,Intermediate,1,,50512
,CHEMBL625429,,U,BAO_0000218,,,,,12644,,6504,,1,,Plasma clearance was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL625430,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12645,,14925,,1,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625431,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12646,,13197,,1,,Plasma clearance rate was determined for the compound in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627307,9520.0,U,BAO_0000218,Saimiri,,,,12647,,13197,,1,,Plasma clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL627308,,U,BAO_0000218,,,,,12648,,3437,,1,,Slow clearance (CL) was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL627309,,U,BAO_0000218,,,,,12649,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL627310,,U,BAO_0000218,,,,,12650,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,Autocuration,0,,22224
,CHEMBL627311,,U,BAO_0000218,,,,,12651,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL627312,,U,BAO_0000218,,,,,12652,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL627313,,U,BAO_0000218,,,,,12653,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL627314,,U,BAO_0000218,,,,,12654,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL627315,,U,BAO_0000218,,,,,12655,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL627316,,U,BAO_0000218,,,,,12656,,9196,,1,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL627317,,U,BAO_0000218,,,,,12657,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,Autocuration,0,,22224
,CHEMBL627318,,U,BAO_0000218,,,,,12658,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL627999,,U,BAO_0000218,,,,,12659,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628000,,U,BAO_0000218,,,,,12660,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,Autocuration,0,,22224
,CHEMBL628001,,U,BAO_0000218,,,,,12661,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL628002,,U,BAO_0000218,,,,,12662,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL625610,,U,BAO_0000218,,,,,12663,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL625611,,U,BAO_0000218,,,,,12664,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL625612,,U,BAO_0000218,,,,,12665,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,Autocuration,0,,22224
,CHEMBL625613,,U,BAO_0000218,,,,,12666,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,Autocuration,0,,22224
,CHEMBL875479,,U,BAO_0000218,,,,,12667,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,Autocuration,0,,22224
,CHEMBL625614,,U,BAO_0000218,,,,,12668,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,Autocuration,0,,22224
,CHEMBL625615,,U,BAO_0000218,,,,,12669,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,Autocuration,0,,22224
,CHEMBL626302,,U,BAO_0000218,,,,,12670,,9196,,1,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,Autocuration,0,,22224
,CHEMBL626303,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12671,178.0,8374,,1,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627420,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12672,178.0,8374,,1,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Intermediate,1,,50597
,CHEMBL627421,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12673,,13477,,1,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,,,Intermediate,1,,50597
,CHEMBL625695,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12674,,13477,,1,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,,,Intermediate,1,,50597
,CHEMBL625696,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12675,,13477,,1,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,,,Intermediate,1,,50597
,CHEMBL875606,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12676,955.0,10009,,1,,Distribution of compound in mice brain was measured after 1 hr,A,,,Intermediate,1,,50594
,CHEMBL625697,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12677,955.0,10009,,1,,Distribution of compound in mice brain was measured after 24 hr r,A,,,Intermediate,1,,50594
,CHEMBL625698,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12678,955.0,10009,,1,,Distribution of compound in mice brain was measured after 2 hr,A,,,Intermediate,1,,50594
,CHEMBL625699,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12679,955.0,10009,,1,,Distribution of compound in mice brain was measured after 3 hr,A,,,Intermediate,1,,50594
,CHEMBL625700,10090.0,N,BAO_0000218,Mus musculus,,,Brain,12680,955.0,10009,,1,,Distribution of compound in mice brain was measured after 6 hr,A,,,Intermediate,1,,50594
,CHEMBL625701,10090.0,N,BAO_0000218,Mus musculus,,,,12681,,10009,,1,,Distribution of compound in mice liver was measured after 1 hr,A,,,Intermediate,1,,50594
,CHEMBL625702,10090.0,N,BAO_0000218,Mus musculus,,,,12682,,10009,,1,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,,,Intermediate,1,,50594
,CHEMBL625703,10090.0,N,BAO_0000218,Mus musculus,,,,12683,,10009,,1,,Distribution of compound in mice liver was measured after 2 hr,A,,,Intermediate,1,,50594
,CHEMBL625704,10090.0,N,BAO_0000218,Mus musculus,,,,12684,,10009,,1,,Distribution of compound in mice liver was measured after 3 hr,A,,,Intermediate,1,,50594
,CHEMBL625705,10090.0,N,BAO_0000218,Mus musculus,,,,12685,,10009,,1,,Distribution of compound in mice liver was measured after 6 hr,A,,,Intermediate,1,,50594
,CHEMBL625706,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12686,1236.0,8170,,1,,Distribution in dog adrenal medulla 30 min after administration.,A,,,Intermediate,1,,50588
,CHEMBL625707,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12687,1236.0,8170,,1,,Distribution in dog adrenal medulla 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL625708,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12688,,8170,,1,,Distribution in female dog Ovary 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL625709,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12689,,8170,,1,,Distribution in female dog Ovary 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624180,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12690,,8170,,1,,Distribution in female dog adipose 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624181,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12691,,8170,,1,,Distribution in female dog adipose 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624182,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal cortex,12692,1235.0,8170,,1,,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624183,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal cortex,12693,1235.0,8170,,1,,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624184,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12694,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL877489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12695,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624185,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12696,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624186,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12697,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624187,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12698,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624188,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12699,2107.0,8594,,1,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624189,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12700,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624190,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12701,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12702,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624192,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12703,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624193,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12704,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624194,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12705,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12706,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL624892,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12707,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL624893,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12708,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL627632,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12709,2048.0,8594,,1,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627633,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12710,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627634,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12711,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627635,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12712,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL627636,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12713,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12714,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12715,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626818,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12716,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626819,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12717,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626820,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12718,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626821,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12719,,8594,,1,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626822,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12720,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626823,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12721,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626824,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12722,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626825,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12723,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626826,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12724,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626827,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12725,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626828,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12726,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL626829,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12727,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626830,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12728,2046.0,8594,,1,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627150,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12729,,8594,,1,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL627151,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12730,,8594,,1,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627152,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12731,,8594,,1,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Intermediate,1,,50597
,CHEMBL627153,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12732,,8594,,1,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL627154,,U,BAO_0000019,,,,,12733,,12904,,1,,Rate of acetate production by the compound was determined,A,,,Autocuration,0,,22224
,CHEMBL627155,,U,BAO_0000019,,,,,12734,,12904,,1,,Rate of acetate production by the compound was determined; Not determined,A,,,Autocuration,0,,22224
,CHEMBL627156,,U,BAO_0000019,,,,,12735,,3730,,1,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,,,Autocuration,0,,22224
,CHEMBL627157,,U,BAO_0000019,,,,,12736,,3627,,1,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,,,Autocuration,0,,22224
,CHEMBL627158,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12737,,13799,,1,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Intermediate,1,,50592
,CHEMBL627159,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Plasma,12738,1969.0,13799,,1,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Intermediate,1,,50592
,CHEMBL627160,10090.0,N,BAO_0000218,Mus musculus,,,,12739,,13799,,1,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Intermediate,1,,50594
,CHEMBL628540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12740,,13799,,1,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Intermediate,1,,50597
,CHEMBL628541,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12741,1969.0,13799,,1,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Intermediate,1,,50597
,CHEMBL628542,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12742,1969.0,13799,,1,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Intermediate,1,,50597
,CHEMBL628543,,U,BAO_0000100,,,,,12743,,6629,,1,,Solubility after at a pH 1.2,P,,,Autocuration,0,,22229
,CHEMBL628544,,U,BAO_0000100,,,,,12744,,6629,,1,,Solubility after at pH 1.2,P,,,Autocuration,0,,22229
,CHEMBL628545,,U,BAO_0000100,,,,,12745,,6629,,1,,Solubility after injection of water,P,,,Autocuration,0,,22229
,CHEMBL628546,,U,BAO_0000019,,,,,12746,,14000,,1,,Statistical significance of IC 50 values; Expressed as R value,A,,,Autocuration,0,,22224
,CHEMBL874455,,U,BAO_0000019,,,,,12747,,8267,,1,,Systemic availability with respect to methyldopa was determined,A,,,Autocuration,0,,22224
,CHEMBL628547,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12748,,13799,,1,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Intermediate,1,,50597
,CHEMBL628548,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12749,1969.0,13799,,1,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Intermediate,1,,50597
,CHEMBL628549,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12750,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL628550,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12751,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL628551,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12752,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,,,Intermediate,1,,50592
,CHEMBL628552,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12753,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,,,Intermediate,1,,50592
,CHEMBL628553,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12754,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,,,Intermediate,1,,50592
,CHEMBL628554,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12755,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,,,Intermediate,1,,50592
,CHEMBL628555,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12756,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL628556,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12757,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL628557,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Kidney,12758,2113.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL628558,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12759,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL628559,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12760,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,,,Intermediate,1,,50592
,CHEMBL628560,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12761,1988.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL874456,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12762,1088.0,7132,,1,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,,,Intermediate,1,,50592
,CHEMBL628561,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12763,1988.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,,,Intermediate,1,,50592
,CHEMBL628562,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12764,1988.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,,,Intermediate,1,,50592
,CHEMBL628563,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12765,1088.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,,,Intermediate,1,,50592
,CHEMBL628564,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12766,1088.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,,,Intermediate,1,,50592
,CHEMBL628565,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12767,1088.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL631248,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12768,1088.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL631249,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,12769,1088.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,,,Intermediate,1,,50592
,CHEMBL627214,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Kidney,12770,2113.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL874591,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12771,1988.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL627215,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12772,1988.0,7132,,1,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,,,Intermediate,1,,50592
,CHEMBL625471,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,12773,1988.0,7132,,1,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,,,Intermediate,1,,50592
,CHEMBL625472,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12774,,7132,,1,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,,,Intermediate,1,,50592
,CHEMBL625473,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12775,,7132,,1,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,,,Intermediate,1,,50592
,CHEMBL625474,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12776,,13317,,1,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625475,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12777,,15341,,1,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625476,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12778,,15341,,1,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625477,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12779,,15341,,1,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625478,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12780,,15341,,1,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625479,10116.0,N,BAO_0000218,Rattus norvegicus,,,esophageal tunica muscularis mucosae,12781,,12801,,1,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Intermediate,1,,50597
,CHEMBL625480,10116.0,N,BAO_0000218,Rattus norvegicus,,,esophageal tunica muscularis mucosae,12782,,12801,,1,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Intermediate,1,,50597
,CHEMBL625481,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12783,1969.0,14856,,1,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625482,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12784,,14062,,1,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625483,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12785,,14062,,1,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625484,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12786,,14062,,1,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625485,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12787,,14062,,1,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625486,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12788,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625487,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12789,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625488,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12790,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12791,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625490,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12792,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625491,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,12793,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625492,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,12794,1969.0,14346,,1,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625493,9606.0,N,BAO_0000218,Homo sapiens,,,Plasma,12795,1969.0,15711,,1,,plasma clearance in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL625494,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12796,,14886,,1,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625495,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12797,,14886,,1,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625496,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12798,,14886,,1,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625497,,U,BAO_0000100,,,,,12799,,4115,,1,,1-Octanol/water partition coefficient measured at 7.4,P,,,Autocuration,0,,22229
,CHEMBL625498,,U,BAO_0000100,,,,,12800,,13733,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625499,,U,BAO_0000019,,,,,12801,,12102,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL625500,,U,BAO_0000100,,,,,12802,,12676,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625501,,U,BAO_0000100,,,,,12803,,13733,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625502,,U,BAO_0000100,,,,,12804,,13740,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625503,,U,BAO_0000100,,,,,12805,,12766,,1,,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,,,Autocuration,0,,22229
,CHEMBL625504,,U,BAO_0000100,,,,,12806,,2764,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625505,,U,BAO_0000100,,,,,12807,,12355,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625506,,U,BAO_0000100,,,,,12808,,11314,,1,,Calculated partition coefficient of the compound,P,,,Autocuration,0,,22229
,CHEMBL625507,,U,BAO_0000019,,,,,12809,,12706,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL625508,,U,BAO_0000100,,,,,12810,,12645,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625509,,U,BAO_0000100,,,,,12811,,13668,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625510,,U,BAO_0000100,,,,,12812,,12819,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL883125,,U,BAO_0000100,,,,,12813,,13668,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625511,,U,BAO_0000100,,,,,12814,,13017,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL874650,,U,BAO_0000019,,,,,12815,,2448,,1,,Partition coefficient of the compound,A,,,Autocuration,0,,22224
,CHEMBL625512,,U,BAO_0000019,,,,,12816,,11526,,1,,Partition coefficient of the compound,A,,,Autocuration,0,,22224
,CHEMBL625513,,U,BAO_0000019,,,,,12817,,12426,,1,,Partition coefficient of compound was determined,A,,,Autocuration,0,,22224
,CHEMBL625514,,U,BAO_0000019,,,,,12818,,2448,,1,,Partition coefficient was determined,A,,,Autocuration,0,,22224
,CHEMBL625515,,U,BAO_0000100,,,,,12819,,12001,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625516,,U,BAO_0000100,,,,,12820,,12426,,1,,partition coefficient of compound was determined,P,,,Autocuration,0,,22229
,CHEMBL625517,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12821,,13204,,1,,The total body administered intravenously in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625518,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12822,,13204,,1,,The total body administered intravenously in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625519,10090.0,N,BAO_0000218,Mus musculus,,,,12823,,13889,,1,,Time taken for the administration to female NIH mice weighing 25-30 g.,A,,,Intermediate,1,,50594
,CHEMBL625520,,U,BAO_0000019,,,,,12824,,13889,,1,,Time taken for the administration,A,,,Autocuration,0,,22224
,CHEMBL874651,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12825,,17025,,1,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,In vivo,,Intermediate,1,,50588
,CHEMBL625521,314293.0,U,BAO_0000218,Simiiformes,,,,12826,,17025,,1,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,In vivo,,Autocuration,0,,22224
,CHEMBL623171,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12827,,17025,,1,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,In vivo,,Intermediate,1,,50592
,CHEMBL623853,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12828,,17025,,1,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,In vivo,,Intermediate,1,,50597
,CHEMBL623854,,U,BAO_0000019,,,,,12829,,15067,,1,,Plasma clearance for the compound was determined.,A,,,Autocuration,0,,22224
,CHEMBL874405,,U,BAO_0000100,,,,,12830,,3091,,1,,CLog P value of the compound,P,,,Autocuration,0,,22224
,CHEMBL623855,,U,BAO_0000100,,,,,12831,,15592,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL623856,,U,BAO_0000100,,,,,12832,,14738,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL623857,,U,BAO_0000100,,,,,12833,,14738,,1,,ClogP value of the compound; nd ='no data',P,,,Autocuration,0,,22224
,CHEMBL623858,,U,BAO_0000100,,,,,12834,,14738,,1,,ClogP value of the compound; nd ='not determined',P,,,Autocuration,0,,22224
,CHEMBL623859,,U,BAO_0000100,,,,,12835,,6076,,1,,CLog P was determined,P,,,Autocuration,0,,22224
,CHEMBL839829,,U,BAO_0000100,,,,,12836,,17840,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL623860,,U,BAO_0000019,,,,,12837,,13589,,1,,CLogP was calculated,A,,,Autocuration,0,,22224
,CHEMBL623861,,U,BAO_0000019,,,,,12838,,17655,,1,,CLogP value was determined,A,,,Autocuration,0,,22224
,CHEMBL623862,,U,BAO_0000019,,,,,12839,,5867,,1,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,,,Autocuration,0,,22224
,CHEMBL874406,,U,BAO_0000100,,,,,12840,,5867,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL623863,,U,BAO_0000100,,,,,12841,,10783,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624021,,U,BAO_0000100,,,,,12842,,14849,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624022,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12843,1236.0,8170,,1,,Distribution in female dog adrenal medulla 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624023,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Adrenal medulla,12844,1236.0,8170,,1,,Distribution in female dog adrenal medulla 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624024,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12845,,8170,,1,,Distribution in female dog bile 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624025,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12846,,8170,,1,,Distribution in female dog bile 72 hr after administration.,A,,,Intermediate,1,,50588
,CHEMBL624026,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12847,,8170,,1,,Distribution in female dog blood 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624027,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12848,,8170,,1,,Distribution in female dog blood 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624028,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12849,,8170,,1,,Distribution in female dog heart 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624029,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12850,,8170,,1,,Distribution in female dog heart 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624030,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12851,,8170,,1,,Distribution in female dog kidney 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624031,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12852,,8170,,1,,Distribution in female dog kidney 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624032,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Intestine,12853,160.0,8170,,1,,Distribution in female dog large intestine 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL874407,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Intestine,12854,160.0,8170,,1,,Distribution in female dog large intestine 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624033,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12855,,8170,,1,,Distribution in female dog liver 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624034,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12856,,8170,,1,,Distribution in female dog liver 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624035,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12857,,8170,,1,,Distribution in female dog lung 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624036,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12858,,8170,,1,,Distribution in female dog lung 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624037,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Muscle tissue,12859,2385.0,8170,,1,,Distribution in female dog muscle 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624038,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Muscle tissue,12860,2385.0,8170,,1,,Distribution in female dog muscle 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624039,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12861,,8170,,1,,Distribution in female dog pancreas 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624040,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12862,,8170,,1,,Distribution in female dog pancreas 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624041,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Intestine,12863,160.0,8170,,1,,Distribution in female dog small intestine 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624042,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Intestine,12864,160.0,8170,,1,,Distribution in female dog small intestine 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624043,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Spleen,12865,2106.0,8170,,1,,Distribution in female dog spleen 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624044,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Spleen,12866,2106.0,8170,,1,,Distribution in female dog spleen 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624045,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Stomach,12867,945.0,8170,,1,,Distribution in female dog stomach 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624046,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Stomach,12868,945.0,8170,,1,,Distribution in female dog stomach 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624047,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Thyroid gland,12869,2046.0,8170,,1,,Distribution in female dog thyroid 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624048,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Thyroid gland,12870,2046.0,8170,,1,,Distribution in female dog thyroid 72 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL874408,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,12871,1088.0,8170,,1,,Distribution in female dog urine 24 hours after administration.,A,,,Intermediate,1,,50588
,CHEMBL624049,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,12872,1088.0,8170,,1,,Distribution in female dog urine 72 hr after administration.,A,,,Intermediate,1,,50588
,CHEMBL624050,,U,BAO_0000218,,,,Plasma,12873,1969.0,14283,,1,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL624051,,U,BAO_0000019,,,,,12874,,5623,,1,,Plasma concentration at 7 hr after intravenous dosing,A,,,Autocuration,0,,22224
,CHEMBL623278,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12875,,13477,,1,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623279,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12876,,13477,,1,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623280,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12877,,13477,,1,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623963,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12878,,13477,,1,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623964,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12879,,13477,,1,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623965,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12880,,13477,,1,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL623966,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12881,,13477,,1,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,,,Intermediate,1,,50597
,CHEMBL874415,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12882,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,,,Intermediate,1,,50597
,CHEMBL623967,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12883,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,,,Intermediate,1,,50597
,CHEMBL623968,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12884,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,,,Intermediate,1,,50597
,CHEMBL623969,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12885,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,,,Intermediate,1,,50597
,CHEMBL628409,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12886,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,,,Intermediate,1,,50597
,CHEMBL628410,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12887,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,,,Intermediate,1,,50597
,CHEMBL628411,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12888,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,,,Intermediate,1,,50597
,CHEMBL628412,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12889,,13477,,1,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,,,Intermediate,1,,50597
,CHEMBL628413,,U,BAO_0000019,,,,,12890,,12553,,1,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,,,Autocuration,0,,22224
,CHEMBL628414,,U,BAO_0000019,,,,Plasma,12891,1969.0,14548,,1,,The concentration in plasmat; Not determined,A,,,Autocuration,0,,22224
,CHEMBL628415,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12892,,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in blood,A,,,Intermediate,1,,50597
,CHEMBL628416,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12893,,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,,,Intermediate,1,,50597
,CHEMBL628417,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12894,,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in heart,A,,,Intermediate,1,,50597
,CHEMBL874908,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12895,2107.0,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in liver,A,,,Intermediate,1,,50597
,CHEMBL628418,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12896,,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,,,Intermediate,1,,50597
,CHEMBL628419,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,12897,2385.0,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,,,Intermediate,1,,50597
,CHEMBL628420,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12898,,14393,,1,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,,,Intermediate,1,,50597
,CHEMBL628421,,U,BAO_0000019,,,,,12899,,1629,,1,,Water solubility at 37 degree C.,A,,,Autocuration,0,,22224
,CHEMBL626726,,U,BAO_0000100,,,,,12900,,8194,,1,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,Autocuration,0,,22229
,CHEMBL626727,,U,BAO_0000100,,,,,12901,,8194,,1,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626728,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12902,178.0,8594,,1,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626729,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12903,178.0,8594,,1,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626730,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12904,178.0,8594,,1,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626731,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12905,178.0,8594,,1,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626732,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,12906,178.0,8594,,1,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626733,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12907,948.0,8594,,1,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626734,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12908,948.0,8594,,1,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626735,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12909,948.0,8594,,1,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL874909,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12910,948.0,8594,,1,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626736,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,12911,948.0,8594,,1,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL626737,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12912,2113.0,8594,,1,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630999,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12913,2113.0,8594,,1,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631000,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12914,2113.0,8594,,1,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631001,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12915,2113.0,8594,,1,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631002,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,12916,2113.0,8594,,1,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631003,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12917,2107.0,8594,,1,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631004,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12918,2107.0,8594,,1,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631005,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12919,2107.0,8594,,1,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631006,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12920,2107.0,8594,,1,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631007,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,12921,2107.0,8594,,1,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631008,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12922,2048.0,8594,,1,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631009,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12923,2048.0,8594,,1,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631010,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12924,2048.0,8594,,1,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631011,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12925,2048.0,8594,,1,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL631012,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,12926,2048.0,8594,,1,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630271,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12927,2046.0,8594,,1,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630272,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12928,2046.0,8594,,1,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630273,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12929,2046.0,8594,,1,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12930,2046.0,8594,,1,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630275,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,12931,2046.0,8594,,1,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL875782,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12932,,8594,,1,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630276,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12933,,8594,,1,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630277,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12934,,8594,,1,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630278,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12935,,8594,,1,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630279,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12936,,8594,,1,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,,,Intermediate,1,,50597
,CHEMBL630280,,U,BAO_0000019,,,,,12937,,8151,,1,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL630281,,U,BAO_0000019,,,,,12938,,8151,,1,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL630282,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12939,,7132,,1,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,,,Intermediate,1,,50592
,CHEMBL630283,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12940,,7132,,1,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,,,Intermediate,1,,50592
,CHEMBL630284,,U,BAO_0000019,,,,,12941,,5797,,1,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,,,Autocuration,0,,22224
,CHEMBL630285,,U,BAO_0000019,,,,,12942,,7849,,1,,Alkylating activity was determined,A,,,Autocuration,0,,22224
Microsomes,CHEMBL630286,,U,BAO_0000251,,,,,12943,,14220,,1,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,,,Autocuration,0,,22224
,CHEMBL630069,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12944,,8650,,1,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,,,Intermediate,1,,50592
,CHEMBL630070,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12945,,8650,,1,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,,,Intermediate,1,,50592
,CHEMBL630071,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12946,,8650,,1,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,,,Intermediate,1,,50592
,CHEMBL630072,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12947,,8650,,1,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,,,Intermediate,1,,50592
,CHEMBL875110,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12948,,8650,,1,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,,,Intermediate,1,,50592
,CHEMBL630073,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12949,,7116,,1,,Compound was tested for antidiuretic activity in rats,A,,,Intermediate,1,,50597
,CHEMBL630074,,U,BAO_0000019,,,,,12950,,14131,,1,,Compound was tested for inactivation kinetic values,A,,,Autocuration,0,,22224
,CHEMBL630075,,U,BAO_0000218,,,,,12951,,7415,,1,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,In vivo,,Autocuration,0,,22224
,CHEMBL630076,,U,BAO_0000019,,,,,12952,,13178,,1,,Dissociation rate calculated from the first-order equation using the t1/2 value,A,,,Autocuration,0,,22224
,CHEMBL630077,,U,BAO_0000100,,,,,12953,,8815,,1,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,,,Autocuration,0,,22229
,CHEMBL630078,,U,BAO_0000100,,,,,12954,,1450,,1,,Aqueous solubility was measured,P,,,Autocuration,0,,22229
,CHEMBL630079,,U,BAO_0000100,,,,,12955,,1450,,1,,Aqueous solubility was measured at a pH 4,P,,,Autocuration,0,,22229
,CHEMBL630080,,U,BAO_0000100,,,,,12956,,1450,,1,,Aqueous solubility (pH 7),P,,,Autocuration,0,,22229
,CHEMBL630081,,U,BAO_0000100,,,,,12957,,1450,,1,,Aqueous solubility was measured at a pH 9,P,,,Autocuration,0,,22229
,CHEMBL630082,,U,BAO_0000019,,,,,12958,,12711,,1,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,,,Autocuration,0,,22224
,CHEMBL630083,,U,BAO_0000019,,,,,12959,,12711,,1,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,Autocuration,0,,22224
,CHEMBL630084,,U,BAO_0000019,,,,,12960,,12711,,1,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,Autocuration,0,,22224
,CHEMBL629198,,U,BAO_0000100,,,,,12961,,15032,,1,,Aqueous solubility of the compound,P,,,Autocuration,0,,22229
,CHEMBL629199,,U,BAO_0000100,,,,,12962,,9964,,1,,Aqueous solubility at 37 degree Celsius at pH 7.38,P,,,Autocuration,0,,22229
,CHEMBL629200,,U,BAO_0000100,,,,,12963,,14962,,1,,Aqueous solubility in pH 7.4 phosphate buffer,P,,,Autocuration,0,,22229
,CHEMBL629201,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12964,,12487,,1,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Intermediate,1,,50588
,CHEMBL629202,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,12965,,12487,,1,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,,,Intermediate,1,,50588
,CHEMBL875111,9606.0,N,BAO_0000218,Homo sapiens,,,,12966,,10026,,1,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,,,Intermediate,1,,50587
,CHEMBL629203,9606.0,N,BAO_0000218,Homo sapiens,,,,12967,,10026,,1,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,,,Intermediate,1,,50587
,CHEMBL629204,9606.0,N,BAO_0000218,Homo sapiens,,,,12968,,10026,,1,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,,,Intermediate,1,,50587
,CHEMBL629205,9606.0,N,BAO_0000218,Homo sapiens,,,,12969,,10026,,1,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,,,Intermediate,1,,50587
,CHEMBL629206,9606.0,N,BAO_0000218,Homo sapiens,,,,12970,,10026,,1,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,,,Intermediate,1,,50587
,CHEMBL631185,,U,BAO_0000019,,,,,12971,,10026,,1,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,,,Autocuration,0,,22224
,CHEMBL631186,10116.0,N,BAO_0000218,Rattus norvegicus,,,,12972,,7415,,1,,Compound was evaluated for the average bile flow rat in rats,A,,,Intermediate,1,,50597
,CHEMBL631187,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12973,,17025,,1,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Intermediate,1,,50592
,CHEMBL631188,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,12974,,17025,,1,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Intermediate,1,,50592
,CHEMBL876419,,U,BAO_0000019,,,,,12975,,10184,,1,,Average half life period was determined,A,,,Autocuration,0,,22224
,CHEMBL631189,,U,BAO_0000019,,,,,12976,,10184,,1,,Average half life period was determined,A,,,Autocuration,0,,22224
,CHEMBL631190,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12977,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL631191,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12978,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL631192,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12979,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL632400,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12980,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL630564,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12981,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL630565,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12982,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL630566,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12983,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL631229,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12984,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL631230,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,12985,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL876428,,U,BAO_0000100,,,,,12986,,6030,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631231,,U,BAO_0000100,,,,,12987,,6147,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631232,,U,BAO_0000100,,,,,12988,,14556,,1,,Calculated partition coefficient (clogP) (MacLogP),P,,,Autocuration,0,,22229
,CHEMBL631233,,U,BAO_0000019,,,,,12989,,768,,1,,Hydrophilicity was determined,A,,,Autocuration,0,,22224
,CHEMBL631234,,U,BAO_0000100,,,,,12990,,14452,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL883126,,U,BAO_0000019,,,,,12991,,5237,,1,,Increased absorption was determined,A,,,Autocuration,0,,22224
,CHEMBL631235,,U,BAO_0000100,,,,,12992,,14378,,1,,Lipophilicity value was evaluated,P,,,Autocuration,0,,22224
,CHEMBL631236,,U,BAO_0000100,,,,,12993,,14418,,1,,Log P value of the compound.,P,,,Autocuration,0,,22224
,CHEMBL631237,,U,BAO_0000019,,,,,12994,,5249,,1,,Partition coefficient of compound was determined,A,,,Autocuration,0,,22224
,CHEMBL631238,,U,BAO_0000100,,,,,12995,,14621,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL876429,,U,BAO_0000100,,,,,12996,,12542,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631414,,U,BAO_0000019,,,,,12997,,12542,,1,,Partition coefficient was measured by medchem software; Not calculated,A,,,Autocuration,0,,22224
,CHEMBL631415,,U,BAO_0000100,,,,,12998,,12542,,1,,Partition coefficient was measured by octanol-water using standard shake-flask method,P,,,Autocuration,0,,22224
,CHEMBL631416,,U,BAO_0000100,,,,,12999,,15462,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631417,,U,BAO_0000019,,,,,13000,,14884,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL631418,,U,BAO_0000100,,,,,13001,,16526,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631419,,U,BAO_0000100,,,,,13002,,13693,,1,,The Octanol/Water partition coefficient CLogP,P,,,Autocuration,0,,22229
,CHEMBL631420,,U,BAO_0000019,,,,,13003,,13693,,1,,The pharmacokinetic parameter C Log p was reported,A,,,Autocuration,0,,22224
,CHEMBL631421,,U,BAO_0000100,,,,,13004,,13779,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631422,,U,BAO_0000100,,,,,13005,,14772,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL631423,,U,BAO_0000100,,,,,13006,,14393,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL876430,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13007,1969.0,14793,,1,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL631424,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13008,1969.0,14793,,1,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL631425,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,13009,1969.0,13744,,1,,Compound was administered intravenously in dog to evaluate plasma clearance values,A,In vivo,,Intermediate,1,,50588
,CHEMBL631426,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,13010,1969.0,13744,,1,,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,In vivo,,Autocuration,0,,22224
,CHEMBL631427,10090.0,N,BAO_0000218,Mus musculus,,,Plasma,13011,1969.0,13744,,1,,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,In vivo,,Intermediate,1,,50594
,CHEMBL631428,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,13012,1969.0,13207,,1,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,In vivo,,Intermediate,1,,50588
Microsomes,CHEMBL631429,9544.0,N,BAO_0000218,Macaca mulatta,,,Liver,13013,2107.0,5669,,1,,Intrinsic clearance in Rhesus liver microsome,A,In vitro,,Intermediate,1,,50797
Microsomes,CHEMBL631430,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Liver,13014,2107.0,5669,,1,,Intrinsic clearance in dog liver microsome,A,In vitro,,Intermediate,1,,50588
Microsomes,CHEMBL631431,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13015,2107.0,5669,,1,,Intrinsic clearance in rat liver microsome,A,In vitro,,Intermediate,1,,50597
,CHEMBL631432,9544.0,N,BAO_0000218,Macaca mulatta,,,Plasma,13016,1969.0,4853,,1,,Low plasma clearance was calculated in rhesus monkey,A,In vivo,,Intermediate,1,,50797
,CHEMBL631433,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13017,,16452,,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Intermediate,1,,50588
,CHEMBL631434,,U,BAO_0000218,,,,,13018,,11954,,1,,Plasma clearance after intravenous dose of 0.3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL631435,,U,BAO_0000218,,,,,13019,,11954,,1,,Plasma clearance after intravenous dose of 1 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL631436,,U,BAO_0000218,,,,,13020,,11954,,1,,Plasma clearance after intravenous dose of 3 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL631437,,U,BAO_0000218,,,,,13021,,11954,,1,,Plasma clearance after intravenous dose of 3.87 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL631438,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13022,,5669,,1,,Plasma clearance after peroral administration at 10 mpk in Rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL876431,9544.0,N,BAO_0000218,Macaca mulatta,,,,13023,,5669,,1,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Intermediate,1,,50797
,CHEMBL631439,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13024,,5669,,1,,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL631440,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13025,,13662,,1,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631441,,U,BAO_0000019,,,,,13026,,8272,,1,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,,,Autocuration,0,,22224
,CHEMBL631442,,U,BAO_0000019,,,,,13027,,13410,,1,,Critical Micellar concentration was determined,A,,,Autocuration,0,,22224
,CHEMBL626525,,U,BAO_0000019,,,,,13028,,13410,,1,,Critical Micellar concentration of the compound. was determined,A,,,Autocuration,0,,22224
,CHEMBL627168,,U,BAO_0000019,,,,,13029,,12628,,1,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,,,Autocuration,0,,22224
,CHEMBL875618,,U,BAO_0000019,,,,,13030,,9675,,1,,Critical micellar concentration was measured in water by the dye solubilization method,A,,,Autocuration,0,,22224
,CHEMBL626612,,U,BAO_0000019,,,,,13031,,12628,,1,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,,,Autocuration,0,,22224
,CHEMBL626613,,U,BAO_0000019,,,,,13032,,12766,,1,,CMR value (relative to BAY K 8644),A,,,Autocuration,0,,22224
,CHEMBL626614,,U,BAO_0000019,,,,,13033,,7849,,1,,Carbamoylating activity was determined,A,,,Autocuration,0,,22224
,CHEMBL626615,314293.0,U,BAO_0000218,Simiiformes,,,,13034,,12187,,1,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,,,Autocuration,0,,22224
,CHEMBL626616,,U,BAO_0000019,,,,,13035,,2040,,1,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,,,Autocuration,0,,22224
,CHEMBL626617,,U,BAO_0000019,,,,,13036,,2040,,1,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,,,Autocuration,0,,22224
,CHEMBL626618,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,13037,1969.0,14180,,1,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Intermediate,1,,50588
,CHEMBL626619,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13038,1969.0,14180,,1,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Intermediate,1,,50597
,CHEMBL626620,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13039,,14474,,1,,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,In vivo,,Intermediate,1,,50588
,CHEMBL626621,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13040,,14474,,1,,"Clearance rate at 5.5 mg/kg, iv, in rat",A,In vivo,,Intermediate,1,,50597
,CHEMBL626622,9541.0,N,BAO_0000218,Macaca fascicularis,,,,13041,,14548,,1,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,In vivo,,Intermediate,1,,100710
,CHEMBL626623,9541.0,N,BAO_0000218,Macaca fascicularis,,,,13042,,14548,,1,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,In vivo,,Intermediate,1,,100710
,CHEMBL626624,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13043,,14548,,1,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,In vivo,,Intermediate,1,,50588
,CHEMBL626625,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13044,,14548,,1,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,In vivo,,Intermediate,1,,50597
,CHEMBL626626,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13045,2107.0,6125,,1,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Intermediate,1,,50597
,CHEMBL626627,,U,BAO_0000218,,,,,13046,,6874,,1,,Tested for the total clearance of the compound,A,In vivo,,Autocuration,0,,22224
,CHEMBL626628,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13047,,15343,,1,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL626629,,U,BAO_0000218,,,,,13048,,6236,,1,,Total body clearance was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL626630,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13049,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626631,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13050,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626632,,U,BAO_0000100,,,,,13051,,8194,,1,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626633,,U,BAO_0000100,,,,,13052,,8194,,1,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626634,,U,BAO_0000100,,,,,13053,,8194,,1,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626635,,U,BAO_0000100,,,,,13054,,8194,,1,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,Autocuration,0,,22229
,CHEMBL626636,,U,BAO_0000100,,,,,13055,,8194,,1,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626637,,U,BAO_0000100,,,,,13056,,8194,,1,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,Autocuration,0,,22229
,CHEMBL626638,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13057,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,,,Intermediate,1,,50339
,CHEMBL626639,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13058,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,,,Intermediate,1,,50339
,CHEMBL626640,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13059,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,,,Intermediate,1,,50339
,CHEMBL626641,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13060,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,,,Intermediate,1,,50339
,CHEMBL627272,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13061,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,,,Intermediate,1,,50339
,CHEMBL627273,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13062,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,,,Intermediate,1,,50339
,CHEMBL627441,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13063,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL628355,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13064,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL628356,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13065,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL628357,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13066,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL628358,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13067,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL622307,4754.0,N,BAO_0000218,Pneumocystis carinii,,,,13068,,13273,,1,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,,,Intermediate,1,,50339
,CHEMBL622527,,U,BAO_0000019,,,,,13069,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,,,Autocuration,0,,22224
,CHEMBL622528,,U,BAO_0000019,,,,,13070,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,,,Autocuration,0,,22224
,CHEMBL622529,,U,BAO_0000019,,,,,13071,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,,,Autocuration,0,,22224
,CHEMBL622992,,U,BAO_0000019,,,,,13072,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,,,Autocuration,0,,22224
,CHEMBL622993,,U,BAO_0000019,,,,,13073,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,,,Autocuration,0,,22224
,CHEMBL622994,,U,BAO_0000019,,,,,13074,,13118,,1,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,,,Autocuration,0,,22224
,CHEMBL622995,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13075,,10633,,1,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,,,Intermediate,1,,50597
,CHEMBL622996,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13076,,10633,,1,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,,,Intermediate,1,,50597
,CHEMBL622997,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13077,,10633,,1,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,,,Intermediate,1,,50597
,CHEMBL622998,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13078,,10633,,1,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,,,Intermediate,1,,50597
,CHEMBL622999,,U,BAO_0000218,,,,,13079,,5767,,1,,Cp max following ip administration at 1 mg/kg,A,,,Autocuration,0,,22224
,CHEMBL623000,,U,BAO_0000218,,,,Plasma,13080,1969.0,3302,,1,,Maximum concentration in plasma was reported at 0.5 hour,A,In vivo,,Autocuration,0,,22224
,CHEMBL623001,,U,BAO_0000218,,,,Plasma,13081,1969.0,3302,,1,,Maximum concentration in plasma was reported at 2 hour,A,In vivo,,Autocuration,0,,22224
,CHEMBL623002,10090.0,N,BAO_0000218,Mus musculus,,,,13082,,12467,,1,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,,,Intermediate,1,,50594
,CHEMBL623003,,U,BAO_0000100,,,,,13083,,11778,,1,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,,,Autocuration,0,,22229
,CHEMBL623004,,U,BAO_0000019,,,,,13084,,4321,,1,,Steady state concentration was evaluated,A,,,Autocuration,0,,22224
,CHEMBL623005,,U,BAO_0000019,,,,,13085,,14884,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL623006,,U,BAO_0000019,,,,,13086,,15234,,1,,Partition coefficient (logD7.4),A,,,Autocuration,0,,22224
,CHEMBL623007,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13087,2107.0,14198,,1,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623008,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,13088,10000001.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL876654,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13089,2037.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623009,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13090,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623010,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13091,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623011,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13092,948.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623012,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,13093,160.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623013,,U,BAO_0000019,,,,,13094,,8151,,1,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL623014,,U,BAO_0000019,,,,,13095,,8151,,1,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL623015,,U,BAO_0000019,,,,Urine,13096,1088.0,8151,,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL623016,,U,BAO_0000019,,,,Urine,13097,1088.0,8151,,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL624858,,U,BAO_0000019,,,,Urine,13098,1088.0,8151,,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,,,Autocuration,0,,22224
,CHEMBL624859,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13099,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,,,Intermediate,1,,50597
,CHEMBL624860,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13100,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL624861,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13101,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Intermediate,1,,50597
,CHEMBL624862,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13102,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,Intermediate,1,,50597
,CHEMBL624863,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13103,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,,,Intermediate,1,,50597
,CHEMBL876655,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13104,,8151,,1,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Intermediate,1,,50597
,CHEMBL624864,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13105,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Intermediate,1,,50588
,CHEMBL624865,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13106,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Intermediate,1,,50588
,CHEMBL624866,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13107,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Intermediate,1,,50588
,CHEMBL624867,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13108,,6996,,1,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,,,Expert,1,,50588
,CHEMBL624868,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13109,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Intermediate,1,,50588
,CHEMBL628450,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13110,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,,,Intermediate,1,,50588
,CHEMBL628451,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13111,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Intermediate,1,,50588
,CHEMBL628452,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13112,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Intermediate,1,,50588
,CHEMBL628453,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13113,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Intermediate,1,,50588
,CHEMBL628454,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13114,,6996,,1,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,,,Intermediate,1,,50588
,CHEMBL628455,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13115,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Intermediate,1,,50588
,CHEMBL628456,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13116,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Intermediate,1,,50588
,CHEMBL628457,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13117,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Intermediate,1,,50588
,CHEMBL877505,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13118,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,,,Intermediate,1,,50588
,CHEMBL628458,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13119,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,,,Intermediate,1,,50588
,CHEMBL628459,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13120,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Intermediate,1,,50588
,CHEMBL628460,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13121,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Intermediate,1,,50588
,CHEMBL628461,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13122,,6996,,1,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Intermediate,1,,50588
,CHEMBL628462,,U,BAO_0000218,,,,,13123,,6996,,1,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,,,Autocuration,0,,22224
,CHEMBL628463,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13124,,6996,,1,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Intermediate,1,,50588
,CHEMBL625666,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13125,,6996,,1,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,,,Expert,1,,50597
,CHEMBL625667,,U,BAO_0000218,,,,,13126,,6996,,1,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,,,Autocuration,0,,22224
,CHEMBL625668,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13127,,6996,,1,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Expert,1,,50597
,CHEMBL625669,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13128,,6996,,1,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Intermediate,1,,50597
,CHEMBL625670,,U,BAO_0000019,,,,,13129,,7114,,1,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,,,Autocuration,0,,22224
,CHEMBL625671,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13130,,7114,,1,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,,,Intermediate,1,,50597
,CHEMBL625672,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13131,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,,,Intermediate,1,,50602
,CHEMBL625673,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13132,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,,,Intermediate,1,,50602
,CHEMBL625674,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13133,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,,,Intermediate,1,,50602
,CHEMBL625675,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13134,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,,,Intermediate,1,,50602
,CHEMBL627637,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13135,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Intermediate,1,,50602
,CHEMBL627638,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13136,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,,,Intermediate,1,,50602
,CHEMBL627639,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13137,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,,,Intermediate,1,,50602
,CHEMBL627640,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13138,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,,,Intermediate,1,,50602
,CHEMBL627641,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13139,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,,,Intermediate,1,,50602
,CHEMBL627642,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13140,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Intermediate,1,,50602
,CHEMBL877506,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,13141,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Intermediate,1,,50602
,CHEMBL627275,10090.0,N,BAO_0000218,Mus musculus,,,,13142,,8613,,1,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Intermediate,1,,50594
,CHEMBL627643,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13143,,11219,,1,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,,,Intermediate,1,,50506
,CHEMBL631246,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13144,,11219,,1,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Intermediate,1,,50506
,CHEMBL631247,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13145,,11219,,1,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Intermediate,1,,50506
,CHEMBL629532,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13146,,11219,,1,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Intermediate,1,,50506
,CHEMBL629533,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13147,,11219,,1,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,,,Intermediate,1,,50506
,CHEMBL629534,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13148,,11219,,1,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Intermediate,1,,50506
,CHEMBL629535,9669.0,N,BAO_0000218,Mustela putorius furo,,,,13149,,11219,,1,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,,,Intermediate,1,,50506
,CHEMBL625932,,U,BAO_0000019,,,,,13150,,14837,,1,,Pharmacokinetic parameter :drug bound to plasma was reported,A,,,Autocuration,0,,22224
,CHEMBL625933,,U,BAO_0000019,,,,,13151,,14837,,1,,compound was evaluated for drug bound in plasma,A,,,Autocuration,0,,22224
,CHEMBL625934,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13152,,15343,,1,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,,,Intermediate,1,,50597
,CHEMBL625935,9347.0,U,BAO_0000218,Eutheria,,,,13153,,13761,,1,,Bioavailability,A,,,Autocuration,0,,22224
,CHEMBL625936,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13154,,14810,,1,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,,,Intermediate,1,,50597
,CHEMBL625937,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13155,,14810,,1,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,,,Intermediate,1,,50597
,CHEMBL625938,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13156,,13249,,1,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,,,Intermediate,1,,50588
,CHEMBL625939,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13157,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL625940,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13158,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL874464,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13159,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL625941,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13160,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL625942,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13161,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL625943,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bile,13162,1970.0,9267,,1,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,,,Intermediate,1,,50597
,CHEMBL625944,9606.0,N,BAO_0000218,Homo sapiens,,,Serum,13163,1977.0,15549,,1,,In vitro protein binding in human serum at 5 ug/ml,A,,,Intermediate,1,,50587
,CHEMBL625945,,U,BAO_0000019,,,,,13164,,10929,,1,,Serum protein binding ability was measured,A,,,Autocuration,0,,22224
,CHEMBL625946,,U,BAO_0000019,,,,,13165,,15444,,1,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Autocuration,0,,22224
,CHEMBL625947,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,13166,,12860,,1,,Oral bioavailability in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL625948,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13167,,12170,,1,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625949,,U,BAO_0000218,,,,,13168,,15173,,1,,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625950,,U,BAO_0000218,,,,,13169,,15173,,1,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL625951,9347.0,U,BAO_0000218,Eutheria,,,,13170,,15173,,1,,Oral bioavailability (dose 15 mg/kg i.v.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625952,,U,BAO_0000218,,,,,13171,,15173,,1,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,In vivo,,Autocuration,0,,22224
,CHEMBL625953,,U,BAO_0000218,,,,,13172,,15173,,1,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,In vivo,,Autocuration,0,,22224
,CHEMBL625954,,U,BAO_0000218,,,,,13173,,15173,,1,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,In vivo,,Autocuration,0,,22224
,CHEMBL882959,,U,BAO_0000218,,,,,13174,,15173,,1,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,In vivo,,Autocuration,0,,22224
,CHEMBL625955,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13175,,11767,,1,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,In vivo,,Intermediate,1,,50588
,CHEMBL625956,9669.0,U,BAO_0000218,Mustela putorius furo,,,,13176,,11219,,1,,Bioavailability in ferret,A,In vivo,,Autocuration,0,,22224
,CHEMBL625957,9541.0,N,BAO_0000218,Macaca fascicularis,,,,13177,,12186,,1,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,In vivo,,Intermediate,1,,100710
,CHEMBL625958,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13178,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL625959,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13179,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626642,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13180,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL631330,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13181,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL631331,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13182,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL631332,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13183,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Intermediate,1,,50597
,CHEMBL631333,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13184,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632018,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13185,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632019,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13186,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632020,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13187,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632021,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13188,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632022,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13189,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632023,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13190,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632024,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13191,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL874472,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13192,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632025,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13193,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632026,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13194,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632027,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13195,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL632028,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13196,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626430,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13197,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626431,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13198,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626432,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13199,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626433,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13200,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL626434,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13201,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627280,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13202,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627281,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13203,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627282,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13204,,11510,,1,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627283,,U,BAO_0000019,,,,,13205,,7199,,1,,Total body clearance was measured at given dose,A,,,Autocuration,0,,22224
,CHEMBL627284,,U,BAO_0000218,,,,,13206,,7199,,1,,Total body clearance was measured at given dose.,A,,,Autocuration,0,,22224
,CHEMBL627285,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13207,,7095,,1,,Metabolic clearance from the body in rat,A,,,Intermediate,1,,50597
,CHEMBL627286,,U,BAO_0000218,,,,,13208,,7095,,1,,Renal clearance from the body,A,In vivo,,Autocuration,0,,22224
,CHEMBL875477,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13209,,7095,,1,,Renal clearance from the body in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627287,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13210,,12528,,1,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL627288,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13211,,12528,,1,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL627289,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13212,,7095,,1,,Total clearance from the body in rat,A,,,Intermediate,1,,50597
,CHEMBL627290,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13213,1969.0,14223,,1,,Clearance into cortex from rat plasma or PBS,A,In vivo,,Intermediate,1,,50597
,CHEMBL627291,,U,BAO_0000218,,,,,13214,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL627292,,U,BAO_0000218,,,,,13215,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL627293,,U,BAO_0000218,,,,,13216,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL627294,,U,BAO_0000218,,,,,13217,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL875478,,U,BAO_0000218,,,,,13218,,13569,,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL627295,,U,BAO_0000218,,,,,13219,,13979,,1,,Clearance was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL627296,10090.0,N,BAO_0000218,Mus musculus,,,,13220,,14315,,1,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,In vivo,,Intermediate,1,,50594
,CHEMBL626119,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,,13221,,14315,,1,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,In vivo,,Intermediate,1,,50592
,CHEMBL626120,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13222,,14315,,1,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,In vivo,,Intermediate,1,,50597
,CHEMBL626121,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13223,,12174,,1,,Clearance in rat after iv dose (100 ug/kg),A,In vivo,,Intermediate,1,,50597
,CHEMBL626122,10141.0,U,BAO_0000218,Cavia porcellus,,,,13224,,12797,,1,,Clearance in guinea pig,A,In vivo,,Autocuration,0,,22224
,CHEMBL626123,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13225,,12797,,1,,Compound was evaluated for clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623456,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13226,,12797,,1,,Compound was evaluated for the clearance in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL623457,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13227,,12797,,1,,Compound was evaluated for the clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623458,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13228,,11500,,1,,Compound was tested in vivo for clearance after iv administration in the rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL623459,,U,BAO_0000218,,,,,13229,,15173,,1,,IV clearance determined at an iv dose of 14 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL875484,,U,BAO_0000218,,,,,13230,,15173,,1,,IV clearance determined at an iv dose of 15.2 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL623460,,U,BAO_0000218,,,,,13231,,15173,,1,,IV clearance determined at an iv dose of 15 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL623461,,U,BAO_0000218,,,,,13232,,15173,,1,,IV clearance determined at an peroral dose of 30 mg/kg.,A,In vivo,,Autocuration,0,,22224
,CHEMBL623462,,U,BAO_0000218,,,,,13233,,15173,,1,,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,In vivo,,Autocuration,0,,22224
,CHEMBL627386,,U,BAO_0000218,,,,,13234,,15173,,1,,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,In vivo,,Autocuration,0,,22224
,CHEMBL627387,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13235,2113.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627388,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13236,2107.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627389,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13237,2048.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627390,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13238,2385.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627391,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13239,1969.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627392,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13240,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627393,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13241,2106.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627394,10116.0,N,BAO_0000218,Rattus norvegicus,,,Trachea,13242,3126.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627395,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,13243,10000001.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL875485,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13244,2037.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627396,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13245,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627397,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13246,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627398,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13247,948.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627399,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,13248,10000001.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627400,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13249,2113.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627401,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13250,2107.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627402,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13251,2048.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627403,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13252,2385.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL627404,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13253,1969.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623101,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13254,,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL877480,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13255,2106.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623102,10116.0,N,BAO_0000218,Rattus norvegicus,,,Trachea,13256,3126.0,14198,,1,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623103,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,13257,10000001.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623104,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13258,2037.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623105,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13259,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623106,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13260,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623107,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13261,948.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623108,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,13262,160.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623109,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13263,2113.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623110,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13264,2107.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL623111,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13265,2048.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625060,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13266,2385.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625061,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13267,1969.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625062,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13268,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625063,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13269,2106.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625064,10116.0,N,BAO_0000218,Rattus norvegicus,,,Trachea,13270,3126.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625065,10116.0,N,BAO_0000218,Rattus norvegicus,,,Bone,13271,10000001.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625066,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13272,2037.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625067,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13273,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625068,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13274,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622159,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13275,948.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622160,10116.0,N,BAO_0000218,Rattus norvegicus,,,Intestine,13276,160.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622161,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13277,2113.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622162,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13278,2048.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622163,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13279,2385.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622313,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13280,1969.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622314,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13281,,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622315,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13282,2106.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622316,10116.0,N,BAO_0000218,Rattus norvegicus,,,Trachea,13283,3126.0,14198,,1,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL877486,562.0,N,BAO_0000218,Escherichia coli,,,,13284,,15599,,1,,Normal diffusion coefficient in water for Escherichia coli,A,,,Intermediate,1,,50212
,CHEMBL622317,,U,BAO_0000019,,,,,13285,,8204,,1,,Average max percent decrease in RVR (renal vascular resistance) was determined,A,,,Autocuration,0,,22224
,CHEMBL622318,,U,BAO_0000019,,,,,13286,,8204,,1,,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,,,Autocuration,0,,22224
,CHEMBL622319,,U,BAO_0000019,,,,,13287,,6154,,1,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL622320,,U,BAO_0000019,,,,,13288,,6154,,1,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL622321,,U,BAO_0000019,,,,,13289,,6154,,1,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,,,Autocuration,0,,22224
,CHEMBL622322,,U,BAO_0000019,,,,,13290,,6154,,1,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL622323,,U,BAO_0000019,,,,,13291,,7114,,1,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,,,Autocuration,0,,22224
,CHEMBL622324,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13292,,7114,,1,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,,,Intermediate,1,,50597
,CHEMBL622325,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13293,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622326,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13294,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL877487,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13295,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622327,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13296,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622328,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13297,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622329,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13298,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622330,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13299,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622331,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13300,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622332,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13301,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL622333,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13302,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL627658,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13303,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL630428,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13304,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL630429,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13305,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL630430,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13306,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL630431,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13307,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL630432,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13308,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL630433,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13309,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL630434,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13310,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629372,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13311,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629553,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13312,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629554,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13313,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL874447,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13314,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629555,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13315,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629556,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13316,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629557,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13317,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629558,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13318,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629559,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13319,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629560,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13320,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629561,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13321,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629562,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13322,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629563,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13323,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629564,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13324,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629565,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13325,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629566,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13326,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629567,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13327,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629568,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13328,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629569,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13329,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629570,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13330,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL629571,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13331,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL629572,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13332,,12170,,1,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Autocuration,0,,22224
,CHEMBL629573,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13333,,12170,,1,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Autocuration,0,,22224
,CHEMBL629574,9347.0,U,BAO_0000218,Eutheria,,,,13334,,4985,,1,,Bioavailability (dose 20 mg/kg),A,In vivo,,Autocuration,0,,22224
,CHEMBL629575,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,13335,,15145,,1,,Bioavailability in dog,A,In vivo,,Autocuration,0,,22224
,CHEMBL874448,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13336,,14080,,1,,Bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Autocuration,0,,22224
,CHEMBL629576,9443.0,U,BAO_0000218,Primates,,,,13337,,11219,,1,,Bioavailability in monkey (dose 10 mg/kg i.d.),A,In vivo,,Autocuration,0,,22224
,CHEMBL629577,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13338,,15145,,1,,Bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL629578,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13339,,15145,,1,,Bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL629579,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,13340,,1202,,1,,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,In vivo,,Autocuration,0,,22224
,CHEMBL882958,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,13341,,1202,,1,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,In vivo,,Autocuration,0,,22224
,CHEMBL629580,9598.0,N,BAO_0000218,Pan troglodytes,,,,13342,,1202,,1,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,In vivo,,Intermediate,1,,50505
,CHEMBL629581,9347.0,U,BAO_0000218,Eutheria,,,,13343,,4026,,1,,Bioavailability,A,In vivo,,Autocuration,0,,22224
,CHEMBL629582,9520.0,U,BAO_0000218,Saimiri,,,,13344,,1492,,1,,Bioavailability in squirrel monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL628522,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13345,,12793,,1,,Bioavailability was evaluated in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL625432,10026.0,N,BAO_0000218,Cricetinae,,,,13346,,12793,,1,,Bioavailability was evaluated in hamster,A,In vivo,,Intermediate,1,,100712
,CHEMBL625433,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13347,,12793,,1,,Bioavailability in rat,A,In vivo,,Autocuration,0,,22224
,CHEMBL625434,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13348,1969.0,14793,,1,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL625435,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13349,1969.0,14793,,1,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,In vivo,,Intermediate,1,,50597
,CHEMBL625436,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13350,,14793,,1,,Bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Autocuration,0,,22224
,CHEMBL874588,9541.0,N,BAO_0000218,Macaca fascicularis,,,,13351,,14731,,1,,Bioavailability was measured in cynomolgus monkeys.,A,In vivo,,Intermediate,1,,100710
,CHEMBL625437,10090.0,N,BAO_0000218,Mus musculus,,,,13352,,14731,,1,,Bioavailability was measured in nude mice.,A,In vivo,,Intermediate,1,,50594
,CHEMBL625438,9669.0,U,BAO_0000218,Mustela putorius furo,,,,13353,,12187,,1,,Bioavailability in ferret (dose 10 mg/kg i.d.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625439,314293.0,U,BAO_0000218,Simiiformes,,,,13354,,12187,,1,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL625440,314293.0,U,BAO_0000218,Simiiformes,,,,13355,,12187,,1,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,In vivo,,Autocuration,0,,22224
,CHEMBL625441,314293.0,U,BAO_0000218,Simiiformes,,,,13356,,12187,,1,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,In vivo,,Autocuration,0,,22224
,CHEMBL625442,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13357,,12187,,1,,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Autocuration,0,,22224
,CHEMBL625443,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13358,,12187,,1,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,In vivo,,Intermediate,1,,50597
,CHEMBL625444,,U,BAO_0000218,,,,,13359,,17431,,1,,Bioavailability was determined; extremely poor,A,In vivo,,Autocuration,0,,22224
,CHEMBL625445,10090.0,N,BAO_0000218,Mus musculus,,,,13360,,13318,,1,,% bioavailability in mice after oral administration of prodrug,A,In vivo,,Intermediate,1,,50594
,CHEMBL625446,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13361,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,In vivo,,Intermediate,1,,50588
,CHEMBL882960,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13362,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,In vivo,,Intermediate,1,,50588
,CHEMBL625447,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13363,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,In vivo,,Intermediate,1,,50588
,CHEMBL625448,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13364,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,In vivo,,Intermediate,1,,50588
,CHEMBL625449,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13365,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,In vivo,,Intermediate,1,,50588
,CHEMBL874589,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13366,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,In vivo,,Intermediate,1,,50588
,CHEMBL625450,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13367,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,In vivo,,Intermediate,1,,50588
,CHEMBL625451,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13368,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,In vivo,,Intermediate,1,,50588
,CHEMBL626584,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13369,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,In vivo,,Intermediate,1,,50588
,CHEMBL626585,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13370,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,In vivo,,Intermediate,1,,50588
,CHEMBL626586,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13371,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,In vivo,,Intermediate,1,,50588
,CHEMBL626587,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13372,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,In vivo,,Intermediate,1,,50588
,CHEMBL626588,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13373,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,In vivo,,Intermediate,1,,50588
,CHEMBL626589,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13374,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,In vivo,,Intermediate,1,,50588
,CHEMBL626590,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13375,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,In vivo,,Intermediate,1,,50588
,CHEMBL626591,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13376,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,In vivo,,Intermediate,1,,50588
,CHEMBL627181,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13377,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,In vivo,,Intermediate,1,,50588
,CHEMBL628083,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13378,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,In vivo,,Intermediate,1,,50588
,CHEMBL628084,,U,BAO_0000218,,,,,13379,,15173,,1,,IV clearance determined at an peroral dose of 15 mg/kg.,A,In vivo,,Autocuration,0,,22224
,CHEMBL628085,102285.0,N,BAO_0000218,Hymenolepis nana,,,,13380,,7732,,1,,Mouse oral clearance was measured against Hymenolepiasis nana.,F,In vivo,,Expert,1,,50064
,CHEMBL628086,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13381,,7732,,1,,Mouse oral clearance was measured against Nematospiroides dubius,F,In vivo,,Expert,1,,50545
,CHEMBL628087,,U,BAO_0000218,,,,,13382,,7732,,1,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,In vivo,,Autocuration,0,,22224
,CHEMBL628088,10090.0,N,BAO_0000218,Mus musculus,,,,13383,,7732,,1,,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,In vivo,,Intermediate,1,,50594
,CHEMBL628089,,U,BAO_0000218,,,,,13384,,7732,,1,,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,In vivo,,Autocuration,0,,22224
,CHEMBL628090,,U,BAO_0000218,,,,,13385,,8328,,1,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL628091,,U,BAO_0000218,,,,,13386,,8328,,1,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL628092,,U,BAO_0000218,,,,,13387,,8328,,1,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL628093,,U,BAO_0000218,,,,,13388,,8328,,1,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL875607,,U,BAO_0000218,,,,,13389,,8328,,1,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL625710,,U,BAO_0000218,,,,,13390,,8328,,1,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL625711,,U,BAO_0000218,,,,,13391,,8328,,1,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL625712,,U,BAO_0000218,,,,,13392,,8328,,1,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL625713,,U,BAO_0000218,,,,,13393,,8328,,1,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,Autocuration,0,,22224
,CHEMBL625714,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13394,,13376,,1,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,In vivo,,Intermediate,1,,50588
,CHEMBL625715,9544.0,N,BAO_0000218,Macaca mulatta,,,,13395,,13477,,1,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,In vivo,,Intermediate,1,,50797
,CHEMBL625716,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13396,,13477,,1,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625717,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13397,,13477,,1,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625718,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13398,,13313,,1,,Plasma clearance was determined for the compound in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL625719,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13399,,12504,,1,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,In vivo,,Intermediate,1,,50597
,CHEMBL625720,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13400,,12504,,1,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,In vivo,,Intermediate,1,,50597
,CHEMBL625721,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13401,,12504,,1,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,In vivo,,Intermediate,1,,50597
,CHEMBL625722,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13402,,12504,,1,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,In vivo,,Intermediate,1,,50597
,CHEMBL625723,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13403,,13129,,1,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625724,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13404,,7732,,1,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,In vivo,,Intermediate,1,,50545
,CHEMBL625725,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13405,,7732,,1,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,In vivo,,Intermediate,1,,50545
,CHEMBL625726,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13406,,7732,,1,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,In vivo,,Intermediate,1,,50545
,CHEMBL875608,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13407,,7732,,1,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,In vivo,,Intermediate,1,,50545
,CHEMBL625727,6339.0,N,BAO_0000218,Heligmosomoides polygyrus,,,,13408,,7732,,1,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,In vivo,,Intermediate,1,,50545
,CHEMBL625728,10116.0,U,BAO_0000218,Rattus norvegicus,,,Urine,13409,1088.0,9278,,1,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Autocuration,0,,22224
,CHEMBL625729,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13410,,9278,,1,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Autocuration,0,,22224
,CHEMBL625730,10116.0,U,BAO_0000218,Rattus norvegicus,,,,13411,,9278,,1,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Autocuration,0,,22224
,CHEMBL625731,10116.0,U,BAO_0000218,Rattus norvegicus,,,Urine,13412,1088.0,9278,,1,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Autocuration,0,,22224
,CHEMBL626417,10116.0,U,BAO_0000218,Rattus norvegicus,,,Urine,13413,1088.0,9278,,1,,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,In vivo,,Autocuration,0,,22224
,CHEMBL626418,9606.0,N,BAO_0000218,Homo sapiens,,,Urine,13414,1088.0,9278,,1,,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,In vivo,,Intermediate,1,,50587
,CHEMBL626419,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13415,1088.0,9278,,1,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,In vivo,,Intermediate,1,,50588
,CHEMBL626592,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,13416,1969.0,5932,,1,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50588
,CHEMBL626593,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13417,1969.0,5932,,1,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Intermediate,1,,50597
,CHEMBL626594,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13418,,5182,,1,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL625035,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13419,,10499,,1,,Clearance rate in dogs,A,In vivo,,Intermediate,1,,50588
,CHEMBL625036,,U,BAO_0000019,,,,,13420,,6051,,1,,Compound was measured for intrinsic clearance,A,In vitro,,Autocuration,0,,22224
,CHEMBL625037,,U,BAO_0000100,,,,,13421,,17508,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625038,,U,BAO_0000100,,,,,13422,,6228,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625039,,U,BAO_0000100,,,,,13423,,6231,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625040,,U,BAO_0000100,,,,,13424,,17740,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625041,,U,BAO_0000100,,,,,13425,,6495,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625042,,U,BAO_0000100,,,,,13426,,2171,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL874411,,U,BAO_0000019,,,,,13427,,3255,,1,,Partition coefficient of the compound,A,,,Autocuration,0,,22224
,CHEMBL625043,,U,BAO_0000019,,,,,13428,,6821,,1,,Permeability,A,,,Autocuration,0,,22224
,CHEMBL625044,,U,BAO_0000100,,,,,13429,,2685,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625045,,U,BAO_0000019,,,,,13430,,17584,,1,,Partition coefficient (logD),A,,,Autocuration,0,,22224
,CHEMBL625046,,U,BAO_0000100,,,,,13431,,13824,,1,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,Autocuration,0,,22229
,CHEMBL625047,,U,BAO_0000100,,,,,13432,,13824,,1,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,Autocuration,0,,22229
,CHEMBL625048,,U,BAO_0000100,,,,,13433,,16479,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625049,,U,BAO_0000100,,,,,13434,,11997,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625050,,U,BAO_0000100,,,,,13435,,2988,,1,,Calculated logarithm of partition coefficient (P) was determined,P,,,Autocuration,0,,22229
,CHEMBL625051,,U,BAO_0000100,,,,,13436,,931,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL874412,,U,BAO_0000100,,,,,13437,,4381,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625052,,U,BAO_0000100,,,,,13438,,4397,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL625053,,U,BAO_0000100,,,,,13439,,5889,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL623250,,U,BAO_0000019,,,,,13440,,6154,,1,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL623251,,U,BAO_0000019,,,,,13441,,6154,,1,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL623252,,U,BAO_0000019,,,,,13442,,6154,,1,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL623253,,U,BAO_0000019,,,,,13443,,6154,,1,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,,,Autocuration,0,,22224
,CHEMBL623254,,U,BAO_0000019,,,,,13444,,6154,,1,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL623255,,U,BAO_0000019,,,,,13445,,6154,,1,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,,,Autocuration,0,,22224
,CHEMBL626831,,U,BAO_0000019,,,,,13446,,6887,,1,,Percent degradation of compound at a pH of 1 over a 18 hr period,A,,,Autocuration,0,,22224
,CHEMBL877494,,U,BAO_0000019,,,,,13447,,6887,,1,,Percent degradation of compound at pH of 1 over an 18 hr period,A,,,Autocuration,0,,22224
,CHEMBL626832,,U,BAO_0000019,,,,,13448,,14116,,1,,Delta Logarithm of Partition Coefficient value was determined.,A,,,Autocuration,0,,22224
,CHEMBL626833,,U,BAO_0000019,,,,,13449,,11137,,1,,Delta logPoct-cyc,A,,,Autocuration,0,,22224
,CHEMBL626834,,U,BAO_0000100,,,,,13450,,7230,,1,,Lipophilicity estimated on reversed phase TLC,P,,,Autocuration,0,,22224
,CHEMBL626835,,U,BAO_0000019,,,,,13451,,15741,,1,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,,,Autocuration,0,,22224
,CHEMBL626836,,U,BAO_0000019,,,,,13452,,9663,,1,,Delta logPoct-cyc,A,,,Autocuration,0,,22224
,CHEMBL626837,,U,BAO_0000100,,,,,13453,,9663,,1,,Change in logarithm of partition coefficient of the compound,P,,,Autocuration,0,,22229
,CHEMBL626838,,U,BAO_0000019,,,,,13454,,13807,,1,,Delta logD (pH 6.5),A,,,Autocuration,0,,22224
,CHEMBL626839,,U,BAO_0000100,,,,,13455,,13807,,1,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,,,Autocuration,0,,22224
,CHEMBL626840,,U,BAO_0000019,,,,,13456,,17425,,1,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,,,Autocuration,0,,22224
,CHEMBL626841,,U,BAO_0000019,,,,,13457,,12143,,1,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,,,Autocuration,0,,22224
,CHEMBL626842,,U,BAO_0000219,,,,,13458,,12608,,1,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,,,Autocuration,0,,22224
,CHEMBL626843,,U,BAO_0000219,,,,,13459,,12608,,1,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,,,Autocuration,0,,22224
,CHEMBL626844,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13460,,8649,,1,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,,,Intermediate,1,,50597
,CHEMBL877495,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13461,,8649,,1,,Amount of deuterium retained was reported after normal workup in rats,A,,,Intermediate,1,,50597
,CHEMBL626845,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13462,,8649,,1,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,,,Intermediate,1,,50597
,CHEMBL626846,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13463,,8649,,1,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,,,Intermediate,1,,50597
,CHEMBL626847,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13464,,8649,,1,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Intermediate,1,,50597
,CHEMBL628677,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13465,,8649,,1,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Intermediate,1,,50597
,CHEMBL628678,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13466,,8649,,1,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,,,Intermediate,1,,50597
,CHEMBL628679,,U,BAO_0000019,,,,,13467,,9659,,1,,Compound was subjected to electrochemical oxidation,A,,,Autocuration,0,,22224
,CHEMBL628680,,U,BAO_0000019,,,,,13468,,9659,,1,,Compound was subjected to photochemical oxidation,A,,,Autocuration,0,,22224
,CHEMBL628681,,U,BAO_0000019,,,,,13469,,9659,,1,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,,,Autocuration,0,,22224
,CHEMBL628682,,U,BAO_0000019,,,,,13470,,9659,,1,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,,,Autocuration,0,,22224
,CHEMBL628683,,U,BAO_0000019,,,,,13471,,9659,,1,,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,,,Autocuration,0,,22224
,CHEMBL628684,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13472,,9607,,1,,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,,,Intermediate,1,,50597
,CHEMBL877501,,U,BAO_0000100,,,,,13473,,7057,,1,,Dissociation constant (pKa),P,,,Autocuration,0,,22229
,CHEMBL628685,,U,BAO_0000100,,,,,13474,,7057,,1,,Dissociation constant value of the compound; ND means not determined.,P,,,Autocuration,0,,22224
,CHEMBL628686,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13475,178.0,7911,,1,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL628687,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13476,178.0,7911,,1,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL628688,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13477,,7911,,1,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL628689,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13478,,7911,,1,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL628690,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13479,2107.0,7911,,1,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629363,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13480,2107.0,7911,,1,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629364,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13481,2106.0,7911,,1,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629365,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13482,2106.0,7911,,1,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629366,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13483,,7911,,1,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629367,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13484,1088.0,7911,,1,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629368,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,13485,1988.0,7911,,1,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL877502,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13486,1088.0,7911,,1,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Intermediate,1,,50597
,CHEMBL629369,10090.0,N,BAO_0000218,Mus musculus,,,Cerebellum,13487,2037.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,,,Intermediate,1,,50594
,CHEMBL629370,10090.0,N,BAO_0000218,Mus musculus,,,Brain,13488,955.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,,,Intermediate,1,,50594
,CHEMBL629371,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13489,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL626276,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13490,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL626277,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13491,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL631250,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13492,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL631251,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13493,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631252,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13494,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631253,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13495,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631254,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13496,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631255,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13497,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631256,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13498,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL631257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13499,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628009,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13500,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628010,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13501,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628011,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13502,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628012,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13503,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628013,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13504,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628014,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13505,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628015,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13506,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628016,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13507,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL874461,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13508,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628017,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13509,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628018,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13510,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628019,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13511,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628020,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13512,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628021,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13513,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628022,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13514,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628023,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13515,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Intermediate,1,,50588
,CHEMBL628024,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13516,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL628025,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13517,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL628026,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13518,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL628027,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13519,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL628028,314293.0,U,BAO_0000218,Simiiformes,,,Urine,13520,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Autocuration,0,,22224
,CHEMBL628029,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13521,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628030,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13522,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628031,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13523,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628032,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13524,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628033,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13525,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628034,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13526,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628035,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13527,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628036,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13528,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL874462,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13529,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL628037,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13530,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,In vivo,,Intermediate,1,,50588
,CHEMBL628123,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13531,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,In vivo,,Intermediate,1,,50588
,CHEMBL628124,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13532,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,In vivo,,Intermediate,1,,50588
,CHEMBL628125,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13533,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,In vivo,,Intermediate,1,,50588
,CHEMBL628126,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13534,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,In vivo,,Intermediate,1,,50588
,CHEMBL628127,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13535,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,In vivo,,Intermediate,1,,50588
,CHEMBL628128,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13536,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,In vivo,,Intermediate,1,,50588
,CHEMBL628129,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13537,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,In vivo,,Intermediate,1,,50588
,CHEMBL628130,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13538,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,In vivo,,Intermediate,1,,50588
,CHEMBL628131,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13539,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,In vivo,,Intermediate,1,,50588
,CHEMBL628132,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13540,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,In vivo,,Intermediate,1,,50588
,CHEMBL628133,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13541,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,In vivo,,Intermediate,1,,50588
,CHEMBL628134,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13542,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,In vivo,,Intermediate,1,,50588
,CHEMBL628135,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13543,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,In vivo,,Intermediate,1,,50588
,CHEMBL628136,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13544,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,In vivo,,Intermediate,1,,50588
,CHEMBL628137,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13545,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,In vivo,,Intermediate,1,,50588
,CHEMBL628138,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13546,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,In vivo,,Intermediate,1,,50588
,CHEMBL628139,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13547,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,In vivo,,Intermediate,1,,50588
,CHEMBL628140,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13548,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,In vivo,,Intermediate,1,,50588
,CHEMBL628141,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13549,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,In vivo,,Intermediate,1,,50588
,CHEMBL628142,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13550,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,In vivo,,Intermediate,1,,50588
,CHEMBL628143,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13551,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,In vivo,,Intermediate,1,,50588
,CHEMBL628144,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13552,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,In vivo,,Intermediate,1,,50588
,CHEMBL628145,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13553,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,In vivo,,Intermediate,1,,50588
,CHEMBL628146,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13554,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,In vivo,,Intermediate,1,,50588
,CHEMBL625355,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13555,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,In vivo,,Intermediate,1,,50588
,CHEMBL625356,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13556,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,In vivo,,Intermediate,1,,50588
,CHEMBL625357,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13557,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,In vivo,,Intermediate,1,,50588
,CHEMBL625527,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13558,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,In vivo,,Intermediate,1,,50588
,CHEMBL875473,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13559,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,In vivo,,Intermediate,1,,50588
,CHEMBL625528,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13560,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,In vivo,,Intermediate,1,,50588
,CHEMBL626304,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13561,,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,In vivo,,Intermediate,1,,50597
,CHEMBL624138,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Artery,13562,1637.0,9025,,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,In vivo,,Intermediate,1,,50588
,CHEMBL624139,,U,BAO_0000100,,,,,13563,,6448,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624140,,U,BAO_0000100,,,,,13564,,17221,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624141,,U,BAO_0000100,,,,,13565,,6545,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624142,,U,BAO_0000100,,,,,13566,,577,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624143,,U,BAO_0000100,,,,,13567,,6285,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624144,,U,BAO_0000100,,,,,13568,,6500,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624145,,U,BAO_0000100,,,,,13569,,6716,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624146,,U,BAO_0000100,,,,,13570,,13658,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624147,,U,BAO_0000100,,,,,13571,,6549,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL883123,,U,BAO_0000100,,,,,13572,,14685,,1,,Calculated partition coefficient (clogP) (MacLogP),P,,,Autocuration,0,,22229
,CHEMBL624148,,U,BAO_0000019,,,,,13573,,6893,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL874416,,U,BAO_0000019,,,,,13574,,3687,,1,,Kinetic parameter was determined,A,,,Autocuration,0,,22224
,CHEMBL624149,,U,BAO_0000100,,,,,13575,,4207,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624150,,U,BAO_0000100,,,,,13576,,4626,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL624151,,U,BAO_0000100,,,,,13577,,1021,,1,,Lipophilicity was determined,P,,,Autocuration,0,,22224
,CHEMBL624152,,U,BAO_0000100,,,,,13578,,3777,,1,,Lipophilicity was determined,P,,,Autocuration,0,,22224
,CHEMBL622139,,U,BAO_0000100,,,,,13579,,17533,,1,,Lipophilicity was determined,P,,,Autocuration,0,,22224
,CHEMBL622140,,U,BAO_0000100,,,,,13580,,6524,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL622141,,U,BAO_0000100,,,,,13581,,17533,,1,,Lipophilicity was determined,P,,,Autocuration,0,,22224
,CHEMBL622142,,U,BAO_0000100,,,,,13582,,6480,,1,,Lipophilicity in octanol-water,P,,,Autocuration,0,,22224
,CHEMBL622143,,U,BAO_0000100,,,,,13583,,17606,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL622144,,U,BAO_0000100,,,,,13584,,6863,,1,,Octanol-water partition coefficient was determined,P,,,Autocuration,0,,22229
,CHEMBL877473,,U,BAO_0000019,,,,,13585,,1356,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL622145,,U,BAO_0000100,,,,,13586,,3326,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL622146,,U,BAO_0000019,,,,,13587,,1356,,1,,Partition coefficient was determined; ND means not determined,A,,,Autocuration,0,,22224
,CHEMBL622147,,U,BAO_0000100,,,,,13588,,12984,,1,,Calculated partition coefficient (clogP),P,,,Autocuration,0,,22229
,CHEMBL622148,,U,BAO_0000019,,,,,13589,,17363,,1,,Partition coefficient of the compound,A,,,Autocuration,0,,22224
,CHEMBL883124,,U,BAO_0000019,,,,,13590,,6827,,1,,Permeability was determined,A,,,Autocuration,0,,22224
,CHEMBL622149,,U,BAO_0000100,,,,,13591,,261,,1,,The compound was evaluated for the partition coefficient,P,,,Autocuration,0,,22229
,CHEMBL622150,,U,BAO_0000019,,,,,13592,,2685,,1,,Partition coefficient (logP),A,,,Autocuration,0,,22224
,CHEMBL622151,,U,BAO_0000100,,,,,13593,,414,,1,,The lipophilicity was reported,P,,,Autocuration,0,,22224
,CHEMBL622152,,U,BAO_0000100,,,,,13594,,15769,,1,,logarithm of the octanol-water partition coefficient for the compound,P,,,Autocuration,0,,22229
,CHEMBL622153,,U,BAO_0000019,,,,,13595,,17248,,1,,Clogp value was determined,A,,,Autocuration,0,,22224
,CHEMBL877474,,U,BAO_0000218,,,,,13596,,16935,,1,,Clp at a dose of 1.5 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL622154,,U,BAO_0000218,,,,,13597,,16935,,1,,Clp at a dose of 2.0 mg/kg,A,In vivo,,Autocuration,0,,22224
,CHEMBL622155,,U,BAO_0000218,,,,Plasma,13598,1969.0,14832,,1,,"Clp, plasma clearance at a dose of 10 mg/kg",A,In vivo,,Autocuration,0,,22224
,CHEMBL622156,,U,BAO_0000218,,,,Plasma,13599,1969.0,14832,,1,,"Clp, plasma clearance at a dose of 50 mg/kg",A,In vivo,,Autocuration,0,,22224
,CHEMBL622157,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13600,1969.0,2399,,1,,Compound was tested for plasma clearance in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622158,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13601,1969.0,2399,,1,,Compound was tested for plasma clearance in rat; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622807,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13602,,6227,,1,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Intermediate,1,,50597
,CHEMBL622808,9544.0,N,BAO_0000218,Macaca mulatta,,,,13603,,6227,,1,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,In vivo,,Intermediate,1,,50797
,CHEMBL622809,,U,BAO_0000218,,,,,13604,,5623,,1,,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,In vivo,,Autocuration,0,,22224
,CHEMBL622810,,U,BAO_0000218,,,,,13605,,4854,,1,,Plasma clearance determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL876653,10026.0,N,BAO_0000218,Cricetinae,,,,13606,,4493,,1,,Plasma clearance after iv administration at 3 mg/kg in hamster,A,In vivo,,Intermediate,1,,100712
,CHEMBL622811,10026.0,N,BAO_0000218,Cricetinae,,,,13607,,4493,,1,,Plasma clearance after iv administration at 4 mg/kg in hamster,A,In vivo,,Intermediate,1,,100712
,CHEMBL622986,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13608,,14956,,1,,Rate of clearance in rat was determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL622987,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13609,1969.0,15372,,1,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622988,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13610,1969.0,15372,,1,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622989,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13611,1969.0,15372,,1,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622990,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13612,1969.0,15372,,1,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622991,314293.0,U,BAO_0000218,Simiiformes,,,Plasma,13613,1969.0,15604,,1,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,In vivo,,Autocuration,0,,22224
,CHEMBL622227,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,13614,1969.0,15604,,1,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622228,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,13615,1969.0,15604,,1,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL622229,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13616,,14964,,1,,Clpl value in rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL622230,10141.0,N,BAO_0000218,Cavia porcellus,,,,13617,,15240,,1,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Intermediate,1,,50512
,CHEMBL622231,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13618,,16449,,1,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,In vivo,,Intermediate,1,,50597
,CHEMBL622232,9541.0,N,BAO_0000218,Macaca fascicularis,,,,13619,,16449,,1,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,In vivo,,Intermediate,1,,100710
,CHEMBL622233,,U,BAO_0000218,,,,,13620,,12902,,1,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622234,,U,BAO_0000218,,,,,13621,,12902,,1,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622235,,U,BAO_0000218,,,,,13622,,12902,,1,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622236,,U,BAO_0000218,,,,,13623,,12902,,1,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622237,,U,BAO_0000218,,,,,13624,,12902,,1,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL877482,,U,BAO_0000218,,,,,13625,,12902,,1,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622238,,U,BAO_0000218,,,,,13626,,12902,,1,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622239,,U,BAO_0000218,,,,,13627,,12902,,1,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,In vivo,,Autocuration,0,,22224
,CHEMBL622240,,U,BAO_0000218,,,,Blood,13628,178.0,11149,,1,,Cmax was calculated as maximum concentration reached in the blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL622241,,U,BAO_0000218,,,,Blood,13629,178.0,11149,,1,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,In vivo,,Autocuration,0,,22224
,CHEMBL631013,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13630,,5669,,1,,Cmax was determine after peroral administration at 10 mpk in Rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631014,9544.0,N,BAO_0000218,Macaca mulatta,,,,13631,,5669,,1,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Intermediate,1,,50797
,CHEMBL631015,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13632,,5669,,1,,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Intermediate,1,,50588
,CHEMBL631016,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13633,,5669,,1,,Cmax was determine after peroral administration at 160 mpk in Rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631017,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13634,,5669,,1,,Cmax was determine after peroral administration at 20 mpk in Rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631018,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13635,,5669,,1,,Cmax was determine after peroral administration at 50 mpk in Rat,A,In vivo,,Intermediate,1,,50597
,CHEMBL631019,,U,BAO_0000218,,,,,13636,,4236,,1,,Cmax was determined,A,In vivo,,Autocuration,0,,22224
,CHEMBL875761,10090.0,N,BAO_0000218,Mus musculus,,,Brain,13637,955.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,,,Intermediate,1,,50594
,CHEMBL631020,10090.0,N,BAO_0000218,Mus musculus,,,Brain,13638,955.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,,,Intermediate,1,,50594
,CHEMBL631669,10090.0,N,BAO_0000218,Mus musculus,,,Brain,13639,955.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,,,Intermediate,1,,50594
,CHEMBL631670,10090.0,N,BAO_0000218,Mus musculus,,,Brain,13640,955.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,,,Intermediate,1,,50594
,CHEMBL631671,10090.0,N,BAO_0000218,Mus musculus,,,Striatum,13641,2435.0,13792,,1,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,,,Intermediate,1,,50594
,CHEMBL631672,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13642,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,,,Intermediate,1,,50597
,CHEMBL631673,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13643,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,,,Intermediate,1,,50597
,CHEMBL631856,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13644,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,,,Intermediate,1,,50597
,CHEMBL631857,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13645,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,,,Intermediate,1,,50597
,CHEMBL631858,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13646,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,,,Intermediate,1,,50597
,CHEMBL631859,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13647,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,,,Intermediate,1,,50597
,CHEMBL631860,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13648,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,,,Intermediate,1,,50597
,CHEMBL631861,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13649,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,,,Intermediate,1,,50597
,CHEMBL631862,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13650,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,,,Intermediate,1,,50597
,CHEMBL631863,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13651,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,,,Intermediate,1,,50597
,CHEMBL631864,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13652,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,,,Intermediate,1,,50597
,CHEMBL631865,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13653,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,,,Intermediate,1,,50597
,CHEMBL631866,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13654,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,,,Intermediate,1,,50597
,CHEMBL629360,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13655,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,,,Intermediate,1,,50597
,CHEMBL629361,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13656,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,,,Intermediate,1,,50597
,CHEMBL629362,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13657,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,,,Intermediate,1,,50597
,CHEMBL630740,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13658,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,,,Intermediate,1,,50597
,CHEMBL630741,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13659,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,,,Intermediate,1,,50597
,CHEMBL630742,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13660,178.0,8418,,1,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,,,Intermediate,1,,50597
,CHEMBL630743,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13661,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,,,Intermediate,1,,50597
,CHEMBL630744,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13662,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,,,Intermediate,1,,50597
,CHEMBL630745,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13663,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,,,Intermediate,1,,50597
,CHEMBL630746,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13664,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,,,Intermediate,1,,50597
,CHEMBL630747,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13665,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,,,Intermediate,1,,50597
,CHEMBL630748,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13666,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,,,Intermediate,1,,50597
,CHEMBL632056,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13667,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,,,Intermediate,1,,50597
,CHEMBL632057,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13668,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,,,Intermediate,1,,50597
,CHEMBL632058,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13669,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,,,Intermediate,1,,50597
,CHEMBL632059,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13670,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,,,Intermediate,1,,50597
,CHEMBL632060,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13671,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,,,Intermediate,1,,50597
,CHEMBL632061,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13672,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,,,Intermediate,1,,50597
,CHEMBL629207,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13673,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,,,Intermediate,1,,50597
,CHEMBL629208,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13674,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,,,Intermediate,1,,50597
,CHEMBL629209,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13675,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,,,Intermediate,1,,50597
,CHEMBL629210,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13676,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,,,Intermediate,1,,50597
,CHEMBL629211,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13677,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,,,Intermediate,1,,50597
,CHEMBL629212,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13678,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,,,Intermediate,1,,50597
,CHEMBL629213,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13679,,8418,,1,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,,,Intermediate,1,,50597
,CHEMBL629214,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13680,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629215,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13681,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL635154,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13682,1088.0,8133,,1,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,,,Intermediate,1,,50597
,CHEMBL629216,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13683,,6996,,1,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL629217,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13684,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL629218,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13685,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL629219,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13686,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL629220,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13687,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL629221,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13688,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL631127,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13689,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631128,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13690,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL631129,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13691,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631130,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13692,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631131,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13693,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL631132,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13694,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL631133,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13695,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631134,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13696,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL875120,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13697,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631135,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13698,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631136,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13699,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL631137,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13700,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL631138,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13701,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631139,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13702,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,,,Intermediate,1,,50597
,CHEMBL631140,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13703,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631141,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13704,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631142,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13705,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Intermediate,1,,50597
,CHEMBL631143,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13706,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Intermediate,1,,50597
,CHEMBL631144,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13707,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Intermediate,1,,50597
,CHEMBL631145,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13708,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL631146,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13709,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631147,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13710,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL631148,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13711,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631149,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13712,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631150,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13713,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631151,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13714,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631152,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13715,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631443,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13716,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631444,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13717,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631445,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13718,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL631446,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13719,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Intermediate,1,,50588
,CHEMBL631447,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13720,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631448,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13721,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL631449,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13722,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,,,Intermediate,1,,50588
,CHEMBL631450,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13723,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Intermediate,1,,50588
,CHEMBL629724,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,13724,,6996,,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Intermediate,1,,50588
,CHEMBL629725,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,13725,14.0,9716,,1,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL629726,10090.0,N,BAO_0000218,Mus musculus,,,Zone of skin,13726,14.0,9716,,1,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL629727,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,13727,2106.0,9716,,1,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630404,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,13728,2106.0,9716,,1,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630405,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,13729,2106.0,9716,,1,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630406,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,13730,2106.0,9716,,1,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630407,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,13731,945.0,9716,,1,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630573,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,13732,945.0,9716,,1,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630574,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,13733,945.0,9716,,1,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630575,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,13734,945.0,9716,,1,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630576,10090.0,N,BAO_0000218,Mus musculus,,,,13735,,9716,,1,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630577,10090.0,N,BAO_0000218,Mus musculus,,,,13736,,9716,,1,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630578,10090.0,N,BAO_0000218,Mus musculus,,,,13737,,9716,,1,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630579,10090.0,N,BAO_0000218,Mus musculus,,,,13738,,9716,,1,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Intermediate,1,,50594
,CHEMBL630580,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,13739,2113.0,12192,,1,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630581,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,13740,2113.0,12192,,1,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,,,Intermediate,1,,50594
,CHEMBL630582,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,13741,2113.0,12192,,1,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630583,10090.0,N,BAO_0000218,Mus musculus,,,,13742,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,,,Intermediate,1,,50594
,CHEMBL630584,10090.0,N,BAO_0000218,Mus musculus,,,,13743,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630585,10090.0,N,BAO_0000218,Mus musculus,,,,13744,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,,,Intermediate,1,,50594
,CHEMBL630586,10090.0,N,BAO_0000218,Mus musculus,,,,13745,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630587,10090.0,N,BAO_0000218,Mus musculus,,,,13746,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,,,Intermediate,1,,50594
,CHEMBL630588,10090.0,N,BAO_0000218,Mus musculus,,,,13747,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630589,10090.0,N,BAO_0000218,Mus musculus,,,,13748,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,,,Intermediate,1,,50594
,CHEMBL630590,10090.0,N,BAO_0000218,Mus musculus,,,,13749,,12192,,1,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,,,Intermediate,1,,50594
,CHEMBL630591,,U,BAO_0000019,,,,Feces,13750,1988.0,12192,,1,,Removal of 238-Plutonium(IV) in feces at 24 h,A,,,Autocuration,0,,22224
,CHEMBL630592,,U,BAO_0000019,,,,Feces,13751,1988.0,12192,,1,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630593,,U,BAO_0000019,,,,,13752,,12192,,1,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,,,Autocuration,0,,22224
,CHEMBL630594,,U,BAO_0000019,,,,,13753,,12192,,1,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630595,,U,BAO_0000019,,,,Urine,13754,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630596,,U,BAO_0000019,,,,Urine,13755,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630597,,U,BAO_0000019,,,,Urine,13756,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,,,Autocuration,0,,22224
,CHEMBL630598,,U,BAO_0000019,,,,Urine,13757,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630599,,U,BAO_0000019,,,,Urine,13758,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,,,Autocuration,0,,22224
,CHEMBL630600,,U,BAO_0000019,,,,Urine,13759,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630601,,U,BAO_0000019,,,,Urine,13760,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,,,Autocuration,0,,22224
,CHEMBL630602,,U,BAO_0000019,,,,Urine,13761,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630603,,U,BAO_0000019,,,,Urine,13762,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL630604,,U,BAO_0000019,,,,Urine,13763,1088.0,12192,,1,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,,,Autocuration,0,,22224
,CHEMBL624869,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13764,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL624870,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13765,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623189,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13766,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL623190,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13767,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623191,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13768,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623192,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13769,,12017,,1,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623193,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13770,,12017,,1,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623194,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13771,,12017,,1,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL623195,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13772,,12017,,1,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623196,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13773,,12017,,1,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623197,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13774,,11836,,1,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623198,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13775,,11836,,1,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623199,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13776,,11836,,1,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623200,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13777,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623201,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13778,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623202,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13779,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623203,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13780,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623204,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13781,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13782,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13783,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623207,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13784,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623208,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13785,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623209,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13786,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623210,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13787,2385.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Intermediate,1,,50597
,CHEMBL623211,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13788,,11836,,1,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623212,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,13789,995.0,11836,,1,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Intermediate,1,,50597
,CHEMBL623213,,U,BAO_0000019,,,,,13790,,12640,,1,,Tested in vitro for intrinsic activity relative to quinpirole,A,,,Autocuration,0,,22224
,CHEMBL623214,,U,BAO_0000019,,,,,13791,,14218,,1,,"Relative ion enhancement, determined in pulsed ultrafiltration",A,,,Autocuration,0,,22224
,CHEMBL623215,,U,BAO_0000019,,,,,13792,,11296,,1,,% ionization at the pH 7.4 at 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL623216,,U,BAO_0000019,,,,,13793,,10929,,1,,Percentage ionization was measured,A,,,Autocuration,0,,22224
,CHEMBL623217,9913.0,N,BAO_0000218,Bos taurus,,,,13794,,13841,,1,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,,,Intermediate,1,,50591
,CHEMBL623218,,U,BAO_0000019,,,,,13795,,10431,,1,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,,,Autocuration,0,,22224
,CHEMBL623913,,U,BAO_0000019,,,,,13796,,10431,,1,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,,,Autocuration,0,,22224
,CHEMBL623914,,U,BAO_0000019,,,,,13797,,10431,,1,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,,,Autocuration,0,,22224
,CHEMBL623915,,U,BAO_0000100,,,,,13798,,8826,,1,,Compound was evaluated for the partition coefficient in octanol/water,P,,,Autocuration,0,,22229
,CHEMBL624080,,U,BAO_0000100,,,,,13799,,8826,,1,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,,,Autocuration,0,,22229
,CHEMBL624081,,U,BAO_0000019,,,,,13800,,9884,,1,,Equilibrium constant measured by the pulse radiolysis at pH 7,A,,,Autocuration,0,,22224
,CHEMBL624082,9606.0,N,BAO_0000218,Homo sapiens,,,,13801,,9827,,1,,In vitro hydrolytic rate constant determined in human blood,A,,,Intermediate,1,,50587
,CHEMBL625054,9606.0,N,BAO_0000218,Homo sapiens,,,,13802,,10009,,1,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,,,Intermediate,1,,50587
,CHEMBL877485,,U,BAO_0000019,,,,,13803,,10009,,1,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,,,Autocuration,0,,22224
,CHEMBL625055,10090.0,N,BAO_0000218,Mus musculus,,,,13804,,10009,,1,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,,,Intermediate,1,,50594
,CHEMBL625056,10090.0,N,BAO_0000218,Mus musculus,,,,13805,,10009,,1,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,,,Intermediate,1,,50594
,CHEMBL625057,9606.0,N,BAO_0000218,Homo sapiens,,,,13806,,10009,,1,,In vitro oxidation of compound in presence of human plasma,A,,,Intermediate,1,,50587
,CHEMBL625058,,U,BAO_0000019,,,,,13807,,10009,,1,,In vitro oxidation of compound in presence of hydrogen peroxide,A,,,Autocuration,0,,22224
,CHEMBL625059,10090.0,N,BAO_0000218,Mus musculus,,,,13808,,10009,,1,,In vitro oxidation of compound in presence of mouse brain homogenate,A,,,Intermediate,1,,50594
,CHEMBL629536,10090.0,N,BAO_0000218,Mus musculus,,,,13809,,10009,,1,,In vitro oxidation of compound in presence of mouse liver homogenate,A,,,Intermediate,1,,50594
,CHEMBL629537,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13810,,11510,,1,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629538,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13811,,11510,,1,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629539,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13812,,11510,,1,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL874445,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13813,,11510,,1,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629540,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13814,,11510,,1,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629541,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13815,,11510,,1,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629542,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13816,,11510,,1,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630243,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13817,,11510,,1,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Intermediate,1,,50597
,CHEMBL630244,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13818,,11510,,1,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630245,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13819,,11510,,1,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630246,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13820,,11510,,1,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630247,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13821,,11510,,1,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630248,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13822,,11510,,1,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL630249,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13823,178.0,13100,,1,,Biodistribution in rat blood at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630250,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13824,178.0,13100,,1,,Biodistribution in rat blood at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630251,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13825,178.0,13100,,1,,Biodistribution in rat blood at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630252,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13826,178.0,13100,,1,,Biodistribution in rat blood at 3 hr after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630408,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,13827,178.0,13100,,1,,Biodistribution in rat blood at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630409,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13828,2037.0,13100,,1,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL874446,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13829,2037.0,13100,,1,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630410,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13830,2037.0,13100,,1,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630411,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13831,2037.0,13100,,1,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630412,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13832,2037.0,13100,,1,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630413,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13833,2037.0,13100,,1,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630414,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13834,2037.0,13100,,1,,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630415,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,13835,2037.0,13100,,1,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630416,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13836,,13100,,1,,Biodistribution in rat cortex at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630417,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13837,,13100,,1,,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630418,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13838,,13100,,1,,Biodistribution in rat cortex at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630419,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13839,,13100,,1,,Biodistribution in rat cortex at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630420,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13840,,13100,,1,,Biodistribution in rat cortex at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630421,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13841,,13100,,1,,Biodistribution in rat cortex at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630422,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13842,,13100,,1,,Biodistribution in rat cortex at 3 hr after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630423,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13843,,13100,,1,,Biodistribution in rat cortex at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630424,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13844,948.0,13100,,1,,Biodistribution in rat heart at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630425,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13845,948.0,13100,,1,,Biodistribution in rat heart at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL629462,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13846,948.0,13100,,1,,Biodistribution in rat heart at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630426,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13847,948.0,13100,,1,,Biodistribution in rat heart at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630427,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13848,948.0,13100,,1,,Biodistribution in rat heart at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625877,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13849,948.0,13100,,1,,Biodistribution in rat heart at 3 hr after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625878,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,13850,948.0,13100,,1,,Biodistribution in rat heart at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625879,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,13851,10000000.0,13100,,1,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625880,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,13852,10000000.0,13100,,1,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625881,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,13853,10000000.0,13100,,1,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625882,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,13854,10000000.0,13100,,1,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625883,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,13855,10000000.0,13100,,1,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625884,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13856,2113.0,13100,,1,,Biodistribution in rat kidney at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625885,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13857,2113.0,13100,,1,,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628649,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13858,2113.0,13100,,1,,Biodistribution in rat kidney at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628650,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13859,2113.0,13100,,1,,Biodistribution in rat kidney at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628651,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13860,2113.0,13100,,1,,Biodistribution in rat kidney at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628652,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13861,2113.0,13100,,1,,Biodistribution in rat kidney at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628653,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13862,2113.0,13100,,1,,Biodistribution in rat kidney at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628654,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13863,2107.0,13100,,1,,Biodistribution in rat liver at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628655,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13864,2107.0,13100,,1,,Biodistribution in rat liver at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625238,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13865,2107.0,13100,,1,,Biodistribution in rat liver at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625239,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13866,2107.0,13100,,1,,Biodistribution in rat liver at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625240,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13867,2107.0,13100,,1,,Biodistribution in rat liver at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625241,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13868,2107.0,13100,,1,,Biodistribution in rat liver at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625242,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13869,2107.0,13100,,1,,Biodistribution in rat liver at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL874587,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13870,2048.0,13100,,1,,Biodistribution in rat lung at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625405,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13871,2048.0,13100,,1,,Biodistribution in rat lung at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625406,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13872,2048.0,13100,,1,,Biodistribution in rat lung at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625407,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13873,2048.0,13100,,1,,Biodistribution in rat lung at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625408,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13874,2048.0,13100,,1,,Biodistribution in rat lung at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625409,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13875,2048.0,13100,,1,,Biodistribution in rat lung at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625410,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13876,1515.0,12361,,1,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,,,Intermediate,1,,50597
,CHEMBL625411,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13877,1515.0,12361,,1,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,,,Intermediate,1,,50597
,CHEMBL625412,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13878,1515.0,12361,,1,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,,,Intermediate,1,,50597
,CHEMBL625413,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13879,1515.0,12361,,1,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,,,Intermediate,1,,50597
,CHEMBL625414,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13880,1515.0,12361,,1,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,,,Intermediate,1,,50597
,CHEMBL625415,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13881,1515.0,12361,,1,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Intermediate,1,,50597
,CHEMBL625416,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thoracic aorta,13882,1515.0,12361,,1,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Intermediate,1,,50597
,CHEMBL625417,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13883,1088.0,12712,,1,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,,,Intermediate,1,,50597
,CHEMBL625418,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,13884,1988.0,7415,,1,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,,,Intermediate,1,,50597
,CHEMBL625419,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13885,1088.0,7415,,1,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,,,Intermediate,1,,50597
,CHEMBL625420,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13886,,7415,,1,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626996,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13887,,7415,,1,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,,,Intermediate,1,,50597
,CHEMBL626997,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,13888,1988.0,7415,,1,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,,,Intermediate,1,,50597
,CHEMBL626998,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,13889,1088.0,7415,,1,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,,,Intermediate,1,,50597
,CHEMBL626999,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13890,,7415,,1,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,,,Intermediate,1,,50597
,CHEMBL627000,10090.0,N,BAO_0000218,Mus musculus,,,,13891,,8050,,1,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,,,Intermediate,1,,50594
,CHEMBL627001,10090.0,N,BAO_0000218,Mus musculus,,,,13892,,8050,,1,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,,,Intermediate,1,,50594
,CHEMBL627002,10090.0,N,BAO_0000218,Mus musculus,,,,13893,,8050,,1,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,,,Intermediate,1,,50594
,CHEMBL627003,10090.0,N,BAO_0000218,Mus musculus,,,,13894,,8050,,1,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,,,Intermediate,1,,50594
,CHEMBL627004,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13895,1088.0,8050,,1,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,,,Intermediate,1,,50594
,CHEMBL627005,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13896,1088.0,8050,,1,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,,,Intermediate,1,,50594
,CHEMBL874594,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13897,1088.0,8050,,1,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,,,Intermediate,1,,50594
,CHEMBL627006,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13898,1088.0,8050,,1,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,,,Intermediate,1,,50594
,CHEMBL627007,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13899,1088.0,8050,,1,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,,,Intermediate,1,,50594
,CHEMBL627884,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13900,1088.0,8050,,1,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,,,Intermediate,1,,50594
,CHEMBL627885,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13901,1088.0,8050,,1,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,,,Intermediate,1,,50594
,CHEMBL627886,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13902,1088.0,8050,,1,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,,,Intermediate,1,,50594
,CHEMBL627887,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13903,1088.0,8050,,1,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,,,Intermediate,1,,50594
,CHEMBL627888,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13904,1088.0,8050,,1,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,,,Intermediate,1,,50594
,CHEMBL628057,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13905,1088.0,8050,,1,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,,,Intermediate,1,,50594
,CHEMBL627405,10090.0,N,BAO_0000218,Mus musculus,,,Urine,13906,1088.0,8050,,1,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,,,Intermediate,1,,50594
,CHEMBL627406,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13907,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627407,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13908,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627408,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13909,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627409,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13910,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL875486,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13911,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627410,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13912,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627411,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13913,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627412,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13914,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627413,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13915,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627414,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13916,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627415,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13917,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627416,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13918,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627417,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13919,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627418,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13920,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627419,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13921,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627320,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13922,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627321,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,13923,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627322,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13924,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627323,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13925,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627491,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13926,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL627492,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13927,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627493,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,13928,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627494,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13929,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627495,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13930,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13931,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL627497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13932,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627498,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,13933,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627499,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13934,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627500,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13935,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL627501,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13936,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL625616,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13937,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625617,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,13938,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625618,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13939,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625619,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13940,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625620,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13941,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL625621,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13942,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625622,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,13943,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625788,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13944,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625789,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13945,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL625790,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13946,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL625791,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13947,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL622334,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13948,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL622335,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,13949,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL622336,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,13950,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL622337,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,13951,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL622338,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,13952,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL622339,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,13953,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL624153,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13954,,12017,,1,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL628430,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13955,,12017,,1,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL628431,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13956,,12017,,1,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL628432,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13957,,12017,,1,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL628433,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13958,,12017,,1,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL628434,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13959,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL626789,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13960,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL626790,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13961,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,In vivo,,Intermediate,1,,50597
,CHEMBL626791,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13962,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL626792,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13963,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL626793,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,13964,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL627436,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13965,,11510,,1,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627437,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13966,,11510,,1,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627438,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13967,,11510,,1,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627439,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13968,,11510,,1,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627440,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13969,,11510,,1,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627602,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13970,,11510,,1,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627603,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13971,,11510,,1,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627604,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13972,,11510,,1,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13973,,11510,,1,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13974,,11510,,1,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627607,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13975,,11510,,1,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13976,,11510,,1,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627609,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13977,,11510,,1,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627610,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13978,,11510,,1,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13979,,11510,,1,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627612,10116.0,N,BAO_0000218,Rattus norvegicus,,,,13980,,11510,,1,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL627613,,U,BAO_0000100,,,,,13981,,8362,,1,,Octanol:water partition coefficient is evaluated,P,,,Autocuration,0,,22229
,CHEMBL627614,,U,BAO_0000100,,,,,13982,,8257,,1,,Partition coefficient in 1-octanol/water system,P,,,Autocuration,0,,22224
,CHEMBL627615,,U,BAO_0000100,,,,,13983,,8257,,1,,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,,,Autocuration,0,,22224
,CHEMBL627616,,U,BAO_0000100,,,,,13984,,9468,,1,,Partition coefficient in octanol/water system was determined,P,,,Autocuration,0,,22224
,CHEMBL627617,,U,BAO_0000100,,,,,13985,,9468,,1,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,,,Autocuration,0,,22224
,CHEMBL627618,,U,BAO_0000019,,,,,13986,,10568,,1,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,,,Autocuration,0,,22224
,CHEMBL627619,,U,BAO_0000019,,,,,13987,,10568,,1,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,,,Autocuration,0,,22224
,CHEMBL627620,,U,BAO_0000019,,,,,13988,,15359,,1,,Pseudo-first-order rate constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL627621,,U,BAO_0000019,,,,,13989,,15359,,1,,Pseudo-first-order rate constant with 1-min time point,A,,,Autocuration,0,,22224
,CHEMBL627622,,U,BAO_0000019,,,,,13990,,15359,,1,,Pseudo-first-order rate constant without 1-min time point,A,,,Autocuration,0,,22224
,CHEMBL627623,,U,BAO_0000019,,,,,13991,,10431,,1,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,,,Autocuration,0,,22224
,CHEMBL627624,,U,BAO_0000019,,,,,13992,,10431,,1,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,,,Autocuration,0,,22224
,CHEMBL627625,,U,BAO_0000019,,,,,13993,,10431,,1,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,,,Autocuration,0,,22224
,CHEMBL628523,,U,BAO_0000019,,,,,13994,,15704,,1,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,,,Autocuration,0,,22224
,CHEMBL628524,,U,BAO_0000019,,,,,13995,,15287,,1,,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,,,Autocuration,0,,22224
,CHEMBL628525,,U,BAO_0000019,,,,,13996,,7516,,1,,The efflux rate constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL625732,,U,BAO_0000019,,,,,13997,,12973,,1,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,Autocuration,0,,22224
,CHEMBL625733,,U,BAO_0000019,,,,,13998,,12973,,1,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,Autocuration,0,,22224
,CHEMBL625734,,U,BAO_0000019,,,,,13999,,12973,,1,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,,,Autocuration,0,,22224
,CHEMBL625913,,U,BAO_0000019,,,,,14000,,12973,,1,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,,,Autocuration,0,,22224
,CHEMBL625914,,U,BAO_0000019,,,,,14001,,8696,,1,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,,,Autocuration,0,,22224
,CHEMBL625915,,U,BAO_0000019,,,,,14002,,15052,,1,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,,,Autocuration,0,,22224
,CHEMBL625916,,U,BAO_0000019,,,,,14003,,15052,,1,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,,,Autocuration,0,,22224
,CHEMBL625917,,U,BAO_0000019,,,,,14004,,10503,,1,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,,,Autocuration,0,,22224
,CHEMBL625918,,U,BAO_0000019,,,,,14005,,8354,,1,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625919,,U,BAO_0000019,,,,,14006,,8354,,1,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625920,,U,BAO_0000019,,,,,14007,,8354,,1,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL874453,,U,BAO_0000019,,,,,14008,,8354,,1,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625921,,U,BAO_0000019,,,,,14009,,8354,,1,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625922,,U,BAO_0000019,,,,,14010,,10503,,1,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,,,Autocuration,0,,22224
,CHEMBL625923,,U,BAO_0000019,,,,,14011,,8354,,1,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625924,,U,BAO_0000019,,,,,14012,,8354,,1,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625925,,U,BAO_0000019,,,,,14013,,8354,,1,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL625926,,U,BAO_0000019,,,,,14014,,8354,,1,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL627704,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14015,2048.0,13100,,1,,Biodistribution in rat lung at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627705,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14016,,13100,,1,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627706,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14017,,13100,,1,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627707,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14018,,13100,,1,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL627708,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14019,,13100,,1,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628361,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14020,,13100,,1,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628362,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14021,,13100,,1,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628363,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14022,2435.0,13100,,1,,Biodistribution in rat striatum at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628364,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14023,2435.0,13100,,1,,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628365,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14024,2435.0,13100,,1,,Biodistribution in rat striatum at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL874454,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14025,2435.0,13100,,1,,Biodistribution in rat striatum at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628531,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14026,2435.0,13100,,1,,Biodistribution in rat striatum at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628532,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14027,2435.0,13100,,1,,Biodistribution in rat striatum at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628533,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14028,2435.0,13100,,1,,Biodistribution in rat striatum at 3 hr after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628534,10116.0,N,BAO_0000218,Rattus norvegicus,,,Striatum,14029,2435.0,13100,,1,,Biodistribution in rat striatum at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628535,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14030,2046.0,13100,,1,,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628536,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14031,2046.0,13100,,1,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628537,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14032,2046.0,13100,,1,,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628538,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14033,2046.0,13100,,1,,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628539,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14034,2046.0,13100,,1,,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630297,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14035,2046.0,13100,,1,,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630298,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14036,2046.0,13100,,1,,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL630299,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14037,955.0,13100,,1,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628094,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14038,955.0,13100,,1,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628095,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14039,955.0,13100,,1,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL874648,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14040,955.0,13100,,1,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628096,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14041,955.0,13100,,1,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628097,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14042,955.0,13100,,1,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628098,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14043,955.0,13100,,1,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,In vivo,,Intermediate,1,,50597
,CHEMBL628099,,U,BAO_0000019,,,,,14044,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,,,Autocuration,0,,22224
,CHEMBL628100,,U,BAO_0000019,,,,,14045,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,Autocuration,0,,22224
,CHEMBL628101,,U,BAO_0000019,,,,,14046,,13331,,1,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,,,Autocuration,0,,22224
,CHEMBL628102,,U,BAO_0000019,,,,,14047,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,,,Autocuration,0,,22224
,CHEMBL628103,,U,BAO_0000019,,,,,14048,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,,,Autocuration,0,,22224
,CHEMBL628104,,U,BAO_0000019,,,,,14049,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,Autocuration,0,,22224
,CHEMBL628105,,U,BAO_0000019,,,,,14050,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,,,Autocuration,0,,22224
,CHEMBL628106,,U,BAO_0000019,,,,,14051,,13331,,1,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,,,Autocuration,0,,22224
,CHEMBL628107,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14052,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL628108,,U,BAO_0000218,,,,Urine,14053,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,,,Autocuration,0,,22224
,CHEMBL628109,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14054,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL625299,,U,BAO_0000218,,,,Urine,14055,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,,,Autocuration,0,,22224
,CHEMBL625300,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14056,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL625301,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14057,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL625302,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14058,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL874649,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14059,1088.0,10086,,1,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,,,Intermediate,1,,50597
,CHEMBL625303,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14060,,13248,,1,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,,,Intermediate,1,,50597
,CHEMBL625463,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14061,,13248,,1,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,,,Intermediate,1,,50597
,CHEMBL625464,9606.0,N,BAO_0000218,Homo sapiens,,,Liver,14062,2107.0,14527,,1,,In vitro metabolism in human liver microsomes,A,,,Intermediate,1,,50587
,CHEMBL625465,9606.0,N,BAO_0000218,Homo sapiens,,,,14063,,3008,,1,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,,,Intermediate,1,,50587
,CHEMBL625466,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14064,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625467,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14065,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625468,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14066,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625469,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14067,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625470,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14068,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL632418,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14069,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627250,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14070,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627251,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14071,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627252,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14072,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627253,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14073,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627254,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14074,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875471,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14075,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627255,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14076,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627256,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14077,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14078,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14079,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627259,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14080,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627260,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14081,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623256,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14082,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL874413,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14083,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14084,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14085,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623259,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14086,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623260,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14087,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623261,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14088,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623262,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14089,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623263,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14090,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623264,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14091,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623265,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14092,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623266,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14093,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623267,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14094,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623268,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14095,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623269,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14096,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623270,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14097,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623271,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14098,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623272,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14099,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623273,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14100,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14101,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL874414,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14102,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623275,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14103,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL629150,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14104,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623276,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14105,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623277,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14106,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623112,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14107,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623113,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14108,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623800,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14109,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623801,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14110,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623802,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14111,2106.0,12017,,1,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Intermediate,1,,50597
,CHEMBL623803,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,14112,995.0,12017,,1,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623970,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,14113,995.0,12017,,1,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623971,10116.0,N,BAO_0000218,Rattus norvegicus,,,Uterus,14114,995.0,12017,,1,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL623972,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14115,178.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623973,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14116,178.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623974,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14117,178.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623975,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14118,178.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623976,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14119,955.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623977,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14120,955.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623978,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14121,955.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623979,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14122,955.0,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623980,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14123,,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL623981,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14124,,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL626278,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14125,,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL626279,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14126,,14045,,1,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,In vivo,,Intermediate,1,,50597
,CHEMBL626280,10090.0,N,BAO_0000218,Mus musculus,,,,14127,,14045,,1,,Biodistribution in mice bladder plus excreted urine was determined,A,In vivo,,Intermediate,1,,50594
,CHEMBL626281,10090.0,N,BAO_0000218,Mus musculus,,,,14128,,14045,,1,,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626282,10090.0,N,BAO_0000218,Mus musculus,,,,14129,,14045,,1,,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626283,10090.0,N,BAO_0000218,Mus musculus,,,,14130,,14045,,1,,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626284,10090.0,N,BAO_0000218,Mus musculus,,,,14131,,14045,,1,,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626285,10090.0,N,BAO_0000218,Mus musculus,,,Brain,14132,955.0,14045,,1,,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626286,10090.0,N,BAO_0000218,Mus musculus,,,Brain,14133,955.0,14045,,1,,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626287,10090.0,N,BAO_0000218,Mus musculus,,,Brain,14134,955.0,14045,,1,,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626288,10090.0,N,BAO_0000218,Mus musculus,,,Brain,14135,955.0,14045,,1,,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626289,10090.0,N,BAO_0000218,Mus musculus,,,,14136,,14045,,1,,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626290,10090.0,N,BAO_0000218,Mus musculus,,,,14137,,14045,,1,,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626291,10090.0,N,BAO_0000218,Mus musculus,,,,14138,,14045,,1,,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL839888,10090.0,N,BAO_0000218,Mus musculus,,,,14139,,14045,,1,,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626292,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,14140,160.0,14045,,1,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626293,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,14141,160.0,14045,,1,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626294,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,14142,160.0,14045,,1,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL626295,10090.0,N,BAO_0000218,Mus musculus,,,Intestine,14143,160.0,14045,,1,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL627659,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14144,2107.0,14045,,1,,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL627660,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14145,2107.0,14045,,1,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,,,Intermediate,1,,50594
,CHEMBL627661,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14146,2107.0,14045,,1,,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL627662,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14147,2107.0,14045,,1,,Biodistribution in mice liver at 60 minutes of post injection,A,In vivo,,Intermediate,1,,50594
,CHEMBL627663,10090.0,N,BAO_0000218,Mus musculus,,,Lung,14148,2048.0,14045,,1,,Biodistribution in mice lungs at 10 min of post injection,A,In vivo,,Intermediate,1,,50594
,CHEMBL627664,10090.0,N,BAO_0000218,Mus musculus,,,,14149,,14045,,1,,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL627665,10090.0,N,BAO_0000218,Mus musculus,,,,14150,,14045,,1,,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,,,Intermediate,1,,50594
,CHEMBL627666,10090.0,N,BAO_0000218,Mus musculus,,,Lung,14151,2048.0,14045,,1,,Biodistribution in mice lungs at 60 min of post injection,A,In vivo,,Intermediate,1,,50594
,CHEMBL627667,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,14152,2106.0,14045,,1,,Percentage biodistribution in mouse spleen,A,,,Intermediate,1,,50594
,CHEMBL627668,10090.0,N,BAO_0000218,Mus musculus,,,Stomach,14153,945.0,14045,,1,,Percentage biodistribution in mouse stomach,A,,,Intermediate,1,,50594
,CHEMBL627669,10090.0,N,BAO_0000218,Mus musculus,,,Urine,14154,1088.0,11745,,1,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,,,Intermediate,1,,50594
,CHEMBL627670,,U,BAO_0000218,,,,Urinary bladder,14155,1255.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,In vivo,,Autocuration,0,,22224
,CHEMBL627671,,U,BAO_0000218,,,,Blood,14156,178.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627672,,U,BAO_0000218,,,,Bone element,14157,1474.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,In vivo,,Autocuration,0,,22224
,CHEMBL627673,,U,BAO_0000218,,,,,14158,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,In vivo,,Autocuration,0,,22224
,CHEMBL627674,,U,BAO_0000218,,,,Kidney,14159,2113.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,In vivo,,Autocuration,0,,22224
,CHEMBL627675,,U,BAO_0000218,,,,Liver,14160,2107.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,In vivo,,Autocuration,0,,22224
,CHEMBL627676,,U,BAO_0000218,,,,Lung,14161,2048.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,In vivo,,Autocuration,0,,22224
,CHEMBL627677,,U,BAO_0000218,,,,Muscle tissue,14162,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627678,,U,BAO_0000019,,,,,14163,,8354,,1,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL627679,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,14164,1977.0,7095,,1,,Affinity for protein binding expressed as association constant in fresh rat serum,A,,,Intermediate,1,,50597
,CHEMBL627680,,U,BAO_0000019,,,,,14165,,12185,,1,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,Autocuration,0,,22224
,CHEMBL627681,,U,BAO_0000019,,,,,14166,,12185,,1,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,Autocuration,0,,22224
,CHEMBL627682,,U,BAO_0000019,,,,,14167,,12185,,1,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,Autocuration,0,,22224
,CHEMBL627683,,U,BAO_0000019,,,,,14168,,12185,,1,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,Autocuration,0,,22224
,CHEMBL627684,,U,BAO_0000019,,,,,14169,,12686,,1,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,,,Autocuration,0,,22224
,CHEMBL874441,,U,BAO_0000019,,,,,14170,,12686,,1,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,Autocuration,0,,22224
,CHEMBL627685,,U,BAO_0000019,,,,,14171,,12686,,1,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,,,Autocuration,0,,22224
,CHEMBL627686,,U,BAO_0000019,,,,,14172,,12686,,1,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,Autocuration,0,,22224
,CHEMBL627687,,U,BAO_0000019,,,,,14173,,8057,,1,,Apparent rate constant Koff for inactivation of dTMP synthase.,A,,,Autocuration,0,,22224
,CHEMBL627688,,U,BAO_0000019,,,,,14174,,15778,,1,,The irreversible inhibitor activity by second order rate equation.,A,,,Autocuration,0,,22224
,CHEMBL628038,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14175,,12375,,1,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL628039,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14176,,12375,,1,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,,,Intermediate,1,,50597
,CHEMBL628040,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14177,,12375,,1,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,,,Intermediate,1,,50597
,CHEMBL628041,,U,BAO_0000019,,,,,14178,,13588,,1,,Dissociation rate calculated from the first-order equation using t1/2 value,A,,,Autocuration,0,,22224
,CHEMBL630226,,U,BAO_0000019,,,,,14179,,15039,,1,,The compound was tested for Binding constant against DNA,A,,,Autocuration,0,,22224
,CHEMBL628042,,U,BAO_0000019,,,,,14180,,9500,,1,,First order rate constant for cyclization of the compound,A,,,Autocuration,0,,22224
,CHEMBL625232,,U,BAO_0000019,,,,,14181,,10014,,1,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,Autocuration,0,,22224
,CHEMBL625233,,U,BAO_0000019,,,,,14182,,10014,,1,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,Autocuration,0,,22224
,CHEMBL625979,,U,BAO_0000019,,,,,14183,,568,,1,,Hydrolysis rate constant was determined,A,,,Autocuration,0,,22224
,CHEMBL625980,,U,BAO_0000019,,,,,14184,,10026,,1,,Observed first order rate constant,A,,,Autocuration,0,,22224
,CHEMBL625981,,U,BAO_0000019,,,,,14185,,10281,,1,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,Autocuration,0,,22224
,CHEMBL625982,,U,BAO_0000019,,,,,14186,,10281,,1,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,Autocuration,0,,22224
,CHEMBL625983,,U,BAO_0000019,,,,,14187,,9680,,1,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL625984,,U,BAO_0000019,,,,,14188,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625985,,U,BAO_0000019,,,,,14189,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625986,,U,BAO_0000019,,,,,14190,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625987,,U,BAO_0000019,,,,,14191,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625988,,U,BAO_0000019,,,,,14192,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625989,,U,BAO_0000019,,,,,14193,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625990,,U,BAO_0000019,,,,,14194,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625991,,U,BAO_0000019,,,,,14195,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625992,,U,BAO_0000019,,,,,14196,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL625993,,U,BAO_0000019,,,,,14197,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL631973,,U,BAO_0000019,,,,,14198,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632143,,U,BAO_0000019,,,,,14199,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632144,,U,BAO_0000019,,,,,14200,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632145,,U,BAO_0000019,,,,,14201,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632146,,U,BAO_0000019,,,,,14202,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632147,,U,BAO_0000019,,,,,14203,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632148,,U,BAO_0000019,,,,,14204,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632149,,U,BAO_0000019,,,,,14205,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632150,,U,BAO_0000019,,,,,14206,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632151,,U,BAO_0000019,,,,,14207,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL632152,9606.0,N,BAO_0000218,Homo sapiens,,,,14208,,3008,,1,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,,,Intermediate,1,,50587
,CHEMBL632153,9606.0,N,BAO_0000218,Homo sapiens,,,,14209,,4509,,1,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Intermediate,1,,50587
,CHEMBL632154,9606.0,N,BAO_0000218,Homo sapiens,,,,14210,,4509,,1,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Intermediate,1,,50587
,CHEMBL632155,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14211,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL632156,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14212,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,,,Intermediate,1,,50602
,CHEMBL632157,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14213,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL632158,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14214,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL632159,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14215,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,,,Intermediate,1,,50602
,CHEMBL626305,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14216,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL626306,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14217,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,,,Intermediate,1,,50602
,CHEMBL626307,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14218,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL626308,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14219,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL626479,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14220,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL626480,10298.0,N,BAO_0000218,Human herpesvirus 1,,,,14221,,8613,,1,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,,,Intermediate,1,,50602
,CHEMBL626481,,U,BAO_0000100,,,,,14222,,6021,,1,,Calculated partition coefficient (clogP) (MlogP),P,,,Autocuration,0,,22229
,CHEMBL626482,,U,BAO_0000019,,,,,14223,,9348,,1,,Equipotent potent ratio relative to carbachol (nicotinic activity),A,,,Autocuration,0,,22224
,CHEMBL626483,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14224,,15592,,1,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,,,Intermediate,1,,50588
,CHEMBL626484,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14225,,15592,,1,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,,,Intermediate,1,,50588
,CHEMBL626485,,U,BAO_0000100,,,,,14226,,15592,,1,,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,,,Autocuration,0,,22229
,CHEMBL626486,,U,BAO_0000100,,,,,14227,,15592,,1,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,,,Autocuration,0,,22229
,CHEMBL626487,,U,BAO_0000100,,,,,14228,,15592,,1,,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,,,Autocuration,0,,22229
,CHEMBL626488,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Plasma,14229,1969.0,15592,,1,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Intermediate,1,,50588
,CHEMBL626489,10116.0,N,BAO_0000218,Rattus norvegicus,,,Serum,14230,1977.0,7095,,1,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,,,Intermediate,1,,50597
,CHEMBL626490,,U,BAO_0000019,,,,,14231,,16618,,1,,Area under the MAP curve measured over 5 min; ND means Not determined,A,,,Autocuration,0,,22224
,CHEMBL626491,,U,BAO_0000100,,,,,14232,,16835,,1,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,,,Autocuration,0,,22224
,CHEMBL626492,,U,BAO_0000100,,,,,14233,,15284,,1,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,,,Autocuration,0,,22229
,CHEMBL626493,,U,BAO_0000019,,,,,14234,,15750,,1,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,,,Autocuration,0,,22224
,CHEMBL626494,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14235,,16618,,1,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Intermediate,1,,50597
,CHEMBL626495,,U,BAO_0000218,,,,,14236,,16618,,1,,Half life after oral tested,A,In vivo,,Autocuration,0,,22224
,CHEMBL626496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,14237,1969.0,15812,,1,,Half life was determined in plasma of rat; NT indicates not tested,A,,,Intermediate,1,,50597
,CHEMBL626497,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14238,,16618,,1,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Intermediate,1,,50597
,CHEMBL626498,,U,BAO_0000218,,,,,14239,,16618,,1,,Oral bioavailability after oral tested,A,In vivo,,Autocuration,0,,22224
,CHEMBL626499,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14240,,13098,,1,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,,,Intermediate,1,,50597
,CHEMBL626500,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14241,,13098,,1,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,,,Intermediate,1,,50597
,CHEMBL626501,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,14242,1969.0,15812,,1,,half life was determined in plasma of rat; NT indicates not tested,A,,,Intermediate,1,,50597
,CHEMBL626502,10116.0,N,BAO_0000218,Rattus norvegicus,,,Plasma,14243,1969.0,15812,,1,,half life was determined in plasma of rat; NT means not tested,A,,,Intermediate,1,,50597
,CHEMBL626503,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14244,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,,,Intermediate,1,,50597
,CHEMBL626504,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14245,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,,,Intermediate,1,,50597
,CHEMBL626505,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14246,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,,,Intermediate,1,,50597
,CHEMBL626506,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14247,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,,,Intermediate,1,,50597
,CHEMBL626507,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14248,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,,,Intermediate,1,,50597
,CHEMBL626508,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14249,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,,,Intermediate,1,,50597
,CHEMBL626509,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14250,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,,,Intermediate,1,,50597
,CHEMBL875480,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14251,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,,,Intermediate,1,,50597
,CHEMBL626510,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14252,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,,,Intermediate,1,,50597
,CHEMBL626511,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14253,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,,,Intermediate,1,,50597
,CHEMBL626512,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14254,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,,,Intermediate,1,,50597
,CHEMBL628208,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14255,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,,,Intermediate,1,,50597
,CHEMBL628209,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14256,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,,,Intermediate,1,,50597
,CHEMBL628210,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14257,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,,,Intermediate,1,,50597
,CHEMBL628211,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14258,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,,,Intermediate,1,,50597
,CHEMBL628212,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14259,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,,,Intermediate,1,,50597
,CHEMBL628213,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14260,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,,,Intermediate,1,,50597
,CHEMBL628214,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14261,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628215,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14262,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628216,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14263,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626595,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14264,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626596,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14265,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626597,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14266,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626598,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14267,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622242,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14268,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622243,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14269,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622244,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14270,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622245,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14271,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622246,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14272,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622247,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14273,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622248,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14274,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL877483,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14275,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622249,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14276,1088.0,12582,,1,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL622250,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14277,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622251,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14278,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622252,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14279,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622253,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14280,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622254,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14281,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622255,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14282,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622256,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14283,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622257,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14284,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622258,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14285,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622259,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14286,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622927,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14287,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622928,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14288,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL622929,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14289,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL623182,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14290,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL623183,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14291,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL623184,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14292,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623185,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14293,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL877484,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14294,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL627274,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14295,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623186,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14296,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623187,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14297,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL623188,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14298,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628055,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14299,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628056,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14300,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628200,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14301,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628201,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14302,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628202,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14303,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628203,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14304,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628204,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14305,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628205,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14306,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628206,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14307,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628207,,U,BAO_0000218,,,,Prostate gland,14308,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,In vivo,,Autocuration,0,,22224
,CHEMBL627220,,U,BAO_0000218,,,,Prostate gland,14309,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627221,,U,BAO_0000218,,,,Muscle tissue,14310,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627222,,U,BAO_0000218,,,,Prostate gland,14311,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,In vivo,,Autocuration,0,,22224
,CHEMBL627223,,U,BAO_0000218,,,,,14312,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL632062,,U,BAO_0000218,,,,Muscle tissue,14313,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL632063,,U,BAO_0000218,,,,Spleen,14314,2106.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,In vivo,,Autocuration,0,,22224
,CHEMBL632064,,U,BAO_0000218,,,,Urinary bladder,14315,1255.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,In vivo,,Autocuration,0,,22224
,CHEMBL632065,,U,BAO_0000218,,,,Blood,14316,178.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL632066,,U,BAO_0000218,,,,Bone element,14317,1474.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,In vivo,,Autocuration,0,,22224
,CHEMBL632067,,U,BAO_0000218,,,,,14318,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,In vivo,,Autocuration,0,,22224
,CHEMBL629188,,U,BAO_0000218,,,,Kidney,14319,2113.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,In vivo,,Autocuration,0,,22224
,CHEMBL629189,,U,BAO_0000218,,,,Liver,14320,2107.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,In vivo,,Autocuration,0,,22224
,CHEMBL629190,,U,BAO_0000218,,,,Lung,14321,2048.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,In vivo,,Autocuration,0,,22224
,CHEMBL629191,,U,BAO_0000218,,,,Muscle tissue,14322,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629192,,U,BAO_0000218,,,,Prostate gland,14323,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,In vivo,,Autocuration,0,,22224
,CHEMBL629193,,U,BAO_0000218,,,,Muscle tissue,14324,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629194,,U,BAO_0000218,,,,Prostate gland,14325,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,In vivo,,Autocuration,0,,22224
,CHEMBL629195,,U,BAO_0000218,,,,,14326,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629373,,U,BAO_0000218,,,,Muscle tissue,14327,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629374,,U,BAO_0000218,,,,Spleen,14328,2106.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,In vivo,,Autocuration,0,,22224
,CHEMBL629375,,U,BAO_0000218,,,,Prostate gland,14329,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629376,,U,BAO_0000218,,,,Urinary bladder,14330,1255.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,In vivo,,Autocuration,0,,22224
,CHEMBL629377,,U,BAO_0000218,,,,Blood,14331,178.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629378,,U,BAO_0000218,,,,Bone element,14332,1474.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,In vivo,,Autocuration,0,,22224
,CHEMBL629379,,U,BAO_0000218,,,,,14333,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,In vivo,,Autocuration,0,,22224
,CHEMBL629151,,U,BAO_0000218,,,,Kidney,14334,2113.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,In vivo,,Autocuration,0,,22224
,CHEMBL629152,,U,BAO_0000218,,,,Liver,14335,2107.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,In vivo,,Autocuration,0,,22224
,CHEMBL629153,,U,BAO_0000218,,,,Lung,14336,2048.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,In vivo,,Autocuration,0,,22224
,CHEMBL629154,,U,BAO_0000218,,,,Muscle tissue,14337,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629155,,U,BAO_0000218,,,,Prostate gland,14338,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,In vivo,,Autocuration,0,,22224
,CHEMBL629156,,U,BAO_0000218,,,,Prostate gland,14339,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629157,,U,BAO_0000218,,,,Muscle tissue,14340,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629158,,U,BAO_0000218,,,,Prostate gland,14341,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,In vivo,,Autocuration,0,,22224
,CHEMBL629159,,U,BAO_0000218,,,,,14342,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629160,,U,BAO_0000218,,,,Muscle tissue,14343,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629161,,U,BAO_0000218,,,,Spleen,14344,2106.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,In vivo,,Autocuration,0,,22224
,CHEMBL629162,,U,BAO_0000218,,,,Urinary bladder,14345,1255.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,In vivo,,Autocuration,0,,22224
,CHEMBL629163,,U,BAO_0000218,,,,Blood,14346,178.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL629164,,U,BAO_0000218,,,,Bone element,14347,1474.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,In vivo,,Autocuration,0,,22224
,CHEMBL629165,,U,BAO_0000218,,,,,14348,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,In vivo,,Autocuration,0,,22224
,CHEMBL629166,,U,BAO_0000218,,,,Liver,14349,2107.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,In vivo,,Autocuration,0,,22224
,CHEMBL629167,,U,BAO_0000218,,,,Lung,14350,2048.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,In vivo,,Autocuration,0,,22224
,CHEMBL629168,,U,BAO_0000218,,,,Muscle tissue,14351,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL629169,,U,BAO_0000019,,,,,14352,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,,,Autocuration,0,,22224
,CHEMBL629170,,U,BAO_0000019,,,,,14353,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,,,Autocuration,0,,22224
,CHEMBL631153,,U,BAO_0000019,,,,,14354,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,,,Autocuration,0,,22224
,CHEMBL875121,,U,BAO_0000019,,,,,14355,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,,,Autocuration,0,,22224
,CHEMBL631154,,U,BAO_0000019,,,,,14356,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,,,Autocuration,0,,22224
,CHEMBL631155,,U,BAO_0000019,,,,,14357,,2193,,1,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,,,Autocuration,0,,22224
,CHEMBL631156,,U,BAO_0000019,,,,,14358,,568,,1,,Hydrolysis rate constant was determined,A,,,Autocuration,0,,22224
,CHEMBL631157,,U,BAO_0000019,,,,,14359,,9680,,1,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL631158,,U,BAO_0000019,,,,,14360,,9680,,1,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL631159,,U,BAO_0000019,,,,,14361,,9680,,1,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL631160,,U,BAO_0000019,,,,,14362,,10026,,1,,Observed second order rate constant,A,,,Autocuration,0,,22224
,CHEMBL631161,,U,BAO_0000019,,,,,14363,,10281,,1,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,Autocuration,0,,22224
,CHEMBL631162,,U,BAO_0000019,,,,,14364,,10014,,1,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,Autocuration,0,,22224
,CHEMBL630313,,U,BAO_0000019,,,,,14365,,10014,,1,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,Autocuration,0,,22224
,CHEMBL630314,,U,BAO_0000019,,,,,14366,,9680,,1,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL630315,,U,BAO_0000019,,,,,14367,,9680,,1,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL630316,,U,BAO_0000019,,,,,14368,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630986,,U,BAO_0000019,,,,,14369,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630987,,U,BAO_0000019,,,,,14370,,13028,,1,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630988,,U,BAO_0000019,,,,,14371,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630989,,U,BAO_0000019,,,,,14372,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630990,,U,BAO_0000019,,,,,14373,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630991,,U,BAO_0000019,,,,,14374,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630992,,U,BAO_0000019,,,,,14375,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630993,,U,BAO_0000019,,,,,14376,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630994,,U,BAO_0000019,,,,,14377,,13028,,1,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,Autocuration,0,,22224
,CHEMBL630995,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14378,,10014,,1,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,,,Intermediate,1,,50597
,CHEMBL629252,,U,BAO_0000019,,,,,14379,,9962,,1,,Association constant for compound at 31 degree C was determined,A,,,Autocuration,0,,22224
,CHEMBL629253,,U,BAO_0000019,,,,,14380,,12029,,1,,Calculated antagonist equilibrium dissociation constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL629944,,U,BAO_0000019,,,,,14381,,12029,,1,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,,,Autocuration,0,,22224
,CHEMBL629945,10141.0,N,BAO_0000218,Cavia porcellus,,,Trachea,14382,3126.0,10583,,1,,Dissociation constants vs LTE4 on guinea pig trachea,A,,,Intermediate,1,,50512
,CHEMBL629946,,U,BAO_0000019,,,,,14383,,568,,1,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,,,Autocuration,0,,22224
,CHEMBL629947,,U,BAO_0000019,,,,,14384,,568,,1,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,,,Autocuration,0,,22224
,CHEMBL629948,,U,BAO_0000019,,,,,14385,,568,,1,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,,,Autocuration,0,,22224
,CHEMBL856024,,U,BAO_0000019,,,,,14386,,568,,1,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,,,Autocuration,0,,22224
,CHEMBL629949,,U,BAO_0000019,,,,,14387,,7493,,1,,Affinity constant KD value was derived from TMP,A,,,Autocuration,0,,22224
,CHEMBL629950,,U,BAO_0000019,,,,,14388,,8371,,1,,Apparent dissociation (binding) rate constant was evaluated,A,,,Autocuration,0,,22224
,CHEMBL630127,,U,BAO_0000100,,,,,14389,,13114,,1,,Dissociation constant (KD) of the compound,P,,,Autocuration,0,,22224
,CHEMBL630128,,U,BAO_0000100,,,,,14390,,15515,,1,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,,,Autocuration,0,,22224
,CHEMBL630129,,U,BAO_0000100,,,,,14391,,522,,1,,Dissociation constant from ESR titration experiments,P,,,Autocuration,0,,22224
,CHEMBL630130,,U,BAO_0000019,,,,,14392,,13888,,1,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,Autocuration,0,,22224
,CHEMBL875234,,U,BAO_0000100,,,,,14393,,2616,,1,,Dissociation constant was evaluated.,P,,,Autocuration,0,,22224
,CHEMBL630131,,U,BAO_0000100,,,,,14394,,3798,,1,,Dissociation constant was reported,P,,,Autocuration,0,,22224
,CHEMBL630132,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14395,,8731,,1,,Dissociation constant was determined in rat pituitary cells.,A,,,Intermediate,1,,50597
,CHEMBL630133,,U,BAO_0000019,,,,,14396,,11892,,1,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,,,Autocuration,0,,22224
,CHEMBL630134,,U,BAO_0000019,,,,,14397,,11892,,1,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,,,Autocuration,0,,22224
,CHEMBL630135,,U,BAO_0000019,,,,,14398,,2582,,1,,Equilibrium dissociation constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL630136,,U,BAO_0000019,,,,,14399,,11892,,1,,Equilibrium dissociation constant was determined,A,,,Autocuration,0,,22224
,CHEMBL630137,,U,BAO_0000019,,,,,14400,,13396,,1,,Kinetic constant KD was evaluated,A,,,Autocuration,0,,22224
,CHEMBL630138,,U,BAO_0000019,,,,,14401,,603,,1,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,,,Autocuration,0,,22224
,CHEMBL630139,,U,BAO_0000019,,,,,14402,,15673,,1,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,,,Autocuration,0,,22224
,CHEMBL630140,,U,BAO_0000019,,,,,14403,,10368,,1,,Rate constant for hydrolysis in aqueous acetone.,A,,,Autocuration,0,,22224
,CHEMBL875235,,U,BAO_0000019,,,,,14404,,14228,,1,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,,,Autocuration,0,,22224
,CHEMBL876439,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14405,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,,,Intermediate,1,,50597
,CHEMBL630605,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14406,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,,,Intermediate,1,,50597
,CHEMBL630606,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14407,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,,,Intermediate,1,,50597
,CHEMBL630607,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14408,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,,,Intermediate,1,,50597
,CHEMBL630608,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14409,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,,,Intermediate,1,,50597
,CHEMBL630609,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14410,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,,,Intermediate,1,,50597
,CHEMBL630610,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14411,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,,,Intermediate,1,,50597
,CHEMBL630611,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14412,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,,,Intermediate,1,,50597
,CHEMBL629552,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14413,,11510,,1,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,,,Intermediate,1,,50597
,CHEMBL629733,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14414,,11510,,1,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629734,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14415,,11510,,1,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629735,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14416,,11510,,1,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629736,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14417,,11510,,1,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629737,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14418,,11510,,1,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629738,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14419,,11510,,1,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629739,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14420,,11510,,1,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629740,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14421,,11510,,1,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Intermediate,1,,50597
,CHEMBL629741,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14422,,11510,,1,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629742,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14423,,11510,,1,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629743,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14424,,11510,,1,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629744,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14425,,11510,,1,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629745,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14426,,11510,,1,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629746,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14427,,11510,,1,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629747,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14428,,11510,,1,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629748,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14429,,11510,,1,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629749,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14430,,11510,,1,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629750,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14431,,11510,,1,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629751,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14432,,11510,,1,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629752,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14433,,11510,,1,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629753,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14434,,11510,,1,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629754,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14435,,11510,,1,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629755,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14436,,11510,,1,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629756,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14437,,11510,,1,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629757,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14438,,11510,,1,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629758,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14439,,11510,,1,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629759,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14440,,11510,,1,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629760,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14441,,11510,,1,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL876443,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14442,,11510,,1,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Intermediate,1,,50597
,CHEMBL629761,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14443,,8310,,1,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Intermediate,1,,50588
,CHEMBL629762,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14444,,8310,,1,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,,,Intermediate,1,,50588
,CHEMBL629763,10090.0,N,BAO_0000218,Mus musculus,,,,14445,,8310,,1,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629764,10090.0,N,BAO_0000218,Mus musculus,,,,14446,,8310,,1,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629765,10090.0,N,BAO_0000218,Mus musculus,,,,14447,,8310,,1,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629766,10090.0,N,BAO_0000218,Mus musculus,,,,14448,,8310,,1,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629767,10090.0,N,BAO_0000218,Mus musculus,,,,14449,,8310,,1,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629768,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14450,,8310,,1,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,,,Intermediate,1,,50588
,CHEMBL629769,10090.0,N,BAO_0000218,Mus musculus,,,,14451,,8310,,1,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629770,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14452,,8310,,1,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Intermediate,1,,50588
,CHEMBL629771,9615.0,N,BAO_0000218,Canis lupus familiaris,,,,14453,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,,,Intermediate,1,,50588
,CHEMBL629772,10090.0,N,BAO_0000218,Mus musculus,,,,14454,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL629773,10090.0,N,BAO_0000218,Mus musculus,,,,14455,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL625455,10090.0,N,BAO_0000218,Mus musculus,,,,14456,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL625456,10090.0,N,BAO_0000218,Mus musculus,,,,14457,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL625457,10090.0,N,BAO_0000218,Mus musculus,,,,14458,,8310,,1,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,,,Intermediate,1,,50594
,CHEMBL625458,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14459,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625459,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14460,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875483,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14461,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL634779,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14462,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625460,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14463,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626117,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14464,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626118,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14465,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628342,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14466,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628343,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14467,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628344,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14468,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628345,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14469,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628346,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14470,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628347,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14471,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628348,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14472,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628349,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14473,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875611,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14474,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628350,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14475,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628351,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14476,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628352,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14477,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628353,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14478,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628354,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14479,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626667,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14480,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626668,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14481,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626669,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14482,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626670,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14483,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626671,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14484,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626672,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14485,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626673,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14486,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626674,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14487,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626675,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14488,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626676,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14489,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626677,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14490,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626678,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14491,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626679,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14492,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875612,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14493,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626680,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14494,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626681,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14495,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626682,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14496,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626683,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14497,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626684,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14498,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626685,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14499,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626686,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14500,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626687,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14501,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL624978,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14502,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL624979,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14503,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL624980,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14504,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL624981,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14505,1088.0,12582,,1,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL624982,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14506,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627564,,U,BAO_0000218,,,,Prostate gland,14507,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,In vivo,,Autocuration,0,,22224
,CHEMBL627565,,U,BAO_0000218,,,,Prostate gland,14508,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,In vivo,,Autocuration,0,,22224
,CHEMBL627566,,U,BAO_0000218,,,,,14509,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627567,,U,BAO_0000218,,,,Muscle tissue,14510,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627568,,U,BAO_0000218,,,,Spleen,14511,2106.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,In vivo,,Autocuration,0,,22224
,CHEMBL627569,,U,BAO_0000218,,,,Kidney,14512,2113.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,In vivo,,Autocuration,0,,22224
,CHEMBL627570,,U,BAO_0000218,,,,Urinary bladder,14513,1255.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,In vivo,,Autocuration,0,,22224
,CHEMBL627571,,U,BAO_0000218,,,,Blood,14514,178.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627572,,U,BAO_0000218,,,,Bone element,14515,1474.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,In vivo,,Autocuration,0,,22224
,CHEMBL627573,,U,BAO_0000218,,,,,14516,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,In vivo,,Autocuration,0,,22224
,CHEMBL627574,,U,BAO_0000218,,,,Kidney,14517,2113.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,In vivo,,Autocuration,0,,22224
,CHEMBL627575,,U,BAO_0000218,,,,Liver,14518,2107.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,In vivo,,Autocuration,0,,22224
,CHEMBL627576,,U,BAO_0000218,,,,Lung,14519,2048.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,In vivo,,Autocuration,0,,22224
,CHEMBL627577,,U,BAO_0000218,,,,Muscle tissue,14520,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627578,,U,BAO_0000218,,,,Prostate gland,14521,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,In vivo,,Autocuration,0,,22224
,CHEMBL627579,,U,BAO_0000218,,,,Prostate gland,14522,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627580,,U,BAO_0000218,,,,Muscle tissue,14523,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627581,,U,BAO_0000218,,,,Prostate gland,14524,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,In vivo,,Autocuration,0,,22224
,CHEMBL627582,,U,BAO_0000218,,,,,14525,,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627583,,U,BAO_0000218,,,,Muscle tissue,14526,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627584,,U,BAO_0000218,,,,Spleen,14527,2106.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,In vivo,,Autocuration,0,,22224
,CHEMBL627585,,U,BAO_0000218,,,,Prostate gland,14528,2367.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,In vivo,,Autocuration,0,,22224
,CHEMBL627586,,U,BAO_0000218,,,,Muscle tissue,14529,2385.0,13257,,1,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,In vivo,,Autocuration,0,,22224
,CHEMBL627587,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14530,,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL627588,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14531,,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628250,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14532,,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628251,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14533,,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628252,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14534,10000000.0,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628253,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14535,10000000.0,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628254,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14536,1898.0,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL877493,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14537,1898.0,15413,,1,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628255,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14538,,15413,,1,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628256,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14539,,15413,,1,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628257,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14540,10000000.0,15413,,1,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628258,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14541,1898.0,15413,,1,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628259,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14542,,15413,,1,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL628429,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14543,,15413,,1,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL626862,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14544,10000000.0,15413,,1,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Intermediate,1,,50597
,CHEMBL626863,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14545,1898.0,15413,,1,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL625886,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,14546,2037.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,In vivo,,Intermediate,1,,50597
,CHEMBL625887,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,14547,2037.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625888,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14548,,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,In vivo,,Intermediate,1,,50597
,CHEMBL625889,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14549,,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625890,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14550,10000000.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,In vivo,,Intermediate,1,,50597
,CHEMBL625891,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14551,10000000.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625892,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14552,1898.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,In vivo,,Intermediate,1,,50597
,CHEMBL625893,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14553,1898.0,15413,,1,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,In vivo,,Intermediate,1,,50597
,CHEMBL625894,10116.0,N,BAO_0000218,Rattus norvegicus,,,Cerebellum,14554,2037.0,15413,,1,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,In vivo,,Intermediate,1,,50597
,CHEMBL625895,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14555,,15413,,1,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,In vivo,,Intermediate,1,,50597
,CHEMBL625896,,U,BAO_0000019,,,,,14556,,12404,,1,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,Autocuration,0,,22224
,CHEMBL625897,,U,BAO_0000019,,,,,14557,,568,,1,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,,,Autocuration,0,,22224
,CHEMBL625898,,U,BAO_0000019,,,,,14558,,568,,1,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,Autocuration,0,,22224
,CHEMBL625899,,U,BAO_0000019,,,,,14559,,568,,1,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,Autocuration,0,,22224
,CHEMBL626124,,U,BAO_0000019,,,,,14560,,12404,,1,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,Autocuration,0,,22224
,CHEMBL628500,562.0,N,BAO_0000218,Escherichia coli,,,,14561,,7624,,1,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,,,Intermediate,1,,50212
,CHEMBL857856,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14562,,7624,,1,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,,,Intermediate,1,,50597
,CHEMBL628501,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14563,,7624,,1,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,,,Intermediate,1,,50597
,CHEMBL628502,,U,BAO_0000019,,,,,14564,,4643,,1,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,,,Autocuration,0,,22224
,CHEMBL628503,,U,BAO_0000019,,,,,14565,,11532,,1,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,,,Autocuration,0,,22224
,CHEMBL628504,,U,BAO_0000019,,,,,14566,,11018,,1,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL628505,,U,BAO_0000019,,,,,14567,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,Autocuration,0,,22224
,CHEMBL874452,,U,BAO_0000019,,,,,14568,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,Autocuration,0,,22224
,CHEMBL628506,,U,BAO_0000019,,,,,14569,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,,,Autocuration,0,,22224
,CHEMBL628507,,U,BAO_0000019,,,,,14570,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,Autocuration,0,,22224
,CHEMBL628508,,U,BAO_0000019,,,,,14571,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,Autocuration,0,,22224
,CHEMBL628509,,U,BAO_0000019,,,,,14572,,8949,,1,,Michaelis constant (KM) was evaluated,A,,,Autocuration,0,,22224
,CHEMBL628510,,U,BAO_0000019,,,,,14573,,12404,,1,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,Autocuration,0,,22224
,CHEMBL628511,,U,BAO_0000019,,,,,14574,,7625,,1,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,,,Autocuration,0,,22224
,CHEMBL628512,,U,BAO_0000019,,,,,14575,,7625,,1,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,,,Autocuration,0,,22224
,CHEMBL628513,,U,BAO_0000019,,,,,14576,,7625,,1,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,,,Autocuration,0,,22224
,CHEMBL628514,,U,BAO_0000019,,,,,14577,,7625,,1,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,,,Autocuration,0,,22224
,CHEMBL628515,,U,BAO_0000019,,,,,14578,,12908,,1,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,,,Autocuration,0,,22224
,CHEMBL628516,,U,BAO_0000019,,,,,14579,,10368,,1,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,,,Autocuration,0,,22224
,CHEMBL628517,,U,BAO_0000019,,,,,14580,,13108,,1,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,Autocuration,0,,22224
,CHEMBL628518,,U,BAO_0000019,,,,,14581,,13108,,1,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,Autocuration,0,,22224
,CHEMBL628519,,U,BAO_0000019,,,,,14582,,15217,,1,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,,,Autocuration,0,,22224
,CHEMBL628520,,U,BAO_0000019,,,,,14583,,15217,,1,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,,,Autocuration,0,,22224
,CHEMBL628521,,U,BAO_0000019,,,,,14584,,10933,,1,,Binding constant was determined,A,,,Autocuration,0,,22224
,CHEMBL630443,,U,BAO_0000019,,,,,14585,,2363,,1,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL630444,,U,BAO_0000019,,,,,14586,,2363,,1,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,,,Autocuration,0,,22224
,CHEMBL857732,,U,BAO_0000019,,,,,14587,,2276,,1,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,,,Autocuration,0,,22224
,CHEMBL630445,,U,BAO_0000100,,,,,14588,,14915,,1,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,,,Autocuration,0,,22224
,CHEMBL630446,,U,BAO_0000019,,,,,14589,,8847,,1,,Catalytic rate constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL630447,,U,BAO_0000019,,,,,14590,,15357,,1,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,,,Autocuration,0,,22224
,CHEMBL630448,,U,BAO_0000019,,,,,14591,,2869,,1,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,,,Autocuration,0,,22224
,CHEMBL630449,,U,BAO_0000019,,,,,14592,,3484,,1,,Catalytic rate constant against phospholipase A2 was determined,A,,,Autocuration,0,,22224
,CHEMBL630450,,U,BAO_0000019,,,,,14593,,1373,,1,,"Compound was evaluated for catalytic constant, Kcat",A,,,Autocuration,0,,22224
,CHEMBL630451,,U,BAO_0000019,,,,,14594,,8142,,1,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,,,Autocuration,0,,22224
,CHEMBL630452,,U,BAO_0000019,,,,,14595,,14131,,1,,Kcat calculated from 0.693/T1/2,A,,,Autocuration,0,,22224
,CHEMBL630453,,U,BAO_0000019,,,,,14596,,17269,,1,,Kcat was determined,A,,,Autocuration,0,,22224
,CHEMBL630454,,U,BAO_0000019,,,,,14597,,3485,,1,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,,,Autocuration,0,,22224
,CHEMBL630455,,U,BAO_0000019,,,,,14598,,3485,,1,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,,,Autocuration,0,,22224
,CHEMBL631487,,U,BAO_0000019,,,,,14599,,3485,,1,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,,,Autocuration,0,,22224
,CHEMBL631488,,U,BAO_0000019,,,,,14600,,5962,,1,,Kcat value was determined,A,,,Autocuration,0,,22224
,CHEMBL876440,,U,BAO_0000019,,,,,14601,,3133,,1,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,,,Autocuration,0,,22224
,CHEMBL631489,,U,BAO_0000019,,,,,14602,,3133,,1,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,,,Autocuration,0,,22224
,CHEMBL857742,,U,BAO_0000019,,,,,14603,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,Autocuration,0,,22224
,CHEMBL631490,,U,BAO_0000019,,,,,14604,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,Autocuration,0,,22224
,CHEMBL631491,,U,BAO_0000019,,,,,14605,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,,,Autocuration,0,,22224
,CHEMBL631492,,U,BAO_0000019,,,,,14606,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,Autocuration,0,,22224
,CHEMBL631493,,U,BAO_0000019,,,,,14607,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,Autocuration,0,,22224
,CHEMBL631494,,U,BAO_0000019,,,,,14608,,4892,,1,,Kinetic parameter for rate of conversion to PABA was determined,A,,,Autocuration,0,,22224
,CHEMBL631495,,U,BAO_0000019,,,,,14609,,3133,,1,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,Autocuration,0,,22224
,CHEMBL631496,10116.0,N,BAO_0000218,Rattus norvegicus,,,Feces,14610,1988.0,11488,,1,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Intermediate,1,,50597
,CHEMBL631497,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14611,1088.0,11488,,1,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Intermediate,1,,50597
,CHEMBL631498,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14612,1088.0,11488,,1,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Intermediate,1,,50597
,CHEMBL629776,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14613,1088.0,11488,,1,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Intermediate,1,,50597
,CHEMBL629777,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14614,1088.0,11488,,1,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Intermediate,1,,50597
,CHEMBL629778,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14615,1088.0,11488,,1,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Intermediate,1,,50597
,CHEMBL630456,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14616,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630457,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14617,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630458,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14618,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630459,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14619,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630460,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14620,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL876550,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14621,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630461,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14622,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630462,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14623,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630463,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14624,,11488,,1,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630464,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14625,,11488,,1,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630465,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14626,,11488,,1,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630466,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14627,,11488,,1,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630467,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14628,,11488,,1,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630633,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14629,,11488,,1,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630634,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14630,,11488,,1,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630635,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14631,,11488,,1,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630636,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14632,,11488,,1,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630637,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14633,,11488,,1,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,,,Intermediate,1,,50597
,CHEMBL630638,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14634,1988.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Intermediate,1,,50592
,CHEMBL630639,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14635,1988.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Intermediate,1,,50592
,CHEMBL630640,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14636,1988.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL876551,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14637,1988.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL630641,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14638,1088.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Intermediate,1,,50592
,CHEMBL630642,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14639,1088.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Intermediate,1,,50592
,CHEMBL630643,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14640,1088.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL630644,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14641,1088.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL630645,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14642,1088.0,7132,,1,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Intermediate,1,,50592
,CHEMBL625599,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14643,1988.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Intermediate,1,,50592
,CHEMBL625600,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14644,1988.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Intermediate,1,,50592
,CHEMBL625601,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14645,1988.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL625602,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Feces,14646,1988.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL627470,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14647,1088.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Intermediate,1,,50592
,CHEMBL627471,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14648,1088.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Intermediate,1,,50592
,CHEMBL627472,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14649,1088.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Intermediate,1,,50592
,CHEMBL627473,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14650,1088.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Intermediate,1,,50592
,CHEMBL627474,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Urine,14651,1088.0,7132,,1,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Intermediate,1,,50592
,CHEMBL627475,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14652,178.0,13925,,1,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL627476,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14653,178.0,13925,,1,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL627477,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14654,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627478,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14655,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627479,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14656,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627480,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14657,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627481,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14658,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627482,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14659,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL627483,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14660,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL875636,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14661,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625764,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14662,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625765,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14663,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625766,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14664,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625767,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14665,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625768,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14666,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625769,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14667,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625770,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14668,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625771,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14669,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625772,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14670,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625773,9615.0,N,BAO_0000218,Canis lupus familiaris,,,Urine,14671,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Intermediate,1,,50588
,CHEMBL625774,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14672,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625775,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14673,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625776,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14674,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625777,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14675,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625778,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14676,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625779,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14677,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625780,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14678,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL625781,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14679,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875637,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14680,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626473,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14681,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626474,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14682,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626475,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14683,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626476,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14684,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL634397,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14685,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL626477,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14686,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631069,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14687,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631070,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14688,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631071,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14689,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631072,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14690,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631073,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14691,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631074,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14692,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631075,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14693,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631725,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14694,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631726,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14695,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631727,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14696,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631728,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14697,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631729,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14698,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631730,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14699,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631731,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14700,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631910,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14701,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631911,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hippocampus,14702,10000000.0,15413,,1,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,In vivo,,Intermediate,1,,50597
,CHEMBL631912,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14703,1898.0,15413,,1,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,In vivo,,Intermediate,1,,50597
,CHEMBL631913,10116.0,N,BAO_0000218,Rattus norvegicus,,,Hypothalamus,14704,1898.0,15413,,1,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,In vivo,,Intermediate,1,,50597
,CHEMBL631914,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14705,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631915,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14706,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL875778,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14707,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631916,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14708,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631917,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14709,178.0,12017,,1,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631918,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14710,178.0,12017,,1,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631919,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14711,178.0,12017,,1,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631920,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14712,178.0,12017,,1,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631921,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14713,178.0,12017,,1,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631922,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14714,178.0,12017,,1,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631923,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14715,178.0,12017,,1,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631924,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14716,,12017,,1,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630234,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14717,,12017,,1,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630235,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14718,,12017,,1,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630236,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14719,,12017,,1,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630237,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14720,,12017,,1,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630238,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14721,,12017,,1,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630239,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14722,,12017,,1,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630303,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14723,,12017,,1,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630304,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14724,,12017,,1,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630305,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14725,,12017,,1,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630306,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14726,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630307,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14727,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630308,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14728,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630309,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14729,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL629309,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14730,2113.0,12017,,1,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL629993,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14731,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL629994,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14732,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL629995,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14733,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631993,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14734,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631994,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14735,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631995,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14736,2113.0,12017,,1,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631996,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14737,2107.0,12017,,1,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631997,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14738,2107.0,12017,,1,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631998,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14739,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631999,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14740,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL632000,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14741,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL632001,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14742,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL874424,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14743,2107.0,12017,,1,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL632002,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14744,2107.0,12017,,1,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL632003,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14745,2107.0,12017,,1,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL632004,,U,BAO_0000019,,,,,14746,,3133,,1,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,Autocuration,0,,22224
,CHEMBL632005,,U,BAO_0000019,,,,,14747,,2742,,1,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,,,Autocuration,0,,22224
,CHEMBL632006,,U,BAO_0000019,,,,,14748,,2742,,1,,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,,,Autocuration,0,,22224
,CHEMBL632007,,U,BAO_0000019,,,,,14749,,2742,,1,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,,,Autocuration,0,,22224
,CHEMBL632008,,U,BAO_0000019,,,,,14750,,2742,,1,,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,,,Autocuration,0,,22224
,CHEMBL632009,,U,BAO_0000019,,,,,14751,,2742,,1,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,,,Autocuration,0,,22224
,CHEMBL632010,,U,BAO_0000019,,,,,14752,,2742,,1,,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,,,Autocuration,0,,22224
,CHEMBL857750,,U,BAO_0000019,,,,,14753,,2742,,1,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,,,Autocuration,0,,22224
,CHEMBL632011,,U,BAO_0000019,,,,,14754,,2742,,1,,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,,,Autocuration,0,,22224
,CHEMBL632012,,U,BAO_0000019,,,,,14755,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL632013,,U,BAO_0000019,,,,,14756,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL632014,,U,BAO_0000019,,,,,14757,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL629622,,U,BAO_0000019,,,,,14758,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL629623,,U,BAO_0000019,,,,,14759,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL629624,,U,BAO_0000019,,,,,14760,,2276,,1,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,,,Autocuration,0,,22224
,CHEMBL629625,,U,BAO_0000019,,,,,14761,,17269,,1,,Ratio of Kcat to that of Km was determined,A,,,Autocuration,0,,22224
,CHEMBL629626,,U,BAO_0000019,,,,,14762,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,Autocuration,0,,22224
,CHEMBL629627,,U,BAO_0000019,,,,,14763,,2276,,1,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,Autocuration,0,,22224
,CHEMBL629628,,U,BAO_0000019,,,,,14764,,15917,,1,,"Compound was evaluated for constant, Kd",A,,,Autocuration,0,,22224
,CHEMBL629629,,U,BAO_0000019,,,,,14765,,10933,,1,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,,,Autocuration,0,,22224
,CHEMBL629630,,U,BAO_0000019,,,,,14766,,10933,,1,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,,,Autocuration,0,,22224
,CHEMBL856030,,U,BAO_0000019,,,,,14767,,14293,,1,,Dissociation Constant of compound determined,A,,,Autocuration,0,,22224
,CHEMBL629631,,U,BAO_0000019,,,,,14768,,6698,,1,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,,,Autocuration,0,,22224
,CHEMBL629632,,U,BAO_0000019,,,,,14769,,6698,,1,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,,,Autocuration,0,,22224
,CHEMBL629633,,U,BAO_0000100,,,,,14770,,4318,,1,,Dissociation constant of compound with Fructose was determined,P,,,Autocuration,0,,22224
,CHEMBL629634,,U,BAO_0000100,,,,,14771,,4318,,1,,Dissociation constant of compound with Fructose was determined; Not determined,P,,,Autocuration,0,,22224
,CHEMBL629635,,U,BAO_0000100,,,,,14772,,4318,,1,,Dissociation constant of compound with Lactulose was determined,P,,,Autocuration,0,,22224
,CHEMBL629636,,U,BAO_0000100,,,,,14773,,4318,,1,,Dissociation constant of compound with Lactulose was determined; Not determined,P,,,Autocuration,0,,22224
,CHEMBL629637,,U,BAO_0000100,,,,,14774,,14959,,1,,Dissociation constant of the Compound,P,,,Autocuration,0,,22224
,CHEMBL629638,,U,BAO_0000100,,,,,14775,,5913,,1,,Dissociation constant by non-linear regression analysis,P,,,Autocuration,0,,22224
,CHEMBL629639,,U,BAO_0000100,,,,,14776,,14218,,1,,Dissociation constant was determined,P,,,Autocuration,0,,22224
,CHEMBL629640,,U,BAO_0000100,,,,,14777,,10689,,1,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,,,Autocuration,0,,22224
,CHEMBL629641,,U,BAO_0000100,,,,,14778,,13925,,1,,Dissociation constant was determined,P,,,Autocuration,0,,22224
,CHEMBL631344,,U,BAO_0000100,,,,,14779,,16359,,1,,Dissociation constant was determined,P,,,Autocuration,0,,22224
,CHEMBL631345,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14780,2385.0,10944,,1,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,,,Intermediate,1,,50597
,CHEMBL631346,,U,BAO_0000019,,,,,14781,,11080,,1,,The dissociation constant determined by fluorescence displacement assay,A,,,Autocuration,0,,22224
,CHEMBL631524,,U,BAO_0000019,,,,,14782,,17805,,1,,kd value surface plasmon resonance (SPR) method,A,,,Autocuration,0,,22224
,CHEMBL631525,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14783,2385.0,10944,,1,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,,,Intermediate,1,,50597
,CHEMBL631526,,U,BAO_0000019,,,,,14784,,16645,,1,,First dissociation constant of the binding of compound to V30M TTR,F,,,Autocuration,0,,22224
,CHEMBL631527,,U,BAO_0000019,,,,,14785,,16645,,1,,Second dissociation constant of the binding of compound to V30M TTR,F,,,Autocuration,0,,22224
,CHEMBL631528,,U,BAO_0000019,,,,,14786,,7793,,1,,"Compound was evaluated for equilibrium constant, Ke",A,,,Autocuration,0,,22224
,CHEMBL631529,,U,BAO_0000019,,,,Hypothalamus,14787,1898.0,12199,,1,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,,,Autocuration,0,,22224
,CHEMBL631530,,U,BAO_0000019,,,,Hypothalamus,14788,1898.0,12199,,1,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,,,Autocuration,0,,22224
,CHEMBL631531,,U,BAO_0000019,,,,,14789,,9680,,1,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL631532,,U,BAO_0000019,,,,,14790,,9680,,1,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL631533,,U,BAO_0000019,,,,,14791,,9680,,1,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL876552,10090.0,N,BAO_0000218,Mus musculus,,,,14792,,13758,,1,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Intermediate,1,,50594
,CHEMBL631534,10090.0,N,BAO_0000218,Mus musculus,,,,14793,,13758,,1,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Intermediate,1,,50594
,CHEMBL631535,10090.0,N,BAO_0000218,Mus musculus,,,,14794,,13758,,1,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Intermediate,1,,50594
,CHEMBL631536,10090.0,N,BAO_0000218,Mus musculus,,,,14795,,13758,,1,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Intermediate,1,,50594
,CHEMBL631537,10090.0,N,BAO_0000218,Mus musculus,,,,14796,,13758,,1,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,,,Intermediate,1,,50594
,CHEMBL631538,10090.0,N,BAO_0000218,Mus musculus,,,,14797,,13758,,1,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Intermediate,1,,50594
,CHEMBL631539,10090.0,N,BAO_0000218,Mus musculus,,,,14798,,13758,,1,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,,,Intermediate,1,,50594
,CHEMBL631540,10090.0,N,BAO_0000218,Mus musculus,,,,14799,,13758,,1,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Intermediate,1,,50594
,CHEMBL625637,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14800,,14393,,1,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Intermediate,1,,50597
,CHEMBL625638,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14801,,14393,,1,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Intermediate,1,,50597
,CHEMBL625639,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14802,,15078,,1,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Intermediate,1,,50597
,CHEMBL625640,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14803,955.0,13925,,1,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625641,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14804,955.0,13925,,1,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625642,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,14805,948.0,13925,,1,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625643,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,14806,948.0,13925,,1,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625644,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14807,2113.0,13925,,1,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625645,10116.0,N,BAO_0000218,Rattus norvegicus,,,Kidney,14808,2113.0,13925,,1,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625646,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14809,2107.0,13925,,1,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625647,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14810,2107.0,13925,,1,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625648,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14811,2048.0,13925,,1,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625649,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14812,2048.0,13925,,1,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625650,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14813,2385.0,13925,,1,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625651,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14814,2385.0,13925,,1,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625652,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,14815,14.0,13925,,1,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625653,10116.0,N,BAO_0000218,Rattus norvegicus,,,Zone of skin,14816,14.0,13925,,1,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625654,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14817,2106.0,13925,,1,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625655,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14818,2106.0,13925,,1,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Intermediate,1,,50597
,CHEMBL625656,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14819,178.0,9712,,1,,Biodistribution of Compound in rat blood after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625657,10116.0,N,BAO_0000218,Rattus norvegicus,,,Blood,14820,178.0,9712,,1,,Biodistribution of Compound in rat blood after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625658,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14821,955.0,9712,,1,,Biodistribution of Compound in rat brain after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625659,10116.0,N,BAO_0000218,Rattus norvegicus,,,Brain,14822,955.0,9712,,1,,Biodistribution of Compound in rat brain after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625660,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,14823,948.0,9712,,1,,Biodistribution of Compound in rat heart after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625661,10116.0,N,BAO_0000218,Rattus norvegicus,,,Heart,14824,948.0,9712,,1,,Biodistribution of Compound in rat heart after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625662,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14825,2107.0,9712,,1,,Biodistribution of Compound in rat liver after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL625663,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14826,2107.0,9712,,1,,Biodistribution of Compound in rat liver after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL875621,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14827,2048.0,9712,,1,,Biodistribution of Compound in rat lung after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL628382,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14828,2048.0,9712,,1,,Biodistribution of Compound in rat lung after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL628383,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14829,2385.0,9712,,1,,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL628384,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14830,2385.0,9712,,1,,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,In vivo,,Intermediate,1,,50597
,CHEMBL628385,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14831,,13925,,1,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,,,Intermediate,1,,50597
,CHEMBL875753,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14832,,13925,,1,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,,,Intermediate,1,,50597
,CHEMBL628386,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14833,,13925,,1,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,,,Intermediate,1,,50597
,CHEMBL628387,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14834,,6941,,1,,Organ distribution in rat blood 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL628388,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14835,,6941,,1,,Organ distribution in rat blood 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL628389,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14836,,6941,,1,,Organ distribution in rat blood 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL632756,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14837,,6941,,1,,Organ distribution in rat blood 30 min after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL628390,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14838,,6941,,1,,Organ distribution in rat brain 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631811,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14839,,6941,,1,,Organ distribution in rat brain 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631812,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14840,,6941,,1,,Organ distribution in rat brain 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631813,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14841,,6941,,1,,Organ distribution in rat heart 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631814,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14842,,6941,,1,,Organ distribution in rat heart 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631815,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14843,,6941,,1,,Organ distribution in rat heart 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631816,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14844,,6941,,1,,Organ distribution in rat kidney 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL875758,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14845,,6941,,1,,Organ distribution in rat kidney 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631817,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14846,,6941,,1,,Organ distribution in rat kidney 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631818,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14847,2107.0,6941,,1,,Organ distribution in rat liver 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631819,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14848,2107.0,6941,,1,,Organ distribution in rat liver 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631820,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14849,2107.0,6941,,1,,Organ distribution in rat liver 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631821,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14850,,6941,,1,,Organ distribution in rat lung 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631822,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14851,,6941,,1,,Organ distribution in rat lung 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631823,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14852,,6941,,1,,Organ distribution in rat lung 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631824,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14853,2385.0,6941,,1,,Organ distribution in rat muscle 2 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631825,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14854,2385.0,6941,,1,,Organ distribution in rat muscle 2 hr after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631826,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14855,2385.0,6941,,1,,Organ distribution in rat muscle 30 minutes after intravenous injection,A,,,Intermediate,1,,50597
,CHEMBL631827,10090.0,N,BAO_0000218,Mus musculus,,,,14856,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Intermediate,1,,50594
,CHEMBL631828,10090.0,N,BAO_0000218,Mus musculus,,,,14857,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Intermediate,1,,50594
,CHEMBL631829,10090.0,N,BAO_0000218,Mus musculus,,,,14858,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Intermediate,1,,50594
,CHEMBL875759,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14859,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631830,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14860,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631831,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14861,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631832,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14862,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631833,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14863,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631834,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14864,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631835,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14865,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631836,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14866,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631837,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14867,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631838,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14868,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631839,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14869,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631840,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14870,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631841,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14871,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631842,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14872,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631843,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14873,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631844,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14874,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631845,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14875,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631846,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14876,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL875760,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14877,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL632199,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14878,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631847,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14879,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL631848,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14880,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628707,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14881,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628708,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14882,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628709,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14883,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628710,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14884,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628711,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14885,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628712,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14886,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628713,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14887,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628714,10116.0,N,BAO_0000218,Rattus norvegicus,,,Urine,14888,1088.0,12582,,1,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Intermediate,1,,50597
,CHEMBL628715,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14889,,7415,,1,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,,,Intermediate,1,,50597
,CHEMBL629179,,U,BAO_0000019,,,,,14890,,7313,,1,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,,,Autocuration,0,,22224
,CHEMBL629180,,U,BAO_0000019,,,,,14891,,7313,,1,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,,,Autocuration,0,,22224
,CHEMBL875108,,U,BAO_0000019,,,,,14892,,7313,,1,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,,,Autocuration,0,,22224
,CHEMBL629181,,U,BAO_0000019,,,,Adrenal cortex,14893,1235.0,7570,,1,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629182,,U,BAO_0000019,,,,Adrenal cortex,14894,1235.0,7570,,1,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629183,,U,BAO_0000019,,,,,14895,,7570,,1,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629184,,U,BAO_0000019,,,,,14896,,7570,,1,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629185,,U,BAO_0000019,,,,Adrenal cortex,14897,1235.0,7570,,1,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629186,,U,BAO_0000019,,,,Adrenal cortex,14898,1235.0,7570,,1,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629187,,U,BAO_0000019,,,,,14899,,7570,,1,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629887,,U,BAO_0000019,,,,,14900,,7570,,1,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629888,,U,BAO_0000019,,,,,14901,,7570,,1,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629889,,U,BAO_0000019,,,,,14902,,7570,,1,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629890,,U,BAO_0000019,,,,Adrenal cortex,14903,1235.0,7570,,1,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629891,,U,BAO_0000019,,,,,14904,,7570,,1,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629892,,U,BAO_0000019,,,,,14905,,7570,,1,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629893,,U,BAO_0000019,,,,Adrenal cortex,14906,1235.0,7570,,1,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629894,,U,BAO_0000019,,,,,14907,,7570,,1,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL629895,,U,BAO_0000019,,,,,14908,,7570,,1,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,Autocuration,0,,22224
,CHEMBL875109,9615.0,U,BAO_0000218,Canis lupus familiaris,,,,14909,,14122,,1,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,In vivo,,Autocuration,0,,22224
,CHEMBL629896,9541.0,U,BAO_0000218,Macaca fascicularis,,,,14910,,16449,,1,,Absolute bioavailability in male cynomolgus monkeys,A,In vivo,,Autocuration,0,,22224
,CHEMBL629897,10116.0,U,BAO_0000218,Rattus norvegicus,,,,14911,,16449,,1,,Absolute bioavailability in maleSprague-Dawley rats,A,In vivo,,Autocuration,0,,22224
,CHEMBL629898,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14912,2107.0,12017,,1,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630057,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14913,2107.0,12017,,1,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630058,10116.0,N,BAO_0000218,Rattus norvegicus,,,Liver,14914,2107.0,12017,,1,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630059,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14915,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630060,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14916,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630061,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14917,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630062,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14918,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630063,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14919,2048.0,12017,,1,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630064,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14920,2048.0,12017,,1,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630065,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14921,2048.0,12017,,1,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630066,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14922,2048.0,12017,,1,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630067,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14923,2048.0,12017,,1,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630068,10116.0,N,BAO_0000218,Rattus norvegicus,,,Lung,14924,2048.0,12017,,1,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631113,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14925,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631114,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14926,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL631115,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14927,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL631116,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14928,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630528,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14929,2385.0,12017,,1,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630529,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14930,2385.0,12017,,1,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630530,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14931,2385.0,12017,,1,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630531,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14932,2385.0,12017,,1,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630532,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14933,2385.0,12017,,1,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630533,10116.0,N,BAO_0000218,Rattus norvegicus,,,Muscle tissue,14934,2385.0,12017,,1,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630534,10090.0,N,BAO_0000218,Mus musculus,,,Blood,14935,178.0,15045,,1,,Biodistribution in normal mice blood after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630535,10090.0,N,BAO_0000218,Mus musculus,,,Blood,14936,178.0,15045,,1,,Biodistribution in normal mice blood after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630536,10090.0,N,BAO_0000218,Mus musculus,,,Blood,14937,178.0,15045,,1,,Biodistribution in normal mice blood after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630537,10090.0,N,BAO_0000218,Mus musculus,,,Bone,14938,10000001.0,15045,,1,,Biodistribution in normal mice bone after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630538,10090.0,N,BAO_0000218,Mus musculus,,,Bone,14939,10000001.0,15045,,1,,Biodistribution in normal mice bone after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630539,10090.0,N,BAO_0000218,Mus musculus,,,Bone,14940,10000001.0,15045,,1,,Biodistribution in normal mice bone after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630540,10090.0,N,BAO_0000218,Mus musculus,,,Heart,14941,948.0,15045,,1,,Biodistribution in normal mice heart after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630541,10090.0,N,BAO_0000218,Mus musculus,,,Heart,14942,948.0,15045,,1,,Biodistribution in normal mice heart after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630542,10090.0,N,BAO_0000218,Mus musculus,,,Heart,14943,948.0,15045,,1,,Biodistribution in normal mice heart after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630543,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,14944,2113.0,15045,,1,,Biodistribution in normal mice kidney after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630544,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,14945,2113.0,15045,,1,,Biodistribution in normal mice kidney after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630545,10090.0,N,BAO_0000218,Mus musculus,,,Kidney,14946,2113.0,15045,,1,,Biodistribution in normal mice kidney after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630546,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14947,2107.0,15045,,1,,Biodistribution in normal mice liver after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630547,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14948,2107.0,15045,,1,,Biodistribution in normal mice liver after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630548,10090.0,N,BAO_0000218,Mus musculus,,,Liver,14949,2107.0,15045,,1,,Biodistribution in normal mice liver after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630549,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,14950,2106.0,15045,,1,,Biodistribution in normal mice spleen after 120 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630550,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,14951,2106.0,15045,,1,,Biodistribution in normal mice spleen after 24 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL876426,10090.0,N,BAO_0000218,Mus musculus,,,Spleen,14952,2106.0,15045,,1,,Biodistribution in normal mice spleen after 4 hr,A,In vivo,,Intermediate,1,,50594
,CHEMBL630551,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14953,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630552,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14954,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630553,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14955,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630554,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14956,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630555,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14957,2106.0,12017,,1,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630556,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14958,2106.0,12017,,1,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630557,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14959,2106.0,12017,,1,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630558,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14960,2106.0,12017,,1,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Intermediate,1,,50597
,CHEMBL630559,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14961,2106.0,12017,,1,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630560,10116.0,N,BAO_0000218,Rattus norvegicus,,,Spleen,14962,2106.0,12017,,1,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL876427,10116.0,N,BAO_0000218,Rattus norvegicus,,,Thyroid gland,14963,2046.0,12017,,1,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Intermediate,1,,50597
,CHEMBL630561,10116.0,N,BAO_0000218,Rattus norvegicus,,,,14964,,14941,,1,,The Kel values in female wistar rats.,A,,,Intermediate,1,,50597
,CHEMBL630562,,U,BAO_0000019,,,,,14965,,4646,,1,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL630563,,U,BAO_0000019,,,,,14966,,8847,,1,,Hydrolysis rate constant of the compound,A,,,Autocuration,0,,22224
,CHEMBL629673,,U,BAO_0000100,,,,,14967,,11778,,1,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,,,Autocuration,0,,22229
,CHEMBL629674,,U,BAO_0000019,,,,,14968,,2363,,1,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL629675,,U,BAO_0000019,,,,,14969,,2363,,1,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,,,Autocuration,0,,22224
,CHEMBL629676,,U,BAO_0000019,,,,,14970,,2363,,1,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,,,Autocuration,0,,22224
,CHEMBL629677,,U,BAO_0000019,,,,,14971,,2363,,1,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,,,Autocuration,0,,22224
,CHEMBL629678,,U,BAO_0000019,,,,,14972,,8371,,1,,Apparent inactivation rate constant was evaluated,A,,,Autocuration,0,,22224
,CHEMBL629679,,U,BAO_0000019,,,,,14973,,14883,,1,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,,,Autocuration,0,,22224
,CHEMBL629680,,U,BAO_0000019,,,,,14974,,14883,,1,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,,,Autocuration,0,,22224
,CHEMBL629681,,U,BAO_0000019,,,,,14975,,4643,,1,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,,,Autocuration,0,,22224
,CHEMBL629682,,U,BAO_0000019,,,,,14976,,3519,,1,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,,,Autocuration,0,,22224
,CHEMBL629683,,U,BAO_0000019,,,,,14977,,10600,,1,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,,,Autocuration,0,,22224
,CHEMBL629684,,U,BAO_0000019,,,,,14978,,8501,,1,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,,,Autocuration,0,,22224
,CHEMBL629685,,U,BAO_0000100,,,,,14979,,8505,,1,,Dissociation constant was determined,P,,,Autocuration,0,,22224
,CHEMBL629686,,U,BAO_0000100,,,,,14980,,9778,,1,,Dissociation constant was determined,P,,,Autocuration,0,,22224
,CHEMBL872932,,U,BAO_0000100,,,,,14981,,9778,,1,,Dissociation constant at pH 7.4,P,,,Autocuration,0,,22224
,CHEMBL629687,,U,BAO_0000100,,,,,14982,,9778,,1,,Dissociation constant in presence of 1 mM dithiothreitol,P,,,Autocuration,0,,22224
,CHEMBL872931,,U,BAO_0000019,,,,,14983,,13007,,1,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,Autocuration,0,,22224
,CHEMBL628151,,U,BAO_0000019,,,,,14984,,13007,,1,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,Autocuration,0,,22224
,CHEMBL628152,,U,BAO_0000019,,,,,14985,,13007,,1,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,Autocuration,0,,22224
,CHEMBL628153,,U,BAO_0000019,,,,,14986,,13007,,1,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,Autocuration,0,,22224
,CHEMBL628154,,U,BAO_0000019,,,,,14987,,11482,,1,,Kinetic constant for aromatization of androstenedione,A,,,Autocuration,0,,22224
,CHEMBL628155,,U,BAO_0000019,,,,,14988,,11482,,1,,Kinetic constant for aromatization of testosterone,A,,,Autocuration,0,,22224
,CHEMBL628156,,U,BAO_0000019,,,,,14989,,2303,,1,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,,,Autocuration,0,,22224
,CHEMBL628157,,U,BAO_0000019,,,,,14990,,11964,,1,,Local inhibition constant was determined,A,,,Autocuration,0,,22224
,CHEMBL857533,4932.0,N,BAO_0000218,Saccharomyces cerevisiae,,,,14991,,3140,,1,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,,,Intermediate,1,,50347
,CHEMBL628158,,U,BAO_0000100,,,,,14992,,10650,,1,,Dissociation constant value of the compound,P,,,Autocuration,0,,22224
,CHEMBL628159,,U,BAO_0000019,,,,Cornea,14993,964.0,4667,,1,,In vitro permeability through cornea without epithelium,A,,,Autocuration,0,,22224
,CHEMBL875616,,U,BAO_0000019,,,,Cornea,14994,964.0,4667,,1,,In vitro permeability through intact cornea,A,,,Autocuration,0,,22224
,CHEMBL628160,9986.0,N,BAO_0000218,Oryctolagus cuniculus,,,Cornea,14995,964.0,9199,,1,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,,,Intermediate,1,,50592
,CHEMBL628161,,U,BAO_0000019,,,,,14996,,11966,,1,,Rate of enzyme inactivation for the compound was determined,A,,,Autocuration,0,,22224
,CHEMBL628162,,U,BAO_0000019,,,,Cornea,14997,964.0,4667,,1,,In vitro permeability through cornea without epithelium,A,,,Autocuration,0,,22224
,CHEMBL628163,,U,BAO_0000019,,,,Cornea,14998,964.0,4667,,1,,In vitro permeability through intact cornea,A,,,Autocuration,0,,22224
,CHEMBL628164,,U,BAO_0000019,,,,,14999,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628165,,U,BAO_0000019,,,,,15000,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628166,,U,BAO_0000019,,,,,15001,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628167,,U,BAO_0000019,,,,,15002,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628168,,U,BAO_0000019,,,,,15003,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628169,,U,BAO_0000019,,,,,15004,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628170,,U,BAO_0000019,,,,,15005,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628171,,U,BAO_0000019,,,,,15006,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL627434,,U,BAO_0000019,,,,,15007,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL627435,,U,BAO_0000019,,,,,15008,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628110,,U,BAO_0000019,,,,,15009,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628111,,U,BAO_0000019,,,,,15010,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628112,,U,BAO_0000019,,,,,15011,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628260,,U,BAO_0000019,,,,,15012,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628261,,U,BAO_0000019,,,,,15013,,8354,,1,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,Autocuration,0,,22224
,CHEMBL628262,10090.0,N,BAO_0000218,Mus musculus,,,,15014,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Intermediate,1,,50594
,CHEMBL628263,9606.0,N,BAO_0000218,Homo sapiens,,,,15015,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Intermediate,1,,50587
,CHEMBL628264,10090.0,N,BAO_0000218,Mus musculus,,,,15016,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Intermediate,1,,50594
,CHEMBL628265,10090.0,N,BAO_0000218,Mus musculus,,,,15017,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Intermediate,1,,50594
,CHEMBL628266,10090.0,N,BAO_0000218,Mus musculus,,,,15018,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Intermediate,1,,50594
,CHEMBL628267,10090.0,N,BAO_0000218,Mus musculus,,,,15019,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Intermediate,1,,50594
,CHEMBL628268,10090.0,N,BAO_0000218,Mus musculus,,,,15020,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Intermediate,1,,50594
,CHEMBL628269,10090.0,N,BAO_0000218,Mus musculus,,,,15021,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Intermediate,1,,50594
,CHEMBL628270,10090.0,N,BAO_0000218,Mus musculus,,,,15022,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Intermediate,1,,50594
,CHEMBL628271,10090.0,N,BAO_0000218,Mus musculus,,,,15023,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Intermediate,1,,50594
,CHEMBL628272,10090.0,N,BAO_0000218,Mus musculus,,,,15024,,14439,,1,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Intermediate,1,,50594
